ALABAMA MEDICAL CANNABIS COMMISSION

Help

Ala. Code § 36-12-40 (Personally Identifiable Information)

Review

Selected Account:Coosa Medical Manufacturing LLC

Your application has been filed with the Alabama Medical Cannabis Commission.

Ala. Code § 36-12-40 (Personally Identifiable Information)

File Date : **12/28/2022 12:32 PM**

Ala. Code § 36-12-40 (Personally Identifiable Information)

If you do not receive email notifications, please check your spam folder.

You must print or save this page as a PDF as part of your redacted filing.

Request for Business Application Information

Ala. Code § 36-12-40 (Personally Identifiable Information)

General Applicant Information

- **Applicant Name** : Coosa Medical Manufacturing
- **Applying as:** Business Entity
- **Trade Name (DBAs):** N/A

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Business Entity Name** : Coosa Medical Manufacturing, LLC
- **Business Entity Type** : Limited Liability Company

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Date of Qualification, Organization or Incorporation** :07/15/2022

Applicant Street Address

- **Street:** 2347 MONTGOMERY HWY
- **Unit No / Apt No** :
- **City:** CENTREVILLE
- **County:** 04-Bibb
- **State:** Alabama
- **Zip Code:** 35042
- **Address Verified?:** Yes

Applicant Mailing Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Address Verified?:** Yes

Applicant Website : Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Do you have a management service agreement in place?:** No

✔ **Is the applicant: (1) at least 51% owned by (or, in the case of a corporation, 51% of the shares belong to) members of any minority group (as defined by 20-2A-51(b)), and (2) managed and controlled in its daily operations by members of any minority group?** :No

Primary Contact Person

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Address Verified?:** Yes

License Information

✔ **License Type:** Processor

Facility Information

Facility Information

- **Facility Type** : Processing Facility

Physical Address

- **Street:** 2347 MONTGOMERY HWY
- **Unit No / Apt No** :
- **City:** CENTREVILLE
- **County:** 04-Bibb
- **State:** Alabama
- **Zip Code:** 35042
- **Address Verified?** : Yes

Facility Information Questions

- **Applicant's interest in property where proposed facility is located** : Agreement Contingent on Receipt of License
- **Is this facility under construction?** : No
- **The number of days, if awarded a license, within which the Applicant reasonably projects it will commence operations at this facility** : 120
- **The number of days, if awarded a license, within which the Applicant reasonably projects it will reach full capacity at this facility** : 180
- **Does the applicant verify that this proposed facility will be in a permissible location, if applicable, and will maintain compliance with all State and local laws, resolutions and ordinances?** : Yes

Ownership of Applicant

- **Select type of record:** Individual
- **Does the individual have an ownership interest in the applicant?** : Yes

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Ownership Percentage of the Applicant** : 17
- **Role:** Member , Director

Residence Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Address Verified?** : Yes

- **Select type of record:** Individual

- **Does the individual have an ownership interest in the applicant?** : Yes

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Ownership Percentage of the Applicant** : 51
- **Role:** Member , Director

Residence Address

- **Address Verified?** : Yes

- **Select type of record:** Individual

- **Does the individual have an ownership interest in the applicant?** : Yes

Individual

- **Ownership Percentage of the Applicant** : 8

- **Role:** Member , Director

Residence Address

- **Address Verified?** : Yes

- **Select type of record:** Individual

- **Does the individual have an ownership interest in the applicant?** : Yes

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Ownership Percentage of the Applicant** : 12
- **Role:** Member , Director

Residence Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Address Verified?** : Yes

- **Select type of record:** Individual

- **Does the individual have an ownership interest in the applicant?** : Yes

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Ownership Percentage of the Applicant** : 4
- **Role:** Member

Residence Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Address Verified?** : Yes

- **Select type of record:** Individual

- **Does the individual have an ownership interest in the applicant?** : Yes

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Ownership Percentage of the Applicant** : 4
- **Role:** Member

Residence Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Address Verified?** : Yes

- **Select type of record:** Individual

- **Does the individual have an ownership interest in the applicant?** : Yes

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Ownership Percentage of the Applicant** : 4
- **Role:** Member

Residence Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

- **Address Verified?** : Yes

Cannabis Industry Entities

- **Is any individual or entity below connected to any entity that is directly or indirectly involved in the cannabis industry, including, but not limited to, the cultivation, processing, packaging, labeling, testing, transporting, or sale of cannabis or medical cannabis, either in Alabama or any other jurisdiction?**
  (1) an individual with an ownership interest in the applicant;
  (2) the spouse, parent, or child of an individual with an ownership interest in the applicant; or
  (3) an entity with an ownership interest in the applicant. :Yes

- **Select Individual or Entity:** : Individual

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

Suffix:

Ala. Code § 36-12-40 (Competitively Sensitive Information)

- **Entity Type** : Limited Liability Partnership
- **Connection:** Individual **to Cannabis Entity**

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Cannabis Entity's Physical Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Address Verified?** : Yes

Cannabis Entity's Primary Contact/Responsible Person

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Select Individual or Entity:** : Individual

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

Suffix:

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Entity Type** : Limited Liability Partnership

✔ **Connection to Cannabis Entity:** Individual

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Cannabis Entity's Physical Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

Cannabis Entity's Primary Contact/Responsible Person

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Select Individual or Entity:** : Individual

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

Suffix:

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Entity Type** : Limited Liability Partnership

✔ **Connection: to Cannabis Entity** Individual

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Cannabis Entity's Physical Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

Cannabis Entity's Primary Contact/Responsible Person

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Select Individual or Entity:** : Individual

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

Suffix:

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Entity Type** : Limited Liability Partnership

✔ **Connection: to Cannabis Entity** Individual

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Address Verified?** : Yes

Cannabis Entity's Primary Contact/Responsible Person

Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Select Individual or Entity:** : Individual

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

Suffix:

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Entity Type** : Limited Liability Company

✔ **Connection: to Cannabis Entity** Individual

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Cannabis Entity's Physical Address

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Address Verified?** : Yes

Cannabis Entity's Primary Contact/Responsible Person

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Select Individual or Entity:** : Individual

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

Suffix:

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Entity Type** : Limited Liability Company

✔ **Connection: to Cannabis Entity** Individual

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Cannabis Entity's Primary Contact/Responsible Person

Ala. Code § 36-12-40 (Personally Identifiable Information)

✔ **Select Individual or Entity:** : Individual

Individual

Ala. Code § 36-12-40 (Personally Identifiable Information)

Suffix:

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Entity Type** : Limited Liability Company

✔ **Connection: Individual to Cannabis Entity**

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Address Verified?** : Yes

Cannabis Entity's Primary Contact/Responsible Person

Ala. Code § 36-12-40 (Personally Identifiable Information)

Questions and Attestations

✔ **Has the applicant, any ownership entity, or any cannabis entity connected to any individual or entity with an ownership interest in the applicant ever applied for or been granted any commercial license or certificate (not related to cannabis industry) issued by a licensing board or commission, either in Alabama or any other jurisdiction?** : Yes

✔ **Select One** : Related Cannabis Entity

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Was any commercial license or certificate disclosed above denied, restricted, suspended, revoked, or non-renewed?** : No

✔ **Has the applicant, any ownership entity, or any cannabis entity connected to any individual or entity with an ownership interest in the applicant, ever been authorized to participate in the cannabis or medical cannabis industry, licensed (i.e., a "licensee" as defined in Chapter 1 of the AMCC Rules), or provided similar status in any other jurisdiction?** : Yes

✔ **Select One** : Related Cannabis Entity

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Select One** : Related Cannabis Entity

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Select One** : Related Cannabis Entity

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Select One** : Related Cannabis Entity

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Select One** : Related Cannabis Entity

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Select One** : Related Cannabis Entity

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **Select One** : Related Cannabis Entity

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

✔ **During the last 5 years has there been any disciplinary measures taken regarding any cannabis or medical cannabis industry license of the applicant or any entity affiliated with the applicant?** : No

✔ **Has the applicant, any ownership entity, or any cannabis entity connected to any individual or entity with an ownership interest in the applicant, within the last ten (10) years, filed or been served with a complaint or other notice by any governmental body, regarding a delinquency in the payment of, or a dispute over the filings concerning the payment of, any tax required under federal, state, or local law?** : No

✔ **Has the applicant filed, or had filed against it, any proceeding for bankruptcy within the past 7 years?:** No

✔ **Is the applicant currently, or has it been in the past 10 years, a defendant in litigation involving any of its business practices?** : No

✔ **Is any public official of any unit of government:**
(1) an owner (directly or indirectly) of any financial or beneficial interest in the applicant;
(2) a creditor of the applicant;
(3) a holder of any debt instrument issued by the applicant; or (4) a holder of, or interested party in, any contractual or service relationship with the applicant? : No

✔ **Is the spouse, parent or child of a public official of any unit of government:**
(1) an owner (directly or indirectly) of any financial or beneficial interest in the applicant;
(2) a creditor of the applicant;
(3) a holder of any debt instrument issued by the applicant; or
(4) a holder of, or interested party in, any contractual or service relationship with the applicant? : No

✔ **Has any owner, director, board member, or individual with a controlling interest in the applicant ever been indicted for, charged with, arrested for, convicted of, pled guilty or nolo contendere to, or forfeited bail concerning any felony or controlled substance-related misdemeanor, not including traffic violations, regardless of whether the offense has been reversed on appeal or otherwise?** : No

What is the applicant's anticipated or actual number of employees (including all facilities) at the prospective commencement of operations and during the first five calendar years thereafter?

Ala. Code § 36-12-40 (Competitively Sensitive Information)

[redacted]

- ✔ **Does the applicant verify that it has the ability to maintain adequate minimum levels ($2,000,000) of liability and casualty insurance, as required by § 20-2A-53(a)(2), Code of Alabama 1975 (as amended)?** :Yes

- ✔ **Does the applicant consent as required by § 20-2A-55(d), Code of Alabama 1975 (as amended) to the inspections, examinations, searches, and seizures contemplated by § 20-2A-52(a)(3), Code of Alabama 1975 (as amended)?** :Yes

- ✔ **Does the applicant verify that neither it nor its leadership have any economic interest in any other license or applicant for license under the Act? (See § 20-2A-55(e), Code of Alabama 1975 (as amended))** : Yes

- ✔ **I attest that this application is truthful and complete based on the best available information as of the date of filing.** : Yes

Ala. Code § 36-12-40 (Personally Identifiable Information)

[redacted]

✔ **Signature Date:** 12/28/2022

Documents

✔ **Resume or Curriculum Vitae of Individuals with Ownership Interest:**	Exhibit 1_Resume or CV FINAL.pdf (./api/documents/cU1XYo73…
✔ **Residency of Owners:**	Exhibit 2_Residency of Owners FINAL.pdf (./api/documents/ah…
✔ **Criminal Background Check:**	Exhibit 3_Criminal Background Check.pdf (./api/documents/Ih9…
✔ **Demonstration of Sufficient Capital:**	Exhibit 4_Demonstration of Capital.pdf (./api/documents/5e_U2…
✔ **Financial Statements:**	Exhibit 5 - Financial Statements.pdf (./api/documents/r5K3oDd…
✔ **Tax Plan:**	Exhibit 6 - Tax Plan.pdf (./api/documents/6l-6-QVJ6/download)
✔ **Business Formation Documents:**	Exhibit 7_Business Formation Documents.pdf (./api/documents…
✔ **Business License and Authorization of Local Jurisdictions:**	Exhibit 8_Business License and Authorization of Local Authoriti…

✔ **Business Plan:**	Exhibit 9 - Business Plan.pdf (./api/documents/-Djh2uMhh/dow…
✔ **Evidence of Business Relationship with other Licensees and Prospective Licensees:**	Exhibit 10_Evidence of Business Relationshi.pdf (./api/documen…
✔ **Standard Operating Plan and Procedures:**	Exhibit 11 - Standard Operating Plan and Procedures.pdf (./api/…
✔ **Policies and Procedures Manual:**	Exhibit 12 - Coosa Medical - Policies and Procedures Manual.pd…
✔ **Production and Manufacturing Process:**	Exhibit 13 - Production and Manufacturing Process.pdf (./api/d…
✔ **Machinery and Equipment:**	Exhibit 14_Machinery and Equipment - with pages cut.pdf (./api/…
✔ **Receiving and Shipping Plan:**	Exhibit 15 - Receiving and Shipping Plan.pdf (./api/documents/…
✔ **Facilities:**	Exhibit 16_Facilities FINAL _1_.pdf (./api/documents/2ZPYR8Jo…
✔ **Security Plan:**	Exhibit 17 - Security Plan.pdf (./api/documents/uukbd0qHN/do…
✔ **Personnel:**	Exhibit 18_Personnel.pdf (./api/documents/z2J_tYP5i/download)
✔ **Business Leadership Credentials:**	Exhibit 19 - Business Leadership Credentials.pdf (./api/docume…
✔ **Employee Handbook:**	Exhibit 20_Employee Handbook.pdf (./api/documents/ccDxIOH…
✔ **Quality Control and Quality Assurance Plan:**	Exhibit 21 - Quality Control and Quality Assurance Plan.pdf (./ap…
✔ **Contamination and Recall Plan:**	Exhibit 22 - Contamination and Recall Plan.pdf (./api/document…
✔ **Marketing and Advertising Plan:**	Exhibit 23 - Marketing and Advertising Plan.pdf (./api/document…
✔ **Website and Social Media:**	Exhibit 24 - Website and Social Media.pdf (./api/documents/4x…
✔ **Ownership Entity Individuals (if applicable):**	Coosa letter - signed.pdf (./api/documents/19GQQ4uJh/downlo…
✔ **Proof of Minimum Liability and Casualty Insurance:**	Insurance Letter Coosa.pdf (./api/documents/HjJbk9K-G/downl…
✔ **Affidavit - Entity Applicant:**	Coosa - Form K.pdf (./api/documents/91j7lt1rE/download)

Payments

- **Payment Options:** Credit Card

License Type: Processor

REDACTED COPY

Exhibit 1 – Resume or Curriculum Vitae of Individuals with Ownership Interest in Applicant

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

FORM A: OWNERSHIP RESUME / CURRICULUM VITAE

Coosa Medical Manufacturing, LLC	Processor
Business License Applicant Name	License Type
Ala. Code § 36-12-40 (Personally Identifiable Information)	8 %
Individual with Ownership Interest in Applicant	Individual's Ownership Percentage in Applicant

Residential History

Provide all residential addresses, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

07/2021	Present
Date Resided From (MM/YYYY)	Date Resided To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

07/2019	07/2021
Date Resided From (MM/YYYY)	Date Resided To (MM/YYYY).

Ala. Code § 36-12-40 (Personally Identifiable Information)

05/2014	07/2019
Date Resided From (MM/YYYY)	Date Resided To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

05/2011	05/2014
Date Resided From (MM/YYYY)	Date Resided To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

03/2001 — Date Resided From (MM/YYYY)

05/2011 — Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Education

Provide all institutions of higher education attended; attach additional form(s) if necessary.

University of North Alabama | Florence | AL

Institution | City | State

[redacted]

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Troy State University | Troy | AL

[redacted]

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Employment History

Provide all employers, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

[redacted]

City | State | Zip

03/2019 | Present

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

03/2013 02/2019

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

08/2010 03/2013

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

03/2001 03/2013

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

FORM A: OWNERSHIP RESUME / CURRICULUM VITAE

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual with Ownership Interest in Applicant

4 %
Individual's Ownership Percentage in Applicant

Residential History

Provide all residential addresses, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

04/2004
Date Resided From (MM/YYYY)

Present
Date Resided To (MM/YYYY)

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY).

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Education

Provide all institutions of higher education attended; attach additional form(s) if necessary.

Harvard University | Cambridge | MA

Institution | City | State

Ala. Code § 36-12-40 (Personally Identifiable Information)

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Employment History

Provide all employers, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City | State | Zip

04/2021 | Present

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

12/2008
Date Employed From (MM/YYYY)

04/2021
Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

07/2007
Date Employed From (MM/YYYY)

12/2008
Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

04/2004
Date Employed From (MM/YYYY)

06/2007
Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

07/1996
Date Employed From (MM/YYYY)

04/2004
Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

FORM A: OWNERSHIP RESUME / CURRICULUM VITAE

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual with Ownership Interest in Applicant

4 %
Individual's Ownership Percentage in Applicant

Residential History

Provide all residential addresses, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

05/2020
Date Resided From (MM/YYYY)

Present
Date Resided To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

01/2010
Date Resided From (MM/YYYY)

05/2020
Date Resided To (MM/YYYY).

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

06/2007
Date Resided From (MM/YYYY)

01/2010
Date Resided To (MM/YYYY)

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Education

Provide all institutions of higher education attended; attach additional form(s) if necessary.

Princeton University | Princeton | NJ

Ala. Code § 36-12-40 (Personally Identifiable Information)

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Employment History

Provide all employers, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City | State | Zip

04/2021 | Present

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

01/2013
Date Employed From (MM/YYYY)

04/2021
Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

07/2005
Date Employed From (MM/YYYY)

10/2012
Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY)

Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY)

Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

FORM A: OWNERSHIP RESUME / CURRICULUM VITAE

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual with Ownership Interest in Applicant

51 %
Individual's Ownership Percentage in Applicant

Residential History

Provide all residential addresses, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

10/2019
Date Resided From (MM/YYYY)

Present
Date Resided To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

05/2014
Date Resided From (MM/YYYY)

10/2019
Date Resided To (MM/YYYY).

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

10/1999
Date Resided From (MM/YYYY)

05/2014
Date Resided To (MM/YYYY)

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Education

Provide all institutions of higher education attended; attach additional form(s) if necessary.

University of Alabama | Tuscaloosa | AL

Institution | City | State

Ala. Code § 36-12-40 (Personally Identifiable Information)

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

University of Alabama School of Medicine | Birmingham | AL

Institution | City | State

Ala. Code § 36-12-40 (Personally Identifiable Information)

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

Employment History

Provide all employers, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City | State | Zip

01/2022 | Present

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

05/2020 Present

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

01/2020 02/2022

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

07/2018 12/2019

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

06/2017 05/2018

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

[redacted]

City State Zip

07/2014 07/2017

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

FORM A: OWNERSHIP RESUME / CURRICULUM VITAE

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual with Ownership Interest in Applicant

12 %
Individual's Ownership Percentage in Applicant

Residential History

Provide all residential addresses, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

08/2015
Date Resided From (MM/YYYY)

Present
Date Resided To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

08/2009
Date Resided From (MM/YYYY)

08/2015
Date Resided To (MM/YYYY).

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

06/2003
Date Resided From (MM/YYYY)

08/2009
Date Resided To (MM/YYYY)

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Education

Provide all institutions of higher education attended; attach additional form(s) if necessary.

University of Alabama | Tuscaloosa | AL
Institution | City | State

[redacted]

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

University of Alabama | Tuscaloosa | AL
Institution | City | State

[redacted]

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

University of Alabama | Tuscaloosa | AL
Institution | City | State

[redacted]

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

Employment History

Provide all employers, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

[redacted]

City | State | Zip

01/2022 | Present

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

12/2018 Present

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

04/2018 Present

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

02/2018 01/2022

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

07/2012 01/2020

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

[redacted]

City State Zip

01/2007 07/2012

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Employer Contact Person Telephone

Business Address

City State Zip

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

FORM A: OWNERSHIP RESUME / CURRICULUM VITAE

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual with Ownership Interest in Applicant

12 %
Individual's Ownership Percentage in Applicant

Residential History

Provide all residential addresses, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

09/2008
Date Resided From (MM/YYYY)

Present
Date Resided To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

07/2001
Date Resided From (MM/YYYY)

07/2008
Date Resided To (MM/YYYY).

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Education

Provide all institutions of higher education attended; attach additional form(s) if necessary.

Meharry Medical College | Nashville | TN

Institution | City | State

Ala. Code § 36-12-40 (Personally Identifiable Information)

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

Morehouse College | Atlanta | GA

Institution | City | State

Ala. Code § 36-12-40 (Personally Identifiable Information)

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

---

Employment History

Provide all employers, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City | State | Zip

08/2017 | Present

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

06/2017 Present

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

05/2017 Present

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

06/2014 03/2016

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

10/2012 Present

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

07/2012 04/2017

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

05/2008 05/2017

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

05/2008 06/2012

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

06/2000 05/2008

Date Employed From (MM/YYYY) Date Employed To (MM/YYYY)

FORM A: OWNERSHIP RESUME / CURRICULUM VITAE

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual with Ownership Interest in Applicant

4 %
Individual's Ownership Percentage in Applicant

Residential History

Provide all residential addresses, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

03/1997
Date Resided From (MM/YYYY)

Present
Date Resided To (MM/YYYY)

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY).

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City State Zip

Date Resided From (MM/YYYY)

Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Residential Street Address

City | State | Zip

Date Resided From (MM/YYYY) | Date Resided To (MM/YYYY)

Education

Provide all institutions of higher education attended; attach additional form(s) if necessary.

Emory University | Atlanta | GA

Institution | City | State

[redacted]

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Institution | City | State

Date Attended From (MM/YYYY) | Date Attended To (MM/YYYY) | Degree Received

Employment History

Provide all employers, in reverse chronological order, for 15 years prior to date of application; attach additional form(s) if necessary.

[redacted]

City | State | Zip

08/1978 | Present

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

Employer | Contact Person | Telephone

Business Address

City | State | Zip

Date Employed From (MM/YYYY) | Date Employed To (MM/YYYY)

REDACTED COPY

License Type: Processor

Exhibit 2 – Residency of Owners

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

The owners of Coosa Medical Manufacturing LLC are:

[redacted] is the majority owner and has lived in Alabama for over 15 years. Attached are [redacted] of Residency documents. [redacted] are all Alabama residents as well. Please see attachment identified as "Residency of Owners – Coosa Medical Manufacturing - Attachment to Exhibit 2" for additional information.

Table of Contents:

November 18, 2022

Alabama Medical Cannabis Commission
P. O. Box 309585
Montgomery, Alabama 36130

Re: Proof of Residency for Coosa Medical Manufacturing

Dear Sir or Madam:

To satisfy the residency requirement set forth in Section 528-x-3-.05(3)(m)(4) of the Alabama Medical Cannabis Commission Rules and Regulations, attached are proof of residency records showing fifteen (15) years of residency in the State of Alabama by Ala. Code § 36-12-40 (Personally Identifiable Information) 2006 to 2010, Ala. Code § 36-12-40 (Personally Identifiable Information) rgraduate student at the University of Alabama and resided with Ala. Code § 36-12-40 (Personally Identifiable Information) at Ala. Code § 36-12-40 (Personally Identifiable Information) Ala. Code § 36-12-40 (Personally Identifiable Information) 2010 to 2014, Ala. Code § 36-12-40 (Personally Identifiable Information) al school student at the University of Alabama at Birmingham and resided Ala. Code § 36-12-40 (Personally Identifiable Information) Ala. Code § 36-12-40 (Personally Identifiable Information) From 2014 to present Ala. Code § 36-12-40 (Personally Identifiable Information) The following records are attached to evidence the foregoing residencies:

Ala. Code § 36-12-40 (Personally Identifiable Information)

Sincerely,

Ala. Code § 36-12-40 (Personally Identifiable Information)

Enclosures

11/7/22, 9:32 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2006
Nov 07, 2022 09:29 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Freshman

Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
40994	CBH 101 001	Computer Based Honors	Main Campus (Tuscaloosa)		4.000	UG	Aug 23, 2006	Dec 08, 2006	M	6:00 pm - 6:50 pm	Nott Hall 176	Evans-Young
							Aug 23, 2006	Dec 08, 2006	MWF	1:00 pm - 1:50 pm	Nott Hall 173	Evans-Young
44071	EC 110 007	Honors Prin Of Microeconomics	Main Campus (Tuscaloosa)		3.000	UG	Aug 23, 2006	Dec 08, 2006	TR	9:30 am - 10:45 am	Bidgood Hall 13	Souki
45511	EN 103 012	Advanced English Composition	Main Campus (Tuscaloosa)		3.000	UG	Aug 23, 2006	Dec 08, 2006	TR	3:30 pm - 4:45 pm	Morgan Hall 310	Durant
46049	GBA 145 011	Freshman Compass: Cba	Main Campus (Tuscaloosa)		1.000	UG	Aug 23, 2006	Dec 08, 2006	R	11:00 am - 11:50 am	Bidgood Hall 34	Heggem
44036	SP 103 007	Intensive Review Intro Spanish	Main Campus (Tuscaloosa)	Traditional	4.000	UG	Aug 23, 2006	Dec 08, 2006	MWF	11:00 am - 11:50 am	B B Comer Hall 257	Cristofaro
							Aug 23, 2006	Dec 08, 2006		TBA	TBA	Cristofaro
			Total Credits:	15.000								

RELEASE: 8.7.1

https://ssb.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1



11/7/22, 9:37 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2007
Nov 07, 2022 09:36 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Sophomore
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Iden ifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
30124	CBH 102 001	Computer Based Honors	Main Campus (Tuscaloosa)		4.000	UG	Jan 10, 2007	May 04, 2007	MWF	1:00 pm - 1:50 pm	Nott Hall 173	Evans-Young
							Jan 10, 2007	May 04, 2007	M	6:00 pm - 6:50 pm	Nott Hall 173	Evans-Young
35146	MATH 146 001	Honors Calculus II	Main Campus (Tuscaloosa)	Traditional	4.000	UG	Jan 10, 2007	May 04, 2007	T	6:30 pm - 7:50 pm	TBA	Evans
							Jan 10, 2007	May 04, 2007	MTWR	11:00 am - 11:50 am	Gordon Palmer Hall 226	Evans
32607	SP 201 003	Intermediate Spanish	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 10, 2007	May 04, 2007	MWF	12:00 pm - 12:50 pm	B B Comer Hall 243	Morris
36970	ST 260 003	Statistcl Data Analysis	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 10, 2007	May 04, 2007	TR	8:00 am - 9:15 am	Bidgood Hall 240	Barrett

Total Credits: 14.000

RELEASE: 8.7.1

https://ssb.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2007
Nov 07, 2022 09:37 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Sophomore
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
40018	AC 210 004	Intro To Accounting	Main Campus (Tuscaloosa)		4.000	UG	Aug 22, 2007	Dec 07, 2007	TR	12:30 pm - 1:45 pm	Bidgood Hall 210	Abernathy
40013	AC 210 010	Intro To Accounting	Main Campus (Tuscaloosa)		0.000	UG	Aug 22, 2007	Dec 07, 2007	F	10:00 am - 10:50 am	Bidgood Hall 210	Piper
43599	CBH 201 004	Computer Based Honors	Main Campus (Tuscaloosa)		3.000	UG	Aug 22, 2007	Dec 07, 2007	R	11:00 am - 11:50 am	TBA	Sharpe
45813	CBH 425 002	Comp Based Honors Proj	Main Campus (Tuscaloosa)		1.000	UG	Aug 22, 2007	Dec 07, 2007	T	8:00 pm - 9:00 pm	Nott Hall 173	Sharpe
45200	GBA 481 001	Business Honors Seminar I	Main Campus (Tuscaloosa)		1.500	UG	Aug 22, 2007	Dec 07, 2007	M	12:00 pm - 12:50 pm	Bidgood Hall 121	Cashman
43483	SP 202 002	Intermediate Spanish	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Aug 22, 2007	Dec 07, 2007	TR	9:30 am - 10:45 am	B B Comer Hall 261	Boris Tarre
46712	UH 300 007	Seminar:Honors Field Archeol	Main Campus (Tuscaloosa)	Non-Traditional	3.000	UG	Aug 22, 2007	Dec 07, 2007	TR	2:00 pm - 4:45 pm	Ten Hoor Hall 27	Knight
			Total Credits:	**15.500**								

RELEASE: 8.7.1

4865-8913-8750.1

11/7/22, 9:40 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2008
Nov 07, 2022 09:38 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Junior
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
14553	CBH 202 003	Computer Based Honors	Main Campus (Tuscaloosa)		3.000	UG	Jan 09, 2008	May 02, 2008	W	12:00 pm - 12:50 pm	TBA	Sharpe
13232	EC 308 002	Intermed Microeconomics	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 09, 2008	May 02, 2008	TR	11:00 am - 12:15 pm	Bidgood Hall 310	Jindapon
13461	FI 302 001	Business Finance	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 09, 2008	May 02, 2008	TR	3:30 pm - 4:45 pm	Alston Hall 10	Downs
13466	FI 302 006	Laboratory	Main Campus (Tuscaloosa)		0.000	UG	Jan 09, 2008	May 02, 2008	M	11:00 am - 11:50 am	Bidgood Hall 115	TBA
14907	GBA 482 001	Business Honors Seminar II	Main Campus (Tuscaloosa)		1.500	UG	Jan 09, 2008	May 02, 2008	M	12:00 pm - 12:50 pm	Bidgood Hall 121	Cashman
14310	MATH 227 007	Calculus III	Main Campus (Tuscaloosa)	Traditional	4.000	UG	Jan 09, 2008	May 02, 2008	T	6:30 pm - 7:50 pm	TBA	Moore
							Jan 09, 2008	May 02, 2008	MTWR	1:00 pm - 1:50 pm	Gordon Palmer Hall 228	Moore
12223	SP 353 003	Spanish Conversation	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 09, 2008	May 02, 2008	TR	9:30 am - 10:45 am	B B Comer Hall 259	Toledo
			Total Credits:	**17.500**								

RELEASE: 8.7.1

https://sso.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1

11/7/22, 9:41 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2008
Nov 07, 2022 09:40 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Senior

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Undergraduate
College: Business

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
42752	BSC 300 001	Cell Biology	Main Campus (Tuscaloosa)		3.000	UG	Aug 20, 2008	Dec 05, 2008	TR	12:30 pm - 1:45 pm	Biology 127	Johnson
43189	CBH 301 004	Computer Based Honors	Main Campus (Tuscaloosa)		3.000	UG	Aug 20, 2008	Dec 05, 2008	R	11:00 am - 11:50 am	TBA	Sharpe
43342	CH 231 002	Elem Organic Chemistry I	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Aug 20, 2008	Dec 05, 2008	TR	9:30 am - 10:45 am	Shelby Hall 151	Snowden
							Aug 20, 2008	Dec 05, 2008	T	6:30 pm - 7:50 pm	Shelby Hall 151	Snowden
44566	GBA 483 001	Business Honors Seminar III	Main Campus (Tuscaloosa)		1.500	UG	Aug 20, 2008	Dec 05, 2008	W	12:00 pm - 12:50 pm	Bidgood Hall 121	Cashman
42618	PH 101 001	General Physics I	Main Campus (Tuscaloosa)		4.000	UG	Aug 20, 2008	Dec 05, 2008	MW	9:00 am - 10:50 am	Gallalee Hall 203	Tipping
							Aug 20, 2008	Dec 05, 2008	F	9:00 am - 9:50 am	Gallalee Hall 203	Tipping

Total Credits: 14.500

RELEASE: 8.7.1

https://ssb.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2009
Nov 07, 2022 09:41 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Senior
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
10094	CBH 302 002	Computer Based Honors	Main Campus (Tuscaloosa)		3.000	UG	Jan 07, 2009	May 01, 2009	W	10:00 am - 10:50 am	TBA	Sharpe
11184	CH 232 001	Elem Organic Chem II	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 07, 2009	May 01, 2009	MWF	9:00 am - 9:50 am	Shelby Hall 107	Shaughnessy
							Jan 07, 2009	May 01, 2009	T	5:00 pm - 6:20 pm	Shelby Hall 107	Shaughnessy
11186	CH 237 001	Elementary Organic Chemistry Laboratory	Main Campus (Tuscaloosa)	Traditional	2.000	UG	Jan 07, 2009	May 01, 2009	M	12:00 pm - 12:50 pm	Shelby Hall 151	Schiel
							Jan 07, 2009	May 01, 2009	M	1:00 pm - 5:50 pm	Shelby Hall L333	Schiel
14413	GBA 484 001	Business Honors Seminar IV	Main Campus (Tuscaloosa)		1.500	UG	Jan 07, 2009	May 01, 2009	W	12:00 pm - 12:50 pm	Bidgood Hall 121	Cashman
11718	MUS 121 006	Intro To Listening	Main Campus (Tuscaloosa)		3.000	UG	Jan 07, 2009	May 01, 2009	TR	11:00 am - 12:15 pm	Moody Music Building 140	Myers
13352	PH 102 001	General Physics II	Main Campus (Tuscaloosa)		4.000	UG	Jan 07, 2009	May 01, 2009	TR	9:00 am - 10:50 am	Gallalee Hall 329	Harrell
							Jan 07, 2009	May 01, 2009	F	10:00 am - 10:50 am	Gallalee Hall 329	Harrell
			Total Credits:	10.500								

RELEASE: 8.7.1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2009
Nov 07, 2022 09:44 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Senior
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
41101	AC 351 002	Managerl Acctg Decisions	Main Campus (Tuscaloosa)		3.000	UG	Aug 19, 2009	Dec 04, 2009	TR	3:30 pm - 4:45 pm	Bidgood Hall 379	Robbins
44836	EN 207 001	World Literature I	Main Campus (Tuscaloosa)		3.000	UG	Aug 19, 2009	Dec 04, 2009	MW	3:00 pm - 4:15 pm	Ten Hoor Hall 118	McWaters
43761	FI 301 990	Intro Financl Instit Mkt	Main Campus (Tuscaloosa)		3.000	UG	Aug 19, 2009	Dec 04, 2009	MW	5:00 pm - 6:15 pm	Bidgood Hall 310	McLeod
45736	MGT 300 001	Org Theory & Behavior	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Aug 19, 2009	Dec 04, 2009	TR	2:00 pm - 3:15 pm	TBA	Bachrach
43980	MIS 200 001	Fundamentals Mgt Info Systems	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Aug 19, 2009	Dec 04, 2009	TR	12:30 pm - 1:45 pm	Alston Hall 30	Chau

Total Credits: 15.000

RELEASE: 8.7.1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2010
Nov 07, 2022 09:48 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information) **Address:** Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Senior

Level: Undergraduate
College: Business

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
10572	GBA 490 004	Strategic Management	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 06, 2010	Apr 30, 2010	TR	11:00 am - 12:15 pm	Bidgood Hall 140	Dulek
17643	HCM 370 003	Intro Health Systems	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 06, 2010	Apr 30, 2010	TR	9:30 am - 10:45 am	Bidgood Hall 117	Williams
10827	MGT 395 008	Managerl Communictn Strategy	Main Campus (Tuscaloosa)	Traditional	0.000	UG	Jan 06, 2010	Apr 30, 2010	T	2:30 pm - 4:10 pm	Bidgood Hall 373	Crew
17199	MGT 395 901	Managerl Communictn Strategy	Online - Distance Students	Non-Traditional	3.000	UG	Jan 06, 2010	Apr 30, 2010		TBA	Online-all instruction via web	Meyer
10059	MKT 313 003	Consumer Behavior	Main Campus (Tuscaloosa)		3.000	UG	Jan 06, 2010	Apr 30, 2010	MW	3:30 pm - 4:45 pm	Bidgood Hall 379	Mothersbaugh
15019	OM 300 991	Intro Operations Management	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 06, 2010	Apr 30, 2010	TR	5:00 pm - 6:15 pm	Bruno-Bashinsky Library Info 4	Weaver
			Total Credits:	15.000								

RELEASE: 8.7.1

4865-8913-8750.1



11/7/22, 9:50 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2012
Nov 07, 2022 09:49 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification:

Address Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Medical
College: Community Health Sciences
Major and Department: Medicine, Community Health Sciences
Community Health Sciences

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
43104	CHS 701 001	Clinical Clerkship	Main Campus (Tuscaloosa)		18.000	MD	Aug 22, 2012	Dec 07, 2012		TBA	TBA	Gresham
			Total Credits:	**18.000**								

RELEASE: 8.7.1

© 2022 Ellucian Company L.P. and its affiliates.

https://ssb.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1



11/7/22, 9:43 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2013
Nov 07, 2022 09:43 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Iden ifiable Information)
Classification:

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Medical
College: Community Health Sciences
Major and Department: Medicine, Community Health Sciences
Community Health Sciences

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
13131	CHS 702 001	Clinical Clerkship	Main Campus (Tuscaloosa)		18.000	MD	Jan 09, 2013	Apr 26, 2013	MTWRF	8:00 am - 4:00 pm	TBA	Gresham
			Total Credits:	**18.000**								

RELEASE: 8.7.1

https://ssb.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2013
Nov 07, 2022 09:51 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classific

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Medical
College: Community Health Sciences
Major and Department: Medicine, Community Health Sciences
Community Health Sciences

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
42951	CHS 801 001	Clinical Clerkship	Main Campus (Tuscaloosa)		18.000	MD	Aug 21, 2013	Dec 06, 2013	TBA	TBA		Gresham
			Total Credits:	**18.000**								

RELEASE: 8.7.1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2014
Nov 07, 2022 09:52 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification:

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Medical
College: Community Health Sciences
Major and Department: Medicine, Community Health Sciences
Community Health Sciences

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
12957	CHS 802 001	Clinical Clerkship	Main Campus (Tuscaloosa)		18.000	MD	Jan 08, 2014	Apr 25, 2014	MTWRF	8:00 am - 4:00 pm	TBA	Gresham
			Total Credits:	**18.000**								

RELEASE: 8.7.1

Alabama Power

P. O. Box 2641
Birmingham, AL 35291-0024

Tel: 1-800-245-2244

11/4/2022

Ala. Code § 36-12-40 (Personally Identifiable Information)

REF: Ala. Code § 36-12-40 (Personally Identifiable Information)

To Whom It May Concern:

The following information is being provided from our records as requested:

Alabama Power provided electric service to:

Ala. Code § 36-12-40 (Personally Identifiable Information)

Sincerely,

Customer Service
Alabama Power

Alabama Power

P. O. Box 2641
Birmingham, AL 35291-0024

Tel: 1-800-245-2244

11/8/2022

Ala. Code § 36-12-40 (Personally Identifiable Information)

REF: Ala. Code § 36-12-40 (Personally Identifiable Information)

To Whom It May Concern:

The following information is being provided from our records as requested:

Alabama Power provided electric service to:

Ala. Code § 36-12-40 (Personally Identifiable Information)

Sincerely,

Customer Service
Alabama Power

AFFIDAVIT OF [redacted] IN SUPPORT OF
APPLICANT FOR ALABAMA MEDICAL CANNABIS LICENSE.

STATE OF ALABAMA)
[redacted]
)

Before me, the undersigned notary, did appear the Affiant, who after being by me first duly sworn, did state under oath as follows:

1. My name is [redacted] I am the age of nineteen, of sound mind, have personal knowledge of the facts set forth herein, and am otherwise competent to testify. All matters stated herein are true and correct and are based on my personal knowledge.
2. I am currently a resident of [redacted] and have continuously resided in the State of Alabama for the last fifteen (15) years.
3. From 2006 to 2010, I was an undergraduate student at the University of Alabama. My official University of Alabama transcript for the 2006 to 2010 school years is attached hereto as Exhibit A.
4. From 2010 to 2014, I was a medical school student at the University of Alabama at Birmingham School of Medicine. My official University of Alabama at Birmingham academic summary for the 2010 to 2014 school years is attached hereto at Exhibit B.
5. From 2006 to 2014, while attending the University of Alabama and, sequentially, the University of Alabama at Birmingham, I resided [redacted] Attached hereto at Exhibit C is a record of my grades by semester at each university, listing [redacted]
6. From 2014 to pre[redacted]

FURTHER AFFIANT SAYETH NO[redacted]

Sworn to and subscribed before me on this 18th day of November, 2022.

BRAUNAGEL HILL MY COMMISSION EXPIRES FEBRUARY 15, 2026 NOTARY PUBLIC STATE OF ALABAMA

Paige Braunagel Hill
Notary Public

My Commission Expires: _____

My Commission Expires:
February 15, 2026

4865-8913-8750.1

Exhibit A

The University of Alabama

Tuscaloosa, Alabama 35487

OFFICIAL ACADEMIC TRANSCRIPT

Ala. Code § 36-12-40 (Personally Identifiable Information) Ala. Code § 36-12-40 (Personally Identifiable Information)

Date Issued: 07-NOV-2022
Page: 1

Course Level: Undergraduate

Current Program:
B S Commerce Business Admin
College : Business
Major : General Business
Minor : Computer Based Honors Program

Degrees Awarded: B S Commerce Business Admin 08-MAY-2010
Primary Degree:
College : Business
Major : General Business
Minor : Computer Based Honors Program
Inst. Honors: Computer Based Honors Program
cum laude
University Honors Program

SUBJ	NO.	COURSE TITLE	CRED	GRD PTS	R

TRANSFER CREDIT ACCEPTED BY THE INSTITUTION:

FALL 2006 Advanced Placement

BSC	114	PRINCIPLES OF BIOLOGY I	3.000	P
BSC	115	LABORATORY BIOLOGY I	1.000	P
BSC	116	PRINCIPLES BIOLOGY II	3.000	P
BSC	117	BIOLOGY II LABORATORY	1.000	P
HN	101	ENGLISH COMPOSITION	3.000	P
HY	203	AMER CIVILIZATN TO 1865	3.000	P
HY	204	AMER CIVILIZATN SC 1865	3.000	P
MATH	125	CALCULUS I	4.000	P
PSC	101	INTRO AMERICAN POLITICS	3.000	P
Ehrs:		24.000 QPts:	0.000	
GPA-Hrs:		0.000 GPA:	0.000	

Summer 2008 University of Montevallo

PHL	106	CRITICAL THINKING	3.000	A
Ehrs:		3.000 QPts:	12.000	
GPA-Hrs:		3.000 GPA:	4.000	

Spring 2008 CHEA/CLEP credit

EC	111	Prin Of Macroeconomics	3.000	P
LGS	200	Legal Environmt Business	3.000	P
Ehrs:		6.000 QPts:	0.000	
GPA-Hrs:		0.000 GPA:	0.000	

Summer 2008 Shelton State Comm College

MKT	197	Prin of Marketing	3.000	A
Ehrs:		3.000 QPts:	12.000	
GPA-Hrs:		3.000 GPA:	4.000	

********** CONTINUED ON NEXT COLUMN **********

SUBJ	NO.	COURSE TITLE	CRED	GRD PTS	R

INSTITUTION CREDIT:

Fall 2006
Business
Pre-Business

CBH	101	Computer Based Honors	4.000	A	16.000
EC	110	Honors Prin Of Microeconomics	3.000	A	11.010
HN	103	Advanced English Composition	3.000	A	11.010
CHA	145	Freshman Compass: Chs	1.000	P	.000
SP	103	Intensive Review Intro Spanish	4.000	A	16.000
Ehrs:		15.000 QPts:	54.020		
GPA-Hrs:		14.000 GPA:	3.859		

Dean's List
Good Standing

Spring 2007
Business
Pre-Business

CBH	102	Computer Based Honors	4.000	A	16.000
MATH	146	Honors Calculus II	4.000	B	12.000
SP	201	Intermediate Spanish	3.000	B+	9.990
ST	250	Statistical Data Analysis	3.000	A+	12.990
Ehrs:		14.000 QPts:	50.980		
GPA-Hrs:		14.000 GPA:	3.641		

Dean's List
Good Standing

Fall 2007
Business
Pre-Business

AC	210	Intro To Accounting	4.000	B+	13.320
AC	210	Intro To Accounting	0.000	NG	.000
CBH	201	Computer Based Honors	3.000	A	12.000
CBH	425	Comp Based Honors Proj	1.000	A	4.000
GBA	481	Business Honors Seminar I	1.000	A	4.000

********** CONTINUED ON PAGE 2 **********

K.H. Foshee
University Registrar

This transcript processed and delivered by Parchment

4865-8913-8750.1

The University of Alabama

Tuscaloosa, Alabama 35487

OFFICIAL ACADEMIC TRANSCRIPT

Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

Date Issued: 07-NOV-2022

Page: 2

Institution Information continued:

SUBJ	NO.	COURSE TITLE	CRED	GRD	PTS	R
SP	202	Intermediate Spanish	3.000	B+	9.990	
UH	400	Seminar:Honors Field Archeol.	3.000	B+	9.990	
	Ehrs:	15.500 GPEs:	55.300			
	GPA-Hrs:	15.500 GPA:	3.568			
Dean's List						
Good Standing						
Spring 2008						
Business						
Finance						
CHM	202	Computer Based Honors	3.000	A	12.000	
SC	308	Internmd Microcomputation	3.000	B	9.000	
FI	302	Business Finance	3.000	B+	9.990	
FI	302	Laboratory	0.000	NG	.000	
HNA	462	Business Honors Seminar II	1.500	A	6.000	
MATH	227	Calculus III	4.000	B	12.000	
SP	454	Spanish Conversation	3.000	W	.000	
	Ehrs:	16.500 GPEs:	48.990			
	GPA-Hrs:	14.500 GPA:	3.379			
Good Standing						
Summer 2008						
Business						
Finance						
CH	101	General Chemistry	4.000	A	16.000	
CH	101	General Chemistry	0.000	NG	.000	
CH	102	General Chemistry	4.000	B	12.000	
CH	102	General Chemistry	0.000	NG	.000	
	Ehrs:	8.000 GPEs:	28.000			
	GPA-Hrs:	8.000 GPA:	3.500			
Good Standing						
Fall 2008						
Business						

********** CONTINUED ON NEXT COLUMN **********

Term Information continued:

Finance

SUBJ	NO.	COURSE TITLE	CRED	GRD	PTS	R
BSC	306	Cell Biology	3.000	B+	9.990	
CHM	201	Computer Based Honors	3.000	A	12.000	
CH	231	Elem Organic Chemistry I	3.000	B	9.000	
HNA	462	Business Honors Seminar III	1.500	A	6.000	
PH	107	General Physics I	4.000	A-	14.680	
	Ehrs:	14.500 GPEs:	51.670			
	GPA-Hrs:	14.500 GPA:	3.563			
Dean's List						
Good Standing						
Spring 2009						
Business						
Finance						
CHM	390	Computer Based Honors	3.000	A	12.000	
CH	232	Elem Organic Chem II	3.000	A	12.000	
CH	237	Elem Organic Chem Lab I	3.000	B	9.000	
HNA	464	Business Honors Seminar IV	1.500	A	6.000	
MUS	121	Intro To Listening	3.000	A-	12.990	
PH	102	General Physics II	4.000	A-	14.680	
	Ehrs:	16.500 GPEs:	60.670			
	GPA-Hrs:	16.500 GPA:	3.859			
Dean's List						
Good Standing						
Fall 2009						
Business						
General Business						
AC	351	Managerl Accty Decisions	3.000	A	12.000	
EN	207	World Literature I	3.000	A	12.000	
FI	381	Intro Financl Instit Mkt	3.000	A-	11.010	
MGT	300	Org Theory & Behavior	3.000	A	12.000	
MIS	200	Fundamentals Mgt Info Systems	3.000	A-	12.990	

********** CONTINUED ON PAGE 3 **********

K.H. Foshee
University Registrar

This transcript processed and delivered by Parchment

4865-8913-8750.1

The University of Alabama

Tuscaloosa, Alabama 35487

OFFICIAL ACADEMIC TRANSCRIPT

Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

Date Issued: 07-NOV-2022

Page: 3

Level: Undergraduate

SUBJ	NO.	COURSE TITLE	CRED	GRD	GRD PTS	R
Institution Information continued:						
	Khrs:	15.000 QPts:	58.000			
	GPA Hrs:	15.000 GPA:	4.000			
Dean's List						
Good Standing						
Spring 2016						
Business						
General Business						
GBA	490	Strategic Management	3.000	A	12.000	
HCM	370	Intro Health Systems	3.000	A-	11.010	
MGT	385	Managerl Communicte Strategy	0.000	NS	.000	
MGT	385	Managerl Communicte Strategy	3.000	A	11.010	
MKT	315	Consumer Behavior	3.000	A-	11.010	
OM	300	Intro Operations Management	3.000	A-	11.010	
	Khrs:	15.000 QPts:	56.040			
	GPA Hrs:	15.000 GPA:	3.736			
Dean's List						
Good Standing						
********** TRANSCRIPT TOTALS **********						
INSTITUTION	Khrs:	128.000 QPts:	468.670			
	GPA Hrs:	127.000 GPA:	3.690			
TRANSFER	EHrs:	36.000 QPts:	24.000			
	GPA Hrs:	6.000 GPA:	4.000			
OVERALL	EHrs:	164.000 QPts:	492.670			
	GPA Hrs:	133.000 GPA:	3.704			
********** END OF TRANSCRIPT **********						

This transcript processed and delivered by Parchment

K.H. Foshee
University Registrar

4865-8913-8750.1

Exhibit B

University of Alabama School of Medicine
Student Academic Summary

Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

Campus	Class	Type	Status
T	4	MD	Active in Good Standing

			Course #	Course Title	Letter Grade	Raw Score	Weight	Rank*	Weeks
AG	Matriculate		07/26/2010						
	Promoted		06/03/2011						
	07/26/2010 - 12/19/2010	Preclinical-1st year	PCL1130	INTRODUCTION TO CLINICAL MEDICINE I	P	83	6.00	P4	21.00
	07/26/2010 - 08/15/2010	Preclinical-1st year	PCL1100	PATIENT, DOCTOR, & SOCIETY	P		2.00		3.00
	08/16/2010 - 10/17/2010	Preclinical-1st year	PCL1110	FUNDAMENTALS I	P	79	9.00	P4	9.00
	10/25/2010 - 12/19/2010	Preclinical-1st year	PCL1120	FUNDAMENTALS II	P	85	8.00	P3	8.00
	01/03/2011 - 02/06/2011	Preclinical-1st year	PCL1160	CARDIOVASCULAR	P	81	5.00	P4	5.00
	01/03/2011 - 05/29/2011	Preclinical-1st year	PCL1150	INTRODUCTION TO CLINICAL MEDICINE II	P	86	4.00	P4	21.00
	02/07/2011 - 03/13/2011	Preclinical-1st year	PCL1165	PULMONARY	P	87	5.00	P3	5.00
	03/21/2011 - 04/24/2011	Preclinical-1st year	PCL1175	GASTROINTESTINAL	P	79	5.00	P4	5.00
	04/25/2011 - 05/29/2011	Preclinical-1st year	PCL1170	RENAL	P	80	5.00	P4	5.00
	Campus change		10/31/2011						
	Campus change		06/01/2012						
	Promoted		06/01/2012						
	07/25/2011 - 03/25/2012	Preclinical-2nd year	PCL1190	INTRODUCTION TO CLINICAL MEDICINE III	P	85	5.00	P4	32.00
	07/25/2011 - 12/18/2011	Co-enrolled Elective	06-404	HEALTH CARE SYSTEMS	P		0.00		2.00
	08/08/2011 - 09/11/2011	Preclinical-2nd year	PCL1180	MUSCULOSKELETAL & SKIN	P	75	5.00	P4	5.00
	09/12/2011 - 11/20/2011	Preclinical-2nd year	PCL2215	NEUROSCIENCES	P	82	9.00	P4	10.00
	11/21/2011 - 12/18/2011	Preclinical-2nd year	PCL2225	HEMATOLOGY/ONCOLOGY	P	88	4.00	P4	4.00
	01/02/2012 - 01/08/2012	Special Topic	STP2053	DIRECTED RESEARCH CONTINUATION OF SUMMER PROJECT	P		0.00		1.00
	01/09/2012 - 01/15/2012	Special Topic	STP2082	LIFE & PRACTICE IN RURAL ALABAMA	P				1.00
	01/16/2012 - 02/12/2012	Preclinical-2nd year	PCL2235	ENDOCRINE SYSTEMS	P	82	4.00	P4	4.00
	02/13/2012 - 03/04/2012	Preclinical-2nd year	PCL2245	REPRODUCTIVE SYSTEMS	P	90	3.00	P3	3.00
	03/05/2012 - 03/25/2012	Preclinical-2nd year	PCL2255	INTEGRATION	P		3.00		3.00
	04/30/2012 - 05/27/2012	Clerkship	02-302	FAMILY MEDICINE CLERKSHIP	P	88	4.00	P3	4.00
	05/28/2012 - 06/24/2012	Clerkship	03-302	RURAL MEDICINE CLERKSHIP	P		0.00		4.00

rpt009: Student Academic Summary - Generated by: UABdmhardin on: 4/24/2014 5:12:09 PM

4865-8913-8750.1

University of Alabama School of Medicine

Ala. Code § 36-12-40 (Personally Identifiable Information)

Summary

					Campus	Class	Type	Status	
					T	4	MD	Active in Good Standing	
					Letter Grade	Raw Score	Weight	Rank*	Weeks
Promoted			06/07/2013						
	06/25/2012 - 08/19/2012	Clerkship	02-282	MEDICINE CLERKSHIP	P	84	8.00	P4	8.00
	08/20/2012 - 10/14/2012	Clerkship	02-802	SURGERY CLERKSHIP	P	84	8.00	P4	8.00
	10/22/2012 - 12/16/2012	Scholarly Activity	15-102	SCHOLARLY ACTIVITY					8.00
	12/17/2012 - 12/23/2012	Special Topic	STP10105	ONE-WEEK CONTINUATION OF SCHOLARLY ACTIVITY	P				1.00
	01/07/2013 - 03/03/2013	Clerkship	02-402	OBSTETRICS/GYNECOLOGY CLERKSHIP	P	82	8.00	P4	8.00
	03/04/2013 - 03/31/2013	Clerkship	02-682	PSYCHIATRY CLERKSHIP	P	83	4.00	P4	4.00
	04/01/2013 - 04/28/2013	Clerkship	02-352	NEUROLOGY CLERKSHIP	P	84	4.00	P4	4.00
	04/29/2013 - 05/05/2013	Special Topic	STP2084	GENERAL SURGERY	P				1.00
	05/06/2013 - 06/30/2013	Clerkship	02-522	PEDIATRICS CLERKSHIP	P	84	8.00	P4	8.00
	07/01/2013 - 07/28/2013	Elective	80-601	GENERAL/VASCULAR SURGERY - PRINCETON SERVICE	P				4.00
	08/26/2013 - 09/22/2013	Critical Care Al	09-100	EMERGENCY MEDICINE	P				4.00
	09/23/2013 - 10/20/2013	Surgery Al-Inpatient	91-983	GENERAL SURGERY	P				4.00
	10/21/2013 - 10/27/2013	Special Topic	STP10206	NUTRITION SUPPORT	P				1.00
	10/28/2013 - 11/24/2013	Other Al-Ambulatory	30-240	SENIOR RURAL/FAMILY MEDICINE	P				4.00
	11/25/2013 - 12/22/2013	Elective	91-917	GERIATRICS	P				4.00
	01/06/2014 - 02/02/2014	Medicine Al-Inpatient	91-939H	MEDICINE ACTING INTERNSHIP - HOSPITALIST SERVICE	P				4.00
	01/06/2014 - 04/13/2014	Co-enrolled Elective	06-416T	INTERPROFESSIONAL PRACTICE	P				2.00
	02/03/2014 - 03/02/2014	Elective	91-970	EMERGENCY MEDICINE	P				4.00

rpt009: Student Academic Summary - Generated by: UABjdmhardin on: 4/24/2014 5:12:09 PM

Page 2 of 3

4865-8913-8750.1

University of Alabama School of Medicine

[redacted] ary

					Campus	Class	Type	Status	
					T	4	MD	Active in Good Standing	
					Letter Grade	Raw Score	Weight	Rank*	Weeks
	03/03/2014 - 03/30/2014	Elective	91-920	COMMUNITY MEDICINE					4.00

USMLE Step 1

Test Date	Pass Fail	Total Score
04/18/2012	P	210

USMLE Step 2 CK

Test Date	Pass Fail	Total Score
08/20/2013	P	234

USMLE Step 2 CS

Test Date	Pass Fail	Total Score
09/26/2013	P	0

Current Ranking*

	Rank
Pre-Clinical	P4
Clinical	P4
Overall	P4

MCAT

Test Date	Verbal	Physical Science	Writing	Basic Science
06/18/2009	11	9	N	9

These are your grades as recorded on GRASS. This is provided so that you may verify your records. If you have any questions, please contact Room P109 Volker Hall Plaza, Medical Student Services.

* Class rank becomes stable at graduation. Until then, it is a snapshot in time. Ranking is given in quartiles with 1 being the top quartile (top 25%) and 4 being the lowest quartile. Your rank can fluctuate each time raw scores for any person or course are recorded. Rank can also fluctuate when class membership changes and can vary as students begin and return from leaves of absence. Your rank for Pre-Clinical, Clinical and Overall averages and for clerkships is based on students who apply for residency in the same year as you. For pre-clinical courses, your rank is based on the students who took the course with you.

rpt009: Student Academic Summary - Generated by: UABdmhardin on: 4/24/2014 5:12:09 PM

4865-8913-8750.1

Exhibit C

11/7/22, 9:32 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2006
Nov 07, 2022 09:29 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Freshman
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
40994	CBH 101 001	Computer Based Honors	Main Campus (Tuscaloosa)		4.000	UG	Aug 23, 2006	Dec 08, 2006	M	6:00 pm - 6:50 pm	Nott Hall 176	Evans-Young
							Aug 23, 2006	Dec 08, 2006	MWF	1:00 pm - 1:50 pm	Nott Hall 173	Evans-Young
44071	EC 110 007	Honors Prin Of Microeconomics	Main Campus (Tuscaloosa)		3.000	UG	Aug 23, 2006	Dec 08, 2006	TR	9:30 am - 10:45 am	Bidgood Hall 13	Souki
45511	EN 103 012	Advanced English Composition	Main Campus (Tuscaloosa)		3.000	UG	Aug 23, 2006	Dec 08, 2006	TR	3:30 pm - 4:45 pm	Morgan Hall 310	Durant
46049	GBA 145 011	Freshman Compass: Cba	Main Campus (Tuscaloosa)		1.000	UG	Aug 23, 2006	Dec 08, 2006	R	11:00 am - 11:50 am	Bidgood Hall 34	Heggem
44036	SP 103 007	Intensive Review Intro Spanish	Main Campus (Tuscaloosa)	Traditional	4.000	UG	Aug 23, 2006	Dec 08, 2006	MWF	11:00 am - 11:50 am	B B Comer Hall 257	Cristofaro
							Aug 23, 2006	Dec 08, 2006		TBA	TBA	Cristofaro
			Total Credits:	**15.000**								

RELEASE: 8.7.1

https://ssb.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2007
Nov 07, 2022 09:36 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Informa ion)
Classification: Sophomore

Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
30124	CBM 102 001	Computer Based Honors	Main Campus (Tuscaloosa)		4.000	UG	Jan 10, 2007	May 04, 2007	MWF	1:00 pm - 1:50 pm	Nott Hall 173	Evans-Young
							Jan 10, 2007	May 04, 2007	M	6:00 pm - 6:50 pm	Nott Hall 173	Evans-Young
35146	MATH 146 001	Honors Calculus II	Main Campus (Tuscaloosa)	Traditional	4.000	UG	Jan 10, 2007	May 04, 2007	T	6:30 pm - 7:50 pm	TBA	Evans
							Jan 10, 2007	May 04, 2007	MTWR	11:00 am - 11:50 am	Gordon Palmer Hall 226	Evans
32607	SP 201 003	Intermediate Spanish	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 10, 2007	May 04, 2007	MWF	12:00 pm - 12:50 pm	B B Comer Hall 243	Morris
36970	ST 260 003	Statistcl Data Analysis	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 10, 2007	May 04, 2007	TR	8:00 am - 9:15 am	Bidgood Hall 240	Barrett

Total Credits: 14.000

RELEASE: 8.7.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2007
Nov 07, 2022 09:37 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Sophomore
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
40018	AC 210 004	Intro To Accounting	Main Campus (Tuscaloosa)		4.000	UG	Aug 22, 2007	Dec 07, 2007	TR	12:30 pm - 1:45 pm	Bidgood Hall 210	Abernathy
40013	AC 210 010	Intro To Accounting	Main Campus (Tuscaloosa)		0.000	UG	Aug 22, 2007	Dec 07, 2007	F	10:00 am - 10:50 am	Bidgood Hall 210	Piper
43599	CBH 201 004	Computer Based Honors	Main Campus (Tuscaloosa)		3.000	UG	Aug 22, 2007	Dec 07, 2007	R	11:00 am - 11:50 am	TBA	Sharpe
45813	CBH 425 002	Comp Based Honors Proj	Main Campus (Tuscaloosa)		1.000	UG	Aug 22, 2007	Dec 07, 2007	T	8:00 pm - 9:00 pm	Nott Hall 173	Sharpe
45200	GBA 481 001	Business Honors Seminar I	Main Campus (Tuscaloosa)		1.500	UG	Aug 22, 2007	Dec 07, 2007	M	12:00 pm - 12:50 pm	Bidgood Hall 121	Cashman
43483	SP 202 002	Intermediate Spanish	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Aug 22, 2007	Dec 07, 2007	TR	9:30 am - 10:45 am	B B Comer Hall 261	Boris Tarre
46712	UH 300 007	Seminar:Honors Field Archeol	Main Campus (Tuscaloosa)	Non-Traditional	3.000	UG	Aug 22, 2007	Dec 07, 2007	TR	2:00 pm - 4:45 pm	Ten Hoor Hall 27	Knight
			Total Credits:	**15.500**								

RELEASE: 8.7.1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2008
Nov 07, 2022 09:38 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Junior

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Undergraduate
College: Business

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
14553	CBH 202 003	Computer Based Honors	Main Campus (Tuscaloosa)		3.000	UG	Jan 09, 2008	May 02, 2008	W	12:00 pm - 12:50 pm	TBA	Sharpe
13232	EC 308 002	Intermed Microeconomics	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 09, 2008	May 02, 2008	TR	11:00 am - 12:15 pm	Bidgood Hall 310	Jindapon
13461	FI 302 001	Business Finance	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 09, 2008	May 02, 2008	TR	3:30 pm - 4:45 pm	Alston Hall 10	Downs
13466	FI 302 006	Laboratory	Main Campus (Tuscaloosa)		0.000	UG	Jan 09, 2008	May 02, 2008	M	11:00 am - 11:50 am	Bidgood Hall 115	TBA
14907	GBA 482 001	Business Honors Seminar II	Main Campus (Tuscaloosa)		1.500	UG	Jan 09, 2008	May 02, 2008	M	12:00 pm - 12:50 pm	Bidgood Hall 121	Cashman
14310	MATH 227 007	Calculus III	Main Campus (Tuscaloosa)	Traditional	4.000	UG	Jan 09, 2008	May 02, 2008	T	6:30 pm - 7:50 pm	TBA	Moore
							Jan 09, 2008	May 02, 2008	MTWR	1:00 pm - 1:50 pm	Gordon Palmer Hall 228	Moore
12223	SP 353 003	Spanish Conversation	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 09, 2008	May 02, 2008	TR	9:30 am - 10:45 am	B B Comer Hall 259	Toledo
			Total Credits:	**17.500**								

RELEASE: 8.7.1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2008
Nov 07, 2022 09:40 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Iden ifiable Information)
Classification: Senior

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Undergraduate
College: Business

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
42752	BSC 300 001	Cell Biology	Main Campus (Tuscaloosa)		3.000	UG	Aug 20, 2008	Dec 05, 2008	TR	12:30 pm - 1:45 pm	Biology 127	Johnson
43189	CBH 301 004	Computer Based Honors	Main Campus (Tuscaloosa)		3.000	UG	Aug 20, 2008	Dec 05, 2008	R	11:00 am - 11:50 am	TBA	Sharpe
43342	CH 231 002	Elem Organic Chemistry I	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Aug 20, 2008	Dec 05, 2008	TR	9:30 am - 10:45 am	Shelby Hall 151	Snowden
							Aug 20, 2008	Dec 05, 2008	T	6:30 pm - 7:50 pm	Shelby Hall 151	Snowden
44566	GBA 483 001	Business Honors Seminar III	Main Campus (Tuscaloosa)		1.500	UG	Aug 20, 2008	Dec 05, 2008	W	12:00 pm - 12:50 pm	Bidgood Hall 121	Cashman
42618	PH 101 001	General Physics I	Main Campus (Tuscaloosa)		4.000	UG	Aug 20, 2008	Dec 05, 2008	MW	9:00 am - 10:50 am	Gallalee Hall 203	Tipping
							Aug 20, 2008	Dec 05, 2008	F	9:00 am - 9:50 am	Gallalee Hall 203	Tipping

Total Credits: 14.500

RELEASE: 8.7.1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2009
Nov 07, 2022 09:41 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Senior

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Undergraduate
College: Business

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
10094	CBH 302 002	Computer Based Honors	Main Campus (Tuscaloosa)		3.000	UG	Jan 07, 2009	May 01, 2009	W	10:00 am - 10:50 am	TBA	Sharpe
11184	CH 232 001	Elem Organic Chem II	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 07, 2009	May 01, 2009	MWF	9:00 am - 9:50 am	Shelby Hall 107	Shaughnessy
							Jan 07, 2009	May 01, 2009	T	5:00 pm - 6:20 pm	Shelby Hall 107	Shaughnessy
11186	CH 237 001	Elementary Organic Chemistry Laboratory	Main Campus (Tuscaloosa)	Traditional	2.000	UG	Jan 07, 2009	May 01, 2009	M	12:00 pm - 12:50 pm	Shelby Hall 151	Schiel
							Jan 07, 2009	May 01, 2009	M	1:00 pm - 5:50 pm	Shelby Hall L333	Schiel
14413	GBA 484 001	Business Honors Seminar IV	Main Campus (Tuscaloosa)		1.500	UG	Jan 07, 2009	May 01, 2009	W	12:00 pm - 12:50 pm	Bidgood Hall 121	Cashman
11718	MUS 121 006	Intro To Listening	Main Campus (Tuscaloosa)		3.000	UG	Jan 07, 2009	May 01, 2009	TR	11:00 am - 12:15 pm	Moody Music Building 140	Myers
13352	PH 102 001	General Physics II	Main Campus (Tuscaloosa)		4.000	UG	Jan 07, 2009	May 01, 2009	TR	9:00 am - 10:50 am	Gallalee Hall 329	Harrell
							Jan 07, 2009	May 01, 2009	F	10:00 am - 10:50 am	Gallalee Hall 329	Harrell
			Total Credits:	**16.500**								

RELEASE: 8.7.1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2009
Nov 07, 2022 09:44 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Senior
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
41101	AC 351 002	Managerl Acctg Decisions	Main Campus (Tuscaloosa)		3.000	UG	Aug 19, 2009	Dec 04, 2009	TR	3:30 pm - 4:45 pm	Bidgood Hall 379	Robbins
44836	EN 207 001	World Literature I	Main Campus (Tuscaloosa)		3.000	UG	Aug 19, 2009	Dec 04, 2009	MW	3:00 pm - 4:15 pm	Ten Hoor Hall 118	McWaters
43761	FI 301 990	Intro Financl Instit Mkt	Main Campus (Tuscaloosa)		3.000	UG	Aug 19, 2009	Dec 04, 2009	MW	5:00 pm - 6:15 pm	Bidgood Hall 310	McLeod
45736	MGT 300 001	Org Theory & Behavior	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Aug 19, 2009	Dec 04, 2009	TR	2:00 pm - 3:15 pm	TBA	Bachrach
43980	MIS 200 001	Fundamentals Mgt Info Systems	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Aug 19, 2009	Dec 04, 2009	TR	12:30 pm - 1:45 pm	Alston Hall 30	Chau

Total Credits: 15.000

RELEASE: 8.7.1

4865-8913-8750.1

11/7/22, 9:49 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2010
Nov 07, 2022 09:48 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification: Senior
Level: Undergraduate
College: Business

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
10572	GBA 490 004	Strategic Management	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 06, 2010	Apr 30, 2010	TR	11:00 am - 12:15 pm	Bidgood Hall 140	Dulek
17643	HCM 370 003	Intro Health Systems	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 06, 2010	Apr 30, 2010	TR	9:30 am - 10:45 am	Bidgood Hall 117	Williams
10827	MGT 395 008	Managerl Communictn Strategy	Main Campus (Tuscaloosa)	Traditional	0.000	UG	Jan 06, 2010	Apr 30, 2010	T	2:30 pm - 4:10 pm	Bidgood Hall 373	Crew
17199	MGT 395 901	Managerl Communictn Strategy	Online - Distance Students	Non-Traditional	3.000	UG	Jan 06, 2010	Apr 30, 2010		TBA	Online-all instruction via web	Meyer
10059	MKT 313 003	Consumer Behavior	Main Campus (Tuscaloosa)		3.000	UG	Jan 06, 2010	Apr 30, 2010	MW	3:30 pm - 4:45 pm	Bidgood Hall 379	Mothersbaugh
15019	OM 300 991	Intro Operations Management	Main Campus (Tuscaloosa)	Traditional	3.000	UG	Jan 06, 2010	Apr 30, 2010	TR	5:00 pm - 6:15 pm	Bruno-Bashinsky Library Info 4	Weaver
			Total Credits:	**15.000**								

RELEASE: 8.7.1

https://ssb.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2012
Nov 07, 2022 09:49 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification:

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Medical
College: Community Health Sciences
Major and Department: Medicine, Community Health Sciences
Community Health Sciences

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
43104	CHS 701 001	Clinical Clerkship	Main Campus (Tuscaloosa)		18.000	MD	Aug 22, 2012	Dec 07, 2012	TBA	TBA		Gresham
			Total Credits:	**18.000**								

RELEASE: 8.7.1

4865-8913-8750.1

11/7/22, 9:43 PM Concise Student Schedule

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2013
Nov 07, 2022 09:43 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classificatio

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Medical
College: Community Health Sciences
Major and Department: Medicine, Community Health Sciences
Community Health Sciences

CRN	Course Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
13131	CHS 702 001 Clinical Clerkship	Main Campus (Tuscaloosa)		18.000	MD	Jan 09, 2013	Apr 26, 2013	MTWRF	8:00 am - 4:00 pm	TBA	Gresham
		Total Credits:	**18.000**								

RELEASE: 8.7.1

https://ssb.ua.edu/pls/PROD/bwskcrse.P_CrseSchdDetl 1/1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Fall 2013
Nov 07, 2022 09:51 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classificati

Addres Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Medical
College: Community Health Sciences
Major and Department: Medicine, Community Health Sciences
Community Health Sciences

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
42951	CHS 801 001	Clinical Clerkship	Main Campus (Tuscaloosa)		18.000	MD	Aug 21, 2013	Dec 06, 2013		TBA	TBA	Gresham
			Total Credits:	18.000								

RELEASE: 8.7.1

4865-8913-8750.1

Ala. Code § 36-12-40 (Personally Identifiable Information)

Concise Student Schedule

Spring 2014
Nov 07, 2022 09:52 pm

This page lists the classes for which you are registered for the term. All of the detail information about the class is included.

Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Classification:

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Level: Medical
College: Community Health Sciences
Major and Department: Medicine, Community Health Sciences
Community Health Sciences

CRN	Course	Title	Campus	Instructional Method	Credits	Level	Start Date	End Date	Days	Time	Location	Instructor
12957	CHS 802 001	Clinical Clerkship	Main Campus (Tuscaloosa)		18.000	MD	Jan 08, 2014	Apr 25, 2014	MTWRF	8:00 am - 4:00 pm	TBA	Gresham
			Total Credits:	**18.000**								

RELEASE: 8.7.1

4865-8913-8750.1

REDACTED COPY

License Type: Processor

Exhibit 3 – Criminal Background Check

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

The owners and directors of Coosa Medical Manufacturing are:



3.1 Form B: Background Check Applicant Verification

Form B is attached as "Background Check Applicant Verification - Coosa Medical Manufacturing, LLC Attachment to Exhibit 3, Section 3.1"

3.2 Form C: State Background Check (ALEA)

Form C is attached as "Form C State Background Check ALEA- Coosa Medical Manufacturing, LLC Attachment to Exhibit 3, Section 3.2"

3.3 Form D: National Background Check (FBI)

Form D is attached as "Form D National Background Check FBI- Coosa Medical Manufacturing, LLC Attachment to Exhibit 3, Section 3.3"

3.4 Form E: Background Check Individual Verification

Form E is attached as "Background Check Individual Verification- Coosa Medical Manufacturing, LLC Attachment to Exhibit 3, Section 3.4"

Background Check Applicant Verification - Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.1

DocuSign Envelope ID: 75518F33-F06F-4184-84A1-7A9E16A83157

FORM B: BACKGROUND CHECK APPLICANT VERIFICATION

Coosa Medical Manufacturing, LLC — Business License Applicant Name

Processor — License Type

Provide the name and title of each individual identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) (i.e., each owner, shareholder, director, board member, and individual with an economic interest in the Applicant). Attach additional forms if necessary.

NAME	ROLE (select all that apply)
[redacted] Ala. Code § 36-12-40 (Personally Identifiable Information)	☑ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☑ Owner ☐ Shareholder ☑ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☑ Owner ☐ Shareholder ☑ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☑ Owner ☐ Shareholder ☑ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☑ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☑ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☑ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☐ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☐ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant
	☐ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant

Applicant Verification: The undersigned hereby verifies that the individuals listed hereinabove (and attached, as necessary) are all of the individuals identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) with respect to the Applicant. The undersigned further verifies that each individual listed hereinabove (and attached, as necessary) has requested a state criminal background check from the Alabama Law Enforcement Agency (ALEA) and a national criminal background check from the FBI.

David Hardin — Printed Name of Verifying Individual

CEO/Owner — Title of Verifying Individual

David Hardin — Signature of Verifying Individual

12/15/2022 | 8:52 AM PST — Verification Date

Form C State Background Check ALEA- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.2

ALABAMA LAW ENFORCEMENT AGENCY

APPLICATION TO REVIEW ALABAMA CRIMINAL HISTORY RECORD INFORMATION

PERSONAL INFORMATION

Full Name *(First, Middle, Last, Suffi* [redacted] **Sex/Gender:** ■ Male ☐ Female

Aliases/Nickname:

Applicant Current Address [redacted]

City [redacted]

Date of [redacted]

Race: ■ White ☐ Black ☐ Asian ☐ Indian ☐ Other *(please specify)*

Home Phone: ( ) [redacted] **ork Phone:** ( )

WORK INFORMATION

Employer Name: Coosa Medical Manufacturing, LLC **Employer Phone:** [redacted]

Contractor Name: **Contractor Phone:** ( )

State Agency: **Agency Phone:** ( )

Work Email Address:

Job Role/Classification: Owner **Supervisor Name:**

Included with my Release are the following items:

- ☑ Completed Application signed by applicant and **two witnesses *OR* notarized**.
- ☑ The required copy of my valid photo identification.
- ☒ A classifiable copy of my own fingerprints taken by an authorized law enforcement agency as required.
- ☐ ***If applying for state employment/licensure/certification, reference that agency's fee requirements for a backgroundcheck.***
- ☑ ***PERSONAL REQUESTS ONLY:*** **The required $25.00 administrative fee *(must be in the form of a money order or Cashier's check made payable to the ALEA, Criminal Records and Identification Unit).***

AFFIDAVIT FOR RELEASE INFORMATION

I hereby authorize the Alabama Law Enforcement Agency to release any and all criminal history information to:

ALABAMA MEDICAL CANNABIS COMMISSION (AMCC)

Name & Address of Requesting Agency or Authorized Agent*

I, the above referenced individual, hereby request to release any and all criminal history record information (CHRI) maintained by both the Alabama Law Enforcement Agency, the Federal Bureau of Investigation, and any information relating to my past record and character whether it be financial, academic, military, employment, judicial, or personal reference. I hereby release all parties contributing such information from any charges or liability whatsoever because of furnishing said information. By signing below and submitting this application, I hereby verify that the information listed in my application and in the attached documentation is correct. I also acknowledge that I understand that, in accordance with Section 41-9-601 of the Code of Alabama 1975, that any person who willfully requests, obtains or seeks to obtain criminal offender record information under false pretenses, or who willfully communicates or seeks to communicate criminal offender record information to any agency or person without authorization, may be guilty of a felony, and shall be fined not less than $5,000 nor more than $10,000 or imprisoned in the state penitentiary for not more than five years or both. § 41-9-601 Code of Ala. (1975). Furthermore, as set forth at Title 28, Code of Federal Regulations (CFR), Section 16.34 I have the right to challen [redacted]

Applicant Si [redacted]

Name of Wi [redacted]

Address of Witness **Address of Witness**

City, State and Zip **City, State and Zip**

Sworn to and subscribed before me this 8th **day of** November, 2022.

Notary Signature **My Commission Expires** February 15, 2026

PAUL MANGEL HILL NOTARY PUBLIC STATE OF ALABAMA MY COMMISSION EXPIRES FEBRUARY 15, 2026

FOR ALEA OFFICIAL USE ONLY: TCN: SID: AL	Billed: Paid: No Charge:
Received By (Initials): /Date: / / Processed By (Initials): /Date: / /	Check#:
Walk-In/Hand Delivered ☐ Mailed ☐ Status: Initials: Date: / /	Background Check Qty: Total: $
	Certified Letter Qty: Total: $

SBI Form 46 Rev. 10-01-17

Form C State Background Check ALEA- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.2

ALABAMA LAW ENFORCEMENT AGENCY

APPLICATION TO REVIEW ALABAMA CRIMINAL HISTORY RECORD INFORMATION

PERSONAL INFORMATION

Full Name *(First, Mi* Ala. Code § 36-12-40 (Personally Identifiable Information) **Sex/Gender:** ■ Male ☐ Female

Aliases/Nickname

Applicant Current Ala. Code § 36-12-40 (Personally Identifiable Information)

City: Ala. Code § 36-12-40 (Personally Identifiable Information)

Date of Birth Ala. Code § 36-12-40 (Personally Identifiable Information)

Race: ■ White ☐ Black ☐ Asian ☐ Indian ☒ Other *(please specify)* UNKOWN

Home Phone: ( ) **Mobile** Ala. Code § 36-12-40 (Personally Identifiable Information) ( )

WORK INFORMATION

Employer Name: Coosa Medical Manufacturing, LLC **Employer Phone:** Ala. Code § 36-12-40 (Personally Identifiable In

Contractor Name: **Contractor Phone:** ( )

State Agency: **Agency Phone:** ( )

Work Email Address:

Job Role/Classification: Owner **Supervisor Name:**

Included with my Release are the following items:

- ☒ Completed Application signed by applicant and **two witnesses *OR* notarized.**
- ☒ The required copy of my valid photo identification.
- ☒ A classifiable copy of my own fingerprints taken by an authorized law enforcement agency as required.
- ☐ ***If applying for state employment/licensure/certification, reference that agency's fee requirements for a background check.***
- ☒ ***PERSONAL REQUESTS ONLY:*** **The required $25.00 administrative fee *(must be in the form of a money order or Cashier's check made payable to the ALEA, Criminal Records and Identification Unit).***

AFFIDAVIT FOR RELEASE INFORMATION

I hereby authorize the Alabama Law Enforcement Agency to release any and all criminal history information to:

ALABAMA MEDICAL CANNABIS COMMISSION (AMCC)

Name & Address of Requesting Agency or Authorized Agent*

I, the above referenced individual, hereby request to release any and all criminal history record information (CHRI) maintained by both the Alabama Law Enforcement Agency, the Federal Bureau of Investigation, and any information relating to my past record and character whether it be financial, academic, military, employment, judicial, or personal reference. I hereby release all parties contributing such information from any charges or liability whatsoever because of furnishing said information. By signing below and submitting this application, I hereby verify that the information listed in my application and in the attached documentation is correct. I also acknowledge that I understand that, in accordance with Section 41-9-601 of the Code of Alabama 1975, that any person who willfully requests, obtains or seeks to obtain criminal offender record information under false pretenses, or who willfully communicates or seeks to communicate criminal offender record information to any agency or person w for not more than f right to challenge o

Ala. Code § 36-12-40 (Personally Identifiable Information)

Applicant Signa

Name of Witne

Address of Witness **Address of Witness**

City, State and Zip **City, State and Zip**

AMELIA RAE SERBAN
Notary Public - State of New York
NO. 01SE6417771
Qualified in New York County
My Commission Expires May 24, 2025

Sworn to and subscribed before me this 30 **day of** November, 2022.

Notary Signature **My Commission Expires** , 20 .

FOR ALEA OFFICIAL USE ONLY: TCN: **SID: AL**

Received By (Initials): /Date: / / Processed By (Initials): /Date: / /

Walk-in/Hand Delivered ☐ Mailed ☐ Status: Initials: Date: / /

Billed: Paid: No Charge:

Check#:

Background Check Qty: Total: $

Certified Letter Qty: Total: $

SBI Form 46 Rev. 10-01-17

Form C State Background Check ALEA- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.2



ALABAMA LAW ENFORCEMENT AGENCY

APPLICATION TO REVIEW ALABAMA CRIMINAL HISTORY RECORD INFORMATION

PERSONAL INFORMATION

Full Name (First, Middle, [redacted] Sex/Gender: ■ Male ☐ Female

Aliases/Nickname: _____

Applicant Current Add[redacted]

City [redacted]

Dat[redacted]

Race: ■ White ☐ Black ☐ Asian ☐ Indian ☐ Other (please specify) _____

Home Phone: (___) _____ M[redacted]

WORK INFORMATION

Employer Name: Coosa Medical Manufacturing, LLC Employer Phone: [redacted]

Contractor Name: _____ Contractor Phone: (___) _____

State Agency: _____ Agency Phone: (___) _____

Work Email Address: _____

Job Role/Classification: Owner Supervisor Name: _____

Included with my Release are the following items:

- ☑ Completed Application signed by applicant and **two witnesses *OR* notarized**.
- ☑ The required copy of my valid photo identification.
- ☑ A classifiable copy of my own fingerprints taken by an authorized law enforcement agency as required.
- ☐ ***If applying for state employment/licensure/certification, reference that agency's fee requirements for a background check.***
- ☑ ***PERSONAL REQUESTS ONLY:*** **The required $25.00 administrative fee *(must be in the form of a money order or Cashier's check made payable to the ALEA, Criminal Records and Identification Unit).***

AFFIDAVIT FOR RELEASE INFORMATION

I hereby authorize the Alabama Law Enforcement Agency to release any and all criminal history information to:

ALABAMA MEDICAL CANNABIS COMMISSION (AMCC)

Name & Address of Requesting Agency or Authorized Agent*

I, the above referenced individual, hereby request to release any and all criminal history record information (CHRI) maintained by both the Alabama Law Enforcement Agency, the Federal Bureau of Investigation, and any information relating to my past record and character whether it be financial, academic, military, employment, judicial, or personal reference. I hereby release all parties contributing such information from any charges or liability whatsoever because of furnishing said information. By signing below and submitting this application, I hereby verify that the information listed in my application and in the attached documentation is correct. I also acknowledge that I understand that, in accordance with Section 41-9-601 of the Code of Alabama 1975, that any person who willfully requests, obtains or seeks to obtain criminal offender record information under false pretenses, or who willfully communicates or seeks to communicate criminal offender record information to any agency or person without authorization, may be guilty of a felony, and shall be fined not less than $5,000 nor more than $10,000 or imprisoned in the state penitentiary for not more than five ye[redacted] right to challenge or appe[redacted]

Applicant Signature [redacted]

Name of Witness _____ Name of Witness _____

Address of Witness _____ Address of Witness _____

City, State and Zip _____ City, State and Zip _____

Sworn to and subscribed before me this 30 day of November, 2022.

Notary Signature _____ My Commission Expires _____, 20__

AMELIA RAE SERBAN
Notary Public - State of New York
NO. 01SE6417771
Qualified in New York County
My Commission Expires May 24, 2025

FOR ALEA OFFICIAL USE ONLY: TCN: _____ SID: AL _____

Received By (Initials): _____ /Date: ___/___/___ Processed By (initials): _____ /Date: ___/___/___

Walk-In/Hand Delivered ☐ Mailed ☐ Status: _____ Initials: _____ Date: ___/___

Billed: _____ Paid: _____ No Charge: _____

Check#: _____

Background Check Qty: Total: $_____

Certified Letter Qty: Total: $_____

SBI Form 46 Rev. 10-01-17

Form C State Background Check ALEA- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.2

ALABAMA LAW ENFORCEMENT AGENCY

APPLICATION TO REVIEW ALABAMA CRIMINAL HISTORY RECORD INFORMATION

PERSONAL INFORMATION

Full Name *(First, Middle,* Ala. Code § 36-12-40 (Personally Identifiable Information) **Sex/Gender:** ☐ Male ■ Female

Aliases/Nickname:

Applicant Current Addr Ala. Code § 36-12-40 (Personally Identifiable Information)

City: Ala. Code § 36-12-40 (Personally Identifiable Information)

Date of I Ala. Code § 36-12-40 (Personally Identifiable Information)

Race: ■ White ☐ Black ☐ Asian ☐ Indian ☐ Other *(please specify)*

Home Phone: ( ) **Mobil** Ala. Code § 36-12-40 (Personally Identifiable Information)

WORK INFORMATION

Employer Name: Coosa Medical Manufacturing, LLC **Employer Phone:** Ala. Code § 36-12-40 (Personally Identifiable Infor

Contractor Name: **Contractor Phone:** ( )

State Agency: **Agency Phone:** ( )

Work Email Address:

Job Role/Classification: Owner **Supervisor Name:**

Included with my Release are the following items:

- ☑ Completed Application signed by applicant and **two witnesses *OR* notarized.**
- ☒ The required copy of my valid photo identification.
- ☒ A classifiable copy of my own fingerprints taken by an authorized law enforcement agency as required.
- ☐ ***If applying for state employment/licensure/certification, reference that agency's fee requirements for a backgroundcheck.***
- ☒ ***PERSONAL REQUESTS ONLY:* The required $25.00 administrative fee *(must be in the form of a money order or Cashier's check made payable to the ALEA, Criminal Records and Identification Unit).***

AFFIDAVIT FOR RELEASE INFORMATION

I hereby authorize the Alabama Law Enforcement Agency to release any and all criminal history information to:

ALABAMA MEDICAL CANNABIS COMMISSION (AMCC)

Name & Address of Requesting Agency or Authorized Agent*

I, the above referenced individual, hereby request to release any and all criminal history record information (CHRI) maintained by the Alabama Law Enforcement Agency, the Federal Bureau of Investigation, and any information relating to my past record and character whether it be financial, academic, military, employment, judicial, or personal reference. I hereby release all parties contributing such information from any charges or liability whatsoever because of furnishing said information. By signing below and submitting this application, I hereby verify that the information listed in my application and in the attached documentation is correct. I also acknowledge that I understand that, in accordance with Section 41-9-601 of the Code of Alabama 1975, that any person who willfully requests, obtains or seeks to obtain criminal offender record information under false pretenses, or who willfully communicates or seeks to communicate criminal offender record information to any agency or person without authorization, may be guilty of a felony, and shall be fined not less than $5,000 nor more than $10,000 or imprisoned in the penitentiary for not more than five years or both. § 41-9-601, Code of Ala. (1975). Furthermore, as set forth at Title 28, Code of Federal Regulations (CFR), Section 16.34 I have the right to challenge or appeal

TAYLOR GALLUP NOTARY PUBLIC STATE AT LARGE My Comm. Expires May 20, 2026

Applicant Signatur Ala. Code § 36-12-40 (Personally Identifiable Information)

Name of Witness

Address of Witness

City, State and Zip

Sworn to and subscribed before me this 10th **day of** November, 2022

Notary Signature M Taylor Gallup **My Commission Expires** May 20, 2022

FOR ALEA OFFICIAL USE ONLY: TCN: SID: AL	Billed: Paid: No Charge:
Received By (Initials): /Date: / / Processed By (initials): /Date: / /	Check#:
Walk-in/Hand Delivered ☐ Mailed ☐ Status: Initials: Date: / /	Background Check Qty: Total: $
	Certified Letter Qty: Total: $

SBI Form 46 Rev. 10-01-17

REDACTED COPY

Form C State Background Check ALEA- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.2

ALABAMA LAW ENFORCEMENT AGENCY

APPLICATION TO REVIEW ALABAMA CRIMINAL HISTORY RECORD INFORMATION

PERSONAL INFORMATION

Full Name *(First, Middle, Last, Suff* [redacted] **Sex/Gender:** ■ Male ☐ Female

Aliases/Nickname: _____

Applicant Current Add [redacted]

City: [redacted]

Date of Birt [redacted]

Race: ■ White ☐ Black ☐ Asian ☐ Indian ☐ Other *(please specify)* _____

Home Phone: (___) _____ **Mobile Phone:** (___) _____ **W** [redacted]

WORK INFORMATION

Employer Name: Coosa Medical Manufacturing, LLC **Employer Phone:** [redacted]

Contractor Name: _____ **Contractor Phone:** (___) _____

State Agency: _____ **Agency Phone:** (___) _____

Work Email Address: _____

Job Role/Classification: Owner **Supervisor Name:** _____

Included with my Release are the following items:

- ☒ Completed Application signed by applicant and **two witnesses *OR* notarized.**
- ☒ The required copy of my valid photo identification.
- ☒ A classifiable copy of my own fingerprints taken by an authorized law enforcement agency as required.
- ☐ ***If applying for state employment/licensure/certification, reference that agency's fee requirements for a backgroundcheck.***
- ☒ ***PERSONAL REQUESTS ONLY:*** **The required $25.00 administrative fee *(must be in the form of a money order or Cashier's check made payable to the ALEA, Criminal Records and Identification Unit).***

AFFIDAVIT FOR RELEASE INFORMATION

I hereby authorize the Alabama Law Enforcement Agency to release any and all criminal history information to:

ALABAMA MEDICAL CANNABIS COMMISSION (AMCC)

Name & Address of Requesting Agency or Authorized Agent*

I, the above referenced individual, hereby request to release any and all criminal history record information (CHRI) maintained by both the Alabama Law Enforcement Agency, the Federal Bureau of Investigation, and any information relating to my past record and character whether it be fi[illegible] employment, judicial, or personal reference. I hereby release all parties contributing such information from any charges or liability whatsoever because of said information. By signing below and submitting this application, I hereby verify that the information listed in my application and in the attached documentation is correct. I also acknowledge that I understand that, in accordance with Section 41-9-601 of the Code of Alabama 1975, that any person who knowingly requests, obtains or seeks to obtain criminal offender record information under false pretenses, or who willfully communicates or seeks to communicate crimi[illegible] information to any agency or person without authorization, may be guilty of a felony, and shall be fined not less than $5,000 nor more than $10,000 or [illegible] penitentiary for not more than five years or both. § 41-9-601, Code of Ala. (1975). Furthermore, as set forth at Title 28, Code of Federal Regulations [illegible] 16.34 I have the right to challenge or appe

TAYLOR GALLUPS NOTARY PUBLIC ALABAMA STATE AT LARGE My Comm. Expires May 26, 2025

Applicant Signatur [redacted]

Name of Witness [redacted]

Address of Witnes [redacted]

City, State and Zip [redacted]

Sworn to and subscribed before me this 21 **day of** November, 20 22.

Notary Signature M. Taylor Gallups **My Commission Expires** May 26, 2025

FOR ALEA OFFICIAL USE ONLY: TCN: _____ SID: AL _____	Billed: _____ Paid: _____ No Charge: _____
Received By (Initials): _____ /Date: ___/___/___ Processed By (initials): _____ /Date: ___/___/___	Check#: _____
Walk-in/Hand Delivered ☐ Mailed ☐ Status: _____ Initials: _____ Date: ___/___/___	Background Check Qty: Total: $_____
	Certified Letter Qty: Total: $_____

Form C State Background Check ALEA- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.2

ALABAMA LAW ENFORCEMENT AGENCY

APPLICATION TO REVIEW ALABAMA CRIMINAL HISTORY RECORD INFORMATION

PERSONAL INFORMATION

Full Name *(First, Middle, Last, Su* Ala. Code § 36-12-40 (Personally Identifiable Information) **Sex/Gender:** ■ Male ☐ Female

Aliases/Nickname: _____

Applicant Current Addr Ala. Code § 36-12-40 (Personally Identifiable Information)

Cit

Date of Bi Ala. Code § 36-12-40 (Personally Identifiable Information)

Race: ☐ White ■ Black ☐ Asian ☐ Indian ☐ Other *(please specify)* _____

Home Phone: (____) _____ **Mol** Ala. Code § 36-12-40 (Personally Identifiable Information))_____

WORK INFORMATION

Employer Name: Coosa Medical Manufacturing, LLC **Employer Phone:** Ala. Code § 36-12-40 (Personally Identifiable Informa

Contractor Name: _____ **Contractor Phone:** (____) _____

State Agency: _____ **Agency Phone:** (____) _____

Work Email Address: _____

Job Role/Classification: Owner **Supervisor Name:** _____

Included with my Release are the following items:

- ☒ Completed Application signed by applicant and **two witnesses *OR* notarized**.
- ☒ The required copy of my valid photo identification.
- ☒ A classifiable copy of my own fingerprints taken by an authorized law enforcement agency as required.
- ☐ ***If applying for state employment/licensure/certification, reference that agency's fee requirements for a background check.***
- ☒ ***PERSONAL REQUESTS ONLY:* The required $25.00 administrative fee *(must be in the form of a money order or Cashier's check made payable to the ALEA, Criminal Records and Identification Unit).***

AFFIDAVIT FOR RELEASE INFORMATION

I hereby authorize the Alabama Law Enforcement Agency to release any and all criminal history information to:

ALABAMA MEDICAL CANNABIS COMMISSION (AMCC)

Name & Address of Requesting Agency or Authorized Agent*

I, the above referenced individual, hereby request to release any and all criminal history record information (CHRI) maintained by both the Alabama Law Enforcement Agency, the Federal Bureau of Investigation, and any information relating to my past record and character whether it be financial, academic, military, employment, judicial, or personal reference. I hereby release all parties contributing such information from any charges or liability whatsoever because of furnishing said information. By signing below and submitting this application, I hereby verify that the information listed in my application and in the attached documentation is correct. I also acknowledge that I understand that, in accordance with Section 41-9-601 of the Code of Alabama 1975, that any person who willfully requests, obtains or seeks to obtain criminal offender record information under false pretenses, or who willfully communicates or seeks to communicate criminal offender record information to any agency or person without authorization, may be guilty of a felony, and shall be fined not less than $5,000 nor more than $10,000 or imprisoned in the state penitentiary for not more than five years or both. § 41-9-601, Code of Ala. (1975). Furthermore, as set forth at Title 28, Code of Federal Regulations (CFR), Section 16.34 I have the right to challenge or appeal any portion of my state and/or federal CHRI that I believe to be inaccurate (see "Appendix A" for contact information).

Applicant Sign Ala. Code § 36-12-40 (Personally Identifiable Information)

Name of Witn

Address of Wi

City, State and

Sworn to and

Notary Signature_____ **My Commission Expires**_____, 20___.

FOR ALEA OFFICIAL USE ONLY: TCN:_____ **SID: AL**_____	Billed:_____ Paid:_____ No Charge: _____
Received By (Initials):_____/Date:___/___/___ Processed By (Initials):_____/Date:___/___/___	Check#:_____
Walk-in/Hand Delivered ☐ Mailed ☐ Status:_____ Initials:_____ Date: ___/___	Background Check Qty: Total: $_____
	Certified Letter Qty: Total: $_____

SBI Form 46 Rev. 10-01-17

Form C State Background Check ALEA- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.2

ALABAMA LAW ENFORCEMENT AGENCY

APPLICATION TO REVIEW ALABAMA CRIMINAL HISTORY RECORD INFORMATION

PERSONAL INFORMATION

Full Name *(First, Middle, Last, Su* Ala. Code § 36-12-40 (Personally Identifiable Information) **Sex/Gender:** ■ Male ☐ Female

Aliases/Nickname: _____

Applicant Current Ad Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

Race: ☒ White ☐ Black ☐ Asian ☐ Indian ☐ Other *(please specify)* _____

Home Phone: (____) _____ **Mob** Ala. Code § 36-12-40 (Personally Identifiable Information) ____) _____

WORK INFORMATION

Employer Name: Coosa Medical Manufacturing, LLC **Employer Phone:** Ala. Code § 36-12-40 (Personally Identifiable In _____

Contractor Name: _____ **Contractor Phone:** (____) _____

State Agency: _____ **Agency Phone:** (____) _____

Work Email Address: _____

Job Role/Classification: Owner **Supervisor Name:** _____

Included with my Release are the following items:

- ☐ Completed Application signed by applicant and **two witnesses *OR* notarized**.
- ☐ The required copy of my valid photo identification.
- ☐ A classifiable copy of my own fingerprints taken by an authorized law enforcement agency as required.
- ☐ ***If applying for state employment/licensure/certification, reference that agency's fee requirements for a background check.***
- ☐ ***PERSONAL REQUESTS ONLY:* The required $25.00 administrative fee *(must be in the form of a money order or Cashier's check made payable to the ALEA, Criminal Records and Identification Unit).***

AFFIDAVIT FOR RELEASE INFORMATION

I hereby authorize the Alabama Law Enforcement Agency to release any and all criminal history information to:

ALABAMA MEDICAL CANNABIS COMMISSION (AMCC)

Name & Address of Requesting Agency or Authorized Agent*

I, the above referenced individual, hereby request to release any and all criminal history record information (CHRI) maintained by both the Alabama Law Enforcement Agency, the Federal Bureau of Investigation, and any information relating to my past record and character whether it be financial, academic, military, employment, judicial, or personal reference. I hereby release all parties contributing such information from any charges or liability whatsoever because of furnishing said information. By signing below and submitting this application, I hereby verify that the information listed in my application and in the attached documentation is correct. I also acknowledge that I understand that, in accordance with Section 41-9-601 of the Code of Alabama 1975, that any person who willfully requests, obtains or seeks to obtain criminal offender record information under false pretenses, or who willfully communicates or seeks to communicate criminal offender record information to any agency or person without authorization, may be guilty of a felony, and shall be fined not less than $5,000 nor more than $10,000 or imprisoned in the state penitentiary for not more than five years or both. § 41-9-601, Code of Ala. (1975). Furthermore, as set forth at Title 28, Code of Federal Regulations (CFR), Section 16.34 I have the right to challenge or app

Applicant Signatur Ala. Code § 36-12-40 (Personally Identifiable Information)

Name of Witness_

Address of Witnes

City, State and Zip

Sworn to and subscribed before me this____**day of**_____, 20___.

Notary Signature_____ **My Commission Expires**_____, 20___.

FOR ALEA OFFICIAL USE ONLY: TCN:_____ SID: AL_____ Received By (Initials):_____/Date:___/___/___ Processed By (initials):_____/Date:___/___/___ Walk-in/Hand Delivered ☐ Mailed ☐ Status:_____Initials:_____Date: ___/___	Billed:_____Paid:_____No Charge: _____ Check#:_____ Background Check Qty: Total: $_____ Certified Letter Qty: Total: $_____

SBI Form 46 Rev. 10-01-17

Form D National Background Check FBI- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.3

I-783 (Rev. 06-01-2020) OMB-1110-0052

IDENTITY HISTORY SUMMARY REQUEST FORM

Information ** Denotes Required Fields*

*Last Name [redacted]	*First Na[redacted]
Middle Name [redacted]	e Name 2
*Date of Birth: [redacted]	*Place of Birth: [redacted]
*U.S. Citizen or Legal Permanent Resident: ■ Yes ☐ No	
*Country of Citizenship: USA	Country of Residence:
Prisoner Number (if applicable):	
*Last Four Digits of Social Security Nu[redacted]	

*Race *(please check appropriate box)*: ☐ Asian ☐ Black ■ Caucasian ☐ Native American ☐ Unknown

*Sex *(please check appropriate box)*: ■ Male ☐ Female ☐ Other

Address

C/O AMCC	ATTN Background Check
*Address P.O. Box 309585	
*City Montgomery	*State Alabama
*Postal (Zip) Code 36130	*Country USA
Phone Number	E-Mail

Payment Enclosed: *(please check appropriate box)*

☒ CERTIFIED CHECK ☐ MONEY ORDER ☐ CREDIT CARD FORM

You may request a copy of your own Identity History Summary to review it or obtain a change, correction, or an update to the summary. This is not a national background check and may not include information from state repositories which would be included on an employment background check. If you are requesting a background check for employment or licensing within the U.S., you may be required by state statute or federal law to submit your request through your state identification bureau, the requesting federal agency, or another authorized channeling agency.

*** REQUESTOR SIGNATU**[redacted] **DATE** 11/18/22

Mail the signed requestor information form, fingerprint card, and payment of $18 U.S. dollars to the following address:

FBI CJIS Division – Summary Request
1000 Custer Hollow Road
Clarksburg, West Virginia 26306

PRIVACY ACT STATEMENT

The FBI's acquisition, retention, and sharing of information submitted on this form is generally authorized under 28 USC 534 and 28 CFR 16.30-16.34. The purpose for requesting this information from you is to provide the FBI with a minimum of identifying data to permit an accurate and timely search of FBI identification records. Providing this information (including your Social Security Account Number) is voluntary; however, failure to provide the information may affect the completion of your request. The information reported on this form may be disclosed pursuant to your consent and may also be disclosed by the FBI without your consent pursuant to the Privacy Act of 1974 and all applicable routine uses.

PAPERWORK REDUCTION ACT STATEMENT:

Under the Paperwork Reduction Act, you are not required to complete this form unless it contains a valid OMB control number. The form takes approximately 3 minutes to complete.

Form D National Background Check FBI- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.3

I-783 (Rev. 06-01-2020) OMB-1110-0052

IDENTITY HISTORY SUMMARY REQUEST FORM

Information ** Denotes Required Fields*

*Last Name [redacted]	*First Name [redacted]
Middle Name [redacted]	Middle Name 2
[redacted]	*U.S. Citizen or Legal Permanent Resident: ☒ Yes ☐ No
*Country of Citizenship: USA	Country of Residence:
Prisoner Number (if applicable):	
*Last Four Digits of Social Security [redacted]	

*Race *(please check appropriate box)*:
☐ Asian ☐ Black ☒ Caucasian ☐ Native American ☒ Unknown

*Sex *(please check appropriate box)*:
☒ Male ☐ Female ☐ Other

Address

C/O AMCC	ATTN Background Check
*Address P.O. Box 309585	
*City Montgomery	*State Alabama
*Postal (Zip) Code 36130	*Country USA
Phone Number	E-Mail

Payment Enclosed: *(please check appropriate box)*
☒ CERTIFIED CHECK ☐ MONEY ORDER ☐ CREDIT CARD FORM

You may request a copy of your own Identity History Summary to review it or obtain a change, correction, or an update to the summary. This is not a national background check and may not include information from state repositories which would be included on an employment background check. If you are requesting a background check for employment or licensing within the U.S., you may be required by state statute or federal law to submit your request through your state identification bureau, the requesting federal agency, or another authorized cha[redacted]

*** REQUESTOR SIGNATUR[redacted] DATE** 11/30/2022

Mail the signed requestor information form, fingerprint card, and payment of $18 U.S. dollars to the following address:

FBI CJIS Division – Summary Request
1000 Custer Hollow Road
Clarksburg, West Virginia 26306

PRIVACY ACT STATEMENT
The FBI's acquisition, retention, and sharing of information submitted on this form is generally authorized under 28 USC 534 and 28 CFR 16.30-16.34. The purpose for requesting this information from you is to provide the FBI with a minimum of identifying data to permit an accurate and timely search of FBI identification records. Providing this information (including your Social Security Account Number) is voluntary; however, failure to provide the information may affect the completion of your request. The information reported on this form may be disclosed pursuant to your consent and may also be disclosed by the FBI without your consent pursuant to the Privacy Act of 1974 and all applicable routine uses.

PAPERWORK REDUCTION ACT STATEMENT:
Under the Paperwork Reduction Act, you are not required to complete this form unless it contains a valid OMB control number. The form takes approximately 3 minutes to complete.

Form D National Background Check FBI- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.3

I-783 (Rev. 06-01-2020) OMB-1110-0052

IDENTITY HISTORY SUMMARY REQUEST FORM

Information ***Denotes Required Fields***

*Last Nam [redacted]	*First Name [redacted]
Middle Name 1	Middle Name 2
*Date of Birth: [redacted]	*Place of Birth: [redacted]
*U.S. Citizen or Legal Permanent Resident: ■ Yes ☐ No	
*Country of Citizenship: USA	Country of Residence:
Prisoner Number (if applicable):	
*Last Four Digits of Social Security Num [redacted]	

*Race *(please check appropriate box)*:
☐ Asian ☐ Black ■ Caucasian ☐ Native American ☐ Unknown

*Sex *(please check appropriate box)*:
■ Male ☐ Female ☐ Other

Address

C/O AMCC	ATTN Background Check
*Address P.O. Box 309585	
*City Montgomery	*State Alabama
*Postal (Zip) Code 36130	*Country USA
Phone Number	E-Mail

Payment Enclosed: *(please check appropriate box)*

☒ CERTIFIED CHECK ☐ MONEY ORDER ☐ CREDIT CARD FORM

You may request a copy of your own Identity History Summary to review it or obtain a change, correction, or an update to the summary. This is not a national background check and may not include information from state repositories which would be included on an employment background check. If you are requesting a background check for employment or licensing within the U.S., you may be required by state statute or federal law to submit your request through your state identification bureau, the requesting federal agency, or another authorized channeling agency.

*** REQUESTOR SIGNATURE** [redacted] **DATE** 11/30/22

Mail the signed requestor information form, fingerprint card, and payment of $18 U.S. dollars to the following address:

FBI CJIS Division – Summary Request
1000 Custer Hollow Road
Clarksburg, West Virginia 26306

PRIVACY ACT STATEMENT
The FBI's acquisition, retention, and sharing of information submitted on this form is generally authorized under 28 USC 534 and 28 CFR 16.30-16.34. The purpose for requesting this information from you is to provide the FBI with a minimum of identifying data to permit an accurate and timely search of FBI identification records. Providing this information (including your Social Security Account Number) is voluntary; however, failure to provide the information may affect the completion of your request. The information reported on this form may be disclosed pursuant to your consent and may also be disclosed by the FBI without your consent pursuant to the Privacy Act of 1974 and all applicable routine uses.

PAPERWORK REDUCTION ACT STATEMENT:
Under the Paperwork Reduction Act, you are not required to complete this form unless it contains a valid OMB control number. The form takes approximately 3 minutes to complete.

Form D National Background Check FBI- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.3

I-783 (Rev. 06-01-2020) OMB-1110-0052

IDENTITY HISTORY SUMMARY REQUEST FORM

Information ** Denotes Required Fields*

*Last Name: Ala. Code § 36-12-40 (Personally Identifiable Information)	*First Name: Ala. Code § 36-12-40 (Personally Identifiable Information)
Middle Name: Ala. Code § 36-12-40 (Personally Identifiable Information)	Middle Name 2

*Date of Birth: Ala. Code § 36-12-40 (Personally Identifiable Information)	*Place of Birth:	*U.S. Citizen or Legal Permanent Resident: ■ Yes ☐ No
*Country of Citizenship: USA	Country of Residence:	Prisoner Number (if applicable):
*Last Four Digits of Social Security Number: Ala. Code § 36-12-40 (Personally Identifiable Information)		

*Race *(please check appropriate box)*:
☐ Asian ☐ Black ■ Caucasian ☐ Native American ☐ Unknown

*Sex *(please check appropriate box)*:
☐ Male ■ Female ☐ Other

Address

C/O AMCC	ATTN Background Check
*Address: P.O. Box 309585	
*City Montgomery	*State Alabama
*Postal (Zip) Code 36130	*Country USA
Phone Number	E-Mail

Payment Enclosed: *(please check appropriate box)*

☒ CERTIFIED CHECK ☐ MONEY ORDER ☐ CREDIT CARD FORM

You may request a copy of your own Identity History Summary to review it or obtain a change, correction, or an update to the summary. This is not a national background check and may not include information from state repositories which would be included on an employment background check. If you are requesting a background check for employment or licensing within the U.S., you may be required by state statute or federal law to submit your request through your state identification bureau, the requesting federal agency, or another authorized channeling agency.

*** REQUESTOR SIGNATURE** Ala. Code § 36-12-40 (Personally Identifiable Information) **DATE** 11-9-22

Mail the signed requestor information form, fingerprint card, and payment of $18 U.S. dollars to the following address:

FBI CJIS Division – Summary Request
1000 Custer Hollow Road
Clarksburg, West Virginia 26306

PRIVACY ACT STATEMENT
The FBI's acquisition, retention, and sharing of information submitted on this form is generally authorized under 28 USC 534 and 28 CFR 16.30-16.34. The purpose for requesting this information from you is to provide the FBI with a minimum of identifying data to permit an accurate and timely search of FBI identification records. Providing this information (including your Social Security Account Number) is voluntary; however, failure to provide the information may affect the completion of your request. The information reported on this form may be disclosed pursuant to your consent and may also be disclosed by the FBI without your consent pursuant to the Privacy Act of 1974 and all applicable routine uses.

PAPERWORK REDUCTION ACT STATEMENT:
Under the Paperwork Reduction Act, you are not required to complete this form unless it contains a valid OMB control number. The form takes approximately 3 minutes to complete.

Form D National Background Check FBI- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.3

I-783 (Rev. 06-01-2020) OMB-1110-0052

IDENTITY HISTORY SUMMARY REQUEST FORM

Information ** Denotes Required Fields*

*Last Name [redacted]	*First Name [redacted]
Middle Name [redacted]	Middle Name 2
*Date of Birth: [redacted]	*Place of Birth:
*U.S. Citizen or Legal Permanent Resident: ■ Yes ☐ No	
*Country of Citizenship: USA	Country of Residence:
Prisoner Number (if applicable):	
*Last Four Digits of Social Security Num [redacted]	

*Race *(please check appropriate box)*:
☐ Asian ☐ Black ■ Caucasian ☐ Native American ☐ Unknown

*Sex *(please check appropriate box)*:
■ Male ☐ Female ☐ Other

Address

C/O AMCC	ATTN Background Check
*Address P.O. Box 309585	
*City Montgomery	*State Alabama
*Postal (Zip) Code 36130	*Country USA
Phone Number	E-Mail

Payment Enclosed: *(please check appropriate box)*

☒ CERTIFIED CHECK ☐ MONEY ORDER ☐ CREDIT CARD FORM

You may request a copy of your own Identity History Summary to review it or obtain a change, correction, or an update to the summary. This is not a national background check and may not include information from state repositories which would be included on an employment background check. If you are requesting a background check for employment or licensing within the U.S., you may be required by state statute or federal law to submit your request through your state identification bureau, the requesting federal agency, or another authorized channeling agency.

*** REQUESTOR SIGNATURE** [redacted] **DATE** 11/09/22

Mail the signed requestor informat[redacted]U.S. dollars to the following address:

FBI CJIS Division – Summary Request
1000 Custer Hollow Road
Clarksburg, West Virginia 26306

PRIVACY ACT STATEMENT
The FBI's acquisition, retention, and sharing of information submitted on this form is generally authorized under 28 USC 534 and 28 CFR 16.30-16.34. The purpose for requesting this information from you is to provide the FBI with a minimum of identifying data to permit an accurate and timely search of FBI identification records. Providing this information (including your Social Security Account Number) is voluntary; however, failure to provide the information may affect the completion of your request. The information reported on this form may be disclosed pursuant to your consent and may also be disclosed by the FBI without your consent pursuant to the Privacy Act of 1974 and all applicable routine uses.

PAPERWORK REDUCTION ACT STATEMENT:
Under the Paperwork Reduction Act, you are not required to complete this form unless it contains a valid OMB control number. The form takes approximately 3 minutes to complete.

Form D National Background Check FBI- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.3

1-783 (Rev. 06-01-2020) OMB-1110-0052

IDENTITY HISTORY SUMMARY REQUEST FORM

Information ** Denotes Required Fields*

*Last Name [redacted]	*First Name [redacted]
Middle Name [redacted]	

*Date of Birth: [redacted]	*Place of Birth:	*U.S. Citizen or Legal Permanent Resident: ☒ Yes ☐ No
*Country of Citizenship: USA	Country of Residence:	Prisoner Number (if applicable):
*Last Four Digits of Social Security N[redacted]		

*Race *(please check appropriate box)*:
☐ Asian ☒ Black ☐ Caucasian ☐ Native American ☐ Unknown

*Sex *(please check appropriate box)*:
☒ Male ☐ Female ☐ Other

Address

C/O AMCC	ATTN Background Check
*Address P.O. Box 309585	
*City Montgomery	*State Alabama
*Postal (Zip) Code 36130	*Country USA
Phone Number	E-Mail

Payment Enclosed: *(please check appropriate box)*
☒ CERTIFIED CHECK ☐ MONEY ORDER ☐ CREDIT CARD FORM

You may request a copy of your own Identity History Summary to review it or obtain a change, correction, or an update to the summary. This is not a national background check and may not include information from state repositories which would be included on an employment background check. If you are requesting a background check for employment or licensing within the U.S., you may be required by state statute or federal law to submit your request through your state identification bureau, the requesting federal agency, or another authorized channeling agency.

*** REQUESTOR SIGNATURE** [redacted] **DATE** 11/30/22

Mail the signed requestor information form, fingerprint card, and payment of $18 U.S. dollars to the following address:

FBI CJIS Division – Summary Request
1000 Custer Hollow Road
Clarksburg, West Virginia 26306

PRIVACY ACT STATEMENT
The FBI's acquisition, retention, and sharing of information submitted on this form is generally authorized under 28 USC 534 and 28 CFR 16.30-16.34. The purpose for requesting this information from you is to provide the FBI with a minimum of identifying data to permit an accurate and timely search of FBI identification records. Providing this information (including your Social Security Account Number) is voluntary; however, failure to provide the information may affect the completion of your request. The information reported on this form may be disclosed pursuant to your consent and may also be disclosed by the FBI without your consent pursuant to the Privacy Act of 1974 and all applicable routine uses.

PAPERWORK REDUCTION ACT STATEMENT:
Under the Paperwork Reduction Act, you are not required to complete this form unless it contains a valid OMB control number. The form takes approximately 3 minutes to complete.

REDACTED COPY

Form D National Background Check FBI- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.3

OMB-1110-0052

I-783 (Rev. 06-01-2010)

IDENTITY HISTORY SUMMARY REQUEST FORM

Information * *Denotes Required Fields*

*Last Name [redacted] *First Name [redacted]

Middle Name [redacted]

*Date of Birth: [redacted] *Place of Birth: [redacted] *U.S. Citizen or Legal Permanent Resident: ■ Yes ☐ No

*Country of Citizenship: USA Country of Residence: USA Prisoner Number (if applicable):

*Last Four Digits of Social Security N [redacted]

*Race *(please check appropriate box)*: ☐ Asian ☐ Black ☑ Caucasian ☐ Native American ☐ Unknown

*Sex *(please check appropriate box)*: ■ Male ☐ Female ☐ Other

Address

C/O AMCC ATTN Background Check

*Address P.O. Box 309585

*City Montgomery *State Alabama

*Postal (Zip) Code 36130 *Country USA

Phone Number E-Mail

Payment Enclosed: *(please check appropriate box)*

☐ CERTIFIED CHECK ☐ MONEY ORDER ☐ CREDIT CARD FORM

You may request a copy of your own Identity History Summary to review it or obtain a change, correction, or an update to the summary. This is not a national background check and may not include information from state repositories which would be included on an employment background check. If you are requesting a background check for employment or licensing within the U.S., you may be required by state statute or federal law to submit your request through your state identification bureau, the requesting federal agency, or another authorized channeling agency.

* REQUESTOR SIGNATUR [redacted] DATE 12-19-22

Mail the signed requestor information form, fingerprint card, and payment of $18 U.S. dollars to the following address:

FBI CJIS Division – Summary Request
1000 Custer Hollow Road
Clarksburg, West Virginia 26306

PRIVACY ACT STATEMENT
The FBI's acquisition, retention, and sharing of information solicited on this form is generally authorized under 28 USC 534 and 28 CFR 16.30-16.34. The purpose for requesting this information from you is to provide the FBI with a minimum of identifying data to permit an accurate and timely search of FBI identification records. Providing this information (including your Social Security Account Number) is voluntary; however, failure to provide the information may affect the completion of your request. The information reported on this form may be disclosed pursuant to your consent and may also be disclosed by the FBI without your consent pursuant to the Privacy Act of 1974 and all applicable routine uses.

PAPERWORK REDUCTION ACT STATEMENT:
Under the Paperwork Reduction Act, you are not required to complete this form unless it contains a valid OMB control number. The form takes approximately 3 minutes to complete.

Background Check Individual Verification- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.4

FORM E: BACKGROUND CHECK INDIVIDUAL VERIFICATION

Each individual identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) (i.e., each owner, shareholder, director, board member, and individual with an economic interest in the Applicant) must complete a separate form.

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)

Individual's Role (select all that apply): ☑ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant

Verification

The undersigned, as identified above, hereby verifies all of the following:

- That the individual's role(s) in the Applicant's business is one or more of the roles identified by § 20-2A-55(b), Code of Alabama 1975 (as amended).
- That the individual shall, as required by § 20-2A-55(b), Code of Alabama 1975 (as amended), submit to a state and national criminal background check, to be conducted and/or coordinated by the Alabama Law Enforcement Agency.
- That the individual has submitted its completed state criminal background check application form (ALEA SBI Form 46), and all other items required therewith, to ALEA
- That the individual has submitted its national criminal background check form (FBI Identity History Summary Request Form), and all other items required therewith, to the FBI.
- That the individual, on his/her state and national background check forms, has authorized ALEA and the FBI, as applicable, to release any and all criminal history information of the individual to the Alabama Medical Cannabis Commission.
- That the individual will promptly respond to any request from ALEA, the FBI, and/or the Alabama Medical Cannabis Commission regarding the processing of the individual's state and national criminal background checks.
- That the individual has confirmed that his/her name and role(s) have been included, by the Applicant, on the Background Check Applicant Verification Form.

Ala. Code § 36-12-40 (Personally Identifiable Information)

11/30/2022
Verification Date

Background Check Individual Verification- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.4

FORM E: BACKGROUND CHECK INDIVIDUAL VERIFICATION

Each individual identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) (i.e., each owner, shareholder, director, board member, and individual with an economic interest in the Applicant) must complete a separate form.

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual's Name

Individual's Role (select all that apply): ☑ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant

Verification

The undersigned, as identified above, hereby verifies all of the following:

- That the individual's role(s) in the Applicant's business is one or more of the roles identified by § 20-2A-55(b), Code of Alabama 1975 (as amended).
- That the individual shall, as required by § 20-2A-55(b), Code of Alabama 1975 (as amended), submit to a state and national criminal background check, to be conducted and/or coordinated by the Alabama Law Enforcement Agency.
- That the individual has submitted its completed state criminal background check application form (ALEA SBI Form 46), and all other items required therewith, to ALEA
- That the individual has submitted its national criminal background check form (FBI Identity History Summary Request Form), and all other items required therewith, to the FBI.
- That the individual, on his/her state and national background check forms, has authorized ALEA and the FBI, as applicable, to release any and all criminal history information of the individual to the Alabama Medical Cannabis Commission.
- That the individual will promptly respond to any request from ALEA, the FBI, and/or the Alabama Medical Cannabis Commission regarding the processing of the individual's state and national criminal background checks.
- That the individual has confirmed that his/her name and role(s) have been included, by the Applicant, on the Background Check Applicant Verification Form.

Ala. Code § 36-12-40 (Personally Identifiable Information)
Signature of Verifying Individual

11/30/22
Verification Date

Background Check Individual Verification- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.4

FORM E: BACKGROUND CHECK INDIVIDUAL VERIFICATION

Each individual identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) (i.e., each owner, shareholder, director, board member, and individual with an economic interest in the Applicant) must complete a separate form.

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

[redacted] Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual's Name

Individual's Role (select all that apply): ☑ Owner ☐ Shareholder ☑ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant

Verification

The undersigned, as identified above, hereby verifies all of the following:

- That the individual's role(s) in the Applicant's business is one or more of the roles identified by § 20-2A-55(b), Code of Alabama 1975 (as amended).
- That the individual shall, as required by § 20-2A-55(b), Code of Alabama 1975 (as amended), submit to a state and national criminal background check, to be conducted and/or coordinated by the Alabama Law Enforcement Agency.
- That the individual has submitted its completed state criminal background check application form (ALEA SBI Form 46), and all other items required therewith, to ALEA
- That the individual has submitted its national criminal background check form (FBI Identity History Summary Request Form), and all other items required therewith, to the FBI.
- That the individual, on his/her state and national background check forms, has authorized ALEA and the FBI, as applicable, to release any and all criminal history information of the individual to the Alabama Medical Cannabis Commission.
- That the individual will promptly respond to any request from ALEA, the FBI, and/or the Alabama Medical Cannabis Commission regarding the processing of the individual's state and national criminal background checks.
- That the individual has confirmed that his/her name and role(s) have been included, by the Applicant, on the Background Check Applicant Verification Form.

[redacted] Ala. Code § 36-12-40 (Personally Identifiable Information)
Signature of Verifying Individual

11. 7. 22
Verification Date

Background Check Individual Verification- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.4

FORM E: BACKGROUND CHECK INDIVIDUAL VERIFICATION

Each individual identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) (i.e., each owner, shareholder, director, board member, and individual with an economic interest in the Applicant) must complete a separate form.

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual's Name

Individual's Role (select all that apply): ☑ Owner ☐ Shareholder ☑ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant

Verification

The undersigned, as identified above, hereby verifies all of the following:

- That the individual's role(s) in the Applicant's business is one or more of the roles identified by § 20-2A-55(b), Code of Alabama 1975 (as amended).
- That the individual shall, as required by § 20-2A-55(b), Code of Alabama 1975 (as amended), submit to a state and national criminal background check, to be conducted and/or coordinated by the Alabama Law Enforcement Agency.
- That the individual has submitted its completed state criminal background check application form (ALEA SBI Form 46), and all other items required therewith, to ALEA
- That the individual has submitted its national criminal background check form (FBI Identity History Summary Request Form), and all other items required therewith, to the FBI.
- That the individual, on his/her state and national background check forms, has authorized ALEA and the FBI, as applicable, to release any and all criminal history information of the individual to the Alabama Medical Cannabis Commission.
- That the individual will promptly respond to any request from ALEA, the FBI, and/or the Alabama Medical Cannabis Commission regarding the processing of the individual's state and national criminal background checks.
- That the individual has confirmed that his/her name and role(s) have been included, by the Applicant, on the Background Check Applicant Verification Form.

Ala. Code § 36-12-40 (Personally Identifiable Information)
Signature of Verifying Individual

11/09/22
Verification Date

Background Check Individual Verification- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.4

FORM E: BACKGROUND CHECK INDIVIDUAL VERIFICATION

Each individual identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) (i.e., each owner, shareholder, director, board member, and individual with an economic interest in the Applicant) must complete a separate form.

Coosa Medical Manufacturing, LLC — Business License Applicant Name

Processor — License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)

Individual's Name

Individual's Role (select all that apply): ☑ Owner ☐ Shareholder ☑ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant

Verification

The undersigned, as identified above, hereby verifies all of the following:

- That the individual's role(s) in the Applicant's business is one or more of the roles identified by § 20-2A-55(b), Code of Alabama 1975 (as amended).
- That the individual shall, as required by § 20-2A-55(b), Code of Alabama 1975 (as amended), submit to a state and national criminal background check, to be conducted and/or coordinated by the Alabama Law Enforcement Agency.
- That the individual has submitted its completed state criminal background check application form (ALEA SBI Form 46), and all other items required therewith, to ALEA
- That the individual has submitted its national criminal background check form (FBI Identity History Summary Request Form), and all other items required therewith, to the FBI.
- That the individual, on his/her state and national background check forms, has authorized ALEA and the FBI, as applicable, to release any and all criminal history information of the individual to the Alabama Medical Cannabis Commission.
- That the individual will promptly respond to any request from ALEA, the FBI, and/or the Alabama Medical Cannabis Commission regarding the processing of the individual's state and national criminal background checks.
- That the individual has confirmed that his/her name and role(s) have been included, by the Applicant, on the Background Check Applicant Verification Form.

Ala. Code § 36-12-40 (Personally Identifiable Information)

Signature of Verifying Individual

11/18/22

Verification Date

Background Check Individual Verification- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.4

FORM E: BACKGROUND CHECK INDIVIDUAL VERIFICATION

Each individual identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) (i.e., each owner, shareholder, director, board member, and individual with an economic interest in the Applicant) must complete a separate form.

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

[redacted] Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual's Name

Individual's Role (select all that apply): ☑ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant

Verification

The undersigned, as identified above, hereby verifies all of the following:

- That the individual's role(s) in the Applicant's business is one or more of the roles identified by § 20-2A-55(b). Code of Alabama 1975 (as amended)
- That the individual shall, as required by § 20-2A-55(b), Code of Alabama 1975 (as amended), submit to a state and national criminal background check, to be conducted and/or coordinated by the Alabama Law Enforcement Agency.
- That the individual has submitted its completed state criminal background check application form (ALEA SBI Form 46), and all other items required therewith, to ALEA
- That the individual has submitted its national criminal background check form (FBI Identity History Summary Request Form), and all other items required therewith, to the FBI.
- That the individual, on his/her state and national background check forms, has authorized ALEA and the FBI, as applicable, to release any and all criminal history information of the individual to the Alabama Medical Cannabis Commission.
- That the individual will promptly respond to any request from ALEA, the FBI, and/or the Alabama Medical Cannabis Commission regarding the processing of the individual's state and national criminal background checks.
- That the individual has confirmed that his/her name and role(s) have been included, by the Applicant, on the Background Check Applicant Verification Form.

[redacted] Ala. Code § 36-12-40 (Personally Identifiable Information)
Signature of Verifying Individual

12/6/2022
Verification Date

Background Check Individual Verification- Coosa Medical Manufacturing, LLC

Attachment to Exhibit 3, Section 3.4

FORM E: BACKGROUND CHECK INDIVIDUAL VERIFICATION

Each individual identified by § 20-2A-55(b), Code of Alabama 1975 (as amended) (i.e., each owner, shareholder, director, board member, and individual with an economic interest in the Applicant) must complete a separate form.

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Ala. Code § 36-12-40 (Personally Identifiable Information)
Individual's Name

Individual's Role (select all that apply): ☑ Owner ☐ Shareholder ☐ Director ☐ Board Member ☐ Individual with Economic Interest in Applicant

Verification

The undersigned, as identified above, hereby verifies all of the following:

- That the individual's role(s) in the Applicant's business is one or more of the roles identified by § 20-2A-55(b), Code of Alabama 1975 (as amended).
- That the individual shall, as required by § 20-2A-55(b), Code of Alabama 1975 (as amended), submit to a state and national criminal background check, to be conducted and/or coordinated by the Alabama Law Enforcement Agency.
- That the individual has submitted its completed state criminal background check application form (ALEA SBI Form 46), and all other items required therewith, to ALEA
- That the individual has submitted its national criminal background check form (FBI Identity History Summary Request Form), and all other items required therewith, to the FBI.
- That the individual, on his/her state and national background check forms, has authorized ALEA and the FBI, as applicable, to release any and all criminal history information of the individual to the Alabama Medical Cannabis Commission.
- That the individual will promptly respond to any request from ALEA, the FBI, and/or the Alabama Medical Cannabis Commission regarding the processing of the individual's state and national criminal background checks.
- That the individual has confirmed that his/her name and role(s) have been included, by the Applicant, on the Background Check Applicant Verification Form.

Ala. Code § 36-12-40 (Personally Identifiable Information)
Signature of Verifying Individual

12-19-22
Verification Date

REDACTED COPY

License Type: Processor

Exhibit 4 – Demonstration of Sufficient Capital

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

License Type: Processor

Coosa Medical Manufacturingl Dispensaries
17 20th North Street Suite 300
Birmingham, AL 35203

December 9, 2022

To Whom It May Concern,

Coosa Medical Manufacturingl Dispensaries, LLC (the "Company") has liquidity of approximately Ala. Code § 36-12-40 (Private Financial Information) Additionally, the Company has access to debt capital in an amount of Ala. Code § 36-12-40 (Private Financial Information) Ala. Code § 36-12-40 (Private Financial Information) in the medical cannabis market.

This Ala. Code § 36-12-40 (Private Financial Information) is more than sufficient to cover the combined budgets for the first three years of operation of Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information) in liquid capital from their earnings in Ala. Code § 36-12-40 (Private Financial Information) in liquid capital from Ala. Code § 36-12-40 (Private Financial Information) business. Ala. Code § 36-12-40 (Private Financial Information) .

There is a 5 page limit to this document which prevents Coosa from providing the actual bank statements for all of the liquidity but Coosa is happy to provide these documents at the request of the commission. Below are the bank names and account balances Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Also attached are the demonstrations of sufficient capital and verification of the funds existence by Independent Certified Public Accountants.

Sincerely,

Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Private Financial Information)

November 29, 2022

To whom it may concern:

This letter is to confirm Ala. Code § 36-12-40 (Private Financial Information) since June 2016. As of the date of this letter, Ala. Code § 36-12-40 (Private Financial Information)

It has been my pleasure to have Ala. Code § 36-12-40 (Private Financial Information)

Please do not hesitate to Ala. Code § 36-12-40 (Private Financial Information).

Sincerely,

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

12/13/2022

Ala. Code § 36-12-40 (Private Financial Information)

Dear Ala. Code § 36-12-40 (Private Financial Information)

Please accept this letter as confirmation that as of market close on 12/12/2022, you held a balance in excess of Ala. Code § 36-12-40 (Private Financial Information) The balance is based on the total market value of all positions in the account, including core, minus any outstanding debit balances and any amount required to cover short option positions that are in-the-money.

You may withdraw any amount up to and including the full value of the account(s), pending the settlement of any applicable liquidating trade transactions. Account value(s) may change due to factors such as market conditions or customer activities; therefore, the amount available to withdraw may differ from the value provided above.

Per IRS regulations, withdrawals from an IRA made prior to age 59½ may be subject to a 10% early withdrawal penalty. Please consult a tax advisor to review your individual situation.

I hope you find this information helpful. If you have any questions, Ala. Code § 36-12-40 (Private Financial Information) Ala. Code § 36-12-40 (Private Financial Information)

Sincerely,

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

December 9, 2022

RE: Proof of Funds

To whom it may concern,

This letter it to certify that Ala. Code § 36-12-40 (Private Financial Information) since 2021 and is in a good standing.

The company has a total funding commitment Ala. Code § 36-12-40 (Private Financial Information) remaining Ala. Code § 36-12-40 (Private Financial Information). The availability is subject to certain term and conditions.

If you require any further information, please do not hesitate Ala. Code § 36-12-40 (Private Financial Information) Ala. Code § 36-12-40 (Private Financial Information)

Sincerely,

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

December 2, 2022

Coosa Medical Manufacturing LLC:

Ala. Code § 36-12-40 (Private Financial Information)

This is to advise you that Ala. Code § 36-12-40 (Private Financial Information) current fund in subscriptions. These funds are available where the capital will be called upon in the manner necessary in order to consummate the loan for the financing to Coosa Medical Manufacturing LLC. Please allow this to serve as my attestation to support the Ala. Code § 36-12-40 (Private Financial Information) Ala. Code § 36-12-40 (Private Financial Information) nd their ability to execute on said transaction. This transaction will not affect the operations nor the financial stability Ala. Code § 36-12-40 (Private Financial Information)

Thank you very much for your time and attention to these matters; please feel free to contact me if you have any further questions.

Very truly yours,

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

License Type: Proc Ala. Code § 36-12-40 (Private Financial Information)

CONFIDENTIAL

December 2, 2022

Coosa Medical Manufacturing LLC

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Thank you for sharing the details and allowing us to provide a Letter of Intent for Coosa Medical Manufacturing LLC ("Borrower" or "Company"). Set forth below are the preliminary principal non-binding terms and conditions under Ala. Code § 36-12-40 (Private Financial Information) proposes to provide a Loan (the "Transaction" or "Loan"). Ala. Code § 36-12-40 (Private Financial Information) shall work with the Company to begin due-diligence and will begin to draft final Agreements.

1.	**Terms and Letter of Intent**	Contemplated terms of the Loan are reflected below: Borrower: Coosa Medical Manufacturing LLC Ala. Code § 36-12-40 (Private Financial Information) Use of Proceeds: The proceeds may be used for general business purposes. This Loan is not intended to act as a personal or individual loan to the above named. Ala. Code § 36-12-40 (Private Financial Information) Amortization: The Loan will be an interest only loan, with no amortization prior to the term of the loan. Upon maturity, the entire Loan Amount Ala. Code § 36-12-40 (Private Financial Information) balloon payment. Ala. Code § 36-12-40 (Private Financial Information) Funding: The Loan will be funded at closing, in an exact amount up to Loan Amount determined by Borrower after the Borrower is issued a State of Alabama Processing License. Ala. Code § 36-12-40 (Private Financial Information) Ala. Code § 36-12-40 (Private Financial Information)
2.	**Confidentiality**	The parties mutually agree that all information and/or documents reviewed by the recipient or given to the recipient belong to the disclosure of such information and are to be treated as highly confidential. The parties agree that it shall at all times do everything that is necessary to safeguard the said confidentiality and it shall not divulge the confidential information to any third party (other than the recipient's advisors) and further agree that it shall not use the confidential information in any manner whatsoever, be it directly or indirectly, in the event that the Transaction is not concluded Ala. Code § 36-12-40 (Private Financial Information) will share limited information regarding the property to its prospective limited partners with regard to syndicating the property or portfolio of properties. Lastly, Company agrees Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

3.	**Expenses**	1. The expenses incurred by each party in connection with the Transaction shall be paid by the respective party. Ala. Code § 36-12-40 (Private Financial Information) for by the Company shall be presented to, reviewed by and approved in advance of spending. 2. Transaction fees will be included in the Loan Amount list above and deducted from proceeds at closing.
5.	**Non-Binding Agreement**	The matters set forth in this letter agreement constitutes an expression of the parties' mutual intent only and do not constitute a binding agreement among the parties with respect to the Transaction (or any other proposed transaction) or otherwise impose any obligations on the parties. Any such obligation shall only arise upon execution and delivery by the parties of a Definitive Agreement with respect to the Transaction, and only to the extent provided therein. No party may bring any claim or action against any other party as a result of a failure to agree on or enter into a Definitive Agreement as contemplated hereby. Without limiting the foregoing, the provisions of this letter agreement are subject Ala. Code § 36-12-40 (Private Financial Information) Except with respect to Paragraph 2 and 3 which is intended to be binding between the parties, this letter agreement is a non-binding expression of the parties' present interest and does not create legally binding obligations between the parties.
6.	**Counterparts**	This letter agreement may be executed in one or more counterparts which may be delivered by facsimile transmission, each of which will be deemed to be an original and all of which, taken together, will constitute one and the same agreement. The term "including" shall have the inclusive meaning of "including without limitation" in this letter.
7.	**Closing / Lease Payments**	Lease payments shall commence immediately upon closing which will occur only upon possession of property after the Conditional Use Permit is issued.

See signatures on following page

Ala. Code § 36-12-40 (Private Financial Information)

Acknowledged and Agreed as of December 2, 2022:

Coosa Medical Manufacturing LLC

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

December 12, 2022

To Whom It May Concern:

I am writing to you in response to a request from our client Ala. Code § 36-12-40 (Private Financial Information) client of our firm since 2012. Based on review of asset balance letters Ala. Code § 36-12-40 (Private Financial Information) Ala. Code § 36-12-40 (Private Financial Information), I confirm Ala. Code § 36-12-40 (Private Financial Information) brokerage and retirement accounts in excess of Ala. Code § 36-12-40 (Private Financial Information).

Should you need any further information, please let me know.

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)ype: Processor

December 27, 2022

Re: Ala. Code § 36-12-40 (Private Financial Information)

Dear Sirs:

This letter is to inform you Ala. Code § 36-12-40 (Private Financial Information) exceeding Ala. Code § 36-12-40 (Private Financial Information) have been a client of ours more than forty years. They should qualify as an accredited investor as defined by rule 501 of the Securities Act.

Should you need any information, please do not hesitate to contact me.

Sincerely yours,

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

December 22, 2022

To Whom it May Concern:

Ala. Code § 36-12-40 (Private Financial Information) has reported income from accounts Ala. Code § 36-12-40 (Private Financial Information) Ala. Code § 36-12-40 (Private Financial Information) filed for the tax year ended December 31, 2021, and is up to date with income tax compliance requirements for these accounts.

Please contact us if you have any questions or need additional information.

Sincerely,

Ala. Code § 36-12-40 (Private Financial Information)

Ala. Code § 36-12-40 (Private Financial Information)

License Type: Processor

Exhibit 5 – Financial Statements

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

5.1 – Balance sheet report, providing a snapshot of the value of assets, liabilities and equity at commencement, or for projections, as of December 31 of each year.

Below we detail quarterly financials for the company assuming a start date in July 2023 with initial sales in January 2024. Our forecast assumes $4m equity, alongside $2.7m in debt funding to help fund capital expenditures as well as support working capital needs. During the first 4 months we plan to scale the facility to its full capacity of 12,000 square feet. We intend to produce topicals, gelatins, tinctures, and suppositories with the optionality of expanding into other form factors as state law permits. For conservatism, we do not incorporate other form factors into our forecast as this juncture. In our model, we assume the price of flower declines throughout our forecast as more cultivators come online and compete for market share. Based on our experience in several other medical marijuana markets, we intend to price the products based on milligrams of THC per product ranging from $0.14 - $0.20 cents per milligram. While we are confident we will garner more than the implied market share based on our combined several decades of experience in limited license medical marijuana markets, we were cautious in our forward looking TAM and only incorporated a uniform market share based on the total manufacturers in the state. In other words, we assume all manufacturers have equal market share.

On an annual basis, our model assumes we are EBITDA positive in 2025 and free cash flow positive in 2026, aided by gross margins that we expect to expand from 35% in 2024 to 51% in 2028 driven by operating efficiencies and a decrease in the price of certain input costs to include bulk flower. Moreover, we expect to gain operating leverage as our facility matures bolstering EBITDA margin towards 32% in 2028.

The projected cash balance underscores our ability to withstand the start up costs associated with the build out and initial working capital requirements ahead of the first revenue generation event in January 2024. Moreover, we incorporate annual inflationary assumptions on input and labor costs where appropriate to ensure our business can withstand additional stress.

Balance Sheet

	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F
	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26	3Q26	4Q26	1Q27	2Q27	3Q27	4Q27	1Q28	2Q28	3Q28	4Q28
Cash	4,829,811	3,727,685	2,432,344	2,762,970	2,163,537	2,384,097	1,186,800	1,712,540	1,627,308	1,506,632	941,315	1,643,516	1,062,244	1,596,573	541,442	1,481,627	1,395,821	1,609,346	1,124,988	2,251,160	1,700,982	2,694,449
Accounts Receivable	0	0	178,187	171,989	258,242	450,890	237,582	229,319	344,322	601,187	296,978	286,648	430,403	751,483	356,374	343,978	516,483	901,780	415,769	401,308	602,564	1,052,077
Inventory	0	86,594	898,120	370,493	684,762	202,103	1,317,888	707,187	595,959	543,615	1,177,844	503,901	965,070	341,278	1,614,505	816,581	856,272	637,531	1,485,459	615,204	1,192,827	279,338
Other Current Assets	0	0	18,593	15,495	25,824	49,582	24,791	20,659	34,432	66,110	30,989	25,824	43,040	82,637	37,187	30,989	51,648	99,165	43,385	36,154	60,256	115,692
Total Current Assets	**4,829,811**	**3,814,279**	**3,527,244**	**3,320,946**	**3,132,365**	**3,086,673**	**2,767,061**	**2,669,705**	**2,602,022**	**2,717,544**	**2,447,126**	**2,459,890**	**2,500,757**	**2,771,972**	**2,549,508**	**2,673,175**	**2,820,224**	**3,247,822**	**3,069,600**	**3,303,825**	**3,556,630**	**4,141,555**
Net Fixed Assets	2,035,667	2,574,167	2,507,667	2,441,167	2,374,667	2,308,167	2,241,667	2,175,167	2,108,667	2,042,167	1,975,667	1,909,167	1,842,667	1,776,167	1,709,667	1,643,167	1,576,667	1,510,167	1,443,667	1,377,167	1,310,667	1,244,167
Total Assets	**6,865,478**	**6,388,446**	**6,034,911**	**5,762,113**	**5,507,032**	**5,394,840**	**5,008,728**	**4,844,872**	**4,710,688**	**4,759,710**	**4,422,792**	**4,369,056**	**4,343,423**	**4,548,138**	**4,259,174**	**4,316,341**	**4,396,891**	**4,757,989**	**4,513,267**	**4,680,991**	**4,867,296**	**5,385,722**
Accounts Payable	46,117	49,450	103,933	98,376	116,900	159,506	114,878	107,701	131,622	186,640	125,784	117,105	146,033	212,569	136,710	126,645	160,192	237,350	147,738	136,405	174,181	261,067
Notes Payable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Wages Payable	64,396	64,396	65,040	65,040	65,040	65,040	66,347	66,347	66,347	66,347	68,357	68,357	68,357	68,357	71,133	71,133	71,133	71,133	74,762	74,762	74,762	74,762
Total Current Liabilites	**110,513**	**113,846**	**168,973**	**163,416**	**181,940**	**224,546**	**181,225**	**174,048**	**197,969**	**252,987**	**194,141**	**185,463**	**214,391**	**280,926**	**207,843**	**197,779**	**231,325**	**308,483**	**222,500**	**211,167**	**248,943**	**335,829**
Long Term Debt	2,636,758	2,601,016	2,564,191	2,526,250	2,487,159	2,446,884	2,405,388	2,362,635	2,318,587	2,273,204	2,226,446	2,178,271	2,128,636	2,077,497	2,024,809	1,970,524	1,914,595	1,856,970	1,797,600	1,736,430	1,673,407	1,608,475
Total Liabilites	**2,747,270**	**2,714,862**	**2,733,163**	**2,689,665**	**2,669,099**	**2,671,429**	**2,586,613**	**2,536,684**	**2,516,556**	**2,526,191**	**2,420,587**	**2,363,733**	**2,343,027**	**2,358,424**	**2,232,652**	**2,168,303**	**2,145,920**	**2,165,453**	**2,020,099**	**1,947,597**	**1,922,350**	**1,944,303**
Equity	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000	4,500,000
Retained Earnings	(381,793)	(826,415)	(1,198,252)	(1,427,553)	(1,662,067)	(1,776,590)	(2,077,885)	(2,191,812)	(2,305,868)	(2,266,481)	(2,497,795)	(2,494,677)	(2,499,604)	(2,310,285)	(2,473,477)	(2,351,962)	(2,249,029)	(1,907,465)	(2,006,833)	(1,766,606)	(1,555,054)	(1,058,582)
Total Equity	**4,118,207**	**3,673,585**	**3,301,748**	**3,072,447**	**2,837,933**	**2,723,410**	**2,422,115**	**2,308,188**	**2,194,132**	**2,233,519**	**2,002,205**	**2,005,323**	**2,000,396**	**2,189,715**	**2,026,523**	**2,148,038**	**2,250,971**	**2,592,535**	**2,493,167**	**2,733,394**	**2,944,946**	**3,441,418**

5.2 – Profit and loss report, summarizing any income, expenses and net profit from the applicant's inception to date of commencement and as projected over each calendar year thereafter, including the year of commencement.

Below we detail quarterly financials for the company assuming a start date in July 2023 with initial sales in January 2024. Our forecast assumes $4m of equity, alongside $2.7m in debt funding to help fund capital expenditures as well as support working capital needs. During the first 4 months we plan to scale the facility to its full capacity of 12,000 square feet. We intend to produce topicals, gelatins, tinctures, and suppositories with the optionality of expanding into other form factors as state law permits. For conservatism, we do not incorporate other form factors into our forecast as this juncture. In our model, we assume the price of flower declines throughout our forecast as more cultivators come online and compete for market share. Based on our experience in several other medical marijuana markets, we intend to price the products based on milligrams of THC per product ranging from $0.14 - $0.20 cents per milligram. While we are confident we will garner more than the implied market share based on our combined several decades of experience in limited license medical marijuana markets, we were cautious in our forward looking TAM and only incorporated a uniform market share based on the total manufacturers in the state. In other words, we assume all manufacturers have equal market share.

On an annual basis, our model assumes we are EBITDA positive in 2025 and free cash flow positive in 2026, aided by gross margins that we expect to expand from 35% in 2024 to 51% in 2028 driven by operating efficiencies and a decrease in the price of certain input costs to include bulk flower. Moreover, we expect to gain operating leverage as our facility matures bolstering EBITDA margin towards 32% in 2028.

The projected cash balance underscores our ability to withstand the start up costs associated with the build out and initial working capital requirements ahead of the first revenue generation event in January 2024. Moreover, we incorporate annual inflationary assumptions on input and labor costs where appropriate to ensure our business can withstand additional stress.

Income Statement

	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F
	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26	3Q26	4Q26	1Q27	2Q27	3Q27	4Q27	1Q28	2Q28	3Q28	4Q28
Revenue	0	0	464,835	805,714	774,725	1,063,956	619,780	1,074,285	1,032,967	1,418,608	774,725	1,342,857	1,291,208	1,773,259	929,670	1,611,428	1,549,450	2,127,911	1,084,615	1,879,999	1,807,692	2,482,563
COGS	0	0	363,938	516,763	502,869	632,539	427,776	625,123	607,182	774,628	488,918	727,578	705,881	908,380	547,514	824,276	799,116	1,033,944	603,773	915,427	887,095	1,151,529
Gross Margin	**0**	**0**	**100,897**	**288,951**	**271,856**	**431,417**	**192,004**	**449,163**	**425,785**	**643,980**	**285,807**	**615,279**	**585,327**	**864,880**	**382,156**	**787,152**	**750,334**	**1,093,968**	**480,842**	**964,572**	**920,597**	**1,331,034**
Salary	211,250	211,250	213,363	213,363	213,363	213,363	217,651	217,651	217,651	217,651	224,246	224,246	224,246	224,246	233,351	233,351	233,351	233,351	245,255	245,255	245,255	245,255
Overhead	21,125	21,125	21,336	21,336	21,336	21,336	21,765	21,765	21,765	21,765	22,425	22,425	22,425	22,425	23,335	23,335	23,335	23,335	24,525	24,525	24,525	24,525
SG&A Operating Expenses	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750	3,750
Professional Services	32,500	32,500	32,825	32,825	32,825	32,825	33,485	33,485	33,485	33,485	34,499	34,499	34,499	34,499	35,900	35,900	35,900	35,900	37,731	37,731	37,731	37,731
Insurance	10,000	10,000	10,100	10,100	10,100	10,100	10,303	10,303	10,303	10,303	10,615	10,615	10,615	10,615	11,046	11,046	11,046	11,046	11,610	11,610	11,610	11,610
Non-Interest Finance & Distribution Costs	3,750	3,750	3,788	3,788	3,788	3,788	3,864	3,864	3,864	3,864	3,981	3,981	3,981	3,981	4,142	4,142	4,142	4,142	4,354	4,354	4,354	4,354
Corporate Travel and Events	2,500	2,500	2,525	2,525	2,525	2,525	2,576	2,576	2,576	2,576	2,654	2,654	2,654	2,654	2,762	2,762	2,762	2,762	2,902	2,902	2,902	2,902
Other Operational Expenses	6,250	6,250	6,313	6,313	6,313	6,313	6,439	6,439	6,439	6,439	6,635	6,635	6,635	6,635	6,904	6,904	6,904	6,904	7,256	7,256	7,256	7,256
Digital	12,000	12,000	12,120	12,120	12,120	12,120	12,364	12,364	12,364	12,364	12,738	12,738	12,738	12,738	13,255	13,255	13,255	13,255	13,932	13,932	13,932	13,932
Other Marketing	1,250	1,250	1,263	1,263	1,263	1,263	1,288	1,288	1,288	1,288	1,327	1,327	1,327	1,327	1,381	1,381	1,381	1,381	1,451	1,451	1,451	1,451
D&A	24,333	61,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500
Total SG&A	**328,708**	**365,875**	**373,881**	**373,881**	**373,881**	**373,881**	**379,984**	**379,984**	**379,984**	**379,984**	**389,369**	**389,369**	**389,369**	**389,369**	**402,327**	**402,327**	**402,327**	**402,327**	**419,266**	**419,266**	**419,266**	**419,266**
Operating Profit	**(328,708)**	**(365,875)**	**(272,984)**	**(84,930)**	**(102,026)**	**57,535**	**(187,980)**	**69,178**	**45,800**	**263,995**	**(103,563)**	**225,910**	**195,958**	**475,510**	**(20,171)**	**384,825**	**348,007**	**691,641**	**61,576**	**545,306**	**501,330**	**911,768**
Interest Expense	53,084	78,748	77,665	76,549	75,399	74,215	72,994	71,737	70,442	69,107	67,732	66,315	64,855	63,351	61,802	60,205	58,560	56,865	55,119	53,320	51,467	49,557
Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tax	0	0	21,188	67,822	57,090	97,843	40,321	111,369	89,415	155,502	60,019	156,477	136,029	222,841	81,220	203,104	186,515	293,211	105,825	251,759	238,312	365,738
Net Income	**(381,793)**	**(444,623)**	**(371,837)**	**(229,300)**	**(234,515)**	**(114,522)**	**(301,295)**	**(113,927)**	**(114,056)**	**39,387**	**(231,314)**	**3,118**	**(4,926)**	**189,318**	**(163,192)**	**121,516**	**102,932**	**341,565**	**(99,368)**	**240,227**	**211,552**	**496,472**
EBITDA Build																						
Net Income	(381,793)	(444,623)	(371,837)	(229,300)	(234,515)	(114,522)	(301,295)	(113,927)	(114,056)	39,387	(231,314)	3,118	(4,926)	189,318	(163,192)	121,516	102,932	341,565	(99,368)	240,227	211,552	496,472
Interest Expense	53,084	78,748	77,665	76,549	75,399	74,215	72,994	71,737	70,442	69,107	67,732	66,315	64,855	63,351	61,802	60,205	58,560	56,865	55,119	53,320	51,467	49,557
Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tax	0	0	21,188	67,822	57,090	97,843	40,321	111,369	89,415	155,502	60,019	156,477	136,029	222,841	81,220	203,104	186,515	293,211	105,825	251,759	238,312	365,738
D&A	24,333	61,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500
EBITDA	**(304,375)**	**(304,375)**	**(206,484)**	**(18,430)**	**(35,526)**	**124,035**	**(121,480)**	**135,678**	**112,300**	**330,495**	**(37,063)**	**292,410**	**262,458**	**542,010**	**46,329**	**451,325**	**414,507**	**758,141**	**128,076**	**611,806**	**567,830**	**978,268**
Margin Analysis																						
Gross Margin	NM	NM	22%	36%	35%	41%	31%	42%	41%	45%	37%	46%	45%	49%	41%	49%	48%	51%	44%	51%	51%	54%
SG&A as % of Sales	NM	NM	80%	46%	48%	35%	61%	35%	37%	27%	50%	29%	30%	22%	43%	25%	26%	19%	39%	22%	23%	17%
Operating Margin	NM	NM	-59%	-11%	-13%	5%	-30%	6%	4%	19%	-13%	17%	15%	27%	-2%	24%	22%	33%	6%	29%	28%	37%
EBITDA Margin	NM	NM	-44%	-2%	-5%	12%	-20%	13%	11%	23%	-5%	22%	20%	31%	5%	28%	27%	36%	12%	33%	31%	39%
Net Income Margin	NM	NM	-80%	-28%	-30%	-11%	-49%	-11%	-11%	3%	-30%	0%	0%	11%	-18%	8%	7%	16%	-9%	13%	12%	20%
Sequential Growth Analysis																						
Revenue				73%	-4%	37%	-42%	73%	-4%	37%	-45%	73%	-4%	37%	-48%	73%	-4%	37%	-49%	73%	-4%	37%
Gross Margin				186%	-6%	59%	-55%	134%	-5%	51%	-56%	115%	-5%	48%	-56%	106%	-5%	46%	-56%	101%	-5%	45%
EBITDA		0%	NM	NM	93%	NM	NM	NM	NM	194%	NM	NM	NM	107%	NM	874%	NM	83%	NM	378%	NM	72%
Net Income		16%	NM	NM	2%	NM	163%	NM	0%	NM	NM	NM	NM	NM	NM	NM	NM	232%	NM	NM	NM	135%

5.3 – Statement of cash flow, examining the cash flowing into and out of the Applicant's business from inception to commencement and during each calendar year thereafter, including the year of commencement.

Below we detail quarterly financials for the company assuming a start date in July 2023 with initial sales in January 2024. Our forecast assumes $4m of equity, alongside $2.7m in debt funding to help fund capital expenditures as well as support working capital needs. During the first 4 months we plan to scale the facility to its full capacity of 12,000 square feet. We intend to produce topicals, gelatins, tinctures, and suppositories with the optionality of expanding into other form factors as state law permits. For conservatism, we do not incorporate other form factors into our forecast as this juncture. In our model, we assume the price of flower declines throughout our forecast as more cultivators come online and compete for market share. Based on our experience in several other medical marijuana markets, we intend to price the products based on milligrams of THC per product ranging from $0.14 - $0.20 cents per milligram. While we are confident we will garner more than the implied market share based on our combined several decades of experience in limited license medical marijuana markets, we were cautious in our forward looking TAM and only incorporated a uniform market share based on the total manufacturers in the state. In other words, we assume all manufacturers have equal market share.

On an annual basis, our model assumes we are EBITDA positive in 2025 and free cash flow positive in 2026, aided by gross margins that we expect to expand from 35% in 2024 to 51% in 2028 driven by operating efficiencies and a decrease in the price of certain input costs to include bulk flower. Moreover, we expect to gain operating leverage as our facility matures bolstering EBITDA margin towards 32% in 2028.

The projected cash balance underscores our ability to withstand the start up costs associated with the build out and initial working capital requirements ahead of the first revenue generation event in January 2024. Moreover, we incorporate annual inflationary assumptions on input and labor costs where appropriate to ensure our business can withstand additional stress.

Statement of Cash Flow

	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F	F
	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26	3Q26	4Q26	1Q27	2Q27	3Q27	4Q27	1Q28	2Q28	3Q28	4Q28
Net Income	(381,793)	(444,623)	(371,837)	(229,300)	(234,515)	(114,522)	(301,295)	(113,927)	(114,056)	39,387	(231,314)	3,118	(4,926)	189,318	(163,192)	121,516	102,932	341,565	(99,368)	240,227	211,552	496,472
D&A	24,333	61,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500	66,500
Accounts Receivable	0	0	(178,187)	6,198	(86,253)	(192,648)	213,308	8,264	(115,004)	(256,864)	304,209	10,330	(143,755)	(321,080)	395,110	12,396	(172,505)	(385,297)	486,011	14,462	(201,256)	(449,513)
Inventory	0	(86,594)	(811,526)	527,628	(314,269)	482,659	(1,115,784)	610,701	111,228	52,344	(634,228)	673,942	(461,169)	623,792	(1,273,227)	797,924	(39,691)	218,741	(847,928)	870,255	(577,624)	913,490
Other Current Assets	0	0	(18,593)	3,099	(10,330)	(23,758)	24,791	4,132	(13,773)	(31,678)	35,121	5,165	(17,216)	(39,597)	45,451	6,198	(20,659)	(47,516)	55,780	7,231	(24,103)	(55,436)
Accounts Payable	46,117	3,333	54,483	(5,557)	18,524	42,606	(44,628)	(7,176)	23,921	55,018	(60,857)	(8,679)	28,928	66,535	(75,859)	(10,064)	33,547	77,158	(89,612)	(11,333)	37,776	86,886
Wages Payable	64,396	0	644	0	0	0	1,307	0	0	0	2,010	0	0	0	2,776	0	0	0	3,629	0	0	0
Cash Flow from Operations	**-246,947**	**-466,384**	**-1,258,516**	**368,567**	**-560,342**	**260,836**	**-1,155,802**	**568,493**	**-41,184**	**-75,293**	**-518,559**	**750,376**	**-531,637**	**585,468**	**-1,002,443**	**994,469**	**-29,876**	**271,150**	**-424,988**	**1,187,341**	**-487,154**	**1,058,399**
CAPEX	-2,060,000	-600,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flow from Investing	**-2,060,000**	**-600,000**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**
Equity	4,500,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Notes Payable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Debt	2,636,758	-35,742	-36,825	-37,941	-39,091	-40,275	-41,496	-42,753	-44,048	-45,383	-46,758	-48,175	-49,635	-51,139	-52,688	-54,285	-55,930	-57,624	-59,370	-61,169	-63,023	-64,933
Cash Flow from Financing	**7,136,758**	**-35,742**	**-36,825**	**-37,941**	**-39,091**	**-40,275**	**-41,496**	**-42,753**	**-44,048**	**-45,383**	**-46,758**	**-48,175**	**-49,635**	**-51,139**	**-52,688**	**-54,285**	**-55,930**	**-57,624**	**-59,370**	**-61,169**	**-63,023**	**-64,933**
Beginning Cash	0	4,829,811	3,727,685	2,432,344	2,762,970	2,163,537	2,384,097	1,186,800	1,712,540	1,627,308	1,506,632	941,315	1,643,516	1,062,244	1,596,573	541,442	1,481,627	1,395,821	1,609,346	1,124,988	2,251,160	1,700,982
Change in Cash	4,829,811	-1,102,126	-1,295,341	330,626	-599,433	220,561	-1,197,297	525,740	-85,232	-120,676	-565,317	702,201	-581,272	534,329	-1,055,131	940,185	-85,806	213,526	-484,359	1,126,172	-550,177	993,467
Ending Cash	**4,829,811**	**3,727,685**	**2,432,344**	**2,762,970**	**2,163,537**	**2,384,097**	**1,186,800**	**1,712,540**	**1,627,308**	**1,506,632**	**941,315**	**1,643,516**	**1,062,244**	**1,596,573**	**541,442**	**1,481,627**	**1,395,821**	**1,609,346**	**1,124,988**	**2,251,160**	**1,700,982**	**2,694,449**

License Type: Processor

Exhibit 6 – Tax Plan

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

Introduction

Our comprehensive tax and financial plan are written in accordance with the Generally Accepted Accounting Principles ("GAAP"). This includes accounting and tax reporting practices that comply with all applicable laws. Coosa Medical Manufacturing, LLC is structured as a Limited Liability Company "LLC" to maintain distinction between business and owner personal liability. We have a business tax identification number, provided to us by the Alabama State Treasury. The net worth of our limited liability entity will be calculated by the capital accounts of our owners. Ala. Code § 40-14A-23(b). We will prepare annually for the Department of Revenue a report of our income and deductions with the names and addresses of each partner and their percentage of share. Ala. Code § 40-18-28.

Our Chief Financial Officer ("CFO") will oversee this plan for efficiency and continual compliance. We will disclose to the Alabama Medical Cannabis Commission ("AMCC") and the Department of Revenue of the State of Alabama ("the Department") all relevant records, including tax information. Ala. Code § 20-2A-55(d). We will maintain good standing with the IRS and secure all financing without backing from federally insured financial institutions. 31 US Code § 5311-118.3745(a)(4); IRC 280(e).

Financial Practices

We will maintain our business' financial accounts in the United States. 31 U.S.C. § 5311 118.3745(a)(4). We will fully disclose all credit practices. F.D.I.C. C.2 § 121. Our financial records will be physically and digitally secured, and all staff will be trained on proper recordkeeping. Our SOPs include details on our electronic financial recordkeeping systems, and which personnel are allowed in restricted access cash storage areas. 31 U.S.C. § 5311(b)(3-4). From these records, we will supply any documentation requested for law enforcement purposes. 31 U.S.C. § 5311 (b)(1-2). We will comply with guidance issued by the Financial Crimes Enforcement Network ("FinCEN"), and we will only work with vendors or financial institutions who also comply with the Bank Secrecy Act. 31 USC § 5311-BSA 34.

We will contract with vendors for accounting and armored-car services. Access to banking for cannabis businesses regularly comes with high monthly fees and extra expenses. We have proactively created a positive relationship with Commerce One Bank to support our business in this matter. Commerce One is based in Birmingham, Alabama and

has over half a billion dollars in assets under management. We will maintain honest candor with financial entities about our cannabis transactions by providing details on our license, and all necessary information for compliance with banking customer identification programs. 31 CFR § 1020.220(a)(2)(i)(A).

Accounting

Our double entry accounting system will record, analyze, and classify our transactions, and will provide accountability of our assets and liabilities. Our CFO will oversee monthly and year-end financial reconciliation of accounts payable and receivable. We will also work with a certified accountant familiar with the cannabis industry for tax filing.

Gain, loss, income, basis earning, and profit statements of our business will be determined in accordance with Alabama state tax law, not based on federal income tax regulations. Ala. Code § 40-18-1.1(a); USC Title 26. Taxable income will include gross income less allowable deductions. Ala. Code § 40-18-15.1; Ala. Code § 40-18-15.3(a)(2),(c). We will file a net operating loss only if, prior to any deductions or modifications, our entire net operating finances are a loss for the entire taxable year. Ala. Code § 40-18-15.2.

With this system we will fully disclose our financial results and maintain GAAP conformity, including recognizing revenues and expenses on the accrual basis and reconciliation of all accounts in a timely manner. All financial records will be maintained securely at our facility and made available to the AMCC. Ala. Code § 20-2A-52(a)(5). Our records will include gross sales, gross proceeds, gross receipts, and other books to determine our tax liability. Ala. Code § 40-23-9.

Insurance and Affiliates

We will maintain adequate levels of liability and casualty insurance. Ala. Code § 20-2A-53(a)(2). Our insurance will be provided by an A-rated insurer. AMCC Application Guide, Processor, page 24. We have paid all appropriate taxes on our insurance plans and premiums. We will acquire additional surety bonds if required by the Department. Ala. Code § 40-23-6. Neither we nor any of our affiliates have outstanding tax debt or tax delinquency. Ala. Admin Code. r. 538-x-4-.07.05; Ala. Code § 20-2A-55(a)(6). We and our affiliates will fully disclose tax history. Ala. Admin Code r. 538-x-3-.05.03.d-f.

Taxes Levied by the State and Payment of the Same

We will pay all taxes in a prompt manner. Ala. Code § 40-11-4; Ala. Code § 40-23-7. All taxes that are payable to the Department will include the name of our business and our Chief Executive Officer; location and legal description of our business; total amount of gross sales, receipts, and loans, on a daily, monthly, and quarterly basis; and any other information required or requested. Ala. Code § 40-1-5(a)(1-8). We will pay all applicable privilege taxes levied against our net worth each year. Ala. Code § 20-2A-80(b)(1); Ala. Code § 40-14A-23. We will utilize charts provided by the State in Article 2 of the Alabama Business Privilege and Corporation Shares Tax regulations, and any related amendments, to calculate the amount of tax owed. Ala. Code § 40-14A-22(b); Ala. Code § 20-2A-80(b)(2).

Our certified accountant will appropriately file all taxes related to our business. All other related taxes will be filed concurrently with federal income returns, no later than April 15th of each year. Ala. Code § 20-2A-80(b)(3); Treasury Regulation § 26.6072(b). Our first tax return will be filed two and a half months after our license approval. Ala. Code § 20-2A-80(b)(3). Tax payments due to the Commissioner of Revenue will be completed with a designated form. Ala. Code § 40-17A-2; Ala. Code § 20-2A-80(b)(5). Any circumstances resulting in a lack of form will not prevent us from promptly paying our due taxes. Our tax payment will be considered complete once the money is received by the state. Ala. Code § 40-1-5(b). Tax proceeds will, in part, support the Medical Cannabis Commission Fund set forth by the Alabama State Treasury. Ala. Code § 20-2A-10(a)(1).

We will submit to a 9% tax rate for gross proceeds of sales. Ala. Code § 20-2A-80(a); Ala. Code § 40-23-1. We will only pay municipal or county tax once per sale. Ala. Code § 40-23-2.1. All money collected from this taxation will be paid to the Department. Ala. Code § 40-23-26(d).

Our property will be assessed for ad valorem tax purposes at 20% as a Class II property. Ala. Code § 40-8-1(a). We will pay annually a tax of .065% based on our assessed property value. Ala. Code § 40-8-2. For any vehicles in our fleet purchased outside this state, we will pay a 2% excise tax. Ala. Code § 40-23-102(a). We will submit to a 6.5% income tax levied by the State and any further income taxes. Ala. Code § 40-18-2; Ala. Code § 40-18-31(a). At

the request of the Department, we will provide an inventory as proof of income. Ala. Code § 40-18-11.

We understand that refusal or neglect to pay appropriate taxes can result in a lien in favor of the State of Alabama upon all business properties and rights therein. Ala. Code § 40-1-2(a); § 40-1-3. We may motion to dismiss the lien, with a bond in double the amount of the lien filed with the Department. Ala. Code § 40-1-2(c). We will communicate openly with the AMCC, the Department, and the Internal Revenue Service about our financial obligations.

Conclusion

We understand and will comply with all applicable tax laws. Ala. Admin Code. r. 538-x-3-.05.03.m.09. We will accept any fairly regulated additional tax, penalty, or interest assessed upon us by the Department. Ala. Code § 20-2A-80(b)(5). We will always welcome and accommodate the AMCC and their officials for an inspection. Ala. Code § 20-2A-55(d). We understand failure to cooperate could result in the seizure and impound of our books, ledgers, documents, writings, money receptacles, and all other records. Ala. Code § 20-2A-52(a)(3)(b). We will contribute to providing qualified patients with the maximum benefit of medical cannabis through protection of our products, compliant recordkeeping, and appropriate taxation. Ala. Admin Code. r. 538-x-1-.02.

License Type: Processor

Exhibit 7 – Business Formation Documents

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

John H. Merrill
Secretary of State

P. O. Box 5616
Montgomery, AL 36103-5616

STATE OF ALABAMA

I, John H. Merrill, Secretary of State of Alabama, having custody of the Great and Principal Seal of said State, do hereby certify that

as appears on file and of record in this office, the pages hereto attached, contain a true, accurate, and literal copy of the Articles of Formation filed on behalf of Coosa Medical Manufacturing, LLC, as received and filed in the Office of the Secretary of State on 07/15/2022.

In Testimony Whereof, I have hereunto set my hand and affixed the Great Seal of the State, at the Capitol, in the city of Montgomery, on this day.

11/14/2022

Date

John H. Merrill

John H. Merrill Secretary of State

20221114000007664

STATE OF ALABAMA

DOMESTIC LIMITED LIABILITY COMPANY (LLC)
CERTIFICATE OF FORMATION

PURPOSE: In order to form a Limited Liability Company (LLC) under Section 10A-5A-2.01 of the *Code of Alabama 1975*, this Certificate of Formation and the appropriate filing fees must be filed with the Office of the Secretary of State. **The information required in this form is required by Title 10A.**

1. The name of the limited liability company (must contain the words "Limited Liability Company" or the abbreviation "L.L.C." or "LLC," and comply with *Code of Alabama*, Section 10A-1-5.06. You may use Professional or Series before Limited Liability Company or LLC (or PLLC or SLLC) if they apply:

   Coosa Medical Manufacturing, LLC

2. **A copy of the Name Reservation Certificate from the Office of the Secretary of State must be attached.**

3. The name of the registered agent (only one agent): [redacted]

   Street (**no PO Boxes**) address of registered office (must be located in Alabama): [redacted]

   *COUNTY of above address: [redacted]

   Mailing address in Alabama of registered office (if different from street address): _____

4. The undersigned certify that there is at least one member of the limited liability company.

(For SOS Office Use Only)

Alabama
Sec. Of State

001-029-960 DLL

Date	07/15/2022
Time	14:01:00
File	$100.00
County	$100.00
Total	$200.00

DOMESTIC LIMITED LIABILITY COMPANY (LLC) CERTIFICATE OF FORMATION

5. Check **only** if the type applies to the Limited Liability Company being formed:

   ○ Series LLC complying with Title 10A, Chapter 5A, Article 11

   ○ Professional LLC complying with Title 10A, Chapter 5A, Article 8

   ○ Non-Profit LLC complying with Section 10A-5A-1.04(c)

6. The filing of the limited liability company is effective immediately on the date received by the office of the Secretary of State, Business Services Division or at the delayed filing date (cannot be prior to the filing date) specified in this filing complying with Section 10A-1-4.12
   The undersigned specify 7 / 15 / 2022 as the effective date (must be on or after the date filed in the office of the Secretary of State, but no later than the 90th day after the date this instrument was signed) and the time of filing to be 2 : 0 ○ AM or ◉ PM. (cannot be noon or midnight – 12:00)

☐ Attached are any other matters the members determine to include herein (if this item is checked there must be attachments with the filing).

7 / 15 / 2022
Date (MM/DD/YYYY)

Ala. Code § 36-12-40 (Personally Identifiable Information)
Signature as required by 10A-5A-2.04

Member
Typed title (organizer or attorney-in-fact)

*County of Registered Agent is requested in order to determine distribution of County filing fees.

John H. Merrill
Secretary of State

P.O. Box 5616
Montgomery, AL 36103-5616

STATE OF ALABAMA

I, John H. Merrill, Secretary of State of Alabama, having custody of the Great and Principal Seal of said State, do hereby certify that

pursuant to the provisions of Title 10A, Chapter 1, Article 5, Code of Alabama 1975, and upon an examination of the entity records on file in this office, the following entity name is reserved as available:

Coosa Medical Manufacturing, LLC

This name reservation is for the exclusive use of [redacted] for a period of one year beginning July 15, 2022 and expiring July 15, 2023

In Testimony Whereof, I have hereunto set my hand and affixed the Great Seal of the State, at the Capitol, in the city of Montgomery, on this day.

July 15, 2022

Date

J. H. Merrill

John H. Merrill **Secretary of State**

RES034561

License Type: Processor

Exhibit 8 – Business License and Authorization of Local Authorities

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

8.1 Certified Copies of Business License

Applicant has submitted for its business license with the City of Centreville. This application cannot be approved until the Applicant has received a Medical Cannabis Processing License from the AMCC. This application is identified as "Business License – Coosa Medical Manufacturing - Attachment to Exhibit 8, Section 8.1"

8.2 Resolution(s) or Ordinance(s) by local jurisdiction(s) approving the Applicant's business presence

Processing license applicants are not required to locate in a city/county that has specifically approved a medical cannabis ordinance. Please see the email from Alabama Medical Cannabis Commission dated 10.14.22 which is part of the Attachment noted below. Processing applicants are required to show zoning compliance. The applicant has included a letter from the City of Centreville confirming that Medical Cannabis Processing is allowed on the property located at 2347 Montgomery Highway, Centreville, AL 35042. (This address was just recently assigned to the property which is why the zoning letter indicates Parcel ID 1609293000015000.) This letter is identified as "Zoning Ordinance – Coosa Medical Manufacturing - Attachment to Exhibit 8, Section 8.2". The applicant has also included a letter of support from the Mayor of Centreville for Coosa locating there.

AVENU

Application For Business License

2023

Confirmation # 49GCSFS4U8

Avenu Account #	000000		
Company Name	Coosa Medical Manufacturing, LLC		
Trade Name	COOSA MEDICAL MANUFACTURING		
Location Name	COOSA MEDICAL MANUFACTURING, LLC		
Mailing Address	[redacted]		[redacted]
Physical Address	2347 Montgomery Hwy		Centreville, AL 35042-6015

City of Centreville, Alabama

Section	License Type	PJ	CL	Filing	Start Date	Gross	Units	Cert #	Flat Fee	Add. Fee	Total Fee	Penalty
312-00	MANUFACTURER LICENSE	No	Yes	New	8/1/2023				$250.00	$0.00	$250.00	$0.00

Issuance Fee	$14.00
Total Fee	$250.00
Penalty	$0.00
Subtotal	$264.00
Convenience Fee	$0.00
Total Remitted	**$264.00**
Payment Type	Checking/Savings

MAILING A PAPER CHECK: Please follow the instructions below to avoid any delay in processing your Business License Application.

Please make checks payable to: Tax Trust Account. Please write your Avenu account number on your check and mail your payment along with a copy of this Confirmation Receipt and a copy of required certifications/additional documentation to:

Business Licensing Division
Attn: Online Business License Filing
PO Box 830900
Birmingham, AL 35283-0900

****Important Information - Read Thoroughly****

Certain license types require additional documentation such as certification from a regulatory board or agency. During your online filing process, you may have been prompted to enter your certification number. This is an indication that you are required to submit to Avenu a copy of your certification. If applicable, please remit a legible copy to Avenu via email, fax or mail.

The confirmation number listed confirms only that you have successfully submitted your tax filing and payment information through this website. The confirmation number does not in any way confirm that your payment has been accepted or that the checking account information / credit card account information submitted is valid. If your payment does not process successfully, you will be contacted by Avenu. If you have any questions regarding your filing and/or payment history, please contact Avenu at (800) 556-7274.

****Please reference your Avenu Account # (also known as your Filing Authority #) on all correspondence. This # is needed to ensure that the information supplied is applied appropriately to your account. Failure to supply this information can further delay the issuance of your license.*

SWORN STATEMENT

I hereby swear that the amount of capital invested or value of goods, stocks, furniture and fixtures or amount of sales or receipts as required for disclosure in order to obtain a business license has been examined by me and to the best of my knowledge is true correct and complete. I understand issuance of license does not permit business operation unless business is properly zoned, and/or in compliance with all applicable laws/rules. As the preparer of this return, I have authorized payment via the payment type listed above and have accepted the convenience fees/surcharge amount charged as applicable.

Avenu Insights & Analytics
Attn: Business License Department
PO Box 830900
Birmingham, AL 35283-0900

Fax: (844) 528-6529
Email: businesslicensesupport@avenuinsights.com
Phone: (800) 556-7274
Website: www.avenuinsights.com

Signed: _____ Print Name: [redacted]

Date Filed: **12/12/2022** Phone: [redacted] Title: **Managing Member**

Monday, December 12, 2022 at 09:20:20 Central Standard Time

Subject: RE: Question re: local approval
Date: Friday, October 14, 2022 at 9:02:43 AM Central Daylight Time
From: Applications (AMCC)
To: Jeff Rabren
Attachments: image001.png

That is correct. The statute only requires local authorization for dispensing sites.

From: Jeff Rabren <Jeff@redlevelstrategies.com>
Sent: Friday, October 14, 2022 8:58 AM
To: Applications (AMCC) <applications@amcc.alabama.gov>
Subject: Question re: local approval

The requirement that a city or county affirmatively approve operation of a dispensing site via ordinance or resolution only applies to dispensaries, right? There is no requirement in the statute or proposed rules that requires this approval for a cultivation facility or a processing facility, correct?

Thank you.

Jeff Rabren
Red Level Strategies, LLC

445 Dexter Ave
5th Floor
Montgomery, AL 36104

PO Box 59386
Birmingham, AL 35259

205-901-8315
www.redlevelstrategies.com

City of Centreville

"Zoning Authorization"

The property located at **Parcel I.D. 1609293000015000** and containing 15+/- acres is zoned for **Commercial/M1.** The Centreville Zoning Ordinances permits Medical Cannabis Processing and Distribution in this District.

Signature of Administrator

11-28-22
Date

Please see attachment "A" for reference


Exhibit "A"
120
MONTGOMERY HIGHWAY
HIGHWAY
HIGHWAY
100
100
15+/- Ac.
N

City of Centreville

Mike Oakley, Mayor
1270 Walnut Street
Centreville, AL 35042
Phone (205) 926-4995
Fax (205) 926-5443

Coosa Medical Manufacturing

Letter of Support

Greetings,

I am writing this letter in support of Coosa Medical Manufacturing, LLC's application for a processing license. I have interacted with their team, been in touch via text, phone and Zoom with various members and have listened to and heard their plans. I firmly believe they are fully qualified to safely operate a business dealing with medical cannabis.

This business will provide an immediate economic impact, job creation and much-needed housing in our city limits. Their team, highly qualified and certified, will be an asset to our community and our county.

I would be more than happy to assist them should they be awarded a license.

Feel free to contact me if you require more information.

Sincerely,

Mike Oakley, Mayor

City of Centreville, AL

License Type: Processor

Exhibit 9 – Business Plan

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

9.1 – Business Structure

Our company is a limited liability company (LLC), formed in the state of Alabama on July 15th, 2022. Our entity adheres to a traditional structure of LLC's with an operating agreement and a limitation of less than 101 shareholders.

The entity's membership consists of [redacted]. with 51 shares, [redacted] with 12 shares, [redacted] with 12 shares, and [redacted] with 8 shares, [redacted] with 4 shares, [redacted] with 4 shares, and [redacted] with 4 shares equaling the total distributed share count of 100.

9.2 – Business Goals

Our business goals over the next five years are guided by our mission statement, "To strive for excellence in medical cannabis formulation, manufacturing, consistency, and results."

Below are our cornerstone goals for years one through five. Year one is counted from the time of license awardance, projected June 12, 2023 until December 31, 2024. Year two is counted from January 1, 2025 until December 31, 2025. This pattern of time measurement continues in years three through five.

Year One:

- Become one of four licensed medical cannabis processors.
- Construct our processing facility.
- Pass all state, county, and municipal inspections.
- Receive all applicable government permits, licenses, and certifications.
- Onboard all pre-evaluated staff. Screen and hire for associate positions.
- Manufacture the first batch of Phase I product line.
- Conduct quality control and assurance testing on the first batch to confirm consistency, safety, and potency.
- Officially launch Phase I product line into the twelve independent licensed dispensaries.

Year Two:

- Petition the dispensaries owned by the five integrated licensees to sell our products.
- Scale with the market demand for medical cannabis.
- Conduct business to business marketing campaign emphasizing our attention to quality control, sustainable inputs, and low cost production.
- Seek independent feedback on the product line from certified dispensers, physicians, and registered patients via initial yearlong digital survey.

Year Three:

- Implement feedback received from digital survey.
- Begin executing internal research goals for proving the benefits of medical cannabis via published journal articles and improving or expanding our formulations as needed.
- Design and budget for three studies over three years.
- Conduct study on treatment of cancer.

Year Four:

- Audit current environmental sustainability from carbon emissions, resource utilization, waste and manufacturing byproducts, and input sourcing.
- Adjust sustainability metrics, plan, and tasks.
- Begin research into Phase II product line of tablets, nebulizers, and transdermal patches for their viability to treat specific qualifying conditions, formulation design, safety, and cost to produce.
- Conduct study on treatment of chronic pain.

Year Five:

- Scale with the market demand for medical cannabis.
- Seek independent feedback on the product line from certified dispensers, physicians, and registered patients via second yearlong digital survey.
- Conduct study on treatment of panic disorders.

9.3 – Organizational Chart



9.4 – Job Descriptions of All Managerial Positions.

Chief Executive Officer (CEO); Reports to Ownership:

Description - The CEO provides leadership for all aspects of the company's operations with an emphasis on long-term goals, growth, profit, and return on investment. The CEO ensures that all departments are properly managed, the company is free of conflict, and is focused on its highest priorities.

Qualification - The CEO must have experience in executive leadership, healthcare, a deep knowledge of all corporate departments, and the ability to hire and direct other leaders.

Duty - The CEO must plan, develop, implement and direct the organization's operational and fiscal function and performance, analyze the effects of long-term growth initiatives, and implement policies and procedures which will increase the effectiveness of the company.

Chief Operating Officer (COO); Reports to CEO:

Description - The COO is the second in command managing day-to-day operations and providing strategic information to the CEO. They oversee daily tasks and interact with all departments including processing, quality control, security, finance, and marketing.

Ultimately, the COO is responsible for ensuring all aspects of operations run smoothly every day and addressing any issues that come up.
Qualification - The COO must have experience in executive leadership, healthcare, pharmaceutical manufacturing, understand of advanced business planning and regulatory compliance, analyze data and performance metrics, and create solutions quickly.
Duty - The COO must design and implement business strategies, plans and procedures, execute comprehensive goals for performance and growth, oversee daily operations of the company and the work of executives, and lead employees to encourage maximum efficiency.

Chief Financial Officer (CFO); Reports to CEO:
Description - The CFO directs and oversees the financial activities of the corporation, the preparation of current financial reports and summaries, develops and monitors the master budget, and creates forecasts predicting future growth.
Qualification - The CFO must hold a bachelor's and masters in accounting or finance, a certified public accountant license, strong management and supervisory skills, and excellent analytical, database, and organizational skills.
Duty - The CFO must drive the company's financial planning, analyze the organization's liabilities and investments, ensure cash flow is appropriate for the organization's operations, and supervise all finance personnel.

Chief Processing Officer (CPO); Reports to CEO:
Description - The CPO creates manufacturing processes, reviews the quality of execution and product results, formulates products, supervises laboratory staff, and analyzes the qualitative and quantitative environment within the processing department.
Qualification - The CP must have a bachelor's and master's degree in chemistry, experience in laboratory management, and pharmaceutical manufacturing.
Duty - The CPO must supervise the manufacturing processes, review the work of staff and support, plans analytical procedures, reviews monthly inventory of supplies and equipment, and checks accuracy of laboratory weights, balances, and volumetric glassware.

Chief Medical Officer (CMO); Reports to CEO:

Description - The CMO works closely with the CEO, COO, and CPO to provide advice on the quality of products, adherence to third-party standards, the efficaciousness of products, the current state of medical service, and gives an independent perspective on all relevant matters to their field.
Qualification - The CMO must hold a medical doctorate, experience in executive leadership, and experience in medical business management.
Duty - The CMO must provide clinical guidance to executives and staff, suggest policy improvements, audit quality control and assurance standards, lead research and development efforts, and work with external medical representatives.

Infusion and Formulation Director; Reports to CPO:
Description - The IFD will be managing the laboratory processes day-to-day, directly managing laboratory staff, working with the QACD to audit product quality, and communicating with the CPO on all items.
Qualification - The IFD must have 5 years experience with cannabis manufacturing, a background in chemistry, and have leadership experience.
Duty - The IFD must adhere to all standard operating procedures, manage staff, and report all occurrences to the CPO.

Supply Chain Manager - Reports to COO:
Description - The SCM ensures that all aspects of the facilities supply chain are continuous, in-tact, high quality, and on-time. The SCM manages the inflow of inputs, materials, and equipment as well as the outflow of finished products to dispensaries and waste materials to disposal centers.
Qualification - The SCM must have 5 years experience in managing supply chains, procuring equipment, have a background in engineering, and be able to analyze the quality of various materials and tools.
Duty - The SCM must communicate with all departments to know their supply chain needs, monitor the inflow and outflow of materials, work with secure transporters and state testing laboratories, and conduct quality control audits on all manufacturing materials and equipment.

Quality Assurance and Control Director; Reports to COO:

Description - The QACD monitors, audits, quarantines, removes, and approves all cannabis flower, extracted oil, and finished products within the facility.

Qualification - The QACD must have 5 years experience in cannabis analytical testing, a bachelors or masters in chemistry or biology, and experience in quality and control assurance for a laboratory.

Duty - The QACD will implement, follow, and enforce all quality control and assurance policies and procedures, take and test internal cannabis samples and analyze results from third-party laboratories, communicate all findings with the CPO and COO, and work to further improve quality.

Compliance Director; Reports to COO:

Description - The CD manages all legal paperwork, business formation and control documents, external reports and logs to government agencies, and handles all external communications with regulators. The CD ensures regulatory compliance with all municipal, county, state, and federal requirements.

Qualification - The CD must have a juris doctorate, have experience in regulatory compliance, healthcare law, and government relations.

Duty - The CD must implement compliance policies, monitor the compliance of all departments, continually update procedures to match the current regulations, and communicate with all relevant government entities.

Human Resources Director; Reports to COO:

Description - The HRD manages the hiring, promotion, disciplinary, termination, compensation, and benefits packages of all staff. The HRD will negotiate with healthcare insurance providers, 401K providers, and additional benefits packages. The HRD will mediate all workplace issues and report them to the relevant authorities, external or internal.

Qualification - The HRD must have 5 years experience in human resources management, and hiring and evaluating healthcare staff.

Duty - The HRD must create, house, and manage all employment paperwork for all staff, protect the private information of personnel, and create a healthy, happy workplace.

Security Director; Reports to COO:

Description - The SD must protect the staff, facility, and cannabis product from harm, damage, or thief. The SD will use the security system, lead security staff, and implement security policies to protect all assets. The SD will ensure that zero cannabis is ever diverted from the facility either via external attack or internal sabotage.

Qualification - The SD must have 5 years experience in law enforcement or corporate security, an understanding of military or law enforcement tactics, and experience with asset protection.

Duty - The SD must manage all security staff, monitor and use the security system to protect staff and cannabis products, collaborate with the QCAD to reconcile all inventory, and continually improve the effectiveness of the facility's security system.

Information Technology Director; Reports to Security Director:

Description - The ITD designs, manages, and improves the digital infrastructure of the operation. This includes interfacing with the seed-to-sale tracking software, implementing software and applications to optimize operations, and monitoring all digital activity across the business. The ITD is responsible for the cybersecurity of all data including protecting the privacy of all individuals involved in the business.

Qualification - The ITD must have 5 years of experience in information technology, managing software, and using cybersecurity protocols.

Duty - The ITD must manage and support all operational activity from a digital perspective, listen to each staff member and troubleshoot issues, and improve the speed of the facility via digital tools.

Sales and Marketing Manager; Reports to Compliance Director:

Description - The SMM is responsible for developing marketing plans and maximizing sales in a compliant manner.

Qualification - The SMM must have a background in pharmaceutical sales and marketing, experience with healthcare regulatory compliance, and have a track record of revenue growth.
Duty - The SMM must propose a sales and marketing plan with measurable metrics, receive approval from the executive team, implement this plan, and continually adjust the plan until revenue goals are achieved.

Community Outreach & Social Equity Manager; Reports to Sales & Marketing Director:
Description - The COSEM will manage the business's relationship with the community. The COSEM will improve community relations through collaborations, outreach, hosting events, and connecting with key stakeholders. The COSEM will attempt to improve the standing of disenfranchised groups in the cannabis business by hiring, educating, and training those parties when possible.
Qualification - The COSEM must have experience in community outreach, relationship building, and social equity enhancement.
Duty - The COSEM must actively work to improve community relations, outreach, cannabis education, and economic opportunities for locals.

9.5 – Job Descriptions of All Non-Managerial Employee Positions

Extraction Tech (ET); Report to Infusion and Formulation Director:
Description - ETs must follow all procedures within the laboratory created by the CPO and IFD. ETs will extract, test, manufacture, package, label, and store products.
Qualification - ETs must have a bachelor's degree, and experience in a manufacturing or scientific setting.
Duty - ETs must follow all directions, work together, be positive, ethical, and work hard.

Security Guard; Report to Security Director:
Description - SDs must follow all procedures created by the SD and COO. SD's must protect staff, the facility, and cannabis products from harm.
Qualification - SDs must have a high school diploma and experience in security.

Duty - SDs must protect all staff, operations, and cannabis products from harm or thief.

Accountant; Reports to CFO:

Description - ATs must follow all procedures created by the CFO, adhere to Generally Accepted Accounting Practices, and record all financial transactions.

Qualification - ATs must have a bachelor's in accounting, have 3 years experience in private or public accounting, and have integrity.

Duty - ATs must accurately produce and execute all financial records, transactions, and events in a timely manner.

Executive Assistant (EA); Reports to Assigned Executive:

Description - EAs must assist executives with a wide-variety of one-off or recurring tasks custom to the executive in question.

Qualification - EAs must have a high school degree, be persistent, hard working, and punctual.

Duty - EAs must complete all tasks asked of them.

Project Manager (PM); Reports to Assigned Manager:

Description - PMs must manage long-term and short-term projects assigned to them by a manager.

Qualification - PMs must have a bachelor's degree, 2 years experience in project management, and preferably have project manager certification.

Duty - PMs must manage to completion all projects assigned to them.

Strategic Advisor; Report to CEO and Executives:

Description - SAs assist the executives with the strategic vision, operational goals, and advise on solutions as seen through their unique experience.

Qualification - SAs must have a great amount of depth or breadth of experience in their career.

Duty - SAs must honestly communicate with the executive team and be proactive in their advice.

Medical Advisor; Reports to CMO and Executives:

Description - MAs advise the CMO, CPO, and QCAD on the impact of medical cannabis, potential issues with product design, clinical study design, and research and development programs.

Qualification - MAs must have a strong background in medicine and are preferably medical doctors.

Duty - MAs must adhere to a strict code of medical ethics, grounded in research, and be proactive in their advice.

9.6 – Executive Summary

The components of this executive summary demonstrate our ability to succeed as medical cannabis processor for the Alabama Medical Cannabis Program created by the Darren Wesley 'Ato' Hall Compassion Act of 2021.

The core tenants of our success will be our team and their experience, our operating process and procedures, and our financial planning. We are committed to maximizing our success as demonstrated by our superior medically-focused culture, operational experience, product offering, intellectual property expertise, cost of production, risk management approach, and capitalization.

Our company is led by an exceptional team of Alabama residents who have come together with the common goal of bringing the finest quality medical cannabis to those who are in need. We have engaged national and international experts who share the same vision of helping others, positively impacting the local community, and providing biopharmaceutical-grade medical cannabis in a safe, consistent, and transparent manner to patients who need immediate results. We are uniquely qualified to operate a sustainable, clean, and modern processing facility that emphasizes quality control, industry best practices, and the triple bottom line of social, economic, and environmental responsibility. Through thorough research and development projects, we have designed a uniquely effective infused product line. The concentrates and infused products market within the

cannabis industry is the fastest growing segment of the industry. Patient demand for medicine in alternative forms other than flower continues to increase, month over month, in existing medical cannabis markets. As the demand for these products have increased, licensed processors, scientists, and equipment manufacturers have flooded the industry with new technologies and methodologies. This ever-changing environment has increased the complexity for participants in the industry.

To thrive in this evolving environment, we have enlisted the help of qualified individuals that have a strong understanding of plant science, clinical medicine, botanical extraction, pharmaceutical manufacturing, expertise in traditional extraction technology and methodologies, mastery of applicable laws and regulations, and an ability to execute in all necessary arenas. We have assembled an ideal mix of operationally experienced executives, managers, and advisors with a proven track record of success to thrive in this landscape in Alabama.

This executive summary represents a realistic and achievable vision for our medical cannabis processor facility. We believe that Alabama's medical cannabis regulatory framework provides an incredible opportunity for our team to manufacture superior medical cannabis, and for us to become a leader in the marketplace by way of corporate stewardship, pharmaceutical quality control, and patient satisfaction.

Mission Statement

Our mission statement is "To strive for excellence in medical cannabis formulation, manufacturing, consistency, and results."

Vision and Philosophy

Our vision is to serve patients with compassion and medical professionalism. We are committed to creating a professional medical cannabis healthcare organization with a clear orientation toward traditional medical-grade care. We will manufacture only the highest-quality medical cannabis, subjecting it to rigorous processing and secure handling.

Our staff will be well trained in applying our care philosophy and strive to meet the needs of our dispensaries and patients with respect and compassion.

Our team believes in:

- *Responsiveness* - in our dealings with dispensaries, employees, lenders, public officials, regulators, neighbors, and the community at large.
- *Highest Quality Products* - by manufacturing safe, high-quality medicinal products subject to established production processes, using pharmaceutical-grade excipients and sustainable ingredients, protected by tight quality control and quality assurance testing.
- *Education and Research* - through disseminating facts and conducting publishable research to help the medical community, businesses, regulators, and patients better understand the responsible and effective use of medical cannabis.
- *Transparency* - by regularly auditing our financial data using an independent accounting firm and using third-party seed-to-sale software.
- *Being a Good Neighbor* - as we work with the city, the wider community, the county, the city, and police department as a responsible service provider.
- *Community Service* - conducting varied and ongoing outreach activities to serve our community.

Our core values are:

- *Independent Quality Standards* - We abide by third-party standards so we can be fairly judged by our peers including by not limited to Good Manufacturing Practices (cGMP), Good Laboratory Practices (GLP), and the International Organization for Standardization's (ISO) 9001:2015 Quality Management System.
- *Safety* - Whether we're ensuring consistent dosages, protecting our employees from harm, preventing product diversion, or reviewing our physical security protocols, we take the safety of our patients and community seriously. When it comes to medicine, we only produce the highest-quality, contaminant-free cannabis products.
- *Service* - Service is what drives us. Serving our patients with compassion and professionalism is what fueled the founding team.

- *Community* - Community is what empowers us. We realize we can't thrive without the support of the communities in which we operate in and interact with. Our goal is to be a good neighbor and invest conscious capital in our communities to create jobs and increase economic activity.

Medically-Focused Culture

One of the key differentiators of our business is that our culture will be medically-focused. Our majority shareholder of 51%, [redacted] and a minority shareholder of 12%, [redacted] are both medical doctors. [redacted] has worked as a pain management specialist for eight years and [redacted] has worked as a sport medicine specialist for twenty-one years.

Each of our team members deeply believes in medical cannabis as an effective alternative to traditional treatments without excessive negative side effects. However, each has seen that medical cannabis is not always viewed with great respect in other states and countries due to a lack of published research, pharmaceutical-grade process management, pure ingredients, internal quality controls, or professional managers.

This desire to create a medical culture is also influenced by [redacted] 8% shareholder, and [redacted] 12% shareholder. [redacted] has worked as a chemist, scientist, and operations director for pharmaceutical companies assisting with clinical trials, process improvement, facility design, and working in leadership roles managing hundreds of people. This includes his operational position with Greer Labs Inc. which was later merged to form Stallergenes Greer's International AG, a global biopharmaceutical company specializing in the development and commercialisation of allergy immunotherapy (AIT).

[redacted] has worked as an analytical chemist, independent chemistry consultant, and most recently founded a hemp formulation business in Alabama. Over her 20 year career, she fell in love with the fine details of biochemical assays, analytical laboratory techniques, quality and standard operating procedure implementation, and quality management adherence. Committed to lending her expertise to building a safe, sustainable

foundation for the medical cannabis industry, she serves as a voting member on American Society for Testing and Materials (ASTM) International's D37 Committee on Cannabis.

Coming from traditional pharmaceutical and biopharmaceutical backgrounds, Ala. Code § 36-12-40 (Per [redacted] were shocked that many licensed “medical cannabis” processors in other states were not following any quality management accreditations from the Institute Organization for Standardization or were familiar with any standard pharmaceutical manufacturing or analytical chemical processes. It is common to go to 10 different medical cannabis laboratories in legal medical cannabis states and see 10 completely different manufacturing or quality management processes. Usually, one sees a lack of quality management and sophisticated manufacturing processes.

In addition, our team has seven more team members and advisors who come from medical backgrounds.

Ala. Code § 36-12-40 (Personally Identifiable Information) and the rest of the founding team have made a commitment to uphold the standards found in their medical backgrounds in this new Alabama industry. They want to show the state government, the regulating bodies, their communities, and other cannabis operators what is possible with knowledge, dedication, and the consistent application of base principles.

Operational Experience

Our team members have extensive experience in the medical cannabis and hemp sectors in Alabama, California, Colorado, Oregon, and Colombia. Several members of our team have a proven track record of success in working with botanical extraction, pharmaceutical manufacturing, analytical chemistry, pharmaceutical distribution, and traditional medicine in Alabama, North Carolina, and Ohio. They are eager to bring their skills to the emerging medical processing sector of Alabama. An in-depth explanation of our team’s experience will be discussed in the “Leadership Background and Qualifications” and “Key Personnel” sections below.

Our team prides itself on professionalism and integrity, which means safety is paramount to our operations. We're committed to providing patients with only the highest quality, biocide-free, lab-tested, and properly labeled medical cannabis. Our commitment to safety also extends to the wider community, which is why we utilize industry best practices including proper internal checks and balances, enterprise resourcing planning and inventory control software, and effective security solutions to prevent our medical cannabis from diverting into the illicit market. Through the team's wide variety of experience, they have used or created policies and procedures which will ensure a safe, compliant, secure, and effective environment for manufacturing medical cannabis to meet the needs of the market.

Our standard operating procedures follow the standards set forth by American's for Safe Access (ASA) Patient Focused Certification (PFC). PFC is the nation's only certification program for medical cannabis businesses that meets or exceeds the American Herbal Product Association (AHPA) and the American Herbal Pharmacopoeia (AHP) cannabis monograph guidelines to guarantee a consistent, uncontaminated, and effective product to every patient.

<u>Leadership Background and Qualifications</u>

Operational Ownership

Ala. Code § 36-12-40 (Personally Identifiable Information) **Chief Executive Officer** - Ala. Code § 36-12-40 (Personal) is board certified in internal medicine and has been a doctor of medicine since 2014. After finishing his residency, he went through a sport medicine fellowship while rotating through interventional pain and addiction medicine. These three fields have been the focus of his practice and his publications. He has had eight presentations at medical conferences and six published papers.

Currently, he is a practicing pain and addiction medicine physician with Preferred Pain Associates of Alabama and he is Chief Medical Officer of Fitomics Nutrition and Fitness, an educational firm. He is licensed to practice medicine in Alabama, Mississippi, and

Tennessee. He holds certifications in Basic Life, Advanced Cardiovascular, and Advanced Wilderness Life Support.

[redacted] is a member of the Medical Association of Alabama, the Jefferson County Medical Society, the founding Treasurer for the West Alabama Program of All-Inclusive Care for the Elderly, and a physician consultant for E3 Partners Medical Missions, a Christian non-profit.

[redacted] **Chief Operating Officer** - [redacted] is a biopharmaceutical scientist, operational director, entrepreneur, and inventor. Over the past 20 years had held multiple roles within biopharmaceutical companies starting as a research chemist, advancing to clinical trial design and material manufacturing, and rising to two leadership positions with multinational biopharmaceutical companies.

For Greer Labs, Inc. he was their director of operations managing a team of 300 people and responsible for the manufacturing, engineering, supply chain, research, and maintenance departments for a 30,000 SKU product line. He managed the capital budgeting and allocation, improved several sites and processes, and developed a five year plan for sales growth of 150%. He led the transition team when Greer Labs, Inc. merged with Stallergenes to form Stallergenes Greer International AG.

He was a senior manager at Alkermes, Inc., a biopharmaceutical company which focuses on diseases of the central nervous system such as schizophrenia, bipolar disorder, and depression, addiction, and cancer. He oversaw their growth from 30 employees to over 500 at their Ohio manufacturing facility. He assisted with taking multiple clinical medications, i.e. Risperdal Consta and Vivitrol, through research into the Federal Drug and Administration's approval process concluding with commercial success.

[redacted] has spent the past ten years as an early stage entrepreneur and executive at two companies, Inventure Renewables, Inc. and StenCo, LLC. Inventure Renewables assists customers with the sustainable extraction of valuable biochemical and material building materials from agribusiness residue and other waste streams. StenCo has created a new

oxygen-excluding, biodegradable film that can be used as a substitute for existing non-degradable plastic packaging to prevent environmental pollution. He holds dual Bachelor Degrees in Chemistry and Physics in addition to his Master's of Business Administration.

Ala. Code § 36-12-40 (Personally Identifiable Information) **Chief Processing Officer** - Ala. Code § 36-12-40 (Personally Identifiable Inform is a Ph.D analytical chemist who has 20 years of experience spanning chemical research, manufacturing, formulation, analytics, and compliance implementation and management, for companies ranging from start-ups to Fortune Global 200 corporations. She obtained her B.S., M.S., and Ph.D all from the University of Alabama, and has been based in Alabama for the entirety of her working career.

While working towards her M.S. and Ph.D, Ala. Code § 36-12-40 (Pe worked as a Science and Calculus teacher at North River Christian Academy, a high school in Tuscaloosa, Alabama. After obtaining her Ph.D, she worked as a Postdoctoral Research Stimulating Fellow at the University of Alabama. She then worked at Inventure Renewables, a company that sustainably extracts valuable biochemicals and materials from waste streams, as their Director of Analytical Services.

While working at Entropy Solutions, the first company to produce 100% renewable phase change material, Heather established ISO 9001 accreditation standards in less than seven months as she foresaw that the company would soon move from the R&D stage to manufacturing consumer products. Ala. Code § 36-12-40 (Personal consulting engagements include expeditiously diagnosing and restarting a Fortune Global 200 company's malfunctioning refinery, which three of the company's internal labs could not accomplish.

Currently Ala. Code § 36-12-40 (Pe is the Founder and CEO of Southern Apothecary, a hemp formulation, white labeling, and manufacturing company that manufactures hemp products in an FDA-registered, Alabama Department of Agriculture licensed facility. She also founded TASC Labs, a boutique analytical laboratory that conducts analysis on complex materials for formulators, inventors, and large manufacturing facilities.

[redacted] has multiple affiliations pertaining to chemistry and analytical standards, including but not limited to the American Oil Chemists Society, the American Society for Mass Spectrometry, and the ASTM D37 Committee on Cannabis. She has co-authored multiple research papers published in publications such as Biochemistry, and Journal of Mass Spectrometry, and regularly presents at scientific conferences across the United States. She holds a Bachelor's, Master's, and Ph.D. in Chemistry. Her Ph.D. education was centered around analytical chemistry and mass spectronomy.

[redacted] **Chief Medical Officer** - [redacted] is board certified in family medicine and has been a medical doctor since 1995. After completing his residency in family practice, he went on to complete a sports medicine fellowship. Sports medicine became a lifelong passion. After his fellowship, he went on to work with the National Football League in Germany, Scotland, and the Netherlands as an assistant medical director. Simultaneously, he was able to become the head physician for the University of California at Berkeley and the chief of non-medical orthopedics at two Kaiser Permanente locations.

He went on to become the team physician at Alabama State University and Miles College. He held additional posts as the medical director for Legion Field, one of the largest stadiums in Alabama, the fellowship director of the American Osteopathic Sports Medicine Fellowship, and the division chief of family medicine at the Grandview Medical Center.

He currently operates his own sports medicine practice at Princeton Hospital. He has served the community as a founder of the All Access Sports Medicine Camp, a volunteer physician for the Fit for Life Boxing League, as chair of the United Negro College Fund Gala, and as a boardmember of the Midnight Basketball League.

He receives frequent media requests for sports medicine advice and has interviewed with XM Radio, Sports Illustrated, and ESPN Radio. He was awarded the Physician of the Year in 2014 by the National Athletic Trainer Association.

[redacted] holds medical licenses in Alabama and California. He is a member of the National Football League's Physician Society, the American College of Sports Medicine, the American Association of Family Practice, and the American Medical Association.

*Additional Executive*s

[redacted] **Chief Financial Officer** - [redacted] is an experienced accountant who has worked in public accounting, for a large Fortune 500 company, and lean startups. He began his career performing external audits of credit unions for Pearce Bevill Leesburg & Moore, a public accounting firm. He moved on to private accounting for Regions Bank assisting with budgeting, forecasting, and general accounting practices.

He then joined Shipt, the delivery service company, as an accounting manager. He rose to the Director of Accounting managing all accounting staff, became responsible for tracking all revenue and expenditures, and managed special projects as the company developed. This includes during their high growth where he took over the management of shopper card funding, sales and income taxes, cash forecasting, being the point of contact for large vendors, and converting the company to a new enterprise resource planning software. He assisted with their transition when it was acquired by Target for $550 million.

[redacted] now works as the accounting lead for Flatfile, a technology startup, and was their first accounting hire. He manages all operational accounting activities and assisted in designing all processes in the department. He holds a Bachelor's and Master's of Accounting.

<u>Key Personnel</u>

Upper and Middle Management

[redacted] **Security Director** - [redacted] is U.S. military veteran and an active-duty police officer with the Alabaster Police Department. He joined the U.S. Coast Guard and served honorably. He held many roles including Board Officer, Operational Commander of Search and Rescue, and Team Leader for a crew of twenty.

In his tenure, he led various missions within his branch and in collaboration with several different federal law enforcement agencies. This included the search and seizure of narcotics and illegal contraband, search and rescue to protect lives and property, and other planned operations with various military and commercial entities. He was awarded the Coast Guard Meritorious Team Commendation, the National Defense Service Medal, and the Coast Guard Good Conduct Medal.

Upon military retirement, Ala. Code § 36-12-40 (Person entered law enforcement with the Mobile Police Department. He started as a patrol officer assisting with community safety, investigations of accidents and crimes, emergency and disaster containment, courtroom duties, and conducting routine sweeps. He later became a founding team member and investigator of the Gun Intelligence Unit, a collaboration between the National Integrated Ballistic Information Network and the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF). He received from the Mobile Police Department's Life Saving Metal, the Police Chief's Award, and the Physical Fitness Award.

Ala. Code § 36-12-40 (Personally Identifiable Information) **Information Technology Director** - Ala. Code § 36-12-40 (Personally Identifiable Information) is a software engineer with experience in back-end, front-end, and cloud computing. He started his career as a quality assurance engineer at Influence Health performing product testing searching for errors and failures. He then became a software engineer at Shipt where he collaborated with other team members to improve front-end customer workflows, improve their RESTful application programming interface (API), and create operational databases.

He advanced at Shipt to Senior Software Engineer and then to Software Engineering Manager. In these roles, he mentored junior developers to increase productivity, improved idiomatic syntax, created extensible systems, and worked in Agile development. He has worked with thirteen different brands of softwares, applications, and web hosting.

Ala. Code § 36-12-40 (Personally Identifiable Information) **Supply Chain Manager** - Ala. Code § 36-12-40 (Personally Identifiable Informa is mechanical engineer with 16 years of experience in engineering development, sourcing materials, manufacturing, and project management. She first worked at Summit Products, creating toy concepts, testing

and manufacturing proven designs, and troubleshooting issues. She moved on to become a senior mechanical engineer with Mattel, working on toy projects for Disney, Thomas & Friends, etc. She collaborated with industrial designers, packaging designers, and marketing managers.

Afterwards, she joined Apple as an iPhone engineering project manager. She tracked and managed the development schedule, the suppliers, ensured on-time delivery of materials for prototypes, and traveled internationally. She left to become the vice-president of operations for InRoad Toys. She created their infrastructure and supply chain from scratch, delivered on-time production for global retailers such as Walmart and Target, and managed the manufacturing, fulfillment, and warehousing of materials and inventory.

Ala. Code § 36-12-40 then took a new position as director of product operations with Babyation, an Food and Drug Administration-approved breast pump and medical device company, where she built their supply chain, managed their fulfillment, and warehousing of materials and inventory. She currently operates her own independent engineering, operations, and supply chain consulting firm, Cahaba Industries. She holds a Bachelor's in Mechanical Engineering.

Ala. Code § 36-12-40 (Personally Identifiable Information) **Infusion and Formulation Director** - Ala. Code § 36-12-40 (Personally Identifiable Informa is a geochemist, analytical chemist, and cannabis extractor. He began his career as a chemist for heavy metal, pesticide, and food containment analytical laboratories. He then became a senior hydrographer for a large city collecting water samples and testing for contamination.

He moved on to be the director of chemistry at Metagreen Ventures, cannabis extractor and infused product manufacturer in California. He instituted their analytical testing, managed their product development, intellectual property research, and manufacturing processes. He was promoted to vice-president and expanded his footprint in the company managing multi-million dollar cannabis fulfillment orders. He took his skills and founded his own consulting company, Northwise Solutions, where he assisted many clients in their business planning, development, laboratory design, manufacturing process execution, and local approvals. He had clients in several locations including Oregon and Columbia.

[redacted] was offered a position as director of product technology and operation at True Terpenes, a cannabis laboratory company specializing in flavonoid, terpene, and terpenoid extraction. He led the development of their quality control and assurance program, the creation of 1,150 SKUs, and worked with cannabis scientists to produce improved quality. He filed the companies first patent and managed their trade secrets. He is currently their senior science advisor. He holds a bachelor's in chemistry and a master's in geochemistry.

[redacted] **Quality Assurance and Control Director -** [redacted] is an analytical chemist, biologist, and cannabis scientist. He started as an assistant technician with the University of Hawaii and the research assistant with the University of North Carolina at Chapel Hill. In these roles, he ran isotope, fluorescence, and spectrophotometric analysis on biological specimens.

He became an associate biologist for Avista Pharma Solutions, a contract researcher, manufacturer, and analytical testing company for generic pharmaceuticals. He used liquid chromatography and mass spectronomy on chemical extractions, analyzed biological assets of ectoparasites, and generated reports on the toxicity of experimental parasiticides.

Next, [redacted] became the vice-president of scientific operations of Steep Hill Labs in Hawaii, a cannabis laboratory testing, quality assurance, and data analytics company. As vice-president, he brought the laboratory into ISO 17025 Testing and Calibration accreditation, wrote all of the procedures for testing residual solvents, heavy metals, terpenes, cannabinoids, and microbiological contaminants, led a team of five scientists, and implemented a new laboratory information management system to increase efficiency.

He was eventually promoted to the director of process development and implementation of Steep Hill Labs in California. In this role, he brought this lab into ISO 17025 accreditation, trained a team of fifteen scientists on improving testing turnaround times, and created new processes for testing heavy metals, pesticides, and mycotoxins. Then, he became director of development and implementation for Front Range Biosciences, a hemp biotechnology

company. He designed methodology for the quantification of 32 cannabinoids and 65 terpenes, conducted phytochemical analytical tests of 6,000 unique samples, and assisted in breeding 150 cannabis germplasms.

Presently, [redacted] is the co-founder and chief chemistry officer of Trytomics, an analytical chemistry lab specializing in medicinal fungi quality control and research. He has three published papers and nine conference presentations. He received a Congressional Service Award in 2007. He holds a Bachelor's in Biology and Chemistry, and a Master's in Marine Science.

[redacted] **Human Resources Director** - [redacted] is a lifelong human resources professional with 16 years of experience. Upon graduation from college in 2003 until 2019, she worked for Protective Life Insurance Company as a Human Resources Administrative Assistant, Human Resources Benefits Coordinator, and Human Resources Leave and Benefits Administrator.

In her journey through these roles, she performed daily operational tasks related to employee records, carrying out interviews, background check screenings, etc. She managed the employee benefits program for group health, flexible spending accounts, retirement, dental, vision, COBRA, and wellness coverage. She held annual evaluations and critiques of healthcare provider coverage seeking to optimize employee benefits.

She oversaw accident and leave of absence reimbursements, disability coverage, tuition reimbursement, managed the company's charitable foundation, and hosted corporate events. She became a talent advisor for St. Vincent's Hospital where she recruited for all healthcare positions, created metrics of analysis, screened potential candidates, and gave recommendations for approval.

She is now a recruiter for Avita Pharmacy, the largest national provider of pharmacy services, focused on hiring talent at the upper management level. She is a volunteer for Big Brothers, Big Sisters and the Christian Service Mission. She has a Bachelor's in Social Work.

[redacted] **Compliance Director** - [redacted] has been a practicing attorney in Alabama for the past 13 years. He has specialized in criminal defense, estate administration, probate law, and family law. He started his career with the County Public Defender's Officer. He has been heading his own legal practice since 2007. He has a wealth of understanding related to legal compliance, courtroom proceedings, and litigation. He is respected for his attention to detail, his due diligence, and his hard work in protecting client rights.

[redacted] is a member of the Alabama Criminal Defense Association and the Alabama Family Law Association. He received training from the Geoffrey Fieger Trial Practice Program and is in good standing with the North District of Alabama. He has a Bachelor's in Political Science and a Juris Doctorate.

[redacted] **Sales and Marketing Director** - [redacted] is a specialist in pharmaceutical marketing and sales. He has managed pharmaceutical sales for Alabama pharmacies for the past 13 years. He began as a territory sales representative for Victory Pharma becoming taking it to #10 out of 103 districts in his first two years. He then took his district to #1 out of 103 districts by his third year.

In his successive role at River Crossing Pharmacy, he was the district manager, where he trained and managed a team of five across four states, growing revenue month over month, and taking greater market share away from the competition. At Accurx, he was the sales manager, where he marketed specialty products for their pharmacy, managed their entire sales force, and grew the customer base.

[redacted] currently works for CareDirect Rx Pharmacy as the vice-president of sales and marketing where he has created year over year growth, developed quality control checks for ensuring compliance with marketing and sales regulations, and has improved staff quality. He has an Associates in Pre-Business and a Bachelor's in Marketing.

[redacted] **Community Outreach and Social Equity Director** - [redacted] is an experienced program coordinator, academic, and fundraiser. Her first job after graduation was as a consultant for Chicken Soup of the Soul, the socially conscious and self-empowerment company. She went on to a performance consultant for the National Football League's European branch providing behavioral health assessments.

She left to become a senior analyst followed by a promotion to principal analyst for the Center of Workforce Development at University of California at Berkeley. She then became the program coordinator for the Jefferson County Committee for Economic Opportunity. Afterwards she served as the Executive Director and the Liaison for Grants and Charitable Giving for the City of Birmingham. She now resides as the provost and vice president of Miles College. She has a Bachelor's in Psychology, a Master of Legal Studies in Psychology, and a Doctorate of Psychology.

Advisors

[redacted] **Medical Advisor** - [redacted] is a board certified internist and has been a physician since 2014. After completing his residency where he was the Chief Internal Medicine Resident, he worked for Concentric Hospitalist Group followed by the Grandview Medical Center. He currently works as a General Internist for Southview Medical Group. He has recently taken an interest in cannabis as an effective medical treatment and is looking forward to assisting in its study.

[redacted] **Medical Advisor** - [redacted] is a board certified adult neurologist and vascular neurologist. He has been a physician since 2015. He has been a practicing neurologist at Grandview Medical Center since the completion of his neurology residency and vascular neurology fellowship. He is currently the Chairman of the Neurology Department and the Stroke Program Medical Director at Grandview Medical Center. He is a member of the Society of Vascular and Interventional Neurology, the American Heart Association, the Jefferson County Medical Society, and the American College of Physicians. He has four published papers.

Ala. Code § 36-12-40 (Personally Identifiable Information) **Strategic Advisor -** Ala. Code § 36-12-40 (Personally Identifiable Information) began his career in the biochemical transcription of microbes. In the 1990's when faced with a research funding deficient, he looked into combining biotechnology and intellectual property i.e. DNA sequencing, RNA analysis, in vitro analysis, and codon optimization. This led him to becoming an independent patent scientist and retained patient agent for law firms and biotech companies. He has served as a director of intellectual property for multiple biotech firms in the preceding years both domestic and international. His last position before joining the cannabis industry was as Sequenom's senior patent agent.

In 2014, he joined Steep Hill Labs, the world's first commercial cannabis analytical testing laboratory, as its chief scientific officer. He was later promoted to its president. After improving operations, hiring competent staff, and stabilizing the financials, he moved on to Front Range Biosciences, a cannabis biotechnology research and development firm. He was the director of intellectual property before being promoted to vice-president of research and development.

Ala. Code § 36-12-40 (Personally Identifiable Information) has been an active speaker at cannabis conferences and interviewee media publications. He has nine published papers, five of which pertain to cannabis research including modeling cannabinoids from *Cannabis sativa* chemotypes, the genomic characterization of *Cannabis sativa's* terpene synthase, and medical cannabis's infectious risks for immunocompromised patients. He has a Bachelor's in Microbial Genetics, a Ph.D. in Molecular Genetics, and a Post-Doctorate in Plant Genetics.

Ala. Code § 36-12-40 (Personally Identifiable Information) **Strategic Advisor -** Ala. Code § 36-12-40 (Personally Identifiable Information) is a serviced-disabled Navy veteran and medical sales professional. In the Navy, he finished at the top third pilot from flight school. He went on to serve in the Gulf War being awarded the Navy Achievement Medal twice for superior performance. In addition, at different points, he served as a Pilot Instructor, Chief Naval Officer for Special Projects, Chief Pilot for Executive Transport. One year before his retirement, he was the number one ranked lieutenant at the Naval Air Base in Belle Chasse, New Orleans.

In his civilian career, [redacted] served as pharmaceutical and analytical testing sales representative. He excelled in all roles over the past twenty-two years. He consistently ranked between number 10 and number 1 in sales volume in his nine roles. He has worked for SmithKline Beecham, the billion dollar pharmaceutical manufacturer, Forest Labories, another billion dollar pharmaceutical company, Heritage Pharmacy, and currently serves Core Diagnostic Laboratories. He is the director of coaching for the Birmingham United Soccer Association.

Facility Location and Facility Function

The facility is located at 2347 Montgomery Highway, Centreville, AL 35042. The coordinates are 32.94199191573772, -87.10212765035135.

Facility Function

The facility function is to optimize top-tier cannabis products by way of well-designed and consistent manufacturing processes. Our facility will be fabricated to function as a small scale biopharmaceutical manufacturing facility using [redacted] experience with Stallergenes Greer's International AG, [redacted] laboratory design experience with TASC Labs, and [redacted] experience with infused cannabis production.

This means that our facility will be built to withstand a multitude of threats both external and internal. The facility operates year-round consistently producing ready to consume infused medical products while maintaining a perfectly controlled environment for optimal manufacturing. Our planned facility has a unique, standardized workflow that guarantees a perfect product 99.9% time due to the intense quality control procedures including using [redacted] process for instituting lean sigma practices and creating redundancies to reduce error.

We highly doubt that any product will make it through our process with fault, but if that does occur, we have rigorous and immediate recall notification and product collection procedures to mitigate public threat. It is through this rigorous attention to detail that our

team has been able to maintain their position as leaders in their respective industry sub-sectors.

Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis

We have identified several factors which may impact our success as detailed below.

The following **strengths** will be internal to our company:

- Heavy reliance on financial and operations data and systems (e.g., QuickBooks, inventory control, digital infrastructure).
- Sophisticated processing approach: the most sophisticated and advanced manufacturing practices backed up by rigorous scientific testing.
- Clean, professional environment.
- Competitive salary for processing staff that exceeds the area's living wage requirements.
- Modern, secure processing location.
- Strong leadership team, advisors, and network.
- High-quality employee selection and staff training.

The following **weaknesses** will be internal to our company:

- Lack of absolute clarity about the future size of Alabama medical cannabis.
- Unknown if integrated dispensaries will purchase from external vendors.

The following **opportunities** will be available to our company:

- General public acceptance of cannabis use as a medicine is growing.
- Existing federal administration policies toward legal business are more tolerant.
- Ability to serve the community and promote a scientific standard in a commercial medical market.

The following **threats** could impact our company:

- There are still significant preconceived negatives by society at large about medical marijuana use.

- The dynamic tension between federal and state governments regarding legalities of medical marijuana is not fully resolved.
- There is a pre-existing illicit-market competition. However, illicitly-sourced cannabis cannot match the quality and safety (e.g. free of contamination, reputable source of medicine, privacy of transaction) of that provided by regulated medical cannabis producers.

9.7 – Description of Services and/or Products

Product Type	Packaging Description	Formula	Total THC per Package	THC per Single Dosage
Tinctures	Glass Bottle with Dropper 50 milliliters	92.9% MCT coconut oil 1.2% cannabinoid distillate 3.1% cannabis internally-extracted terpenes	400	25
Gelatins	Bioplastic Jar 14.02 cubic inches	96.5% gelatin mixture (pectin, distilled water, corn syrup, sugar, citric acid) .25% MCT coconut oil .25% cannabinoid distillate 3% peach-flavored botanical terpenes	300	20
Topicals	Bioplastic Jar 4 ounce	97.5% body balm base (coconut oil beeswax, peppermint essential oil, lemon essential oil) .25% MCT coconut oil .25% cannabinoid distillate 2% cannabis internally-extracted	300	10

		terpenes		
Suppositories	Bioplastic Case 10.61 cubic inches	94.8% Polypeg suppository base 2.6% MCT coconut oil 2.6% cannabinoid distillate	250	25

Product Type	Lifespan in Months	Pricing per Package Wholesale to Dispensary	Pricing per Package Retail at Dispensary (Estimated)	Patents
Tinctures	12	$28.00	$56.00	N/A
Gelatins	12	$30.00	$60.00	N/A
Topicals	12	$30.00	$60.00	N/A
Suppositories	18	$17.50	$35.00	N/A

9.8 – Advertising/Marketing Analysis and Strategy

Market Research and Analysis

Our team has studied all of the medical cannabis markets in the United States to better predict demographics, growth rates, patient populations, and economic outcomes in Alabama. In particular, we are focused on analyzing medical markets which were more restricted in product offerings, politically conservative to regulated cannabis, and had fewer licensed businesses. Of course, there are external mitigating or growth factors which are impossible to predict, but greatly affect the outcome such as the number of doctors who register with the program, the willingness of the registered doctors to certify patients, the qualifying condition list, and the general public's cultural reaction to medical cannabis.

The most important metric when predicting the health of a medical cannabis market is the patient population. In general, a mature medical market equals 2% of the total population holding medical cannabis cards. There are medical markets which exceed this 2% such as

Maine, Oklahoma, Michigan, etc., but these are unlimited license markets whereas Alabama is a limited license market.

For several potential outcomes to the growth of the market, our team concludes that the markets of Minnesota, Connecticut, Delaware, Utah, Louisiana, and Arkansas provide reasonable backdrops for our financial model. We chose Minnesota, Connecticut, and Delaware as an analytical group because they are older medical cannabis markets with limited licenses and cannabis conservatism where growth has been slow. It took Delaware 5 years to reach 1.13% in patient population, it took Connecticut 6 years to reach 1.29% in patient population, and it took Minnesota 7 years to reach .52% in patient population.

It is more than possible that given the political, cultural, and regulatory climate in Alabama, that it will take at least 5 years for the patient population to meet or exceed 1%. Utah was selected because it is a newer market, has a similar regulatory structure to Alabama, is highly religious, and politically conservative. However, instead of being slow, Utah's market grew to 1.6% in patient population in two years.

We selected Louisiana and Arkansas because they share the same geographic region, a similar demographic makeup, and a similar culture. In 4 years, Louisiana has grown to .75% in patient population and Arkansas has grown to 3.07%. After integrating all of our captured data, we concluded that over 6 years, Alabama would achieve a 1.4% patient population.

Using the estimates of the patient population with the assumption of .4% in patient population by the end of 2023 and an additional .2% in total market growth each year, we were able to model out the total market size, the annual retail demand for wholesale infused products, its market share, gross profit, and net profit. The data from these comparable markets offers insight into how Alabama's medical cannabis program could evolve in the early years. We have taken a prudent approach to forecasting our capital and human resource needs to develop a plan that will efficiently provide access to high quality

medical marijuana products to patients while having sustainable profits to continue our operations.

Since the number of processing facilities is fixed at this time, we are working under the assumption that all 4 processing licensees and the processing divisions of the 5 integrated licensees will become operational. Based on that assumption, we have designed a phasing plan for our processing operation that assumes that we will supply 1/9th or 11.1% of the demand for products in Alabama. This phasing will allow us to both save on upfront costs and avoid oversupply while providing cost effective medicine to Alabama patients. We concluded that within our Phase I product mix and its respective sales percentage: topicals will be 5%, gelatins will be 25%, suppositories will be 25%, and tinctures will be 45%.

	2023	**2024**	**2025**	**2026**	**2027**	**2028**
Patients as Percentage of Population	.4%	.6%	.8%	1%	1.2%	1.4%
Total Market Size	$39,144,000	$58,716,000	$78,288,000	$97,860,000	$117,432,000	$137,004,000
Infused Product Market	$19,572,000	$29,358,000	$39,144,000	$48,930,000	$58,716,000	$68,502,000
Applicant's Market Share	11.1%	11.1%	11.1%	11.1%	11.1%	11.1%

Marketing and Branding Strategy

Due to the extensive restrictions on marketing, we have chosen to focus our efforts on communicating directly with dispensaries in a business to business manner. Our team will

place all of its efforts into brand building by “living its values” and demonstrating to its dispensary customers that it is the best choice for patients.

Our company will not be marketing to the public and will only have a website which is informational, restricted to patients, vendors/customers, regulators, and those who are 21 years or older who live in a medical cannabis state.

Compliance with Advertising and Marketing Regulations

- Our company will seek approval from the Alabama Medical Cannabis Commission before launching any branding, marketing, or advertising activity of any kind.
- Our company will adhere to the Darren Wesley 'Ato' Hall Compassion Act.
- Our company will adhere to all rules created by the Alabama Medical Cannabis Commission.
- Our company will adhere to any regulations established by its county and municipality.
- Our company will adhere to the provisions of the Standards of Practice of the American Association of Advertising Agencies.

For our brand, which will be communicated via our company culture, product quality, packaging, website, and business to business interactions, we will be living the core values of patient well-being, corporate stewardship, and community involvement. Our brand is designed to better meet the needs of patients who seek a modern, clean, safe, and professionally managed facility. Specific differentiators that appeal to dispensaries and patients include the following:

- **Focus on Wellness** – We emphasize health and wellness, not misuse. We are a patient-focused organization whose mission is to help Alabama’s patients heal and achieve the highest possible quality of life.
- **Service Orientation** – Our core staff are medical professionals. We will enrich the medical industry of Alabama through our dedication to research, community outreach, and public-private sector collaboration.

- **Higher Quality Medical Cannabis** – Our team's focus is on using biopharmaceutical and cannabis-industry standards to produce the highest quality possible.
- **Use of Current Technology** – We will utilize quality management software, inventory tracking software, and enterprise resourcing planning software to manage our process and transactions.

9.9 – Community Engagement Plan

Community of Operation

We will be operating its processing facility in Centreville, Alabama which is the county seat of Bibb County. This location was chosen because it is a sparsely populated city, on a 15 acre wooded plot, in a low-population county which is centrally located in the state. First and foremost, the location is physically secure against intruders, it does not have a great amount of traffic exposure, and it will not negatively impact this small local community.

Second, the municipality and county want more economic activity. As of the 2020 Census, Centreville has a population of 2,800 and Bibb County has a population of 22,293. The county experienced a -4.5% population decline in the past ten years. Bibb is 44th least populous county out of 67 counties in Alabama.

Third, our team has operated small businesses, multinational businesses, cannabis businesses, analytical testing laboratories, medical practices, legal practices, and engineering companies. Our team members have found some of their greatest successes by going above and beyond with regard to our community engagement. We always want to make a sustained effort for positive community impact to build long-term, mutually beneficial relationships with local leaders, organizations, and the general populace.

Local Support and Collaboration

We do not want to operate in any community where our operations are not desired. Our team has searched throughout the state to find a community which wanted to work with it, was safe, and was located along an optimal distribution pathway.

Our team was able to create a working relationship with Centreville and the community was very receptive throughout our search and vetting process. We have attached a letter of reference below from the Mayor of Centreville, Mike Oakley. We also attached a letter of reference below from Julie Holdsambeck, a Centreville native, who says that local residents want manufacturing work and that the municipality is perfect for another medical business as it has an expanding retirement facility as well as a small hospital.

City of Centreville

Mike Oakley, Mayor

Coosa Medical Manufacturing

Letter of Support

Greetings,

I am writing this letter in support of Coosa Medical Manufacturing, LLC's application for a processing license. I have interacted with their team, been in touch via text, phone and Zoom with various members and have listened to and heard their plans. I firmly believe they are fully qualified to safely operate a business dealing with medical cannabis.

This business will provide an immediate economic impact, job creation and much-needed housing in our city limits. Their team, highly qualified and certified, will be an asset to our community and our county.

I would be more than happy to assist them should they be awarded a license.

Feel free to contact me if you require more information.

Sincerely,

Mike Oakley, Mayor

City of Centreville, AL

Julie Holdsambeck
eXp Realty, LLC Central
REALTOR®
2325 Haysop Church Road
Centreville, AL 35042
205-928-9376
julie@yourcentralalabama.com
14 December 2022

Coosa Medical Manufacturing
Letter of Support

Greetings,

I am writing this letter in support of Coosa Medical Manufacturing, LLC's application for a processing license. I have interacted with their team, listened to their plans, and believe that they are qualified to safely operate a medical cannabis business.

As a longtime resident of Centreville, I can tell you our area is ripe for development and the job market is ready. We have historically been a forestry and manufacturing community, but local manufacturing has dwindled in the past couple of decades as consumer needs have changed. We are more recently known for our rapidly expanding retirement facility, which is run in conjunction with our hospital. We have evolved into a medical community.

Local residents are hungry for local manufacturing work, and Centreville is strategically located between the University of Alabama and the University of Montevallo, where higher-level professionals are coming out of school and waiting to be hired.

I would be happy to assist them should they be awarded a license.

Please feel free to contact me if you require more information.

Sincerely,
Julie Holdsambeck
REALTOR®

Julie Anne Holdsambeck

Listed below are a few of the outreach and programs that we will implement as part of our holistic community engagement plan.

Community Service

As a celebration of our commitment to the community each year our staff will spend one day volunteering. The volunteer day will be followed by a reception for staff and the community to bond and converse. Furthermore, we will contribute one community service project per year. The organization we support for this community service project will change from year to year so that we can benefit multiple aspects of the community over time. We will also seek beautification projects from year to year such as updating outdoor parks.

Educational Training Program

We have a memorandum of understanding with Miles College, which is a historically black college located in Birmingham, to create a cannabis training program. Our Community Outreach and Social Equity Director, [redacted] is the Provost and Senior Vice President of Academic Affairs at Miles College so this will create a strong and fruitful collaboration. Currently, Oregon State University, Ohio State University, Hofstra University, Denver University, and Harvard University offer classes on the emerging cannabis industry. We believe these skills should be brought to our community as well and we have the ability to facilitate that.

Economic Development Plan

Our team knows that every single community's economy is unique and needs to be treated as such. However, we have also found universal similarities between each of the communities that we have worked in especially since we prefer to work with disadvantaged and disenfranchised communities that want our operations in their neighborhood. To further this effort, we have developed our economic development plan from the Environmental Protection Agency's Framework for Smart Economic Development and Economic Development Best Practices which have been fused with its personal experience working across the United States and internationally. Below is our economic development plan for how we intend to have a positive impact on Centreville and Bibb County.

Job Creation

Job creation is immensely important to our team because of the positive impact that increased personal income has on the local community. We will hire and train locals who want to work hard, improve the lives of medical cannabis patients, and who have high integrity. Our company will have a staff of 20 in the first year. We foresee that over the next five years that many additional jobs will be created.

Just Wages and Economic Stimulus

Our goal is to further economic development by hiring people in Centerville and Bibb County, which have a recognized need for financial stimulation, by paying them just wages with quality benefits packages. Paying people a just wage is the most direct way to

positively impact communities for generations to come. In this spirit, we also intend to work with the local community to identify quality contractors and employees for our facility. We provide just wages that allow for economic empowerment of the people in our community. While the Alabama legal minimum wage is $7.25, the living wage for one adult in Bibb County is $17.40 an hour according to the Massachusetts Institute of Technology Living Wage Calculator. The lowest paid annual salary for our manufacturing facility is $40,000 or $19.23 an hour. The living wage calculator includes the bare minimum of food, childcare, medical, housing, transportation, and a small amount for other basic necessities.

9.10 – Environmental Impact Statement

Upon award of a license, and prior to the beginning of construction of our proposed facilities, our internal plan calls for us to complete and document a comprehensive, localized environmental impact assessment and ecosystem management plan. These plans include efforts to support biodiversity issues in and around the area where our facility will be. All areas of our operation will be detailed as they relate to positive or negative environmental impacts. Systems of enhancement and or remediation of negative impacts will be included.

Carbon Footprint: Our sustainability plan includes actions to minimize our carbon footprint, including greenhouse gasses and other energy-use-related emissions. We calculate our carbon footprint based on the scale of our operations within the facility, and we calculate new baselines as we increase the scale of these operations, and at the same time develop new reduction goals as we become more efficient with our operations.

Alternative Energy: Our sustainability plan, and our existing operations are focused on increasing the share of renewable energy in the energy mix used for production. We are exploring opportunities with several companies regarding the design and use of Renewable Energy System (RES) configurations to reduce the use of local grid power to assure successful processing. These systems could provide up to 50% of the total required energy load on site, in some cases, supplementing and reducing the reliance on local utility grid

power. These integrated RES components include mini-wind turbine systems, solar panels, and large format lithium-ion batteries.

Lighting: Lighting is one of the largest sources of energy consumption within our production facilities. Our sustainability plan requires the use of LED (light emitting diode) lighting for our processing operations. LED lights are more efficient than nearly any other type of artificial light, plus they only give off a fraction of the heat of conventional lighting, which reduces energy-consuming HVAC requirements. We will also use hoods for our outdoor lighting security purposes, which reduces unwanted light pollution to neighbors. Further, we will minimize the use of lighting during peak times as defined by the electric utility and use lighting motion detectors in our common areas to reduce unnecessary energy consumption.

Air Quality: Our sustainability plan calls for the use of energy-efficient cooling and ventilation systems for our facility, as well as the installation of automated climate controllers and strong protocols regarding the care of coils, fans and vents to maximize energy efficiency. All building intakes and interior filters will be rated MERV-11 to prevent any outside pollution or contaminants from entering the facility. Additionally, HVAC units providing air to processing rooms and other places where medical cannabis is handled are equipped with filters rated MERV-13 to prevent contamination via mold spores, bacteria, virus carriers, pollen, pesticides, and other microscopic pathogens.

9.11 – Insurance Plan

We have spoken to and evaluated multiple insurers. At present we have acquired a letter of intent from AssuredPartners, an A-rated insurance carrier. We have received tentative acceptance of insurance coverage contingent upon licensure from AssuredPartners. The insurance coverage includes the requirement of a minimum of two million dollars of liability and casualty insurance as per § 20-2A-53(a)(2) classified as General Liability and Product Liability by AssuredPartners. We will also be receiving Commercial Property, Workers Compensation, Professional Liability, Cyber Liability, and Employment Practice Liability insurance from AssuredPartners.

AssuredPartners

December 13, 2022

Coosa Medical Manufacturing, LLC
3841 Village Center Dr.,
Hoover, AL 35226

Re: Letter of Intent: Coosa Medical Manufacturing, LLC

To Whom It May Concern:

It is a pleasure for me to have the opportunity to recommend one of our valued clients: Coosa Medical Manufacturing, LLC and David Hardin, CEO. Coosa Medical Manufacturing, LLC has engaged our Cannabis Practice as their outsourced risk management and insurance team to help develop a risk analysis that will include several stages of their development:

1. Leasing/purchasing of the location
2. Construction activity to ready the site for operations
3. Operational stage (once cannabis is on the premise)

Part of this analysis will also consist of standard safety and loss control measures for entering and egress of the facility, burglar alarms, fire protection, specific requirements for storing the inventory, cash and vendor tracking systems.

Per our review, Coosa Medical Manufacturing, LLC can meet the minimum requirements of insurance required by the state of Alabama for $2,000,000 in casualty, workers' compensation, liability and (as applicable) auto liability coverage. These coverages will be secured by insurance carriers with a minimum financial rating of AM Best A- VII.

The property and casualty insurance lines of coverage will include:

1. Property Coverages: TBD per buildout
   a. Building coverage
   b. Tenant Improvements and betterments
   c. Business Personal property
   d. Business Income and Extra Expense
   e. Indoor Crop Coverage
   f. Cannabis Inventory and finished products
2. Auto Liability: $2,000,000 combined single limit

AssuredPartners

   a. Owned and Hired Non-Owned
3. General liability: $2,000,000 per occurrence; $2,000,000 aggregate
   a. Assault & Battery
4. Product Liability: $2,000,000 per occurrence; $2,000,000 aggregate
   a. Product withdrawal sub limits: $100,000
5. Workers Compensation: statutory limits
   a. Job descriptions
   b. Safety program
6. Professional Liability (E&O): $2,000,000 per occurrence and aggregate
7. Cyber Liability: $1,000,000 per occurrence; $2,000,000 aggregate
8. Employment Practice Liability: $1,000,000 per occurrence; $1,000,000 aggregate

Our history and review of David Hardin's ownership, management team, insurance and risk management plans clearly indicate a company thoroughly versed in the cannabis industry with a strong depth of experienced processes, procedures, and personnel.

Based upon our experience, our discussions and reviewing their preliminary applications for our Cannabis and Hemp insurance programs; we can foresee no difficulty in fulfilling the insurance policies required for managing their operations and compliance for all the city, county and state requirements.

If you have any questions, feel free to call our office.

Sincerely,

Douglas Esposito

Doug Esposito
Energy & Cannabis Practice Leader
AssuredPartners

1425 River Park Dr. Ste. 226, Sacramento, CA 95815 | www.assuredpartners.com | #0M07762

License Type: Processor

Exhibit 10 – Evidence of Business Relationship with Other Licensees and Prospective Licensees

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

Coosa Medical Manufacturing, LLC has members who have been involved in the cannabis industry in different parts of the country. We have never had issues engaging in sale agreements with dispensaries after license award. We have never had issues engaging in purchase agreements with cultivators after license award. We have included engagements with other applicants as well as our standard template agreements for supply, lab testing and secure transport. You will find the following in this Exhibit:

10.1 Any Cultivator or prospective Cultivator

The applicant has provided template purchase agreement to be used with a licensed Cultivator and a signed purchase agreement with Gulf Shore Remedies, LLC. Both of these documents are identified as "Business Relationships- Coosa Medical Processing Facility- Attachment to Exhibit 10, Section 10.1"

10.2 Any Secure Transporter or prospective Secure Transporter

The applicant has provided a template Secure Transport Agreement to be used with a licensed Transporter after license award. Identified as "Business Relationships- Coosa Medical Processing Facility- Attachment to Exhibit 10, Section 10.2"

10.3 Any Dispensary or prospective Dispensary

The applicant has provided template sale agreement to be used with a licensed Dispensary and a signed sale agreement with Yellowhammer Medical Dispensaries, LLC. Both of these documents are identified as "Business Relationships- Coosa Medical Processing Facility- Attachment to Exhibit 10, Section 10.3"

10.4 Any Integrated Facility or prospective Integrated Facility

The applicant has provided a purchase agreement with INSA Alabama LLC and AlaBloom both of which are applicant's for an Integrated Licenses. Both of these documents are identified as "Business Relationships- Coosa Medical Processing Facility- Attachment to Exhibit 10, Section 10.4"

10.5 Any State Testing Laboratory or prospective State Testing Laboratory

The applicant has provided a MOU for testing with Certus Labs and a template Lab Testing agreement for use after license award with other state licensed lab companies. Both of these documents are identified as "Business Relationships- Coosa Medical Processing Facility- Attachment to Exhibit 10, Section 10.5"

MEDICAL CANNABIS PURCHASE AGREEMENT
between
COOSA MEDICAL MANUFACTURING, LLC
and
_____

Coosa Medical Manufacturing, LLC ("**Buyer**") and Alabama Cannabis License Holder, _____ ("**Seller**", and together with Buyer, the "**Parties**", and each, a "**Party**") hereby enter into this Cannabis Purchase Agreement (this "**Agreement**"), setting forth the terms of sale and purchase of approved forms of medical cannabis product, as permitted under the applicable Alabama laws and regulations and subject to availability, (the "**Product**") by the Parties.

Buyer:	Coosa Medical Manufacturing, LLC Ala. Code § 36-12-40 (Personally Identifiable Information) [redacted]
Seller:	Alabama Cannabis Company Address City, State, Zip
Scope:	This Agreement applies to the purchase (the "**Purchase**") of the Product by Purchaser from Seller, in accordance with the terms set forth herein.
Term:	Twelve months from the date of the first delivery of Product with the option to extend for one additional one-year term, at Purchaser's sole option to be exercised on or before July 31st of the prior year.
Scheduling:	Seller will ensure that sufficient transportation contractors, as applicable, are available at all relevant times to accommodate delivery.
Supply Terms:	Seller shall deliver to Purchaser, FOB Purchaser's facility listed above, packaged and labeled Product specified in **Exhibit A** ("**Order Form**"), as attached hereto and incorporated herein. In the event of any conflict between the terms of this Agreement and the terms of any purchase order or any other document issued by Purchaser, the terms of this Agreement prevail.
Product Quantities and Pricing:	The purchase prices and/or base quantity and Product availability shall be determined by Seller. Throughout the Term, Seller reserves the right to unilaterally update the Prices and/or Base Quantity and Product availability and shall provide such notice to Purchaser. All prices are exclusive of all sales, use and excise taxes, and any other similar taxes, duties, and charges of any kind imposed by any governmental authority on any amounts payable by Purchaser.

Payment Terms:	Seller reserves the right to require that Purchaser make a deposit payment in order for Seller to accept and fulfill Purchaser's order. On the date that Seller delivers the Product, Seller shall present an accounting of the amount due, which shall include the Price of the Product delivered, quantity, name of Product, any taxes, delivery fees, subject to any credit adjustment for Purchaser's deposit payments, and the correlated RFID number applied through the Alabama Medical Cannabis Seed-to-Sale system. Payment will be made in full in immediately available funds on the Payment Due Date as set forth in the Order Form, Ex. A, (the "**Payment Due Date**") via cash, automated clearing house, or certified check payable as directed by Seller. Purchaser shall pay an 8% (eight percent) per annum interest charge on overdue amounts for the Product purchased hereunder.
Representations:	During the Term, Seller shall comply with and manufacture the Product in accordance with regulations established by the Alabama Office of Medical Cannabis (the "**OMC**") and the State of Alabama related to the manufacture, production, handling, and transportation of medical cannabis and cannabis products ("**Applicable Regulations**"). In the event that any Product sold hereunder does not comply with Applicable Regulations, or does not comply with the terms of this Agreement, Purchaser shall notify Seller in writing of any such non-compliance within two (2) business days following the Delivery Date of the relevant Product to Purchaser, stating in reasonable detail the nature of such non-compliance and type and aggregate quantity of the Product to which such non-compliance applies (a "**Non-Compliance Notice**"). If such non-compliance can only be demonstrated by laboratory testing, the Non-Compliance Notice shall include documentation of the relevant test results. Seller shall have the right to replace any such non-complying Product with compliant Product within five (5) business days of receipt of the Non-Compliance Notice, which shall constitute full compliance by Seller of its obligation to supply Products with respect to such Purchase Order. If Seller does not provide replacement within five (5) business days, then Purchaser's sole remedy shall be to receive a refund of the Price paid for the non-conforming Product based upon the price set forth in this Agreement. In the event of return of the Product by Purchaser, Purchaser shall pay Seller a restocking charge equal to fifteen percent (15%) of the Price.
Transport:	Seller shall make delivery FOB Purchaser's facility. Title to the purchased Products shall pass to Purchaser upon delivery and acceptance of the Product by Purchaser on the day of delivery. The risk of loss or damage to the Product sold hereunder shall pass from Seller to Purchaser upon delivery of the Product by Purchaser. Purchaser shall be responsible for a

	delivery fee to be calculated by Seller and added to the purchase price for each order. Throughout the Term, Seller reserves the right to unilaterally update the delivery fee for any order. All Products delivered hereunder shall be packaged in accordance with all applicable state laws and regulations, with the Product packaged separately and clearly labeled with identification of the applicable strain and weight of the contents.
Governing Law:	This Agreement shall be governed by the laws of the State of Alabama. Purchaser submits to the jurisdiction and venue of any state court sitting in the State of Alabama.
Force Majeure:	The obligations of the Parties are contingent upon earthquakes, fires, storms, floods, freezes, material reductions, accidents, labor disputes, transportation embargoes, significant oil price increases, failure of machinery, acts of God or of any government (including the OMC), pandemics (including the COVID-19 pandemic) and any circumstances related to COVID-19 or any related epidemic, pandemic, state of emergency, government orders, government shutdowns, unavailability of labor, or materials or reasonable substitutes therefor, or other causes beyond any Party's reasonable control that relates thereto, including ceasing of operations by Seller, acts of war or terrorism, and other interferences beyond the Parties' reasonable control, to the extent the same prevent or delay the performance of the obligations herein contained.
Taxes:	Unless otherwise indicated herein, prices do not include state, county, and/or municipal sales, use, excise or similar taxes applicable to the purchased Product, or the purchased Product's use by Purchaser or the Purchaser's customers. If Seller should be required to pay the same, Purchaser shall be liable to pay to and to reimburse Seller for any such taxes. If required by law, Seller may collect sales or use taxes on its invoices for Product sold to Purchaser hereunder.
Security Interest:	Purchaser hereby grants to Seller a security interest in the purchased Product to secure the payment of Seller's invoice for all or any portion of the purchase price that remains unpaid at any time. Purchaser hereby authorizes Seller to execute on behalf of Purchaser and to file one or more financing statements to evidence and perfect a security interest in the purchased Product with any governmental authority in any jurisdiction as Seller, in its sole and absolute discretion, deems necessary or desirable to protect the Seller's interests. Purchaser shall execute at Seller's request any documents required by Seller to evidence and perfect such security interest, including individual or blanket financing statements, chattel mortgages, or similar instruments for filing in any such jurisdictions. Seller shall have all of the rights of a secured creditor under the Uniform Commercial Code or any similar law that may be

	applicable, including the right of repossession for non-payment.
Liability:	TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL SELLER BE LIABLE TO PURCHASER FOR LOSS OF PROFITS, REVENUE OR INCOME, OR FOR ANY INDIRECT, PUNITIVE, SPECIAL, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THIS AGREEMENT OR RELATED TO PURCHASER'S DEVELOPMENT, PRODUCTION OR SALE OF ANY NEW OR MODIFIED FORMULATIONS OR COMBINATIONS OF THE PURCHASED PRODUCT MADE BY PURCHASER, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. PURCHASER'S SOLE REMEDY FOR LIABILITY OR DAMAGES UNDER THIS AGREEMENT SHALL BE STRICTLY LIMITED TO REPLACEMENT OF ANY NON-CONFORMING PRODUCT OR A REFUND OF ANY FEES PAID FOR THE NON-CONFORMING PRODUCT BASED UPON THE PRICE AND ON THE TERMS OTHERWISE SET FORTH IN THIS AGREEMENT. PURCHASER UNDERSTANDS THAT IT MAY BE WAIVING RIGHTS WITH RESPECT TO CLAIMS THAT ARE AT THIS TIME UNKNOWN OR UNSUSPECTED.
Indemnification:	Purchaser shall indemnify, protect, defend, and hold Seller, its affiliates, and its and their respective officers, directors, employees, affiliates, equity holders, managers, members, contractors, agents, consultants, advisors, and representatives harmless for, from, and against all losses, costs, expenses, penalties, and other damages (including reasonable attorneys' fees and costs) of any nature, kind or description directly resulting from or arising out of third party claims stemming from: (a) any breach, inaccuracy or non-fulfillment of any representations, warranties, covenants or agreements made by Purchaser in this Agreement or resulting from failure of Purchaser to comply with the Alabama Medical Cannabis Act, as amended from time to time, and all Alabama regulations promulgated or otherwise thereunder, (b) any negligence, willful misconduct, defective sales-process, or defective handling of the purchased Product, excepting in each instance claims stemming from the gross negligence or willful misconduct of the Seller or its officers, directors, employees, or agents, or (c) the manufacturing, processing, design, formulation, and sale by Purchaser of any processed products using the Product.
Use of Names and Marks; Reverse Engineering:	Purchaser represents, warrants and covenants that it shall not use, make reference to, publish, copy or otherwise designate, either orally or in writing, any logo, trademark, servicemark or tradename of the Seller ("**Mark(s)**"), except for the limited purpose of product displays or patient production information and only as allowable under the Applicable Regulations, without prior written consent of Seller. Upon the termination of this Agreement or at the written direction of Seller, Purchaser shall discontinue the use of all Marks of the Seller and all legends adopted in accordance with this Section. Purchaser shall leave in place all designations of Marks placed on the

	purchased Product (including Marks on any and all packaging therefor) by the Seller. Purchaser shall not use any portion of the purchased Product, whether through planting, researching, studying, dissecting or through any other actions or methods (whether or not related to botany), to grow, create, genetically engineer, reverse engineer, or otherwise imitate or copy the Product. In the event of a breach of any of the covenants contained in this Section, Seller shall be entitled to injunctive or other equitable relief because Seller will be caused irreparable injury and damage as a result of such breach. This right to injunctive relief shall include the right to both preliminary and permanent injunctions. Seller shall not be required to post a bond or any similar assurance if it brings any action in order to enforce any of the covenants contained in this Section.
Medical Cannabis:	Each Party represents and warrants that it has obtained all AMCC and local approvals, permits, licenses, certificates, necessary for it to perform its obligations under this Agreement, and each Party covenants and agrees that, during the Term, it will maintain all such approvals and obtain any and all additional approvals that may be necessary for it to perform its obligations hereunder. Each Party will notify the other Party within 24 hours in writing if it learns or reasonably believes that it is not in full compliance with the terms of this Section. The Parties acknowledge that they are aware of and fully understand that despite the laws of the State of Alabama and the terms and conditions of this Agreement, holders of licenses to sell medical Cannabis may still be arrested by federal officers and prosecuted under federal law. The Parties also expressly waive federal illegality as a defense to any Agreement enforcement action.
WAIVER OF JURY TRIAL:	THE PARTIES KNOWINGLY AND WILLINGLY WAIVE ANY RIGHT THEY HAVE UNDER APPLICABLE LAW TO A TRIAL BY JURY IN ANY DISPUTE ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT OR THE ISSUES RAISED BY THAT DISPUTE.
Attorneys' Fees:	In the event that any legal action or other proceeding is brought for the enforcement of these terms and conditions or in connection with any provision contained herein, the prevailing Party shall be entitled to recover its reasonable attorneys' fees, court costs and expenses, court costs, including, but not limited to, fees, costs and expenses incurred to collect fees, costs and expenses, and those fees and costs incurred incidentally to arbitration, mediation, investigation, discovery, travel, appellate proceedings, bankruptcy, collection, retention of expert witnesses, and post judgment proceedings.
Additional Provisions:	The provisions of this Agreement shall, except as otherwise provided herein, endure to the benefit of and be binding upon the Parties and their respective executors, administrators, successors, and assigns, each and every person so bound shall make, execute and deliver all documents necessary to carry out this Agreement.

This Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and the transactions herein contemplated and replace all previous agreements and understandings, if any, between the parties with respect to the subject matter hereof and the transaction contemplated herein. Any Purchase Order previously entered into between the Parties shall also be governed by the terms of this Agreement.

Any notice to be given under this Agreement shall be in writing and delivered, faxed or mailed by prepaid registered mail or electronic mail, addressed to the party to whom it is to be given at the address hereinabove mentioned and such notice shall be deemed to have been given on the day of delivery or on the day it is faxed or e-mailed or on the fifth business day after mailing as aforesaid, as the case may be.

If any provision of this Agreement shall be held invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall attach only to such provision in such jurisdiction and shall not in any manner affect or render invalid or unenforceable such provision in any other jurisdiction or any other provision of this Agreement in any jurisdiction.

Except as provided therein, the failure on the part of one Party, in any one or more instances, to insist upon the keeping, performance or observance of any of the terms, conditions or provisions of this Agreement, or to exercise any right or privilege herein conferred, shall not be construed as relinquishment of that Party's right to require the future keeping, performance or observance of any such terms, conditions or provisions.

This agreement may be executed in any number of counterparties, each of which will be deemed an original and all of which taken together will constitute one and the same agreement. Delivery of a signed counterpart of this Agreement by email or facsimile transmission will constitute valid and sufficient delivery thereof by the parties.

AGREED AND ACCEPTED:

COOSA MEDICAL MANUFACTURING, LLC

By:_____

Name: [redacted]

Title: CEO

Address: [redacted]

Telephone: [redacted]

Facsimile: n/a

Date: tbd

ALABAMA CANNABIS COMPANY

By:_____

Name: TBD

Title:TBD

Address: TBD

Telephone: TBD

Facsimile: TBD

Date: TBD

MEDICAL CANNABIS PURCHASE AGREEMENT
between
COOSA MEDICAL MANUFACTURING, LLC
and
GULF SHORE REMEDIES, LLC

Coosa Medical Manufacturing, LLC ("**Buyer**") and Alabama Cannabis License Holder, Gulf Shore Remedies, LLC ("**Seller**", and together with Buyer, the "**Parties**", and each, a "**Party**") hereby enter into this Cannabis Purchase Agreement (this "**Agreement**"), setting forth the terms of sale and purchase of approved forms of medical cannabis product, as permitted under the applicable Alabama laws and regulations and subject to availability, (the "**Product**") by the Parties.

Buyer:	Coosa Medical Manufacturing, LLC Ala. Code § 36-12-40 (Personally Identifiable Information) [redacted]
Seller:	Gulf Shore Remedies, LLC Ala. Code § 36-12-40 (Personally Identifiable Information) [redacted]
Scope:	This Agreement applies to the purchase (the "**Purchase**") of the Product by Purchaser from Seller, in accordance with the terms set forth herein.
Term:	Twelve months from the date of the first delivery of Product with the option to extend for one additional one-year term, at Purchaser's sole option to be exercised on or before July 31st of the prior year.
Scheduling:	Seller will ensure that sufficient transportation contractors, as applicable, are available at all relevant times to accommodate delivery.
Supply Terms:	Seller shall deliver to Purchaser, FOB Purchaser's facility listed above, packaged and labeled Product specified in **Exhibit A** ("**Order Form**"), as attached hereto and incorporated herein. In the event of any conflict between the terms of this Agreement and the terms of any purchase order or any other document issued by Purchaser, the terms of this Agreement prevail.
Product Quantities and Pricing:	The purchase prices and/or base quantity and Product availability shall be determined by Seller. Throughout the Term, Seller reserves the right to unilaterally update the Prices and/or Base Quantity and Product availability and shall provide such notice to Purchaser. All prices are exclusive of all sales, use and excise taxes, and any other similar taxes, duties, and charges of any kind imposed by any governmental authority on any

amounts payable by Purchaser.

Payment Terms: Seller reserves the right to require that Purchaser make a deposit payment in order for Seller to accept and fulfill Purchaser's order. On the date that Seller delivers the Product, Seller shall present an accounting of the amount due, which shall include the Price of the Product delivered, quantity, name of Product, any taxes, delivery fees, subject to any credit adjustment for Purchaser's deposit payments, and the correlated RFID number applied through the Alabama Medical Cannabis Seed-to-Sale system. Payment will be made in full in immediately available funds on the Payment Due Date as set forth in the Order Form, Ex. A, (the "**Payment Due Date**") via cash, automated clearing house, or certified check payable as directed by Seller. Purchaser shall pay an 8% (eight percent) per annum interest charge on overdue amounts for the Product purchased hereunder.

Representations: During the Term, Seller shall comply with and manufacture the Product in accordance with regulations established by the Alabama Office of Medical Cannabis (the "**OMC**") and the State of Alabama related to the manufacture, production, handling, and transportation of medical cannabis and cannabis products ("**Applicable Regulations**"). In the event that any Product sold hereunder does not comply with Applicable Regulations, or does not comply with the terms of this Agreement, Purchaser shall notify Seller in writing of any such non-compliance within two (2) business days following the Delivery Date of the relevant Product to Purchaser, stating in reasonable detail the nature of such non-compliance and type and aggregate quantity of the Product to which such non-compliance applies (a "**Non-Compliance Notice**"). If such non-compliance can only be demonstrated by laboratory testing, the Non-Compliance Notice shall include documentation of the relevant test results. Seller shall have the right to replace any such non-complying Product with compliant Product within five (5) business days of receipt of the Non-Compliance Notice, which shall constitute full compliance by Seller of its obligation to supply Products with respect to such Purchase Order. If Seller does not provide replacement within five (5) business days, then Purchaser's sole remedy shall be to receive a refund of the Price paid for the non-conforming Product based upon the price set forth in this Agreement. In the event of return of the Product by Purchaser, Purchaser shall pay Seller a restocking charge equal to fifteen percent (15%) of the Price.

Transport: Seller shall make delivery FOB Purchaser's facility. Title to the purchased Products shall pass to Purchaser upon delivery and acceptance of the Product by Purchaser on the day of delivery. The risk of loss or damage to the Product sold hereunder shall pass from Seller to Purchaser upon delivery of

	the Product by Purchaser. Purchaser shall be responsible for a delivery fee to be calculated by Seller and added to the purchase price for each order. Throughout the Term, Seller reserves the right to unilaterally update the delivery fee for any order. All Products delivered hereunder shall be packaged in accordance with all applicable state laws and regulations, with the Product packaged separately and clearly labeled with identification of the applicable strain and weight of the contents.
Governing Law:	This Agreement shall be governed by the laws of the State of Alabama. Purchaser submits to the jurisdiction and venue of any state court sitting in the State of Alabama.
Force Majeure:	The obligations of the Parties are contingent upon earthquakes, fires, storms, floods, freezes, material reductions, accidents, labor disputes, transportation embargoes, significant oil price increases, failure of machinery, acts of God or of any government (including the OMC), pandemics (including the COVID-19 pandemic) and any circumstances related to COVID-19 or any related epidemic, pandemic, state of emergency, government orders, government shutdowns, unavailability of labor, or materials or reasonable substitutes therefor, or other causes beyond any Party's reasonable control that relates thereto, including ceasing of operations by Seller, acts of war or terrorism, and other interferences beyond the Parties' reasonable control, to the extent the same prevent or delay the performance of the obligations herein contained.
Taxes:	Unless otherwise indicated herein, prices do not include state, county, and/or municipal sales, use, excise or similar taxes applicable to the purchased Product, or the purchased Product's use by Purchaser or the Purchaser's customers. If Seller should be required to pay the same, Purchaser shall be liable to pay to and to reimburse Seller for any such taxes. If required by law, Seller may collect sales or use taxes on its invoices for Product sold to Purchaser hereunder.
Security Interest:	Purchaser hereby grants to Seller a security interest in the purchased Product to secure the payment of Seller's invoice for all or any portion of the purchase price that remains unpaid at any time. Purchaser hereby authorizes Seller to execute on behalf of Purchaser and to file one or more financing statements to evidence and perfect a security interest in the purchased Product with any governmental authority in any jurisdiction as Seller, in its sole and absolute discretion, deems necessary or desirable to protect the Seller's interests. Purchaser shall execute at Seller's request any documents required by Seller to evidence and perfect such security interest, including individual or blanket financing statements, chattel mortgages, or similar instruments for filing in any such jurisdictions. Seller shall have all of the rights of a secured creditor under the

	Uniform Commercial Code or any similar law that may be applicable, including the right of repossession for non-payment.
Liability:	TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL SELLER BE LIABLE TO PURCHASER FOR LOSS OF PROFITS, REVENUE OR INCOME, OR FOR ANY INDIRECT, PUNITIVE, SPECIAL, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THIS AGREEMENT OR RELATED TO PURCHASER'S DEVELOPMENT, PRODUCTION OR SALE OF ANY NEW OR MODIFIED FORMULATIONS OR COMBINATIONS OF THE PURCHASED PRODUCT MADE BY PURCHASER, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. PURCHASER'S SOLE REMEDY FOR LIABILITY OR DAMAGES UNDER THIS AGREEMENT SHALL BE STRICTLY LIMITED TO REPLACEMENT OF ANY NON-CONFORMING PRODUCT OR A REFUND OF ANY FEES PAID FOR THE NON-CONFORMING PRODUCT BASED UPON THE PRICE AND ON THE TERMS OTHERWISE SET FORTH IN THIS AGREEMENT. PURCHASER UNDERSTANDS THAT IT MAY BE WAIVING RIGHTS WITH RESPECT TO CLAIMS THAT ARE AT THIS TIME UNKNOWN OR UNSUSPECTED.
Indemnification:	Purchaser shall indemnify, protect, defend, and hold Seller, its affiliates, and its and their respective officers, directors, employees, affiliates, equity holders, managers, members, contractors, agents, consultants, advisors, and representatives harmless for, from, and against all losses, costs, expenses, penalties, and other damages (including reasonable attorneys' fees and costs) of any nature, kind or description directly resulting from or arising out of third party claims stemming from: (a) any breach, inaccuracy or non-fulfillment of any representations, warranties, covenants or agreements made by Purchaser in this Agreement or resulting from failure of Purchaser to comply with the Alabama Medical Cannabis Act, as amended from time to time, and all Alabama regulations promulgated or otherwise thereunder, (b) any negligence, willful misconduct, defective sales-process, or defective handling of the purchased Product, excepting in each instance claims stemming from the gross negligence or willful misconduct of the Seller or its officers, directors, employees, or agents, or (c) the manufacturing, processing, design, formulation, and sale by Purchaser of any processed products using the Product.
Use of Names and Marks; Reverse Engineering:	Purchaser represents, warrants and covenants that it shall not use, make reference to, publish, copy or otherwise designate, either orally or in writing, any logo, trademark, servicemark or tradename of the Seller ("**Mark(s)**"), except for the limited purpose of product displays or patient production information and only as allowable under the Applicable Regulations, without prior written consent of Seller. Upon the termination of this Agreement or at the written direction of Seller, Purchaser shall discontinue the use of all Marks of the Seller and all legends adopted in accordance with this Section.

Purchaser shall leave in place all designations of Marks placed on the purchased Product (including Marks on any and all packaging therefor) by the Seller.

Purchaser shall not use any portion of the purchased Product, whether through planting, researching, studying, dissecting or through any other actions or methods (whether or not related to botany), to grow, create, genetically engineer, reverse engineer, or otherwise imitate or copy the Product.

In the event of a breach of any of the covenants contained in this Section, Seller shall be entitled to injunctive or other equitable relief because Seller will be caused irreparable injury and damage as a result of such breach. This right to injunctive relief shall include the right to both preliminary and permanent injunctions. Seller shall not be required to post a bond or any similar assurance if it brings any action in order to enforce any of the covenants contained in this Section.

Medical Cannabis: Each Party represents and warrants that it has obtained all AMCC and local approvals, permits, licenses, certificates, necessary for it to perform its obligations under this Agreement, and each Party covenants and agrees that, during the Term, it will maintain all such approvals and obtain any and all additional approvals that may be necessary for it to perform its obligations hereunder. Each Party will notify the other Party within 24 hours in writing if it learns or reasonably believes that it is not in full compliance with the terms of this Section. The Parties acknowledge that they are aware of and fully understand that despite the laws of the State of Alabama and the terms and conditions of this Agreement, holders of licenses to sell medical Cannabis may still be arrested by federal officers and prosecuted under federal law. The Parties also expressly waive federal illegality as a defense to any Agreement enforcement action.

WAIVER OF JURY TRIAL: THE PARTIES KNOWINGLY AND WILLINGLY WAIVE ANY RIGHT THEY HAVE UNDER APPLICABLE LAW TO A TRIAL BY JURY IN ANY DISPUTE ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT OR THE ISSUES RAISED BY THAT DISPUTE.

Attorneys' Fees: In the event that any legal action or other proceeding is brought for the enforcement of these terms and conditions or in connection with any provision contained herein, the prevailing Party shall be entitled to recover its reasonable attorneys' fees, court costs and expenses, court costs, including, but not limited to, fees, costs and expenses incurred to collect fees, costs and expenses, and those fees and costs incurred incidentally to arbitration, mediation, investigation, discovery, travel, appellate proceedings, bankruptcy, collection, retention of expert witnesses, and post judgment proceedings.

Additional Provisions: The provisions of this Agreement shall, except as otherwise provided herein, endure to the benefit of and be binding upon the Parties and their respective executors, administrators, successors, and assigns, each and every person so bound shall make, execute and deliver all

documents necessary to carry out this Agreement.

This Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and the transactions herein contemplated and replace all previous agreements and understandings, if any, between the parties with respect to the subject matter hereof and the transaction contemplated herein. Any Purchase Order previously entered into between the Parties shall also be governed by the terms of this Agreement.

Any notice to be given under this Agreement shall be in writing and delivered, faxed or mailed by prepaid registered mail or electronic mail, addressed to the party to whom it is to be given at the address hereinabove mentioned and such notice shall be deemed to have been given on the day of delivery or on the day it is faxed or e-mailed or on the fifth business day after mailing as aforesaid, as the case may be.

If any provision of this Agreement shall be held invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall attach only to such provision in such jurisdiction and shall not in any manner affect or render invalid or unenforceable such provision in any other jurisdiction or any other provision of this Agreement in any jurisdiction.

Except as provided therein, the failure on the part of one Party, in any one or more instances, to insist upon the keeping, performance or observance of any of the terms, conditions or provisions of this Agreement, or to exercise any right or privilege herein conferred, shall not be construed as relinquishment of that Party's right to require the future keeping, performance or observance of any such terms, conditions or provisions.

This agreement may be executed in any number of counterparties, each of which will be deemed an original and all of which taken together will constitute one and the same agreement. Delivery of a signed counterpart of this Agreement by email or facsimile transmission will constitute valid and sufficient delivery thereof by the parties.

AGREED AND ACCEPTED:

COOSA MEDICAL MANUFACTURING, LLC

By: Ala. Code § 36-12-40 (Personally Identifiable Information)

Name: Ala. Code § 36-12-40 (Personally Ide

Title: CEO

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)
Ala. Code § 36-12-40 (Personally I

Telephone: Ala. Code § 36-12-40 (Personally Identifia

Facsimile: n/a

Date: 12/16/22

GULF SHORE REMEDIES, LLC

Name: Ala. Code § 36-12-40 (Personally Identifiable Infor

Title:CEO

Address: Ala. Code § 36-12-40 (Personally Identifiable Information)
Ala. Code § 36-12-40 (Personally Identifiable Information)

Telephone: Ala. Code § 36-12-40 (Personally Identifiab

Facsimile: n/a

Date: 12/16/22

MEDICAL CANNABIS TRANSPORT AGREEMENT

between

COOSA MEDICAL MANUFACTURING, LLC

and

_____

Coosa Medical Manufacturing, LLC ("**Coosa**") and Alabama Transport License Holder, _____ ("**Carrier**", and together with Coosa, the "**Parties**", and each, a "**Party**") hereby enter into this Medical Cannabis Transport Agreement (this "**Agreement**"), setting forth the terms of transporting approved forms of medical cannabis product, as permitted under the applicable Alabama laws and regulations, (the "**Product**") by the Parties.

Seller: Coosa Medical Manufacturing, LLC
Ala. Code § 36-12-40 (Personally Identifiable Information)

Buyer: _____
_____
_____

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set out herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Carrier and Licensee (hereinafter, collectively, the "Parties," or each, individually, a "Party") agree as follows:

1. **STANDARD WARRANTIES.** Each Party represents and warrants to the other Party that:

   (A) Prior to performing any transportation services, it has obtained each necessary license from the Alabama Medical Cannabis Commission ("**Commission**");

   (B) It has the full right, corporate power, and authority to enter into this Agreement and to perform its obligations hereunder;

   (C) The execution of this Agreement by each individual whose signature is set forth at the end of this Agreement and the delivery of this Agreement have been duly authorized by all necessary corporate action;

   (D) The execution, delivery, and performance of this Agreement will not violate, conflict with, require consent under or result in any material breach or default under the provisions of any contract or agreement to which it is a party; and

   (E) This Agreement has been executed, and delivered by the Party and (assuming due authorization, execution, and delivery by the other Party) constitutes the legal, valid, and binding obligation of the Party, enforceable against the Party in accordance with its terms, except as may be limited by any applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws and equitable principles related to or affecting creditors' rights generally or the effect of general principles of equity.

2. **TERM, TERMINATION, AND SURVIVAL**.

(A) **Term of Services.** The term of Transportation Services will commence the first day Carrier provides Transportation Services to the Licensee and will continue thereafter until the completion of the Transportation Services as set forth in this Agreement (the "Service Term"), unless sooner terminated pursuant to this Agreement.

(B) **Term of Agreement**. This Agreement shall commence as of the Effective Date and shall continue thereafter until the completion of the Service Term ("Term of Agreement" or "Term") unless sooner terminated pursuant to this Agreement.

(C) **Renewal Term**. Upon expiration of the initial Term, this Agreement shall automatically renew for additional successive one (1) year terms unless and until either Party provides written notice of nonrenewal at least sixty (60) days prior to the end of the then-current term, or unless and until earlier terminated as provided under this Agreement. In the event either Party provides timely notice of their intent not to renew this Agreement, then, unless earlier terminated in accordance with its terms, this Agreement terminates on the expiration of the then-current Service Term. In the event of automatic renewal, the fee and rate schedules shall be changed to reflect Carrier's fee and rate structure and expenses in effect at the time of renewal.

(A) **Exclusive Use of Transportation Services**. Licensee shall use exclusively the Transportation Services of Carrier during the Term of this Agreement.

(D) **Termination**. Either Party may terminate this Agreement before expiration of the Term, effective upon written notice to the other Party (the "Defaulting Party"), if the Defaulting Party:

(i) materially breaches this Agreement *or* any individual shipment transaction, and such breach is incapable of cure, or with respect to a material breach capable of cure, the Defaulting Party does not cure such breach within seven (7) days after receipt of written notice of such breach.

(ii) Becomes insolvent or admits its inability to pay its debts generally as they become due;

(iii) Is dissolved or liquidated or takes any corporate action for such purpose;

(iv) Makes a general assignment for the benefit of creditors; or

(v) Has a receiver, trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business.

(E) **Termination for Failure to Pay**. Notwithstanding anything to the contrary in this Agreement, Carrier may terminate this Agreement before the expiration date of the Term on written notice if Licensee fails to pay any amount when due hereunder:

(i) and such failure continues for five (5) business days after Licensee's receipt of written notice of nonpayment; or

(ii) two (2) or more times in any six (6) month period.

(F) Any Notice of termination under this Agreement automatically operates as a cancellation of any shipments that are scheduled to be picked-up after the effective date of termination, whether or not Carrier had accepted any shipment request. Regarding any shipments that are still in transit on termination of this Agreement, Carrier may require, in its sole and absolute discretion, that all deliveries of such shipments be made on either a cash-only or certified check basis.

(G) Upon the termination of the Agreement, each Party shall promptly return to the other Party any equipment, materials or other property in its possession or control, belonging to the other Party.

(H) **Survival**. The rights and obligations of the Parties set forth in this Agreement which, by its nature, should survive termination or expiration of this Agreement, will survive any such termination or expiration of this Agreement.

3. **TRANSPORTATION SERVICES**. Carrier shall provide to Licensee services in the location(s) and amounts, and pursuant to the schedules and rates as set forth herein and as further described in the accepted Statement of Work attached hereto and incorporated herein by reference as **Attachment A** (the "Transportation Services"). Additional and amended Statements of Work will be deemed issued and accepted only if signed and dated in writing by the Carrier and Licensee.

(B) During the term of this Agreement, Carrier shall provide the Transportation Services, which includes, but is not limited to, the following:

(i) Transporting pre-packaged medical cannabis raw and processed materials and medical cannabis products for final sale (the "Goods") from a Department-authorized location where Goods are available for collection and loading (the "Originating Location,") using Carrier's Department-approved vehicle to a Department-authorized location where Goods will be unloaded and delivered (the "Destination Location"), both Originating and Destination Locations located exclusively within the State of Alabama, and either the Originating or Destination Location identified as a Licensee facility on the manifest and trip plan;

(ii) Supplying and making available the requisite vehicle and Transport Personnel when Licensee requests a shipment within forty-eight (48) to seventy-two (72) hours of the shipment being tendered hereunder;

(iii) Collecting, loading, transporting, unloading, and delivering shipments using Carrier's standard methods for shipment;

(iv) Monitoring the vehicle, Goods in the vehicle, and the vehicle's immediate surroundings for criminal activity, destruction of property, diversion of medical cannabis, and reasonably recognizable threats directly related to the Transportation Services;

(v) Maintaining a system of communicating and delivering or receiving manifests, trip plans, and delivery notifications, as appropriate, via METRC, telephone, emails, text messages, and other electronic communication methods;

(vi) Notifying Licensee of all accidents and occurrences Transport Personnel have actual knowledge of which materially impair the safety, condition, or delay the collection or delivery of the Goods; and

(vii) Maintaining a field supervisor on-call 24-hours a day, but in no event shall Carrier be required to monitor the Transport Personnel contemporaneously with the Transportation Services.

(C) Licensee shall cooperate with Carrier in its performance of the Transportation Services; provide access to Licensee's premises, employees, contractors, and equipment as required to enable Carrier to provide the Transportation Services; and take all steps necessary to prevent Licensee-caused delays in Carrier's provision of the Transportation Services.

(D) **Commission Action**. Transportation Services shall not include additional transportation-related services that the Commission requires Licensee to undertake in response to a Licensee complaint, investigation, suspension, revocation, or similar investigation or disciplinary matter (collectively, "Commission Action"). In the event the Commission requires Licensee's transportation service provider to assume additional responsibilities related to Commission Action, Carrier and Licensee agree to negotiate in good faith the terms and consideration for such additional services in a written supplemental statement of work. Failure to reach an agreement shall not be deemed a "material breach" or be cause for termination of Transportation Services under this Agreement. As set forth in Attachment A, an Administrative Fee while Commission Action is pending will be charged to Licensee if a DH Commission SS Action directly or indirectly effects the Transportation Services, and such Administrative Fee shall be invoiced and due separate and distinct from entering a supplemental statement of work.

4. **TRANSPORT PERSONNEL**. Carrier shall furnish Licensee with armed drivers (the "Transport Driver"), and, if required, armed passengers (collectively, the "Transport Personnel").

(A) **No Tolerance Policy for Workplace Harassment**. Carrier maintains a strict policy against all types of workplace harassment, including sexual harassment and other forms of workplace harassment. All forms of harassment of, or by, employees, vendors, visitors, customers, and clients are strictly prohibited and will not be tolerated. By entering this Agreement, Licensee agrees to abide by this policy in matters involving Transport Personnel. A copy of Carrier's workplace harassment policy is available upon request.

(B) **Communicating Personnel Matters**. Each Party shall contact the other Party as soon as possible, but no later than twenty-four (24) hours, after learning of a personnel complaint or concern involving or related to Transport Personnel and any Licensee personnel, vendor, visitor, customer, or client (ex., allegations of workplace harassment). When investigating a personnel complaint or concern involving Transport Personnel, Licensee shall notify Carrier prior to interviewing its Transport Personnel.

5. **SHIPMENT AND DELIVERY; PACKAGED GOODS**.

(A) **Shipment Requests; Shipment Scheduling Systems Currently in Place and Under Development**.

(i) Licensee shall initiate all shipment requests using Carrier's online website-based scheduling system or by completing Carrier's shipment request form and emailing it to Alabama Transport Email. For email-initiated shipments, Licensee shall contact Carrier's Shipping Contact identified in **Attachment A** to confirm receipt of the shipment request and Carrier's acceptance of the shipment request. Carrier shall accept any shipment request by confirming acceptance of the request by email or other electronic communication to the Licensee's shipping contact identified in **Attachment A** or by picking up the Goods specified in the shipment request. Carrier's acceptance of a shipment request, whether or not Carrier sends an email or other electronic communication following the request, shall serve as Carrier's acknowledgement that the requested Transportation Services are governed by the terms of this Agreement.

(ii) Licensee shall notify Carrier a minimum of seventy-two (72) hours prior to Licensee's first shipment request. If applicable, Licensee shall notify Carrier of the date of the Commission's

onsite commencement inspection(s) and the result of the Commission on site commencement inspections as soon as practicable.

(iii) Licensee shall provide Carrier with the representative name(s) and contact information for the Originating and Destination Locations. Carrier shall provide Licensee with Commission and METRC required information, including a description of Carrier's vehicle and the name(s) and Facility Agent Identification Card number(s) of Transport Personnel, to create a manifest or trip plan.

(B) **Manifests and Trip Plans**. Each shipment under this Agreement shall be evidenced by a METRC-generated Cannabis Transportation Manifest (the "Manifest") showing the kind and quantity of Goods to be collected by Carrier at the Originating Location and to be delivered by Carrier to the Destination Location. Licensee and representatives of the Originating and Destination Locations are solely responsible for creating the Manifest including entering into METRC the inventory of Goods to be shipped or received and the accuracy or inaccuracy of the inventory and Manifest. Carrier and its Transport Personnel shall not enter the inventory of Goods in METRC or create the Manifest. Prior to transporting the Goods, Carrier shall print the Manifest and create a trip plan. Carrier will provide the Manifest and trip plan to the Licensee and representatives of the non-Licensee Originating and Destination Location(s) as appropriate.

6. **CONDITION OF ORIGINATING AND DESTINATION LOCATIONS**. Licensee shall maintain the areas of Licensee-controlled Originating and Destination Locations where Goods will be loaded and unloaded free of debris and hazards. Transport Personnel shall not collect, load, unload or deliver Goods in any location, regardless of whether or not in Licensee's control, that Carrier or its Transport Personnel determine to be in an unreasonably hazardous condition. Carrier will not be liable for any penalty, loss, or damages sustained by Licensee or any third-party for not collecting or delivering Goods pursuant to this Section 5.

7. **GOODS TENDERED; WEIGHING GOODS**.

(A) Licensee shall tender, or cause representatives of third-party Originating and Destination Locations to tender Goods for shipment that are properly pre-packaged, marked, addressed, labeled, or otherwise identified in a manner appropriate to the Goods shipped to ensure safe transportation during ordinary handling in transit.

(B) Licensee and representatives of third-party Originating and Destination Locations shall determine and record the weight of each package shipped and are solely responsible for the accuracy or inaccuracy of the recorded package weight. Carrier and its Transport Personnel shall not weigh or record the weight of packages.

(C) Licensee shall properly and accurately describe the Goods in a shipment and declare its actual monetary value for transportation purposes on the Manifest;

(D) Licensee agrees to be bound by the accuracy of all descriptions, valuations, and other particulars furnished to the Carrier.

(E) Carrier shall not be liable for the content of packaged Goods. Carrier shall solely rely upon labeling provided by the Originating Location and what is discernable from the exterior of the packaged Goods.

8. **PRE-EXISTING OR CONCEALED DAMAGE**. Carrier shall not be liable for any preexisting or concealed damage of the Goods. So long as packaging remains sealed while in Carrier's custody and control, Carrier shall not be liable for any change in the cannabis including, but not limited to, mold, water content, pests, pesticides, and cross-contamination.

   (A) **Prohibited Shipments**. LICENSEE SHALL NOT TENDER, OR CAUSE TO BE TENDERED, TO CARRIER HAZARDOUS MATERIAL, CANNABIS WASTE, PESTICIDES, HERBICIDES, ITEMS PROHIBITED BY ANY LAWS OR REGULATIONS THROUGH WHICH THE ITEMS ARE TO BE TRANSPORTED, OR OTHER ITEMS THAT THE PARTIES AGREE WILL NOT BE TRANSPORTED BY CARRIER UNDER THIS AGREEMENT.

   (B) **Limitation on the Actual Value of Goods Shipped**. UNLESS OTHERWISE SPECIFICALLY AGREED IN A PRIOR WRITING, LICENSEE SHALL NOT TENDER OR CAUSE TO BE TENDERED TO CARRIER ANY SHIPMENT WITH AN ACTUAL VALUE IN EXCESS OF $250,000 (TWO HUNDRED FIFTY THOUSAND DOLLARS) OR ANY SHIPMENT IN EXCESS OF THE DECLARED VALUE (the "Declared Value"). Providing a Declared Value significantly below the actual value of the shipment, without the prior written consent of Carrier, constitutes fraud against Carrier and may constitute insurance fraud.

   (C) **Delivery Schedule; Required Number of Transport Personnel**. One (1) Transport Personnel will perform the Transportation Services for a Licensee shipment with an estimated roundtrip period of twelve (12) hours or less. Two (2) Transport Personnel shall perform the Transportation Services for any shipment with an estimated roundtrip period of greater than twelve (12) hours, and under extreme weather conditions or elevated threat risk; and Licensee shall pay the hourly rate of all Transport Personnel. If Carrier reasonably anticipates that it will not be able to provide any portion of the Transportation Services on an agreed upon schedule, Carrier shall promptly notify Licensee and the Commission of the delay in delivery and the proposed revised delivery schedule. Any time quoted by Carrier for collection and delivery are estimates only. Carrier will not be liable for any penalty, loss, or damages sustained by Licensee or any third-party resulting from a missed appointment or delay in the collection or delivery of Goods.

9. **NON-CONFORMING AND REJECTED GOODS; UNDELIVERABLE SHIPMENTS**.

   (A) Carrier shall promptly notify Licensee, upon the actual knowledge of Carrier or its Transport Personnel, of any shipment of Goods or packages**:**

      (i) From the Originating Location that do not conform to the Manifest;

      (ii) That are rejected by the on-site employee or agent of the Destination Location; or

      (iii) That are undeliverable, despite Carrier's commercially reasonable efforts to deliver same.

   (B) Upon notification, Licensee shall provide Carrier with instructions for the immediate, efficient, and proper handling and disposition of the non-conforming, rejected, or undeliverable shipment or packages. Carrier shall not render any medical cannabis unusable. For Goods and shipments under Section 8(A), Carrier shall not be liable for any resultant third-party charges; Licensee shall reimburse Carrier for any resultant third-party charges or expenses paid by Carrier; and Licensee shall pay Carrier any additional fees pursuant to the terms of this Agreement.

10. **RECORDKEEPING**. Carrier and Licensee shall maintain complete and accurate records relating to the provision of the Transportation Services under this Agreement for a period of five (5) years.

11. **DESIGNATED CONTACT**. Each Party shall:

(A) Designate one of its employees or agents to serve as its primary contact with respect to this Agreement and to act as its authorized representative with respect to matters pertaining to this Agreement with such designation to remain in force unless and until a successor is appointed and the other Party is notified of the appointed successor.

(B) Require that a Party's designated employee or agent respond promptly to the other Party's request to ship, provide instructions, information, approvals, authorizations, or decisions that are reasonably necessary for a Party to perform its obligations in accordance with the requirements of this Agreement and ensure that the Party's materials or information are complete and accurate in all material respects.

12. **FEES, EXPENSES, AND PAYMENT TERMS**.

(A) In consideration of the provision of the Transportation Services by the Carrier and the rights granted to Licensee under this Agreement, Licensee shall pay the fees and rates set out in the Statement of Work attached hereto and made part hereof as **Attachment A**. Payment to Carrier of such fees and the reimbursement of expenses pursuant to this Section 11 shall constitute payment in full for the performance of the Transportation Services. Unless otherwise provided in the Statement of Work, Carrier shall invoice Licensee on a monthly basis and Licensee shall render payment to Carrier, without abatement, reduction, or setoff, within fifteen (15) days of Licensee's receipt of the invoice from Carrier. Carrier's invoice shall set forth in reasonable detail the calculation of the rates and charges arising during the period of time covered by the invoice. At Licensee's request, each invoice submitted to Licensee shall be accompanied by a copy of all Manifests, trip plans, or other receipts or documentation pertaining thereto.

(B) **Expenses**. Licensee shall reimburse Carrier for all reasonable expenses incurred in accordance with the Statement of Work within fifteen (15) days of Licensee's receipt of Carrier's request for reimbursement accompanied by receipts and reasonable supporting documentation.

(C) **Surcharges**. Carrier reserves the right to add a surcharge on its rates in the event of an increase in its costs resulting from any significant increases in insurance, fuel costs, introduction of government taxes on Transportation Services, or any other circumstances beyond Carrier's control and affecting the transportation industry in general and Alabama's medical cannabis industry in particular. All adjustments shall become affective thirty (30) days following Carrier's written notice of such surcharge.

(D) **Non-Disclosure**. The terms of this Agreement and the provisions, rates, and charges set forth in **Attachment A** were negotiated specifically between the Parties and only apply to shipments transported by Carrier for Licensee. Therefore, Licensee agrees that it shall not disclose to any third parties the terms of this Agreement and the content of **Attachment A** without Carrier's prior consent.

(E) **Method of Payment**. Payment shall be made in US dollars any commercially accepted manner that does not incur service fees, such as by check, direct deposit, or wire transfer among others, to be communicated by Carrier to Licensee. Licensee shall pay any payment service fees if it is unable

to make payment pursuant to Carrier's preferred non-fee payment methods and for any checks returned for non-payment.

(F) **Late Payments**. Except for invoiced payments that the Licensee has successfully disputed, all late payments shall bear interest at the lesser of (a) the rate of eight percent (8%) per month and (b) the highest rate permissible under applicable law, calculated daily and compounded monthly. Licensee shall also reimburse Carrier for all costs incurred in collecting any late payments, including, without limitation, attorneys' fees. In addition to all other remedies available under this Agreement or at law (which Carrier does not waive by the exercise of any rights hereunder), Carrier shall be entitled at its option to suspend the provision of any Transportation Services if the Licensee fails to pay any amounts when due hereunder and such failure continues for seven (7) days following written notice thereof, and such suspension or withholding of Transportation Services shall not be considered a breach or default of any of Carrier's obligations under this Agreement.

(G) **No Set-Off Right**. Licensee shall not withhold payment of any amounts due and payable by reason of any set-off of any claim or dispute with Carrier, whether relating to Carrier's breach, bankruptcy or otherwise.

(H) **Overcharge/Undercharge Claims**. Claims for alleged overcharges or undercharges shall be filed with the appropriate Party within one (1) month of the date of Carrier's invoice. Failure to file a claim with the other Party within said 1-month period shall forever bar any action at law for recovery of same. Any action at law to recover alleged overcharges or undercharges shall be commenced no later than one (1) year from the date that Carrier or Licensee has given written notice it has disallowed any part of the overcharge or undercharge claim.

(I) **Unsatisfactory Credit Status**. If Carrier reasonably determines that Licensee's financial condition or creditworthiness is inadequate or unsatisfactory, then in addition to Carrier's other rights, Carrier may without liability or penalty take any of the following actions:

(i) Accelerate all amounts owed by Licensee to Carrier under this Agreement and any individual shipment transaction;

(ii) On seven (7) day's prior written Notice, modify the payment terms specified under this Section 11 for outstanding and future individual shipment transactions, including requiring Licensee to pay cash in advance;

(iii) Cancel any previously accepted shipment requests;

(iv) Delay any future shipments;

(v) On seven (7) day's prior written Notice, terminate this Agreement; or

(vi) Any combination of the above.

(J) No actions taken by Carrier under Section 11(I) (nor any failure of Carrier to act under this Section 11) constitute a waiver by Carrier of any of its rights to enforce Licensee's obligations under this Agreement including, but not limited to, the obligation of Licensee to make payments as required under this Agreement.

13. **TAXES**. Licensee is responsible for all sales, use, and excise taxes, and any other similar taxes, duties, and charges of any kind imposed by any federal, state, or local governmental entity on any amounts

payable by Licensee hereunder; provided, that, in no event shall Licensee pay or be responsible for any taxes imposed on, or with respect to, Carrier's income, revenues, gross receipts, personnel, or real or personal property, or other assets.

14. **RISK OF LOSS**. Carrier shall bear all risk of loss of and damage to or theft of the Goods commencing when Carrier accepts the Manifest containing the shipment of Goods in METRC. While on the property of the Originating Location, Carrier shall make reasonable efforts to confirm that the proffered Goods appear to match the description on the Manifest, load the Goods in the vehicle, and lock the cargo hold of Carrier's vehicle prior to accepting the Manifest in METRC. Said risk of loss ends when the on-site employee or agent of the Destination Location takes custody of the Goods even if the Destination Location's on-site employee or agent does not immediately weigh, scan, reject, or accept the delivery of all or some of the Goods into METRC.

15. **INSURANCE**. During the term of this Agreement, Carrier shall carry and maintain in full force insurance coverage which shall include workers' compensation insurance as required by Alabama laws covering all persons employed and contracted by Carrier engaged in the furnishing of services under this Agreement and general liability coverage for personal injury and property damage, which coverage shall cover the risks of false arrest, false imprisonment, malicious prosecution, libel, slander, and violation of right of privacy. Carrier shall carry and maintain a $5,000,000 (five million dollars) excess liability policy and the certificate of insurance shall name Licensee as an additional insured. In the event Licensee requires insurance in types and amounts different than or greater than the coverage carried by Carrier, Carrier shall, if available, obtain such additional insurance at an additional charge to Licensee, with such additional charge to be determined after Carrier consults with its insurance carriers. Licensee acknowledges that Carrier is not an insurer and that Licensee is solely responsible for assessing and obtaining adequate insurance coverage for all locations of Licensee where Carrier will perform Transportation Services, including, without limitation, all of Licensee's real and personal property and the business(es) conducted by Licensee at such locations. Each Party shall obtain and maintain insurance in amounts sufficient to cover their agreement to indemnify the other against losses, liabilities, and damages under this Agreement.

16. **INSURANCE CERTIFICATES**. On the written request of a Party, the other Party shall provide copies of certificates of insurance and policy endorsements for all insurance coverage required by under this Agreement, and shall not do anything to invalidate such insurance. This Section 15 shall not be construed in any manner as waiving, restricting, or limiting the liability of either Party for any obligations imposed under this Agreement (including but not limited to, any provisions requiring a Party hereto to indemnify, defend, and hold the other harmless under this Agreement).

17. **SERVICE WARRANTY**.

    (A) **Limited Warranty**. Carrier warrants to Licensee that it shall perform the Transportation Services using personnel of required skill, experience, and qualifications and in a professional and workmanlike manner in accordance with commercially reasonable industry standards for similar services and shall devote adequate resources to meet its obligations under this Agreement.

    (B) **Licensee's Exclusive Remedy for Breach of Service Warranty**. Except to the extent any claim is actually covered by applicable insurance policies, Licensee's exclusive remedy for Carrier's breach of the service warranty contained in Section 18(A) regarding any shipment is Carrier's refund of the purchase price of the corresponding individual shipment transaction. THIS SECTION

18(B) SETS FORTH LICENSEE'S SOLE REMEDY AND CARRIER'S ENTIRE LIABILITY FOR ANY BREACH OF THE LIMITED WARRANTY SET FORTH IN SECTION 18(A).

(C) **Disclaimer**. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 18(A), 30(A) (GENERAL COMPLIANCE WITH LAWS), AND 30(B) (COMPLIANCE WITH ALABAMA MEDICAL CANNABIS LAW), CARRIER MAKES NO WARRANTY, EXPRESS OR IMPLIED, WHATSOEVER REGARDING THE TRANSPORTATION SERVICES, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE; WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE, OR OTHERWISE. LICENSEE ACKNOWLEDGES THAT IT HAS NOT RELIED ON ANY REPRESENTATION OR WARRANTY MADE BY CARRIER, OR ANY OTHER PERSON ON CARRIER'S BEHALF, EXCEPT AS SPECIFICALLY PROVIDED IN SECTIONS 18(A), 30(A), AND 30(B) OF THIS AGREEMENT.

18. **INDEMNIFICATION**.

(A) **Mutual Indemnification.** Subject to the terms and conditions set forth in Section 19(B) (Exceptions and Limitations on Indemnification) and Section 20 (Indemnification Procedures), each Party ("Indemnitor") shall indemnify, hold harmless, and defend the other Party and its managers, officers, directors, employees, agents, successors, and permitted assigns (collectively, "Indemnitee") against any and all losses**,** damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including professional fees and reasonable attorneys' fees, that are incurred by Indemnitee (collectively, "Losses"), to the extent they arise out of any third-party claim alleging:

(i) any negligent or more culpable act or omission of Indemnitor (including any reckless or willful misconduct) in connection with the performance of its obligations under this Agreement; or

(ii) any bodily injury, death of any person, or damage to real or tangible personal property caused by the negligent or more culpable acts or omissions of Indemnitor (including any reckless or willful misconduct).

Notwithstanding anything to the contrary in this Agreement, this Section 19(A) does not apply to any claim (whether direct or indirect) for which a sole or exclusive remedy is provided under another section of this Agreement.

(B) **Exceptions and Limitations on Indemnification**. Notwithstanding anything to the contrary in this Agreement, Indemnitor is not obligated to indemnify, hold harmless, or defend Indemnitee against any claim (whether direct or indirect) if such claim or corresponding Losses arise out of or result from Indemnitee's:

(i) negligence or more culpable act or omission (including recklessness or willful misconduct); or

(ii) bad faith failure to comply with any of its obligations set forth in this Agreement.

(C) **Sole Remedy**. SECTION 19(A) SETS FORTH THE ENTIRE LIABILITY AND OBLIGATION OF THE INDEMNITOR AND THE SOLE AND EXCLUSIVE REMEDY FOR THE INDEMNITEE FOR ANY DAMAGES COVERED UNDER SECTION 19(A).

(D) Notwithstanding anything herein to the contrary in this Agreement, the amount of losses, liabilities,

and damages against which Indemnitor is obligated to indemnify, defend and hold harmless Indemnitee is limited to and shall not exceed the amount of insurance obtained by Indemnitor to cover his or its agreement to indemnify Indemnitor under this Agreement. To the extent the obligations of the Parties hereto to indemnify the other are covered by insurance, the Parties waive all rights against each other except such rights as they may have to the proceeds of such insurance as set forth in this Section.

(E) Each Party waives all of its rights of recovery under subrogation against the Indemnitees.

19. **INDEMNIFICATION PROCEDURES**.

(A) **Notice of Third-Party Claims**. Indemnitee shall give Indemnitor prompt written notice (a "Claim Notice") of any Losses or discovery of facts on which Indemnitee intends to base a request for indemnification under Section 19(A). Indemnitee's failure to provide a Claim Notice to Indemnitor under this Section 20 does not relieve Indemnitor of any liability that Indemnitor may have to Indemnitee, but in no event shall Indemnitor be liable for any Losses that result from a delay in providing a Claim Notice.

(B) **Control of Defense.**

(i) **Indemnitor Control of Defense**. Indemnitor may assume, at its sole option, control of the defense, appeal, or settlement of any third-party claim that is reasonably likely to give rise to an indemnification claim under Section 19(A) (an "Indemnified Claim") by sending written notice of the assumption to Indemnitee on or before ten (10) business days after receipt of a Claim Notice to acknowledge responsibility for the defense of such Indemnified Claim and undertake, conduct, and control, through reputable independent counsel of its own choosing (which Indemnitee shall find reasonably satisfactory) and at Indemnitor's sole cost and expense, the settlement or defense thereof. Indemnitee shall fully cooperate with Indemnitor in connection therewith; and may employ, at any time, separate counsel to represent it; provided, that Indemnitee is solely responsible for the costs and expenses of any such separate counsel.

(ii) **Indemnitee Control of Defense**. Notwithstanding anything to the contrary in this Section 20, Indemnitee may defend an Indemnified Claim with counsel of its own choosing and without the Indemnitor's participation if the Indemnified Claim is one for which Indemnitee properly gave Indemnitor a Claim Notice under Section 20(A) (Notice of Third-Party Claims), and Indemnitor fails to assume the defense or refuses to defend the Indemnified Claim under Section 20(B)(i) (Indemnitor Control of Defense). If Indemnitee assumes control of the defense, Indemnitor shall (a) reimburse Indemnitee promptly and periodically for the reasonable costs properly incurred in defending against the Indemnified Claim (including reasonable attorneys' fees and expenses); and (b) remain responsible to Indemnitee for any Losses indemnified under Section 19(A).

(C) **Settlement**. Indemnitor shall give prompt written notice to Indemnitee of any proposed settlement of an Indemnified Claim. Indemnitor may not, without Indemnitee's prior written consent, which Indemnitee shall not unreasonably withhold, condition, or delay, settle or compromise any indemnification-related claim or consent to the entry of any indemnification-related judgment. Indemnitee may not settle or compromise any claim or consent to the entry of any judgment regarding which it is seeking indemnification hereunder without the prior written consent of Indemnitor, which Indemnitor shall not unreasonably withhold, condition, or delay, unless the

Indemnified Claim is one for which Indemnitee properly gave Indemnitor a Claim Notice under Section 20(A), and Indemnitor fails to assume the defense or refuses to defend the Indemnified Claim under Section 20(B)(i). Indemnitor's obligations under Section 19(A) shall terminate when a settlement is reached by one or both Parties the Indemnified Claim.

20. **LIMITATION OF LIABILITY.**

(A) **No Consequential or Indirect Damages**. EXCEPT FOR OBLIGATIONS TO MAKE PAYMENT UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE UNDER THIS AGREEMENT TO THE OTHER PARTY OR ANY THIRD-PARTY FOR CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR ENHANCED DAMAGES, LOST PROFITS OR REVENUES,OR DIMINUTION IN VALUE ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH ANY BREACH OF THIS AGREEMENT, REGARDLESS OF (A) WHETHER SUCH DAMAGES WERE FORESEEABLE, (B) WHETHER OR NOT IT WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND (C) THE LEGAL OR EQUITABLE THEORY (CONTRACT, TORT OR OTHERWISE) UPON WHICH THE CLAIM IS BASED.

(B) **Maximum Liability**. EXCEPT FOR OBLIGATIONS TO MAKE PAYMENT UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY'S AGGREGATE LIABILITY ARISING OUT OF OR RELATED TO THIS AGREEMENT, WHETHER ARISING OUT OF OR RELATED TO BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EXCEED THE TOTAL OF THE AMOUNTS PAID TO CARRIER PURSUANT TO THIS AGREEMENT IN THE SIX (6) MONTH PERIOD PRECEDING THE EVENT GIVING RISE TO THE CLAIM OR TWO HUNDRED FIFTY THOUSAND DOLLARS ($250,000), WHICHEVER IS LESS.

21. **CUMULATIVE REMEDIES**. All rights and remedies provided in this Agreement are cumulative and not exclusive, and the exercise by either Party of any right or remedy does not preclude the exercise of any other rights or remedies that may now or subsequently be available at law, in equity, by statute, in any other agreement between the Parties or otherwise. Notwithstanding the foregoing, the Parties intend that a Party's rights under Sections 18(B) (Licensee's Exclusive Remedy for Breach of Service Warranties), 19 (Indemnification), and 21 (Limitation of Liability) are the Party's exclusive remedies for the events specified therein.

22. **INTELLECTUAL PROPERTY**. All intellectual property rights, including copyrights, patents, patent disclosures, and inventions (whether patentable or not), trademarks, service marks, trade secrets, know-how, and other confidential information, trade dress, trade names, logos, corporate names, and domain names, together with all of the goodwill associated therewith, derivative works, and all other rights (collectively, "Intellectual Property Rights") in and to all documents, work product, and other materials that are delivered to Licensee under this Agreement or prepared by or on behalf of the Carrier in the course of performing the Transportation Services except for any Confidential Information of Licensee or Licensee materials shall be owned by Carrier. Carrier hereby grants Licensee a license to use all Intellectual Property Rights free of additional charge and on a non-exclusive, worldwide, non-transferable, non-sublicensable, fully paid-up, royalty-free, and perpetual basis to the extent necessary to enable Licensee to make reasonable use of any deliverables and the Transportation Services.

23. **CONFIDENTIALITY**. All non-public, confidential, or proprietary information of the Parties, including, but not limited to, business plans and practices, concepts, products, services, software, code,

security information, intellectual property, experimental work or prototypes, costs, sources of supply, pricing methods, client lists, prospective client lists, financial or technical matters, trade secrets, designs, plans, drawings, documents, data, business operations, know-how, inventions, operations, the marketing or promotion of products or services, pricing, discounts, rebates and business and information received from others, disclosed by either Party to the other Party, whether disclosed orally or disclosed or accessed in written, electronic or other form or media, and whether or not marked, designated, or otherwise identified as "confidential," in connection with this Agreement is confidential, solely for the use of performing this Agreement and may not be disclosed or copied unless authorized by a Party in writing. This Section 24 shall not apply to information that is: (a) in the public domain; (b) known to a Party at the time of disclosure; (c) rightfully obtained by a Party on a non-confidential basis from a third-party; d) was or is independently developed by either Party without using any Confidential Information; e) disclosed in writing or orally pursuant to a Commission written request to Carrier; or f) disclosed by Carrier officers or managers to the Commission in the event Carrier has a good faith belief that Licensee implicated or intends to implicate Carrier in a DHSS Action. Upon either Party's request, the other Party shall promptly return all documents and other materials received from the requesting Party. The requesting Party shall be entitled to injunctive relief for any violation of this Section.

24. **RELATIONSHIP OF THE PARTIES**. The relationship between the Parties is that of independent contractors. Nothing contained in this Agreement shall be construed as creating any agency, partnership, joint venture or other form of joint enterprise, employment, or fiduciary relationship between the Parties, and neither Party shall have authority to contract for or bind the other Party in any manner whatsoever.

25. **NON-SOLICITATION**. Each Party agrees that during the Term of this Agreement and for a period of six (6) months following the termination or expiration of this Agreement, it shall not make any solicitation to employ the other Party's personnel or independent contractors without the prior written consent of the other Party to be given or withheld in the other Party's sole discretion.

26. **NON-EXCLUSIVE PROVISION OF SERVICES**. The Carrier retains the right to perform the same or similar type of services for third parties during the Term of this Agreement. Pursuant to Commission regulations, Carrier will not, however: (a) cultivate, process or dispense cannabis; (b) perform the functions of a State Testing Laboratory; (c) make home delivery of cannabis or medical cannabis to anyone; (d) transport patients or caregivers to or from dispensing sites or any other licensees' facilities; or (e) transport any cargo except cannabis, medical cannabis and associated products, materials, packages or containers.

27. **ACKNOWLEDGMENT OF CANNABIS BUSINESS**. Parties hereby acknowledge and agree that the Darren Wesley "Ato" Hall Compassion Act and its implementing regulations authorize the use and regulation of medical cannabis within the State of Alabama, and that the Alabama Medical Cannabis Commission and Alabama Department of Agriculture and Industries oversee the medical cannabis program in Alabama. The activities contemplated by this Agreement may be illegal under state law unless each Party acts in compliance with applicable state and local laws, regulations, and ordinances. Under current Federal Cannabis Laws, the cultivation, harvesting, production, processing, marketing, distribution, sale, transfer, possession, and use of cannabis are currently illegal. "Federal Cannabis Law" means any U.S. federal law, civil, criminal, or otherwise, that is directly or indirectly related to the cultivation, harvesting, production, processing, marketing, distribution, sale, transfer, possession, and use of cannabis, cannabis, or related substances or products containing cannabis, cannabis, or

related substances, including without limitation the prohibition on drug trafficking under the Controlled Substances Act (21 U.S.C. § 801, et seq.), the conspiracy statute under 18 U.S.C. § 846, the bar against aiding and abetting the conduct of an offense under 18 U.S.C. § 2, the bar against misprision of a felony (concealing another's felonious conduct) under 18 U.S.C. § 4, the bar against being an accessory after the fact to criminal conduct under 18 U.S.C. § 3, and federal money laundering statutes under 18 U.S.C. §§ 1956, 1957 and 1960.

28. **WAIVER OF ILLEGALITY DEFENSE**. Each Party agrees that this Agreement's invalidity for public policy reasons or its violation of Federal Cannabis Laws is not a valid defense to any dispute or claim arising out of this Agreement. Each Party expressly waives the right to present any defense related to the federal illegality of cannabis and agrees that such defense shall not be asserted, and will not apply, in any dispute or claim arising out of this Agreement.

29. **COMPLIANCE WITH LAWS; LICENSES**.

(A) **General Compliance with Laws**. Except as provided under Section 30(B), each Party is and throughout the Term shall be in compliance with all federal, state, and local laws, ordinances, regulations, and orders that are applicable to this Agreement and its performance hereunder, other than Federal Cannabis Laws, except to the extent that failure to comply *would not*, in the aggregate, have a material adverse effect on a Party's ability to comply with its obligations under this Agreement. Licensee shall not request Transportation Services that would require Carrier or any of its representatives, subcontractors, or others to violate any law.

(B) **Compliance with Alabama Medical Cannabis Law**. Each Party is and throughout the Term shall be in compliance with all material requirements of State of Alabama and local medical cannabis laws, ordinances, orders, and regulations, including Commission Regulations (collectively, "Alabama Medical Cannabis Law") that are applicable to this Agreement and its performance hereunder, except to the extent that failure to comply *could not,* in the aggregate, reasonably be expected to have an adverse effect on its ability to comply with its obligations under this Agreement. Licensee shall not request Transportation Services that would require Carrier or any of its representatives, subcontractors, or others to violate any Alabama Medical Cannabis Law.

(C) Without limiting the generality of the foregoing subsections (A) and (B), each Party shall at all times, at its own expense, obtain and maintain all certifications, credentials, fingerprint-based background checks, authorizations, licenses, and permits (including Alabama Medical Cannabis Facility Licenses and Facility Agent Identification Cards) necessary to conduct its business relating to the exercise of its rights and the performance of its obligations under this Agreement.

(D) In the event of a change of laws, rules or regulations impacting the Transportation Services under this Agreement, Licensee shall be responsible for any additional expenses incurred as a result of those changes.

30. **FURTHER ASSURANCES**. The Parties hereto shall, from time to time at the request of the other Party, without any additional consideration, and promptly following the receipt of the request, furnish the other Party such further information or assurances, execute and deliver such additional documents, instruments, and conveyances, and take such other actions and do such other things, as may be reasonably necessary or appropriate to carry out the provisions of this Agreement and give effect to the transactions contemplated hereby and thereby.

31. **ENTIRE AGREEMENT**. This Agreement, including and together with any related Statements of Work, exhibits, and schedules, constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, regarding such subject matter.

32. **NOTICES**. All notices, requests, consents, claims, demands, waivers, and other communications under this Agreement (each, a "Notice," and with the correlative meaning "Notify") must be in writing and addressed to the other Party at its address set forth below (or to such other address that the receiving Party may designate from time to time). Unless otherwise agreed herein, all Notices must be delivered by personal delivery, nationally recognized overnight courier, certified or registered mail (in each case, return receipt requested, postage prepaid), or email with confirmation of receipt. Except as otherwise provided in this Agreement, a Notice is effective only (a) on receipt by the receiving Party; and (b) if the Party giving the Notice has complied with the requirements herein.

Notice to Licensee

Ala. Code § 36-12-40 (Personally Identifiable Information)
[redacted]

Notice to Carrier
Alabama Transport Company
Address,
City, State, zip
Phone
Email

33. **SEVERABILITY**. If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.

34. **AMENDMENT AND MODIFICATION**. This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each Party hereto.

35. **HEADINGS**. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

36. **WAIVER**. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the Party so waiving. No waiver by any Party shall operate or be construed as a waiver in respect of any failure, breach, or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power, or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power, or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege.

37. **ASSIGNMENT AND DELEGATION**. Except as explicitly stated in this Agreement, neither Party may assign any of its rights or delegate any of its obligations hereunder without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that Licensee may assign its rights and delegate its obligations in whole only, without such consent and upon thirty (30) days prior written notice to Carrier, to an entity to which Licensee's medical cannabis license identified in the Statement of Work is transferred pursuant to the Alabama Medical Cannabis Law. No

assignment or delegation shall relieve the Licensee of any of its obligations hereunder unless the Carrier enters into a novation releasing the Licensee of its obligations under the Agreement. Any purported assignment or delegation in violation of this Agreement shall be null and void.

38. **SUCCESSORS AND ASSIGNS**. This Agreement is binding on and inures to the benefit of the Parties to this Agreement and their respective permitted successors and permitted assigns.

39. **NO THIRD-PARTY BENEFICIARIES**. This Agreement benefits solely the Parties to this Agreement and their respective permitted successors and assigns and nothing in this Agreement, express or implied, confers on any other person or entity any legal or equitable right, benefit, or remedy of any nature whatsoever under or by reason of this Agreement.

40. **GOVERNING LAW**. This Agreement and all related documents including all exhibits attached hereto, and all matters arising out of or relating to this Agreement, whether sounding in contract, tort, or statute are governed by, and construed in accordance with, the laws of the State of Alabama, including its statutes of limitations, without giving effect to the conflict of law provisions thereof to the extent such principles or rules would require or permit the application of the laws of any jurisdiction other than those of the State of Alabama.

41. **SUBMISSION TO JURISDICTION**. Any legal suit, action, or proceeding arising out of or relating to this Agreement, the other transaction documents or the transactions contemplated hereby shall be instituted in state court located in the state of Alabama in the city of Fairhope and the County of Baldwin, and each Party irrevocably submits to the exclusive jurisdiction of such court in any such suit, action, or proceeding.

42. **COUNTERPARTS**. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A handwritten signed or secure e-signature copy of this Agreement delivered by email, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

43. **FORCE MAJEURE**. No Party shall be liable or responsible to the other Party, nor be deemed to have defaulted under or breached this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement (except for any obligations to make payments to the other Party hereunder), when and to the extent such failure or delay is caused by or results from acts beyond the affected Party's reasonable control, including, without limitation, acts of God, flood, fire, earthquake, explosion, governmental actions, war, invasion or hostilities (whether war is declared or not), terrorist threats or acts, riot, or other civil unrest, national or regional emergency, revolution, insurrection, epidemic, pandemic, lock-outs, strikes or other labor disputes (whether or not relating to either Party's workforce), or restraints or delays affecting carriers or inability or delay in obtaining supplies of adequate or suitable materials, or telecommunication breakdown or power outage. The Party suffering a Force Majeure Event shall give notice within seven (7) days of the Force Majeure Event to the other Party, stating the period of time the occurrence is expected to continue and shall use diligent efforts to end the failure or delay and ensure the effects of such Force Majeure Event are minimized.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective Date by their respective duly authorized officers.

COOSA MEDICAL MANUFACTURING, LLC **Alabama Transport Company TBD**

By: _____
Ala. Code § 36-12-40 (Personally Ide
CEO, President

By: _____
NAME
Position

ATTACHMENT A

STATEMENT OF WORK

I. TRANSPORTATION SERVICES.

A. **Summary of Transportation Services**. Alabama Transport Company TBD ("Carrier") shall provide Gulf Shore Remedies, LLC ("Licensee") with Transportation Services, including the collection, loading, transporting, unloading, and delivery of shipments of medical cannabis within the State of Alabama.

1. **Service Term**: One (1) year. The Service Term will commence the first day Carrier provides Transportation Services to the Licensee.

2. **First Day of Services**: Although the date may vary, Licensee projects that it will require Transportation Services for the first time on or about January 2023.

3. **Licensee Location**: Ala. Code § 36-12-40 (Personally Identifiable Information)

4. **Licensee Location Telephone No(s)**.: Ala. Code § 36-12-40 (Personally Ident

5. **Licensee Hours of Operation**: 9:00 a.m. CST – 5:00 p.m. CST

6. **Licensee Medical Cannabis License Nos.**: TBD

B. **Contacts**.

1. **Designated Contacts.**

Licensee Designated Contact:
Ala. Code § 36-12-40 (Personally Ide

P) Ala. Code § 36-12-40 (Personally Ident

Carrier Designated Contact:
TBD

2. **Shipping Contacts**.

Licensee Shipping Contact:
Ala. Code § 36-12-40 (Personally Ide

P) Ala. Code § 36-12-40 (Personally Ident

Carrier Shipping Contact:
TBD

3. **Emergency contacts and telephone numbers**.

In case of an emergency,
Carrier shall contact:
Ala. Code § 36-12-40 (Personally Identifi

P) Ala. Code § 36-12-40 (Personally Ident

In case of an emergency,
Licensee shall contact:
TBD

C. **Vehicles**. Carrier's fleet of vehicles that will appear in ALABAMA STATE TRACKING SYSTEM include:

TBD

II. SCHEDULES.

A. **Rate and Fee Schedules**

1. **Monthly Rate:** TBD
2. **Transit Rate:** TBD
3. **Minimum Transit Time per shipment**: Two (2) hours
4. **Shipments Allotted per month:** TBD
5. **Shipment Rate above monthly allotment**: TBD
6. **Administrative Fee during DHSS Action**: TBD

B. **Number of Transport Personnel per Shipment**.

1. Two (2) Transport Personnel for all shipments.

C. **Transit Time Calculation**.

1. Estimated roundtrip travel time between Licensee Originating Location and the Destination Location(s) pursuant to Google Maps, MapQuest, or similar program or application; *plus*
2. Thirty (30) minutes for unloading procedures at the non-Licensee Destination Location(s). In the event Transport Personnel are required to wait or perform Transportation Services at the non-Licensee Destination Location(s) for longer than forty-five (45) minutes through no fault of Carrier, all such time shall be added to the transit time calculation in Carrier's sole discretion.

D. **Invoice and Payment Schedules**.

1. **Monthly Fee**. Carrier will invoice Licensee the first monthly fee upon execution of this Agreement. Licensee shall make full payment of the first monthly fee prior to the earlier of (i) the anticipated First Day of Services identified above, or (ii) the first scheduled shipment. Thereafter, Licensee will be invoiced the monthly fee one month prior to the first day of the month for which the fee applies and full payment is due within fifteen (15) days of Licensee's receipt of Carrier's invoice. The monthly fee shall be paid prior to the first day of the month for which the monthly fee applies.

2. **Transit Time Fees**. Transit Time Fees will be invoiced after the fees are incurred. Full payment is due within fifteen (15) days of Licensee's receipt of Carrier's invoice.

COOSA MEDICAL MANUFACTURING, LLC	**Alabama Transport License Holder**
_____	_____
Ala. Code § 36-12-40 (Personally Ide[redacted]	NAME
CEO, President	Position
Date: _____	Date: _____

MEDICAL CANNABIS SALE AGREEMENT
between
COOSA MEDICAL MANUFACTURING, LLC
and
_____

Coosa Medical Manufacturing, LLC ("**Seller**") and Alabama Dispensary License Holder, _____ ("**Purchaser**", and together with Seller, the "**Parties**", and each, a "**Party**") hereby enter into this Cannabis Purchase Agreement (this "**Agreement**"), setting forth the terms of sale and purchase of approved forms of medical cannabis product, as permitted under the applicable Alabama laws and regulations and subject to availability, (the "**Product**") by the Parties.

Seller:	Coosa Medical Manufacturing, LLC Ala. Code § 36-12-40 (Personally Identifiable Information) [redacted]
Buyer:	ALABAMA DISPENSARY ADDRESS CITY, STATE, ZIP
Scope:	This Agreement applies to the purchase (the "**Purchase**") of the Product by Purchaser from Seller, in accordance with the terms set forth herein.
Term:	Twelve months from the date of the first delivery of Product with the option to extend for one additional one-year term, at Purchaser's sole option to be exercised on or before July 31st of the prior year.
Scheduling:	Seller will ensure that sufficient transportation contractors, as applicable, are available at all relevant times to accommodate delivery.
Supply Terms:	Seller shall deliver to Purchaser, FOB Purchaser's facility listed above, packaged and labeled Product specified in **Exhibit A** ("**Order Form**"), as attached hereto and incorporated herein. In the event of any conflict between the terms of this Agreement and the terms of any purchase order or any other document issued by Purchaser, the terms of this Agreement prevail.
Product Quantities and Pricing:	The purchase prices and/or base quantity and Product availability shall be determined by Seller. Throughout the Term, Seller reserves the right to unilaterally update the Prices and/or Base Quantity and Product availability and shall provide such notice to Purchaser. All prices are exclusive of all sales, use and excise taxes, and any other similar taxes, duties, and charges of any kind imposed by any governmental authority on any amounts payable by Purchaser.

Payment Terms:	Seller reserves the right to require that Purchaser make a deposit payment in order for Seller to accept and fulfill Purchaser's order. On the date that Seller delivers the Product, Seller shall present an accounting of the amount due, which shall include the Price of the Product delivered, quantity, name of Product, any taxes, delivery fees, subject to any credit adjustment for Purchaser's deposit payments, and the correlated RFID number applied through the Alabama Medical Cannabis Seed-to-Sale system. Payment will be made in full in immediately available funds on the Payment Due Date as set forth in the Order Form, Ex. A, (the "**Payment Due Date**") via cash, automated clearing house, or certified check payable as directed by Seller. Purchaser shall pay an 8% (eight percent) per annum interest charge on overdue amounts for the Product purchased hereunder.
Representations:	During the Term, Seller shall comply with and manufacture the Product in accordance with regulations established by the Alabama Office of Medical Cannabis (the "**OMC**") and the State of Alabama related to the manufacture, production, handling, and transportation of medical cannabis and cannabis products ("**Applicable Regulations**"). In the event that any Product sold hereunder does not comply with Applicable Regulations, or does not comply with the terms of this Agreement, Purchaser shall notify Seller in writing of any such non-compliance within two (2) business days following the Delivery Date of the relevant Product to Purchaser, stating in reasonable detail the nature of such non-compliance and type and aggregate quantity of the Product to which such non-compliance applies (a "**Non-Compliance Notice**"). If such non-compliance can only be demonstrated by laboratory testing, the Non-Compliance Notice shall include documentation of the relevant test results. Seller shall have the right to replace any such non-complying Product with compliant Product within five (5) business days of receipt of the Non-Compliance Notice, which shall constitute full compliance by Seller of its obligation to supply Products with respect to such Purchase Order. If Seller does not provide replacement within five (5) business days, then Purchaser's sole remedy shall be to receive a refund of the Price paid for the non-conforming Product based upon the price set forth in this Agreement. In the event of return of the Product by Purchaser, Purchaser shall pay Seller a restocking charge equal to fifteen percent (15%) of the Price.
Transport:	Seller shall make delivery FOB Purchaser's facility. Title to the purchased Products shall pass to Purchaser upon delivery and acceptance of the Product by Purchaser on the day of delivery. The risk of loss or damage to the Product sold hereunder shall pass from Seller to Purchaser upon delivery of the Product by Purchaser. Purchaser shall be responsible for a

	delivery fee to be calculated by Seller and added to the purchase price for each order. Throughout the Term, Seller reserves the right to unilaterally update the delivery fee for any order. All Products delivered hereunder shall be packaged in accordance with all applicable state laws and regulations, with the Product packaged separately and clearly labeled with identification of the applicable strain and weight of the contents.
Governing Law:	This Agreement shall be governed by the laws of the State of Alabama. Purchaser submits to the jurisdiction and venue of any state court sitting in the State of Alabama.
Force Majeure:	The obligations of the Parties are contingent upon earthquakes, fires, storms, floods, freezes, material reductions, accidents, labor disputes, transportation embargoes, significant oil price increases, failure of machinery, acts of God or of any government (including the OMC), pandemics (including the COVID-19 pandemic) and any circumstances related to COVID-19 or any related epidemic, pandemic, state of emergency, government orders, government shutdowns, unavailability of labor, or materials or reasonable substitutes therefor, or other causes beyond any Party's reasonable control that relates thereto, including ceasing of operations by Seller, acts of war or terrorism, and other interferences beyond the Parties' reasonable control, to the extent the same prevent or delay the performance of the obligations herein contained.
Taxes:	Unless otherwise indicated herein, prices do not include state, county, and/or municipal sales, use, excise or similar taxes applicable to the purchased Product, or the purchased Product's use by Purchaser or the Purchaser's customers. If Seller should be required to pay the same, Purchaser shall be liable to pay to and to reimburse Seller for any such taxes. If required by law, Seller may collect sales or use taxes on its invoices for Product sold to Purchaser hereunder.
Security Interest:	Purchaser hereby grants to Seller a security interest in the purchased Product to secure the payment of Seller's invoice for all or any portion of the purchase price that remains unpaid at any time. Purchaser hereby authorizes Seller to execute on behalf of Purchaser and to file one or more financing statements to evidence and perfect a security interest in the purchased Product with any governmental authority in any jurisdiction as Seller, in its sole and absolute discretion, deems necessary or desirable to protect the Seller's interests. Purchaser shall execute at Seller's request any documents required by Seller to evidence and perfect such security interest, including individual or blanket financing statements, chattel mortgages, or similar instruments for filing in any such jurisdictions. Seller shall have all of the rights of a secured creditor under the Uniform Commercial Code or any similar law that may be

	applicable, including the right of repossession for non-payment.
Liability:	TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL SELLER BE LIABLE TO PURCHASER FOR LOSS OF PROFITS, REVENUE OR INCOME, OR FOR ANY INDIRECT, PUNITIVE, SPECIAL, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THIS AGREEMENT OR RELATED TO PURCHASER'S DEVELOPMENT, PRODUCTION OR SALE OF ANY NEW OR MODIFIED FORMULATIONS OR COMBINATIONS OF THE PURCHASED PRODUCT MADE BY PURCHASER, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. PURCHASER'S SOLE REMEDY FOR LIABILITY OR DAMAGES UNDER THIS AGREEMENT SHALL BE STRICTLY LIMITED TO REPLACEMENT OF ANY NON-CONFORMING PRODUCT OR A REFUND OF ANY FEES PAID FOR THE NON-CONFORMING PRODUCT BASED UPON THE PRICE AND ON THE TERMS OTHERWISE SET FORTH IN THIS AGREEMENT. PURCHASER UNDERSTANDS THAT IT MAY BE WAIVING RIGHTS WITH RESPECT TO CLAIMS THAT ARE AT THIS TIME UNKNOWN OR UNSUSPECTED.
Indemnification:	Purchaser shall indemnify, protect, defend, and hold Seller, its affiliates, and its and their respective officers, directors, employees, affiliates, equity holders, managers, members, contractors, agents, consultants, advisors, and representatives harmless for, from, and against all losses, costs, expenses, penalties, and other damages (including reasonable attorneys' fees and costs) of any nature, kind or description directly resulting from or arising out of third party claims stemming from: (a) any breach, inaccuracy or non-fulfillment of any representations, warranties, covenants or agreements made by Purchaser in this Agreement or resulting from failure of Purchaser to comply with the Alabama Medical Cannabis Act, as amended from time to time, and all Alabama regulations promulgated or otherwise thereunder, (b) any negligence, willful misconduct, defective sales-process, or defective handling of the purchased Product, excepting in each instance claims stemming from the gross negligence or willful misconduct of the Seller or its officers, directors, employees, or agents, or (c) the manufacturing, processing, design, formulation, and sale by Purchaser of any processed products using the Product.
Use of Names and Marks; Reverse Engineering:	Purchaser represents, warrants and covenants that it shall not use, make reference to, publish, copy or otherwise designate, either orally or in writing, any logo, trademark, servicemark or tradename of the Seller ("**Mark(s)**"), except for the limited purpose of product displays or patient production information and only as allowable under the Applicable Regulations, without prior written consent of Seller. Upon the termination of this Agreement or at the written direction of Seller, Purchaser shall discontinue the use of all Marks of the Seller and all legends adopted in accordance with this Section. Purchaser shall leave in place all designations of Marks placed on the

	purchased Product (including Marks on any and all packaging therefor) by the Seller. Purchaser shall not use any portion of the purchased Product, whether through planting, researching, studying, dissecting or through any other actions or methods (whether or not related to botany), to grow, create, genetically engineer, reverse engineer, or otherwise imitate or copy the Product. In the event of a breach of any of the covenants contained in this Section, Seller shall be entitled to injunctive or other equitable relief because Seller will be caused irreparable injury and damage as a result of such breach. This right to injunctive relief shall include the right to both preliminary and permanent injunctions. Seller shall not be required to post a bond or any similar assurance if it brings any action in order to enforce any of the covenants contained in this Section.
Medical Cannabis:	Each Party represents and warrants that it has obtained all AMCC and local approvals, permits, licenses, certificates, necessary for it to perform its obligations under this Agreement, and each Party covenants and agrees that, during the Term, it will maintain all such approvals and obtain any and all additional approvals that may be necessary for it to perform its obligations hereunder. Each Party will notify the other Party within 24 hours in writing if it learns or reasonably believes that it is not in full compliance with the terms of this Section. The Parties acknowledge that they are aware of and fully understand that despite the laws of the State of Alabama and the terms and conditions of this Agreement, holders of licenses to sell medical Cannabis may still be arrested by federal officers and prosecuted under federal law. The Parties also expressly waive federal illegality as a defense to any Agreement enforcement action.
WAIVER OF JURY TRIAL:	THE PARTIES KNOWINGLY AND WILLINGLY WAIVE ANY RIGHT THEY HAVE UNDER APPLICABLE LAW TO A TRIAL BY JURY IN ANY DISPUTE ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT OR THE ISSUES RAISED BY THAT DISPUTE.
Attorneys' Fees:	In the event that any legal action or other proceeding is brought for the enforcement of these terms and conditions or in connection with any provision contained herein, the prevailing Party shall be entitled to recover its reasonable attorneys' fees, court costs and expenses, court costs, including, but not limited to, fees, costs and expenses incurred to collect fees, costs and expenses, and those fees and costs incurred incidentally to arbitration, mediation, investigation, discovery, travel, appellate proceedings, bankruptcy, collection, retention of expert witnesses, and post judgment proceedings.
Additional Provisions:	The provisions of this Agreement shall, except as otherwise provided herein, endure to the benefit of and be binding upon the Parties and their respective executors, administrators, successors, and assigns, each and every person so bound shall make, execute and deliver all documents necessary to carry out this Agreement.

This Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and the transactions herein contemplated and replace all previous agreements and understandings, if any, between the parties with respect to the subject matter hereof and the transaction contemplated herein. Any Purchase Order previously entered into between the Parties shall also be governed by the terms of this Agreement.

Any notice to be given under this Agreement shall be in writing and delivered, faxed or mailed by prepaid registered mail or electronic mail, addressed to the party to whom it is to be given at the address hereinabove mentioned and such notice shall be deemed to have been given on the day of delivery or on the day it is faxed or e-mailed or on the fifth business day after mailing as aforesaid, as the case may be.

If any provision of this Agreement shall be held invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall attach only to such provision in such jurisdiction and shall not in any manner affect or render invalid or unenforceable such provision in any other jurisdiction or any other provision of this Agreement in any jurisdiction.

Except as provided therein, the failure on the part of one Party, in any one or more instances, to insist upon the keeping, performance or observance of any of the terms, conditions or provisions of this Agreement, or to exercise any right or privilege herein conferred, shall not be construed as relinquishment of that Party's right to require the future keeping, performance or observance of any such terms, conditions or provisions.

This agreement may be executed in any number of counterparties, each of which will be deemed an original and all of which taken together will constitute one and the same agreement. Delivery of a signed counterpart of this Agreement by email or facsimile transmission will constitute valid and sufficient delivery thereof by the parties.

AGREED AND ACCEPTED:

COOSA MEDICAL MANUFACTURING, LLC

By:_____

Name: [redacted]

Title: CEO

Address: [redacted]

Telephone: [redacted]

Facsimile:

Date: tbd

ALABAMA DISPENSARY LLC

By:_____

Name: TBD

Title: TBD

Address: TBD

Telephone: TBD

Facsimile: TBD

Date: TBD

SALE AND PURCHASE AGREEMENT

Date: December 15, 2022

Seller Name: [redacted]
Seller Position: CEO
Seller Corporate Entity: Coosa Medical Manufacturing, LLC
Seller Address: Ala. Code § 36-12-40 (Personally Identifiable Information)

Dear [redacted]:

This letter agreement (the "**Agreement**") confirms the engagement of Yellowhammer Medical Dispensaries, LLC, an Alabama Limited Liability Company located at [redacted] ("**Buyer**"), and Coosa Medical Manufacturing, LLC, an Alabama Limited Liability Company located at Ala. Code § 36-12-40 (Personally Identifiable Information) ("**Seller**", and together with Buyer, the "**Parties**", and each a "**Party**") to render the sale of medical cannabis products in compliance under applicable Alabama laws and regulations ("**Product**"). Buyer and Seller hereby enter into this Agreement.

Effective Date:	This Agreement shall be in effect from November 31st, 2023 until November 31st, 2024. (the "**Term**").
Scope:	This Agreement applies to the purchase (the "**Purchase**") of the Product by Buyer from Seller, in accordance with the terms set forth herein.
Product Prices and Base Quantity:	The purchase prices and/or base quantity and Product availability shall be determined by Seller. Throughout the Term, Seller reserves the right to unilaterally update the Prices and/or Base Quantity and Product availability and shall provide such notice to Buyer. All prices are exclusive of all sales, use and excise taxes, and any other similar taxes, duties, and charges of any kind imposed by any governmental authority on any amounts payable by Buyer.
Delivery:	Seller shall make delivery FOB Buyer's facility. Title to the purchased Products shall pass to Buyer upon delivery and acceptance of the Product by Buyer on the day of delivery. The risk of loss or damage to the Product sold hereunder shall pass from Seller to Buyer upon delivery of the Product by Buyer. Buyer shall be responsible for a delivery fee to be calculated by Seller and added to the purchase price for each order. Throughout the Term, Seller reserves the right to unilaterally update the delivery fee for any order. All Products delivered hereunder shall be packaged in accordance with all applicable state laws and regulations, with the Product packaged separately and clearly labeled with identification of the applicable strain and weight of the contents.

Supply:	Seller shall deliver to Buyer, FOB Buyer's facility listed above, packaged and labeled Product specified in **Exhibit A** ("**Order Form**"), as attached hereto and incorporated herein. In the event of any conflict between the terms of this Agreement and the terms of any purchase order or any other document issued by Buyer, the terms of this Agreement prevail.
Payment:	Seller reserves the right to require that Buyer make a deposit payment in order for Seller to accept and fulfill Buyer's order. On the date that Seller delivers the Product, Seller shall present an accounting of the amount due, which shall include the Price of the Product delivered, quantity, name of Product, any taxes, delivery fees, subject to any credit adjustment for Buyer's deposit payments, and the correlated RFID number applied through the Medical Marijuana Seed-to-Sale ALABAMA system. Payment will be made in full in immediately available funds on the Payment Due Date as set forth in the Order Form, Ex. A, (the "**Payment Due Date**") via cash, automated clearing house, or certified check payable as directed by Seller. Buyer shall pay an 8% (eight percent) per annum interest charge on overdue amounts for the Product purchased hereunder.
Representations:	During the Term, Seller shall comply with and manufacture the Product in accordance with regulations established by the Alabama Office of Medical Cannabis (the "**OMC**") and the State of Alabama related to the manufacture, production, handling, and transportation of medical cannabis and cannabis products ("**Applicable Regulations**"). In the event that any Product sold hereunder does not comply with Applicable Regulations, or does not comply with the terms of this Agreement, Buyer shall notify Seller in writing of any such non-compliance within two (2) business days following the Delivery Date of the relevant Product to Buyer, stating in reasonable detail the nature of such non-compliance and type and aggregate quantity of the Product to which such non-compliance applies (a "**Non-Compliance Notice**"). If such non-compliance can only be demonstrated by laboratory testing, the Non-Compliance Notice shall include documentation of the relevant test results. Seller shall have the right to replace any such non-complying Product with compliant Product within five (5) business days of receipt of the Non-Compliance Notice, which shall constitute full compliance by Seller of its obligation to supply Products with respect to such Purchase Order. If Seller does not provide replacement within five (5) business days, then Buyer's sole remedy shall be to receive a refund of the Price paid for the non-conforming Product based upon the price set forth in this Agreement. In the event of return of the Product by Buyer, Buyer shall pay Seller a restocking charge equal to fifteen percent (15%) of the Price.

Governing Law:	This Agreement shall be governed by the laws of the State of Alabama. Buyer submits to the jurisdiction and venue of any state court sitting in the State of Alabama.
Force Majeure:	The obligations of the Parties are contingent upon earthquakes, fires, storms, floods, freezes, material reductions, accidents, labor disputes, transportation embargoes, significant oil price increases, failure of machinery, acts of God or of any government (including the OMC), pandemics (including the COVID-19 pandemic) and any circumstances related to COVID-19 or any related epidemic, pandemic, state of emergency, government orders, government shutdowns, unavailability of labor, or materials or reasonable substitutes therefor, or other causes beyond any Party's reasonable control that relates thereto, including ceasing of operations by Seller, acts of war or terrorism, and other interferences beyond the Parties' reasonable control, to the extent the same prevent or delay the performance of the obligations herein contained.
Taxes	Unless otherwise indicated herein, prices do not include state, county, and/or municipal sales, use, excise or similar taxes applicable to the purchased Product, or the purchased Product's use by Buyer or the Buyer's customers. If Seller should be required to pay the same, Buyer shall be liable to pay to and to reimburse Seller for any such taxes. If required by law, Seller may collect sales or use taxes on its invoices for Product sold to Buyer hereunder.
Security Interest	Buyer hereby grants to Seller a security interest in the purchased Product to secure the payment of Seller's invoice for all or any portion of the purchase price that remains unpaid at any time. Buyer hereby authorizes Seller to execute on behalf of Buyer and to file one or more financing statements to evidence and perfect a security interest in the purchased Product with any governmental authority in any jurisdiction as Seller, in its sole and absolute discretion, deems necessary or desirable to protect the Seller's interests. Buyer shall execute at Seller's request any documents required by Seller to evidence and perfect such security interest, including individual or blanket financing statements, chattel mortgages, or similar instruments for filing in any such jurisdictions. Seller shall have all of the rights of a secured creditor under the Uniform Commercial Code or any similar law that may be applicable, including the right of repossession for non-payment.
Limitation and Exculpation of Liability	TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL SELLER BE LIABLE TO BUYER FOR LOSS OF PROFITS, REVENUE OR INCOME, OR FOR ANY INDIRECT, PUNITIVE, SPECIAL, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR OTHER DAMAGES

	ARISING FROM OR RELATED TO THIS AGREEMENT OR RELATED TO BUYER'S DEVELOPMENT, PRODUCTION OR SALE OF ANY NEW OR MODIFIED FORMULATIONS OR COMBINATIONS OF THE PURCHASED PRODUCT MADE BY BUYER, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. BUYER'S SOLE REMEDY FOR LIABILITY OR DAMAGES UNDER THIS AGREEMENT SHALL BE STRICTLY LIMITED TO REPLACEMENT OF ANY NON-CONFORMING PRODUCT OR A REFUND OF ANY FEES PAID FOR THE NON-CONFORMING PRODUCT BASED UPON THE PRICE AND ON THE TERMS OTHERWISE SET FORTH IN THIS AGREEMENT. BUYER UNDERSTANDS THAT IT MAY BE WAIVING RIGHTS WITH RESPECT TO CLAIMS THAT ARE AT THIS TIME UNKNOWN OR UNSUSPECTED.
Indemnification	Buyer shall indemnify, protect, defend, and hold Seller, its affiliates, and its and their respective officers, directors, employees, affiliates, equity holders, managers, members, contractors, agents, consultants, advisors, and representatives harmless for, from, and against all losses, costs, expenses, penalties, and other damages (including reasonable attorneys' fees and costs) of any nature, kind or description directly resulting from or arising out of third party claims stemming from: (a) any breach, inaccuracy or non-fulfillment of any representations, warranties, covenants or agreements made by Buyer in this Agreement or resulting from failure of Buyer to comply with the Alabama Medical Cannabis Act, as amended from time to time, and all Alabama regulations promulgated or otherwise thereunder, (b) any negligence, willful misconduct, defective sales-process, or defective handling of the purchased Product, excepting in each instance claims stemming from the gross negligence or willful misconduct of the Seller or its officers, directors, employees, or agents, or (c) the manufacturing, processing, design, formulation, and sale by Buyer of any processed products using the Product.
Use of Names and Marks; Reverse Engineering	Buyer represents, warrants and covenants that it shall not use, make reference to, publish, copy or otherwise designate, either orally or in writing, any logo, trademark, servicemark or tradename of the Seller ("**Mark(s)**"), except for the limited purpose of product displays or patient production information and only as allowable under the Applicable Regulations, without prior written consent of Seller. Upon the termination of this Agreement or at the written direction of Seller, Buyer shall discontinue the use of all Marks of the Seller and all legends adopted in accordance with this Section. Buyer shall leave in place all designations of Marks placed on the purchased Product (including Marks on any and all packaging therefor) by the Seller. Buyer shall not use any portion of the purchased Product, whether

	through planting, researching, studying, dissecting or through any other actions or methods (whether or not related to botany), to grow, create, genetically engineer, reverse engineer, or otherwise imitate or copy the Product. In the event of a breach of any of the covenants contained in this Section, Seller shall be entitled to injunctive or other equitable relief because Seller will be caused irreparable injury and damage as a result of such breach. This right to injunctive relief shall include the right to both preliminary and permanent injunctions. Seller shall not be required to post a bond or any similar assurance if it brings any action in order to enforce any of the covenants contained in this Section.
Medical Marijuana	Each Party represents and warrants that it has obtained all AMCC and local approvals, permits, licenses, certificates, necessary for it to perform its obligations under this Agreement, and each Party covenants and agrees that, during the Term, it will maintain all such approvals and obtain any and all additional approvals that may be necessary for it to perform its obligations hereunder. Each Party will notify the other Party within 24 hours in writing if it learns or reasonably believes that it is not in full compliance with the terms of this Section. The Parties acknowledge that they are aware of and fully understand that despite the laws of the State of Alabama and the terms and conditions of this Agreement, holders of licenses to sell medical marijuana may still be arrested by federal officers and prosecuted under federal law. The Parties also expressly waive federal illegality as a defense to any Agreement enforcement action.
WAIVER OF JURY TRIAL	THE PARTIES KNOWINGLY AND WILLINGLY WAIVE ANY RIGHT THEY HAVE UNDER APPLICABLE LAW TO A TRIAL BY JURY IN ANY DISPUTE ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT OR THE ISSUES RAISED BY THAT DISPUTE.
Attorneys' Fees	In the event that any legal action or other proceeding is brought for the enforcement of these terms and conditions or in connection with any provision contained herein, the prevailing Party shall be entitled to recover its reasonable attorneys' fees, court costs and expenses, court costs, including, but not limited to, fees, costs and expenses incurred to collect fees, costs and expenses, and those fees and costs incurred incidentally to arbitration, mediation, investigation, discovery, travel, appellate proceedings, bankruptcy, collection, retention of expert witnesses, and post judgment proceedings.
Additional Provisions:	The provisions of this Agreement shall, except as otherwise provided herein, endure to the benefit of and be binding upon the Parties and their respective executors, administrators, successors, and assigns, each and every person so bound shall make, execute

and deliver all documents necessary to carry out this Agreement.

This Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and the transactions herein contemplated and replace all previous agreements and understandings, if any, between the parties with respect to the subject matter hereof and the transaction contemplated herein. Any Purchase Order previously entered into between the Parties shall also be governed by the terms of this Agreement.

Any notice to be given under this Agreement shall be in writing and delivered, faxed or mailed by prepaid registered mail or electronic mail, addressed to the party to whom it is to be given at the address hereinabove mentioned and such notice shall be deemed to have been given on the day of delivery or on the day it is faxed or e-mailed or on the fifth business day after mailing as aforesaid, as the case may be. Notices to Buyer shall include an email copy to

EMAIL: [redacted]

NAME: [redacted]

Notices to Seller shall include an email copy to Jane Doe. Notice of change of address may be given by any Party in the same manner.

If any provision of this Agreement shall be held invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall attach only to such provision in such jurisdiction and shall not in any manner affect or render invalid or unenforceable such provision in any other jurisdiction or any other provision of this Agreement in any jurisdiction.

Except as provided therein, the failure on the part of one Party, in any one or more instances, to insist upon the keeping, performance or observance of any of the terms, conditions or provisions of this Agreement, or to exercise any right or privilege herein conferred, shall not be construed as relinquishment of that Party's right to require the future keeping, performance or observance of any such terms, conditions or provisions.

This Agreement may be executed in one or more counterparts each of which when so executed shall be deemed to be an original and such counterparts together shall constitute but one of the same instrument.

Coosa Medical Manufacturing, LLC

By:_ Ala. Code § 36-12-40 (Personally Identifiable Information)

Name: Ala. Code § 36-12-40 (Personally Ident

Title: CEO

Date: 12/15/2022 | 10:20 AM PST

Yellowhammer Medical Dispensaries, LLC

Name: Ala. Code § 36-12-40 (Personally I

Title: CEO

Date: 12/15/2022 | 10:29 AM PST

MEMORANDUM OF UNDERSTANDING

THIS MEMORANDUM OF UNDERSTANDING (this "MOU"), dated as of December 7, 2022 sets forth certain nonbinding understandings and binding agreements between AlaBloom, LLC, an Alabama limited liability company ("AlaBloom"), and Coosa Medical Manufacturing, LLC, an Alabama limited liability company (the "Processor"), relating to the proposed business relationship between AlaBloom and Processor, whereby, pursuant to the Darren Wesley 'Ato' Hall Compassion Act, and the rules and regulations promulgated thereunder (the "Act"), and in compliance with the Act, the Parties intend to sell and buy medical cannabis products to and from each other (the "Proposed Transaction"). AlaBloom and Processor are sometimes referred to individually as a "Party" and collectively as the "Parties".

1. MOU Subject to Definitive Agreement. This MOU is for discussion purposes only, and is not intended to constitute a legally binding or enforceable agreement or commitment on either Party, except for Section 3 which shall be binding on the Parties in accordance with its terms.

2. Scope. This Section 2 sets forth the nonbinding understandings of the Parties with respect to the Proposed Transaction. It is the present intention of the Parties that AlaBloom may sell cannabis feedstock for processing to Processor, and each Party purchase from or sell to the other Party certain medical cannabis products and materials for each Party's use in manufacturing their products, respectively, and AlaBloom may purchase from Processor products for sale in AlaBloom's dispensaries on the terms and conditions set forth in the Definitive Agreement entered into between the Parties upon each Party's successful receipt of a license from the Alabama Medical Cannabis Commission pursuant to the Act.

(a) Definitive Agreement. The Parties intend to negotiate a formal written agreement that would govern the Proposed Transaction ("Definitive Agreement"). Binding obligations with respect to the Proposed Transaction shall only arise upon the execution of the Definitive Agreement by both Parties.

(b) Customary Provisions. The Definitive Agreement would contain such covenants, conditions, indemnities, representations and warranties as are customary for this type of transaction and as the Parties would mutually agree, including, but not limited to, purchase terms, purchase price, quality standards in line with GMP (Good Manufacturing Practices), freight/delivery terms, timelines, term length, and confidentiality.

3. Binding Agreements. This Section 3 shall constitute a legally binding and enforceable agreement between the Parties. In consideration of the expenses that the Parties will incur in pursuing the Proposed Transaction and drafting and negotiating the Definitive Agreement, the Parties agree as follows:

(a) Due Diligence. Conclusion of the Proposed Transaction is subject to completion of a due diligence investigation by the Parties that yields satisfactory results to each Party.

(b) Costs and Expenses. Each Party shall be responsible for all of its costs and expenses associated with pursuing the Proposed Transaction, including without limitation

(i) the performance of its obligations under this MOU, (ii) conducting its due diligence investigation, and (iii) and drafting and negotiating the Definitive Agreement.

(c) Confidentiality. During the term of this MOU, either Party (in this capacity, referred to as the "Disclosing Party") may disclose or make available to the other Party (in this capacity, referred to as the "Receiving Party") information about its business affairs, products/services, confidential intellectual property, trade secrets, third-party confidential information and other sensitive or proprietary information, whether orally or in written, electronic or other form or media, and whether or not marked, designated or otherwise identified as "confidential" (collectively, "Confidential Information").

Confidential Information shall not include information that, at the time of disclosure: (i) is or becomes generally available to and known by the public other than as a result of, directly or indirectly, any breach of this Section 3(c) by the Receiving Party or any of its representatives; (ii) is or becomes available to the Receiving Party on a non-confidential basis from a third-party source, provided that such third party is not and was not prohibited from disclosing such Confidential Information; (iii) was known by, or in the possession of, the Receiving Party or its representatives before being disclosed by or on behalf of the Disclosing Party as established by documentary evidence; (iv) was or is independently developed by the Receiving Party without reference to or use, in whole or in part, of any of the Disclosing Party's Confidential Information; or (v) is required to be disclosed under applicable federal, state or local law, regulation or a valid order issued by a court or governmental agency of competent jurisdiction.

The Receiving Party shall: (i) protect and safeguard the confidentiality of the Disclosing Party's Confidential Information with at least the same degree of care as the Receiving Party would protect its own Confidential Information, but in no event with less than a commercially reasonable degree of care; (ii) not use the Disclosing Party's Confidential Information, or permit it to be accessed or used, for any purpose other than to exercise its rights or perform its obligations under this MOU and ultimately the Definitive Agreement, if the Parties come to terms; and (iii) not disclose any such Confidential Information to any person or entity, except to the Receiving Party's representatives who need to know the Confidential Information to assist the Receiving Party, or act on its behalf, to exercise its rights or perform its obligations under this MOU. The Receiving Party shall be responsible for any breach of this Section 3(c) caused by any of its representatives.

(d) Term and Termination. The rights and obligations of the Parties contained in this MOU shall expire upon the execution of the Definitive Agreement. Either Party may terminate this MOU after twelve (12) months from the date of this MOU without any obligation or liability to the other Party, provided however that Section 3(c), Section 3(e), and Section 3(f) shall survive such termination.

(e) Governing Law. This MOU shall be governed by and construed in accordance with the internal laws of the state of Alabama, without giving effect to any choice or conflict of law provision or rule (whether of the state of Alabama or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the state of Alabama.

(f) No Third-Party Beneficiaries. Nothing herein is intended or shall be construed to confer upon any person or entity other than the Parties and their successors or assigns, any rights or remedies under or by reason of this MOU.

(g) No Assignment. Neither this MOU, nor any rights or obligations hereunder may be assigned, delegated or conveyed by either Party without the prior written consent of the other Party.

(h) Counterparts. This MOU may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one agreement.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Parties hereto have executed this MOU as of the date set forth above.

AlaBloom, LLC,
an Alabama limited liability company.

By: _____
Name: Shon Williams
Title: Chief Executive Officer

Coosa Medical Manufacturing, LLC

By: _____
Ala. Code § 36-12-40 (Personally Identifiable Information)
Title: Managing Member

INTEGRATED FACILITY AND PROCESSOR

MUTUAL SERVICES AGREEMENT

This Mutual Services Agreement ("**Agreement**") is entered into as of December 7, 2022, 2022 (the "**Effective Date**") by and between Coosa Medical Manufacturing, LLC, an Alabama limited liability company, with its principle place of business at [redacted] ("**Processor**") and INSA ALABAMA, LLC, an Alabama limited liability company, with its principle place of business at 218 Commerce St. Montgomery, AL 36104 Montgomery, Alabama ("**Integrated Facility**").

RECITALS

WHEREAS, Processor shall operate a processor that shall be duly licensed and certified under all applicable state, local and other statutes and regulations to purchase or transfer cannabis from a cultivator, to process cannabis into medical cannabis which shall include properly packaging and labeling medical cannabis products, and to sell or transfer of medical cannabis to a dispensary;

WHEREAS, Integrated Facility shall operate an integrated facility that shall be duly licensed and certified under all applicable state, local and other statutes and regulations to, cultivate cannabis, process cannabis into medical cannabis, including proper packaging and labeling of medical cannabis products, to dispense and sell medical cannabis only to a registered qualified patient or registered caregiver, to transport cannabis or medical cannabis between its facilities, and to sell or transfer medical cannabis to a dispensary;

WHEREAS, Integrated Facility desires to engage Processor and Processor desires to engage Integrated Facility, to provide services in accordance with the terms and conditions herein;

NOW, THEREFORE, in consideration of the above recitals, the representations, warranties and covenants contained herein, and for other good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the parties hereto agree as follows.

AGREEMENT

1. Services.

1.1 Engagement. Integrated Facility hereby engages Processor and Processor hereby engages Integrated Facility to perform, upon the terms and conditions set forth in this Agreement, the duties and responsibilities more particularly described in Section 1.2 below (the "Services").

1.2 Services.

(a) Processor Services: From time to time upon request of and in agreement with the Integrated Facility, Processor shall (i) process cannabis into medical cannabis for Integrated Facility which shall include properly packaging and labeling medical cannabis

products, (ii) purchase cannabis from Integrated Facility cultivation, or (ii) sell medical cannabis to Integrated Facility dispensary(ies), in compliance with all Laws and Regulations (as defined herein).

(b) Integrated Facility Services: From time to time upon request upon request and agreement of the Processor, Integrated Facility shall (i) engage Processor in processing cannabis into medical cannabis for Integrated Facility which shall include properly packaging and labeling medical cannabis products, (ii) sell cannabis from Integrated Facility cultivation to Processor, or (iii) purchase from Processor medical cannabis for Integrated Facility dispensary(ies) in compliance with all Laws and Regulations (as defined herein).

1.3 Limitation of Authority and Independent Contractor Status. Processor and Integrated Facility agree that any authority granted to it by the other under this Agreement relates solely to the Services. Neither party shall undertake any other activities for the other without the prior written consent and shall not have any authority to bind the other, other than any authority granted pursuant to this Agreement. The relationship of Processor to Integrated Facility and Integrated Facility to Processor is that of an independent contractor and nothing herein shall be construed as creating any other relationship.

1.4 Cooperation. Integrated Facility and Processor agree to cooperate in good faith with one another in order to furnish the Services.

2. Compensation and Expenses.

2.1 Compensation. Any party providing Services hereunder shall be compensated for its Services pursuant to this Agreement in a manner reasonably consistent with the nature and extent of the Services provided. Processor and Integrated Facility acknowledge and agree that reasonable fees for the Services shall be paid at the time of performance. Upon providing Services and invoice shall be submitted and payment shall by due within thirty (30) days of such invoice date, unless otherwise agreed.

2.2 Expenses. Any party providing Services hereunder shall be entitled to reimbursement for reasonable incurred in performing the Services pursuant to this Agreement. All such expenses shall be directly related to the provision of Services and shall be subject to the prior approval of the other party. A reasonably detailed itemization of all approved expenses incurred s in connection with the provision of Services shall be included with any invoice.

3. Indemnification. The Processor and Integrated Facility agree to indemnify, defend and hold harmless one another and their respective officers, directors, shareholders, agents, contractors, employees, successors and assigns from and against all liabilities, actions, losses or damages (including but not limited to reasonable attorneys' fees), (hereinafter "**claims**") arising out of or relating to any third-party claims based and caused by: (i) a breach of any terms, conditions, representations or warranties made by, or obligation of, the other party to this Agreement, (ii) negligence or willful act or omissions of the other, or its employees, agents, officers or directors or (iii) unauthorized or illegal acts or omissions by the other, or its employees, agents, officers or directors.

In no event shall either Processor or Integrated Facility be liable for any indirect, consequential, exemplary, incidental, special or punitive damages, including also lost profits, lost savings, lost opportunity costs or any other economic loss, of any type or nature, even if such party has been advised of the possibility of such damages.

4. Notices. Any notice required or permitted to be given under this Agreement shall be sent by utilizing electronic mail, with a copy sent prepaid by overnight mail utilizing a national courier with evidence of receipt (or if no electronic mail is available by overnight mail alone), addressed to the party to be notified at the following address or at such other address as may hereafter be furnished in writing to the notifying party:

If to Processor:

Coosa Medical Manufacturing, LLC
Ala. Code § 36-12-40 (Personally Identifiable Information)
[redacted]

If to Integrated Facility:

Insa Alabama, LLC
218 Commerce St
Montgomery AL 36104
Attn: Greg Allen

Any notice sent in accordance with the requirements of this Paragraph 4 shall be effective on the date sent.

5. Nonwaiver. No delay or failure by either party to exercise any right under this Agreement shall constitute a waiver of that or any other right, unless otherwise expressly provided for herein.

6. Severability. If any provision of this Agreement in any way violates the laws of any state or jurisdiction, such provision shall be deemed not to be a part of this Agreement in that jurisdiction, and the parties agree to remain bound by all remaining parts hereof.

7. Confidentiality. Neither Processor nor Integrated Facility shall disclose any Confidential Information (as hereafter defined) of the other or any material terms received in connection with this Agreement or the Services without the other party's consent, except that each party may disclose such information (i) as required by law or applicable regulation, or (ii) as required in carrying out this Agreement. "Confidential Information" shall mean all information, of a party, not of general knowledge in the industry of such party relating to the business now or ever conducted by such party.

8. Term and Termination. The term of this Agreement shall be one (1) year. Processor or Integrated Facility may terminate this Agreement with thirty (30) days' notice to the

other. Upon termination Integrated Facility shall be entitled to payment and approved expenses for Services performed to termination.

9. Privileged Licenses. Processor and Integrated Facility acknowledge that the other and its affiliates conduct business that is subject to, and exists because of, privileged licenses issued by governmental authorities. Processor and Integrated Facility therefore agree that, in the event that Processor or Integrated Facility shall determine, in its reasonable judgment (i) that the other is, or might be, engaged in, or about to be engaged in, any activity or activities that jeopardizes, or could jeopardize, it or its affiliates business licenses, or (ii) that the existence of this Agreement jeopardizes or may jeopardize, its or its affiliates business licenses, they shall have the right, upon notice to the other, to immediately terminate this Agreement, at which time the Agreement shall cease and terminate and be of no further force and effect; provided, however, that the indemnity provisions of this Agreement shall survive any such termination.

10. Compliance with Laws. Throughout the term of the Agreement, each of the Processor and Integrated Facility shall cause its personnel, employees and independent contractors, and other personnel at such parties sole cost and expense, to conform to and comply with all present or future laws, statutes, ordinances, orders and rules, (including but not limited to the Darren Wesley "Ato" Hall Compassion Act (§ 20-2A-1, et seq., Ala. Code 1975 (as amended)) as well as any other regulations or requirements of any state, municipal or other government or department having jurisdiction over the performance of the Agreement or the Services ("Laws and Regulations").

11. Permitting and Licensing. Notwithstanding anything to the Contrary contained herein, Processor and Integrated Facility's obligations under this Agreement shall be contingent upon each party securing all standard, final, unappealable, and commercially acceptable permits and licenses and other approvals from all municipal, state and other authorities necessary to permit each party to enter into this Agreement and complete the transactions contemplated herein. Each party shall proceed diligently in a commercially reasonable manner to secure said permits, licenses, and approvals.

12. Successors. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and assigns. The term "successor" shall include successors by merger or acquisition, including sale of stock or sale of assets.

13. Assignment. This is a personal services contract and may not be assigned or otherwise transferred without the prior written consent of the non-transferring party.

14. Entire Agreement. This Agreement contains the entire agreement of the parties hereto with respect to the subject matter hereof, and no change or modifications hereof shall be valid unless made in writing, signed by all of the parties hereto.

15. Counterparts. This Agreement may be executed in one or more counterparts, each of which so executed shall be deemed to be an original, and all of which shall constitute one and the same agreement and may be executed in the original but electronically transmitted to all parties with the same force and effect as if an original, executed copy thereof had been delivered to all

parties.

16. Governing Law. The validity, interpretation and performance of this Agreement shall be controlled by and construed under the laws of the State of Alabama and all disputes will be submitted to binding arbitration before one American Arbitration Association arbitrator in Montgomery, Alabama for resolution.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

INTEGRATED FACILITY,
INSA ALABAMA, LLC

By _____
Its Stephen A. Reilly, Authorized Signatory

PROCESSOR,
COOSA MEDICAL MANUFACTURING, LLC

Ala. Code § 36-12-40 (Personally Identifiable Information)

Its Managing Member

Coosa Medical Manufacturing, LLC
[redacted]

December 8, 2022

MEMORANDUM OF UNDERSTANDING

Dear David,

Certus Laboratories Alabama ("Applicant"), an Alabama limited liability company applying for a State Testing Laboratory License with the State of Alabama Medical Cannabis Commission ("AMCC"), is pleased to share this Memoranda of Understanding ("MOU") detailing the proposed terms of a relationship between Certus Laboratories Alabama and Coosa Medical Manufacturing, LLC.

Certus Laboratories Alabama aims to be a leading State Testing Laboratory with its testing facility in Mobile County. Certus Laboratories Alabama is interested in working with you, provided both companies obtain the requisite licenses issued by AMCC.

Contingent upon licensure by the AMCC, Applicant intends to utilize Coosa Medical Manufacturing, LLC for the following services:

- perform required official testing on behalf of the AMCC, the results of which shall fulfill the testing requirements for cannabis and medical cannabis under the Act (see 20-2A-51, Code of Alabama 1975 (as amended)) and the Rules and Regulations of State Testing Laboratories for the AMCC.

While this document shall not itself constitute a binding legal agreement, the parties to this MOU will endeavor to finalize and execute a definitive agreement between the parties if Applicant is awarded a State Testing Laboratory license and Coosa Medical Manufacturing, LLC is awarded a Cultivator license. Any agreement between the parties as described herein will be subject to and conditioned upon the execution of a formal written agreement.

We look forward to working with you.

Sincerely,

Amber Miller-Walker, Owner
Certus Laboratories Alabama

MEDICAL CANNABIS TESTING AGREEMENT
between
COOSA MEDICAL MANUFACTURING, LLC
and
_____

Coosa Medical Manufacturing, LLC ("**Client**") and _____, ("**Testing Lab**", and together with Client, the "**Parties**", and each, a "**Party**") hereby enter into this Cannabis Testing Agreement (this "**Agreement**"), setting forth the terms of testing approved forms of medical cannabis product, as permitted under the applicable Alabama laws and regulations, (the "**Product**") by the Parties.

Client:	Coosa Medical Manufacturing, LLC Ala. Code § 36-12-40 (Personally Identifiable Information) [redacted]
Testing Lab:	_____ _____ _____
Scope:	This Agreement applies to the analytical testing (the "**Testing**") of the Product by Testing Lab from Client, in accordance with the terms set forth herein.
Term:	This Agreement will become effective as of the Effective Date and will continue in effect for any Order placed by the Client thereafter. The termination of this Agreement will not release Client from any payment obligation that has already accrued under this Agreement.
Scheduling:	Client will ensure that sufficient transportation contractors, as applicable, are available at all relevant times to accommodate delivery.
Delivery:	Client will deliver or arrange for delivery of samples to Testing Lab unless otherwise agreed by the parties. Client agrees that any sample(s) delivered to Testing Lab's facility has appropriate chain of custody documentation, including Alabama state traceability manifests, is/are documented accurately in all paperwork, and is/are representative of the harvest or lot indicated in the documentation.
Use of Results and Data:	Individual Certificates of Analysis (COAs), also referred to as Results or Reports are not to be altered in any way without the express written consent of Testing Lab. Individual COAs must be used in full and may not be represented in any other way except to lawfully represent the product, lot or batch assigned to

	the Report. Testing Lab will not release COAs and data contained therein to any third parties without the written consent of the Client, unless required by law.
Retest Policy:	Retests performed at Client's request may be charged to Client if the retest confirms the original result. If the retest results are significantly different from the original result, (outside of the reported and accepted tolerances) or are incurred from lab error, Client will not be charged for the retest.
Payment Terms:	Client shall pay to Testing Lab fees in accordance with an agreed rate per test between the parties (the "Fees"). Testing Lab's rate schedule is subject to change without notice to Client. Client shall pay all Fees at the time of delivery of the sample to Testing Lab, unless otherwise agreed by the parties, and must be paid by cash, check or money order in US dollars.
Representations:	During the Term, Client shall comply with and manufacture the Product in accordance with regulations established by the Alabama Medical Cannabis Commission (the "**AMCC**") and the State of Alabama related to the testing, manufacture, production, handling, and transportation of medical cannabis and cannabis products ("**Applicable Regulations**"). In the event that any Product sold hereunder does not comply with Applicable Regulations, or does not comply with the terms of this Agreement, Testing Lab shall notify Client in writing of any such non-compliance within two (2) business days following the Delivery Date of the relevant Product to Testing Lab, stating in reasonable detail the nature of such non-compliance and type and aggregate quantity of the Product to which such non-compliance applies (a "**Non-Compliance Notice**"). If such non-compliance can only be demonstrated by laboratory testing, the Non-Compliance Notice shall include documentation of the relevant test results.
Governing Law:	This Agreement shall be governed by the laws of the State of Alabama. Testing Lab submits to the jurisdiction and venue of any state court sitting in the State of Alabama.
Force Majeure:	The obligations of the Parties are contingent upon earthquakes, fires, storms, floods, freezes, material reductions, accidents, labor disputes, transportation embargoes, significant oil price increases, failure of machinery, acts of God or of any government (including the AMCC), pandemics (including the COVID-19 pandemic) and any circumstances related to COVID-19 or any related epidemic, pandemic, state of emergency, government orders, government shutdowns, unavailability of labor, or materials or reasonable substitutes therefor, or other causes beyond any Party's reasonable control that relates thereto,

	including ceasing of operations by Client, acts of war or terrorism, and other interferences beyond the Parties' reasonable control, to the extent the same prevent or delay the performance of the obligations herein contained.
Taxes:	Unless otherwise indicated herein, prices do not include state, county, and/or municipal sales, use, excise or similar taxes applicable to the tested Product, or the tested Product's use by Testing Lab or the Testing Lab's customers. If Client should be required to pay the same, Testing Lab shall be liable to pay to and to reimburse Client for any such taxes. If required by law, Client may collect sales or use taxes on its invoices for Product sold to Testing Lab hereunder.
Limitation and Exculpation of Liability:	TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL CLIENT BE LIABLE TO TESTING LAB FOR LOSS OF PROFITS, REVENUE OR INCOME, OR FOR ANY INDIRECT, PUNITIVE, SPECIAL, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THIS AGREEMENT OR RELATED TO TESTING LAB'S DEVELOPMENT, PRODUCTION OR SALE OF ANY NEW OR MODIFIED FORMULATIONS OR COMBINATIONS OF THE TESTED PRODUCT MADE BY TESTING LAB, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. TESTING LAB'S SOLE REMEDY FOR LIABILITY OR DAMAGES UNDER THIS AGREEMENT SHALL BE STRICTLY LIMITED TO REPLACEMENT OF ANY NON-CONFORMING PRODUCT OR A REFUND OF ANY FEES PAID FOR THE NON-CONFORMING PRODUCT BASED UPON THE PRICE AND ON THE TERMS OTHERWISE SET FORTH IN THIS AGREEMENT. TESTING LAB UNDERSTANDS THAT IT MAY BE WAIVING RIGHTS WITH RESPECT TO CLAIMS THAT ARE AT THIS TIME UNKNOWN OR UNSUSPECTED.
Indemnification:	Client agrees, at its expense, to indemnify, defend and hold harmless Testing Lab, its parent and affiliates, and their respective members, directors, employees, and agents, with respect to any claim, suit, demand, or expense of whatever kind (including reasonable attorneys' fees) (collectively, "Losses"), arising out of or related to (a) any breach by Client of any term or condition of this Agreement, or (b) Client's operation of its business, including any such Losses related to investigations, claims, or violations imposed by any state administrative agency.
Use of Names and Marks; Reverse Engineering:	Testing Lab represents, warrants and covenants that it shall not use, make reference to, publish, copy or otherwise designate, either orally or in writing, any logo, trademark, servicemark or

	tradename of the Client ("**Mark(s)**"), except for the limited purpose of product displays or patient production information and only as allowable under the Applicable Regulations, without prior written consent of Client. Upon the termination of this Agreement or at the written direction of Client, Testing Lab shall discontinue the use of all Marks of the Client and all legends adopted in accordance with this Section. Testing Lab shall leave in place all designations of Marks placed on the tested Product (including Marks on any and all packaging therefor) by the Client. Testing Lab shall not use any portion of the tested Product, whether through planting, researching, studying, dissecting or through any other actions or methods (whether or not related to botany), to grow, create, genetically engineer, reverse engineer, or otherwise imitate or copy the Product. In the event of a breach of any of the covenants contained in this Section, Client shall be entitled to injunctive or other equitable relief because Client will be caused irreparable injury and damage as a result of such breach. This right to injunctive relief shall include the right to both preliminary and permanent injunctions. Client shall not be required to post a bond or any similar assurance if it brings any action in order to enforce any of the covenants contained in this Section.
Medical Marijuana:	Each Party represents and warrants that it has obtained all AMCC and local approvals, permits, licenses, certificates, necessary for it to perform its obligations under this Agreement, and each Party covenants and agrees that, during the Term, it will maintain all such approvals and obtain any and all additional approvals that may be necessary for it to perform its obligations hereunder. Each Party will notify the other Party within 24 hours in writing if it learns or reasonably believes that it is not in full compliance with the terms of this Section. The Parties acknowledge that they are aware of and fully understand that despite the laws of the State of Alabama and the terms and conditions of this Agreement, holders of licenses to sell and test medical marijuana may still be arrested by federal officers and prosecuted under federal law. The Parties also expressly waive federal illegality as a defense to any Agreement enforcement action.
WAIVER OF JURY TRIAL:	THE PARTIES KNOWINGLY AND WILLINGLY WAIVE ANY RIGHT THEY HAVE UNDER APPLICABLE LAW TO A TRIAL BY JURY IN ANY DISPUTE ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT OR THE ISSUES RAISED BY THAT DISPUTE.
Attorneys' Fees:	In the event that any legal action or other proceeding is brought for the enforcement of these terms and conditions or in

connection with any provision contained herein, the prevailing Party shall be entitled to recover its reasonable attorneys' fees, court costs and expenses, court costs, including, but not limited to, fees, costs and expenses incurred to collect fees, costs and expenses, and those fees and costs incurred incidentally to arbitration, mediation, investigation, discovery, travel, appellate proceedings, bankruptcy, collection, retention of expert witnesses, and post judgment proceedings.

Additional Provisions:

The provisions of this Agreement shall, except as otherwise provided herein, endure to the benefit of and be binding upon the Parties and their respective executors, administrators, successors, and assigns, each and every person so bound shall make, execute and deliver all documents necessary to carry out this Agreement.

This Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and the transactions herein contemplated and replace all previous agreements and understandings, if any, between the parties with respect to the subject matter hereof and the transaction contemplated herein. Any Purchase Order previously entered into between the Parties shall also be governed by the terms of this Agreement.

Any notice to be given under this Agreement shall be in writing and delivered, faxed or mailed by prepaid registered mail or electronic mail, addressed to the party to whom it is to be given at the address hereinabove mentioned and such notice shall be deemed to have been given on the day of delivery or on the day it is faxed or e-mailed or on the fifth business day after mailing as aforesaid, as the case may be.

If any provision of this Agreement shall be held invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall attach only to such provision in such jurisdiction and shall not in any manner affect or render invalid or unenforceable such provision in any other jurisdiction or any other provision of this Agreement in any jurisdiction.

Except as provided therein, the failure on the part of one Party, in any one or more instances, to insist upon the keeping, performance or observance of any of the terms, conditions or provisions of this Agreement, or to exercise any right or privilege herein conferred, shall not be construed as relinquishment of that Party's right to require the future keeping, performance or observance of any such terms, conditions or provisions.

This agreement may be executed in any number of counterparties, each of which will be deemed an original and all of which taken together will constitute one and the same agreement. Delivery of

a signed counterpart of this Agreement by email or facsimile transmission will constitute valid and sufficient delivery thereof by the parties.

AGREED AND ACCEPTED:

COOSA MEDICAL MANUFACTURING, LLC	_____
By:_____	By:_____
Name:	Name:
Title:	Title:
Address:	Address:
Telephone:	Telephone:
Facsimile:	Facsimile:
Date:	Date:

License Type: Processor

Exhibit 11 – Standard Operating Plan and Procedures

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

Introduction

We will provide complete physical or digital copies of our standard operating procedures ("SOPs"), or any other business documentation, to the Alabama Medical Cannabis Commission ("the AMCC") as requested. In addition to the compliant standard operating procedures SOPs listed directly below, we have provided for subsections 11.3, 11.4, and 11.11 in our application materials as exhibits 21, 22, and 17, respectively, as requested by the AMCC processor application guide.

11.1 – SOPs – Information Technology ("IT")

Accurate Record Accountability: We will obtain, install, and maintain our internal tracking systems through a third-party inventory system, specifically Dutchie, which will interact with the Alabama Medical Cannabis Patient Registry System, the statewide seed-to-sale tracking system, and the AMCC website. Ala. Admin. Code r. 538-x-4-.07.12.o.01. Our third-party inventory and tracking system will properly interface with the statewide seed-to-sale tracking system and the Patient Registry System, as applicable. Our Director of Compliance will confirm that all information is secured in alignment with regulatory guidance. Upon licensure we will demonstrate proof of purchasing and accessing our IT platforms, and our platforms will be regularly maintained and properly updated. Ala. Admin. Code r. 538-x-4-.07.12.o.01.

Our IT Director, Brandon Easterling, will consistently maintain and annually review our plan for accurate recordkeeping and coordination of information and systems with vendors, patients, and others, as applicable. Ala. Admin. Code r. 538-x-4-.07.12.o.01. Our Director of We will support, participate in, and contribute to the statewide seed-to-sale tracking system, and our technology and uploads to the statewide seed-to-sale tracking system will be sufficient to allow access by the AMCC, and, to the extent necessary and appropriate, patients and caregivers, qualified certifying physicians, other state agencies, vendors, other licensees, and law enforcement personnel, for all purposes as applicable. Ala. Admin. Code r. 538-x-4-.05.04. We will train all employees on their duties with our IT system and test their proficiency in the system before they begin any duties. All employees will fulfill their assigned duties and will learn to interact appropriately with the patient registry, the AMCC website, or the statewide seed-to-sale tracking system, as applicable. Ala. Admin. Code r.

538-x-4-.05.05. These individuals will undergo pre-employment and pre-commencement IT certification administered by a third-party IT provider, or another as designated by the AMCC, for each database with which they must interact, demonstrating their proficiency in respect to those databases. Ala. Admin. Code r. 538-x-4-.05.05.

Furthermore, our Quality Assurance and Quality Control Director ("QAQCD") Caleb King will be our designated tracking system liaison with the AMCC for the purposes of coordinating, monitoring, and updating statewide seed-to-sale tracking system. Ala. Admin. Code r. 538-x-4-.05.06.

Compliance with Inventory Protocols: Upon licensure and an announced inspection, we will make our facilities, personnel, operations, and documentation available for review and audits at the request of an AMCC inspector, and we will make available all IT files, including but not limited to our test results, any third-party inventory control and tracking systems, and the statewide seed-to-sale tracking system. Ala. Admin. Code r. 538-x-4-.02.02.b.02. Upon licensure, our third-party inventory and tracking systems will properly interface with the statewide seed-to-sale tracking system, and, as appropriate, with the patient registry. Ala. Admin. Code r. 538-x-4-.05.04. Product tracking information will be updated in our databases at least daily and will be maintained for a minimum of six years (or more if requested by the AMCC, law enforcement personnel, or a court system with jurisdiction over a related matter). Ala. Admin. Code r. 538-x-4-.05.01.

During our processing operations we will inventory and track cannabis and medical cannabis within the facility and to interface with the Statewide Seed-to-Sale Tracking system. Ala. Code § 20-2A-54(b)(2). We will enter all transactions into the statewide seed-to-sale tracking system operated by the AMCC, including at a minimum the inventory of cannabis and products within our facility, the location of cannabis products when they leave our facility, and the documentation showing any products or cannabis material destroyed and disposed of at our facility.

In the event of a recall, our notification protocols will alert other licensees and the AMCC through our internal inventory system and the statewide seed-to-sale tracking system. If aspects of our IT plan contributed to unsafe conditions requiring a recall, we will analyze and adjust our IT plan and internal protocols and processes to avoid recurrence. Ala. Admin. Code r. 538-x-6-.06.03.h.08.

Coordination of Information and Systems: We will coordinate our information and systems with vendors, customers, and others based on our detailed plan to inventory and track cannabis and medical cannabis within the facility and to interface with, as applicable, the patient registry and the statewide seed-to-sale tracking system. Ala. Admin. Code r. 538-x-4-.05.04.

Working with the statewide seed-to-sale tracking system, we will retain a record of the date, time, amount, and price of each sale or transfer of cannabis products to another licensee, access to and coordination of which will be paid for and maintained by us. Ala. Code § 20-2A-54. At the time of transfer, our QAQCD, or another processor employee under their supervision, will enter into the statewide seed-to-sale tracking system all required product information, and they will attach a physical copy of the record to the package containing medical cannabis.

We will adopt and use primarily a third-party inventory control and tracking system that is capable of interfacing with the statewide seed-to-sale tracking system to allow us to enter or access information in the statewide seed-to-sale tracking system as required, and we will pay for and maintain our system. Our third-party Dutchie inventory tracking system will feature all capabilities necessary to comply with the applicable requirements and more. Ala. Code § 20-2A-60. Dutchie is an all-in-one technology platform that offers a full suite of solutions for compliant cannabis operations. Based in Oregon, Dutchie has been working with cannabis companies for more than five years and provides consumers and licensed businesses with safe and easy access to cannabis tracking. Their software is now in over 5,000 dispensaries, with thousands of available software integrations.

11.2 – SOPs – Maintenance and Storage

We are committed to maintaining and storing cannabis and associated products in a way that prevents contamination, diversion, and loss in compliance with all relevant regulations and requirements from the AMCC. Ala. Admin. Code r. 538-x-3-.05-3.m.16.b. Our processor facility will feature numerous process controls, protocols, and SOPs for maintaining and storing our cannabis safely and compliantly, and our employees will be thoroughly trained on all applicable procedures before beginning operations.

Managers will train all employees in their respective departments on all SOPs for secure storage and recordkeeping, including SOPs for accessing the vault, secure storage areas, and any restricted access areas ("RAAs") housing cannabis, cannabis products, or in-process materials. We will require all employees to complete training on storage SOPs and access to RAAs prior to beginning work at our facility. Our storage SOPs will integrate those for recordkeeping activities as well. Employees will be required to log all storage activities in our electronic inventory control system and statewide seed-to-sale tracking system to ensure traceability of all cannabis within our facility, no matter what stage of processing the item is undergoing.

We will teach employees that cannabis and products should only be moved into and out of storage areas when necessary, and only when directed and accompanied by a manager. Managers will supervise all movement of products in and out of the vault or secure storage areas. Overnight, all products will remain securely locked and stored until a manager and employees arrive the next morning to begin facility operations.

We will store all cannabis awaiting processing, products in process, and finished products inside of our enclosed, locked storage room or vault within our facility. Ala. Admin. Code r. 538-x-6-.06.03.i.09. The secure storage room will also be equipped with an industry-standard commercial-grade alarm system to alert our staff, security, and authorities of unauthorized entry. Ala. Admin Code. R. 538-x-6-.06.03.i.01. Whenever cannabis is received, individual batches of cannabis being received for storage and/or processing will be appropriately prepared, tagged or otherwise identified, and inserted in containers at the time of receipt. Ala. Admin Code. R. 538-x-6-.06.03.f.01.

Processing employees will retrieve cannabis material from the vault as it becomes needed for production activities. All areas of the facility used for processing will be Restricted Access Areas, with access limited to processing employees who require such access for their employment duties. We will require processing employees to return all raw plant material and in-process materials to the vault or secured locked room if processing and processing activities are not completed by the end of the workday. Once plant material and processed products have passed testing, undergone packaging and labeling, and are ready for sale to other licensees, employees will move inventory ready for sale from the in-process to the final product storage vault or secured, locked room. Keeping inventory

ready for sale separate from other facility inventory serves several purposes to enhance product safety and inventory security. All products that have not passed testing for potency and contaminants will remain in the vault, while products that have been tested, packaged, and approved for sale will be in a separate storage area.

We will conduct regularly scheduled maintenance and cleaning of all storage areas for proper maintenance and clean and orderly condition, free from infestation by insects, rodents, birds, and pests. A minimum of once every two weeks, a manager with appropriate clearance will provide access to storage areas and will supervise employees as they perform all necessary maintenance and cleaning.

The vault and secure storage area will be climate controlled, with specific temperature and humidity settings in place to maintain a cool, dry, and low humidity environment optimal for maintaining the integrity and quality of all medical cannabis and products. These measures will also prevent conditions in the room from becoming hospitable to potential bacteria or pests, which could potentially further compromise the integrity of the products in storage. Storing our cannabis within strict moisture and temperature controls will mitigate the development of mold or other contaminants on our products that could harm Alabama patients. We will also employ Integrated Pest Management ("IPM") techniques and Good Manufacturing Practices ("GMPs") in all areas where cannabis is processed or stored. Additionally, we will incorporate odor controls, such as ONA gel canisters, positive pressure air systems, and air curtains, to prevent odors from escaping storage areas or contaminating other products.

Limitation of Access: To mitigate theft and diversion, we will limit access to cannabis storage areas to essential personnel by position, which may include our Leadership, Inventory Manager, and other select authorized staff members. Our SOPs will identify the personnel with authorization to access our storage areas and will be updated pursuant to change. Furthermore, all storage areas will feature key-card access doors with commercial-grade locks and alarms. We will post signage at the entrance to each RAA notifying personnel that access is restricted and identifying which employees are permitted to access the area, which will feature locks and alarm systems to notify our facility of any unauthorized entries. Ala. Admin Code. r. 538-x-6-.06.03.i.01. Usable cannabis products and cannabis related items will be highly secured and monitored to prevent theft and diversion.

Our surveillance systems will provide 24/7 continuous monitoring of facility entry points and all Restricted Areas such as our cannabis and cannabis product storage areas. Ala. Admin Code. r. 538-x-6-.06.03.i.04. We will maintain security of usable cannabis and related items by maintaining a secure and locked storage area, logging the quantity and quality of all cannabis and cannabis related products into our inventory management system, limiting and restricting access to authorized personnel, and maintaining a 24/7 video surveillance of our storage areas.

11.5 – SOPs – Criminal Activity

Our criminal activity plan details the steps we will take in the event of criminal activity related to cannabis or medical cannabis in our possession and control. We will maintain, review, and update policies to report theft, diversion, or other loss of cannabis or medical cannabis to the AMCC and to law enforcement within 24 hours of the event or its discovery. Once discovered, management will initiate notification and investigation protocols to determine the cause of the criminal activity and will update internal procedures to mitigate any further criminal activity in the future. We will always comply with all investigations into criminal activity at our facility. We recognize the Alabama Law Enforcement Agency ("ALEA"), or a local law enforcement agency, may search our facility and property where there is probable cause to believe that a criminal law has been violated and the search is conducted in conformity with constitutional and state law. Ala. Code § 20-2A-7(f). We understand the AMCC may notify appropriate authorities regarding any misconduct, and we will cooperate fully in any criminal investigation that may lead to the imposition of charges and penalties against our business or any associated entity or individual. Ala. Admin. Code r. 538-x-4-.22.09. We will immediately report to the AMCC and local law enforcement any trespassing on our property or unlawful entry into our facility. Our DOS has a close relationship with the Mayor of Centreville, Mike Oakley, and may also report this or similar incidents to them for community safety. If a trespasser manages to enter the facility, employees will avoid the individual and shelter-in-place by remaining where they are, locking any entrances, activating the silent alarm, and contacting 911. In the event of an armed robbery, employees will follow the procedures outlined in our SOPs. After an event, management will conduct a diversion/theft investigation after any facility interior

trespassing event to determine how the unauthorized individual gained access to the facility and if diversion or theft occurred.

Safety of Employees: We will refrain from any critical operations violation that could pose a clear and present danger to the safety of our employees, patients, caregivers, or the public. Ala. Admin. Code r. 538-x-4-.02.04.b.01. The safety of employees and others on the premises starts with screening for individuals through a national criminal background check. Prior to appointment, employment, or service to our operations, all officers, employees, contractors, and other individuals performing work of any character who would have access to cannabis, a medical cannabis facility, or related equipment or supplies, must submit to a state and national criminal background check. Ala. Code § 20-2A-59(a). Employees will undergo no less than ten hours of continuing education of medical cannabis education and no less than five hours of safety training that will include safety pertaining to criminal activity. Ala. Admin. Code r. 538-x-4-.04.02.b. All employees will complete comprehensive safety training prior to beginning work at our facility, which will include instruction on the facility's Emergency Action Plan ("EAP"), which we will construct to comply with all applicable regulations from the Bureau and the federal Occupational Safety and Health Administration ("OSHA"). We will also train our employees on other topics relating to public health and safety and preventing abuse and diversion of medical cannabis.

Our highest priority in operations is the safety of all personnel and visitors at our facility. Pursuant to guidelines from OSHA, we will establish an Emergency Response Team ("ERT") composed of our Chief Medical Officer ("CMO"), Chief Operating Officer ("COO"), Director of Compliance ("DOC"), and Director of Security ("DOS"). The ERT will: conduct research and compile our emergency and safety procedures, including general emergency response plans, a fire plan, and procedures for security breach and armed robbery response; train employees on these policies; and, supervise evacuations and other emergency response activities. Our ERT will maintain and review at least annually our criminal activity plan. Ala. Admin. Code r. 538-x-3-.05.03.m.16.e.

Reporting Criminal Activity: Our ERT will construct guidelines and procedures for reports to and communication with regulatory bodies, law enforcement, and other licensed medical cannabis organizations. We will implement and train staff on these guidelines prior to the commencement of their work at our facility. We will develop procedures for notification of the AMCC and law enforcement in accordance with the reporting requirements. Procedures will include when notification is required, who is to be notified, how notification is to occur, and who is responsible for performing the notification. A designated manager will notify the AMCC, ALEA, and local law enforcement immediately after discovering any adverse loss, diversion, theft, criminal activity, or suspected criminal activity at our facility or from any vehicle transporting medical cannabis to or from our facility.

Our employees will be trained to contact 911 in the event of an emergency. In the event of any criminal activity, staff will contact law enforcement with jurisdiction over the area to report that a crime has been committed. We will keep lists of emergency phone numbers by all landline telephones. Our DOS will be responsible for immediate notification of local law enforcement and notification of the AMCC within 24 hours becoming aware of any alarm activation, event requiring response by public safety personnel, breach of security; or, failure of the security alarm system due to a loss of electrical support or mechanical malfunction that is expected to last longer than 24 hours. All notifications will include details on the reported incident and any corrective measures taken. We will maintain records of all notifications in an auditable form for at least four years after providing the notification.

Preservation of Cannabis and Maintaining Access: We will maintain a plan, and review at least annually, steps to be taken for the preservation of cannabis or medical cannabis and the reasonable efforts to maintain access to medical cannabis by those who depend on it. Ala. Admin. Code r. 538-x-4-.07.12.o.04. This will include steps for maintaining secure storage of our cannabis stock, maintaining adequate cannabis stock so that patients and caregivers can receive their medicine, notification procedures to our partner licensees, and communication with the AMCC and all law enforcement agencies. We will provide and maintain a plan for sufficient staffing of security guards at each facility where cannabis and

medical cannabis is present to reasonably ensure the safety of employees and others on the premises; and at a minimum, provide one security guard per facility during our business operational hours. Ala. Admin Code. r. 538-x-6-.06.03.i.08. Our parking lot will be monitored and supported for the reasonable safety and security of employees and visitors.

We will also maintain strong relationships with supplying licensees to be able to provide cannabis stock in a short time frame should ours be compromised by criminal activity. After a criminal event occurs, we will notify these licensees of our need for additional cannabis stock immediately. We will also comply with recommendations from the Drug Enforcement Administration ("DEA") for pharmaceutical facilities handling controlled substances. For example, we will store medical cannabis and products in compliance with DEA requirements for Schedule I controlled substances, using securely locked safes or steel cabinets bolted to the ground in our secure storage room. C.F.R. 21 § 1301.71 - 1301.77.

11.6 – SOPs – Emergencies and Disasters

We are committed to compliant and safe operations focused on emergency preparedness and adequately responding to emergencies to maintain employee and visitor safety and to assist in maintaining accountability of all medical cannabis and maintaining access for those who depend on it. Ala. Admin. Code r. 538-x-3-.05.03.m.16.f. To mitigate danger to employees and others on the premises, employees will undergo no less than five hours of safety training including safety pertaining to criminal activity. Ala. Admin. Code r. 538-x-4-.04.02.b. Our DOS and Security Guards will train all staff on responding to various emergencies and natural disasters before they begin work.

Our Director of Security ("DOS") Matthew Towey is an Alabaster Police Department Patrol Officer and previously served in the US Coast Guard. An Alabama native, Matthew Towey has personal connections with the Mobile Public Safety Director, Mobile Chief of Police, Mobile County Communications Director, the A.T.F. and US Marshals that will be leveraged to have a safe and compliant facility. His accolades throughout the military community show his dedication to safety and service. With the Coast Guard, Mr. Towey led successful team missions and managed all personnel on board search and rescue vessels.

He is a disciplined leader with the proven ability to remain calm and deliver results under pressure and his deep experience will result in safety for those involved with our company.

In response to an emergency, we will conduct the following procedures: assess the nature and scope of the emergency to determine which emergency service should be notified; determine the source of the impact, such as a specific employee, process, or outside event; implement measures to minimize damage; contain the emergency and prevent it from spreading, such as by evacuating employees; maintain detailed records of all steps taken; notify all relevant personnel, including management, IT personnel, security, law enforcement, the AMCC, and any affected individuals or businesses; identify and document the extent of the emergency; and, immediately make a forensic copy of applicable surveillance devices, which may be used for later analysis or serve as evidence.

Employees will also be trained on various medical emergency situations. We will install easily accessible voice dialing phone systems, so that employees may quickly contact emergency services. We will keep Emergency Kits in marked locations throughout the facility for rapid access in an emergency. We will have at least one AED on site, and it will be regularly inspected. We will confirm that staff are trained on CPR and AED, and conduct training as needed. Staff will check the emergency kit once per month to verify all contents are present, in working condition, and unexpired. We will also keep an emergency kit inside a designated “shelter in place” location in case severe weather approaches quickly and evacuation is not possible. Our “shelter-in-place” location will be an interior room or rooms within our facility, with space to take refuge. We will also designate an ERT to oversee all emergency plans and protocols at our facility. The ERT’s emergency plans will include procedures for employees to follow in the event of a hazardous situation, security breach, armed robbery, or violent event. The ERT will also develop any additional procedures as required by the AMCC in response to any special security concerns.

If a potential threat or hazardous situation is present outside of the facility, any employee on site will inform other employees and visitors of the threat, remain indoors, verify that all facility entrances are locked, and stay away from doors and windows. Employees will be trained to keep hazards outside and if possible, not allow any hazard or violent individual to access the inside of the facility. If a threat, hazard, or suspicious individual enters the facility, employees will contact security personnel immediately.

Primarily, employees will immediately call 911 or contact law enforcement agencies in response to a potential threat or suspicious individual.

Preservation of Cannabis/Medical Cannabis: We have also developed specific protocols for preserving all cannabis or medical cannabis products at our facility. To maintain an adequate stock of medical cannabis products reserved in case of emergency, we will regularly set aside a portion of our cannabis products in the secure storage area marked as "in case of emergency." Our facility and secure storage areas will feature environmental controls to preserve cannabis products in ideal conditions. Detection equipment, including a professionally monitored fire alarm, will be present throughout the facility to alert building occupants of any emergency conditions. A qualified alarm technician will test all detection equipment at least every 30 days, and we will keep all equipment in good working order. We will strategically position fire alarms to be visible, audible, or perceivable from any location in the facility. A fire sprinkler system will provide coverage throughout the facility to immediately suppress any fire. All facility exterior doors will allow free egress by the facility's occupants in case of an emergency. Ala. Admin Code. r. 538-x-6-.06.03.i.06. Fire extinguishers will be located throughout our facility, with as many available as is feasible for our space and recommended by the local Fire Department. Our facility will also feature other fire suppression equipment, such as overhead sprinklers and partitionable HVAC systems to prevent a fire from spreading from one room of our facility to another. Alabama is at a higher risk than the average state for floods and hurricanes. In the case of flooding, we will train personnel to quickly respond to the threat to human health. Management will monitor persistent rains and storms within one hundred miles using online weather monitoring services, and severe weather alerts will be regularly communicated to personnel via company email, phone calls, and/or announcements over the facility's communication system (e.g., a speaker system).

Reasonable Efforts to Maintain Access: Following an emergency, we are committed to taking reasonable steps to maintain access to medical cannabis for those who depend on it. We plan to develop and maintain a stock of cannabis products reserved in case of emergency. In the event of an emergency that might compromise the safety of the cannabis

at our facility, proper procedures for the safe removal, secure transportation, and compliant temporary storage are paramount to preserving the integrity of our cannabis and protecting the safety of Alabama patients. To prevent our reserve stock of cannabis products from denaturing over time, employees will regularly rotate cannabis from the emergency stock into the normal stock on a first-in, first-out basis, replacing it with new cannabis received from production. This will keep all cannabis stored for emergency in adequate condition for regular distribution to other licensees while ensuring that we do not lose cannabis stored for emergency to denaturing or expiration. Furthermore, all cannabis that is set aside for emergencies will be tested and cleared for dispensing before being set aside.

Though the AMCC has yet to provide guidance on permitted activities following an emergency or disaster, should an emergency or disaster occur, we will request a Temporary Variance from the AMCC and receive approval before implementing our procedures in case an emergency renders our business unable to comply with regulatory requirements. Ala. Admin. Code r. 538-x-1-.08-1; 538-x-4-.08.06. Once approved, our plan will begin by removing cannabis product stock in an orderly and secure fashion by collecting secure storage containers and loading them into emergency transportation vehicles. Staff will ensure that all products that can be preserved by removal are tracked via a handwritten removal log and the statewide seed-to-sale tracking system if the emergency allows. Any product removed that was not tracked and recorded initially will be inventoried once secured in its temporary storage location. After being removed from our primary facility, cannabis product stock will be transported to a secure temporary storage facility (if permitted by the AMCC), from which it can be safely distributed to other licensees. To the extent possible, this temporary secure storage area will meet all requirements for secure storage of cannabis and will be fitted with commercial locks and alarm systems. Access protocols will remain the same and only designated employees will handle and transfer cannabis between the storage area and other areas of the temporary facility.

We will also proactively communicate with our licensee partners following an emergency to facilitate their access to our cannabis products. We will send out notifications via all available communication channels to inform licensees and patients and caregivers that an emergency or disaster has occurred and where and when they will be able to collect

their medical cannabis following the event. However, should the AMCC provide any guidance that differs from our proposed plan, we will alter our procedures to be compliant with any applicable regulatory requirements. Though we may not be able to immediately ship cannabis following an emergency, we will take reasonable steps to do so compliantly as soon as possible.

11.7 – SOPs – Alcohol, Smoke, and Drug Free Workplace

We will develop a clear alcohol, smoke, and drug free workplace policy, which will be included in every employee handbook, and our company policies and procedures manual; we will always maintain compliance in these policies, and they will be reviewed at least annually. Ala. Admin. Code r. 538-x-3-.05.03.m.16.g. Maintaining our workplace as alcohol, smoke, and drug free is paramount to maintaining an environment of security, safety, and health for our employees, all Alabama patients, and any visitors to our medical cannabis facility. Our HR Director will maintain records related to the policy, including the detailed written policy itself and copies of signed employee signature pages confirming understanding of and consent to the policy, all of which will be available to the AMCC. We will require staff to sign documents stating they understand there is zero tolerance for alcohol and drug use at the workplace and they will abstain from such use during work hours or while on our premises.

We are committed to maintaining a safe, alcohol-free, smoke-free, and drug-free work environment for all employees, agents, customers, and visitors. We will therefore explicitly prohibit the use, possession, solicitation for, or sale of personal cannabis, illegal drugs, alcohol, cigarettes, tobacco products, or prescription medication without a prescription on facility premises or while performing work-related assignments. All employees will complete training on our alcohol, smoking, and drug-free policy during onboarding and will read and consent to the policy in writing. Being impaired or under the influence of legal or illegal drugs or alcohol away from company premises, if such impairment or influence adversely affects the employee's work performance, the safety of the employee or of others, or damages our organization's reputation, may result in immediate job termination.

We will prohibit the presence of prohibited substances in employees' urine while at work on company property, or while on company business. We may therefore ask

employees to submit to a drug or alcohol test at any time management feels that an employee may be under the influence of drugs or alcohol. Any company employee involved in an on-the-job accident or injury under circumstances that suggest the possible use or influence of drugs or alcohol in the accident or injury event may be asked to submit to a drug and/or alcohol test. If an employee is tested for drugs or alcohol outside of the employment context, such as by law enforcement, and the results show a violation of this policy, or if an employee refuses a request to submit to testing under this policy, the employee may be subject to appropriate disciplinary action, including discharge from employment. In such a case, the employee will be given an opportunity to explain the circumstances prior to any final employment action becoming effective.

At our facility, we will have surveillance cameras in place to monitor and record staff activity continuously. The cameras, along with "Cameras in Use" signs, will be in conspicuous areas to discourage staff from engaging in any acts which would violate the maintenance of an alcohol, smoke, and drug free workplace. Management will also monitor staff conduct by observing daily operations and make explicit notes if they suspect any activity violating this plan. We will prohibit staff from working while under the influence of any drugs or alcohol, including medical cannabis. Also, all staff are subject to random drug screenings, which can serve as a deterrent for employees.

We will have SOPs in place that guarantee this zero-tolerance policy for alcohol- and drug-use, which will outline the following steps, updated accordingly as the business begins and continues operation. Employees will be subject to testing based on (but not limited to) observations by the supervision of apparent workplace use, possession, or impairment and a member of the management team will be consulted before sending an agent for testing. Employees will also be subject to testing when they cause or contribute to accidents that seriously damage a company vehicle, machinery, equipment, or property or result in an injury to themselves or another employee requiring offsite medical attention in which there is a reasonable basis for concluding that drugs and/or alcohol use could have contributed to the incident.

In addition to random drug tests, we will also train management to uphold our SOPs and written policies. These training programs will help those in management identify key indicators of potential violations of the alcohol, smoke, and drug free workplace and walk

them through the steps to confront any individual they suspect of such violations. Management will also educate and inform staff of these SOPs and inform them of the health and safety risks associated with being intoxicated while working. To maintain a successful alcohol, smoke, and drug free workplace, we will ask staff to submit feedback on the effectiveness of our current SOPs and see if any changes or updates are necessary, with the aim of continuous improvement.

As new staff enter operations throughout our business' lifecycle, it is paramount they are trained at the onset not only on all our SOPs, but specifically about maintaining our alcohol, smoke, and drug free workplace. We may offer drug or alcohol rehabilitation to staff as needed to support our community while upholding internal policies. Management will regularly, and at least annually, review our policies to maintain compliance with all guidance from the AMCC and to ensure the policies reflect our company's vision for a fastidiously maintained alcohol, smoke, and drug free workplace. Our goal to have an alcohol, smoke, and drug free workplace is not only to implement such a policy but to maintain it and engrain it within our company culture. Following each of the steps outlined here, with a special emphasis on education, training, monitoring, and proper deterrence, we will be able to go above and beyond the requirements set by the State of Alabama and the AMCC for our medical cannabis workplace.

11.8 – SOPs – Employee Safety

Our Employee Safety Plan will always comply with parallel OSHA Standards applicable in similar workplaces. We will aid in OSHA's mission of ensuring that employees work in a safe and healthy environment by setting and enforcing standards, and by providing training, outreach, education, and assistance. Under the Occupational Safety and Health Act of 1970, we have a responsibility as employers to provide a safe workplace. To this end, we will comply with all applicable OSHA Standards, which are the regulatory requirements established and published by OSHA pursuant to the Occupational Safety and Health Act of 1970 and subsequent laws. We will comply with the General Duty Clause of the OSH Act, which requires employers to keep their workplace free of serious recognized hazards. 29 USC § 654. We will always follow mandatory standards for the general industry and any other applicable standards, as well as any guidance specific to the cannabis industry. 29

CFR § 1910. We will comply with standards for recording and reporting occupational injuries and illnesses. 29 CFR § 1904. Since we will move and store cannabis and associated products in our facility, we will also account for common hazards and solutions for warehouse workers, such as: Ergonomic and Musculoskeletal Disorders; Forklifts; Materials Handling; Slips, Trips, and Falls; Hazardous Chemicals; Emergency Planning; Electrical Hazards; Lockout/Tagout; Heat Illness; Automation and Robotics; Refrigerated Warehousing; Temporary Workers; and, Stress and Fatigue.

We will demonstrate and maintain standard operating procedures regarding Employee Safety in such a way that they can be readily accessed from the physical site of operations upon the request of inspectors, the AMCC, or AMCC staff. Ala. Admin. Code r. 538-x-3-.05.03.m.16.h. We will always maintain, and review at least annually, our employee safety plan that complies with parallel OSHA standards applicable to similar types of businesses. Ala. Admin. Code r. 538-x-4-.07.12.o.08. Our Director of HR will review our Employee Safety Plan with the leadership team at least annually and adjust as needed.

Due to the potentially hazardous nature of our workplace, all team members are responsible for familiarity and compliance with OSHA, EPA, and state regulations regarding job safety and health protection. We will cooperate with all reasonable OSHA and EPA inspections and compliance reviews. We will provide training and materials explaining the applicable standards and guidelines for all employees during the initial getting acquainted period, and periodically when applicable regulations are revised or added. All employees are required to participate, and a record will be maintained of all those in attendance. OSHA's Hazard Communication Standard requires that warning labels with orange and orange- red biohazard symbols be affixed to containers of regulated waste or, alternatively, red bags may be used. Employees who may come into contact with hazardous materials are required to receive information and training after the start of employment. We will maintain additional information, including a copy of the safety data sheets (“SDS”), about any chemical used or stored in the facility, which is available to employees during working hours. Staff will undergo training on how to maintain OSHA safety protocols while on premises, such as: wearing PPE; allowing rest time for staff between tasks of 10-minute breaks every two hours of work and one hour lunch break between every four hours of work; and, reporting potential workplace hazards to our COO. Applicable material safety

data sheets will be readily available in processing areas. We will use the Hazard Analysis of Critical Control Points ("HACCP") system to identify specific safety hazards and measure and control them to ensure the safety of our products. HACCP is a science-based, systematic tool used in various industries to assess safety hazards and establish control systems that focus on prevention rather than relying exclusively on managing collateral damage. We will use our HACCP system throughout all stages of production to avoid dangerous work environments throughout the processing workflow. Part of this process will be establishing Critical Control points throughout the production process and a system of measurements designed to monitor, evaluate, and control any variance or hazard to employee or visitor safety and security.

We will provide gloves, coveralls, and respirators for use in conjunction with hazardous and potentially health-afflicting materials. We will always refer to the list of registered sanitizing agents kept by the AMCC when procuring our supplies. We will require that PPE be used when participating with certain aspects of infusion. To ensure worker and consumer safety, we will always identify, hold, and store toxic cleaning compounds, sanitizing agents, solvents used in the production of cannabis products, and other chemicals in a manner that protects against contamination. OSHA has identified falling and tripping as being major hazards associated with similar facilities and work environments. This is especially the case when floors are wet, damp, or otherwise coated in a way that makes them increasingly slippery. We will require employees to wear slip-resistant shoes within production areas.

We will utilize the following PPE for our employees' safety: hand protection (e.g., protective gloves, nitrile gloves) where cut hazards or potential exposure to corrosive liquids, blood, chemicals, or other infections materials exist; head protection (e.g., hard hats) where danger of falling objects exist; eye protection (e.g., goggles or glasses) where risk of eye injuries exists, such as punctures, abrasions, contusions, or burns; face protection (e.g., face shields) where danger of flying particles or materials exist; foot protection (e.g., steel-toed boots) where risks of foot injury from corrosive, poisonous, or hot substances, or from falling objects, crushing, or penetrating actions exist; hearing protection (e.g., ear plugs) where risks of hearing damage from occupational noise exist and exceed the acceptable sound levels of the OSHA Noise Standard; respiratory protection

(e.g., respirator, gas masks) where respiratory health risks exist from inhaling smoke, fumes, particulate matter, etc.; clothing protection (e.g., plastic aprons) where risk of splashing chemicals exists; and, sanitation equipment (e.g., shoe booties, hair nets, beard nets) where staff will be handling or manufacturing food or drugs.

We will also keep Emergency Kits in marked locations throughout the facility for quick access in an employee safety emergency. Staff will check the emergency kit once per month to verify all contents are present, in working condition, and unexpired. The emergency kit will include: a fire extinguisher; bottled water; non-perishable food; flashlights with extra batteries; first aid kit (assorted bandages, gauze, antibiotic ointment, sterile gloves, tweezers, antiseptics, cleansing wipes, scissors, and common over-the-counter medications such as Tylenol and Benadryl); a basic toolbox (wrench, pliers, screwdriver, hammer); garbage bags; hand sanitizer; face masks or coverings; buckets; a battery-powered radio; a charged cellular phone with charging cord; and, a USB battery pack.

We will also keep meticulous records of our safety and sanitation efforts, including a daily checklist of required sanitation tasks to include trash collection and disposal, restroom upkeep, floor care, waste reporting, and equipment cleaning and upkeep including the replacement of HVAC filters, vacuum system filters, and the regular cleaning of vents, and door and window seals. Supplemental records in the form of purchase orders and receipts for services or equipment and tools required to efficiently carry out the duties under this emergency plan will be kept in both paper and electronic format. MSDS safety data sheets will be kept in our records and prominently displayed on or near chemical or other cleaning agents, with first aid and other emergency information appended accordingly. We will also use a chemical log to show which chemicals were used, in what area of the facility, and by whom. Our CEO and COO will review these logs and tracking sheets on a quarterly basis to identify and measure key performance indicators within the sanitation program that can improve the sanitation processes.

11.9 – SOPs – Confidential Information and Cybersecurity

We will provide effective controls and procedures to guard against unauthorized access of our electronic systems or our confidential business data. We will create and maintain a plan for maintaining confidential information and providing cybersecurity for sensitive

information, and we will include within that plan a set of protocols for maintaining the security of confidential information in accordance with HIPAA arising from or related to our access to the Patient Registry and/or from any other source. Our controls will include methods that protect against electronic records tampering. We will take all necessary steps to confidentially maintain records with any personally identifying or private business information. Alabama Ala. Admin. Code r. 538-x-4-.05.07. When creating policies for the security of our hardware, software, and data, we have consulted regulations found in Title 45 of the Code of Federal Regulations, including the Health Insurance Portability and Accountability Act ("HIPAA"), and the Health Information Technology for Economic and Clinical Health Act ("HITECH"). We have also adopted best practices for cybersecurity used by HIPAA-compliant medical facilities, to prevent unauthorized access or theft of our data.

Our COO and DOC will oversee our compliant and confidential recordkeeping system. They will also perform regular audits of our records and update standard operating procedures SOP as needed to maintain compliance and accurate recording. Our COO John Brown has actively led small and mid-size organizations, with roles encompassing quality assurance, manufacturing, engineering, and supply chain functions. He has also instituted focused initiatives for accountability and has led multiple entities through global business technology accelerator programs. With over two decades in the biopharmaceutical sector, he has extensive experience with data in sensitive situations and highly regulated industries. Our DOC is a partner at Forrester Law in Birmingham, Alabama. He is a juris doctorate, certified to practice in Alabama, and has provided legal counsel for nearly a decade. Confidentiality has been critical to the success of our DOC.

Our COO will develop and deliver trainings on HIPPA and related policies for our employees related to their job roles. Employees that interact with the patient registry, AMCC website, or seed-to-sale system will earn certifications, prior to beginning their job, for each database they will use. Ala. Admin. Code r. 538-x-4-.05.05. All employee training will include online safety, including how to create strong passwords, avoid dangerous websites, and recognize phishing emails. We will also provide staff with notices of emerging cybersecurity threats, such as software vulnerabilities or new phishing scams. Our IT Director will keep all computer systems updated with an efficient and compliant operating system, software, and firmware updates to patch potential system vulnerabilities. They will

also conduct regular analysis of the information technology market to identify promising new security products and detect newly emerging cybersecurity threats.

We will work with an information technology company to run cybersecurity tests and consult with our IT Director on revisions of policies and procedures. Upon licensure approval, we may contract with additional technology vendors to provide specific database training for employees. Ala. Admin. Code r. 538-x-4-.05.05. Coordination of any data with our vendors will be tracked through the state medical cannabis patient registry and seed-to-sale systems, which we will maintain as applicable. Ala. Code § 20-2A-35.

Our network security will comply with cybersecurity standards set by the International Society of Automation ("ISA") and the International Electrotechnical Commission ("IEC") standard 62443. Ala. Admin. Code r. 538-x-4-.05-.02. We will utilize security software on all company owned devices, to eliminate malware and phishing. Our facility will have computers with different operating systems, and we will safeguard all devices appropriately. Ala. Code § 20-2A-6.

Our inventory system will be directly compatible with the state seed-to-sale system and patient registry, as applicable. Ala. Admin. Code r. 538-x-4-.05-.04. We will use tags to facilitate our inventory tracking that include bar codes, QR codes, RFID tags, NFC tags, or other equivalent systems for assigning unique numbers to cannabis batches received and associated products. Ala. Code § 20-2A-63(i). This process may require additional hardware specific to scanning digital codes. We will create and maintain plans for upgrading all system software and hardware throughout our processor facility. Ala. Admin. Code r. 538-x-4-.07.12.o.01. We will enable automatic system updates on all computers, and systems will be routinely inspected for security. Our financial plan accounts for all software and hardware purchases and their maintenance. Ala. Admin. Code r. 538-x-4-.05.03.

Our cybersecurity plan focuses on minimizing the amount of data we retain and limiting opportunities for security breaches. We will maintain a complete, accurate, and confidential record of all sales, transfers, and destruction of cannabis products. Each record will include the individual or cannabis business to whom the product is sold or transferred, and the quantity, variety, form, and cost of the cannabis items. Any interactions that we conduct with the Alabama Medical Cannabis Patient Registry System will be maintained confidentially in accordance with HIPAA. Ala. Code § 20-2A-35; Ala. Admin. Code r.

538-x-4-.07.12.o.09. Our medical cannabis records will be maintained confidentially and securely. We will also maintain certain business records as confidential. We will keep a record of any individual that has been on our facility premises at any point in time. These records will include an individual name, time and date of entry, time and date of exit, and the reason for their presence, and we will maintain them for at least two years. Ala. Admin. Code r. 538-x-4-.07.12.o.11.i. Additionally, we will privately maintain our employee records including their personal information, resumes, references, payroll details, and job reviews. Our business records can be made available to the AMCC or law enforcement agencies, as necessary.

HIPAA security consists of three areas for compliance: Administrative, Physical and Technical standards, which may include setting up separate networks for systems carrying confidential data, forcing log outs, and other standard security practices. 45 CFR § 164. We will utilize a host of Administrative, Physical, and Technical safeguards to comply with HIPAA at our facility, including but not limited to: security management process, assigned security responsibility, workforce security, information access management, security awareness training, security incident procedures, contingency plan, evacuation, facility access control, workstation use, workstation security and device and media controls, audit controls, integrity controls, person or entity authentication and transmission security.

We will consistently utilize rigid recordkeeping practices throughout our facility, and in all business operations. Our SOPs will always be readily accessible at our facility upon the request of inspectors, the AMCC, or AMCC staff. Ala. Admin. Code r. 538-x-3-.05-.3m.16.i. We will always comply with AMCC inspections and provide access to records, as necessary. Ala. Admin. Code r. 538-x-4-.02.02.b.02.

11.10 – SOPs – Waste Disposal

We are committed to providing a clean and safe experience for not only downstream medical cannabis patients but for our employees and visitors as well. We will do this through a multi-faceted waste disposal plan that incorporates a culture of compliance among our staff, as well as disposal practices and waste management procedures designed to protect the health of our customers, employees, and our local community. Therefore, we will always maintain and review at least annually, a plan for tracking and proper disposal of

waste cannabis or medical cannabis, including all parts thereof, as applicable. Ala. Admin. Code r. 538-x-4-.07.12.o.10. Our plan will, at a minimum, leave no part of the disposed or waste cannabis or medical cannabis either usable or recognizable as such. Ala. Admin. Code r. 538-x-4-.07.12.o.10. Further, we will establish and maintain safe standards, procedures, and requirements for hazardous and chemical waste product storage and disposal, and chemical storage. Ala. Code § 22-27;22-30.

The primary objective of our waste disposal and sanitation plan is the health and safety of our customers, visitors, vendors, local community, and employees, with a particular focus on preventing the contamination of any cannabis and related cannabis products. This plan includes not only the compliant disposal of waste but also the careful management of waste to ensure that cannabis and related cannabis items do not contaminate the environment and extends to the entire interior and exterior of our building.

Our standard operating procedures for waste encompass our cannabis waste, non-cannabis waste, recycling program, sustainability, and efforts to limit waste. Part of our environmental and sustainability plan is an effort to reduce our facility's production of waste and consumption of resources. Our water supplies will be sufficient for our processing activities and derived from a source that is a regulated water system. Our facility structure will include plumbing that is adequate to carry sufficient quantities of water to locations through the facility and convey sewage and waste from the facility without cross contamination of potable water and waste.

Our staff will safely remove litter and waste, so they do not contribute to potential sources of contamination in areas where cannabis or cannabis products are located. Our facility will feature waste receptacles that are properly labeled and emptied at least daily. Since we are not permitted to reuse any tags that have already been affixed to any cannabis or cannabis products, we will be sure to compliantly sort and store these tags, so they are not reused. If we can recycle or compost the tags, we will seek to do so, with AMCC approval.

We will utilize our inventory tracking system to track all cannabis waste linked to unique identification numbers. Ala. Code § 20-2A-60(a)(1). We are committed to conservation and will strive to reduce waste in all segments of operations. Staff will follow detailed instructions related to waste disposal and transport, especially those that concern

destruction and disposal of cannabis waste or hazardous materials. These policies and procedures will ensure maximum compliance with all requirements set forth by the AMCC and all relevant law, preventing diversion of cannabis waste and protecting the environment and people of Alabama from the negative effects of improper waste disposal.

We will demonstrate the ability to destroy unused or waste cannabis in accordance with rules adopted by the Alabama Department of Agriculture. Ala. Code § 20-2A-62(c)(4). We have a detailed plan for the destruction and disposal of cannabis, including parts thereof, and any related materials that cannot or will not be processed, transported, or dispensed. Primarily, any cannabis material that is not used in our medical cannabis products will always be destroyed in such a way as to render the material unusable and unrecognizable. We may render the material unusable and unrecognizable in several ways utilizing grinders, shredders, or combining cannabis waste with non-cannabis organic waste until it is unrecognizable.

Secure disposal and destruction of recalled and unusable cannabis are the final steps to assure that such products do not make their way back into the market and that waste and byproducts do not contaminate the environment. Prior to disposal, staff will remove cannabis products from packaging and render them unrecognizable and unusable. Verification of this event will be performed by a manager and will be conducted in a restricted, secured, and surveilled access area. We will always enter these destruction and disposal records into the statewide seed to-sale tracking system. Should more information about disposal be needed, we will provide, in writing, any additional information the AMCC may request.

Whenever we dispose of or destroy cannabis or products, we will destroy it or render it unusable and will create and maintain a written record of the disposal of the cannabis by our business and weigh the cannabis or product and update it in the inventory prior to disposal or destruction. The entire destruction process will be monitored, documented, and recorded; we will incorporate continuous electronic monitoring in our facility's operation, including unobstructed surveillance and monitoring of areas in which cannabis is destroyed. We will maintain electronic documentation of destruction and disposal for a period of at least five years, will maintain detailed and accurate records of all recalls including the disposition of the cannabis product disposal process, and will immediately

implement additional changes required by future agency guidance on cannabis product waste management.

Our waste disposal will always comply with the associated rules set forth by the AMCC, the state, and our local jurisdiction. We will partner with Clean Management Environmental Group to render the medical cannabis or cannabis products unusable. They will grind and incorporate the cannabis waste with other ground materials, so the resulting mixture is over 50% non-cannabis waste by volume. They will then compliantly dispose of the resultant mixture. Clean Management Environment Group will also dispose of any hazardous waste as needed. They have worked with many licensed cannabis businesses nationwide and have worked closely with the Californica Cannabis Control Board.

If compost waste is permitted, cannabis waste may be mixed with food waste, yard waste, vegetable-based grease oils, agricultural materials, biodegradable products and paper, clean wood, fruits and vegetables, plant matter, compost activators, or other AMCC-approved methods. In addition to cannabis waste, we will also dispose of processing waste, such as residual solvents, as well as any liquid waste, such as wastewater, in a manner compliant with federal, state, and local laws.

We have developed a plan that tracks all waste material throughout our facility from generation to disposal utilizing the statewide seed-to-sale tracking system. We are committed to conservation and will reduce waste in all segments of operations. Staff will follow detailed instructions related to waste disposal, especially those that concern destruction and disposal of cannabis waste, agricultural waste, or hazardous materials. These policies and procedures will ensure maximum compliance with all requirements set forth by the AMCC and all relevant law.

License Type: Processor

Exhibit 12 – Policies and Procedures Manual

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

MANUAL SUMMARY

COOSA MEDICAL MANUFACTURING, LLC'S manual contains more than 25 pages and because of this, the Applicant is required to provide a summary in no more than 5 pages. The Policies and Procedures Manual contains information to specifically inform our employees on how to perform important functions of their jobs, including safety documentation, opening and closing the location, accepting and managing payment, handling product refunds, maintaining a safe and secure workplace, and carrying out other important functions related to our employees. Templates of some of this documentation are included in the Manual's Appendix. Some of the policies included herein are our most important employment policies, and they are also available for reference in our Employee Handbook. The Table of Contents gives a complete overview of the entire Policies and Procedures Manual.

TABLE OF CONTENTS

COOSA MEDICAL MANUFACTURING, LLC

POLICIES AND PROCEDURES MANUAL

Standard Operating Procedures

This manual, titled "Standard Operating Procedures," is intended to comply with 21 CFR parts 210, 211, and 820.

1. Purpose

The purpose of the Standard Operating Procedure (SOP) is to specify the processes used to manage SOPs. This includes the creation, training, review, modification, and archiving of SOPs. This SOP provides details regarding Operating Documents and procedures to ensure regulatory compliance with applicable state and federal law.

2. Scope

This procedure applies to all internal operating documents and the personnel who review, write, and approve them.

3. Responsibility

Non-supervisory employees are encouraged to review and submit recommendations regarding policy and procedure to their supervisor who shall forward the recommendations to the Director of their department. All official recommendations shall be submitted to Coosa Medical Manufacturing employees with the authority to create or modify procedures within the SOP. Authority to create or modify procedures within the SOP is given to upper-level executives, including the Chief Executive Officer, Chief Operations Officer, Director of Compliance, or other employee designated with this responsibility by the Chief Executive Officer.

4. Enforcement

All supervisors are responsible for enforcing this policy. Employees who violate this policy are subject to discipline up to and including termination from employment in accordance with Coosa Medical Manufacturing's Employee Disciplinary Policy.

5. References / Related Document

Operating Documents:

- Operations
- Security
- Extraction
- Internal Controls

6. Procedure

6.1 Standard Operating Procedures must be reviewed or revised annually.

6.2 Standard Operating Procedures may be reviewed or revised as necessary in addition to annual reviews.

6.3 Standard Operating Procedures shall be reviewed by the Director of the department in which the procedures apply.

6.4 Directors reviewing the Standard Operating Procedures must consider all relevant information regarding the procedure(s) under review.

6.5 Directors shall submit their typed recommendation to an Executive Officer, Director of Compliance, or other employee designated with authority to receive and approve recommendations by the Chief Executive Officer.

6.6 Directors reviewing the Standard Operating Procedures shall submit a typed recommendation to create, edit, or maintain the procedure(s) under review within ten (10) business days of initial review.

6.7 Submission extensions or exemptions are granted on a case-by-case basis by an Executive Officer, Director of Compliance, or other employee designated with authority to receive and approve recommendations by the Chief Executive Officer.

6.8 Reviews and/or revisions must be approved, in writing, by an Executive Officer or Director of Compliance within thirty (30) days of receipt of a typed recommendation from a Department Director.

6.9 Current and valid Standard Operating Procedures must include an approval form at the front of the Standard Operating Procedures manual with the following information:

- The name(s) and signature(s) of the reviewer(s) of the Standard Operating Procedure(s);
- The name(s) and signature(s) of the author(s) submitting a typed recommendation (if applicable);
- The name(s) and signature(s) of the employee who authorizes the final version of the Standard Operating Procedure(s);
- Implementation date;
- Page numbers in 1 of 1 format; and
- Version number.

7. Summary of Changes / Revision History Table

7.1 21 CFR Part 820.40 requires that each manufacturer shall establish and maintain procedures to control all documents that are required under document control. The procedures shall provide for the following:

- A table that lists the section, description of changes, version number, approval date, implementation date, and author of the SOP/Operating Document.
- The Revision History table must be updated each time a procedure is updated and approved.

Standard Operating Procedure Manual

Section	Description of Changes	Ver.	Approval Date	Implementation Date	Approved by
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	

Operating Documents

Section	Description of Changes	Ver.	Approval Date	Implementation Date	Approved by
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	
				___ / ___ / ___	

8. Approval Signatures

In compliance with 21 CFR Part 211, a signature page must be included on the cover or back page of each SOP and individual sections within the SOP.

Operating Documents

1. Purpose

Coosa Medical Manufacturing will maintain operating documents in accordance with Alabama Medical Cannabis Law.

2. Scope

Operating Documents apply to all internal operations and the personnel who review, write, and approve them.

3. Analysis

The operating documents describe operational and management practices including:

- Record keeping;
- Security measures to deter and prevent theft;
- Unauthorized entrance into areas containing medical cannabis;
- Types and quantities of medical cannabis products that are produced at the manufacturing facility;
- Methods of planting, harvesting, drying, and storage of medical cannabis;
- Estimated quantity of waste material to be generated;
- Employee training methods for the specific phases of production;
- Biosecurity measures used in production and in manufacturing;
- Strategies for reconciling discrepancies in plant material of medical cannabis;
- Sampling strategy and quality testing for labeling purposes;
- Medical cannabis packaging and labeling procedures;

- Procedures for the mandatory and voluntary recall of medical cannabis;
- Plans for responding to a security breach at a manufacturing facility or while medical cannabis is in transit to a manufacturing facility; and
- Other information requested by the commissioner.

A master binder of these operating documents must be located in the office of the Chief Operations Officer, or their designee, in the administrative office, and documents pertaining specifically to production (harvest, manufacturing, packaging and processing) will be located in the Production office in the back of the manufacturing facility. Equipment certifications and process specific procedures must be kept in a binder in the room where the machinery and activity takes place.

4. Procedure

4.1 Operating Documents must be reviewed or revised annually.

4.2 Operating Documents may be reviewed or revised as necessary in addition to annual reviews.

4.3 Operating Documents must be reviewed and/or revised by the Director of the department in which the Operating Documents apply.

4.4 Reviews and/or revisions must be approved, in writing, by an Executive Officer, Director of Compliance, or other employee designated with authority to receive and approve recommendations by the Chief Executive Officer.

4.5 Current and valid Operating Documents must include an approval form at the front of the Operating Document with the following information:

- The name(s) and signature(s) of the reviewer(s) of the Operating Document;

- The name(s) and signature(s) of the author(s) submitting a typed recommendation (if applicable);
- The name(s) and signature(s) of the employee who authorizes the final version of the Operating Document;
- Implementation date;
- Page numbers in 1 of 1 format; and
- Version number.

4.6 All documentation and record keeping of Coosa Medical Manufacturing operations will be kept for a minimum of five years, unless otherwise directed by law.

Operations

SOP-O01: OPERATION AND MANAGEMENT PRACTICE

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical Manufacturing is dedicated to complying with state statutes and rules regulating the manufacturing of medical cannabis. This SOP describes the location of the required operational documents under the statutes and rules.

2. SCOPE

It is the responsibility of the Director of Compliance to ensure that all SOPs are properly followed. It is also the responsibility of the Director of Compliance to notify management staff of a failure to abide by the SOPs or the statutes or rules regulating medical cannabis manufacturers.

3. REFERENCES

Alabama Medical Cannabis Commission

4. REQUIRED OPERATIONAL DOCUMENTS

4.1 Record Keeping

Individual divisions are required to keep accurate and timely records. General record keeping requirements are in SOP-O02.

Extraction –SOP-L11; SOP-L12; SOP-L13; SOP-L14; SOP-L15

Security – SOP-S05

Finance – SOP-F01

4.2 Security Measures to Deter and Prevent Theft of Medical Cannabis

a. Extraction – SOP-L14

b. Security – SOP-S08

4.3 Unauthorized Entrance into Areas Containing Medical Cannabis

a. Security – SOP-S01; SOP-S02

4.4 4.5 Methods of Planting, Harvesting, Drying, and Storage of Medical Cannabis

a. Extraction – SOP-L14

4.6 Disposal Methods for All Waste Materials

a. Medical Cannabis Waste – SOP-L15

4.9 Employee Training Methods for the Specific Phases of Production

a. SOP-O05

4.10 Biosecurity Measures Used in Production and Manufacturing

a. SOP-L04

4.11 Strategies for Reconciling Discrepancies in Plant Material or Medical Cannabis

a. SOP-O07

4.12 Sampling Strategy and Quality Testing for Labeling Purposes

a. SOP-L11; SOP-L12; SOP-L13

4.13 Medical Cannabis Packaging and Labeling Procedures

a. SOP-L09

4.14 Mandatory and Voluntary Recall of Medical Cannabis Procedures

a. SOP-O03; Appendix I

4.15 Security Breach Procedures

a. SOP-S03

SOP-O02: RECORD KEEPING

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: Signature Date	Next Review Due by:	
Revision(s) by (if applicable): Signature Date	Approved by: Signature Date	

1. POLICY

Alabama Medical Cannabis Law requires that certain records be kept for certain periods of time. It is in the best interest of Coosa Medical Manufacturing to continue to keep records in order to analyze business strategies and customer experiences.

2. SCOPE

It is the responsibility of the Director of Compliance to ensure that all records are kept for the appropriate amount of time and in an accessible format for the Commissioner of health's review.

3. RECORD KEEPING REQUIREMENTS

3.1 All records must be kept for a minimum of five years.

3.2 Records must be complete, legible, and current.

3.3 All records mentioned in this SOP must be kept by the Director of Compliance, unless otherwise delegated by the Director of Compliance or Chief Executive Officer.

4. INVENTORY RECORDS

4.1 The following inventory records must be maintained:

4.1.1 The quantity and form of medical cannabis maintained by Coosa Medical Manufacturing at the manufacturing facility on a daily basis; and

4.1.2 Inventory of medical cannabis.

4.2 Inventory records are to be maintained in Coosa Medical Manufacturing (or applicable program) and must be accessible to the Director of Compliance for review.

5. FINANCIAL RECORDS

5.1 The following financial records must be maintained:

- All financial records that reflect all financial transactions and the financial condition of the business;
- Purchase invoices, bills of lading, sales records, copies of bills of sale, and supporting documents, to include the items or services purchase, from whom the items were purchased, and the date of purchase;
- Bank statements and canceled checks for all business accounts;
- Accounting and tax records; and
- Records of all financial transaction, including contracts and agreements for services performed or services received.

5.2 Financial records are to be maintained by the Chief Financial Officer, or CFO's designee, and Controller and must be accessible by the Director of Compliance.

6. PRODUCTION RECORDS

6.1 The following product records must be maintained:

- Any inputs applied to the plants, or plant material used in production;
- Production records;
- Records of all samples sent to a testing laboratory and the quality assurance test results; and
- Records of theft, loss, or other unaccountability of medical cannabis.

7. PERSONNEL RECORDS

7.1 All personnel records, including, but not limited to, background check dates, hiring information, termination information, and disciplinary actions, must be maintained by either the executive assistant or Counsel.

SOP-O03: RECALLS

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

In the event that a contaminant or other hazard is later discovered, a recall may take place.

See Appendix I – Recall Procedures for full description.

2. SCOPE

This SOP describes when and how a recall will occur. It is the responsibility of all employees to participate in the recall however instructed by the CEO.

3. VOLUNTARY RECALL

3.1 When to Conduct a Voluntary Recall

a. A voluntary recall will be conducted if there is a reasonable belief that there is a danger to the health or safety of the public.

It will be the decision of the CEO whether a voluntary recall will be conducted, with the advice from applicable employees and outside sources, if necessary.

3.2 Procedure for Voluntary Recalls

If excipients contained in a product are the cause of the recall, staff will work with extraction team staff to determine all products that contained the excipient.

All reasonable steps will be taken, including, but not limited to, testing and re-testing products, to determine contaminates in the product if the contaminants are unknown.

4. MANDATORY RECALLS

4.1 Notification of a Mandatory Recall

a. The AMCC or another authorized department or person will notify the company in the event that there is a mandatory recall.

4.2 Procedure for Mandatory Recalls

a. All steps taken during a voluntary recall will be taken during a mandatory recall as well.

Coosa Medical Manufacturing will follow all instructions given by AMCC.

SOP-O04: AMCC INSPECTIONS

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

The AMCC has the authority to reasonably inspect the products and premises of Coosa Medical Manufacturing. This inspection may be at any company location and take place at any time. Coosa Medical Manufacturing and all employees will comply with legal requests made by AMCC.

2. SCOPE

It is the responsibility of the Director of Compliance to ensure that all requests made by AMCC are met. It is also the responsibility of the Director of Compliance to ensure that proprietary information is properly marked and that all requested documents are given to AMCC as quickly as possible.

3. PLANNED INSPECTIONS

The Director of Compliance will communicate with all staff members regarding planned inspections by AMCC.

4. UNANNOUNCED INSPECTIONS

4.1 During Business Hours

a. If AMCC arrives to do an unannounced inspection during business hours, security will allow AMCC into the waiting area of the facility.

Security must be able to verify that AMCC staff are in fact AMCC staff before AMCC staff are allowed to enter restricted access areas.

Security shall immediately contact the Director of Compliance regarding AMCC's arrival.

4.2 After Business Hours

a. If AMCC arrives to do an unannounced inspection after business hours, security will not allow inspectors access until the staff representatives of AMCC can be verified as AMCC staff.

Security must immediately call the Director of Compliance if AMCC arrives to do an after-hours inspection.

Security must not grant inspectors access into the building until the Director of Compliance, CEO, or other designee of the company arrives to verify AMCC's identity.

5. DOCUMENTATION REQUESTS

a. All documents requested by AMCC, whether or not during an inspection, must be turned over to AMCC within the quickest amount of time, unless otherwise instructed by the CEO.

SOP-O05: EMPLOYEE TRAINING METHODS

TABLE OF CONTENTS

Pages: 1 of 2	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All employees will be trained on the specific areas of production that relate to the individual employee's job duties. Employees may be cross-trained on other areas of production in order to better understand the production system as a whole.

2. SCOPE

It is the responsibility of each individual manager to ensure that all employees are properly trained on their individual areas of production.

3. TRAINING CHECKLISTS

1.1 All employees will be given a training check list to be utilized by the employee's supervisor or a designee of the supervisor.

1.2 Training records will be kept with employee files.

SOP-O06: RECONCILIATION OF PRODUCTS

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Accurate record keeping is not only necessary for a productive company but it is also required by law. All employees should take care to enter all records accurately and double check that records are accurately reflected.

2. SCOPE

It is the responsibility of each individual that enters records to ensure that records are entered accurately. This SOP applies to all records relating to plant material and medical cannabis.

3. MEDICAL CANNABIS AT THE MANUFACTURING FACILITY

3.1 An employee that notices a discrepancy in the medical cannabis at the manufacturing facility must immediately notify the Head of Extraction and Quality Control.

3.2 The Head of Extraction and Quality Control must trace the source of the discrepancy.

3.3 If possible, the discrepancy should be fixed and noted in the record that numbers were changed due to the discrepancy and by whom.

3.4 If it is not possible to determine when the discrepancy occurred, the accurate record should be reflected and noted that the accurate record was changed.

3.5 All discrepancies should be reported to the Director of Compliance. The Director of Compliance has discretion on whether or not to open an investigation into the discrepancy.

4. QUARTERLY FINANCIAL CLOSE RECONCILIATION

4.1 As part of the quarterly financial close, the accountant reconciles inventory and investigates differences.

4.2 Using Coosa Medical Manufacturing (or applicable program) inventory tracking software, accountant generates a report of harvested plant material for the period.

Accountant reconciles the total harvested weight to the dry plant material weight processed into oil. The result is the difference in stored dry pant material weight for the period.

SOP-O07: REQUIREMENTS FOR EMPLOYMENT

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All employees must meet requirements as set in law and rule.

2. SCOPE

It is the responsibility of the hiring manager to ensure that each employee meets minimum qualifications.

3. AGE

All employees must be at least twenty-one years of age.

4. DISQUALIFYING FELONY CONVICTIONS

4.1 No employee may have been convicted of a disqualifying felony offense, as defined in Alabama Medical Cannabis Laws.

4.2 Employees must report post-employment convictions for a disqualifying felony offense immediately to the Director of Compliance.

5. ACCESS TO FACILITIES

5.1 Access to Coosa Medical Manufacturing facilities is restricted to current employees that are on file.

5.2 Upon hire, an employee's access to the manufacturing facility will be determined by the Chief Operations Officer, or their designee.

5.3 The Chief Operations Officer, or their designee, may also give on-going authorization to access facilities to contractors that are not employees of Coosa Medical Manufacturing.

6. PROHIBITED ACTIVITES

Per Alabama Medical Cannabis Law, a medical cannabis manufacturer and its employees, agents, or owners may not permit the consumption of medical cannabis at a distribution facility.

SOP-O08: EMPLOYEE DISCIPLINARY POLICY

TABLE OF CONTENTS

Pages: 1 of 5	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All employees are required to follow safety and operating procedures. When needed, employee will be provided with additional training and information, or retraining to maintain their knowledge. Coosa Medical Manufacturing reserves the right to discipline employees who knowingly violate company safety rules or policies. Coosa Medical Manufacturing's disciplinary policy is intended to encourage employee compliance with company safety rules and policies.

2. SCOPE

It is the responsibility of each employee to report employee violation(s) of company safety rules or policies to a supervisor. Supervisors must report violations to Human Resources for appropriate disciplinary action. Employees found performing work in an unsafe manner that would endanger that employee or another employee shall be subject to discipline or termination by management.

3. SANCTIONS

3.1 Disciplinary measures will include, but are not limited to:

a. Coaching (documented) for minor offenses.

b. Verbal warning (documented) for moderate or repeated violations.

c. Written warning for more severe or repeated violations.

Termination

3.2 Human Resources shall determine the course of action best suited to the circumstances. If deemed necessary, steps may be skipped to reflect the severity of the violation. The steps to be taken may include the following:

a. Coaching - The first step in correcting unacceptable behavior, primarily used for more minor offenses. The supervisor/manager shall review the pertinent fact

with the employee. The supervisor will consider the severity of the problem, and the employee's past performance. A coaching will be issued to the employee, which will be documented by the supervisor in the employee's personnel file.

b. Verbal Warning – If the unacceptable performance continues, the next step will be a verbal warning. Verbal warnings can also be the first step in correcting unacceptable behavior if deemed moderately severe. The supervisor/manager shall review the pertinent fact with the employee. The supervisor will consider the severity of the problem, and the employee's past performance. A verbal warning will be issued to the employee, which will be documented by the supervisor in the employee's personnel file. If necessary, the employee will be placed on probation.

c. Written Warning - If the unacceptable performance continues, the next step will be a written warning. The written warning will clearly state the safety policy that was violated and steps the employee must take if it is to be corrected. Probation will be a part of the written warning. It may also include time off without pay. At the completion of the probationary period, the supervisor will meet with the employee to determine if the employee has achieved the required level of performance.

d. Termination - The employee may be terminated if he/she does not improve his/her performance while on probation, or has violated another company safety policy within twelve months.

4. HIPAA VIOLATIONS AND SANCTIONS

4.1 Employees are expected to understand that the categories below are given as examples only and that there are other violations of HIPAA law that will be followed by disciplinary action. Disciplinary action is also dependent upon many variables; sanctions will be commensurate with the severity of noncompliance with Coosa Medical Manufacturing’s policies and procedures on a case-by-case basis. The identification and definition of such sanctions will occur with the appropriate

involvement with Human Resources, Director of Compliance, office management, and possibly legal counsel. All actions will be documented and retained for at least five years.

a. Category 1: Unintentional breach of privacy or security that may be caused by carelessness, lack of knowledge, or lack of judgment, such as a registration error that causes a billing statement to be mailed to the wrong guarantor.

b. Category 2a: Deliberate unauthorized access to confidential information. Examples: snoopers accessing confidential information of a VIP, coworker, or neighbor without legitimate business reason; failure to follow policy without legitimate reason, such as password sharing.

c. Category 2b: Deliberate unauthorized disclosure of PHI or deliberate tampering with data without malice or personal gain. Examples: snooper access and disclosure to the news media; unauthorized modification of an electronic document to expedite a process.

d. Category 3: Deliberate unauthorized disclosure of PHI for malice or personal gain. Examples: selling information to the tabloids or stealing individually identifiable health information to open credit card accounts.

4.2 Factors that may modify application of sanctions:

a. Sanctions may be modified based on mitigating factors. Factors may reflect greater damage caused by the breach and thus work against the offender and ultimately increase the penalty. Examples include:

i. Multiple offenses

ii. Harm to the breach victim(s)

iii. Breach of specially protected information such as HIV-related, psychiatric, substance abuse, and genetic data

iv. High volume of people or data affected

v. High exposure for the institution

vi. Large organizational expense incurred, such as breach notifications

vii. Tampering the investigation

viii. Negative influence of actions on others

Factors that could mitigate sanctioning could include:

i. Breach occurred as a result of attempting to help a customer

ii. Victim(s) suffered no harm

iii. Offender voluntarily admitted the breach and cooperated with the investigation

iv. Offender showed remorse

v. Action was taken under pressure from an individual in a position of authority

vi. Employee was inadequately trained

4.3 Sanctions

b. HIPAA regulations require that imposed sanctions be consistent across the board irrespective of the status of the violator, with comparable discipline imposed for comparable violations. This practice will enable application of general principles that will lead to fair and consistent outcomes.

c. Sanction implementation will follow the following steps. However, depending on the Category level of the incident, an escalated process can be followed if cause is shown.

i. Documented conference with recommendations for additional, specific, documented training, if necessary

ii. First written warning (and training, as above, if warranted)

iii. Final warning, with or without suspension, with or without pay (training included, if warranted)

iv. Severance of formal relationship: employment, contract, staff privileges, and/or volunteer status.

SOP-O09: ALARM AND SECURITY SYSTEMS FAILURE

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

In accordance the Alabama Medical Cannabis Commission ("AMCC"), Coosa Medical Manufacturing trains personnel on the logistics and safe operation of gasoline-powered generators used to backup required systems.

2. SCOPE

All employees are responsible for immediately reporting a power failure to Security personnel.

The Chief Operations Officer (COO), or their designee, is responsible for ensuring that reasonable policy and action is used to secure cannabis at all times.

The Chief Operations Officer, or their designee, is responsible for ensuring that alarm and camera systems operate at all times in Coosa Medical Manufacturing facilities.

Security is responsible to monitor security systems and notify the appropriate on-call employees, within five (5) minutes of a power failure, to activate backup generators.

3. SECURITY ALARM AND/OR CAMERA SYSTEMS FAILURE

3.1 An employee aware of a power failure to any required system must report the failure to Security immediately.

3.2 Coosa Medical Manufacturing security personnel are responsible for monitoring security alarm and camera systems, including required devices to operate the systems, at all times.

3.3 All Coosa Medical Manufacturing facilities must have a main source of reliable power.

3.4 All Coosa Medical Manufacturing facilities must have sufficient secondary backup power.

3.5 All Coosa Medical Manufacturing facilities must utilize main power at all times, when possible, and only use secondary and redundant sources of backup power during a main power failure.

3.6 Secondary and redundant sources of backup power may only be used until main power is restored.

3.7 Emergency back-up generators must be capable of supplying power to required systems and devices before loss of secondary, battery power.

3.8 If deemed necessary by the COO or their designee, a standby generator, in addition to battery back-up power, shall supply power to required systems and devices at each Coosa Medical Manufacturing facility before power loss to required systems.

3.9 It is the responsibility of the COO or their designee, to ensure that Coosa Medical Manufacturing either maintains generators to supplement secondary backup power systems or contracts with an emergency maintenance service provider to repair security and alarm system damage/failure and maintain back-up power.

3.10 The COO, or their designee, is responsible for the coordination and execution of supplying back-up generator power to required systems in accordance with applicable regulations.

3.11 If an imminent and permeant system-wide security systems failure of cameras and alarms occurs at any location during the normal business hours of operation, and no other emergency exists, security personnel shall request non-essential persons in the facility to wait in secure, monitored room and shall lockdown all rooms containing cannabis until systems are restored or appropriate measures are taken to ensure the security of cannabis in compliance with applicable rule.

3.12 During a systems emergency, security personnel shall limit access to rooms containing cannabis to only authorized persons responding to the emergency.

3.13 The COO, CEO, or CEO's designee, has discretion to authorize and order an emergency transfer of cannabis from an unsecure company facility to a secure company facility if the transfer is reasonably necessary to ensure the security of the cannabis product in compliance with applicable rule.

3.14 The COO, CEO, or CEO's designee, has discretion to authorize and order an emergency transfer of cannabis from a company facility to a secure company facility during a systems failure if the transfer is reasonably necessary to ensure the safety and security of the product.

3.15 Before cannabis is transported during an emergency, the COO shall designate at least two Coosa Medical Manufacturing employees to count, secure, and log cannabis onsite before transportation to a facility with operational security systems.

3.16 All medical cannabis products will only be transported by secure transporters who obey all Alabama laws and regulations.

3.17 The COO shall notify the CEO within 1 hour of an alarm or security systems failure.

3.18 All personnel must follow the procedures defined in SOP-L10 when operating backup generators.

SOP-O10: OPERATION OF BACKUP GENERATORS

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

In accordance Alabama Medical Cannabis Commission (AMCC), Coosa Medical Manufacturing trains personnel on the logistics and safe operation of gasoline-powered generators.

Location-specific user guides for each generator must be utilized in accordance with this SOP. The user guides must be reviewed and, if necessary, updated at least annually to consider safety and relevance with applicable rules.

At a minimum, employees assigned to operate backup generators must be trained annually on the procedures and safe operation of their respectively assigned generator(s) prior to assuming on-call duties. The Chief Operations Officer (COO), or their designee, is responsible for creating and maintaining the appropriate training records indicating operational and safety proficiency in the setup and use of backup generators.

2. SCOPE

It is the responsibility of the Chief Operations Officer (COO), or their designee, to ensure that on-call employees are trained to operate backup generators during a power failure.

It is the responsibility of Security to monitor security systems and notify on-call employees within five (5) minutes of a power failure to mobilize and activate backup generators within sixty (60) minutes before battery backup systems fail.

3. OPERATION OF BACKUP GENERATORS

3.1 Coosa Medical Manufacturing security personnel are responsible for monitoring security alarm and camera systems, including required devices to operate the systems, at all times.

3.2 Security personnel shall contact the COO, or their designee, and the appropriate on-call employee(s) within five (5) minutes of a power failure.

3.3 Security personnel shall assist on-call employees as needed during the power failure.

3.4 Only employees trained to operate the generator may use the generator. On-call employees must be trained to operate the generator for the location(s) assigned to them before assuming the responsibilities of an on-call employee. Training for the purposes of this section must occur at least annually. A list of approved users will be kept and managed.

3.5 The generator must be inspected for low oil, low fuel, or leaks prior to operation monthly. Preventative maintenance and inspection records will be kept with the generator.

3.6 On-call employees must be onsite of power failure ready to activate and operate backup generators within 30 minutes of receiving notice of power failure from security personnel.

3.7 Generator power must be disconnected whenever main power is restored.

3.8 On-call employees must follow the generator's operating manual and safe operating procedures.

3.9 Gas generators **must** be operated outside. Doors may be propped open, if necessary, to allow passage of heavy duty extension cables into server rooms. Security must closely monitor rooms where doors are propped open. At least one employee must

monitor the operation of the generator and at least one employee must remain present at an outside door propped open.

3.10 Employees may purchase only regular grade gasoline to continue operation of generator. The amount of gas purchased must be sufficient to maintain operation of security systems until main power is restored.

3.11 Employees must follow 29 CFR 1910.106 when storing and handling flammable liquids:

a. Gasoline and other flammable liquids must only be stored in approved containers based on specifications developed by the Department of Transportation, OSHA, the National Fire Protection Association and the American National Standards Institute.

b. Follow all manufacturers' guidelines for storing flammable and combustible liquids and when using electronic devices near gasoline.

c. Do not use or store gasoline near possible ignition sources such as electrical devices, oil- or gas-fired appliances, or another device with a pilot flame or spark.

d. Never store gasoline in glass or non-reusable plastic containers.

e. Never use gasoline as a cleaning agent.

f. Spills must be cleaned up promptly and all materials discarded properly.

g. No smoking under all circumstances when handling gasoline.

h. Portable gasoline containers should only be filled outdoors.

3.12 Backup generators must supplement the battery backup power within 60 minutes of main power failure.

3.13 Generators must be turned off, unplugged, and safely stored after use. Extra fuel must be safely stored.

3.14 Security personnel must submit an incident report that includes the following information to the COO, or their designee, within 24 hours of the incident: Names of all personnel responding, description of the power failure, date, time, duration, corrective action taken, and any other pertinent information.

SOP-O11: EMPLOYEE CORRESPONDENCE WITH GOV. AGENCIES

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical Manufacturing has and will continue to maintain courteous and honest communication with all state and federal agencies. When not required by law, Coosa Medical Manufacturing is not obligated to correspond with state and federal agencies beyond necessary communication for the normal operation of business.

The Director of Compliance or an Executive must be included in all official, company-related communications between Coosa Medical Manufacturing, LLC and government agencies regardless of whether an employee or a representative of a government agency initiates conversation concerning Coosa Medical Manufacturing, LLC. This rule applies to all state or federal government agencies. Permission to exclude the Director of Compliance or an Executive, from further correspondence between an employee and government agency must come from either the Director of Compliance or an Executive.

2. SCOPE

It is the responsibility of all employees to abide by this policy.

3. DEFINITIONS

Executive in this policy is defined as a C-level executive such as CEO, CMO, CFO, COO, etc.

4. RECEIVING CORRESPONDENCE

4.1 An employee, excluding the Director of Compliance and Executives, must do the following if the employee receives initial correspondence from a government agency:

a. Notify the on-duty supervisor; and

b. Not respond until the Director of Compliance or an Executive is notified of the correspondence and provides written or verbal notice to the employee or employee's supervisor that further action may be taken.

5. INITIATING CORRESPONDENCE

5.1 An employee, excluding the Director of Compliance and Executives, must do the following if the employee receives initial correspondence from a government agency:

a. Notify the on-duty supervisor; and

b. Not respond until the Director of Compliance or an Executive is notified of the intent to communicate with the government agency and provides written or verbal notice to the employee or employee's supervisor that further action may be taken.

6. EXCEPTIONS

6.1 An employee may initiate communication and respond to government correspondence without prior approval for the following situations:

a. Requests to make corrections to grammatical or spelling errors.

b. Requests to make changes (Patient Registry).

c. Other correspondence involving technical registration or technical registrar issues.

7. INSPECTIONS

7.1 Unless multiple inspections occur simultaneously at different sites, the Director of Compliance should be present at every inspection. For the rare instances in which the Director of Compliance, designee, or Executive is unable to be present during an inspection, Managers, designees, and/or Leads on-site may begin an inspection.

7.2 Employees must be ready and compliant at all times.

7.3 Employees should be courteous and respectful to inspectors.

7.4 Employees may only answer government inspection-related questions with replies that fall within the scope of their job description.

7.5 If an employee does not know the answer to an inspection question or the questions is outside their job description, the employee must defer and refer to a supervisor.

SOP-O12: RECORD CONFIDENTIALITY

TABLE OF CONTENTS

Pages: 1 of 9	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical has adopted this Records Confidentiality Policy to provide confidentiality in accordance with Company policy and applicable law for records of employees, clinical trial records of patients, vendors, and visitors.

2. SCOPE

All persons authorized to release medical records and information must read, understand, and comply with this policy.

The Chief Medical Officer, or their designee, and Director of Compliance are responsible for reviewing the laws and regulations specified in this SOP, any new laws and regulations, and amending this policy to comply with changed provisions.

3. ASSUMPTIONS

3.1 Medical practice has a legal and an ethical responsibility to preserve the privacy and confidentiality of sensitive information, and Coosa Medical will likewise preserve the privacy and confidentiality, to the extent permitted by applicable law, of its employees, visitors, and vendors. Accordingly, all personnel will adhere strictly to this basic principle: the individual's prior consent, authorization, or an opportunity to object or a ground specified in the privacy regulations that does not require such consent, authorization, or opportunity to object is required before use or disclosure of patient information.

3.2 Although patient medical records are the "property" of the practice, patients have rights of access to the information contained in the records.

3.3 Other than disclosures authorized by the AMCC Standards on the Privacy of Individually Identifiable Health Information (privacy regulations) and federal and state law, Coosa Medical must obtain a consent or an authorization or give the individual an opportunity to object to a use or disclosure in order to use or disclose medical information.

3.4 Any use or disclosure of confidential patient or other information carries with it the potential for an unauthorized use or re-disclosure that breaches confidentiality.

3.5 Coosa Medical incurs costs when releasing patient information, such as copying, postage, and so forth and may charge a reasonable fee to offset those costs.

4. ADMINISTRATIVE PROCESSES

4.1 Coosa Medical will process requests for information from patient records in a timely, consistent manner as set forth in this policy.

5. PRIORITIES AND TIME FRAMES

5.1 The following priorities and time frames shall apply to release of information requests processed by the health information department:

a. Emergency requests involving immediate emergency care of patient: immediate processing.

b. Priority requests pertaining to current care of patient: within one workday.

c. Patient request for access to own record: within three workdays.

d. Subpoenas and depositions: as required.

e. All other requests: within five workdays.

6. COURTESY NOTIFICATION TO PRACTITIONERS

6.1 Coosa Medical will notify the appropriate health care practitioner when any of the following events occur:

a. Patient or his or her representative requests information from the medical record.

b. Patient or representative requests direct access to the complete medical record.

c. Patient or representative institutes legal action.

7. MONITORING PROCESS

7.1 A Director of Infusion and Formulation will maintain a log to track the step-by-step process toward completion of each request for release of information. The Director of Infusion and Formulation will review and update this log as necessary to give proper priority to requests and to provide early intervention in problem situations. The log shall contain the following information:

a. Date request received;

b. Name of patient;

c. Name and status (patient, parent, guardian) of person making request;

d. Authority for release;

e. Reason for release;

f. Information released;

g. Date released; and

h. Fee charged.

8. FEE SCHEDULE

8.1 Coosa Medical will charge a reasonable fee to offset the costs associated with specific categories of requests. Coosa Medical will base the fee on an assessment of such factors as the costs of equipment and supplies, employee costs, and administrative overhead and shall include postage, including express mail costs when incurred at the request of the authorizing party.

8.2 Coosa Medical may waive fees for good reason and shall note the reason for waiver in the release of information tracking log.

9. PREPARATION OF RESPONSE

9.1 Unless the request specifies release of the complete medical record, Coosa Medical shall release only selected portions of the record.

10. PROHIBTION OF REDISCLOSURE

10.1 Unless a law or regulation requires a more specific prohibition on re-disclosure, each disclosure outside the practice will contain the following notice:

> **The attached medical information pertaining to [name of patient] is confidential and legally privileged. Coosa Medical has provided it to [name of recipient] as authorized by the patient. The recipient may not further disclose the information without the express consent of the patient or as authorized by law.**

11. RETENTION OF REQUEST

11.1 Coosa Medical will retain the original request, the authorization for release of information, and a copy of the cover letter in the patient's medical record for the appropriate record retention period for medical and business-related records or for not less than five years from the date of release, whichever is longer.

12. QUALITY CONTROL

12.1 The Chief Medical Officer, or their designee, shall carry out a routine audit of the release of information at least quarterly, paying particular attention to the following factors:

a. Validity of authorization.

b. Appropriateness of information abstracted in response to the request.

c. Retention of authorization, request, and transmitting cover letter.

d. Procedures for telephone, electronic, and in-person requests.

e. Compliance with designated priorities and time frames.

f. Proper processing of fees.

g. Maintenance of confidentiality.

12.2 The Director of Compliance shall give periodic in-service training to all employees involved in the release of information process.

13. CAPACITY TO AUTHORIZE

13.1 Coosa Medical requires a written, signed, current, valid authorization to release medical information as follows:

Patient Category	Required Signature
Adult patient	The patient or a duly authorized representative, such as court-appointed guardian or attorney. Proof of authorized representation required, such as notarized power of attorney.
Deceased patient	Next of kin as stated on admission face sheet (state relationship on authorization) or executor/ administrator of estate.
Un-emancipated minor	Parent, next of kin, or legally appointed Guardian/attorney (proof of relationship required).
Emancipated minor*	Same as adult patients above.
Psychiatric, drug, alcohol program patients/clients	Same as adult patients above

* State law defines which minors are "emancipated," that is, able to act as an adult. Typical factors resulting in emancipation are marriage, pregnancy, earning a living as an adult, and having moved out of the family home.

14. CONTENT AND FORMAT OF CONSENT

14.1 Coosa Medical must obtain a consent to use or disclose protected health information ("PHI") for treatment, payment, or health care operations. Such a consent must contain the following information:

a. Inform the individual that PHI may be used and disclosed to carry out treatment, payment, or health care operations.

b. Refer the individual to the statement of information practices for a complete description of such uses and disclosures and state that the individual has the right to review the notice before signing the consent.

c. State that Coosa Medical has reserved the right to change its privacy practices that are described in the notice and that the terms of its notice may change and describe how the individual may obtain a revised notice.

d. State that the individual has the right to request that the covered entity restrict how PHI is used or disclosed to carry out treatment, payment, or health care operations and state that the covered entity is not required to agree to the restriction, but that, if it does, the agreement to the restriction is binding.

e. State that the individual has the right to revoke the consent in writing, except to the extent that the covered entity has already taken action in reliance on it.

f. Signature of the individual and date signed.

15. CONTENT AND FORMAT OF AUTHORIZATION

15.1 Written authorization is required for all other uses and disclosures except those such as marketing, practice directories, and involvement of family members that require only an opportunity to object. Written authorization must contain detailed, specific information directing the release of patient information. Authorizations must include the following information:

a. Name and address of the practice;

b. Name of the patient;

c. Person or organization, including complete address, to whom the information is to be released;

d. Purpose of the disclosure;

e. Signature of the patient or duly authorized representative;

f. Date signed;

g. Information to be released; and

h. Signature of witness.

15.2 Coosa Medical shall develop and use an approved authorization form. Coosa Medical personnel will use this form whenever possible. Coosa Medical personnel shall, however, honor letters and other forms, provided that they include all the required information.

16. REVOCATION OF AUTHORIZATION

16.1 A patient or caregiver may revoke an authorization by providing a written statement to Coosa Medical. The revocation shall become effective when Coosa Medical receives it.

17. PATIENT/CAREGIVER EDUCATION

17.1 To facilitate the timely and proper release of information, a pharmacist will provide patients and/or caregivers an explanation of the release of information requirements as part of the initial consultation and/or in its notice of information practices.

18. REFUSAL TO HONOR AUTHORIZATION

18.1 Coosa Medical personnel authorized to release information will not honor a patient authorization when they have a reasonable doubt or question as to the following information:

a. Identity of the person presenting the authorization;

b. Status of the individual as the duly appointed representative of a minor, a deceased, or an incompetent person;

c. Legal age or status as an emancipated minor;

d. Patient capacity to understand the meaning of the authorization;

e. Authenticity of the patient's signature; or

f. Current validity of the authorization.

18.2 In such situations, the employee shall refer the matter to the Chief Medical Officer, or their designee, for review and final decision.

19. ELECTRONIC RECORDS

19.1 The above requirements apply equally to electronic records, such as e- mail, telefacsimile, internet, or other electronically maintained or transmitted PHI. No employee shall release electronic records without complying with this policy. See also Coosa Medical' Email Policy, Telefacsimile Policy, and Internet Policy.

Laboratory Standard Operating Procedures

SOP-L01: PERSONNEL, RECORDS, SAFETY, AND SECURITY IN THE PROCESSING AREA

TABLE OF CONTENTS

Pages: 1 of 6	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All activities and personnel involved in the cannabis process are closely monitored by security. As the foundation of medicinal product, it is important that cannabis plants remain safe from biosecurity hazards and that access to the plants is limited. It is also important that personnel feel safe in their work environment. Work safety includes not only personal safety, but also keeping the company and staff safe through anti-diversion techniques.

2. SCOPE

It is the responsibility of the Director of Infusion and Formulation to ensure that all safety and security guidelines are practiced in the processing areas. These policies apply to all Coosa Medical Manufacturing personnel, including those not regularly assigned to the processing area.

3. ACCESS TO THE PROCESSING AREA

3.1 Personnel Access

a. All personnel assigned to work regularly in the processing area will be given access to the processing area by the Director of Security, or designee.

b. Access to the processing areas requires a retinal scan and a picture identification card specifically programmed to allow access into the processing area. Access will be granted upon employment with the company.

c. Other personnel may also have access to the processing area and access will be determined on a case-by-case basis pursuant to SOP-S01.

d. Unauthorized access will be reported by security to the employee's supervisor for possible discipline.

3.2 Guest access

e. Personnel are not allowed to bring guests into the processing area without the prior permission of the CEO, CMO or COO.

f. Guest tours may be arranged and approved by the CEO, CMO, or COO.

g. Visitors to processing and handling areas shall wear appropriate protective clothing and adhere to all personal hygiene provisions.

4. PERSONNEL

4.1 Knowledge

h. The processing staff should have adequate knowledge of cannabis. This should include botanical identification, all processing and environmental requirements (fertility, plant spacing and lighting requirements), as well as the means of pruning techniques, harvest, and storage.

g. The processing staff involved in the propagation, harvest and post-harvest processing stages of medicinal plant production should maintain appropriate personal hygiene. Personnel who handle medicinal plant materials shall maintain a high degree of personal cleanliness and, where appropriate, wear suitable protective clothing and gloves and footwear. Personnel should always wash their hands at the start of handling activities and after handling medicinal plant or contaminated materials.

h. All personnel known, or suspected, to be suffering from or to be a carrier of disease or illness likely to be transmitted through cannabis plant material should take appropriate precautions to avoid contamination of medicinal plant materials. Persons suffering from disease or illness shall report to management.

5. RECORDS (COOSA MEDICAL MANUFACTURING)

5.1 The Coosa Medical Manufacturing software utilizes a cloud-based server for batch information storage.

5.2 Coosa Medical Manufacturing Global Instructions:

i. The software is split into two operations: Growing and Packaging. All steps prior to 3rd party laboratory sampling are performed in the Grow operation, and all subsequent steps are performed in the Packaging operation. These operations are accessed by a drop down menu at the top of the screen after successful login.

j. When cannabis material is moved between different rooms, it must be recorded on Coosa Medical Manufacturing using the Grow/Plants/Manage Plants pathway.

k. A process involving a quantification of cannabis material (seed/clone count, plant death, non-viable seed/clone, determination of male plant, weight of waste, unfinished, or finished product, etc.) requires verification. Verification is completed by the written record and signature of the employee who completes quantification.

6. BIOSECURITY

6.1 Prohibition on Chemicals

l. The Director of Infusion and Formulation must first approve chemicals that will be brought into the processing areas. The Director of Infusion and Formulation is responsible to limit acceptance of chemicals to only chemicals that were purchased or approved, in containers that are not damaged and are clearly and properly labeled and legible (name of product, active ingredient(s), concentration, manufacturer's name and contact information).

m. All chemicals must be applied by the appropriate person as identified by the Director of Infusion and Formulation and according to label instructions and must be stored appropriately.

n. Personnel are strictly prohibited from bringing chemicals into the processing area unless instructed to do so for work purposes.

6.2 Uniforms

o. All personnel are required to wear uniforms provided by the company when working in the processing area. Uniforms will be assigned to each individual employee.

p. Uniforms are not allowed to leave the manufacturing facility at any time, except when taken to be cleaned. Uniforms worn outside the manufacturing facility must not be worn again.

q. Employees are required to wear shoes that have not been outside the facility. Employees will be provided shoes by the company or may purchase shoes for their own use. All shoes must be kept in the locker room after the work day has ended and must not leave the facility or ever be worn outside the manufacturing facility.

7. PERSONAL PROTECTIVE EQUIPMENT

7.1 Eyewear

r. UV eyewear is provided to every employee that will be working in rooms with bright lighting. This eyewear is encouraged to be worn at all times when working in rooms with bright lighting.

7.2 Skin covers

s. Gloves will be provided to employees for use when working with plant material.

t. Gloves must be worn during harvest and curing.

u. Personnel will also be provided with arm covers for use when working with plant material to prevent oils from sticking to skin. If oils do contact the skin, personnel will be required to clean off any cannabis oils using appropriate methods.

8. PROHIBITION ON DIVERSION

8.1 Legal Consequences

v. Alabama Medical Cannabis Law states that an employee of a medical cannabis manufacturer who intentionally diverts medical cannabis to a person not approved by the registry program is guilty of a felony.

w. An employee who intentionally diverts product from the processing area will be subject to immediate termination.

8.2 Diversion Inspections

x. It is the responsibility of the Director of Infusion and Formulation, or an assignee of the Director of Infusion and Formulation, to do a daily inspection of the cannabis plants to detect suspected diversion.

y. The diversion inspection includes a visual inspection of each plant for noticeable and unexplainable parts of the plant that may be missing. The inspection also includes a daily count of all plants to ensure that no whole plants are missing.

z. The Director of Infusion and Formulation is responsible for the creation and maintenance of a diversion inspection record for the plants. The record must include the date, time, initials of the employee conducting the inspection, description of any discrepancy, and corrective action. Blank and in use forms should be kept in the propagation room and completed forms should be kept by Director of Infusion and Formulation.

aa. If part of the plant is missing and cannot be explained, the Director of Infusion and Formulation must immediately report the incident to the Director of Security, or designee, Chief Operations Officer, and the Director of Compliance for an internal investigation.

SOP-L02: ORGANIZATION & TRAINING

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All activities and personnel involved in cannabis extraction, drug formulation, and internal/external quality efforts are to be overseen by the Processing Director. Training of new employees involved in these activities will be carried out in accordance with this SOP.

2. SCOPE

It is the responsibility of the Processing Director to ensure that all laboratory employees are properly trained in accordance with laboratory SOPs and that this training is properly documented.

3. PROCESS OVERVIEW

3.1 Organization of Laboratory Operations

a. It is the role of the Processing Director to oversee all lab activities involving extraction of cannabinoids, internal/external product testing for product composition, quality, and stability, and inventory management.

It is the role of the Director of Formulation to oversee all formulation and packaging efforts; reporting to the Processing Director.

3.2 Training of Lab Employees

a. Laboratory employees are required to be trained on all laboratory SOPs and several security SOPs (see Laboratory Operations Training Checklist).

The Processing Director or the Director of Formulation and Packaging will personally review all SOPs with new employees prior to scheduling hands-on laboratory training. This training will be documented using the Laboratory Operations Training Checklist.

On the job training of new employees will be led by the Processing Director or the Director of Formulation and Packaging in accordance with laboratory SOPs.

SOP-L03: HYGIENE

TABLE OF CONTENTS

Pages: 1 of 5	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Personal hygiene is an important factor to consider when working in a pharmaceutical laboratory. Maintaining good housekeeping within the laboratory is essential. The following SOP addresses hygiene requirements put in place by Coosa Medical Manufacturing to comply with regulations outlined by the Alabama Department of Health and other state and federal agencies.

2. SCOPE

Laboratory personnel will comply with all hygiene requirements while working in the extraction laboratory.

3. REFERENCES

The hygiene standards and practices outlined in this document were written in compliance with the following rules and regulations set forth by the state of Alabama.

4. DEFINITIONS

Contaminated material is material that has been contaminated with cannabis oil.

Plant material is material or residue from a cannabis plant.

5. LABORATORY PERSONNEL: HYGENE AND ATTIRE STANDARDS

5.1 Proper Handwashing Practices

a. All laboratory personnel must thoroughly wash hands with soap and warm water for about 15 – 20 seconds prior to beginning work in the laboratory.

b. Hand washing is required prior to leaving the laboratory.

c. Lab employees are expected to immediately wash hands when hands have become soiled or contaminated.

5.2 Proper Laboratory Attire

a. All laboratory personnel must wear proper laboratory attire upon entering the laboratory.

b. Clothing: All laboratory personnel are required to wear a clean shirt and pants. Shirts will be provided clothing designated for the laboratory. Options include scrubs, knit pants, t-shirts, or sweatshirts – no pockets allowed.

c. Footwear: Laboratory personnel will have designated laboratory footwear. The footwear must not leave the production facility premises and must never have been worn outdoors.

d. Additional attire may be required when working with medical cannabis product, including but not limited to: hair nets, face masks, disposable sleeves, safety glasses or goggles, and/or nitrile gloves.

5.3 Personal Protective Equipment

a. Heat-resistant gloves must be worn when handling hot items.

5.4 General Hygiene Practices

a. An employee with a communicable disease will not perform tasks that might contaminate plant material or medical cannabis.

b. All employees will be responsible for maintaining personal cleanliness.

6. LAB SANITATION

6.1 Work Surface Sanitation

a. Before and after use, all laboratory surfaces are to be wiped clean with 200 proof ethanol.

b. Any equipment that is used during product formulation or packaging must be sprayed with 70% ethanol solution prior to use. The solution must sit for at least 5 minutes before wiping clean.

6.2 Utensil and Equipment Cleaning Procedures

a. Before use, all equipment is to be sanitized using a 70% ethanol solution, allowing the solution to soak for 5 minutes prior to wiping clean with a paper towel.

b. After use, remove residual cannabis by soaking utensils in 200 proof ethanol.

c. Upon ethanol removal of residual cannabis, the utensils are to be thoroughly washed with soap and water. Then, sanitized with 200 proof ethanol.

d. Once clean and dry, all equipment is to be returned to its designated location.

6.3 Waste Practices

a. For further detail on waste management practices, see SOP-L16.

b. Plant material must be removed from surfaces and floors and disposed of in a designated “Plant Waste” receptacle. All plant material waste must be accurately weighed and logged on the AMCC Waste Inventory Form.

c. Cannabis-contaminated material must be collected separately and disposed of in the “Medical Cannabis Waste” receptacle. All medical cannabis waste must be weighed and logged on the AMCC Waste Inventory Form.

d. Liquid cannabis waste (i.e. ethanol used for cleaning) is to be stored in solvent waste storage containers. Liquid cannabis waste must be weighed and logged on the AMCC Waste Inventory Form.

e. Regular waste that is non-hazardous and non-contaminated waste is to be disposed of in a regular trash receptacle.

f. Litter and waste will be routinely removed from the lab for waste disposal to minimize the development of odor and the potential for waste becoming and attractant, harborage, or breeding place for pests.

7. SAFETY CONSIDERATIONS AND PRECAUTIONS

7.1 Ethanol and other flammable solvents are to be stored in the flammable cabinet located in the laboratory.

7.2 CO2/O2 sensors are located at various locations within the laboratory to monitor air composition.

7.3 Gas cylinders are secured to the wall using a chain.

7.4 When laboratory work is being performed, two scientists should be present when possible. If a scientist is conducting laboratory work alone, the scientist must first tell security and carry a radio issued by security.

SOP-L04: BIOSECURITY PLAN

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Ensuring the health and wellness of our staff is of upmost importance. The following SOP addresses biosecurity requirements put in place by Coosa Medical Manufacturing to comply with regulations outlined by the Alabama Department of Health and other state and federal agencies.

2. SCOPE

Laboratory personnel will comply with all biosecurity requirements while working in the extraction laboratory.

3. REFERENCES

The biosecurity standards and practices outlined in this document were written in compliance with the following rules and regulations set forth by the state of Alabama.

4. LABORATORY PERSONNEL: HYGENE AND ATTIRE STANDARDS (See SOP-L03)

4.1 Proper Handwashing Practices

a. All laboratory personnel must thoroughly wash hands with soap and warm water prior to beginning work in the laboratory.

b. Hand washing is required prior to leaving the laboratory.

c. Lab employees are expected to wash hands at any other time during the workday when hands have become soiled or contaminated.

4.2 Proper Laboratory Attire

a. All laboratory personnel must wear proper laboratory attire upon entering the laboratory.

b. All laboratory personnel are required to wear a clean shirt and pants. Shirts will be provided by Coosa Medical Manufacturing.

c. Footwear: Laboratory personnel will have designated laboratory footwear. The footwear must not leave the production facility premises and must never have been worn outdoors.

d. Additional attire may be required when working with medical cannabis product, including but not limited to: hair nets, face masks, disposable sleeves, safety glasses or goggles, and/or nitrile gloves.

5. PRODUCT STORAGE (See SOP-L15)

5.1 All production rooms within the manufacturing facility are cleaned regularly and kept in an orderly manner. The cleaning of these rooms is the responsibility of those whose job function resides in the room. These rooms are secured and kept in an insect, rodent, bird, and pest-free state.

5.2 The packaging material chosen for the various forms of medical cannabis products is designed to prevent contamination (physical, chemical, and microbial) of the medical cannabis during storage.

5.3 All containers with cannabis or medical cannabis must be securely covered to prevent contamination.

SOP-L05: EXTRACTION EQUIPMENT OPERATION AND CLEANING

TABLE OF CONTENTS

Pages: 1 of 5	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Extraction of cannabinoids and terpenes from plant material is an essential process in the production of cannabis oils used in our drug formulations. At Coosa Medical Manufacturing, cannabis oil is extracted using super critical CO2 – *no hydrocarbon-based extraction processes are used.*

2. SCOPE

This SOP outlines that operation and cleaning of both the Apeks 1500 1 L and Apeks 2000 psi 5LDx5LD super critical CO2 extractors. Laboratory personnel will perform all extraction and cleaning runs in accordance with this SOP.

3. REFERENCES

Operation of the Apeks 1500 psi 1 L and Apeks 2000 psi 5LDx5LD Botanical Oil Extraction Systems are thoroughly outlined in the Owner's Manual accompanying each extraction system.

4. DEFINITIONS

Supercritical CO2 extraction: CO2 extraction performed at conditions exceeding 1083 psi and 88^{o} F.

5. OPERATION OF APEKS 1500 EXTRACTION EQUIPMENT (BENCHTOP)

5.1 Performing an Extraction

a. The procedure for performing an extraction run is outlined on pages 16-23 of the Owner's Manual.

Ensure that the extractor is vented and all pressure gauges read 0 psi; unscrew the bolts on the top of the extraction vessel with an impact wrench and remove lid.

Load the extraction vessel with 270 g ground plant material (ground according to SOP-L05); packing the material with a 1" wooden dowel. Record weight of ground plant

material in the Extraction Notebook, along with relevant run parameters (direction of flow, run time, etc.).

Replace the lid and tighten bolts; verify that the chiller is on and set to 65 º F / 18.3 º Celsius.

Verify that the main power switch is turned on (black switch above green start button); ensure that all values are closed.

Open valves 1 and 4 for top to bottom flow or 2 and 3 for bottom to top flow.

Ensure that the main valve on the CO2 tank is open and that the pressure is above 500 psi; press and hold the "START" button for 3 seconds.

Set the desired extract time (1, 4, 6, or 8 hours) by pressing the green button; default is 4 hours. We typically select 6 or 8 hour run times for maximum yield.

5.2 Recovering Extracted Oil

a. Following extraction, the extractor will automatically begin CO2 recovery and will shut down when finished.

Close the valve on the CO2 cylinder; once all pressure gauges read 0 psi, it is safe to open the extraction and separator vessels.

When all pressure gauges read < 200 psi, slowly open both vents (valve 5 and the separator vent assembly) to depressurize the system.

Unscrew the bolts securing the clamps on the top and bottom of the separator vessel; the extracted oil will be primarily contained within the collection cup located at the bottom of the vessel. Use the round squeegee tool to scrape cannabinoids from the sides of the separator vessel. Record weight of recovered oil in the Extraction Notebook.

5.3 Cleaning and Maintenance of the Extractor

a. Open the lids of both the extraction vessel and Separator 1.

Flush both the separator inlet and outlet line with 200 proof ethanol according to the instructions outlined in the Owner's Manual listed on pages 20-21.

Remove spent plant material using a Shop-Vac vacuum; reseal the vessel.

Before extracting a new cannabis strain, perform a 1-hour cleaning run with an empty extraction vessel (just CO2). Record details of all cleaning runs in the Extraction Notebook.

Perform all routine maintenance (changing pump seals, addition of coolant to the chiller, changing the coalescent filter) in accordance with the manufacturer's guidelines (outlined in the Owner's Manual – pages 28-40). Record all maintenance in the Extraction Notebook.

6. OPERATION OF APEKS 2000 EXTRACTION EQUIPMENT

6.1 Performing an Extraction

a. The procedure for performing an extraction run is outlined on pages 22-34 of the Owner's Manual.

b. Ensure that the extractor is vented and all pressure gauges read 0 psi; use rubber mallet to open lids on extractor vessels.

c. Load each extraction vessel (a & b) with 1,000g ground plant material (ground according to SOP-L05). Record weight of ground plant material in the Extraction Notebook, along with relevant run parameters (direction of flow, run time, etc.).

d. Replace the lids and use rubber mallet to tighten; verify that the chiller is on and set to 80 ^{o} F.

e. Evacuate the system by pressing the 'Evacuate' button on the Maintenance screen. Connect vacuum pump and pump system down to 25 in Hg. Close Valve 10 and disconnect vacuum pump.

f. Verify that valve 10 is closed. Press 'Tare' button on screen. Press the green "START" button and follow prompts on screen to set parameters.

g. Ensure that the main valve on the CO2 tank is open and that the pressure is above 500 psi.

h. After 20 minutes of run time, record the extractor temperature and separator pressure in lab notebook.

6.2 Recovering Extracted Oil

a. Following extraction, the extractor will automatically begin CO2 recovery and will shut down when finished.

Close the valve on the CO2 cylinder; slowly open valve 10 to depressurize the system. Once all pressure gauges read 0 psi it is safe to open the extraction and separator vessels.

Unscrew the bolts securing the clamps on the top and bottom of the separator vessel; the extracted oil will be primarily contained within the collection bowl located at the bottom of the vessel. Use the round squeegee tool to scrape cannabinoids from the sides of the separator vessel. Record weight of recovered oil in the Extraction Notebook.

6.3 Cleaning and Maintenance of the Extractor

a. Remove spent plant material from extractor vessels using a Shop-Vac vacuum; reseal the vessel.

Before extracting a new cannabis strain, perform a 1-hour cleaning run with an empty extraction vessel (just CO_2). Record details of all cleaning runs on paper located on the back of the extractor.

Clean separator 2 as needed; this is dependent on the amount of carryover into the separator vessel per extraction run.

Perform all routine maintenance (changing pump seals, addition of coolant to the chiller, changing the coalescent filter) in accordance with the manufacture's guidelines (outlined in the *Owner's Manual* - pages 38-39). Record all maintenance in the Extraction Notebook.

SOP-L06: GRINDING PLANT MATERIAL FOR EXTRACTION

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Prior to supercritical CO2 extraction, dried cannabis must first be ground to a coffee-ground consistency. This SOP outlines the protocol for grinding dried plant material.

2. SCOPE

Laboratory personnel will carry out grinding of cannabis according to the steps outlined in this SOP.

3. DEFINITIONS

Robo Coupe: Industrial grade food processor.

4. PROTOCOL FOR GRINDING CANNABIS

4.1 Obtain dried plant material in properly sealed and labeled containers from the Team; reweigh the contents to confirm that the weight listed on container.

4.2 Determine which strain is to be extracted and where it fits within the general Coosa Medical Manufacturing product offering:

a. Cobalt: CBD > THC

b. Heather: CBD = THC

c. Tangerine: CBD < THC

4.3 Measure humidity of the dried cannabis using a hydrometer, taking a reading after 15 minutes. Record humidity reading in the Extraction Notebook.

4.4 Place dried plant material in the Robo Coupe until full.

4.5 Firmly attach lid.

4.6 Turn on machine by pushing the green “On” button.

4.7 Set RPM between 2,000 and 2,500 RPM.

4.8 Rotate the plastic scrapper attached to the lid to expose all plant material to the blades.

4.9 When the plant material has reached a uniform consistency, turn off the machine by pushing the red “Off” button.

4.10 Remove lid and Robo Coupe container from the base.

4.11 Weigh and transfer ground plant material to extraction vessel.

SOP-L07: DECARBOXYLATION OF RAW CANNABIS OIL

TABLE OF CONTENTS

Pages: 1 of 2	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

For cannabis oil to be orally active, tetrahydrocannabinolic acid (THCA) and Cannabidiolic acid (CBDA) must be decarboxylated to tetrahydrocannabinol (THC) and Cannabidiol (CBD). This is accomplished by heating.

2. SCOPE

Laboratory personnel will carry out decarboxylation of raw cannabis oil per this SOP.

3. DEFINITIONS

Tetrahydrocannabinol (THC): The principle psychoactive component of Cannabis.

Tetrahydrocannabinolic acid (THCA): A biosynthetic, non-psychoactive component of cannabis.

Cannabidiol (CBD): A non-psychoactive component of cannabis known for its anti-seizure properties.

Cannabidiolic acid (CBDA): Acidic form of CBD.

4. PROCESS FOR DECARBOXYLATION

4.1 Transfer raw cannabis oil to a tared glass beaker; record weight in the Extraction Notebook.

4.2 Place vessel on hot plate with integrated temperature probe.

4.3 Heat oil to 130°C with constant stirring until decarboxylation has reached completion. Time of decarboxylation is one minute per gram of raw oil.

4.4 Test for cannabinoid content by HPLC.

SOP-L08: ASSIGNING PRODUCT BATCH NUMBERS

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All medical cannabis products produced by Coosa Medical Manufacturing will be assigned a unique lot number which will allow us to easily track when and how it was made.

2. SCOPE

Laboratory personnel will assign unique lot numbers to finished formulated products based upon the year in which it was produced and the Product Notebook in which the formulation notes were recorded. In-process samples will be assigned unique batch numbers based upon the Extraction Notebook and page in which notes were recorded.

3. ASSIGNING PRODUCT LOT NUMBERS

3.1 All Coosa Medical Manufacturing product formulations will be documented in a designated Product Notebook to store product information. Lot numbers will be derived from notebook-specific information adhering to the following format:

Lot Number: **YYNNNPPP-F**

YY = Two-digit year

NNN = Notebook number

PPP = Notebook page number

F = Formula number on page

Example: 15001020-2, where 15 designates 2015, 001 is the lab notebook number, 020 is the page number, and 2 designates it as the second formula listed on the page.

4. ASSIGNING IN-PROGRESS BATCH NUMBERS

4.1 All Coosa Medical Manufacturing in-process batches will be documented in a designated Extraction Notebook to store batch information. Batch numbers will be derived from notebook-specific information adhering to the following format:

Batch Number: **NNN-PPP.*S***

NNN = Notebook number

PPP = Notebook page number

S = Sample number on that page

Example: 004-021.1, where 004 is the lab notebook number, 021 is the page number, and 1 designates it is the first sample listed on the page.

SOP-L09: PACKAGING AND LABELING

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

The Alabama Medical Cannabis Commission (AMCC) has specific guidelines about the packaging and labeling of medical cannabis. This SOP outlines Coosa Medical Manufacturing chosen packaging and labeling practices that abide by the state-mandated parameters.

2. SCOPE

Laboratory personnel are expected to understand and follow all regulations set forth by the AMCC in regards to packaging and labeling.

3. REFERENCES

The packaging and labeling protocol outlined in this document were written in compliance with the following rules and regulations set forth by the State of Alabama.

4. PRODUCT LABELING PROTOCOLS

4.1 Required Information on Labels

a. It is the responsibility of laboratory personnel to ensure that all products are properly labeled.

b. Required information for labels added during manufacturing:

   i. Coosa Medical Manufacturing, LLC and current address
   ii. Chemical composition of the medical cannabis medication
   iii. Complete ingredient list, listed with common and unusual names. This includes and colors, artificial flavors, or preservatives. Ingredients are to be listed in descending order by % weight composition.
   iv. Date of manufacture
   v. Batch number

c. Large container bottles will come pre-labeled with required notice statement.

5. PACKAGING PROTOCOLS

5.1 Tinctures Sprays

a. Prepare products pursuant to SOP-L08.

b. Once products are prepared, containers are to be filled by weight, including an appropriate overfill to account for product loss in the container (1 mL for tinctures sprays).

c. Laboratory personnel are responsible for ensuring that the container is tightly sealed post-filling.

d. Containers will then be labeled with an inner label that contains the Batch Number, Coosa Medical Manufacturing information, and a statement that the product contains medical cannabis.

e. Once labeled, the container is wrapped with a cotton coil.

f. Once wrapped, the upright container is placed in the HDPE over-pack.

g. The child-resistant cap is placed on the HDPE over-pack and the container is induction sealed.

h. Once properly packaged, the out bottle is labeled pursuant to this SOP.

5.2 Oral Suspensions

a. Prepare product pursuant to SOP-L08.

b. Once the product is prepared, the bottle will be filled by weight, incorporating a 6 mL overfill.

c. Once filled, close with a child-resistant cap and induction seal.

d. Once properly packaged, the bottle is labeled pursuant to this SOP.

SOP-L10: RECEIVING DELIVERIES AND SHIPPING PRODUCT

Pages: 1 of 1	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. Deliveries will only be received by a licensed secure transporter in our shipping and receiving room. All product will be inspected for quality, counted and audited to ensure that it matches the transport manifest, and then placed into our quarantine cage to undergo additional testing.

2. All delivered received will follow the applicable shipping and receiving regulations (See Chapter 6 and 7).

3. All product being shipped will be shipped by a licensed secure transporter.

SOP-L11: ANALYTICAL TESTING

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical Manufacturing has contracted with Legend Technical Services, INC. to fulfill all analytical testing needs. A sample of products intended for sale will be submitted to Legend for the Certificate of Analysis to ensure product safety and integrity.

2. SCOPE

Laboratory personnel are expected to understand and follow all regulations set forth by the AMCC in regards to packaging and labeling.

3. REFERENCES

The Analytical Testing protocol outlined in this document were written in compliance with the following rules and regulations set forth by the AMCC.

4. OPERATING REQUIRMENTS AND PROCEDURES

4.1 Random Sampling Procedure

a. During packaging, a single sample of the bulk product from each batch is to be taken and submitted to Legend Technical Services, INC. (Legend) for testing.

b. Samples must be taken from the bulk product to ensure a random sample of the entire product.

4.2 Submission of Samples

a. Samples for testing are to be labeled with the product name and assigned a batch number.

b. Chain of Custody forms provided by Legend are to be filled out and submitted electronically prior to sample delivery.

4.3 Required Analytical Tests

a. It is the responsibility of laboratory personnel to ensure that testing includes cannabinoid and terpene profiles, metals, pesticides, and microbial load.

4.4 Retention of Reports

a. All documentation related to analytical testing is to be retained for at least five years. Chain of Custody Forms, laboratory reports, and Certificate of Analyses will be stored electronically pursuant to SOP-O02 and in print in the laboratory.

SOP-L12: QUALITY ASSURANCE

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical Manufacturing has internal guidelines in place to assess product quality, safety, and batch-to-batch reproducibility.

2. SCOPE

Laboratory personnel are expected to use laboratory/Certificate of Analysis (COA) data obtained from Legend Technical Services, INC. to assess product quality, safety, and identify batch-to-catch variation.

3. QUALITY ASSURANCE REQUIRMENTS

3.1 Acceptance Criteria for Contaminants

a. The acceptance criteria for contaminants in excipients and finished products is the standard used to assess the safety of our products. It specifies limits for a variety of metals, toxins, pesticides, solvents, as well as bacterial, yeast, and mold.

3.2 Batch Rejection

a. It is the responsibility of laboratory personnel to review the safety test results to ensure that all values are below the acceptance criteria.

b. A batch that fails one or more tests will be re-tested to ensure accuracy.

c. If the batch fails a second time, the batch must be discarded.

d. If a batch is discarded for contamination, it is the responsibility of laboratory personnel to determine the root cause of the contamination before destroying the compromised material.

e. Laboratory personnel must review the test results for each individual raw material that was tested by Legend Technical Services, Inc. to determine the root cause of the contamination of the bulk product.

f. Laboratory personnel must document the cause of the contamination and, should future action need to be taken to avoid contamination in the future, inform all laboratory staff and update applicable procedures.

g. Contaminated waste is to be stored and destroyed pursuant to SOP-L14.

4. RETAIN SAMPLES

4.1 Collection and Packaging of Samples

a. During packaging, at least one unit will be set aside for retain with the option of another to be set aside for stability studies.

b. Samples must be packaged in the designated containers.

4.2 Storage of Samples

a. Samples must be stored in the vault at room temperature and be clearly labeled as a retain sample.

All retain samples are to be recorded in a log book that tracks batch number, date, and product description.

All retain samples must be kept until one year following the batch's expiration date.

All retain samples will be documented pursuant to SOP-L14.

SOP-L13: PRODUCT STABILITY TESTING

TABLE OF CONTENTS

Pages: 1 of 2	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical Manufacturing is committed to performing ongoing product stability testing of medical cannabis to comply with the guidelines set forth by the AMCC. This testing will allow us to determine optimal storage conditions and product shelf life.

2. SCOPE

Laboratory personnel are expected to collect and perform stability studies in accordance to what is outlined in this SOP.

3. EXPIRATION DATE OF MEDICAL CANNABIS

3.1 Based on limited research, the current expiration date for all medical cannabis products is 1 year. Ongoing stability testing has been initiated and will continue indefinitely to better define product expiration dates. Stability testing is performed by Legend Technical Services in accordance with applicable regulations.

4. STABILITY TESTING

4.1 Testing Protocol

a. Stability samples will be fully packaged.

b. Stability samples will be submitted and stored at Legend Technical Services according to package instructions.

Legend will perform potency testing at the following time points: 0, 3, 6, 9, 12, and 18 months.

Additional stability samples will be maintained at Coosa Medical Manufacturing.

SOP-L14: CANNABIS STORAGE

TABLE OF CONTENTS

Pages: 1 of 5	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

To comply with AMCC regulations, all medical cannabis, regardless of stage of processing, has to be stored in a secure environment away from risk of contamination, diversion, theft, or loss. At the close of business each day, a medical cannabis manufacturer must reconcile all medical cannabis at the manufacturing facility.

2. SCOPE

Extraction and Formulation scientists are expected to ensure that all plant material, extracted oil, and finished products are securely packaged and stored to resist theft and contamination.

3. REFERENCES

The storage practices outlined in this document were written in compliance with the following rules and regulations set forth by the state of Alabama.

4. DEFINITIONS

- Plant Material: dried flower biomass including trichomes, calyxes, stems, and branches.
- Medical Cannabis: extracted oils, formulated products awaiting packaging or shipment, and returned products.
- Other: Tanks, vessels, binds, or bulk containers containing plant material or medical cannabis.
- Secure Locations: Includes all access-controlled production rooms and the manufacturing facility and vaults.

5. STANDARD STORAGE PRACTICES

5.1 Production Rooms

a. All production rooms within the manufacturing facility are cleaned regularly and kept in an orderly manner. The cleaning of these rooms is the responsibility of those whose job function resides in the room. These rooms are secured and kept in an insect, velociraptor, rodent, bird, and pest-free environment.

5.2 Packaging Containers

a. The packaging material chosen for the various dosage forms for Coosa Medical Manufacturing products is designed to prevent contamination of the medical cannabis during storage.

All containers containing cannabis or medical cannabis will be securely covered to prevent contamination.

6. PLANT MATERIAL

6.1 Prior to Extraction

a. Plant material that has been transferred to the laboratory must be kept in containers in which it was transferred and must be stored in the vault or day room when not in use.

7. MEDICAL CANNABIS

7.1 During Formulation Process

a. Medical cannabis that has not yet been packaged is required to be stored in clean containers throughout the work day.

At the end of the workday, all medical cannabis must be moved to the vault for storage. All product must be properly labeled and covered.

7.2 Packaged Medication

a. Properly packaged and labeled medication must be stored in the vault.

7.3 Daily Inventory and Reconciliation

a. All packaged cannabis medication must be stored in a container locked with a numbered, tamper-evident tag.

All packaged cannabis medication must be counted and recorded in a daily inventory and reconciliation form that includes the date, time, batch/lot number, quantity of medication, indication whether evidence of tampering exists, and initials of the employee conducting the inventory check.

If an employee discovers that a container with packaged medical cannabis is missing a security tag or the tag number does not match the initial tag number recorded in the inventory and reconciliation form, the employee must do the following in this order:

i. Have a second employee confirm the discrepancy. If an error is corrected in the inventory records and, as a result, the subject inventory variance is explained and resolved, no further action is required. If the discrepancy is confirmed, continue the steps below.

ii. Both employees must complete a manual product inspection and count of the medical cannabis contents within the container in question. If the discrepancy is corrected after a recount, one of the employees must notify a supervisor of the correction. If the discrepancy is not correct, continue the steps below.

iii. Compare inventory log with product batch record in Coosa Medical Manufacturing or other applicable program (# of bottles made, retains, stability samples, etc.). If the discrepancy is corrected, one of the employees must notify a supervisor of the correction. If the discrepancy is not correct, continue the steps below.

iv. If inventory count is high, verify that all bottles are the same product and/or lot number.

v. If inventory count is low, ensure that product was not put in the incorrect container (if multiple products were made in a given day).

vi. If inventory log, Coosa Medical Manufacturing (or applicable program), batch record, and variance is not corrected and explained, one of the employees must notify a supervisor within the same day of the discrepancy.

vii. Either the reporting employees or a supervisor must re-seal the container and log new count in the inventory and reconciliation form after inspection is complete.

viii. Supervisor informed of the discrepancy must notify the Director of Compliance or designated employee with authorization granted by the Chief Executive Officer within 24 hours of a reported discrepancy.

ix. The Director of Compliance or designated employee will promptly initiate an investigation of the reported discrepancy, and take necessary follow-up actions.

7.4 Returned Medical Cannabis

a. Medical cannabis that is returned will be destroyed.

7.5 Contaminated Medical Cannabis

a. Medical cannabis that has been identified as being contaminated pursuant to SOP-L12 must be kept in the vault and separate from all other medical cannabis.

SOP-L15: LABORATORY WASTE MANAGEMENT

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All cannabis waste generated during extraction and formulation will be accounted for and properly disposed of according to the guidelines set forth by the Alabama Medical Cannabis Laws.

2. SCOPE

Laboratory personnel will dispose of all waste – cannabis, contaminated, and non-hazardous – according to the procedures outlined in this SOP.

3. REFERENCES

The waste management protocol outlined in this document were written in compliance with the following rules and regulations set forth by the State of Alabama.

4. DEFINITIONS

- **Plant Material**: dried flower biomass including trichomes, calyxes, stems, and branches.
- **Plant Material Waste**: Plant material that is not used in the production of medical cannabis in a form allowable under Alabama Medical Cannabis laws.
- **Medical Cannabis Waste**: medical cannabis that is returned, damaged, defective, expired, or contaminated; material/item (e.g. gloves, paper towels, filter paper) soiled with cannabis oil; solvent waste containing cannabis.
- **Other**: Tanks, vessels, binds, or bulk containers containing plant material or medical cannabis.

5. PLANT MATERIAL WASTE

5.1 Waste Collection in the Laboratory

a. A sealed pail will be used to collect all plant material waste generated by laboratory personnel.

b. Laboratory personnel will coordinate with the processing staff for compost preparation and removal of plant material gathered in the.

5.2 Transfer of Waste

a. Prior to handing over the bucket to the processing staff, plant material waste will be weighed and recorded onto the Waste Inventory Form located in the laboratory.

b. Extraction plant material will be added to other plant material waste to be ground and mixed with cocoa prior to transport.

Compostable waste will be removed from the Coosa Medical Manufacturing production facility regularly.

6. MEDICAL CANNABIS WASTE

6.1 Collection of Waste from Laboratory

a. Contaminated materials and items must be stored in their own designated waste container.

b. Once the containers are full, the waste will be weighed and recorded on the Waste Inventory Form.

6.2 Disposal

a. Waste will be transported to a qualified facility on a regular basis.

b. A transport manifest is required for each waste transport to the facility.

7. NON-CANNABIS WASTE

7.1 Trash is collected in its own designated waste container.

7.2 Laboratory personnel are responsible for placing non-hazardous waste in the hallway outside of the lab on Tuesday and Thursday evenings (days subject to change) so that janitorial staff may collect and dispose of the waste accordingly.

8. RETURNED MEDICAL CANNABIS

8.1 Collection

a. Medical cannabis that is returned to a processor will be transported to the facility pursuant to SOP-L10.

Returned medical cannabis will be stored pursuant to SOP-L14.

8.2 Disposal

a. Returned medical cannabis will be separately documented on the AMCC Waste form and properly marked as returned medical cannabis.

b. The returned products, including bottles, will be added to the medical cannabis waste to be incinerated pursuant to this SOP.

9. CONTAMINATED MEDICAL CANNABIS

9.1 Collection

a. Contaminated medical cannabis will be collected and stored pursuant to SOP-L14 and SOP-L15.

9.2 Disposal

a. Contaminated medical cannabis will be separately documented on the AMCC Waste Form and properly marked as contaminated medical cannabis.

Contaminated waste will be added to the medical cannabis waste to be incinerated pursuant to this SOP.

SOP-L16: CANNABINOID PURIFICATION BY PREPARATIVE HPLC

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Preparative high performance liquid chromatography (HPLC) is a technique used to purify components of a mixture based upon their differing interactions with an immobilized stationary phase and a liquid mobile phase. Compared to HPLC systems used for sample analysis, preparative systems operate on a much larger scale allowing for the isolation/purification of appreciable amounts of material. Coosa Medical Manufacturing employs the use of preparative HPLC to purify Cannabidiol (CBD) from raw cannabis oil which can then be used to fine tune product formulations, specifically for our Cobalt product line.

2. SCOPE

Laboratory personnel, with guidance from the Processing Director, will carry out CBD purification using preparative HPLC to be used in Cobalt formulations.

3. PURIFICATION OF CANNABINOIDS BY PREPARATIVE HPLC

3.1 Instrumentation

a. Coosa Medical Manufacturing utilizes an Agilent 1600 preparative HPLC system for CBD purification. The system is comprised of the following modules.

   i. Auto sampler
   ii. Two solvent pumps with gradient capability
   iii. UV detector
   iv. Fraction collector

The system uses the Open Lab software package for operation and data analysis.

3.2 Materials and Methods

a. Sample Preparation

   – Cannabis oil (raw or decarboxylated) is completely dissolved in 200 proof ethanol.

- Two mL of cannabis solution is filtered using a 25 µm filter and placed in an amber auto sampler vial.

Method Details

- Column: Agilent XDB-C18 21.2 x 150 mm, 5 µm (PN 970150-902); maximum pressure 400 bar.
- A gradient of HPLC grade water (A) and 200 proof ethanol (B) are used to achieve separation.
- Flow rate = 18 mL/min
- Gradient: Hold at 65% B for 1 min; increase to 90% B in 7 minutes; hold at 90% B for 1 minute
- UV signals: 200 nm, 260 nm, 280 nm

3.3 Example Chromatogram (see Image II)

3.4 Fraction Collection

a. CBD elutes as a broad peak starting at 5.5 minutes and ending at 6.5 minutes; fractions corresponding to this peak can be collected manually or using the auto sampler set to collect over this timeframe.

Collected fractions are combined in a 1000 L round bottom flask and the solvent is removed by vacuum distillation on a rotary evaporator.

The resulting CBD oil is transferred to a vial and submitted for cannabinoid potency testing to determine purity (typically 96% or greater).

SOP-L17: LABORATORY EQUIP. MAINTENANCE & MONITORING

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

To ensure that all pieces of laboratory equipment maintain high-level and consistent functionality, usage is to be tracked and regular maintenance is to be performed according to the manufacturer guidelines. All maintenance events are to be recorded in a laboratory notebook and monitored by the Director of Lab Services. Periodic checks of recorded maintenance events will be examined periodically to assess consistent functionality.

2. SCOPE

It is the responsibility of the Director of Lab Services to oversee and ensure that all maintenance events are properly documented, as well as perform periodic checks along with the Director of Compliance.

3. LABORATORY EQUIPMENT MAINTENANCE AND MONITORING

3.1 Equipment Use and Maintenance

a. All laboratory equipment is to be operated and cleaned according to manufacturer guidelines.

Use and cleaning logs for the following laboratory equipment are to be maintained by laboratory personnel in the Extraction Notebook:

- Apeks C02 extractor
- Homogenizer

Laboratory equipment subject to maintenance performed by laboratory personnel include:

- Apeks C02 extractor
- Vacuum pumps

- Chillers
- Rotary evaporators
- Homogenizer

Laboratory equipment NOT subject to maintenance by laboratory personnel include:

- Agilent 1600 Preparative HPLC
- All A&D balances

3.2 Periodic Equipment Reviews

a. The Processing Director, with the Director of Compliance, are to review all equipment logs on a quarterly basis to ensure consistent functionality.

Processing Standard Operating Procedures

SOP-P01: GELATIN SOP

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. Scope

This SOP covers the production of infused pectin-based gummies (Pate de Fruits), and the corresponding documentation.

2. Attire

Employees working in the kitchen should don hair/beard nets, nitrile gloves, and face masks.

3. Instrument Calibration

1.1 The most critical factors that determine the success of pectin-based gummies are pH and Brix. The instruments used to monitor these parameters are a pH probe and refractometer respectively. Both must be calibrated before any cooking can begin

1.2 pH probe calibration – follow the manufacturer's directions for calibrating the pH probe. Probes are typically calibrated at three points at a pH of 4, 7, and 10. Traceable solutions should be used to carry out calibration.

1.3 Refractometer calibration – In order to calibrate the refractometer, a sugar solution of known concentration must be prepared.

1.4 In a 50mL centrifuge tube, using a calibrated scale with a resolution of at least 0.01g, measure out 7.00g of sugar and 3.00g of distilled water.

1.5 Place the centrifuge tube containing the sugar solution into a hot water bath and periodically vortex the mixture until the sugar is completely dissolved. Once the sugar is dissolved remove the solution from the hot water bath.

1.6 Place enough solution onto the sight glass of the refractometer to completely cover it. Close the cover of the refractometer and read the brix value; it should read 70 Brix.

1.7 If the Brix reads any value other than 70, loosen the locking screw and adjust the bezel until the value reads 70. Retighten the locking screw.

Preparing the molds

1.8 Transferring the silicone Gelatin molds from sheet pans to the Gelatin depositor is much easier when the molds are placed on sheets of parchment paper. Cut full sheet pan sized parchment paper (16"x24") in half (16"x12") and place the cut parchment paper underneath Gelatin molds. There will be overhang on the sides; this is useful when transferring the molds.

1.9 After placing on parchment paper, Gelatin molds must be sprayed with a release agent. Load the sprayer with release agent and spray a thin even layer onto the molds. It is important to maintain a light coating of the release agent, otherwise the buildup of excess waxes could obscure the details of the mold.

Pre-melt the active ingredients

1.10 Cannabis extracts are viscous, hydrophobic, and difficult to work with. In order to ensure proper infusion, the extracts must be pre-dissolved in oil. Weigh out the cannabis oils with an equal amount of MCT oil all at a 1% overage. For example, if the recipe calls for 20g of CBD isolate and 30g of distillate, you should weigh out 20.2g of distillate, 30.3g of CBD isolate, and 50.5g of MCT oil. Place the mixture on a hot plate to fully dissolve.

Set up the Gelatin depositor

1.11 Pre-warm the depositor by turning the temperature control to both the hopper and the nozzles to 220^0 F.

1.12 Set the dispensing volume to match the molds being used Cooking

1.13. Measure out all the ingredients according to the calculations and recipe found on the Gelatin cooking batch records.

1.14. Add the water to the Gelatin cooker and turn on the heat. Watch closely, and as soon as the water starts to simmer whisk in the pectin/sugar mixture. In order to prevent

clumps from forming it is best to add the mixture while pouring through a sieve while a second person whisks thoroughly.

1.15. Once the pectin has been added, begin agitating the mixture.

1.16. Once the temperature of the solution reaches 150^0 F add in the sugar. At this point the temperature will drop while the sugar begins to dissolve.

1.17. Once the temperature reaches 150^0 F for a second time, add in the corn syrup. Continue heating and stirring.

1.18. When the solution reaches 190-200^0 F it is time to add the active ingredients.

1.19 Place the pre-weighed oil mixture onto a calibrated scale with a resolution of at least 0.01g. Tare the scale.

1.20 Add almost all of the oil mixture to the cooker. The oil mixture should have been prepared with a 1% overage to compensate for transfer loss.

1.21 Place the oil mixture back on the scale to determine how much has been added (this should be displayed as a negative value). Continue adding the oil mixture into the cooker until the quantity calculated on the batch record has been added. For accuracy, the last bit of oil can be collected on a spoon at the scale until the target value is displayed, and then added to the cooker.

1.22 Continue cooking.

1.23. At 215^0 F the mixture must be monitored closely to ensure the proper timing of ingredient additions, and to achieve the correct final sugar concentration. From this point forward, decisions and timing should be based off of Brix rather than temperature.

1.24 To check the Brix, dip a spatula into the mixture and place a sample on the viewing cell of the refractometer. Close the flap on the refractometer and ensure that the sample completely covers the viewing cell.

1.25 Hold the refractometer up to the light and look through the eyepiece. If done correctly you should see a clear line somewhere along the scale designating the Brix of the mixture. It is important to weight 60-90 seconds for a final reading, because as the solution cools the reading will change slightly.

1.26 Once the reading has been taken, quickly clean the refractometer with a wet paper towel to prepare for the next reading.

1.24. Once Brix hits 81-82 add in the flavoring. This will drop the brix value and the mixture will need to cook for a few more minutes.

1.25. When the brix hits 81-82 for a second time add in the 50% citric acid solution. This is a critical step; once the citric acid has been added the pectin will begin to set and there is a limited working time for the mixture.

Kill the heat to the to the cooker

1.26. Collect some of the mixture with a spatula and place in a 50mL centrifuge tube. Place the pH probe into the sample to get a pH reading. DO NOT PROCEED UNTIL THE TARGET pH IS CONFIRMED. The pH of the mixture should read at between 2.8-2.9 while it is still hot.

1.28 If the pH is within spec proceed to transferring and depositing.

1.29 If the pH is too low proceed to transferring and depositing. However, this batch may not set up properly and could be lost.

1.30 If the pH is too high add in 5-10 more grams of 50% citric acid solution and check again. Continue small additions until the pH is correct. Work quickly as the pectin will have begun to set up at this point.

1.31. Once the 50% citric acid solution has been added, measure the brix on last time. The final brix target is between 80-82.

1.32. Record the final pH and final Brix on the batch sheet.

4. Depositing

1.33. Once the pH and Brix are within target, transfer the entire batch into the hopper of the depositor.

1.34. Place the lid on the hopper and begin depositing. It typically takes a few cycles to prime the pistons and start depositing evenly.

1.35. Fill the molds row-by-row working quickly but steadily. The depositor handle should be moved in controlled fluid movements. Do not allow the depositor handle to spring up rapidly as this can affect the fill level.

1.36. Continue filling molds until the entire batch is completed. There is a limited working time with this formulation so depositing cannot be stopped part way through the batch.

5. Demolding and Curing

1.37. Once the batch has been deposited it should set up within 5-10 minutes. At this point the gummies should be demolded and placed on cookie racks to dry and cure.

1.38 Place the silicone mold face-down on a cookie rack and begin peeling-rolling back the edge of the mold. If done properly the gummies should fall out of the mold face-up. Using the proper amount of release agent ensures easy demolding.

1.39 Once all of the gummies have been demolded, place them on a sheet pan rack and store in the curing room overnight.

Finishing and Packaging

1.40 Remove the gummies from the curing room the morning after cooking to ensure that they don't become too dry.

1.41 Load a batch of gummies into the panning machine and begin tumbling. As they tumble the release agent should become evenly distributed throughout the batch.

The gummies should take on a glossy/satin finish and should not feel sticky or oily. If the gummies are still sticking together spray a very small amount of release agent into the panning machine while it is rotating. Use sparingly; a little goes a long way. If the gummies appear and feel oily, then too much was used.

1.42 Remove the gummies from the panning machine., and transfer to a clean sanitized table.

1.43 Count out the gummies 10 at a time into containers, performing a visual quality inspection throughout the entire batch.

1.44 Visually check for air bubbles inside of the gummies.

1.45 Check for proper “casting” of the gummies.

1.46 Ensure the THC logo on the front of the Gelatin was properly transferred from the mold.

1.47 Ensure that the sides, edges, and backs of the gummies are free of any deformation.

1.48 Put lids on the containers and store in at room temperature until the batch is ready for final labels.

SOP-P02: SUPPOSITORY SOP

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. Scope

1.1. This SOP covers the production of polyethylene glycol (PEG) based suppositories suitable for rectal and/or vaginal administration.

2. Attire

1.2. General Attire

1.2.1. Employees producing suppositories should don hair/beard nets, nitrile gloves, lab coats, and face masks.

1.3. Personal Protective Equipment

1.3.1. While producing Suppositories, employees will be handling and transferring solutions with temperatures of up to 60° C (140° F). Exposure to such temperatures can produce burns in a matter of seconds. Appropriate PPE should be utilized to minimize the risk of injury

1.3.1.1. Spill Apron – A full length spill apron that is made of a chemically resistant material, or coated in a chemically resistant material should be utilized while producing suppositories

1.3.1.2. Heat Gloves – Heat gloves must be utilized while handling vessels containing hot solutions

1.3.1.3. Close-toed Non-slip Shoes – To prevent and protect from spills, employees should wear close-toed non-slip shoes while producing suppositories

3. Preparation

1.4. Equipment and Supplies

1.4.1. Large Hot Plate – Used to melt down the Polypeg base, and to keep the solution workable.

1.4.2. Small Hot Plate – Used to melt distillate in preparation for infusion

1.4.3. Overhead Stirrer – Used to blend ingredients and to ensure the homogeneity of the batch. The impeller should be cleaned, sanitized, and completely dry before use.

1.4.4. Scale – A calibrated scale with appropriate resolution and capacity will be used to weigh active ingredients and excipients. The scale should be QC checked the day of formulation before any ingredients/excipients are weighed.

1.4.5. Suppository Mold – Used to form suppositories. The mold should be cleaned, sanitized, and completely dry before use.

1.4.6. Large Stainless-Steel Beaker – Used in conjunction with the large hot plate to melt the Polypeg base, and to homogenize the final formulation. This should be cleaned, sanitized, and completely dry before use.

1.4.7. Small Stainless-Steel Beaker – Used in conjunction with the small hot plate to melt the distillate before it is added to the Polypeg base. This should be cleaned, sanitized, and completely dry before use.

1.4.8. Stainless-Steel Ladle – Used to transfer melted solution from the large beaker into the suppository mold. This should be cleaned, sanitized, and completely dry before use.

1.4.9. Silicone Spatulas – Used to spread solution across the surface of the mold to ensure that the cavities are filled evenly. These should be cleaned, sanitized, and completely dry before use.

1.4.10. Small Lab Spatulas – Useful in mixing the distillate while it is melting, and to measure out the final drops of distillate when infusing the batch. These should be cleaned, sanitized, and completely dry before use.

1.4.11. Heat Gun – Used to pop bubbles that appear while filling the cavities of the suppository mold. It is also useful in melting down any formulation that solidifies on the sides of the large beaker during production.

1.4.12. 8-Quart Food-Grade Storage Container – Storage for finished suppositories before final packaging. This should be cleaned, sanitized, and completely dry before use.

1.4.13. Parchment Paper – Parchment paper is useful in collecting the overfill produced when casting the suppositories, and help transfer back into the large beaker for recycling

1.5. Workstation Preparation

1.5.1. Select a stainless-steel table to work on. Clean it of any dust and debris, then wipe down with IPA to sanitize.

1.5.2. Set up the large hot plate along with the overhead stirrer. Turn the hotplate on and set to 80^{o} C

1.5.3. Set up the small hotplate. Turn on and set to 80^{o} C

1.5.4. Layout the suppository mold along with all utensils to be used during production

4. Formulation

4.1. Weighing & Melting the Polypeg

4.1.1. Weigh the large beaker and record the tare weight on the side

4.1.2. Place the large beaker on the scale and tare the scale. Weigh out the amount of Polypeg base calculated on the *"Batch Records"* [reference specific document here]

4.1.3. Place the beaker and Polypeg onto the large hotplate. Lower the overhead stirrer. As the Polypeg begins to liquefy start the overhead stirrer to assist with melting.

4.2. Weighing and Melting the Distillate

4.2.1. Weigh the small beaker and record the tare weight on the side

4.2.2. Place the small beaker on the scale and tare the scale. Weigh out the amount of distillate calculated on the *"Batch Records"* [reference specific document here]

4.2.2.1. The distillate should be weighed out at a 1% overage to compensate for any transfer loss. For example, if the calculations call for 70.0g, weigh out 70.7g instead.

4.2.3. Place the beaker and distillate onto the small hotplate. Stir the distillate with a lab spatula to assist the melting process

4.3. Infusion

4.3.1. Once the Polypeg and distillate are fully melted it is time to blend them.

4.3.1.1. Place the beaker of distillate onto the scale and turn the small hotplate off.

4.3.1.2. Zero the scale with the beaker of distillate on it.

4.3.1.3. Add <u>almost</u> all the distillate to the melted Polypeg while stirring. Place the beaker back on the scale to determine how much has been added. At this point you should be close but short of the target value (displayed as a negative value on the scale).

4.3.1.4. Continue to add distillate to the Polypeg in very small quantities until you approach the target value. For example, if you are required to add 70.0g of

distillate to the batch, you should pour the distillate into the Polypeg until -68.0g to -69.0g is displayed on the scale.

4.3.1.5. To assist in transferring the last gram or so of distillate to the Polypeg, it is easiest to scoop it up into a lab spatula until the scale shows the target value exactly. At this point you can submerge the spatula with the last bit of distillate into the Polypeg. This method minimizes error as distillate is hot, viscous, and difficult to work with.

4.3.2. Continue stirring and heating the Polypeg/distillate mixture for 15 minutes before forming the suppositories.

5. Producing Suppositories

5.1. Once the formulation has been homogenized you can begin casting the suppositories in the mold.

5.1.1. Remove the overhead stirrer from the large beaker

5.1.2. Use the ladle to transfer the mixture from the large beaker over to the suppository mold. Begin flooding the cavities with the mixture

5.1.2.1. Working quickly, spread the mixture evenly across the mold using a silicone spatula. The mixture will begin to solidify rapidly. It is best to overfill the mold to ensure that all the cavities are completely filled.

5.1.2.2. Scrape any overfill off the mold onto a sheet of parchment paper. Once this excess mixture solidifies it can be easily added back into the large beaker and re-melted.

5.1.2.3. Once the cavities are filled and the overfill has been removed, use the heat gun to melt any bubbles that rise to the surface of the mold

5.1.3. Allow the mold to cool until the suppositories have solidified

5.1.4. Flip the mold over and tap the back until all the suppositories fall out

5.1.5. Place the finished suppositories into the food grade storage container

5.1.6. Collect the overfill along with any broken suppositories or fragments from the casting process and add them back into the large beaker. Overfill and fragments from the casting process can be continuously remelted to reduce waste.

5.1.7. Allow the overfill and fragments to melt back down

5.1.8. Repeat steps 5.1.1 to 5.1.7 until the entire batch has been formed into suppositories

6. Storage & Sampling

6.1. Once the batch is finished, place all the suppositories in an air-tight storage container. Store at room temperature until they are ready for packaging

6.2. Pull a sample for third party testing (as required by regs) and send for full panel testing.

6.2.1. If potency is off target, then the suppositories can be re-melted and reworked. Do not package suppositories until the third-party lab sends back potency results.

7. Packaging

7.1. Once third-party testing has verified potency, the suppositories can be packaged

7.1.1. Count out the suppositories 10 at a time into containers. Performing a visual quality inspection throughout the entire batch while doing this

7.1.2. Put lids on the containers and store in at room temperature until the batch is ready for final labels.

SOP-P03: TINCTURE SOP

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. Scope

1.1. This SOP covers the production of an MCT based tincture formulated for oral administration.

2. Attire

1.2. General Attire

1.2.1. Employees producing tinctures should don hair/beard nets, nitrile gloves, lab coats, and face masks.

1.3. Personal Protective Equipment

1.3.1. Safety Goggles – Safety goggles should be used while transferring and mixing liquids

1.3.2. Heat Gloves – Heat gloves must be utilized while handling vessels containing hot solutions

1.3.3. Close-toed Non-slip Shoes – To prevent and protect from spills, employees should wear close-toed non-slip shoes while producing tinctures

3. Preparation

1.4. Equipment and Supplies

1.4.1. Vevor Manual Filler – Used to fill tincture bottles with formulated product. Reference user manual for cleaning, care, and assembly.

1.4.2. Small Hot Plate – Used to melt and pre-blend distillate in preparation for infusion

1.4.3. Handheld Mixer – Used to blend ingredients and to ensure the homogeneity of the batch. The impeller should be cleaned, sanitized, and completely dry before use.

1.4.4. Scale – A calibrated scale with appropriate resolution and capacity will be used to weigh active ingredients and excipients. The scale should be QC checked the day of formulation before any ingredients/excipients are weighed.

1.4.5. Floor Scale – Used to weigh large volumes of ingredients. The scale should be QC checked the day of formulation before any ingredients/excipients are weighed.

1.4.6. Stainless-Steel Beaker – Used in conjunction with the small hot plate to pre-blend distillate. This should be cleaned, sanitized, and completely dry before use.

1.4.7. Small Lab Spatulas – Used to blend distillate. These should be cleaned, sanitized, and completely dry before use.

1.4.8. 10 Gallon Food-Grade Storage Container – Mixing and storage vessel for tincure formulation. This should be cleaned, sanitized, and completely dry before use.

1.5. Workstation Preparation

1.5.1. Select a stainless-steel table to work on. Clean it of any dust and debris, then wipe down with IPA to sanitize.

1.5.2. Set up the small hotplate. Turn on and set to 80^{o} C

4. Formulation

1.6. Pre-blending the Distillate

1.6.1. Weigh the stainless-steel beaker and record the tare weight on the side

1.6.2. Place beaker on the scale and zero the scale. Weigh out the required amount of distillate and MCT oil as calculated on the *"Batch Records"* [reference specific document here]

1.6.2.1. The distillate and MCT oil should be weighed out at a 1% excess to compensate for transfer loss. For example, if calculations call for 50.0g of distillate and 50.0g of MCT oil, then you should weigh out 50.0g of distillate and 50.5g of MCT Oil.

1.6.3. Place the beaker on the hot plate and fully dissolve the distillate into MCT oil. Use the lab spatulas to help homogenize the mixture.

1.7. Weighing the Inactive Ingredients

1.7.1. Weigh the 10-gallon container on the floor scale and record the tare weight on the side

1.7.2. Place the container back on the on the floor scale and zero the scale. Weigh out the MCT oil as calculated on the *"Batch Records"* [reference specific document here]

1.7.3. Zero the scale again

1.7.4. Weigh out the flavoring as calculated on the *"Batch Records"* [reference specific document here]

1.8. Infusion

1.8.1. Once the distillate is fully dissolved, and the rest of the bulk ingredients have been weighed the batch is ready for infusion

1.8.1.1. Place the beaker of pre-dissolved distillate onto the scale and turn the small hotplate off.

1.8.1.2. Zero the scale while the beaker of distillate mixture is on it.

1.8.1.3. Begin mixing the bulk oil with the hand mixer before adding the distillate mixture. It is best to have a strong agitation going before adding the distillate

1.8.1.4. Add <u>almost</u> all the distillate to the bulk oil while stirring. Place the beaker back on the scale to determine how much has been added. At this point you should be close to but short of the target value (displayed as a negative value on the scale).

1.8.1.5. Continue to add distillate to the bulk oil in small quantities until you approach the target value. For example, if you are required to add 100.0g of distillate mixture to the batch, you should pour the distillate mixture into the bulk oil until -95.0g to -99.0g is displayed on the scale.

1.8.1.6. To assist in transferring the last gram or so of distillate mixture to the bulk oil, it is easiest to scoop it up into a lab spatula until the scale shows the target value exactly. At this point you can submerge the spatula with the last bit of distillate mixture into the bulk oil. This method minimizes error as distillate is hot, viscous, and difficult to work with.

1.8.2. Continue stirring and blending the final mixture for 5 minutes. Visually inspect for homogeneity before storing.

5. Storing & Sampling

1.9. Tinctures can be reformulated if third-party potency numbers do not come back as expected. Before filling bottles, pull samples in compliance with state guidelines and send to the third-party lab. If potency is returned within spec, proceed with filling bottles

6. Filling Bottles

1.10. Set up the Vevor manual filler as outlined in the user manual

1.11. Fill the hopper with tincture oil

1.12. Calibrate the depositor

1.12.1. Obtain a cleaned and sanitized stainless-steel beaker

1.12.2. Tare the beaker on a scale with appropriate resolution; 0.01g is recommended

1.12.3. Dispense one charge from the manual filler into the beaker

1.12.4. Place the beaker on the scale to determine the fill weight.

1.12.4.1. Assuming the density of the tincture liquid is 0.95g/ml, a 30mL dropper bottle should have a target weight of 28.5 ± 0.5g

1.12.5. If the deposited weight does not meet the target range, adjust the dispensing volume in the appropriate direction, tare the beaker, and try again.

1.12.6. Repeat steps 6.3.1 – 6.3.5 until the depositor is consistently dispensing the appropriate weight.

1.12.7. The tincture used to calibrate the depositor can be poured back into the hopper

1.13. Proceed with filling tincture bottles

1.13.1. Cap the bottles immediately after filling

1.13.2. Check the deposit weight every 25-50 units to ensure that the depositor is still calibrated. If the depositor is outside the target range, repeat steps 6.3.1 – 6.3.7 before proceeding.

1.14. Fill bottles until the entire batch is completed

7. Storing and Labeling

1.15. Store filled tincture bottles at room temperature until they are ready to be final labeled.

SOP-P04: TOPICAL SOP

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. Scope

1.1. This SOP covers the production of an oil-based balm/salve formulated for topical administration.

2. Attire

2.1. General Attire

2.1.1. Employees producing topicals should don hair/beard nets, nitrile gloves, lab coats, and face masks.

2.2. Personal Protective Equipment

2.2.1. Safety Goggles – Safety goggles should be used while transferring and mixing liquids.

2.2.2. Heat Gloves – Heat gloves must be utilized while handling vessels containing hot solutions.

2.2.3. Close-toed Non-slip Shoes – To prevent and protect from spills, employees should wear close-toed non-slip shoes while producing topicals.

3. Preparation

3.1. Equipment and Supplies

3.1.1. Piston Filler – Used to fill salve containers with formulated product, and to keep the formulation hot while filling. Reference user manual for cleaning, care, and assembly.

3.1.2. Medium Hot Plate – Used to melt and pre-blend distillate in preparation for infusion.

3.1.3. Handheld Paddle Mixer – Used to blend ingredients and to ensure the homogeneity of the batch. The impeller should be cleaned, sanitized, and completely dry before use.

3.1.4. Scale – A calibrated scale with appropriate resolution and capacity will be used to weigh active ingredients and excipients. The scale should be QC checked the day of formulation before any ingredients/excipients are weighed.

3.1.5. Floor Scale – Used to weigh large volumes of ingredients. The scale should be QC checked the day of formulation before any ingredients/excipients are weighed.

3.1.6. Stainless-Steel Beaker – Used in conjunction with the medium hot plate to pre-blend distillate. This should be cleaned, sanitized, and completely dry before use.

3.1.7. Drum Heater – Used to melt the product during formulation and filling.

3.1.8. 30 Gallon Steel Drum – Used to blend and store product. New drum liners should be used between each batch.

3.1.9. 4Qt Measuring Cup – Used to transfer product into the hopper of the piston filler. Should be cleaned, sanitized, and completely dry before use

3.1.10. Magnetic Stir Bar – Used in conjunction with the medium hotplate to blend the active ingredient mixture. This should be cleaned, sanitized, and completely dry before use.

3.2. Workstation Preparation

3.2.1. Select a stainless-steel table to work on. Clean it of any dust and debris, then wipe down with IPA to sanitize.

4. Formulation

4.1. Weighing out the active ingredient mixture

4.1.1. Weigh the stainless-steel beaker and record the tare weight on the side

4.1.2. Place the beaker on the scale and zero the scale. Weigh out the required amount of distillate and MCT oil as calculated on the *"Batch Records"* [reference specific document here]

4.1.2.1. The distillate and MCT oil should be weighed out at a 0.5% excess to compensate for transfer loss. For example, if calculations call for 200.0g of distillate and 200.0g of MCT oil, then you should weigh out 201.0g of distillate and 201.0g of MCT Oil.

4.2. Weighing the bulk ingredient base

4.2.1. Weigh the 30-gallon drum on the floor scale and record the tare weight on the side.

4.2.2. Place the container back on the on the floor scale and zero the scale. Weigh out the Body Balm base as calculated on the *"Batch Records"* [reference specific document here]

4.3. Blending the Formulation

4.3.1. Place the beaker of distillate and MCT oil onto the medium hotplate. Set to 80^{o} C and add a magnetic stir bar. Set stirring to medium speed. Allow the distillate the distillate to fully dissolve before infusing the base.

4.3.2. Wrap the drum heater around the metal drum containing the bulk ingredient base. Set to 45-50^{o} C. Allow the base to fully liquify before proceeding with infusion.

4.3.3. Infusing the base.

4.3.3.1. Once the beaker of distillate and MCT oil if homogenized, remove it from the hot plate, and turn the hotplate off.

4.3.3.2. Retrieve the magnetic stir bar from the beaker.

4.3.3.3. Place the beaker on the scale. Zero the scale while the beaker of distillate mixture is on it.

4.3.3.4. Begin mixing the bulk base with the hand mixer before adding the distillate mixture. It is best to have a strong agitation going before adding the distillate.

4.3.3.5. Add <u>almost</u> all the distillate mixture to the bulk base while stirring. Place the beaker back on the scale to determine how much has been added. At this point you should be close to but short of the target value (displayed as a negative value on the scale).

4.3.3.6. Continue to add distillate mixture to the bulk base in small quantities until you approach the target value. For example, if you are required to add 400.0g of distillate mixture to the batch, you should pour the distillate mixture into the bulk base until -395.0g to -399.0g is displayed on the scale.

4.3.3.7. To assist in transferring the last gram or so of distillate mixture to the bulk base, it is easiest to scoop it up into a lab spatula until the scale shows the target value exactly. At this point you can submerge the spatula with the last bit of distillate mixture into the bulk base. This method minimizes error as distillate is hot, viscous, and difficult to work with.

4.3.4. Continue stirring and blending the final mixture for 5 minutes. Visually inspect for homogeneity before storing.

5. Storing & Sampling

5.1. Pull a sample for third-party testing

5.1.1. This topical can be reformulated if third-party potency numbers do not come back as expected. Confirm that third-party potencies are within spec before filling tins.

5.2. Seal the drum with the lid. Store at room temperature until ready to fill.

6. Filling Tins

6.1. Wrap the drum heater around the drum of infused salve. Turn the heater on and allow the balm to fully liquify before transferring to the hopper.

6.2. Set up the Piston filler as outlined in the user manual.

6.3. Turn the Hopper heater on.

6.4. Fill the hopper with liquified salve using the 4Qt measuring cup.

6.5. Calibrate the depositor.

6.5.1. Obtain a cleaned and sanitized stainless-steel beaker.

6.5.2. Tare the beaker on a scale with appropriate resolution; 0.01g is recommended.

6.5.3. Dispense one charge from the piston filler into the beaker.

6.5.4. Place the beaker on the scale to determine the fill weight.

6.5.4.1. Assuming the density of the salve is 0.95g/ml, a 60mL tin should have a target weight of 57.0 ± 1.0g.

6.5.5. If the deposited weight does not meet the target range, adjust the dispensing volume in the appropriate direction, tare the beaker, and try again.

6.5.6. Repeat steps 6.3.1 – 6.3.5 until the depositor is consistently dispensing the appropriate weight.

6.5.7. The topical used to calibrate the depositor can be poured back into the drum to be remelted.

6.6. Proceed with filling salve tins

6.6.1. Cap the tins immediately after filling.

6.6.2. Check the deposit weight every 25-50 units to ensure that the depositor is still calibrated. If the depositor is outside the target range, repeat steps 6.3.1 – 6.3.7 before proceeding.

6.7. Fill tins until the entire batch is completed

7. Storing and labeling

7.1. Store the salves at room temperature until they are ready to be final labeled.

Human Resources

TABLE OF CONTENTS

Pages: 1 of 30	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

SOP-HR01: Drug and Alcohol-FREE WORKPLACE POLICY

Coosa is committed to maintaining a workplace free of substance abuse. No employee is allowed to consume, possess, sell, purchase, or be under the influence of alcohol or illegal drugs, as defined by federal law, on any property owned by or leased on behalf of Coosa, or in any vehicle owned or leased on behalf of Coosa.

The use of over-the-counter drugs and legally prescribed drugs is permitted as long as they are used in the manner for which they were prescribed and provided that such use does not hinder an employee's ability to safely perform his or her job. Employees should inform their supervisor if they believe their medication will impair their job performance, safety or the safety of others, or if they believe they need a reasonable accommodation when using such medication.

Coosa will not tolerate employees who report for duty while impaired by the use of alcohol or drugs. All employees should report evidence of alcohol or drug abuse to their supervisor or the General Manager immediately. In cases in which the use of alcohol or drugs creates an imminent threat to the safety of persons or property, employees are required to report the violation. Failure to do so may result in disciplinary action, up to and including termination of employment.

As a part of our effort to maintain a workplace free of substance abuse, Coosa employees may be asked to submit to a medical examination and/or clinical testing for the presence of alcohol and/or drugs. Within the limits of federal, state, and local laws, Coosa reserves the right to examine and test for drugs and alcohol at our discretion.

As a condition of your employment with Coosa, employees must comply with this Drug & Alcohol Use Policy. Be advised that no part of the Drug & Alcohol Use Policy shall be construed to alter or amend the at-will employment relationship between Coosa and its employees.

Employees found in violation of this policy may be subject to disciplinary action, up to and including termination of employment.

SOP-HR02: OCCUPATIONAL HEALTH AND SAFETY ACT POLICY

Coosa is committed to providing a clean, safe, and healthful work environment for its employees. Maintaining a safe work environment, however, requires the continuous cooperation of all employees. Coosa and all employees must comply with all occupational safety and health standards and regulations established by the Occupational Safety and Health Act and state and local regulations.

Coosa's Employee Safety Plan will comply with all applicable OSHA Standards, which are the regulatory requirements established and published by OSHA pursuant to the Occupational Safety and Health Act of 1970 and subsequent laws. Coosa will also follow mandatory standards for general industry and any other applicable standards, as well as any guidance specific to the cannabis industry. 29 CFR 1910. Coosa will comply with standards for recording and reporting occupational injuries and illnesses. 29 CFR 1904. Since we will move and store cannabis plants and products in our facility, we will also account for common hazards and solutions for warehouse workers, such as: Ergonomic and Musculoskeletal Disorders; Forklifts; Materials Handling; Slips, Trips, and Falls; Hazardous Chemicals; Emergency Planning; Electrical Hazards; Lockout/Tagout; Heat Illness; Automation and Robotics; Refrigerated Warehousing; Temporary Workers; and, Stress and Fatigue.

Due to the potentially hazardous nature of our workplace, all team members are responsible for familiarity and compliance with OSHA, EPA, and state regulations regarding job safety and health protection. Coosa will cooperate with all reasonable OSHA and EPA inspections and compliance reviews. Coosa will provide training and materials explaining the applicable standards and guidelines for all employees during the initial getting acquainted period, and periodically when applicable regulations are revised or added. All employees are required to participate, and a record will be maintained of all those in attendance. OSHA's Hazard Communication Standard requires that warning labels with orange and orange- red biohazard symbols be affixed to containers of regulated waste or, alternatively, red bags may be used. Employees who may come into contact with hazardous materials are required to receive information and training after the start of employment. We will maintain additional information, including a copy of the safety data sheets ("SDS"), about any chemical used or

stored in the facility, which is available to employees during working hours. Employees will undergo training on how to maintain OSHA safety protocols while on premises, such as: wearing PPE; allowing rest time for staff between tasks of 10-minute breaks every two hours of work and one hour lunch break between every four hours of work; and, reporting potential workplace hazards to our Chief Operating Officer ("COO"). Applicable material safety data sheets will be readily available in processing areas. We will use the Hazard Analysis of Critical Control Points ("HACCP") system to identify specific safety hazards and measure and control them to ensure the safety of our products. HACCP is a science-based, systematic tool used in various industries to assess safety hazards and establish control systems that focus on prevention rather than relying exclusively on managing collateral damage. Coosa will use the HACCP system throughout all stages of production to avoid dangerous work environments throughout the processing workflow. Part of this process will be establishing Critical Control points throughout the production process and a system of measurements designed to monitor, evaluate, and control any variance or hazard to employee or visitor safety and security.

Next, Coosa will provide gloves, coveralls, and respirators for use in conjunction with hazardous and potentially health-afflicting materials. Coosa will also require PPE be used when participating with certain aspects of infusion. To ensure worker and consumer safety, Coosa will always identify, hold, and store toxic cleaning compounds, sanitizing agents, solvents used in the production of cannabis products, and other chemicals in a manner that protects against contamination. OSHA has identified falling and tripping as being major hazards associated with similar facilities and work environments. This is especially the case when floors are wet, damp, or otherwise coated in a way that makes them increasingly slippery. Coosa will require employees to wear slip-resistant shoes within production areas.

Coosa will utilize the following PPE for our employees' safety: Hand Protection (e.g., protective gloves, nitrile gloves) where cut hazards or potential exposure to corrosive liquids, blood, chemicals, or other infections materials exist; Head Protection (e.g., hard hats) where danger of falling objects exist; Eye Protection (e.g., goggles or glasses) where risk of eye injuries exists, such as punctures, abrasions, contusions, or burns; Face Protection (e.g.,

face shields) where danger of flying particles or materials exist; Foot Protection (e.g., steel-toed boots) where risks of foot injury from corrosive, poisonous, or hot substances, or from falling objects, crushing, or penetrating actions exist; Hearing Protection (e.g., ear plugs) where risks of hearing damage from occupational noise exist and exceed the acceptable sound levels of the OSHA Noise Standard; Respiratory Protection (e.g., respirator, gas masks) where respiratory health risks exist from inhaling smoke, fumes, particulate matter, etc.; Clothing Protection (e.g., plastic aprons) where risk of splashing chemicals exists; and, Sanitation Equipment (e.g., shoe booties, hair nets, beard nets) where staff will be handling or manufacturing food or drugs.

Coosa will also keep Emergency Kits in marked locations throughout the facility for quick access in an employee safety emergency. Employees will check the emergency kit once per month to verify all contents are present, in working condition, and unexpired. The emergency kit will include: a fire extinguisher; bottled water; non-perishable food; flashlights with extra batteries; first aid kit (assorted bandages, gauze, antibiotic ointment, sterile gloves, tweezers, antiseptics, cleansing wipes, scissors, and common over-the-counter medications such as Tylenol and Benadryl); a basic toolbox (wrench, pliers, screwdriver, hammer); garbage bags; hand sanitizer; face masks or coverings; buckets; a battery-powered radio; a charged cellular phone with charging cord; and, a USB battery pack.

In addition, all employees are expected to obey safety rules and exercise caution and common sense in all work activities.

SOP-HR03: REPORTING ACCIDENTS AND INJURIES

Protecting the safety of our employees and visitors is the most important aspect of running our business. All employees have the opportunity and responsibility to contribute to a safe work environment by using commonsense rules and safe practices and by notifying management when any health or safety issues are present. All employees are encouraged to partner with management to ensure maximum safety for all.

In the event of an emergency, notify the appropriate emergency personnel by dialing 911. In case of a work-related injury or accident, please follow this procedure:

1. Report all injuries immediately to the Direct Supervisor who will, if required, call for emergency medical assistance and arrange transportation to an appropriate facility. If emergency medical assistance is not required, the employee must contact their Direct Supervisor within 24 hours for instructions on how to access the nearest workers' compensation medical facility if such care is required. In all instances, the Direct Supervisor must be notified of the injury within 24 hours.

2. After an injury or accident employees may not return to work unless they have submitted the appropriate documentation, establishing they are fit to return to work.

3. If an employee must obtain medical assistance during non-working hours (outside of the employee's usual work schedule), for a work-related injury that was reported by the employee at the time of the injury, but for which no medical assistance was required at the time, the employee should promptly notify their Direct Supervisor by the next scheduled workday. If the employee requires medical assistance after normal work hours, they can go to the nearest walk-in clinic or hospital emergency facility, advising them of the work-related injury. After treatment has been received, the employee must contact their Direct Supervisor so that an injury/accident report may be completed.

SOP-HR04: EQUAL EMPLOYMENT, NON-DISCRIMINATION, AND NON-HARASSMENT POLICY

EQUAL EMPLOYMENT OPPORTUNITY

The Company's policy is to select, place, train, and promote the best qualified individuals based upon relevant factors such as work quality, attitude and experience to provide equal employment opportunity for all employees in compliance with applicable local, state and federal laws. The Company does not discriminate against anyone based upon race, color, religion/creed, sex (including pregnancy), sexual orientation, gender identity, national origin, age, disabilities, height, weight, familial status, veteran status, genetic information, or any other protected classification.

This equal opportunity policy applies to all Company activities including but not limited to recruiting, hiring, training, transfers, promotions and benefits. Any employee who believes he/she/they has been discriminated against or harassed must immediately report this in writing to the Company and contact Human Resources.

Company conducts a pre-employment background check on all prospective employees and keeps a record of the results for the duration of the employee's employment with Company. The results of such background check may be shared with the Cannabis Regulatory Agency (CRA) upon request.

NON-DISCRIMINATION AND REQUESTS FOR ACCOMMODATIONS OF INDIVIDUALS WITH DISABILITIES

In accordance with the Americans with Disabilities Act and the Persons with Disabilities Civil Rights Act, the Company does not discriminate against qualified individuals with disabilities who can perform the essential functions of their positions with or without accommodation.

Qualified individuals with disabilities may make a written request for reasonable accommodation to a Direct Supervisor or Human Resources. Upon receipt of an accommodation request, a meeting may be scheduled with the requesting individual to discuss and identify the precise limitations resulting from the disability and the potential

accommodation that the Company might make to help overcome those limitations without undue hardship to the Company or undue risk to the health and safety of the requesting individual or other employees.

ANTI-DISCRIMINATION AND ANTI-HARASSMENT, INCLUDING SEXUAL HARASSMENT, POLICY

The Company is committed to providing a work environment in which all individuals are treated with respect and dignity. It is the Company's belief that each individual has the right to work in a professional atmosphere that promotes equal employment opportunities and prohibits discriminatory practices, including harassment; therefore, the Company expects that all relationships amongst persons in the workplace will be business-like and free of bias, prejudice, and harassment. Thus, the Company does not and will not tolerate discrimination against or harassment of or by its employees, contractors, consultants, agents, applicants, customers, or vendors. The term "harassment" includes, but is not limited to, slurs, jokes, and other verbal, graphic, or physical conduct relating to an individual's race, color, sex (includes discrimination against or harassment of individuals of the same sex), sexual orientation, gender identity or nonbinary status, pregnancy, religion, national origin, citizenship, age, disability, workers 'compensation claims, marital, veteran, or any other protected status. "Harassment" may include a range of subtle and not so subtle behaviors and also includes unwelcome or unwanted sexual advances, requests or demands for favors, offensive touching, and other types of conduct whether it be physical, verbal, graphic, or electronic communication (including e-mail and facsimiles) of a harassing or sexual nature involving individuals of the same or different gender. This includes, but is not limited to:

- Unwelcome or unwanted physical contact or sexual advances including, but not limited to, patting, grabbing, pinching, brushing-up against, hugging, cornering, kissing, fondling, or any other similar physical contact.

- Unwelcome requests or demands for favors including, but not limited to, subtle or blatant expectations, pressures, requests or demands for sexual, unethical or illegal favors, or unwelcome requests for dates or contacts. Such unwelcome requests or

demands may or may not relate to an implied or stated promise of preferential treatment, or a threat of negative consequences concerning employment, including, but not limited to, promotion, demotion, transfer, layoff, termination, pay or other form of compensation, and selection for training.

- Verbal and written abuse or unwelcome kidding including, but not limited to, that which is sexually-oriented, including same-sex harassment; commentary about an individual's body, sexual prowess or sexual deficiencies; inappropriate comments about race, color, religion, sex, sexual orientation, pregnancy, national origin, citizenship, age, disability, workers' compensation claims, marital, veteran, or other protected status; dirty jokes or other jokes which are unwanted and considered offensive or tasteless; or comments, innuendoes, epithets, slurs, negative stereotyping, leering, catcalls, or other actions that offend, whether sexually oriented or otherwise related to a prohibited form of discrimination or harassment.

- Any form of behavior that unreasonably interferes with work performance, including, but not limited to, unwanted sexual attentions, comments, interruptions, or other communications, whether sexually-oriented or otherwise related to a prohibited form of discrimination or harassment, that reduces productivity or time available to perform work-related tasks or otherwise interferes with work performance.

- Actions that create a work environment that is intimidating, hostile, abusive, or offensive because of unwelcome or unwanted conversations, suggestions, requests, demands, physical contacts or attentions, whether sexually-oriented or otherwise related to a prohibited form of discrimination or harassment.

- The distribution, display, or discussion of any written or graphic material, including calendars, posters, cartoons, or names, that belittles or shows hostility or aversion toward an individual, his/her/their relatives, friends or employees or a group because of race, color, religion, sex (including same sex discrimination or harassment), sexual orientation, gender identity, pregnancy, national origin, citizenship, age, disability, workers' compensation claims, marital, veteran or other protected status.

All employees and applicants are covered by this policy and are strictly prohibited from engaging in any form of discriminatory or harassing conduct. Further, no employee has the authority to suggest to another employee or applicant that the individual's employment, continued employment, or future advancement will be affected in any way by entering into, or refusing to enter into, a personal relationship. Such conduct is a direct violation of this policy.

Conduct prohibited by this policy is unacceptable in the workplace and in any work-related setting outside the workplace, such as business trips, business meetings, and business-related social events. Normal, courteous, mutually respectful, pleasant, and non-coercive interactions between employees, contractors, consultants, agents, applicants, vendors, clients, or customers, that are acceptable to all parties are not considered to be prohibited harassment.

Violation of this policy will subject an employee to disciplinary action, up to and including immediate termination.

Retaliation is Prohibited

The Company prohibits retaliation against any individual who reports discrimination or harassment or participates in an investigation of such reports. Retaliation against an individual for reporting harassment or discrimination or for participating in an investigation of a claim of harassment or discrimination is a serious violation of this policy and, like harassment or discrimination itself, will be subject to disciplinary action, up to and including termination.

Reporting Procedures and Investigation

The Company strongly urges the reporting of all incidents of discrimination, harassment or retaliation, regardless of the offender's identity or position. Individuals who believe that they have experienced conduct that they believe is contrary to the Company's policy or who have concerns about such matters should file their complaints with a Direct Supervisor, whereupon the matter will be discreetly and thoroughly investigated. The Company will then

take immediate steps to stop any behavior which violates this policy and see that it does not repeat itself. Disciplinary action, up to and including termination, calculated to end the discrimination or harassment, will be taken, when appropriate, against the offender(s).

If an employee or applicant suffers discrimination or harassment from a supervisor, manager, or any employee, contractor, consultant, customer, vendor, or other third party and is not able to report, or is not comfortable reporting harassment to a Direct Supervisor or if a complaint concerning another employee, contractor, consultant, customer, vendor, supervisor, manager, or other third party is not handled to satisfaction, the employee must immediately contact Human Resources.

Employees who have experienced conduct that they believe is contrary to this policy have an obligation to take advantage of this complaint procedure. An employee's failure to fulfill this obligation could affect his or her rights in pursuing any claim.

Early reporting and intervention have proven to be the most effective method of resolving actual or perceived incidents of discrimination or harassment; therefore, while no fixed reporting period has been established, the Company strongly urges the prompt reporting of complaints or concerns so that rapid and constructive action can be taken.

The availability of this complaint procedure does not preclude individuals who believe that they are being subjected to harassing conduct from promptly advising the offender that his or her behavior is unwelcome and requesting that it be discontinued.

Responsive Action

Conduct constituting harassment, discrimination, or retaliation will be dealt with appropriately. Responsive action may include training, referral to counseling and/or disciplinary action such as warning, reprimand, withholding of a promotion or pay increase, reassignment, and temporary suspension without pay or termination, as the Company believes appropriate under all of the circumstances.

Patron Conduct

Employees working in a customer facing role with the Company must be aware that they may come into contact with intoxicated persons and must follow all laws, rules, and regulations, regarding any such intoxication. In the event an employee feels harassed by any patron, customer, or visitor, the employee should immediately report to management as set forth above.

Employees should also be aware that the Company strictly forbids discrimination or harassment of any patron. If a patron feels they have suffered discrimination or harassment from an owner, agent, supervisor, manager, or any employee, the patron has the right to speak with an on-site manager.

Note that nothing in this policy shall prevent the management of the Company from refusing entry to or removing anyone who engages in violent, illegal, indecent, profane, or otherwise disorderly conduct, provided that management does not take any such actions in a discriminatory manner.

SOP-HR05: CONFIDENTIALITY, NON-DISCLOSURE, AND NON-CIRCUMVENTION POLICY

CONFIDENTIAL INFORMATION

Employees shall not share information that is confidential and proprietary about the company. This includes information about trademarks, upcoming product releases, upcoming services, sales, finances, number of products sold; number of employees; company strategy; and any other information that has not been publicly released by the company.

These are given as examples only and do not cover the range of what the company considers confidential and proprietary. If an employee has any question about whether information has been released publicly or doubts of any kind, he or she should speak with his or her Direct Supervisor before releasing information that could potentially harm our company, or our current and potential products, employees, partners, and guests. Employees may also want to be aware of the points made in any non-disclosure agreement that each Team Member may have signed when they joined our company.

Coosa's logo and trademarks may not be used without explicit permission in writing from the company. This is to prevent the appearance that an employee speaks for or represents the company officially.

RESPECT AND PRIVACY RIGHTS COMPONENTS

Speak respectfully about the company and our current and potential employees, guests, partners, and competitors. Do not engage in name calling or behavior that will reflect negatively on Coosa's reputation. Note that the use of copyrighted materials, unfounded or derogatory statements, or misrepresentation is not viewed favorably by Coosa and can result in disciplinary action up to and including employment termination.

Coosa encourages each employee to write knowledgeably, accurately, and using appropriate professionalism.

Honor the privacy rights of our current employees by seeking their permission before writing about or displaying internal company happenings that might be considered to be a breach of their privacy and confidentiality.

SOLICITATION

Employees should be able to work in an environment that is free from unnecessary annoyances and interference with their work. In order to protect our employees and visitors, solicitation by employees is strictly prohibited while either the employee being solicited or the employee doing the soliciting is on "working time." "Working time" is defined as time during which an employee is not at a meal, on break, or on the premises immediately before or after his or her shift.

Employees are also prohibited from distributing written materials, handbills, or any other type of literature on working time and, at all times, in "working areas," which includes all office areas. "Working areas" do not include break rooms, parking lots, or common areas shared by employees during nonworking time.

Nonemployees may not trespass or solicit or distribute materials anywhere on company property at any time.

SOP-HR06: HIRING EVALUATION AND BACKGROUND CHECKS

PURPOSE

1.1. The purpose of this procedure is to provide instructions for hiring, termination and upkeep of the recordkeeping at Coosa Medical.

RESPONSIBILITY

1.2. The Director of Operations and/or General Manager is responsible for maintaining and training this P&P.

PROCEDURE

1.3. The following sections outline the process of planning for, acquiring and managing the human resources of Coosa Medical. These staffing processes and procedures are designed to guarantee that Coosa Medical will acquire and maintain adequate numbers of personnel with appropriate skills to meet the operational needs of the organization to meet patient demand, while maintaining complete compliance with regulations and with Coosa Medical's high standards of professionalism and service.

1.3.1. The procedure outlines the process of acquiring personnel, describes responsibilities assigned to each position, discusses transition of staff to new job duties, and describes policies and procedures that the General Manager will use to manage personnel in each position.

1.4. The Director of Operations in coordination with the General Manager will develop and maintain a staffing plan for the facility. The staffing plan will be designed to ensure that the facility is appropriately staffed for efficient operations and that additional positions are filled in accordance with patient demand and financial feasibility.

1.4.1. The Director of Operations and/or General Manager, will review and update the staffing plan quarterly as Coosa Medical proceeds through the business life cycle including the start-up, growth, establishment, expansion and maturity

stages. The General Manager will determine how to fill each position needed utilizing staff or outside resources.

1.5. Agents of Coosa Medical must meet all requirements of the AMCC and be properly registered with the Commission prior to beginning any employment.

1.6. It is a company policy to terminate any agent if they are found to have violated any provision of law or regulation and to report any such violation to the Commission and law enforcement as appropriate and in accordance with company termination policies and AMCC.

1.7. All agents are subject to all applicable policies established by Coosa Medical in this document, the Agent Manual or as otherwise directed by management at any other time. The General Manager is responsible for personnel policy and procedure documentation, maintenance, implementation and training.

1.8. It is Company policy not to employ any person who has a misdemeanor conviction for a drug related offense in any capacity. AMCC prohibits any individual with a drug felony from working as an agent.

1.9. The General Manager will maintain a personnel record (separate from payroll records to be kept for 7 years) for each agent for at least 60 months after termination of the agent's affiliation with the Coosa Medical and will include, at a minimum, the following:

1.9.1. All materials submitted to the Commission pursuant to all applicable laws and regulations;

1.9.2. Documentation of verification of references;

1.9.3. The signed job description or employment contract that includes duties, authority, responsibilities, qualifications and supervision;

1.9.4. Documentation of all required training and the signed statement of the

individual indicating the date, time and place he or she received said training and the topics discussed, including the name and title of presenters;

1.9.5. A copy of the application that the company submitted to the Commission on behalf of any prospective agent;

1.9.6. Documentation of periodic performance evaluations, written warnings and performance notes;

1.9.7. A record of any disciplinary action taken; and

1.9.8. All background check reports obtained in accordance with applicable laws and regulations.

1.10. The Director of Operations and/or General Manager will maintain records documenting the stipend, salary and wages paid to each agent and any executive compensation, bonus, benefit or item of value paid to any individual affiliated with the company, including members of the company. Such records will be maintained for a period of at least five (5) years.

1.11. The staffing process will be managed and directed by the General Manager in coordination with the Administrative Controller, and consists of five continuous elements:

1.11.1. Planning;

1.11.2. Acquisition;

1.11.3. Training;

1.11.4. Transition; and

1.11.5. Termination.

1.12. The plan for facility staffing is based on business plan assumptions and will be adjusted by the Director of Operations and/or the General Manager in accordance

with actual operating needs.

1.13. A substantial level of operational risk is introduced when operating without a sufficient number of staff possessing the necessary skills or experience to fulfill their job tasks, or when relying heavily on outside resources to facilitate operations. In order to avoid introducing operational risk, the job skills needed for each position in the facility will be established and agents will be assessed in accordance with the skills needed for their position, thereby allowing the identification and correction of any job skills risk. The three key components of skill set assessments follow:

1.13.1. The General Manager will prepare a Job Skills Gap Assessment for every position filled in the facility.

1.13.2. Each agent's supervisor will complete a Job Skills Gap Assessment upon acquisition, at the beginning and end of a probationary period, and once per year thereafter in conjunction with the annual review period.

1.14. The Director of Operations and/or General Manager will review the assessments and address any job skills risk.

1.15. The Director of Operations and Board will estimate all staffing needs based on market expectations and current resources.

1.16. The General Manager will periodically conduct Job Skills Gap Assessments to determine human resources needs based on the known skill gaps and strengths of each agent.

1.16.1. Analysis of Job Skills Gap Assessments will help identify situations where demand for certain skills exceeds supply, such as when critical work demand or personnel numbers or competencies will not meet future needs. It will also help identify situations where future supply will likely exceed demand.

1.17. The Director of Operations will review Job Skills Gap Assessments with the General Manager; the two will collaboratively produce suggestions for staffing adjustments,

contained in a staffing estimate for the next quarter.

1.18. If acquisitions or terminations are proposed, the staffing estimate proposal will be presented to the Board who will approve, deny, or modify the estimate in accordance with projected patient demand and the financial situation of the company as a whole.

1.19. Approved staffing estimates will guide additional staff acquisition, termination, transfer, or modification.

1.20. The General Manager will acquire all necessary staff. Acquisition will take place in multiple phases – fewer agents will be needed in initial phases of operation and more agents will be added to adequately staff the facility as the patient population increases.

1.21. In later operational phases, acquisition process may vary depending on the vacant position and any special circumstances including Board approval for a direct non-solicited hire.

1.22. The acquisition process will be managed by the Director of Operations and/or General Manager, and will always include, at a minimum:

1.22.1. Performing a criminal background check on the selected candidate to determine eligibility for Commission registration;

1.22.2. Provide Pre-employment drug screening;

1.22.3. Submittal of fingerprints to the central repository.

1.22.4. Application to the Commission for registration;

1.22.5. Submitted materials of application to include; the name, address, date of birth, social security number, proof of fingerprint submittal to the Central Registry, request for criminal history background of the prospective agent.

1.22.6. Providing new staff with the Employee Manual, which they will be required to

review, accept and acknowledge in writing;

1.22.7. New hire orientation and training upon successful registration; and

1.22.8. Completion of the probationary period.

1.23. The acquisition process typically involves the following:

1.23.1. Identification of need;

1.23.2. Job classification and job description preparation;

1.23.3. Solicitation of the vacant position utilizing the methods that best fit the position including, but not limited to:

1.23.4. Reviewing resumes, cover letters, and required job applications for qualified candidates including those with relevant experience and those with complementary skills and a strong potential for growth;

1.23.5. Internal posting;

1.23.6. Partner posting (consultants, non-profit partners, vendors, etc.);

1.23.7. External posting; or

1.23.8. Executive search firm.

1.24. Performing and recording in the Job Candidate Log reference checks on qualified candidates including:

1.24.1. Verification of address and education; and

1.24.2. Verification of former and current employment.

1.24.3. Recording of information from former supervisors on the candidate's performance if available;

1.24.4. Scheduling first interviews with a member of the Management Team;

1.24.5. Scheduling second interviews (with strong candidates) with the Director of Operations and the General Manager;

1.24.6. Delivery of an offer letter to the 1st choice candidate;

1.24.7. Performing a criminal background check on the selected candidate to determine eligibility for an agent identification card on the basis of Commission requirements and to identify any other possible disqualifying items; and

1.24.8. Completion of the probationary period.

1.25. Consultants may be utilized when approved by the Board and General Manager. All consulting contracts will contain suitability provisions and require compliance with all applicable laws and regulations.

1.25.1. Consultants will receive a written copy and acknowledge all policies and procedures. Consultants may be used for circumstances, including but not limited to, when the staff does not possess the necessary qualifications for necessary operations; where third-party services are desired for separation of duties (i.e. accounting, audit and compliance); if the position does not call for a full-time agent but requires a specific skill set; during the period a necessary position is vacant; or for any other reason deemed acceptable by the Board.

1.26. In order to provide equal employment and advancement opportunities to all individuals, employment decisions at Coosa Medical will be based on merit, qualifications and abilities. All managers and supervisors will comply with Equal Employment Opportunity Commission (EEOC) guidelines when managing personnel issues. Coosa Medical will not discriminate in employment opportunities or practices on the basis of:

1.26.1. Race, national origin or ethnic background;

1.26.2. Height and weight;

1.26.3. Credit rating or economic status;

1.26.4. Religious affiliation or beliefs;

1.26.5. Citizenship;

1.26.6. Marital status, civil partnership or number of children.

REPORTS REQUIRED

1.27. None required

AUTHORIZATION FOR DEVIATION

1.28. The Director of Operations or General Manager must direct any deviation from the standard procedure.

APPROVAL, REVIEW, REVISION AND DISTRIBUTION

1.29. The standard procedure shall be reviewed by the Director of Operations and/or the General Manager yearly, following the issuance or last revision or review date. Any revision must be signed by the General Manager and verified by an executive team member prior to being distributed. Distribution of revisions and collection of any outdated versions shall be the responsibility of the General Manager. The General Manager will scan the originals into the computer and retain the signed originals in a binder in their office.

SOP-HR07: PERFORMANCE EVALUATION AND TERMINATION

JOB PERFORMANCE

Communication between employees and supervisors or managers is very important. Discussions regarding job performance are ongoing and often informal. Employees should initiate conversations with their supervisors if they feel additional ongoing feedback is needed.

Formal performance reviews are offered at various points throughout the year. These reviews include a written performance appraisal and discussion between the employee and the supervisor about job performance and expectations for the future.

TERMINATION OF EMPLOYMENT

Voluntary Termination

While the Company hopes to mutually benefit from each individual's continued employment, it may become necessary for an employee to leave the job. In all cases of voluntary resignation (one initiated by the employee), employees are asked to provide a written notice to their supervisors at least 14 days in advance of the last day of work. Holidays and paid time off (PTO) will not be counted toward the 14-day notice. Employees who provide the requested amount of notice will be considered to have resigned in good standing and generally will be eligible for rehire.

An employee may be considered to have voluntarily resigned if the employee:

- Fails to return from an approved leave of absence; or
- Fails to report to work without notice.

Involuntary Termination

An employee may be involuntarily terminated for any reason.

SOP-HR08: COMPANY PHYSICAL AND INTELLECTUAL PROPERTY POLICY

CONFIDENTIALITY & DATA SAFEGUARDING

Safeguarding customer data containing personal information from unauthorized disclosure, identity theft, or misuse is imperative.

HANDLING A POTENTIAL SECURITY BREACH

Employees who discover, or are notified of, a potential security breach of information held by Company must immediately report it to their Direct Supervisor. This includes lost, stolen, and misplaced information and equipment. The Direct Supervisor will immediately forward the information to his or her supervisor. Employees must immediately report: (a) the date and time of the potential security breach, (b) the type of personal information involved, (c) the type of device the information was stored on, e.g., laptop, USB drive, or tablet, and (d) advise if any law enforcement report was filed (such as in the case of criminal theft).

Coosa management will work with IT to determine if a breach has or is likely to have occurred.

If a security breach occurred or is likely to have occurred, Company and IT will determine whether the breach is likely to cause substantial loss or injury to, or result in identity theft with respect to one or more of Company's customers, and in accordance with applicable law. Upon such determination, the Company will decide whether a review of internal controls is recommended to better ensure the integrity, security, and confidentiality of personal information.

If the Company determines that the security breach has or is likely to cause substantial loss or injury to, or result in identity theft with respect to one or more customers, Coosa shall provide such notice as required by applicable laws.

USE AND PROTECTION OF COMPANY ASSETS

The Company's assets are to be used only for the legitimate business purposes of Coosa (and its related entities) and only by authorized employees or their designees. This includes both tangible and intangible assets.

Some examples of tangible assets include office equipment such as telephones, copy machines, computers, furniture, supplies, and production equipment. Some examples of intangible assets include intellectual property such as pending patent information, trade secrets, or other confidential or proprietary information (whether in printed or electronic form). All electronic media and communication systems, including email, intranet, internet access, and voicemail are Company assets and are to be used for appropriate business purposes only.

Employees, officers, and directors are responsible for ensuring that appropriate measures are taken to assure that the Company's assets are properly protected. Employees, officers, and directors should assist in the protection of confidential and proprietary information including technical, financial, marketing, and other business information that, if made available to the Company's competitors or to the public, would be advantageous to such competitors or detrimental to the Company. No employee, officer, or director should disclose or permit the release to any person (other than a fellow employee having a need to know such information) any confidential or proprietary information except as required by law.

In addition, employees, officers, and directors should take appropriate measures to ensure the efficient use of Company assets.

AGREEMENT TO VIDEO SURVEILLANCE

All team members consent to being recorded as a condition of employment. Our facilities have security cameras and surveillance that record 24/7/365. We want to provide the safest working environment as possible for our team members. Team members will be on camera while on company property, inside and outside. Obvious exceptions to this are restrooms or other areas of personal privacy. Coosa’s security team reviews security footage frequently.

The Company reserves the right to search your belongings if you are on Company property. All suspected criminal activity must and will be reported to the CRA and local authorities within 24 hours of discovery.

SOP-HR09: SAFETY AND SECURITY

Coosa is committed to providing a clean, safe, and healthful work environment for its employees. Maintaining a safe work environment, however, requires the continuous cooperation of all employees. Coosa and all employees must comply with all occupational safety and health standards and regulations established by the Occupational Safety and Health Act and state and local regulations.

Coosa's Employee Safety Plan will comply with all applicable OSHA Standards, which are the regulatory requirements established and published by OSHA pursuant to the Occupational Safety and Health Act of 1970 and subsequent laws. Coosa will also follow mandatory standards for general industry and any other applicable standards, as well as any guidance specific to the cannabis industry. 29 CFR 1910. Coosa will comply with standards for recording and reporting occupational injuries and illnesses. 29 CFR 1904. Since we will move and store cannabis plants and products in our facility, we will also account for common hazards and solutions for warehouse workers, such as: Ergonomic and Musculoskeletal Disorders; Forklifts; Materials Handling; Slips, Trips, and Falls; Hazardous Chemicals; Emergency Planning; Electrical Hazards; Lockout/Tagout; Heat Illness; Automation and Robotics; Refrigerated Warehousing; Temporary Workers; and, Stress and Fatigue.

Due to the potentially hazardous nature of our workplace, all team members are responsible for familiarity and compliance with OSHA, EPA, and state regulations regarding job safety and health protection. Coosa will cooperate with all reasonable OSHA and EPA inspections and compliance reviews. Coosa will provide training and materials explaining the applicable standards and guidelines for all employees during the initial getting acquainted period, and periodically when applicable regulations are revised or added. All employees are required to participate, and a record will be maintained of all those in attendance. OSHA's Hazard Communication Standard requires that warning labels with orange and orange- red biohazard symbols be affixed to containers of regulated waste or, alternatively, red bags may be used. Employees who may come into contact with hazardous materials are required to receive information and training after the start of employment. We will maintain additional information, including a copy of the safety data sheets ("SDS"), about any chemical used or

stored in the facility, which is available to employees during working hours. Employees will undergo training on how to maintain OSHA safety protocols while on premises, such as: wearing PPE; allowing rest time for staff between tasks of 10-minute breaks every two hours of work and one hour lunch break between every four hours of work; and, reporting potential workplace hazards to our Chief Operating Officer ("COO"). Applicable material safety data sheets will be readily available in processing areas. We will use the Hazard Analysis of Critical Control Points ("HACCP") system to identify specific safety hazards and measure and control them to ensure the safety of our products. HACCP is a science-based, systematic tool used in various industries to assess safety hazards and establish control systems that focus on prevention rather than relying exclusively on managing collateral damage. Coosa will use the HACCP system throughout all stages of production to avoid dangerous work environments throughout the processing workflow. Part of this process will be establishing Critical Control points throughout the production process and a system of measurements designed to monitor, evaluate, and control any variance or hazard to employee or visitor safety and security.

Next, Coosa will provide gloves, coveralls, and respirators for use in conjunction with hazardous and potentially health-afflicting materials. Coosa will also require PPE be used when participating with certain aspects of infusion. To ensure worker and consumer safety, Coosa will always identify, hold, and store toxic cleaning compounds, sanitizing agents, solvents used in the production of cannabis products, and other chemicals in a manner that protects against contamination. OSHA has identified falling and tripping as being major hazards associated with similar facilities and work environments. This is especially the case when floors are wet, damp, or otherwise coated in a way that makes them increasingly slippery. Coosa will require employees to wear slip-resistant shoes within production areas.

Coosa will utilize the following PPE for our employees' safety: Hand Protection (e.g., protective gloves, nitrile gloves) where cut hazards or potential exposure to corrosive liquids, blood, chemicals, or other infections materials exist; Head Protection (e.g., hard hats) where danger of falling objects exist; Eye Protection (e.g., goggles or glasses) where risk of eye injuries exists, such as punctures, abrasions, contusions, or burns; Face Protection (e.g.,

face shields) where danger of flying particles or materials exist; Foot Protection (e.g., steel-toed boots) where risks of foot injury from corrosive, poisonous, or hot substances, or from falling objects, crushing, or penetrating actions exist; Hearing Protection (e.g., ear plugs) where risks of hearing damage from occupational noise exist and exceed the acceptable sound levels of the OSHA Noise Standard; Respiratory Protection (e.g., respirator, gas masks) where respiratory health risks exist from inhaling smoke, fumes, particulate matter, etc.; Clothing Protection (e.g., plastic aprons) where risk of splashing chemicals exists; and, Sanitation Equipment (e.g., shoe booties, hair nets, beard nets) where staff will be handling or manufacturing food or drugs.

Coosa will also keep Emergency Kits in marked locations throughout the facility for quick access in an employee safety emergency. Employees will check the emergency kit once per month to verify all contents are present, in working condition, and unexpired. The emergency kit will include: a fire extinguisher; bottled water; non-perishable food; flashlights with extra batteries; first aid kit (assorted bandages, gauze, antibiotic ointment, sterile gloves, tweezers, antiseptics, cleansing wipes, scissors, and common over-the-counter medications such as Tylenol and Benadryl); a basic toolbox (wrench, pliers, screwdriver, hammer); garbage bags; hand sanitizer; face masks or coverings; buckets; a battery-powered radio; a charged cellular phone with charging cord; and, a USB battery pack.

In addition, all employees are expected to obey safety rules and exercise caution and common sense in all work activities.

COMPLAINT AND REPORTING PROCEDURE

Employees should immediately report any unsafe conditions to their supervisor without fear of reprisal. In the case of an accident that results in injury, regardless of how seemingly insignificant the injury may appear, employees must notify their supervisor. If you believe it would be inappropriate to report the matter to your supervisor, you can report it directly to:

General Manager Employees who violate safety standards, cause hazardous or dangerous situations, or fail to report or, where appropriate, remedy such situations may be subject to disciplinary action, up to and including termination of employment.

Security

SOP-S01: AUTHORIZED PERSONNEL IN FACILITIES

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All personnel (i.e. employees or contractors) that have access to the manufacturing facility in Centreville, Alabama, as it pertains to required job functions. Individual personnel access will be limited to the portions of the facility/facilities that their job requires their ability to access.

2. SCOPE

It is the responsibility of all employees and security contractors, to ensure that only authorized personnel are allowed in certain areas of the facility. The Security Director, Director of Compliance, and Chief Operating Officer, or COO's designee, are charged with the implementation and compliance with this policy, including maintaining an active list of current employees on file and immediately deactivating access upon an employee's departure from employment with Coosa Medical Manufacturing, LLC.

3. BADGE POLICY

3.1 Exterior Entrance Badges

a. All personnel will be issued badges that will allow access into the manufacturing facility.

Exterior entrance badges will have no pictures or identification with company in order to prevent lost or stolen cards from being used to gain access to the facility.

Exterior badges require a unique 4-digit code in order to access the two interior doors of the manufacturing facility. Codes will be assigned when exterior badges are issued.

If an employee loses possession of the exterior badge, they are required to immediately report the loss to the Chief Operating Officer or COO's designee, so the badge can be deactivated.

Keychain fobs will also be issued to every employee in order to access the manufacturing facility.

Exterior badges and fobs will allow employee access into the lobby of the manufacturing facility, locker rooms, and the administrative area of the manufacturing facility.

3.2 Interior Badges

a. Interior badges will have the employee's picture, employment classification, and company information.

Interior badges are issued to all employees and limit access to specified areas within the facilities.

Access to the production and manufacturing area is restricted to current employees that are on file, unless otherwise authored pursuant to SOP-S02.

Access to the restricted access areas at the manufacturing facility will require an employee to use the interior badge and pass through a retinal scan to identify the employee.

Access to individual rooms within the restricted access area at the manufacturing facility will require use of the interior badge and is limited only to employees with a business purpose for accessing those individual rooms.

Interior badges at the manufacturing facility are to be picked up at the security desk and returned to the security desk prior to leaving the facility.

Interior badges may only leave the facilities when required by SOPs or with permission from the CEO.

3.3 Exiting the Manufacturing Facility

a. Employees will be required to use their interior badge in order to exit the restricted area in the manufacturing facility.

Employees must not leave the restricted access areas without first utilizing the mats near the door to remove plant material from shoes.

Employees must check shoes prior to leaving the restricted access area in order to ensure that all plant material has been removed.

SOP-S02: VISITORS TO FACILITIES

TABLE OF CONTENTS

Pages: 1 of 5	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Access to the manufacturing facility is restricted to current Coosa Medical Manufacturing employees that are on file, unless otherwise authorized pursuant to SOP-S02.

2. SCOPE

It is the responsibility of the Security Office, Director of Compliance, and Chief Operating Officer, or their designee, to ensure that persons other than employees are allowed access to facilities in limited circumstances.

3. VENDORS

3.1 Manufacturing Facility

a. Vendors must follow written visitor policies unless directed otherwise by authorized personnel as designated by an Executive.

b. Vendors that require access to the manufacturing facility will be allowed to enter the lobby area of the facility by security.

c. Vendors must be added to the Visitor Log, recording: date, name, time in/out, badge issued, and reason for visit.

Security must inform the employee identified by the vendor as the contact person that the vendor has arrived.

Vendors are not allowed into restricted access areas without having been escorted by an authorized employee, unless otherwise approved by senior management.

4. VISITORS

4.1 Manufacturing Facility

a. Visitors must follow written visitor policies unless directed otherwise by authorized personnel as designated by an Executive.

b. Security must be notified of planned visitors prior to their arrival by the host or assignee responsible for the planned visitors.

c. Visitors of employees are allowed into the administrative area of the manufacturing facility after first checking in with security and obtaining a guest ID badge.

Visitors must be added to the Visitor Log, recording: date, name, time in/out, badge issued, and reason for visit.

Visitors of employees are only allowed into the restricted access areas of the manufacturing facility only if approved by one of the following persons:

i. Chief Executive Officer
ii. Chief Financial Officer
iii. Chief Operating Officer

Saturday or Sunday visitors need to be approved in advance so appropriate security staffing levels can be prepared.

5. BIOSECURITY MEASURES FOR NON-EMPLOYEES

5.1 Manufacturing Facility

a. Non-employees entering the production side of the manufacturing facility must wear covers provided by Coosa Medical Manufacturing in order to protect from biosecurity hazards.

Protective covers include disposable zip-up covers, shoe coverings, provided sandals, or other covering provided by Coosa Medical Manufacturing.

6. BOARD MEMBER ACCESS

6.1 Members of the Coosa Medical Manufacturing shall be granted access to the manufacturing facility lobby to retrieve an interior badge pursuant to SOP-S01.

6.2 Interior badges shall not allow access to restricted areas at the manufacturing facility.

6.3 Interior badges shall allow access to the Administration area of the manufacturing facility.

7. UNAUTHORIZED SOLICITORS

7.1 Unauthorized solicitors are not allowed on Coosa Medical Manufacturing property.

Coosa Medical Manufacturing employees and security personnel should direct unauthorized solicitors to contact the "General Contact" information listed on the Coosa Medical Manufacturing website

7.2 Coosa Medical Manufacturing employees and security personnel should then kindly ask unauthorized solicitors to leave Coosa Medical Manufacturing property. Refusal warrants calling the non-emergency number for law enforcement.

SOP-S03: SECURITY EMERGENCIES

TABLE OF CONTENTS

Pages: 1 of 5	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Although all precautions will be taken to prevent security emergencies at either the manufacturing facility, it is possible that a security emergency may arise. The safety of employees and customers is the paramount concern if a security emergency were to arise. Secondary to the safety of persons within the facility is the safety of the medical cannabis stored within the facility. Employees should always protect themselves first in a safety emergency.

2. SCOPE

It is the responsibility of the Chief Operating Officer, or their designee, to regularly update security emergency procedures and to ensure that all personnel are trained on how to act in the event of a security emergency.

3. MANUFACTURING FACILITY

3.1 Unauthorized Access

a. If an unauthorized person gains access to the manufacturing facility, employees will be notified by security via the portable radios.

Security will deactivate the card access security system as quickly as possible to limit access to the unauthorized individual(s) unless this will place an employee in danger. Badge entry doors will still be able to be opened for exit.

It is the responsibility of security to call law enforcement immediately in the event of a security breach. In the event, security is unable to call law enforcement, any and all personnel shall do so.

If employees are notified of a security breach, all employees should keep themselves in a locked area of the building until notified that it is safe to exit. This includes restrooms (in restricted access areas and administration), and the Tooling room.

If employees are encountered by an unauthorized person, employees should protect themselves above anything else.

If a person is threatening employees in return for money, property, cannabis or medical cannabis, employees should comply with the person's requests in order to keep themselves as safe as possible.

Under no circumstances should an employee actively seek out an unauthorized person. Employees should stay in secure areas until told otherwise.

3.2 Threats by Outside Persons

a. If a threat is received by an outside person regarding the manufacturing facility, employees will be notified and evacuated out of the building if safe.

Employees will be instructed by security and law enforcement as to what actions to take based on the specific threat made.

If an employee is threatened personally by an outside person, employees must immediately notify security. If the threat is imminent, employees should first call 911 and report the threat.

If an employee is threatened and cannot contact law enforcement, employees should do whatever necessary to protect themselves, including, but not limited to, complying with the threatening person's requests.

Employees must notify security and law enforcement as soon as possible of an individual threat from an outside person.

SOP-S04: EMERGENCIES & EMERGENCY EQUIPMENT

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Employees will be kept notified of known weather emergencies that may take place. Employees are to keep themselves safe above the safety of property or medical cannabis.

2. SCOPE

It is the responsibility of the Chief Operating Officer, or their designee, and the Director of Compliance to ensure that all employees are made aware of shelter locations to use during a weather emergency and other procedures to follow during a weather emergency. It is also the responsibility of the Chief Operating Officer, or their designee, to ensure that all policies listed in this section are followed by employees and security personnel.

3. NOTIFICATION PROCEDURES

3.1 Manufacturing Facility

a. All employees at a manufacturing facility will be notified by security if there is an impending weather emergency.

Security staff will notify employees in person or through the portal radio system.

4. TAKING SHELTER

4.1 Manufacturing Facility

a. If employees are notified of a weather emergency, employees must take shelter immediately.

If safe, employees should secure cannabis or medical cannabis in the best way possible under the circumstances.

Employees should proceed to identified shelter locations. At the manufacturing facility, shelter locations include: the vault, the security office, and the production area break room.

In the event of a weather emergency, employees should avoid being near windows or doors leading to the outside of the building.

Employees should notify security staff of their location during a weather emergency so that security can account for all personnel.

5. FIRE DRILLS AND EMERGENCY EQUIPMENT CHECKS

5.1 Fire Drills

a. Security will perform, at a minimum, quarterly fire drills to test equipment and train personnel on safe egress procedures.

Upon sounding of the alarm, all persons inside the building will proceed to the nearest assembly area highlighted in posted emergency exit maps and plans. Emergency exit maps depict two escape routes for rooms with high-traffic.

Security will make a count of all persons to determine that the building is clear.

Security will determine when the drill is safely completed and provide the all clear to return to the building.

5.2 Emergency Equipment Checks

a. Security will perform checks on all fire extinguishers and AED devices monthly.

b. The Chief Operating Officer, or their designee, will update posted emergency escape plans and notify security of changes as needed.

The Director of Compliance, or designee, will schedule yearly checks of the fire alarm and fire suppression systems with a contractor licensed and trained to perform said checks.

6. ALARM AND/OR CAMERA SYSTEMS FAILURE

6.1 Manufacturing Facility

a. Alarm and camera systems shall remain operational at all times.

If alarm and camera systems are not operational at all times, refer to procedures listed in SOP-011.

SOP-S06: MONITORING AND SURVEILLANCE

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All facilities owned or operated by Coosa Medical Manufacturing will have 24-hour surveillance by a 24-hour security team.

2. SCOPE

It is the responsibility of the Chief Operating Officer, or their designee, to ensure that all monitoring and surveillance equipment is properly functioning at all times and that equipment meets, at a minimum, the standards required under Alabama Medical Cannabis law and rule.

3. CLOSED CIRCUIT TELEVISION

3.1 All activity in the manufacturing facility is monitored on a constant closed-circuit television.

3.2 All rooms within the manufacturing facility and near every egress and exterior entrance.

4. MONITORING OF MONEY

4.1 It is the responsibility of Security to obtain the name(s) of personnel, date, and time of money being counted from the till at the end of each business day. Personnel responsible for calling security before counting money and securing the money in their vault.

4.2 Security must log the information listed in 4.1 of this section in paper or electronic format and maintain the records for at least five years.

SOP-S07: SECURITY ALARM SYSTEM

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All facilities owned or operated by Coosa Medical Manufacturing has an active security alarm system operating at all times. Authorized employees will be trained on how to operate the alarm system.

2. SCOPE

It is the responsibility of the Chief Operating Officer, or their designee, to ensure that all alarm equipment is properly functioning at all times and that equipment meets, at a minimum, the standards required under Alabama Medical Cannabis law and rule and that only authorized employees have access to the alarm system.

3. ALARM SYSTEM REQUIREMENTS & TESTING

3.1 System Requirements

a. Requirements of the alarm system include, but are not limited to, the ability to detect and alarm based on forced access, glass break, major impact (audible), and motion.

3.2 Testing

a. Security must schedule, conduct, supervise, and report, at a minimum, quarterly tests of all alarm systems at all locations by simulating an event that would trigger the alarm system under normal conditions. An event includes, but is not limited to, activating an emergency call button.

Alarm system reports must be securely stored in paper or electronic formats.

Alarm system reports must include the date, time, location(s), description of the test, responding authorities, name(s) of personnel involved, and name(s) of personnel conducting the test.

Security shall provide to the Chief Operating Officer, or their designee, with a copy of all alarm system reports within 24 hours of the conclusion of testing.

4. ALARM SYSTEM

4.1 Authorized Personnel with Access

a. An employee who regularly opens or closes the facility can be deemed authorized to access alarm codes. Other employees may be authorized to access alarm codes if needed to complete a necessary job function. Use of these codes to disarm the alarm system is overseen by Security.

5. ACCESS AND STORAGE OF ALARM ACCESS INFORMATION

5.1 Authorized Personnel

a. Alarm access codes will be housed in the manufacturing facility security office in a locked area only accessible by security staff.

Copies of alarm access information will also be maintained by the COO, CFO, CEO, and COO.

All copies of alarm access information must be in hard-copy only. Electronic files with alarm access information must be stored on the secure network and password protected.

SOP-S08: PREVENTION OF MEDICAL CANNABIS THEFT

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

It is the responsibility of the Chief Operating Officer and the Director of Compliance to ensure that security measures are in place and followed by all employees in order to deter theft or diversion of cannabis or medical cannabis.

2. SECURITY MEASURES

2.1 Uniform Requirements

a. When working in the production area, all employees are required to wear uniforms issued by Coosa Medical Manufacturing.

All uniforms for employees regularly working in the restricted areas will be pocket-less. Clothing with pockets, worn by employees or non-employees, may be subject to additional review and search.

Employees working in the production area will be provided aprons with pockets.

All aprons must remain in the production area and security will strictly enforce aprons staying in only the secure areas.

2.2 Random Searches

a. All employees are subject to random searches for cannabis material upon exiting the production area.

Random searches will be conducted by a member of security.

Searches will include the recognizance of shoes and the employee shaking out all clothing to determine whether items are contained within clothing.

Employee lockers are also subject to random searches.

Employees will be provided with a lock for individual lockers upon request or may bring in their own lock. However, at the request of the CEO, an employee is required to open the locker for a search or the lock will be broken with approval from the CEO or designee.

2.3 Surveillance

a. All areas where there is cannabis or medical cannabis in a Coosa Medical Manufacturing facility is under constant video surveillance.

Security is monitoring actions in all rooms 24 hours a day.

Employees may be questioned by security for any reason and requested to explain their presence in a certain room or their actions in a certain room.

Employees are required to report to the CEO if the employee, during their employment with Coosa Medical Manufacturing, is charged with a controlled substance related offense.

If an employee is convicted of a disqualifying felony offense during employment, the employee will be subject to immediate termination.

If an employee is convicted of a controlled substance offense that does not constitute a disqualifying felony offense, the CEO retains the right to decide, on a case-by-case basis, whether or not the employee will remain employed with Coosa Medical Manufacturing.

SOP-S09: SECURITY RESPONSE TO SECURITY EMERGENCIES

TABLE OF CONTENTS

Pages: 1 of 6	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Security Directors maintain secure access to the manufacturing facility. Security alarm systems and monitoring are in place to keep employees safe from outside threats. Security Directors will be trained in their responsibilities to respond to an outside threat.

2. SCOPE

It is the responsibility of the Chief Operating Officer to ensure that all security personnel have been trained on the proper response to an outside security threat.

3. MANUFACTURING FACILITY

3.1 Break-In

a. In the event of a break-in, security must immediately notify law enforcement either by phone or by panic button. Panic buttons are located under the security desk. The panic button will immediately notify the dispatch center that an emergency is occurring and the dispatch center will immediately notify police.

Security must stay in the security office.

Security must then lock down the manufacturing facility via the security system. Locking down the facility will result in all badge entry doors being locked from entry. Badge entry doors will still be able to be opened for exit.

If an employee is in the building at the time of the break-in, security must immediately notify all employees that there is a security emergency. Security must notify employees via the radio system or cellphones. Employees will respond by taking actions pursuant to applicable policy.

Upon the arrival of law enforcement, it is security's responsibility to communicate with law enforcement and allow law enforcement access to the building. Security should follow all directions of law enforcement upon their arrival, even if contradictory to this SOP.

3.2 Persons Taken Hostage

a. A hostage situation includes a person who is under current and immediate threat by another person.

If security becomes aware of a hostage situation, security must immediately notify law enforcement by phone or by pressing the panic button located under the security desk.

Security must then lock down the facility using the security system, deactivating the card access system. If the threatening individual threatens to harm the hostage if the doors are not opened, security should open the doors and protect life over all else.

Security must then notify all personnel in the building via the radio system.

If the threatening individual gains access to the restricted area prior to the facility being locked down, security should still lock down the facility so that the individual cannot gain further access to rooms.

Security must then monitor all activity in the facility and report that activity to law enforcement as it occurs.

Security should also keep law enforcement informed of whether or not the outside person(s) still has a hostage and what type of weapon the person was carrying.

Upon the arrival of law enforcement, it is security's responsibility to communicate with law enforcement and allow law enforcement access to the building. Security should follow all directions of law enforcement upon their arrival, even if contradictory to this SOP.

3.3 Inside Threats

a. An inside threat is a person who is already inside the manufacturing facility, whether it be an employee or another person who was authorized to enter the building, that then becomes a threat.

Security should immediately alert law enforcement by phone or by pushing the panic button located under the security desk. Security should also call law enforcement to keep an open line of communication on what is occurring in the building.

Security should also notify all staff by using the radio system and stating, "Security emergency, proceed to safe areas." Staff will have been trained pursuant to SOP-S03 on which safe areas to go.

If the person is already in the manufacturing and production area, security should monitor cameras to watch where the person is going.

Security should then lock down the facility by using the security system.

Upon the arrival of law enforcement, it is security's responsibility to communicate with law enforcement and allow law enforcement access to the building. Security should follow all directions of law enforcement upon their arrival, even if contradictory to this SOP.

4. SEARCHES BY LAW ENFORCEMENT

4.1 If law enforcement arrives at any time and requests to search the facility, security is NOT authorized to allow law enforcement beyond the lobby.

4.2 Security must inform law enforcement that security is not authorized to allow their entry into the building and that the company's attorney will be contacted for further instructions.

4.5 Under no circumstances may law enforcement be allowed to search the facility without a proper warrant as determined either counsel or the CEO.

4.6. If security is unable to contact either counsel or the CEO, security should then call the executive on-call for the evening.

4.7 If security is unable to contact a Coosa Medical Manufacturing executive, security must call local law enforcement to have local law enforcement confirm the identity of the

agency attempting to gain access. Security should also request that local law enforcement verify if the warrant is valid.

4.8 If security still cannot contact counsel or the CEO or other Coosa Medical Manufacturing executive, security should allow law enforcement officials that have a valid warrant into the facility.

4.9 If law enforcement does not have a warrant, they should not be allowed into the facility, unless otherwise instructed by counsel or the CEO.

SOP-S10: WEAPONS POLICY

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Weapons, including firearms, are prohibited on the premises of Coosa Medical Manufacturing. Law enforcement, acting within the scope of their duties, are exempt from this policy. This prohibition applies even if an individual has a legal permit to carry a weapon, but does not prohibit employees from lawfully storing firearms in their locked vehicles in the parking lot. Holders of a legal permit to carry a weapon will be asked to remove their weapon from the premises or face possible charges of trespass.

2. SCOPE

It is the responsibility of the Chief Operating Officer to ensure that all security personnel have been trained on the proper response to the discovery of an unauthorized weapon on Coosa Medical Manufacturing property.

3. DEFINITIONS

Weapons are objects that may be used to attack another. Coosa Medical Manufacturing considers an item to be a weapon if it is created for use as a weapon or is so similar to an item created as a weapon that it appears to be, or is easily used as, a weapon. Weapons include firearms, as well as realistic replicas of firearms that may reasonably be thought to be actual weapons. Such realistic replicas are prohibited because their similarity in appearance to real weapons may allow them to be used to intimidate.

Coosa Medical Manufacturing supervisors have the discretion to determine when a replica is so realistic that it should be prohibited. Partial weapons and parts of weapons also are prohibited because they may be carried separately by collaborators for assembly subsequent to entry to the facility. In addition, partial weapons may appear to be operative and could be used to intimidate. Weapons also include sharp objects that could be effective in intimidating or harming.

The prohibited items list also includes as weapons many club-like items, whether made for use as weapons or made for other purposes but capable of being used as weapons. Examples include items such as batons and night sticks, as well as items of sporting

equipment, such as baseball bats, hockey sticks, lacrosse sticks, and tools such as crowbars.

4. MANUFACTURING FACILITY

4.1 Weapons are not permitted inside the manufacturing facility.

4.2 Security must immediately report threatening or violent behavior, with or without a weapon, to local law enforcement.

4.3 Security must follow law enforcement's instructions and do what is reasonable to ensure the safety of all persons.

4.4 If, at any time, an employee feels threatened by the presence of a weapon, that employee should remove themselves from the situation and, if possible, place a level of security between them and the threat. The employee then must call 911 or activate a panic button and notify security.

4.5 Upon notice of the presence of a weapon in the manufacturing facility and the owner of the weapon is not present, security personnel shall immediately locate the weapon, secure the weapon if safe to do so, and notify the police to confiscate the weapon. Security personnel may refer the owner to the law enforcement agency that confiscated the weapon.

SOP-S11: MANDATORY REPORTING

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical Manufacturing security personnel are required to write and submit an incident report form whenever requested by a Director or Executive, or as outlined in this section.

2. SCOPE

It is the responsibility of the Chief Operating Officer, or their designee, to ensure that all security personnel have been trained on the proper procedures to write and submit an incident report.

3. DEFINTIONS

A reportable incident is defined as an event that:

- Posed or poses an immediate threat to life, health, property, or environment;
- Has already caused loss of life, health detriments, property damage, or environmental damage;
- Has a high probability of escalating to cause immediate danger to life, health, property, or the environment;
- Is considered unlawful activity; or
- Substantially violates the policies and procedures within this document.

A substantial violation of the policies and procedures is defined as an action that deviates from the policies and procedures defined in this SOP that results in the loss trespass, or damage of property, harm to personnel, or violation of state and federal laws.

3. INCIDENT REPORT FORM

3.1 Incident report forms must be readily accessible to security personnel within the security office at all times.

3.2 At the moment security personnel on duty becomes aware of a reportable incident, the security personnel on duty must complete an incident report form and submit to the Chief Operating Officer, or their designee, Chief Operating Officer, and Director of Compliance within 24 hours of an incident.

3.3 Submitted incident report forms must be saved with either the Chief Operating Officer, or their designee, and Director of Compliance and retained for at least five years.

SOP-S12: LABORATORY ACCESS AND SAFETY

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

All activities and personnel are closely monitored by Coosa Medical Manufacturing security. All persons inside the building must be authorized. Employees should always feel safe in their work environments.

2. SCOPE

It is the responsibility of all Coosa Medical Manufacturing employees to control access to facilities and ensure a safe and secure work environment. This SOP is meant to provide advice to employees on how to achieve safety in the work environment.

4. SECURITY EMERGENCIES

4.1 Unauthorized persons

a. If an unauthorized person or persons is inadvertently allowed to enter the facility during business hours, personnel shall accompany the person or persons out of the facility and immediately report the entrance to security staff.

If an unauthorized person or persons enters the facility by force during business hours, personnel shall take all reasonable measures to protect themselves, including, but not limited to, immediately leaving an unsecure area. If personnel can safely do so without unreasonably putting themselves or others in danger of injury or death, personnel shall activate the emergency panic alarm system. If personnel are unable to activate the emergency panic alarm system, personnel shall call 911 as soon as reasonably possible.

4.2 Personal Protection

a. In the event of a situation that presents the threat of harm to individuals, personnel shall always put the safety of themselves as a higher priority to a procedure, including, but not limited to, securing medical cannabis, cash, or other Coosa Medical Manufacturing property.

5. MEDICAL EMERGENCIES

5.1 In the event of a medical emergency, personnel shall immediately call 911.

5.2 Personnel that are properly trained in providing medical emergency response, including, but not limited to, first responder training, CPR certification, or AED operation, may assist the complainant of the medical emergency until first responders arrive.

5.3 Personnel shall ensure that emergency responders have access to the complainant of the medial emergency and shall escort first responders to the area of the medical emergency.

SOP-S13: LABORATORY CRISIS INTERVENTION AND HARASSING PHONE CALLS

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. PURPOSE

This SOP is intended to ensure that patient and staff safety is maintained to the greatest extent possible when intervening with a patient who is demonstrating physical aggression or threatening physical aggression; and

To provide guidelines for utilizing a team approach to crisis intervention that will provide protection for both patients and staff and maintain therapeutic relationships to the greatest extent possible.

2. POLICY

Coosa Medical Manufacturing promotes a model of intervention that treats people with dignity and respect and suggests gradual and graded alternatives for de-escalating and supporting people in behavioral crisis.

To prevent physical injury to employees and non-employees alike, Coosa Medical Manufacturing employees are prohibited from physically restraining or detaining another person. Coosa Medical Manufacturing employees are always encouraged to seek a safe and secure location, call 911, and call security personnel if no safe alternative exists.

3. SCOPE

It is the responsibility of all Coosa Medical Manufacturing employees to control access to facilities and ensure a safe and secure work environment. Site Management is responsible to ensure that all processing employees understand the policies within this section. It is the responsibility of the Site Management to report all employee interventions to security.

4. CRISIS INTERVENTION

4.1 Employees must consider their personal safety as the top priority and must not intervene if unsafe to do so.

4.2 All interventions shall promote keeping people safe and treating people with dignity and respect.

4.3 In all intervention situations, staff may attempt to use verbal/non-physical interventions before notifying law enforcement.

4.4 Staff members may work as a de-escalating team to bring about a reduction in tension in the patient who is demonstrating physical aggression or threatening physical aggression behaviorally disturbed or disordered.

4.5 Site management should provide support to any employee that is the initial responder to a crisis.

4.6 If a crisis occurs, staff must make every effort to inform site management of the crisis situation.

4.7 Site management may communicate with the person in crisis or designate another team member with the best rapport to do so.

4.8 Site management will assess the situation, nature of the problem, and identify resources needed. Resources include other Coosa Medical Manufacturing employees, Coosa Medical Manufacturing security personnel, non-emergency contacts, emergency personnel, and law enforcement.

4.9 Site management or their designee must report all interventions to Coosa Medical Manufacturing Security personnel within 24 hours of the conclusion of the intervention.

5. HARASSING PHONE CALLS

5.1 Coosa Medical Manufacturing contracts with Nextiva, which utilizes Comcast and Nextera port-forwarding, to provide main phone lines. Contact a Nextiva Administrator for detailed location information.

5.2 To report threatening, abusive, or obscene calls following the steps below:

b. Always contact your local Law Enforcement Agency and they will contact Nextiva, Comcast, or Nextera for assistance.

In addition to contacting Law Enforcement, contact Security to assist with the investigation and to document the event in an Incident Report.

SOP-S14: CYBERSECURITY AND DATA PROTECTION

TABLE OF CONTENTS

Pages: 1 of 3	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. PURPOSE

The purpose of this procedure is to provide instructions for IT Security at Coosa Medical.

2. RESPONSIBILITY

The Director of Infusion and Formulation and/or the Manager will ensure the security of the hardware, software, data and communications networks of Coosa Medical.

3. PROCEDURE

The Director of Infusion and Formulation and/or Manager are responsible for all information technology maintenance including:

a. Software registration;
b. Security patches;
c. Malicious software prevention;
d. Account management;
e. Security status and network access monitoring;
f. Disposal and redeployment;
g. Agent IT security training; and
h. Vulnerability assessments.

All agent passwords for software and network access will be changed every six (6) months or immediately upon any resignation, termination or suspension. The information technology consultant will ensure system required password changes.

Access to protected information will be restricted to essential personnel only.

Examples of protected information include:

a. Security and cash management procedures;
b. Asset and inventory lists;
c. Access control and surveillance head-end equipment locations;
d. Network data and credentials;

e. Floor plans of critical areas;
f. Customer records
g. Password and code records; and
h. Agent records.

The Director of Infusion and Formulation and/or designee is required to identify cyber security incidents. Incidents include natural disasters impacting technology infrastructure and unauthorized network access exposing protected information.

Every employer issued device will contain a device-level encryption package. Issued devices include thumb drives, smart phones, tablets, etc. Cyber security measures implemented include:

a. Creation of an internal network and a separate network for guests, if necessary;
b. A secure and encrypted proprietary email system;
c. All Company data will be encrypted and backed up offsite, using secure cloud storage services; and
d. Physical and logical separation will be provided between all security systems, including the building management system, the Seed to Sale system and any other supervisory control access system.

This is very much reflected in both the technology and its process of deployment implemented by Coosa Medical. Coosa Medical believes it can enhance security by utilizing meaningful analytic conclusions out of the types of data that are available. The result is the implementation of methods and technology that are largely unique. To accomplish these objectives, Coosa Medical may analyze the following data channels:

a. Email;
b. Instant Message;
c. VOIP voice mails;
d. COMPANY-provided cell phones;
e. Facebook (public facing);
f. Twitter (public facing);

g. Any other social media that is or becomes in wide use amongst employees;
h. Smartcards keys; and
i. Inventory control System.

These channels will be monitored for the following things:

a. Associations: References to and/or communications with customers, suppliers, and known illegal drug distributors;
b. Topics: Drugs, gambling debts, threats, etc.;
c. Sentiment Analysis: Evidence of extreme agitation;
d. Time-appropriateness, consistency in time and concurrence in time with other events; and
e. Actor-appropriateness and whether the agent is performing the expected task.

4. REPORTS REQUIRED

None Required

5. AUTHORIZATION FOR DEVIATION

The Director of Operations or General Manager must direct any deviation from the standard procedure.

6. APPROVAL, REVIEW, REVISION AND DISTRIBUTION

The standard procedure shall be reviewed by the Director of Infusion and Formulation and/or the Processing Manager yearly, following the issuance or last revision or review date. Any revision must be signed and verified by an executive team member prior to being distributed. Distribution of revisions and collection of any outdated versions shall be the responsibility of the Director or Manager. The Director of Infusion and Formulation will scan the originals into the computer and retain the signed originals in a binder in their office.

Finance

SOP-F01: FINANCE AND PURCHASING

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical Manufacturing engages with vendors to procure raw material inputs, supplies, equipment, utilities, and services to support successful operations. The purpose of this document is to outline the policies and processes that support the most effective and economical vendor relationships.

2. SCOPE

It is the responsibility of each individual manager and the Chief Financial Officer, or CFO's designee, to ensure that all finance and purchasing policies are followed.

3. STANDARD PURCHASING PROCESS

3.1 The standard process for purchasing is as follows:

a. A need is identified and a preferred vendor selected.

b. Approval to purchase is granted by a supervisor or CEO (depending on value).

c. Purchase order is created by Coosa Medical Manufacturing's finance team.

d. Coosa Medical Manufacturing is invoiced by the vendor.

e. Invoices are paid on the 1st and the 15th of each month.

4. PREFERRED VENDOR PROGRAM

4.1 Coosa Medical Manufacturing will make every effort to use preferred vendors where the company has negotiated discounts and/or favorable payment terms.

4.2 The CFO ($5,000 and over) or Controller (less than $5,000) must approve purchases made with a non-preferred vendor.

5. APPROVAL TO PURCHASE

5.1 Low-Value Purchasing Authority: Department Heads and those whom they designate have authority to purchase goods and services directly with suppliers at a value below $500 when no contract is required or an appropriately executed contract already exists.

5.2 High-Value Purchasing Authority: Authority to purchase at a value at or above $5000 is delegated to department heads and requires the approval of the CFO. Approval can be given for individual purchases or on a project basis where a budget exists. No supplier may begin work before a contract is executed or purchase order is issued.

5.3 Signature Authority: Only officers of the corporation may execute procurement agreements (Procurement agreements are written contracts that bind Coosa Medical Manufacturing and a supplier to a purchasing obligation). Such written authority includes terms and conditions, typically including a review by Coosa Medical Manufacturing Counsel, and all such terms and conditions must be followed.

6. PURCHASE ORDERS

6.1 A purchase order will be created by the finance department to initiate any purchase. The purchase order clearly defines the product or service to be purchased, the vendor, and the intended area of use. Information required to create a purchase order:

a. Vendor Name

b. Vendor Address

c. Vendor Email

d. Amount ($)

e. Product Description

f. Area where product/service will be used

7. INVOICES

7.1 Invoices should be addressed to [EMAIL ADDRESS] or provided in hard copy to:

Coosa Medical Manufacturing

Accounts Payable

[INSERT ADDRESS]

7.2 Invoices will be processed and paid on the nearest business day to the 1st and 15th of each month. Coosa Medical Manufacturing reserves the right not to pay an invoice that does not have a coordinating purchase order.

SOP-F02: TRAVEL AND OTHER EXPENSE – REIMBURSEMENT

TABLE OF CONTENTS

Pages: 1 of 8	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

Coosa Medical Manufacturing recognizes that board members, officers, and employees ("Personnel") of Coosa Medical Manufacturing may be required to travel or incur other expenses on occasion to conduct company business and to further the mission of the organization. The purpose of this Policy is to ensure that: (a) an adequate cost of controls are in place; (b) travel and other expenditures are appropriate; and (c) to provide a uniform and consistent approach for the timely reimbursement of authorized expenses incurred by personnel. It is the policy of Coosa Medical Manufacturing to reimburse only reasonable and necessary expenses actual incurred by personnel.

Reimbursement requests shall be reviewed for accuracy, authenticity, and compliance with this chapter by the Controller, or their designee, within ten (10) business days. The Controller, or their designee, shall notify personnel of whether their request is accurate, authentic, and in compliance with this chapter, with explanation, within five (5) business days after initial review of the reimbursement request.

If the reimbursement request is approved by the Controller, or their designee, the Controller or their designee shall submit the reimbursement request to the Chief Financial Officer, or their designee, for final approval within five (5) business days after initial review of the reimbursement request.

The Chief Financial Officer, or their designee, shall either approve or deny the reimbursement request within five (5) business days of receiving the reimbursement request from the Controller or Controller's designee.

Personnel shall be reimbursed the amount approved by the Chief Financial Officer, or their designee, within five (5) business days of the Chief Financial Officer, or their designee's, approval of the personnel's reimbursement request.

2. SCOPE

It is the responsibility of each individual manager and the Chief Financial Officer, or CFO's designee, to ensure that all finance and purchasing policies are followed.

3. EXPECTATIONS

3.1 When incurring business expenses, Coosa Medical Manufacturing expects personnel to:

a. Exercise discretion and good business judgment with respect to those expenses.

b. Be cost conscious and spend Coosa Medical Manufacturing's money as carefully and judiciously.

c. Report expenses, supported by required documentation, as they were actually spent.

4. EXPENSE REPORT

4.1 Expenses will not be reimbursed unless the individual requesting reimbursement submits a written Expense Report. The Expense Report, which should be submitted at least monthly or within two (2) weeks of the completion of travel if travel expenses reimbursed is requested, must include:

a. The individual's name.

If reimbursement for travel is requested: the date, origin, destination and purpose of the trip, including a description of each Company-related activity during the trip.

The name and affiliation of all people for whom expenses are claimed (i.e. people on whom money is spent in order to conduct Coosa Medical Manufacturing Lab's business).

An itemized list of all expenses for which reimbursement is requested.

4.2 If expense reports are submitted well after the fact, the company reserves the right to withhold payment, or agree to a payment plan for large amounts.

5. RECEIPTS

5.1 Receipts are required for all expenditures billed directly to Coosa Medical Manufacturing, such as airfare and hotel charges. No expense in excess of $25.00 will be reimbursed to Personnel unless the individual requesting reimbursement submits with the Expense Report written receipts from each vendor (not a credit card receipt or statement) showing the vendor's name, a description of the services provided (if not otherwise obvious), the date, and the total expenses, including tips (if applicable).

6. GENERAL TRAVEL APPROVAL

6.1 **Advance Approval**: An individual's supervisor must approve, in advance, all trips involving air travel or at least one overnight stay. Additionally, the CEO or CEO's designee must approve out-of-state travel.

6.2 **Necessity of Travel**: In determining the reasonableness and necessity of travel expenses, personnel and the person authorizing the travel shall consider the ways in which Coosa Medical Manufacturing will benefit from the travel and weigh those benefits against the anticipated costs of travel. The same considerations shall be taken into account in deciding whether a particular individual's presence on a trip is necessary. In determining whether the benefits to Coosa Medical Manufacturing outweigh the costs, less expensive alternatives, such as participation by telephone or video conferencing, or the availability of local programs or training opportunities, shall be considered.

6.3 **Personal and Spousal Travel Expenses**: Individuals traveling on behalf of Coosa Medical Manufacturing may incorporate personal travel or business with their company-related trips; however, personnel shall not arrange company travel at a time that is less advantageous to Coosa Medical Manufacturing or involving greater expense to Coosa Medical Manufacturing in order to accommodate personal travel plans. Additional expenses incurred as a result of personal travel, including but not limited to extra hotel nights, additional stopovers, meals or transportation are the

sole responsibility of the individual and will not be reimbursed by Coosa Medical Manufacturing. Expenses associated with travel of an individual's spouse, family, or friends will not be reimbursed by Coosa Medical Manufacturing.

7. AIR TRAVEL

7.1 **General**: Air travel reservations should be made as far in advance as possible in order to take advantage of reduced fares. Coosa Medical Manufacturing will reimburse or pay only the cost of the lowest coach class fare actually available for direct, non-stop flights from the airport nearest the individual's home or office to the airport nearest the destination.

7.2 **Saturday Stays**: Personal traveling on behalf of Coosa Medical Manufacturing are not required to stay over Saturday nights in order to reduce the price of an airline ticket. An individual who choose to stay over a Saturday night shall be reimbursed for reasonable lodging and meal expenses incurred over the weekend to the extent the expenses incurred do not exceed the difference between the price of the Saturday night stay ticket and the price of the lowest price available ticket that would not include a Saturday night stay. To receive reimbursement for such lodging and meal expenses, the individual must supply, along with the Expense Report, documentation of the amount of the differences between the price of the Saturday stay and non-Saturday stay airline tickets.

7.3 **Frequent Flyer Miles and Compensation**: Personnel traveling on behalf of Coosa Medical Manufacturing may accept and retain frequent flyer miles. Individuals may not deliberately patronize a single airline to accumulate frequent flyer miles if less expense comparable tickets are available on another airline.

8. LODGING

8.1 Personnel traveling on behalf of Coosa Medical Manufacturing may be reimbursed at the single room rate for the reasonable cost of hotel accommodations. Convenience, the cost of staying in the city in which the hotel is located, and proximity to other

venues on the individual's itinerary shall be considered in determining reasonableness. Personnel shall make use of available corporate and discount rates for hotels.

9. AIR TRAVEL

9.1 Personnel traveling on behalf of Coosa Medical Manufacturing are reimbursed for the reasonable and actual cost of meals (including tips) subject to a maximum per diem meal allowance of $75 per day.

10. GROUND TRANSPORTATION

10.1 **Courtesy Cars**: Many hotels have courtesy cars, which will take you to and from the airport at no charge. The hotel will generally have a well-marked courtesy phone at the airport if this service is available. Employees should take advantage of this free service whenever possible.

10.2 **Airport Shuttle or Bus**: Airport shuttles or buses generally travel to and from all major hotels for a small fee. At major airports, shuttle or bus services are as quick as a taxi and considerably less expensive. Airport shuttle or bus services are generally located near the airport's baggage claim area.

10.3 **Taxis**: When courtesy cares and airport shuttles are not available, a taxi is often the next most economical and convenient form of transportation when the trip is for a limited time and minimal mileage is involved. A taxi may also be the economical mode of transportation between and individual's home and the airport.

10.4 **Rental Car**: Car rentals are expensive, so other forms of transportation should be considered when practical. Employees will be allowed to rent a car while out of town provided that the individual's supervisor has given advance approval and that the cost is less than alternative methods of transportation.

10.5 **Insurance**: Employees are responsible for insurance coverage. Coosa Medical Manufacturing is not responsible for insurance coverage or associated costs of insurance.

11. PERSONAL CARS

11.1 Personnel are compensated for use of their personal cars when used for company business. When individuals use their personal cars for travel, including travel to and from the airport, reimbursement for mileage will be allowed at the currently approved IRS rate per mile.

11.2 In the situation of an individual using their personal cars to take a trip that would normally be made by air, e.g. travel between two Alabama cities, reimbursement for mileage will be allowed at the currently approved rate; however, the total mileage reimbursement will not exceed the sum of the lowest available round trip coach airfare.

12. PARKING/TOLLS

12.1 Parking and toll expenses, including charges for parking, incurred by personnel traveling on company business will be reimbursed. The costs of parking tickets, fines, car washes, etc. are the responsibility of the employee and will not be reimbursed. On-airport parking is permitted for short business trips. For extended trips, personnel should seek less-expensive alternatives such as off-airport parking, shuttles, and/or taxi service.

13. ENTERTAINMENT AND BUSINESS MEETINGS

13.1 Reasonable expenses incurred for business meetings or other types of business-related entertainment will be reimbursed only if an Officer of Coosa Medical Manufacturing approves the expenditures in advance. Detailed documentation for such an expense must be provided, including:

a. Date and place of entertainment,

b. Nature of expense,

c. Names, titles, and corporate affiliation of those entertained,

d. A complete description of the business purpose for the activity, including the specific business matter discussed; and

e. Vendor receipts (not credit card receipts or statements) showing the vendor's name, description of services provided, date, and the total expenses, including tips (if applicable).

14. OTHER EXPENSES, INCLUDING MOBILE PHONES

14.1 Reasonable Coosa Medical Manufacturing-related telephone and fax charges due to absence of personnel from the individual's place of business are reimbursable. In addition, reasonable and necessary gratuities that are not covered under meals may be reimbursed. Finally, emergency secretarial work and/or postal charges incurred are reimbursable for the purpose of work on behalf of Coosa Medical Manufacturing.

14.2 Coosa Medical Manufacturing will reimburse employees $50 per month for mobile phone usage provided:

a. They use their phone for business purposes, AND

b. Their job requires them to be accessible during after normal, 8 a.m. to 5 p.m., Monday through Friday, business hours.

15. NON-REIMBURSABLE EXPENDITURES

15.1 Coosa Medical Manufacturing maintains a strict policy that expenses in any category that could be perceived as lavish or excessive will not be reimbursed. Expenses that are not reimbursable include, but are not limited to:

a. Illegal drugs of any kind.

b. Travel insurance.

c. First-class tickets or upgrades (unless economy or business class tickets are unavailable).

d. When lodging accommodations have been arranged by Coosa Medical Manufacturing and the individual elects to stay elsewhere, reimbursement is made at the amount no higher than the rate negotiated by Coosa Medical Manufacturing. Reimbursement shall not be made for transportation between alternate lodging and the meeting site.

e. Movies or mini-bar costs.

f. Membership dues at a country club, private club, athletic club, golf club, tennis club, or similar recreational organization.

g. Participation in or attendance at golf, tennis, or sporting events, without the advance approval from an Officer of Coosa Medical Manufacturing.

h. Purchase of golf clubs or other sporting equipment.

i. Spa or exercise charges.

j. Clothing purchases.

k. Business conferences and/or entertainment that is not approved by an Officer of Coosa Medical Manufacturing.

l. Car washes.

m. Toiletry articles.

n. Expenses for spouses, friends, or relatives. If a spouse, friend, or relative accompanies personnel on a trip, it is the responsibility of the personnel to determine the added cost for double occupancy and related expenses and to make the appropriate adjustment in the reimbursement request.

SOP-F03: PURCHASING AND ACCOUNTS PAYABLE

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

This purpose of this document is to outline the policies and processes that support accurate purchasing processes and procedures.

2. SCOPE

It is the responsibility of each manager and the Chief Financial Officer, or CFO's designee, to ensure that all finance and purchasing policies are followed.

3. INTIATING A PURCHASE

3.1 All purchase request forms, employee expense forms, and invoices must be marked with a department identifier. Department identifiers are: Admin, Lab, Grow, Eagan, St. Paul, St. Cloud, and Hibbing.

3.2 All purchase requests are made to the Chief Financial Officer, or CFO's designee. For non-recurring charges, a Purchase Request Form is complete and signed by requester and approved by the Chief Financial Officer, or CFO's designee.

3.3 As invoices are received by either the Chief Financial Officer, or CFO's designee, or Accountant. Accountant reviews and recalculates the invoice, researches the vendor, and the records in QuickBooks as A/P.

a. Vendor's W-9 must be obtained prior to initiation of payment.

b. Proper account coding is reviewed for proper classification of expenses.

c. Expenses are reviewed for potential capitalization to fixed assets, prepaid, etc.

3.4 At the time of check-run, invoices are presented to the Chief Financial Officer, or CFO's designee, for approval. The Chief Financial Officer, or CFO's designee's signature represents approval.

3.5 Accountant will draft all checks (but does not have signing authority). A copy of the invoice and check is made and retained on file.

3.6 The check and accompanying invoice are presented to the Chief Financial Officer. Checks are signed by the Chief Financial Officer, or CFO's designee.

4. QUARTERLY BUDGET-TO-ACTUAL REPORTS

4.1 Budget-to-Actual reports are reviewed by the CEP at every board meeting. Variances are investigated as necessary.

4.2 Bank statements are included in board packets at every meeting.

5. COMPANY DEBIT CARD

5.1 Custody of the Coosa Medical Manufacturing's debit card remains with the Chief Financial Officer, or CFO's designee.

5.2 The requisition form must be completed and approved by the Chief Financial Officer, or CFO's designee, prior to use.

a. Company division and purpose of the purchase should be included to code the purchase properly.

5.3 Receipts are required to be submitted in a timely manner.

6. BANK WIRES

6.1 A documented request is made by a vendor.

6.2 Wires require approval of the Chief Financial Officer, Chief Executive Officer, or CEO's designee.

6.3 The Accountant initiates a wire with the bank. A bank "callback" procedure is initiated.

6.4 Funds are not transferred until the bank verifies and obtains approval from the CFO or CEO.

7. EFTs

7.1 The Accountant is responsible for initiating EFTs.

7.2 EFT's can only be authorized by the Chief Financial Officer, Chief Executive Officer, or CEO's designee.

7.3 EFT's are reviewed by the Accountant on a monthly basis.

7.4 New EFT's must be authorized by the CFO or CEO and recorded on the List of Authorized EFT vendors maintained by the Accountant.

8. EMPLOYEE EXPENSE REIMBURSEMENTS

8.1 Employee purchases should be done in accordance with Coosa Medical Manufacturing T & E Policy where applicable.

8.2 When a purchase is made by an employee, they must complete an Employee Reimbursement Form. The form contains purpose of purchase, amount, vendor, date of purchase, and department identifier. Receipts for all purchases are submitted with the form. The form is approved by the Chief Financial Officer, or CFO's designee, prior to payment.

8.3 Payment is made at the next check run, using standard A/P procedures.

SOP-F04: RECEIPTS AND REVENUE

TABLE OF CONTENTS

Pages: 1 of 4	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. POLICY

This purpose of this document is to outline the policies and processes that support accurate purchasing processes and procedures.

2. SCOPE

It is the responsibility of each manager and the Chief Financial Officer, or CFO's designee, to ensure that all finance and purchasing policies are followed.

3. SALE TRANSACTIONS

At the time of sale shipment to a dispensary, a facility employee enters the quantity and type of product into the Coosa Medical software and ensures that the product is properly packaged and labeled and is accompanied by a proper manifest. The facility employee then also ensures that the products are properly tagged, QR coded, and logged into the seed-to-sale system.

In addition to Coosa Medical Manufacturing software automatically updating its electronic records, facility employees also track all shipments within a hard-copy binder. This includes detailed information on each sale such as product, customer, etc. This log is updated for every sale and every delivery shipped from the facility.

4. MONTHLY RECONCILIATION

On a monthly basis, the Cash Count Forms are reconciled to deposits on bank statements.

4.1 On a monthly basis, the Accountant performs a review and reconciliation of sales and inventory. Monthly sales reports are reconciled to inventory records and transfer manifests.

5. QUARTERLY REVIEW

5.1 Budget-to-actual sales and expenditures are reviewed by the Chief Financial Officer, or CFO's designee.

SOP-F05: SALES & CASH MANAGEMENT

TABLE OF CONTENTS

Pages: 1 of 11	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. PURPOSE

1.1. The purpose of this procedure is to provide instructions that will ensure that all sales and transactions are carried out in accordance with state laws and regulations.

2. RESPONSIBILITY

1.2. The Director of Operations or General Manager is responsible for maintaining and training this P&P.

3. PROCEDURE

1.3. No unlawful sales transactions are permitted or tolerated by Coosa Medical. Required identification and recordkeeping measures are addressed as well as training requirements for agents and terminable offenses.

1.3.1. Additional measures address delivery sales, wholesale sales, preparation of taxes, and required accounting measures. The plan provides a list of prohibited transactions and provisions for secure cash management. The General Manager is assigned oversight responsibilities for ensuring the accuracy and maintenance of all sales records.

1.4. Coosa Medical must ensure that no unlawful sales transactions are permitted or tolerated in accordance with state laws and regulations. All agents must report any diversion or unlawful sales witnessed or suspected to a manager or the General Manager as soon as possible as a condition of employment.

1.5. The General Manager must ensure that no cannabis or cannabis products are sold by Coosa Medical agents unless all required quality assurance testing has been completed and the results are available for viewing by agents, other licensees, patients and caregivers as requested or at time of sale.

1.6. The general manager must ensure all transactions are documented in the inventory control system and all purchases from ‘deli style counter’ (if applicable) are properly

weighed on a NTEP (legal for retail trade) scale that has been inspected and certified and is integrated with the point of sale system.

1.6.1. If products are pre-packaged, the net total weight should be verified at the time of sale on each pre-packaged product. If the package weight is more than 10% different than the labeled net weight, do not sell the product and notify the manager as soon as possible to investigate the difference. Documentation regarding licensing of the scale must be maintained by the General Manager and made available to the Commission upon request.

1.7. The General Manager is responsible for all sale transitions including on-site, on- line and delivery (if applicable) transactions. The General Manager must ensure all agents working in the facility are properly trained on all sales procedures.

1.8. The General Manager, in coordination with the Director of Operations must ensure that any point of sale system used for sales transactions complies with all regulatory requirements, Coosa Medical policies, and provides sufficient controls to prevent unlawful sales or sales over established purchase limits. The point of sale system must interface with Commission systems (METRC) as required. The agent must ensure point of sale system records:

1.8.1. For each person who purchases cannabis or patient products from Coosa Medical:

1.8.2. The number of the patient's registry card;

1.8.3. The date on which the card was issued; and

1.8.4. The date on which the card will expire.

1.8.5. The agent's registration card number;

1.8.6. Any information requested by the Commission regarding nonresidents who have purchased cannabis from the Coosa Medical;

1.8.7. Verification of the identity of a person to whom cannabis or cannabis products are sold or otherwise distributed;

1.8.8. Such other future information as the Commission may require;

1.8.9. The General Manager must ensure the point of sale system encrypts and protects the personal identifying information of registry card holders; and

1.8.10. No personal information of a card holder may be divulged by any agent for any purpose not specifically authorized by law as a condition of employment.

1.9. Prior to any sale, an agent must:

1.9.1. Verify the identity of registry card holder or the designated primary caregiver. If an agent is unsure if the individual present matches the photograph on the registry identification card, he or she should request a second photo ID from the individual for verification;

1.9.2. Confirm that the patient is properly registered in the point of sale system;

1.9.3. Verify the validity of the registry identification card of the patient or the designated primary caregiver. If the agent suspects the registry identification presented is not valid for any reason, he or she should request a review by the unit manager or General Manager for approval; and

1.9.4. Verify the remaining balance of medical cannabis or infused THC products for the patients 30-day supply.

1.10. An agent completing a sales transaction must ensure the following information is properly recorded in the point of sales system for each transaction:

1.10.1. The name and registry card identification number of the patient or their primary caregiver;

1.10.1.1. The amount (total equivalent usable cannabis weight) dispensed;

1.10.1.2. Whether the patient or their caregiver received the medical cannabis;

1.10.1.3. The date and time of the transaction;

1.10.1.4. The agent's registry card identification number; and

1.10.1.5. The registration number of the Coosa Medical.

1.11. If the point of sale system does not record the above information for any reason, the transacting agent must notify the general manager of the system failure immediately.

1.12. All agents must ensure cannabis and cannabis products are stored behind the counter or other barrier so that patients and caregivers visiting the facility do not have direct access to the product. No patient or caregiver is permitted to touch any product containing cannabis or THC prior to the completion of the sale.

1.13. The General Manager must ensure the facility is operational during posted hours. The General Manager shall ensure the hours comply with the hours of operation disclosed to the Commission. The Director of Operations must visibly post the hours of operation in the facility.

1.14. The General Manager must ensure that accurate accompanying material is provided with each sale of cannabis and cannabis products. The accompanying material must be printed in no smaller than 12-point font (no italics allowed) and contain the following:

1.14.1. A disclosure of any pesticides applied to the cannabis plants and growing medium during production and processing (must be provided by the vendor when the inventory is received);

1.14.2. A disclosure of any pesticides applied to the cannabis plants and growing medium during production of the cannabis used to create the extract added to the edible cannabis products or cannabis-infused products and the type of extraction method used, including any solvents, gases, or other chemicals or

compounds used to produce or that are added to the extract;

1.14.3. The following warnings:

1.14.3.1. "Warning: This product may have intoxicating effects and may be habit forming. Smoking is hazardous to your health";

1.14.3.2. "There may be health risks associated with consumption of this product";

1.14.3.3. "Should not be used by women who are pregnant or breast feeding";

1.14.3.4. "For use only by the person named on the label of the dispensed product. Keep out of the reach of children"; and

1.14.3.5. "Marijuana can impair concentration, coordination and judgment. Do not operate a vehicle or machinery under the influence of this drug," or "Products containing marijuana can impair concentration, coordination and judgment. Do not operate a vehicle or machinery under the influence of this drug," and "Caution: When eaten or swallowed, the intoxicating effects of this drug may be delayed by two or more hours."

1.15. Each agent must offer any appropriate patient education or support materials in addition to the accompanying materials at every visit including, but not limited to, test results and the name of the laboratory, manufacturer information, or cannabis genetics information. The General Manager must ensure this information is readily available.

1.16. The Director of Operations and the General Manager must ensure the point of sale system prints labels for each product that are compliant with all regulations.

Each agent must verify the label(s) printed and affixed to all cannabis packages sold contains the following information:

1.16.1. Company's name and address;

1.16.2. Lot number, date of harvest and name and registration number of the vendor's facility;

1.16.3. Date of sale;

1.16.4. Net weight;

1.16.5. Patient's name and registration number (and caregiver name if a caregiver purchase); and

1.16.6. Cannabinoid profile, potency levels and terpene profile.

1.16.7. The total milligrams of active cannabinoids and terpenes in the product (as verified by test results from an independent lab);

1.16.8. Extraction method and solvent, gas and chemicals used (if applicable); and

1.16.9. A list of major allergens.

1.17. No agent may dispense more than 120 grams of cannabis to any one patient or their designated primary caregiver in any single 30-day period. The point of sales system must be reviewed for previous purchases prior to completing any sale.

1.17.1. The maximum allowable quantity of cannabis products and cannabis- infused products is an amount that is equivalent to 120 grams of usable cannabis. Any agent who sells product to an individual that exceeds the 120 gram limit may be terminated;

1.17.2. The Director of Operations and the General Manager must ensure that the point of sale system adequately flags and prohibits any over limit sales. Cannabis product weight must be included in the calculation of the sales limit

based on the total cannabinoid content provider by the manufacturer; and

1.17.3. The General Manager must also ensure a sign is posted in the facility that states unambiguously the legal limits on the possession and sale of cannabis for medical purposes.

1.18. Any Coosa Medical agent may refuse to dispense cannabis or cannabis products to any patient or caregiver that is above allowable limits or in the opinion of the agent, the patient, caregiver or the public would be placed at risk without fear of management retribution. Each time the patient or caregiver requests and does not obtain cannabis or cannabis products from Coosa Medical, the agent must record in the patient record:

1.18.1. The date;

1.18.2. The name and registry card number of the patient; and

1.18.3. The reason the cannabis or cannabis products was not provided.

1.18.4. All agents must refuse to sell cannabis or cannabis products to a patient or caregiver they suspect may be diverting product and notify the unit manager the General Manager immediately.

1.18.5. If an individual attempts to use a qualifying patient or caregiver identification card to whom it has not been issued, any registered agent to whom it is offered shall confiscate it and initiate the return of the card to the Commission within 5 business days.

1.19. Coosa Medical agents may not:

1.19.1. Dispense, deliver or otherwise transfer cannabis to a person other than a patient or caregiver holding a valid registry identification care;

1.19.2. Provide cannabis to another cannabis business except as specified in Coosa Medical policies, and procedures and applicable laws and regulations and

approved by the Director of Operations and/or the General Manager;

1.19.3. Acquire cannabis, cannabis products or cannabis plants, except through the processing of cannabis by another licensee, or patient or caregiver, as specified in applicable laws and regulations and approved by the general manager;

1.19.4. Acquire, possess, cultivate, deliver, transfer, transport, supply or dispense cannabis for any purpose except to assist authorized patient and caregivers in compliance with all Coosa Medical policies and procedures;

1.19.5. Give away any cannabis except in accordance with applicable laws and regulations and as approved by a unit manager;

1.19.6. Adulterate cannabis, including adulteration with psychoactive additives or other illicit substances; and

1.19.7. Violation of any of the above policies may lead to immediate termination.

1.20. All cannabis products for delivery must be packaged for final delivery in the facility processing the sale:

1.20.1. Orders received through the secure website must be verified by phone or email prior to packaging or delivery scheduling;

1.20.2. Two agents are required to verify the accuracy of any order fulfillment, including confirming invoice and manifest information, as follows:

1.20.2.1. Quantities;

1.20.2.2. Weights;

1.20.2.3. Labels;

1.20.2.4. Items;

1.20.2.5. Receipt information;

1.20.2.6. Customer or company information;

1.20.2.7. Payment information; and

1.20.2.8. Estimated delivery schedule.

1.21. All sales, tax transactions and operating expenses must be recorded properly, accurately and completely entered in the point of sale system and accounting system. The general manager must ensure that if the point of sale system is not functional for any reason that all transactions are properly recorded manually and entered into the system as soon as it is available. The Director of Operations and the General Manager must ensure all bookkeeping activities for each transaction are performed accurately and in a timely manner.

1.21.1. Sales records and invoices must be created and maintained in the point of sale system or other cloud based system after termination of operations.

1.22. The Director of Operations and the General Manager must ensure a system of internal controls is maintained for cash handling and accounting functions. Tight controls must remove opportunities for unauthorized access to cash by agents or external parties:

1.22.1. Dual custody is required any time cash is transferred from the register to the safe and from the facility to the bank;

1.22.2. Petty cash must be controlled by the General Manager. The petty cash account should be limited to $1,000. All receipts and vouchers must be accounted for and the drawer must always be in balance;

1.22.3. ATM and pin debit transactions must be reconciled weekly by the General Manager.

1.23. The General Manager must ensure proper separation of duties including the separation of the following activities:

1.23.1. Making deposits and recording accounting entries;

1.23.2. Approving petty cash transaction and replenishing the petty cash account;

1.23.3. Issuing payments and reconciling bank statements; and

1.23.4. Approving expenses and initiating payments.

1.24. The General Manager is responsible for the security of all cash. The following cash security measures must be followed:

1.24.1. All deliveries must be paid online by credit or debit card if applicable. Wholesale sales may be paid by wire transfer only if approved by the Director of Operations;

1.24.2. Cash must be counted in a secure and locked area with appropriate surveillance;

1.24.3. Insurance coverage should be maintained to provide the maximum amount of cash coverage required; and

1.24.4. Cash handlers will be assigned daily.

1.25. Executive management performs oversight of accounting and audit activities:

1.25.1. The Company's CPA firm must be selected by executive management and perform an annual audit of all financial transactions and reporting; and

1.25.2. A "whistle blower" policy exempts agents who report the mishandling of cash from retribution.

4. REPORTS REQUIRED

1.26. None.

5. AUTHORIZATION FOR DEVIATION

1.27. The Director of Operations or General Manager must direct any deviation from the standard procedure.

6. APPROVAL, REVIEW, REVISION AND DISTRIBUTION

1.28. The standard procedure shall be reviewed by the Director of Operations and/or the General Manager yearly, following the issuance or last revision or review date. Any revision must be signed by the General Manager and verified by an executive team member prior to being distributed. Distribution of revisions and collection of any outdated versions shall be the responsibility of the General Manager. The General Manager will scan the originals into the computer and retain the signed originals in a binder in their office.

SOP-F06: Tax Collection and Payment

TABLE OF CONTENTS

Pages: 1 of 12	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

1. ACCOUNTING PROCEDURES

Coosa Medical Manufacturing, LLC will use both internal resources and outside professional services to maintain financial integrity, transparency, and compliance. We will have a dedicated Chief Financial Officer (CFO) who will oversee all financial matters. This includes the maintenance of a documented system of accounting policies and procedures. He or she will oversee the management of all outsourced functions. The CFO will manage the general operations of the accounting department, including the design of an organizational structure adequate for achieving the department's goals and objectives. Finally, the CFO will oversee the management of cash reconciliations and preparation of bank deposits.

To support the CFO, we shall hire a Staff Accountant. The Staff Accountant provides full-cycle accounting services for a legal cannabis retailer on an ongoing basis. The Staff Accountant will be responsible for the following items.

- Transactional Accounting – General bookkeeping, billing, accounts payable, account reconciliation, payroll processing, fixed assets, etc.
- Complex Journal Entries – Creating, adjusting, and entering journal entries
- Prepare Monthly Financial Statements – Balance Sheet, Income Statement, Statement of Cash Flows, Profit & Loss, Budget vs. Actual and financial analysis
- Pre-Tax Preparation – Work with the contracted CPA to complete Annual Tax Organizer and provide accounting support or assist in annual reviews or audits when necessary
- Maintain Electronic/Paper Files – Ensure accurate and organized filing system
- Period Closing & Year-End Reporting
- Advisor Coordination – Circulate information to advisors (i.e., CPA, bankers, attorneys, wealth managers) regarding taxes, legal and insurance, and obtain updated information for financial statement preparation

- Bill Pay – Set up calendar of due dates and bill pay process; work with vendors and purchasing manager to ensure vendor licensing and tax information is on file

It is the commitment of Coosa Medical that all accounting practices are done in accordance with Generally Accepted Accounting Principles (GAAP) rules. Alabama can trust that the company intends on operating a fully compliant cannabis operation that maintains full transparency in financial record keeping.

2. FINANCIAL RECORDKEEPING

Coosa Medical will prepare an annual financial report (hereinafter, the "Annual Report") and submit it to the State Manager (or his or her designee).

The Annual Report will:

- Be filed and submitted no later than April 30 every calendar year for each preceding calendar year.
- Summarize the quarterly reports that were filed with the State Board of Equalization in the previous year.

Have the following appendices:

- A copy of any and all documents, records, or forms submitted to the State Board of Equalization for the reporting year), which in any manner documents transaction activities relating to the operation of the Commercial Cannabis Business. This includes, but is not limited to, Board of Equalization Form 401, or its electronic equivalent.
- Coosa Medical will maintain any and all records or documents that serve as the basis for preparing the Annual Report for a period of seven (7) years.
- Coosa Medical will enter the information required in the inventory tracking system in accordance with finalized state regulations and Alabama State and Municipal Code. The detailed specifications of Coosa Medical inventory tracking system are

included below, and in the Point-of-Sale Software Description section of this application.

Quality Control and Assurance

TABLE OF CONTENTS

Pages: 1 of 24	Implementation Date: [IMP DATE]	Version No. 01
Annual Review Completed by: *Signature* *Date*	Next Review Due by:	
Revision(s) by (if applicable): *Signature* *Date*	Approved by: *Signature* *Date*	

SOP-QC01: CONTINUOUS IMPROVEMENT AND PROCESS IMPROVEMENT

1. Purpose

1.1. To set standards and procedures for continuous improvement and process improvement. The goal is to foster the growth of the company as well as its employees. The intention is to create a learning organization with a high level of employee engagement.

2. Responsibility

2.1. The Director of Operations and the Director of Processing is responsible for maintaining and training of the SOP

3. Procedure

3.1. Continuous improvement and Process improvement is vital to the growth of the company. It fosters innovation, engagement, and efficiency.

3.1.1. Base management decisions on long-term systems thinking, even at the expense of short-term financial goals.

3.1.2. Connect people and processes through continuous process flow to bring problems to the surface.

3.1.3. Work to establish standardized processes as the foundation for continuous improvement.

3.1.4. Adopt and adapt technology that supports your people and processes.

3.1.5. Grow leaders who thoroughly understand the work, live the philosophy, and teach it to others.

3.1.6. Build a culture of stopping to identify out of standard conditions and product quality.

3.1.7. Develop exceptional people and teams who follow the companies Philosophy.

3.1.8. Develop systems to avoid overproduction, excessive input material inventory and minimize down time.

3.1.9. Improvement in productivity and process is a gradual process achieved through the involvement of all employees. Those performing the work will often have the best ideas of how to improve the processes. Involving them in the improvement process allows them to add value and contributes to their growth and job satisfaction.

3.1.10. Always strive to align goals at all levels in the company.

3.1.11. Learn iteratively. To understand an issue, it is best to perform the work yourself. There are no task beneath you that you do not need to understand.

4. Reports required

4.1. None.

5. Authorization for Deviation

5.1. The Director of Operations or Director of Processing must Direct any deviation from the standard procedure.

6. Approval, Review, Revision and distribution

6.1. The standard procedure shall be reviewed by the Director of Operations and/or the Director of Processing yearly, following the issuance or last revision or review date. Any revision must be signed by the Directors and verified by an executive team member prior to being distributed. Distribution of revisions and collection of any outdated versions shall be the responsibility of Management. The Director of Processing will scan the originals into the computer and retain the signed originals in a binder in their office.

SOP-QC02: INTERNAL AND EXTERNAL TESTING

1. PURPOSE

1.1 To set procedures and standards for the internal and external testing of products and environmental conditions regarding contamination of the processing environment or cannabis itself.

2. RESPONSIBILITY

1.2 The Director of Operations or Director of Processing is responsible for maintaining and the training of the SOP.

3. PROCEDURE

1.3 The Director of Processing or designee is responsible for testing both internally and externally. External testing is testing performed by a state approved lab and is considered valid for the purposes of sales, marketing, and transfer of product. Internal testing may be performed by Coosa Medical, or third-party laboratories state approved or otherwise for the purposes of R&D or self-monitoring of environmental conditions/contamination.

1.4 External testing is to be performed on all batches prior to marketing, sales, or transfer. A state approved lab is to provide test results to be entered into the state track and trace system. These results are considered a valid COA or certificate of analysis.

1.5 These results shall be attached to and follow all batches from the point of testing to the customer and be retained for a period of 5 years.

1.6 Retesting may be performed as regulations permit to confirm a failed test, confirm a successful remediation or to retest for cannabinoids or potency.

1.7 External Testing will include cannabinoids of medicinal value such as THC, CBD, CBN, CBC, CBG etc. It may or may not include terpenes.

1.8 External testing results will include and pass all required safety test before being considered valid for sale or transfer. To include but not limited to microbials, heavy metals, pesticides not approved for use on medicinal cannabis and their results.

1.9 Internal testing may be performed for various reasons. The development of new genetics, the monitoring of facilities for contamination of equipment, HVAC systems, contact surfaces, the presences of plant pathogens such as viruses that pose no threat to consumer health but may impact production or product quality etc.

1.10 Internal testing for environmental contamination is to include surface swabs of workspaces, HVAC ducting and equipment, tools and machinery that contact cannabis material and any other area that may be suspect of a source of potential contamination. This is to prevent, isolate or identify sources of contamination that could contaminate medicinal cannabis. The end goal is to ensure cannabis material passes all safety requirements.

1.11 Internal testing for the development of new genetics is for the purpose of determining the potency and other characteristic of plants for R&D purposes. This is typically a situation where individual plants are tested and do not meet the quantity of a production batch (ie. Mother plant selection). These results are not considered valid for any commercial purpose and may be performed in house.

1.12 The testing of plant material for pathogens not tested for during required external testing will be performed. Although these tests do not involve anything that relates to human health, they do involve plant health (ie. Hemp latent viroid). These tests are performed to ensure that plant stock is healthy and there are no pathogen related impacts to production or quality.

1.13 Water sampling will be performed to search for heavy metals, excessive mineral content, microbial pathogens, or any other source of contamination that may be harmful to plants, consumers or the environment.

4. REPORTS REQUIRED

1.14 No reports are required

5. AUTHORIZATION FOR DEVIATION

1.15 The Director of Processing must direct any deviation from or additions to the standard procedure.

6. APPROVAL, REVIEW, REVISION AND DISTRIBUTION

1.16 The standard procedure shall be reviewed by the Director of Operations and/or the Director of Processing yearly, following the issuance or last revision or review date. Any revision must be signed by the Directors and verified by an executive team member prior to being distributed. Distribution of revisions and collection of any outdated versions shall be the responsibility of Management. The Director of Processing will scan the originals into the computer and retain the signed originals in a binder in their office.

SOP-QC03: RECALL AND WITHDRAWAL

1. PURPOSE

1.1. The purpose of this procedure is to provide instructions for Recall and Withdrawal of any cannabis products that have a reasonable probability of causing adverse health consequences based on a testing result, adverse patient reaction, or other reason.

2. RESPONSIBILITY

1.2. The Director of Processing or their designate is responsible for maintaining this SOP.

3. PROCEDURE

1.3. This Plan distinguishes between two levels of product recall: withdrawal and recall. Classification standards and appropriate responses for each type of event are discussed herein. Procedures for handling voluntary withdrawals and mandatory recalls of cannabis products are included herein. Procedures for addressing and recording complaints, including reports of product-related adverse events from customers, are also provided. Incident classification terms are defined, with distinct mitigation procedures for each, as the term “recall” can have legal significance and implications for insurance and liability. The withdrawal and recall procedures provided in this Plan are designed to ensure that cannabis products are withdrawn or recalled quickly and efficiently, whether voluntarily or by mandate. The objectives of withdrawal and recall procedures are to stop distribution of the affected product, effectively notify all relevant parties, efficiently remove the affected product from market, dispose of the affected product, conduct a root cause analysis, report the effectiveness and outcome of the recall, conduct a post-recall meeting for evaluation and report root cause and corrective actions to the Department.

1.4. In accordance with the incident classification schema and the associated definitions, the term “recall” will only be used when the situation mandates. Examples of

incidents to be addressed with recall or withdrawal procedures and guidelines for required mock withdrawal and recall drills are provided in this Plan.

1.5. Additional provisions include plans for tracking affected products in the event of potential or verifiable contamination, and for the establishment of an internal Recall and Withdrawal Team, which will be responsible for executing and coordinating all aspects of a withdrawal or product recall. In the instance of a product recall, the Department as well as the AMCC will be notified immediately.

1.6. As cannabis and cannabis products are not FDA-regulated products, Coosa Medical is not bound by law or rule to comply with United States Food and Drug Administration (FDA) recall requirements. However, Coosa Medical has elected to implement FDA recall standards and procedures as a guideline for self-imposed recall and withdrawal policies and practices.

1.7. The Director of Processing and/or his or her designee must record all complaints in an internal Complaint Log and categorize all complaints as a product complaint or other complaint. Product complaints include, but are not limited to, contamination, adverse reactions, and quality-related product complaints.

1.8. It is Coosa Medical policy to make a good faith effort to resolve any complaint, whether legitimate or frivolous whenever possible. Management must respond to any product-related complaint within twenty-four hours to gather information about the nature of the complaint, the affected parties or products, and determine appropriate steps for resolution.

1.8.1. Assemble the personnel or experts needed to conduct a product complaint investigation;

1.8.2. Conduct a thorough investigation into the complaint;

1.8.3. Determine the nature and potential causes of the problem;

1.8.4. Determine any other cannabis product(s) that may potentially be affected;

1.8.5. Enter all information into the Complaint Log; and

1.8.6. Determine the appropriate action, based on the general classifications provided below, follow the appropriate procedures for that classification, and document all actions taken:

1.8.6.1. Product Recall: Patient safety or health risk due to physical, chemical, biological or immunological cause(s). This includes, but is not limited to, verified or suspected product contamination or test result showing the product does not meet the statutory definition of cannabis. Proceed to Recall and Withdrawal Procedures;

1.8.6.2. Product Withdrawal: Appropriate for a quality-related issue with affected product(s) that does not pose an immediate health or safety risk to patients. Proceed to Recall and Withdrawal Procedures; and

1.8.6.3. No Corrective Actions: An isolated incident with the affected product(s), such as an isolated weight error or minor labeling error, such as misspelled product name.

1.8.6.4. Coosa Medical will review all complaints regarding the quality or safety of medical cannabis within 24 hours to determine if the complaint is substantive.

1.8.7. Review batch or lot production logs to determine if there was deviation from the standard operating procedure during production.

1.9 Patient health and safety is a top priority for Coosa Medical. Coosa Medical is committed to consistently providing high-quality and safe cannabis products to licensed producers. To this end, Coosa Medical will do everything in its power to prevent any spoiled, defective, misrepresented, or contaminated products, or products of insufficient quality, from entering the market. Upon the discovery of product contamination, safety concerns, patient adverse reaction, or quality-related issues, Coosa Medical will quickly and efficiently carry out recall or withdrawal

procedures in accordance with this Plan in order to protect the health and wellbeing of patients. The best way to ensure that a recall or withdrawal is effective is to have a recall and withdrawal plan already in place and to execute the plan as quickly as possible.

1.10 There are two distinct levels of action that involve the removal of cannabis product from market: recall and withdrawal. A recall is generally undertaken when there is verifiable evidence that a cannabis product is defective or has health and safety hazards that reasonably could or already have caused serious adverse effects. A withdrawal is typically conducted when there is a quality-related issue with cannabis products that are not likely to pose health risks, or as a precautionary measure prior to an official recall when health or safety risks are suspected but not yet verifiable. The classification of a recall typically involves the presence of bacteria, a substance that may cause a potential allergic reaction, or some other contaminant that could cause adverse reactions in patients, whether such reaction is serious or temporary. The term “recall” should only be used when mandated by verifiable evidence (i.e., analytical test results) that the affected product poses significant health and safety risks. Any determination to implement recall procedures must be supported by test results or other scientific documentation or expert opinion.

1.11 The tests that will be conducted by the independent testing laboratory are defined by the AMCC. These testing measures serve to ensure that products that do not meet specifications for quality and safety are not released for distribution, thereby preventing hazardous or non-compliant cannabis products from reaching qualified registered patients. However, cannabis products may become contaminated after final testing and packaging due to improper storage conditions that promote the growth of mold, malicious contamination, contamination from unsafe packaging materials, or other factors. Health and safety issues that develop after final testing and packaging may be identified as a result of visual or analytical inspection. Any verifiable test result showing health and safety risks posed by a cannabis product is a critical indicator of a recall event, as opposed to a withdrawal.

1.12 The examples in the following list, which is by no means exhaustive, would constitute an incident requiring a recall or withdrawal:

12.1.1. Cannabis product found to have any amount of pesticide residue from an illegal/restricted chemical.

12.1.2. Known, assumed or suspected cannabis product contamination by chemical, physical or microbiological hazards.

12.1.3. Incorrect labeling which may constitute a breach in product safety, quality, or legality standards.

12.1.4. Known or suspected malicious contamination.

12.1.5. Internal quality assurance re-testing of improperly stored packaged cannabis products reveals contamination or adulteration.

12.1.6. Requested testing of cannabis products or input materials reveals contamination, adulteration, misrepresentation, or non-compliance with statutory definition of cannabis.

1.13 Director of Processing will select and maintain a Recall and Withdrawal Team, composed of Company agents and managers which will be responsible for executing withdrawal and recall procedures. The team will be responsible for coordinating all aspects of a withdrawal or product recall:

13.1.1. All team members must ensure that all procedures are carried out effectively and efficiently;

1.14 The following procedures will be implemented once a product complaint or evidence suggesting quality- or safety-related issues is received.

14.1.1. Gather information from the customer, laboratory or regulator about the nature of the product contamination or concern;

14.1.2. Assemble the personnel or experts needed to conduct an investigation;

14.1.3. Conduct a thorough investigation into the problem with the affected product;

14.1.4. Determine the nature and potential causes of the problem;

14.1.5. If a serious adverse event is involved, this includes requesting sampling and testing of the retention sample of the product in question;

14.1.6. Determine any other product(s) that may potentially be affected;

14.1.7. Determine, from the information provided herein, whether the situation meets criteria for:

14.1.7.1. Product Recall;

14.1.7.2. Product Withdrawal; or

14.1.7.3. No Corrective Action (i.e., an isolated incident with the affected product).

14.1.8. Notify Legal Counsel, Insurance Company, and Board:

14.1.8.1. The Director of Processing must notify the Board of findings from the investigation and discuss proposed event classification;

14.1.8.2. The Board, or the Director of Processing if authorized by the Board, must notify legal counsel in writing that a situation meets the criteria for a recall or withdrawal. Any recommendations by counsel for alternative procedures must be approved by the Board; and

14.1.8.3. The Board, or the Director of Processing if authorized by the Board, must notify the insurance company and determine coverage.

14.1.9. Conduct an assessment to determine the procedures to implement. Items to consider include:

14.1.9.1. Whether or not adverse reactions or serious health issues have already occurred from use of the product;

14.1.9.2. Degree of seriousness of the health hazard to which the population at risk would be exposed;

14.1.9.3. If it is determined that recall procedures are appropriate, assign the recall event to one of the following classes, in accordance with FDA guidelines and the level of hazard involved:

14.1.9.3.1. Class I: A situation in which there is a reasonable probability that the use of or exposure to a product will cause serious adverse health consequences;

14.1.9.3.2. Class II: A situation in which use of or exposure to a product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote; and

14.1.9.3.3. Class III: A situation in which use of or exposure to a product is not likely to cause any adverse health reaction, but may pose safety risks (e.g. non-hazardous labeling violation substantiated by test results).

14.1.10. Seek the Board's approval for event classification. If the Board approves a recall, a press release must be issued to the Department and AMCC immediately.

1.15 Track Affected Product(s)

15.1.1. Determine type of product(s) affected:

15.1.1.1. Finished product = All cannabis products that have been packaged and partially or completely distributed to licensed producers.

15.1.1.2. Work in progress = All cannabis products that have not been distributed and their constituents, including, but not limited to, cannabis and cannabis products in storage, and in-process cannabis products;

15.1.1.3. Packaging material = All packaging material or containers used for work in progress or finished products;

15.1.2. If affected product is finished product:

15.1.2.1. Assemble personnel needed to conduct tracking of a finished product;

15.1.2.2. Identify affected and any other potentially affected product(s), product identifiers(s) and production date(s);

15.1.2.3. Determine the quantity of affected product(s) produced;

15.1.2.4. Determine from Seed to Sale system the last day of shipment/dispensing (and the recipient) for the affected product(s);

15.1.3. If affected product is work in progress:

15.1.3.1. Assemble the personnel needed to conduct tracking of a work-in-progress product;

15.1.3.2. Identify the affected and any other potentially affected product(s), product identifiers(s) and production date(s) from the production records; and

15.1.3.3. Determine from the POS system and production records the quantity of the affected product(s) produced.

15.1.4. Locate the affected product(s) from the production and storage areas.

15.1.5. If affected product is packaging material:

15.1.5.1. Identify affected and any other potentially affected packaging material(s) and lot number(s)/quality control code/receiving date(s);

15.1.5.2. Determine the quantity and receiving date of the affected packaging material(s) received;

15.1.5.3. Based on the type and size of packaging material, determine all the finished product(s) associated with the affected packaging material(s);

15.1.5.4. Determine from the production records the period of use for the affected packaging material(s);

15.1.6. Given the affected period and product, determine from the Seed to Sale system the quantity of the affected product(s) associated with or the affected packaging material(s) in this period;

15.1.6.1. Determine from the production records and Seed to Sale system the day the affected product(s) entered into COMPANY inventory (i.e. packaging date, harvest date etc.);

15.1.6.2. Determine from the STS system the last day of shipment (and the recipient) for the affected product(s);

15.1.6.3. Determine from the STS system all customers or licensed producers who received the product.

15.1.6.4. Determine from the STS system the remaining quantity of the affected product(s) in our inventory; and

15.1.6.5. Locate any remaining affected material(s) from the storage shelves and cabinets;

1.16 Execute Withdrawal or Product Recall:

16.1.1. Assemble the Recall and Withdrawal Team, ensuring adequate resources are available for the severity of the issue;

16.1.2. Gather all information collected in the tracking process;

16.1.3. Detain and segregate all products to be recalled or withdrawn which are in Company's control. Adhere a DO NOT DISTRIBUTE sign, place in quarantine, and complete any relevant internal logs/forms;

16.1.4. Depending on event type, send a Notification of Recall or Notification of Withdrawal to the affected licensed producers or customers.

16.1.5. Ensure the following information is accurately recorded:

16.1.5.1. Name and Product Identifier of the withdrawn/recalled product(s);

16.1.5.2. Production date(s);

16.1.5.3. Reason for withdrawal/recall;

16.1.5.4. Quantity of withdrawn/recalled product(s) distributed;

16.1.5.5. Quantity of withdrawn/recalled product(s) in inventory (for internal use only); and

16.1.5.6. Site(s) of distribution and patients affected (for internal use only).

16.1.6. Coordinate and monitor the recovery of all affected product.

16.1.7. Using the Seed to Sale system, conduct a reconciliation of the total quantity of recalled product and affected product in inventory against the total quantity produced;

16.1.8. Contact the testing laboratory to request sampling and testing of recalled or withdrawn product(s), as appropriate;

16.1.9. Test results and corrective actions must be recorded internally and discussed for prevention of a reoccurrence.

16.1.10. The Director of Processing must prepare an internal Withdrawal and Recall Report, which will be saved in the secure cloud-based records system for a minimum of five (5) years.

1.17 All recalled material will be segregated from unaffected products. The Director of Processing or Manager will place "QUARANTINE - DO NOT DISTRIBUTE" tags on all recalled material, including recalled products returned by other licensees. The Director of Processing or manager will mark all recalled products as quarantined and recalled in the STS system. Records must be kept in the Product Quarantine Log and the STS system. Recalled products will remain in quarantine storage until disposal of the recalled material is authorized by the Department or AMCC.

1.18 After all procedures have been completed and the affected product(s) have been removed from the market and Coosa Medical inventory, the General Manager will request authorization from the Department to destroy and render unusable the product.

1.19 Once authorization is received the affected product will be destroyed on video and video shall be retained no less than 60 days.

1.20 After the above procedures have been carried out conduct a root cause analysis and report the effectiveness and outcome of the recall or withdrawal. The Director of Processing will also conduct a meeting with the Recall and Withdrawal Team, and the Board, and all other involved parties for evaluation and suggestions for improvement.

4. REPORTS REQUIRED

1.21 None needed.

5. AUTHORIZATION FOR DEVIATION

1.22 The Director of Operations and/or the Director of Processing must direct any deviation from the standard procedure.

6. APPROVAL, REVIEW, REVISION AND DISTRIBUTION

1.23 The standard procedure shall be reviewed by the Director of Operations and/or the Director of Processing yearly, following the issuance or last revision or review date. Any revision must be signed by the Directors and verified by an executive team member prior to being distributed. Distribution of revisions and collection of any outdated versions shall be the responsibility of the Director of Processing or the Manager. The Director of Processing will scan the originals into the computer and retain the signed originals in a binder in their office.

SOP-QC04: ADVERSE HEALTH EVENT REPORTS

1. POLICY

In the event of a report of an adverse health event reported to be related to the use of medical cannabis, staff shall immediately document and report in accordance with this policy.

2. SCOPE

It is the responsibility of the employee who receives a call or report to Coosa Medical Manufacturing regarding an adverse health event to report the same to the Alabama Medical Cannabis Commission (AMCC).

This procedure also applies to:

1) All adverse incidents (AIs) and serious adverse incidents (SAIs) as defined by the Alabama Medical Cannabis Law, which are attributable to the use of medical cannabis by the person who experienced the event in question.

2) When Coosa Medical Manufacturing becomes aware of the AI or SAI.

The following are out of scope of this policy:

2) An AI or SAI that does not involve medical cannabis consumption in Alabama.

3) An AI or SAI that Coosa Medical Manufacturing is not made aware of within five (5) days of the reporter's learning of the incident in accordance Alabama Medical Cannabis Law.

3. DEFINTIONS

Adverse Incident (AI): "Adverse incident" means a negative medical occurrence in a person after using medical cannabis, either physical or psychological, including harmful reaction, symptom, or disease.

Serious Adverse Incident (SAI): "Serious adverse incident" means an adverse incident that results in or would lead to one of these outcomes without medical intervention:

a. In-patient hospitalization or additional hospital time for a patient who is already hospitalized;

b. Persistent or significant disability or incapacity;

c. A life-threatening situation; or

d. Death.

Reporter: Persons who must report any serious adverse incident are:

(1) a registered patient;

(2) a registered patient's certifying health care practitioner;

(3) a patient's registered designated caregiver; or

(4) a patient's parent or legal guardian, if the parent or legal guardian is acting as caregiver.

4. MONITORING AND DOCUMENTING ADVERSE INCIDENTS (AI)

4.1 Coosa Medical Manufacturing will maintain and monitor an email address, currently: [INSERT EMAIL ADDRESS], made visible on its website [UPDATE HYPERLINK WHEN WEBSITE IS LIVE], as an optional input mechanism for required persons to report AI information. Adverse incidents (AIs) received by the above email address will be forwarded within 1 business day to Coosa Medical Manufacturing Director or a designated AI management contractor (currently SafetyCall International). Serious Adverse incidents (SAIs) received by the above email address will be forwarded within 24-hours to either Coosa Medical Manufacturing Director or a designated AI management contractor (currently SafetyCall International).

Coosa Medical Manufacturing will maintain or provide a toll-free telephone line, [INSERT PHONE NUMBER], available 24 hours a day, seven days a week, that is staffed by professionals trained in detecting, assessing, understanding, and preventing adverse effects or other drug-related problem. This hotline may be staffed by Coosa Medical

Manufacturing or by contracted qualified persons (currently SafetyCall International). If contracted persons staff the hotline, a Coosa Medical Manufacturing employee assigned to the task will obtain a report from the hotline-staff containing all Adverse Incident (AI) and Serious Adverse Incident (SAI) reports routinely. This report will be in an electronic format which may also be the same online formats described above. If contracted persons staff the hotline, the contract will specify the nature of the reporting procedure from the hotline.

4.4 If the Coosa Medical Manufacturing professional receiving a potential AI or SAI complaint verifies that there is a potential AI or SAI, they will immediately do one of the following:

1) Verify that contracted persons are monitoring or recording AI and SAI information in a database for Coosa Medical Manufacturing (currently SafetyCall International) and then direct the patient to contact the provided 24/7 hotline number noted below in subsection 4.5.

2) If the professional receiving the report is not able to direct the patient to the hotline, they may directly send the information to the provided secure monitored email set up by the contracted database administrator (SafetyCall International) for this purpose (productsupport@safetycall.com). **Include the company name, "*Coosa Medical Manufacturing*", in the Subject line of the email**.

4.5 Coosa Medical Manufacturing currently contracts with SafetyCall International, PLLC, to record and answer potential AIs using the phone number 1-(844) 342-8130, 24/7, on behalf of Coosa Medical Manufacturing as well as monitor email reports for the same purpose. Every report is screened, forwarded, and charged to Coosa Medical Manufacturing. The number above is also listed on Coosa Medical Manufacturing's website under "Contact Us", listed on the product label, and included on written material given to each patient with their product purchase.

4.6 Coosa Medical Manufacturing will report AIs and SAIs to AMCC in a timely manner as required by Alabama Medical Cannabis Law.

Coosa Medical Manufacturing employee(s) Assigned to the responsibility will, where applicable, monitor manufacturer-sponsored social media pages and websites [UPDATE WHEN LIVE] routinely for potential AI reporting and if any potential AI is suspected, the same reporting method described in 4.3 should be followed.

5. RESOURCES TO HELP REPORT AIs

5.1 Coosa Medical Manufacturing will post instructions for reporting suspected AIs and unauthorized possession on its website; and will make printed instructions for reporting suspected AIs available. The phone number to SafetyCall and the AHE email address may be included on Coosa Medical Manufacturing's medical cannabis product labels.

6. DOCUMENTATION PROCEDURE

6.1 The Coosa Medical Manufacturing employee(s) or third-party contractors assigned to monitor for AI reports will collect all AI reports routinely from the website, applicable social media, physical reports turned in and the phone hotline report queue. At a minimum, such monitoring will occur on all days that the facility is open.

6.2 Reports will be maintained in a Coosa Medical Manufacturing database that complies with general validation principles in the United States Food and Drug Administration's Electronic Records; Electronic Signatures, Code of Federal Regulations, title 21, part 11. The information must be classified using the Medical Dictionary for Regulatory Activities (MedDRA) coding. This database may be maintained and managed by a contracted third party (currently SafetyCall International).

6.3 When applicable, reports will also be documented on a form provided by the commissioner and filed in a designated location at Coosa Medical Manufacturing following similar procedures for documentation security as used elsewhere at Coosa Medical Manufacturing. This may be an electronic file. Filed reports with person-identifying information will be maintained in a secure fashion and will only be accessible by the employee(s) assigned to this duty, their manager and Coosa Medical Manufacturing management as well as potential third parties authorized by law to view this information.

6.4 In addition to the reporting process described above, Coosa Medical Manufacturing employee(s) assigned to monitor for AI reports will provide a notification via email to their supervisor and AI management on the same day that an SAI report is found and processed. AI management is assigned by the CMO, or their designee.

6.5 An AI or SAI report should include, at a minimum: The date the Report was filed with Coosa Medical Manufacturing

a. The date the incident occurred;

bb. The person who experienced the AI or SAI;

cc. The reporting person's name, contact information (phone, email and mail) and status (Patient, caregiver etc.);

dd. The cannabis product that was consumed, how much and how was it taken;

ee. The manufacturer;

ff. Other medications, drugs or alcohol that the person involved also may have consumed;

gg. All possible incident specifics:

i. Signs or symptoms, what happened over time;

ii. Did signs or symptoms resolve and when;

iii. Did the person involved go to the hospital, and if so, what happened there;

iv. Was the individual admitted to the hospital, if so what is the name and address of the hospital? What was the outcome after that?

hh. Whether the cannabis medication ingested belonged to the person involved in the incident, and if not, whom it belongs to.

6.6 If an AI or SAI report is discovered that should be reported to another manufacturer, the assigned employee(s) will elevate this report immediately to the supervisor and the AI management who will direct the patient to the appropriate reporting protocol for the non-Coosa Medical Manufacturing product that they are taking.

6.7 If an assigned employee has questions regarding an AI report, they will notify their supervisor on the same day that the report is identified. If the supervisor is unable to resolve the question, they will notify AI management on the same day that they received notice.

7. REPORTS OF ADVERSE HEALTH REPORTS

7.1 Reporting requirements mandated by the state must be followed.

7.2 By the fifth day of every month, the AI manager will compile and submit to the commissioner all adverse incident reports received in the prior calendar month.

7.3 Within ten business days from the day Coosa Medical Manufacturing learns of an AI, the AI manager will report to the commissioner:

a. Any adverse event incident that, based on the "reasonable medical judgment" of the AI manager might have resulted in a serious adverse incident without intervention or medical treatment. or

b. Any case of diversion resulting in an adverse incident.

7.4 When the state mandates that SAIs be reported in a more urgent manner, the AI manager in collaboration with the Director of Compliance and the CMO will report the SAI to the state within the timeframe required by law.

7.5 On [INSERT DATE] of every year beginning in 2023, the AI manager will submit to the commissioner a report that contains a summary and a critical analysis of all reported AIs reported to Coosa Medical Manufacturing over the past July 1st to June 30th.

7.6 The Director of Compliance and the CMO will report the SAI to the CEO as soon as is practical.

7.7 In accordance with Alabama Medical Cannabis Law, recall Procedures must be followed if the CEO determines that a recall of a product is necessary because of an AI/SAI report.

APPENDIX I – RECALL PROGRAM

Recall Program

Introduction

This document outlines Coosa Medical Manufacturing's correction in the field or removal from the marketplace and distribution channels of products which are subject to regulatory action under the Alabama Department of Public Health (AMCC), Alabama Medical Cannabis Commission (AMCC). Product recall is an efficient and effective means of removing sizeable quantities of products from the market place.

A voluntary recall will be conducted if there is a reasonable belief that there is a danger to the health or safety of the public. It will be the decision of the CEO whether a voluntary recall will be conducted, with the advice from applicable employees and outside sources, if necessary.

If a voluntary recall is conducted, staff will identify all customers that received the product involved in the recall. If excipients contained in a product are the cause of the recall, staff will work with extraction team staff to determine all products that contained the excipient. Each patient must be individually called to inform customers of the recall and the purpose of the recall. Patients must be instructed to immediately stop using the product. All reasonable steps will be taken, including, but not limited to, testing and re-testing products, to determine contaminants in the product if the contaminants are unknown.

The AMCC or another authorized department or person at the AMCC will notify the company if there is a mandatory recall. All steps taken during a voluntary recall will be taken during a mandatory recall as well. Coosa Medical Manufacturing will follow all instructions given by the Department of Health.

The procedures implemented should effectively remove the product from circulation to prevent its consumption. The product recall procedures should be undertaken by the processor in an efficient and speedy manner. Once a product is removed from circulation, the recalled product may then be subject to additional testing, corrective action to ensure compliance, or destruction, depending on the nature of the problem.

Recall Classifications

Class I

A situation in which there is a reasonable probability that the use of, or exposure to, a volatile product will cause serious adverse health consequences or death. In a Class I Recall, top priority must be given to the complete and immediate removal of the recalled products from all levels in the distribution chain.

Class II

A situation in which the use of, or exposure to, a volatile product may cause temporary adverse health consequences or where the probability of serious adverse health consequences is remote. In a Class II Recall, products must be removed from all levels in the distribution chain.

Class III

A situation in which the use of, or exposure to, a product is not likely to cause adverse health consequences. In a Class III Recall, product must be removed from all levels of the distribution chain.

Recall Procedures – Flow Diagram

Decision to Recall Products

Assemble the Recall Management Team



Notify the CFIA



Identify all Products to be Recalled



Detain and segregate all products to be recalled which are in company's control



Prepare the Press Release (if required)



Prepare the Distribution List



Prepare and distribute the Notice of Recall



Verify the effectiveness of the recall



Control the recalled product(s)



Fix the cause of the recall

A recall committee is set up within the company. Each member has specific responsibilities and the order of the activities in which they are taken are described below:

Recall Committee

Position	Primary Person / Alternate
Chief Executive Officer / Chief Operations Officer	
Recall Coordinator	
Risk Assessment	
Records	
Product Assessment	
Plant Assessment	

Recall Committee Contact Card

Contact	Position	Work	Cell
	Chief Executive Officer		
	Chief Operating Officer		
	Recall Coordinator		
	Recall Coordinator (Alternate)		
	Risk Assessment		
	Records		
	Records (Alternate)		
	Product Assessment		
	Product Assessment (Alternate)		
	Plant Assessment		
	Plant Assessment (Alternate)		

Decision Chart



Checklist: Recall Coordinator

*Crisis Management Log should be started and completed.

Step 1 – To investigate consumer/customer complaints and to make preliminary decision as to potential health hazard;

Step 2 – Notify CEO
– Notify COO

Step 3 – Complete the Recall Summary and Evaluation Form;

Step 4 – Complete Press Release and email to CEO; and

Step 5 – Fill in Recall Results Form;

Step 6 – Update Crises Management Log(s);

Step 7 – Contact Applicable Facilities with all the necessary information;

Step 8 – Complete Recall Results Form;

Step 9 – Update Recall Committee Members; and

Step 10 – Complete Recall Review Form.

Recall Procedures Checklist for Recall Coordinator

Steps	Procedures	Completed
1	Verification of test results, customer complaints and other information to determine potential health hazard	
2	Recall log started to record decisions, actions and rationale	
3	Notified Chief Executive Officer	
4	Notified Chief Operations Officer	
5	Recall Summary and Evaluation Form completed	
6	Completed Press Release and sent to CEO for review and release within 2 hours	
7	Filled in Recall Results Form	
8	Updated in Crises Management Log(s)	
9	Contacted Applicable Facilities with all necessary information of recall	
10	Completed Recall Results Form	
11	Updated Recall Committee Members	
10	Completed Recall Review Form	

Completed By: _____ Date: _____

Checklist: Chief Executive Officer

*Crisis Management Log should be started and completed.

Step 1 – Notify Recall Committee Members;

Step 2 – Issue Press Release, as necessary;

Step 3 – Spokesperson for fields all media related questions;

Step 4 – Update Recall Committee Members.

Recall Procedures Checklist for Chief Executive Officer

Steps	Procedure	Completed
1	Notified Recall Committee Members of Recall to discuss recall strategy in conjunction with legal counsel	
2	Reviewed and Released Press Release and Health Hazard Alert, as necessary	
3	Spokesperson for fields all media related questions	
4	Recall Committee Members informed of all necessary information	
5		
6		
7		
8		
9		
10		

Completed By: _____ Date: _____

Checklist: Risk Assessment

*Crisis Management Log should be started and completed.

Step 1 – Assess and quantify risk;

Step 2 – Notify legal counsel;

Step 3 – If the source of the recall may involve malicious contamination – notify Product Assessment members and follow instructions; and

Step 4 – Contact State Commission if necessary.

Step 5 – Update Recall Committee Members

Recall Procedures Checklist for Risk Assessment

Steps	Procedure	Completed
1	Origin of recall was established	
2	Status of possible injuries obtained – notified legal counsel and insurance broker as necessary	
3	Identified most likely forensic pathway – contact PR advisor, HR department, Product Assessment, and State Commission as necessary	
4	Determined magnitude of exposure	
5	Contact State Commission if necessary	
6	Recall Committee Members informed of all necessary information	
7		
8		
9		
10		

Completed By: _____ Date: _____

Checklist: Records

*Crisis Management Log should be started and completed.

Step 1 – Receive and update Crisis Management Log from staff;

Step 2 – Contact Recall Coordinator and await instruction;

Step 3 – Notify customers of the situation prior to the initiation of any recall, if possible (i.e. every effort will be made to contact customers while the recall procedures continue);

Step 4 – Send out and collect the following forms involved:
Recall Notification Form;
Recalled Product Information Record; and
Recalled Product Distribution Record.

Step 5 – Instruct customers as to what state the product must be returned in, how, and when the product will be picked up. Determine if the replacement product is required, necessary quantity needed and when replacement product will be available; and

Step 6 – Update Recall Committee Members

Recall Procedures Checklist for Records

Steps	Procedure	Completed
1	Received and updated Crisis Management Log	
2	Contacted Recall Coordinator and Received Instructions	
3	Notified stores and customers of recall situation verbally and through email	
4	Sent out and collected forms: Recall Notification Form; Recalled Product Information Record; and Recalled Product Distribution Record	
5	Communicated and directed customers on how the product should be returned and when product will be picked up	
6	Determined if replacement product is needed and when replacement product will be available	
7	Completed and sent out Customer Service Rep Form	
8	Recall Committee Members informed of all necessary information	
9		
10		

Completed By: _____ Date: _____

Checklist: Product Assessment

*Crisis Management Log should be started and completed.

Step 1 – Provide necessary information regarding production dates, lab test results, and suppliers to Recall Coordinator;

Step 2 – Arrange for storage and quarantine for recall product;

Step 3 – Arrange for carriers to pick up product if required;

Step 4 – Isolate returned recalled product. Notify Recall Committee where the suspect product is to be held in quarantine;

Step 5 – Product Return Manifests are completed and collected upon receipt of returned recalled product;

Step 6 – Keep an inventory of returned recalled product using Recalled Product Distribution Record Form.

Step 7 – Update Recall Committee Members

Recall Procedures Checklist for Product Assessment

Steps	Procedure	Completed
1	Provided production and testing information to Recall Coordinator	
2	Arranged for storage and quarantine for recalled product	
3	Arranged for carriers to pick up recalled product if necessary	
4	Isolated returned recalled product to designated area	
5	Kept an inventory of returned recalled product using Recalled Product Distribution Record Form	
6	Coordinated with Risk Assessment Coordinator for proper disposal of recalled product if necessary	
7	Recall Committee Members informed of all necessary information	
8		
9		
10		

Completed By: _____ Date: _____

Product Recovery & Disposition

To ensure Product Recall is recovered expediently, an accurate record of the quantity picked up from the customers and the quantity received at must be clearly documented.
Upon receipt, product would be segregated and evaluated. Quantity received would be verified against quantity produced and/or distributed. Information would be recorded on the Product Return Slip.

Termination of Recall

The recall is considered complete when satisfactory information on accurate inventory of returned goods and proper disposition of the recalled product is provided. A summary of the corrective measures taken by the company to eliminate manufacturing and distribution processes that caused the recall is required.

Example Notification Form

Date:

[ADDRESS TO INSERT]

Re: Product Removal/Correction

Dear Sir or Madam:

This letter is to apprise you that **Coosa Medical Manufacturing, LLC** has initiated removal/correction of one of our products recently distributed.

A. Product Involved
Identify the product name, lot number, description and packaging date or code (if available)

B. Reason for Action
Identify in short, simple, non-legal terms the problem with the product.
Example: Contamination-filth in cartridge.

C. Evaluation of Risks - Provide a brief description of your health hazard evaluation setting out your conclusions regarding the harm and probability of harm.

D. Distribution
1. Total amount produced, and where and when the product was produced;
2. Amount of product(s) in distribution channels; and
3. The number of products sold.

E. Recall Communications
Provide a copy of the recall communication or proposed recall communication to be sent to the distribution channels and a copy of any proposed press release.

F. Recall Strategy
Provide a short and distinct statement setting out the recall strategy including such things as depth of recall and effectiveness checks.

G. Recall Coordinator
Provide name, title, telephone number of company official who would be contacted concerning the recall

Fill in by: Chief Executive Officer

Notification Attachment

Re: Product Removal/Correction

A. Product Involved - Please identify the following (if available):

Product Name: _____ Size: _____

Description: _____ Product Lot #: _____

B. Reason for Action

Example: Contamination-filth in cartridge.

C. Evaluation of Risks

D. Distribution

1. Total amount produced, and where and when the product was produced.
2. The best guess as to the amount of product(s) in distribution channels.
3. The number of accounts sold (and if requested, identify) and the areas of the country affected.

E. Recall Communications - Provide a copy of the recall communication or proposed recall communication to be sent to the distribution channels and a copy of any proposed press release.

F. Recall Strategy - Provide a short and distinct statement setting out the recall strategy including such things as depth of recall and effectiveness checks.

G. Recall Coordinator

:

Telephone #: .lt. Telephone #:

Recalled Product Information Record

Customer: _____
Date: _____ Batch Number: _____
Time: _____ Product Number: _____
Product Name: _____ Expiration Date:_____
Harvest Date: _____
Reason for Recall: _____

Recalled Product Distribution Record

Product Name: _____ Product Lot #: _____
Harvest Date: _____ Product Batch #: _____
No. Produced: _____ Expiration Date: _____

Customer Name	ID	Product Number	Date Purchased	Quantity	No. Returned

Completed by: _____ Date: _____

Verified by: _____ Date: _____

URGENT – Recall Alert

Recall Notification Form

Re: [Name of Product]

[Product Lot Number]

[Production Date]

We have recently discovered that the above products may show a deficiency, specifically *(A short description of the reason for the recall)*:

_____

_____

_____

To fulfill our joint responsibility to our customers to provide safe and effective medication, we would request your assistance in the removal of this product from distribution.

1. We request that you remove the specified product(s), as listed above, from your inventory and segregate and hold all products meeting the size and code description in this notice.
2. A Coosa Medical Manufacturing employee will contact you to arrange for retrieval of the medication. Arrangements are being made to ship replacement products to you as soon as possible.
3. Please inform all staff to direct all questions to **[name of employee]**, [name of position] at **insert phone number**.

Thank you for your cooperation.

PRODUCT MUST BE RETURNED IN ORIGINAL CONTAINERS.

Recall Summary and Evaluation

Date Recall initiated: _____

Date Recall completed: _____

Product Name: _____

Product Lot #: _____

Product Batch #: _____

Expiration Date: _____

Total # of Cases Produced: _____

Total # of Cases Recovered: _____

Product Disposition: _____

_____

_____

Corrective Action Required to Improve Manufacturing/Distribution Processes:

_____

_____

_____

_____

_____

Signature: _____

Date: _____

RECALL RESULTS FORM

RECALL DONE BY: _____DATE: _____

PRODUCT TO RECALL: _____

AMOUNT PRODUCED: _____

AMOUNT IN DISTRIBUTION: _____

AMOUNT IN INVENTORY: _____

TOTAL TIME REQUIRED TO OBTAIN THE INFORMATION: _____

COMMENT ON ANY PROBLEMS ENCOUNTERED:

_____

_____

_____

_____

_____

Recall Review

Attendees:

Why was there a recall?

What course of action was taken to resolve the issue?

What actions have been taken to ensure this issue does not reoccur?

Who is responsible for verifying and monitoring this plan?

Total length of time for recall: _____

How can we improve next time and be quicker/accurate?

Total cost of recall: _____

Charge to: _____ From: _____

Crisis Management Log

Name: _____ Position: _____

Situation: _____

Date Began: _____ Date Ended: _____

Date	Start Time	Finish Time	Product LOT #	ID #	Describe Issue(s)/Contact Information/Etc.

Signed: _____ Date: _____

REDACTED COPY

License Type: Processor

Exhibit 13 – Production and Manufacturing Process

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

13.1 – Identify which of the approved types of medical cannabis will be produced at each facility where cannabis is to be processed.

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Phase I Product Line

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)

[redacted]

Phase II Product Line

Ala. Code § 36-12-40 (Competitively Sensitive Information)

[redacted]

[redacted]
Ala. Code § 36-12-40 (Competitively Sensitive Information)

13.2 – Provide a summary of the manufacturing processes and methods to be utilized to produce each product, including the machinery, equipment, materials, and personnel necessary to produce each product.

[redacted]
Ala. Code § 36-12-40 (Personally Identifiable Information)

[redacted]

[redacted]
Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

[redacted]

Standards

We operate our manufacturing facility with traditional and cannabis standards. This includes but is not limited to International Organization for Standardization (ISO) 9001:2015 Quality Management System, ISO 17025:2017 Testing and Calibration, ISO International Workshop Agreement (IWA) 37-2:2022 Safety, Security and Sustainability of Cannabis Facilities and Operations, and International Association for Six Sigma Certification (IASSC) Lean Six Sigma Certification, and American's for Safe Access (ASA) Patient Focused Certification (PFC). Furthermore, this facility will follow all applicable guidelines set forth by the current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP).

The ISO, cGMP, and GLP Ala. Code § 36-12-40 (Personally Identifiable Information) [redacted], and independent consultants for cannabis and non-cannabis organizations. The Six Sigma standard Ala. Code § 36-12-40 (Personally Identifiable Information)e with this standard via his work in managing product manufacturing for biopharmaceutical companies. The medical cannabis PFC Ala. Code § 36-12-40 (Personally Identifiable Information) standards will be Ala. Code § 36-12-40 (Personally Identifiable Information)

The purpose of these processes is to establish detailed written procedures, as part of our quality program, for the safe, consistent, and accurate production of manufactured

medical cannabis products. We will obtain and utilize equipment of appropriate design and capacity for the type of manufacturing performed. To further the safety of our personnel and products, we will conduct internal testing via high-performance liquid chromatography (HPLC) in addition to state testing as per Ala. Admin Code r. 538-x-4-.07.12.o.03.d. Our HPLC testing equipment will be provisioned by Agilent. Our products will always have an identifying and compliant label prior to sale or transfer as per Ala. Admin Code. r. 538-x-6-.05. Products in their final packaging will be securely stored until approval by the quality team. Once approved, we will record products as available for sale in our inventory system and move them to a distinct shipping storage area for filling orders.

Cannabis Concentrates

Ala. Code § 36-12-40 (Competitively Sensitive Information)

[redacted]

Ala. Code § 36-12-40 (Competitively Sensitive Information)

[redacted]

Ala. Code § 36-12-40 (Competitively Sensitive Information)



Tincture Manufacturing Process

Ala. Code § 36-12-40 (Competitively Sensitive Information)



Ala. Code § 36-12-40 (Competitively Sensitive Information)

Gelatin Manufacturing Process

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)



Ala. Code § 36-12-40 (Competitively Sensitive Information)

[redacted]

Topical Manufacturing Process

Ala. Code § 36-12-40 (Competitively Sensitive Information)

[redacted]

Ala. Code § 36-12-40 (Competitively Sensitive Information)

[redacted]

Ala. Code § 36-12-40 (Competitively Sensitive Information)

Suppository Manufacturing Process

Ala. Code § 36-12-40 (Competitively Sensitive Information)


Ala. Code § 36-12-40 (Competitively Sensitive Information)

13.3 – Identify specific plans to ensure safety of personnel and facilities based on the types of processes proposed to be utilized.

Culture of Safety

Safety for our employees, the facility, and the medical products is of the utmost importance to us. Safety is a core part of culture and is emphasized in every touch point within our business [redacted: Ala. Code § 36-12-40 (Personally Identifiable Information)], implemented, managed, and audited safety policies for biopharmaceutical production lines, analytical laboratories, and cannabis manufacturing facilities.

Each has an excellent record with regard to safety due to their holistic approach of using third-party standards, fail-safe systems, redundant or fail-safe techniques, and equipment maintenance. As mentioned prior, ISO 9001:2015 Quality Management System, ISO IWA 37-2:2022 Safety, Security and Sustainability of Cannabis Facilities and Operations, cGMP, and GLP's will be adhered to.

Safety in Practice

Below are safety summaries, specific policies, and specific techniques used to protect employees and the facility from harm.

Safety Training

We will require that all employees are trained on our internal safety and sanitation procedures upon hiring. Every six months, existing employees will undergo a refresher course. Each employee will be supplied with a copy of a safety-specific policies and procedures manual, which is an abbreviated version of th along with training manuals for all the production equipment. The safety policies and procedures manual will include emergency and incident response protocols.

Personal Protective Equipment and Safety Equipment

We will supply all employees with laboratory uniforms, including protective lab coats, chemical spill aprons, nitrile gloves, heat gloves, hairnets, facial hairnets, face masks, safety

goggles, and shoe covers. Uniforms will be designed for durability, sanitation, and shielding defense.

Safety googles must be worn at all times in manufacturing areas. Gloves must be worn at all times within the appropriate activities, specialty gloves for use while handling hot products, and aprons for chemical splash risks. Hair nets and beard nets must be worn when completing any task in a production area. Long hair must always be tied up when working in a production area. Loose clothing, huge earrings, jewelry, and watches are forbidden. Closed-toe shoes are required to be worn on site at all times.

3M respirators must be worn when grinding cannabis flowers, which generates dust, to prepare it for extraction. Ear protection will also be available for occupational noise, with OSHA's noise standards being up to 90 dBA in an 8 hour day, which may occur while some equipment is in use. We will also have emergency eye wash stations in all production areas with an emergency shower near the extraction area. Furthermore, there will be fire extinguishers, first aid kits, chemical spill kits, and emergency defibrillators tactically located in each production area.

Employee Sanitation

To maintain a sanitary facility, we will require that all employees bathe/shower before coming to work, wear a clean uniform each day, and maintain adequate personal hygiene while on our premises. All our employees will maintain a high level of personal hygiene; employees who do not comply with policies regarding attire and grooming will be subject to disciplinary action. We will prohibit employees who feel sick or display symptoms of an illness from working their scheduled shift, including handling any cannabis-infused product. Employees with any illness, open lesion (e.g., boils, sores, infected wounds), or any other source of microbial contamination for which there is a reasonable possibility of contact with cannabis will be required to remain at home until their condition is remedied.

Employees with a combined cough and fever will also be required to stay home from work. Any employee with the following illnesses, in accordance with regulations applicable to

food handlers, will not be permitted to come to work or handle cannabis products until cleared by a physician: amebiasis; enterohemorrhagic E. coli; shigellosis; typhoid fever or paratyphoid fever; hepatitis A or viral hepatitis; jaundice of unspecified etiology; or, persistent diarrhea.

Cannabis Oil Extraction Safety

One of the biggest potential safety threats for any cannabis manufacturing facility is the extraction room and extraction process. When cannabis is oil extracted, there are potential which can arise depending on the solvent and equipment used. Our facility will utilize a closed-loop, supercritical carbon dioxide extraction system from Green Mill Supercritical.

In order to prevent malfunction, this equipment will have a daily calibration test and a monthly maintenance audit. This audit will include the replacement of parts such as carbon cartridges and inner seals. The details of maintenance events are recorded in our equipment and machinery maintenance logs.

The extraction room itself is well-ventilated. Furthermore, the extraction machine will have a hood vent over its exit port so that any excess carbon dioxide can be removed from the room. Supplementary exhaust systems will be installed which will have the capability to exchange and ventilate the air within the room within seconds of being activated. As a fail-safe against carbon dioxide poisoning, the extraction room will be equipped with two carbon dioxide monitors on opposite walls.

Carbon dioxide toxicity begins at 1,000 parts per million (PPM) causing fatigue. Unsafe levels begin at 5,000 PPM for over eight hours as per the Occupational Health and Safety Administration (OSHA). At 30,000 PPM carbon dioxide is very unsafe for exposure of greater than 10 minutes. At 40,000 PPM, carbon dioxide becomes an immediate threat to life.

Our facility has set an internal safety limit of carbon dioxide exposure of no greater than 4,500 PPM at any time. To ensure that employees are never exposed at greater than 4,500

PPM, we will be using the RAD-0102-6 model from CO_2 Meter. This model is OSHA compliant and meets the requirements of the National Fire Protection Association (NFPA) 1 - Chapter 38. If a leak occurs, the extraction machine will automatically be turned off by the machine's internal safety system. If carbon dioxide exceeds 4,500 PPM, employees are instructed to properly disengage the extraction machine and activate the exhaust system.

It is important to mention that we selected carbon dioxide because it is the safest commercial solvent available. It's multi-factorial benefits include:

- Being classified as Generally Recognized As Safe (GRAS) by the Food and Drug Administration (FDA). This means that CO_2 is classified as a safe food additive. CO_2 will be purged from the cannabis material, but trace amounts in parts per billion may remain. Many operators will choose to use solvents which leave trace amounts of solvents with carcinogenic properties such as propane or butane. We only want to use a non-toxic solvent approved by the FDA for human ingestion.
- Being non-flammable.
- It allows for botanical extractions at temperatures that are native to the material, minimizing thermal degradation and conversion from the original phytochemical profile in the cannabis flower into the extracted oil.
- It is environmentally sustainable. It does not create toxic byproducts when it is created in a laboratory and does not use up finite resources.
- It is very cost-efficient and will be available forever.

The purity of the solvent is very important for the safety of the extraction technicians and the patients using the product. We require that any carbon dioxide tube be at least 99% pure. To verify the purity of any tube sourced, we will request third-party testing, certificate of analysis (COA), from the manufacturer along with additional data such as Material Safety Data Sheet (MSDS). The manufacturer will be evaluated to ensure that they are in good standing with the state and federal government, meet quality requirements of the FDA regulations, American Society of Mechanical Engineers (ASME), the local fire department, and the state health department. All incoming materials used in the extraction process,

including inputs, raw materials, and solvents, must be recorded by Wendy Gilbreath, our Supply Chain Manager.

Facility Safety

In addition to our policies and procedures, safety equipment, internal standards, and personal protective equipment, we also have designed the facility itself for optimal safety. The construction of the facility will comply with the test specifications set forth in Standard Methods of Fire Tests of Building Construction and Materials, NFPA 251- 1969.

The design and placement includes airlock entry and exit hallways, and laboratory clean rooms. The facilities temperature, humidity, lighting, air quality, and ventilation will be monitored, recorded, and regulated by an environmental control system. Fire-resistant, food-grade stainless steel benches and tables are located in each production work area where cannabis is manufactured.

The facility will be consistently maintained in a good state of repair through the efforts of the facilities management team. Industry best practices will be adhered to including:

- All areas will have adequate lighting and ventilation in all areas for their designated operations.
- All buildings and facilities will be maintained in a clean sanitary condition, free of infestation by rodents, birds, insects and other vermin, with cleanings on a set schedule.
- Potable water will be supplied under continuous positive pressure in a plumbing system free of defects that meet the standards prescribed in the Environmental Protection Agency's Primary Drinking Water Regulations.
- Drains will be of adequate size and, where connected directly to a sewer, will be designed to prevent back-siphonage.
- Adequate washing facilities are currently in place with men’s and women’s locker rooms and showers, including hot and cold water, soap, or detergent, air driers, single-service towels and clean toilet facilities easily accessible to working areas.

- All trash or other refuse in and from the building and immediate premises will be disposed of in a timely, safe and sanitary manner.

Continuous Improvement
Our managerial and quality teams will conduct quarterly risk management assessments. The goal of risk management is to identify all hazards associated with our manufacturing process and apply adequate control measures. Hazard identification will be carried out systematically through the analysis of each work activity. Appropriate controls will be identified for all hazards and risks, and procedures will be updated as needed.

13.4 – Provide a detailed list of formulae and ingredients for each medical cannabis product, including a list of all excipients to be utilized in the manufacture of each product, and the purpose served by each.

Ala. Code § 36-12-40 (Competitively Sensitive Information)



Ala. Code § 36-12-40 (Competitively Sensitive Information)

Ala. Code § 36-12-40 (Competitively Sensitive Information)



License Type: Processor

Exhibit 14 – Machinery and Equipment

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

14.1 Sales contracts and receipts, lease agreements

14.1 – Coosa Medical Manufacturing has produced LOI's for all machinery and equipment to be used in the processing of medical cannabis. Per the email from the AMCC which is attached as "AMCC Email 9.14.22- Attachment to Exhibit 14 Section 14.1) Applicant is not required to show actual ownership of these items. Letters of Intent for the following pieces of equipment are also attached at "Letters of Intent- Attachment to Exhibit 14, Section 14.1) Applicant was not required to show the accessory items such as scales and bottle filling equipment but decided to include this as supplemental information as part of the Letter of Intent with Emerald Scientific.

Please note Applicant has not ordered this equipment yet but will have this equipment on-site within 45 days of license award.

Table of Contents for Letters of Intent Section 14.1

1) Qualicaps Gel Cap System
2) LFA Machines Tablet Press
3) Green Mill CO2 Extraction System
4) Truffly Made Gelatin System
5) Shimadzu Testing Equipment
6) Across International Vacuum Ovens, rotary evaporator system and wiped film evaporation system
7) Baker Perkins Gelatin System STILL NEED
8) Emerald Scientific Fritsch Cutting Mill Pulverisette 19 Grinder and Miscellaneous Items including:

Pallet Racks for bio mass storage
Quarantine Cage
Stainless Steel Tables
Glassware
Scales
Accessories
Bottle Filling System
Wire Racks
Stir plate/hot plate
StirBar Retreiver

stir bar
stir bar
stir bar
Scale
Scale
Scale
Buchner Funnel
Buchner Funnel
Buchner Funnel
Erlenmeyer Flask
Erlenmeyer Flask
Erlenmeyer Flask
Erlenmeyer Flask
Erlenmeyer Flask
Vacuum flask
Vacuum flask
Beaker
Beaker
Beaker
Beaker
Beaker
Volumetric Flask
Volumetric Flask
Volumetric Flask
Volumetric Flask
Volumetric Flask
Volumetric Flask
Volumetric Flask
Volumetric Pipette
Volumetric Pipette
Volumetric Pipette
pipette tips (box)
pipette tips (box)
pipette tips (box)
gloves (box)
weighing paper (box)
Filter paper
Filter paper
Filter paper
Nickel stirriers
stoppers (bag)

Nitrogen (small tank)
Waste (sharps)
ABC fire extinguisher
Liquid waste container
Spill kit
Computer Workstation

14.2 Specifications and operations manuals

We have attached specifications and operations manuals for all equipment listed above and identified as "Operations Manuals- Coosa Medical Manufacturing Processing Facility - Attachment to Exhibit 14, Section 14.2"

Table of Contents for Specifications and operations manuals Section 14.2

1) Qualicaps Gel Cap System
2) LFA Machines Tablet Press
3) Green Mill CO2 Extraction System
4) Truffly Made Gelatin System
5) Shimadzu Testing Equipment
6) Across International Vacuum Ovens, rotary evaporator system and wiped film evaporation system
7) Baker Perkins Gelatin System
8) Emerald Scientific Grinder and Miscellaneous Items

Note: Due to storage limitations in the online submission system, we were forced to pull hundreds of pages from the operations manuals. We are happy to produce the full document set upon notification by the Commission.

Monday, December 12, 2022 at 13:43:09 Central Standard Time

Subject: RE: Questions for clarification
Date: Wednesday, September 14, 2022 at 8:57:43 AM Central Daylight Time
From: Applications (AMCC)
To: Jeff Rabren
Attachments: image001.png

See answers below.

From: Jeff Rabren <Jeff@redlevelstrategies.com>
Sent: Monday, September 12, 2022 3:27 PM
To: Applications (AMCC) <applications@amcc.alabama.gov>
Subject: Questions for clarification

Good afternoon. I represent a few clients that intend to apply for licenses in various categories. Are you able to help us with the questions below? Thank you.

Chapter 6 Processors

-p.10 Do we need to own equipment before we win license?... Can we have an LOI with equipment manufacturers? An applicant must not necessarily own some or all equipment before the award of licenses. However, if equipment is owned, leased, or otherwise in the possession of the applicant at the time of application, then the documents must be provided. Additionally, for any plan or requirement in the rules, including this requirement, applicants will be directed to indicate whether, at the time of application, the plan or requirement is completed, in progress, or not started and the date on which the applicant anticipates it being completed. Any evidence of any in progress or not started requirement (i.e., LOIs with equipment manufacturers) would be relevant in the exhibit.

Qualicaps, Inc.
6505 Franz Warner Parkway
Whitsett, NC 27377-9215 USA

December 9th, 2022

Coosa Medical Manufacturing
3841 Village Center Drive
Hoover, AL 35226
Attention: David Hardin CEO

Re: Alabama Processing Facility Project

Dear David:

In furtherance of the processing license application to be submitted by Coosa Medical Manufacturing LLC (the "Applicant") to the Alabama Medical Cannabis Commission (the "Commission"), Qualicaps agrees to sell Coosa Medical Manufacturing, LLC the item(s) listed in quote KWC 12-12-22-1 for use at their processing facility (the "Facility"), pending the issuance of a medical cannabis processing license by the Commission (the "License").

Based on the information provided by the Applicant, Qualicaps intends to sell the equipment to the Applicant for the amount in quote KWC 12-12-22-1, subject to the issuance of the License. The specifications for the Equipment to be provided to the Applicant for use at the Facility are attached hereto.

Sincerely
Domenick Salvemini

Domenick Salvemini
Director of Sales- Equipt North America
Qualicaps US Equipt Group
Qualicaps Co., Ltd
EM-dsalvemini@qualicaps.com

Qualicaps PROCESSING EQUIPMENT GROUP

BUDGETARY PROPOSAL FOR F-40 CAPSULE FILLING SYSTEM

Attn: Kevin W. Cox

Quote Number- kwc 12-12 -22-1
Submitted- 12/ /22
Valid Till- 2/28/23

Dear Kevin,

F-40 Capsule Filling System makes it possible to fill various types of dosage forms such as powder, two-layer granules, oil and paste/liquids, and tablets, or up to 3 combinations of these dosage forms at the same time.

The machine is separated into two units, a capsule transfer unit and a filling unit. This separation of the unit provides easy access and promotes less time for product changeover and cleaning by simply switching filling units. Our Patented rectification system provides smooth capsule transportation at a high- speed operation and visual check of operation as well as preventing capsule feeding error.

SPECIFICATIONS:

Applicable Capsules- Sizes 00,0, 0EL,1,2,3,4,5

Output- Maximum 40,000/hour

Utility Requirements- Power Supply- 3 Phase, 200-220VAC, 50-60 Hz, 2.1KVA, Compressed air- 0.4Mpa (5kgf/cm2G). 300L/min (normal), Vacuum- 20Kpa (2000 mmH20) 4.5 m3/min

Approximate Dimensions & Weight- Width-775 mm x Depth-685 mm x Height- 1845 mm Weight- 700 kg



Qualicaps PROCESSING EQUIPMENT GROUP

F- 40L Liquid Fill Only Automatic Capsule Filling System
PRICE- USD $ 260,000.00 each

Base unit to include the following items:

-One (1) set of size-specific capsule format change parts
-One (1) Liquid Filling Unit for 00-0 or 1-5 capsules
-Capsule handling device (rectification/transportation of capsules), capsule separation section, capsule joining station, and capsule discharge chute.
-Large 8 Liter Product Hopper with Water Jacketed Heater and Stirrer.
-Additional Heating around Nozzle Block.
-VACUUM NOT INCLUDED.

Vacuum/Blower- Filtered with Remote Control System- PRICE USD $10,000.00

INSTALLATION, TRAINING & VALIDATION

Installation/Training *Package*

Installation consists of vacuum, air and electrical connections. Assembly of any components taken off the machines for shipping purposes, as well as final adjustments after assembly to assure that the machine is properly aligned and ready to run. The training consists of various aspects of operating and maintenance procedures.
PRICE USD $ 8,000.00

Validation Package

To include IQ/OQ Document and execution of IQ/OQ at customer site (PQ Responsibility of Customer) PRICE USD- $10,000.00 each

OPTIONS:

Additional Set of Capsule Size Specific Change Parts- PRICE- USD $24,000.00 each

Additional Liquid Filling Unit – Two sizes of filling units are offered. Sizes offered are for Capsule sizes 00-0 or 1-5. Please specify filling unit size when placing order.
PRICE- $15,000.00

DELIVERY

Delivery Terms- DDP (Pre-pay and Add), or FOB. Shipping Method- Bestway- To be determined at time of order. Lead-time to be confirmed at time of order. Currently F-40L in stock in Japan. Customer is responsible for all shipping charge, duties, taxes, insurance ect... Please contact Qualicaps representative to coordinate shipping method and payment- EM kholmes@qualicaps.com / PH 336-449-3966.

WARRANTY

The S-125 is warranted for 12 months of normal operation beginning immediately following the installation of the equipment.

Qualicaps PROCESSING EQUIPMENT GROUP

PAYMENT TERMS

30% down payment is to be made when the Purchaser issues the purchase order.
50% payment is to be made upon notification of machine shipment.
20% payment is to be made within 30 days from delivery.
**** Final terms decided after credit application is reviewed and approved**

PURCHASE ORDER SHALL BE ADDRESSED TO:

Qualicaps Co., Ltd.
321-5 Ikezawacho Yamatokoriyama
Nara, Japan 639-1032
Attn: Domenick Salvemini
dsalvemini@qualicaps.com

Please include all terms and conditions required on formal Purchase Order (including shipping method and payment)

STANDARD FEATURES

Capsule Rectification System
Qualicaps uses a patented Three Roller Capsule Rectification System for feeding empty capsules. The empty capsule is positioned in a secure manner before sealing by use of three rollers. No additional pressure or impact is exerted during the mechanical transfer and capsules are smoothly rectified by using the diameter difference between "cap" and "body". After rectification, capsules are transferred into filling area by vacuum.



Feeding Error Detection System
A sensor detects the capsules which are improperly set in feed drum and or transfer chute.

Filling Unit (Liquid)
Liquid filling unit has pumping filling mechanism, which are driven by mechanical force. The filling accuracy is controlled by Stroke length of pumping piston. High viscous liquid can also be filled with special product heating mechanism.



Qualicaps PROCESSING EQUIPMENT GROUP

Laser Sensor to Detect Missing Capsules (Liquid)
A Laser sensor confirms for lack of capsules in cavity and automatically stops the filling to avoid any spillage in the cavity which can trigger capsule handling issue. The unfilled capsule is sorted and discharged into separate area.

Product Level Sensor
Product level in the hopper is controlled by a sensor to ensure proper amount of product being feed into fill area. The setting can be adjusted based on product specification.

Joining Section
After capsule filling, cap and body are joined together by using specially designed pusher pins (concave capsule contact point with special bushings) and joining block. Capsules are pushed upward with limited pressures.

Unseparated Capsule Removing System
Unseparated capsule is collected special capsule collection mechanism. The container has a sensor that advises the level of collected capsules. When the container becomes full, the machine activates an alarm, to prevent the overflow.

Capsule Transfer System
Capsules in the machine are handled in a multi-cavity segment with intermittent movement. F-40 has 15 cavities for multi-feeding and handling system all at the same time. Both cap and body holding rings are manufactured as a single assembly for quicker cleaning and change over. The increased number of cavities per segment allow for longer filling dwell time and more accurate capsule fill weight.

Discharge Unit
Capsules are discharged by specially designed pins and exit from the right front side of the machine. Optional discharge methods can be incorporated to sort filled and unfilled capsules (Sorted by sensor and damper in discharge section).

Cleaner System
Empty cavities of cap segments and body ring are cleaned by vacuum after capsules are discharged to insure stable and continuous capsule handling.

OTHER TERMS AND CONDITIONS

To ensure proper handling of the machinery during delivery and installation, the Purchaser will provide a forklift having lifting blades not less than 48" long and capable of lifting 2 tons or 4,000 lbs. The forklift operator will pick up the machinery crate only from its widest side. Seller will provide crate dimensions to Purchaser when available.
The Purchaser will make every attempt to ensure proper handling of the machine during delivery, unloading and uncrating. The crate is designed to provide maximum protection to the machinery during shipping. Any and all damage to machinery during shipping must be promptly documented and reported to Qualicaps, Inc. Upon installation, the Purchaser will provide clean/dry electrical outlet for the machine's main electrical cable and guarantee a fluctuation of voltage to the machinery of greater than 10%. The Purchaser shall provide suitable compressed air.

Qualicaps PROCESSING EQUIPMENT GROUP

By executing this Proposal, Purchaser and Seller agree that Seller will sell and Purchaser will purchase the machine to be sold hereunder above at the Purchase price stated above in accordance with the terms and conditions of this Proposal. Three set of manuals, in English language, are provided. The Purchaser understands that Qualicaps, Inc. must be informed of any changes in the machine's installation schedule. If sufficient notice of a change is not given, the Purchaser will be responsible for all of the travel expenses for the engineer(s) to return at a later date and install the machine.

Cancellation clause: Any cancellation must be done in writing and received and acknowledged by Qualicaps within thirty (30) days after receipt of purchase order by Qualicaps. Such cancellation shall result in payment to Qualicaps by Purchaser in the amount of one third (1/3) of the total purchase order amount. After the thirty day period, Purchaser is responsible for the full purchase order amount.

PRICE SUMMARY

Item	Qty	Unit Price	Total	Options
F-40L Liquid Capsule Filler with one set of Change parts	1	$260,000.00	$260,000.00	
Vacuum/Blower	1	$10,000.00	$10,000.00	
Installation/Training	1	$8,000.00	$8,000.00	
Validation	1	$10,000.00	$10,000.00	
Additional set of Change parts	1	$24,000.00		$24,000.00
Additional Liquid Filling Unit	1	$15,000.00		$15,000.00
Total			$288,000.00	$39,000.00

Total Purchase Price- $288,000.00 (Includes one set of change parts, Vacuum/Blower, Installation/Training and Validations)

If you need additional information or have any questions, please contact me. Thank you for your time and consideration in this matter.

Regards,

Domenick Salvemini

Director of Sales - North America Equipt Group
Cell- 732-546-0802 Email- dsalvemini@qualicaps.com

Qualicaps Engineered to perform
QUALICAPS US EQUIPMENT GROUP

Qualicaps, Inc.
6505 Franz Warner Parkway
Whitsett, NC 27377-9215 USA

December 9th, 2022

Coosa Medical Manufacturing
3841 Village Center Drive
Hoover, AL 35226
Attention: David Hardin CEO

Re: Alabama Processing Facility Project

Dear David:

In furtherance of the processing license application to be submitted by Coosa Medical Manufacturing LLC (the "Applicant") to the Alabama Medical Cannabis Commission (the "Commission"), LFA Machines agrees to sell Coosa Medical Manufacturing, LLC the item(s) listed in quote [Quote # 2447] for use at their processing facility (the "Facility"), pending the issuance of a medical cannabis processing license by the Commission (the "License").

Based on the information provided by the Applicant, LFA Tablet intends to sell the equipment to the Applicant for the amount in quote [Quote # 2447], subject to the issuance of the License and accepted LFA due diligence form and government issued ID. The specifications for the Equipment to be provided to the Applicant for use at the Facility are attached hereto.

Sincerely,

LFA Machines
Katie Johnson
Director of Sales

6601 Will Rogers Blvd, Fort Worth, Texas 76140

QUOTE

Coosa Medical Manufacturing
3841 Village Center Drive
HOOVER AL 35226
UNITED STATES

Date
12 Dec 2022

Expiry
26 Dec 2022

Quote Number
QU-US-2447

LFA Machines DFW LLC
LFA Sales Team
6601 Will Rogers Blvd
FORT WORTH TEXAS
76140
UNITED STATES

Description	Quantity	Unit Price	Tax	Amount USD
TDP 5 Desktop Tablet Press with 8mm flat-faced, beveled-edge, bisect tooling (in stock, lead time 2-3 weeks from time of payment)	1.00	3,995.00	Tax on Sales	3,995.00
Shipping to: 3841 Village Center Drive Hoover AL 35226	1.00	286.72	Tax on Sales	286.72
			Subtotal	4,281.72
			TOTAL USD	**4,281.72**

Terms

For terms and conditions please visit our website:
https://www.lfamachines.com/terms-and-conditions

Registered Office: Attention: LFA Sales Team, 6601 Will Rogers Blvd, Fort Worth, Texas, 76140, United States.

GREEN MILL

7800 Susquehanna Street
Pittsburgh, PA 15208

December 9, 2022

Coosa Medical Manufacturing, LLC
3841 Village Center Drive
Hoover, AL 35226

Attention: David Hardin CEO

Dear David,

This letter is to confirm our agreement to sell Coosa Medical Manufacturing, LLC a Green Mill SFE system.

In furtherance of the processing license application to be submitted by Coosa Medical Manufacturing LLC (the "Applicant") to the Alabama Medical Cannabis Commission (the "Commission"), Green Mill Supercritical agrees to sell Coosa Medical Manufacturing, LLC the items listed in attached quote for use at their processing facility (the "Facility"), pending the issuance of a medical cannabis processing license by the Commission (the "License").

Based on the information provided by the Applicant, Green Mill Supercritical intends to sell the equipment to the Applicant for the amount in quote dated Dec 9, 2022 subject to the issuance of the License. The specifications for the Equipment to be provided to the Applicant for use at the Facility are also attached.

Please let me know if you have any questions or need any additional information at this time. We appreciate your interest in Green Mill and look forward to working with you.

Best regards,

Wes Reynolds
President and CEO

December 9th, 2022

Coosa Medical Manufacturing
3841 Village Center Drive
Hoover, AL 35226
Attention: David Hardin CEO

Re: Alabama Processing Facility Project

Dear David:

In furtherance of the processing license application to be submitted by Coosa Medical Manufacturing LLC (the "Applicant") to the Alabama Medical Cannabis Commission (the "Commission"), Truffly Made Inc. agrees to sell Coosa Medical Manufacturing, LLC the item(s) listed in quote #1210 for use at their processing facility (the "Facility"), pending the issuance of a medical cannabis processing license by the Commission (the "License").

Based on the information provided by the Applicant, Truffly Made Inc. intends to sell the equipment to the Applicant for the amount in quote #1210, subject to the issuance of the License. The specifications for the Equipment to be provided to the Applicant for use at the Facility are attached hereto.

Sincerely

Truffly Made Inc.

Ian
Sales Director

510 SE 25th Ave - Fort Lauderdale, FL 33301

November 28, 2022

Shimadzu Scientific Instruments, Inc.
5429 E Beaumont Center Blvd
Tampa, FL 33634

Attention: Andres Martinez

Re: Alabama Processing Facility Project

Dear Andres:

In furtherance of the processor license application to be submitted by Coosa Medical Manufacturing LLC (the "Applicant") to the Alabama Medical Cannabis Commission (the "Commission"), Shimadzu Scientific Instruments, Inc. has reviewed your proposed plans for the purchase of Shimadzu Scientific Instruments, Inc.'s i-series HPLC Cannabis Analyzer for quantitative potency determination of cannabis matrices for use at their processing facility (the "Facility"), pending the issuance of a medical cannabis processing license by the Commission (the "License").

Based on the information provided by the Applicant and Shimadzu Scientific Instruments, Inc.'s preliminary review of the equipment request for the proposed facility, Shimadzu Scientific Instruments, Inc. intends to offer for purchase Shimadzu Scientific Instruments, Inc. i-series HPLC Cannabis Analyzer for Potency (the "Equipment") to the Applicant in upon such terms and conditions to be agreed to by Shimadzu Scientific Instruments, Inc. and the Applicant, subject to the issuance of the License.

If you have any further questions, please feel free to contact (authorized Shimadzu Scientific Instruments, Inc. sales agent), Wallace Rippy, awrippy@shimadzu.com, (601) 862-0509.

Sincerely,

Wallace Rippy
Sales Representative

Shimadzu Scientific Instruments, Inc.

December 1st, 2022

Across International
119 Dorsa Ave.
Livingston, NJ
07039
Attention: Andres Martinez

Re: Alabama Processing Facility Project

Dear Andres:

In furtherance of the processor license application to be submitted by Coosa Medical Manufacturing LLC (the "Applicant") to the Alabama Medical Cannabis Commission (the "Commission"), Across International agrees to sell Coosa Medical Manufacturing LLC the items listed in quotes 20985 and 20893 (from Across International) which consist of, but not necessarily limited to: two 1.9 cubic foot vacuum ovens, one 20 liter rotary evaporator system, and one 6 inch wiped film evaporation system for use at their processing facility (the "Facility"), pending the issuance of a medical cannabis cultivation license by the Commission (the "License").

In purchasing the equipment listed in quotes 20985 and 20893, Coosa Medical Manufacturing LLC agrees to pay the amount in each quote in full following the terms laid out in both the quotes listed above and any other agreement made between both Across International and the Applicant.

Across International makes no claim of expertise or knowledge of the Applicant's business practices, processing techniques and procedures, etc. Across International only provides expertise in equipment purchase and functionality laid out in the warranty policy, quotes, and other Across International documentation.

If you have any further questions, please feel free to contact (authorized Across International sales agent), Daniel Demetz (201) 888-9283 cell.

Sincerely,

Daniel Demetz
Across International Account Manager

Across International
888-988-0899 | quotes@acrossinternational.com
111 Dorsa Ave. Livingston, NJ 07039 | 600 Spice Island Drive, Sparks, NV 89431

Baker Perkins
schenck process group

December 12, 2022

Coosa Medical Manufacturing
3841 Village Center Drive
Hoover, AL 35226
Attention: David Hardin CEO

Re: Alabama Processing Facility Project

Dear David:

In furtherance of the processing license application to be submitted by Coosa Medical Manufacturing LLC (the "Applicant") to the Alabama Medical Cannabis Commission (the "Commission"), Baker Perkins agrees to sell Coosa Medical Manufacturing, LLC the item(s) listed in Quote [Q123379r0] for use at their processing facility (the "Facility"), pending the issuance of a medical cannabis processing license by the Commission (the "License").

Based on the information provided by the Applicant, Baker Perkins intends to sell the equipment to the Applicant for the amount in Quote [Q123379r0], subject to the issuance of the License. The specifications for the Equipment to be provided to the Applicant for use at the Facility are attached hereto.

Sincerely,

Evan Falk

Evan Falk
Account Manager
Baker Perkins Inc.

Baker Perkins Inc
3223 Kraft Ave SE
Grand Rapids, MI 49512-2027
USA

T: +1 616 784 3111
bpinc@bakerperkins.com
www.bakerperkins.com

EMERALD SCIENTIFIC

December 12th, 2022

Coosa Medical Manufacturing
3841 Village Center Drive
Hoover, AL 35226
Attention: David Hardin, CEO

Re: Alabama Processing Facility Project

Dear David:

In furtherance of the processing license application to be submitted by Coosa Medical Manufacturing LLC (the "Applicant") to the Alabama Medical Cannabis Commission (the "Commission"), Emerald Scientific ("Emerald") has reviewed your equipment list for the construction of a 15,000 square foot processing facility (the "Facility"), pending the issuance of a medical cannabis processing license by the Commission (the "License").

Based on the information provided by the Applicant, Emerald intends to sell the equipment on Exhibit A (the "Equipment") to the Applicant in such quantities and upon such terms and conditions to be agreed to by Emerald and the Applicant, subject to the issuance of the License. The specifications for the Equipment to be provided to the Applicant for use at the Facility are attached hereto.

Sincerely,

Robert Schmidt

Robert Schmidt
Technical Sales Representative
Emerald Scientific, LLC.
bob.schmidt@emeraldscientific.com

Qualicaps Gel Cap System

Doc.No.:06239-01-MAN0011-00

Qualicaps

Fully Automatic Capsule Filling Machine
Instruction Manual

F - 40

Revision History

Rev. No.	Date	Revision content	Relevant position	Reviser
-	Feb.28, 2020	Newly created		F.Kubo

You are requested to carefully read applicable portions of the instructions before starting your work.

Installation worker

Installation worker must read thoroughly chapter 1, 2, 3, 6, 8, 9 of the instructions before starting the installation work.
There is no need to read other chapters.

Machine operator

Machine operator must read thoroughly chapter 1, 2, 4, 6, 8, 9 of the instructions before starting the machine operation.
There is no need to read other chapters.

Maintenance worker

Maintenance worker must read thoroughly chapter 1, 2, 5, and 7 of the instructions before starting the maintenance work.
If necessary, read chapter 3, 4, 6, 8, 9

Contact Address:
321-5, Ikezawa-cho, Yamatokoriyama, Nara, 639-1032, JAPAN
QUALICAPS CO., LTD.
TEL: +81-743-57-8920 FAX: +81-743-56-5113
URL http://www.qualicaps.co.jp/en/

1. Meaning of Signs Used in the Instructions

Following signs are used in the instructions. Fully understand the content of the signs before reading the main body of the instructions.

WARNING: Denote an operation that may result in bodily injury such as serious wound or serious damage to machine if the warning is not observed.

CAUTION: Denote an operation that may result in bodily injury such as wound or damage to equipment if the caution is not observed.

2. Caution for Safety (Important Warning)

<Be sure to read the caution for safety to ensure your safety.>

Incorrect use of the machine is dangerous and may result in bodily injury or failure of machine. Be sure to observe the following to prevent accidents.

(1) Read the instructions before operation.
(2) Observe the caution for safety.
(3) Never touch rotating parts and belts, etc.
(4) Turn off the power of machine before starting the work.
(5) Never release the interlock.
(6) Before starting the power operation, operate the machine by manual to secure the safety. It is possible to prevent troubles beforehand.
(7) Never put any object on the machine. Do not cause the body or objects to be caught in elevating sections.
It may result in bodily injury or failure of machine.

3. Types and Location of Warning Labels

(1) Type of warning labels

Caution for entanglement hazard

Entanglement of hand or clothes, etc. in the belt may result in severe injury or broken bones.

Do not touch.

Caution for entanglement hazard

Entanglement of hand or clothes, etc. in the gear may result in severe injury or broken bones.

Do not touch.

Caution for pinching hazard

Fingers or body if pinched may result in severe injury or broken bones.

Do not touch.

Caution for rotating hazard

Contact with rotating parts may cause injury.

Do not touch.



Caution for electric hazard

Electric shock may result in fire or death.

Do not touch.

Caution for burn wound

Contact to the high temperature parts may result in burn wound.

Do not touch.

Caution for laser (class II)

Staring into the beam may result the laser beam directly. in severe injury.

Do not stare into

Caution for pinching hazard

Fingers if pinched may result in severe injury or broken bones.

Do not touch.

Caution for burn wound

Contact to the high temperature parts may result in burn wound.

Do not touch.

(2) Location of warning labels

No.	Label	Location of Labels
1		• Faulty separated capsule section • Cleaner section • Transfer plate unit section • Rear face of directional control drum
2		• Gear of directional control section • Main motor and clutch section • Main body gear section • Main body cam section • Main body axis section • Oil unit cover
3		• Transfer plate unit section • Separating block section • Faulty separated capsule section • Connected section
4		• Oil unit(stirrer)
5		• Transfer terminal section • Control panel (lower cover) • Touch panel • Oil unit (temperature regulator)
6		• Oil hopper heater • Pumping block heater • Hot water tank
7		• Oil unit (laser sensor)
8		• USC catcher • Transfer plate unit section • Discharging section
9		• Oil unit

4. Location and Function of Interlock

No.	Location of interlock	Qty	Function
1	Front side door of machine	1	Emergency stop
2	Right side door of machine	1	Emergency stop
3	Left side door of machine	1	Emergency stop
4	Back side door of machine	1	Emergency stop
5	Emergency stop switch	1	Emergency stop

1. Name, Model, Application, and Specification of Machine

(1) Name of machine Fully Automatic Capsule Filling Machine

(2) Model F-40

(3) Application

The machine automatically fills a fixed quantity of oil, powder and the like into hard gelatin capsules.

(4) Main specification

Capacity:	40,000 capsules/hour
Application:	Hard gelatin capsule, size No. 0
Power Source:	Single phase AC 200V, 3.0 KVA
Compressed Air:	0.5 MPa, 0.3m^3/min (Supply dry air)
Vacuum:	20 kPa, 4.0 m^3/min
Noise:	Within 85 dB (A)
Equipment Environment:	Temperature 18-28 [degrees Celsius] Humidity 45-55% [RH]
Size of Equipment:	Width: 985 mm Length: 973 mm Height: 1,770 mm (excluding hopper and stack light)
Gross Weight:	Approx. 900 kg

2. Details of Machine and Specification

(1) Appearance of main body

(a) Appearance of main body



(b) Control box operation panel



No.	Description	Function
(1)	Touch panel	Alarm display and operation switch
(2)	Filling changeover switch	Filling ON/OFF changeover
(3)	Start switch	Operation by motor
(4)	Stop switch	Motor stop
(5)	Emergency stop switch	Motor stop (with lock)

(c) Stack light



Display	Meaning
Red (ON)	Machine is stopped when emergency stop switch is pressed or door is opened.
Yellow (ON)	Alarm is given.
Green (ON)	Machine is operating.
White (ON)	More than one setting of the following is made ineffective due to machine setting. "Remainder amount detection" "Thermal alarm" "Fall-out sensor" Machine can be operated; however caution should be exercised because troubles may occur when sensor is made ineffective.

(2) Capsule transfer section



(a) Capsule hopper
Capsule hopper stocks capsules and supplies them to the service hopper.

(b) Service hopper
Service hopper vibrates capsules and supplies them to the feed drum.

(c) Feed drum
Feed drum fills capsules into the pocket of the feed drum and supplies them to the rectifier roller.



(d) Rectifier roller
Rectifier roller controls the direction of capsules.

(e) Transfer roller
Transfer roller transfers capsules from the rectifier roller to the transfer plate.

(f) Transfer plate
Transfer plate receives capsules from the transfer roller continuously and loads them into the cap disk intermittently.

(g) Separating block (upper) (lower)
To separate the body, separating block make a path between the cap disk and the body disk.



(h) Cap disk
Cap disk holds caps and transfers them to each section.

(i) Body disk
Body disk holds bodies and transfers them to each section.

(j) Body support
Body support supports the bottom of body with O ring to relieve the impact during separation.

(k) Faulty separated capsule pusher
Faulty separated capsule pusher pushes up faulty separated capsules, faulty directional capsules and double caps, then stores them into the USC catcher.

(l) Joining unit

Joining block is tightly pressed to the body disk and the body is pushed up by the joining pusher to be stored into the joining block. The joining pusher and the joining block are pushed up at the same time, then joining block is tightly pressed to the cap disk to join the cap.

(m) Discharging unit

Capsules are pushed up over the cap disk by the discharging pusher and discharged to the chute by the air cylinder.

(n) Cleaning unit

Upper shoe collects dust with vacuum from the top surface of cap disk and lower shoe collects dust with vacuum from the bottom surface of body disk.



(3) Oil filling unit

Refer to chapter 6.

(4) Tapping unit

Refer to chapter 8.

1. Points and Notes for Transportation and Handling
   (1) For loading and unloading during transportation, use a forklift over 1-ton capacity and scoop up the bottom of the packaging.
   (2) Set the fork of forklift to the marked position of the packaging material.
   (3) Lift the wooden package box slightly (several centimeters) and confirm whether the wooden package box is stable. If there is no problem, move or lift the wooden package box.
   (4) Handle the machine carefully.
   (5) Keep the machine in the air conditioned area for a long term storage.

2. Method of Unpacking and Lifting
   (1) Pull out nails and remove the outer packaging materials (5 sides except the bottom plate) of the wooden package box.
   (2) Remove barriers and polyethylene bags.
   (3) Remove cushioning materials, etc.
   (4) Remove members securing the machine and the bottom plate.
   (5) Collect cushioning materials, polyethylene bags and drying agent, etc. by the type of materials.
   (6) Lift up the machine by the forklift and remove the bottom plate.
   (7) Unload the machine on the hand pallet lift for carry.
   (8) When hoisting the machine, hoist and transfer the machine with hoisting ropes.

When using hand lift



* Avoid the screws on the bottom face and insert the fork.





3. Installation Procedure
   (1) Load the machine on hand pallet lift and carry it to the location of installation.
   (2) Adjust the level adjuster to set the height from the floor to the frame top surface to 1,744 mm and install the capsule filling machine.
   (3) Place a level on the base plate and adjust the levelness of the machine.
   Levelness shall be within 0.5 mm/m.
   (4) Take out small parts from the cardboard box contained in the same package except for the machine.
   (5) Clean small parts with alcohol.
   (6) Clean the machine with alcohol.
   (7) Install small parts such as capsule hopper contained in the same package.

4. Procedure for Connecting Power Source, Wiring, and Piping
   (1) Connection of power source
      (a) Insert the power line from the machine into the primary side of the power source.
      (b) Power source shall be single phase, AC200~240, 50/60Hz and the power source capacity shall be 3.0 kVA.
      (c) Use the power line of 2.5 mm^2 or larger.
      (d) Turn off the breaker of the machine body and supply the primary side power source. Measure the voltage with tester and verify that the voltage is within the range of AC200~240V. (Verify the voltage at the back side of the machine body breaker)
      (e) Turn on the machine body breaker.
      (f) Reset all alarms of the touch panel.
      (g) Slowly turn the handwheel clockwise until the clutch is engaged.
      (h) After the clutch is engaged, ensure that the handwheel can be turned with light force and that there is no abnormal noise or variation of load.





Caution: Before connecting the power line, be sure to shut off the primary side power source.

Caution: Protect against electric shock.

(2) Vacuum piping

(a) Connect the vacuum pipe to the connecting port shown in the photo using ϕ50 pipe.
Normal vacuum pressure: 20 kPa
Normal vacuum flow rate: 4.0 m^3/min

(b) Start the vacuum blower.

(c) Check the leakage of vacuum from the piping.



(3) Compressed air piping

(a) Connect the compressed air pipe to the connecting port shown in the photo using ϕ10 push-in joint.
* Be sure to supply dry air for compressed air.
Normal compressed air pressure: 0.5 MPa
Normal compressed air flow rate: 1 m^3/min

(b) Supply the primary side compressed air.

(c) Change the valve on the residual pressure exhaust valve counterclockwise to the supply side.

(d) For all the solenoid valves, press the manual operation knob and turn it clockwise to the lock position.



(e) Verify the gauge pressure of the pressure switch is 0.35 MPa or more.
If the compressed air pressure is 0.35 MPa or more when all compressed air is used, the compressed air capacity is acceptable.

(f) After checking the gauge pressure, press the manual operation knob and turn it counterclockwise to the original position.

5. Customer-Furnished Items

(1) Vacuum blower

Customer is requested to provide a vacuum blower of the following specification.
Normal vacuum pressure: 20 kPa
Normal vacuum flow rate: 4 m^3/miu

(1) Drawing

- Outside drawing (including pipe connecting locations)



1. Capability and Training of Workforce

(1) Capability of workforce

Workforce shall be able to read and understand the instructions and work in a calm manner.

(2) Training

After the training is completed, confirm the level of understanding of the workforce. If the level of understanding is insufficient, extend the training period or change the workforce.

WARNING: If the understanding is insufficient, incorrect use is dangerous and may result in bodily injury or failure of machine.

2. Preparation for Operation

(1) Supply of compressed air

Change the valve on residual pressure exhaust valve to the supply side and supply the compressed air. Check leakage of compressed air from the piping. If the compressed air is leaking, there is a possibility that the pipe is disconnected at the compressed air pipe joint. Connect the pipe properly.

Caution: Before connecting the pipe, stop the supply of the compressed air.

(2) Turning on the power source

Turn the handle of the machine body breaker 90degrees clockwise to turn on the power source.

Then, check whether the main power lamp is turned on. If the main power lamp is not turned on, there is a possibility that the power is not supplied. Check the power line or the primary power line and supply the power source.

Alarm is given when the power is supplied. Press the "reset button" of the touch panel to stop the alarm.

Caution: When checking the power source, protect against electric shock.



(3) Log in

Log in from the log in screen of operator on the touch panel.



(4) Setting parameters

Set the parameters for "filling unit" and on the touch panel.



(5) Generation of vacuum

Start the vacuum blower and wait until the vacuum pressure reaches the normal vacuum pressure.

(6) Supply of capsules

Supply the capsules into the capsule hopper.

Caution: When capsules are in the capsule hopper, do not turn the hopper in reverse direction (counterclockwise turn). Capsules will be crushed.

(1) Handwheel

Turn the handwheel counterclockwise and check no abnormal noise from the machine and smooth transfer of capsules. If an abnormal noise is detected, there is a possibility that wrong work is performed during disassembly or assembly. Check and correct the wrong work. If a transfer problem is detected, check conditions of assembly and conditions of compressed air pressure and vacuum pressure, then correct them.

Caution: Before turning the handwheel, ensure that capsules and tools, etc. are not remaining in moving units or operating units in the machine.



(2) Startup

Press the "start switch" of the control box operation panel to flow capsules.

When the supply ratio of capsules on the cap disk has reached 100%, press the "stop switch" on the control box operation panel to stop the machine.



(3) Preparation for operation unit

Refer to (chapter 6) and make preparations for oil filling unit operation.

Refer to (chapter 8) and make preparations for Tapping unit operation.

(4) Filling operation

Change the "Filling Changeover Switch" to ON.

Press the "start switch" for filling operation.



(5) Finishing the operation

Press the "stop switch" of the control box operation panel to stop the machine. Turn the "filling changeover switch" to stop filling operation. Press the "start switch" to operate the machine until there are no capsules in the capsule hopper. Confirm that no capsules remain in the capsule hopper, then press the "stop switch" to stop the machine.



(6) Finish the operation of filling unit

Refer to (chapter 6, 8, 9) and carry out Termiuation of operation.

4. Disassembly

Caution: Before disassembling the machine, press the "emergency stop switch" of the control box operation panel.

Caution: Do not loosen the screws unless otherwise specified.

* Blue letter with under line in this section: Replacement parts according to capsule size

(1) Capsule hopper

Remove the capsule hopper by lifting it to top.

(2) Service hopper

Remove the retaining screw and remove the service hopper.



(3) Feed drum

Remove the retaining screw and remove the feed drum.

* Do not loosen 2 position-adjusting screws. (Circled in red)

(4) Rectifier roller

Loosen the retaining screw and remove the rectifier roller.

* Do not loosen 2 position-adjusting screws. (Circled in red)

(5) Remove the faulty separated capsule catcher.

Bottom plate is a replacement parts according to capsule size.



(6) Transfer roller

Loosen the retaining screw and remove the transfer roller.

* Do not loosen 2 position-adjusting screws. (Circled in red)

(7) Transfer plate unit

(a) Remove the compressed air couplers.
(2 green/yellow compressed air tubes)

(b) Loosen the retaining screws and remove transfer plate unit.

(c) Remove the transfer plate and the transfer plate spacer from transfer plate holder.







(8) Separating block unit

(a) Remove the compressed air couplers and the connector for sensor.
(2 green/yellow compressed air tubes and 1 connector for faulty loading sensor)

(b) Loosen 2 retaining screws of separating block unit and remove it.
(When removing the separating block unit, the transfer plate unit must be on forward position.)





(d) Remove the faulty loading sensor.

(e) Loosen the countersunk screws of the TP shoe base and remove it.



(f) Loosen 3 rataining screws of the upper and lower separating blocks and remove them at the same time.

* Do not loosen 2 position-adjusting screws on separating block (upper). (Circled in red)



* Do not loosen screws circled in red.



* Do not loosen screws circled in red.

(9) Remove the discharging chute.

(a) Remove the compressed air connectors.
(2 green/yellow compressed air tubes)
(2 red/blue compressed air tubes)

(b) Loosen the chute fixing knob and remove the discharging chute.



(10) Remove the upper joining plate.

(11) Remove the cleaner upper shoe.

(12) Remove the cap disk.



(13) Remove the discharging pusher.



(14) Remove the faulty separated capsule pusher.





* Do not loosen the position-adjusting screw. (Circled in Red)

(15) Remove the joining block cleaner shoe.



(16) Remove the joining block.





* Do not loosen the position-adjusting screws. (Circled in Red)

(17) Remove the discharging pusher.





* Do not loosen the position-adjusting screws. (Circled in Red)

(18) Remove the joint.



(19) Remove the body support and its holder.
Remove the body support from the body support holder.





(20) Remove the joining pin guide.



(21) Remove the joining pin.





* Do not loosen the position-adjusting screws. (Circled in Red)



* Do not loosen the position-adjusting screws. (Circled in Red)

(22) Disassembling the filling unit

(a) Oil filling unit

Refer to (chapter 6, 5.) and disassemble the oil filling unit.

5. Washing

(1) The following parts which directly contact with capsules and drug cannot be washed. Wipe these parts with alcohol, etc.

(a) Service hopper
(b) Guide plate
(c) Transfer plate unit (excluding the transfer plate)
(d) Cap disk center base
(e) Discharging chute
(f) Cleaner lower shoe

(2) Parts which can be disassembled other than the above can be washed with warm water, etc. When washing the parts, avoid damage on parts by contact with tip of brush or metal parts.

(3) After washing, blow off the parts with compressed air to remove water drops and allow to dry.

(4) Filling unit

Oil filling unit

Refer to (chapter 6, 7.) and wash the oil filling unit.

5. Assembly

Caution: Before assembling, press the "emergency stop switch" of the control box operation panel.

Caution: Do not loosen the screws unless otherwise specified.

Blue letter with under line in this section: Replacement parts according to capsule size

(1) Install the joining pin.

Joining pin can be positioned by the positioning pins.



(2) Install the joining pin guide.

The joining pin guide can be positioned by the positioning pins.



(3) Install the body support on the body support holder.

The body support can be positioned by spigot joint.



(4) Install the body support holder.

The body support holder can be positioned by spigot joint.

Fix with snap lock.





(5) Install the body disk.

The body disk can be positioned by spigot joint.

* Put the body disk on a position where the stamp mark of disk center base and the size stamp mark on body disk match.





(6) Install the discharging pusher with knurled knob.

The discharging pusher can be positioned by the key and stepped shaft.





(7) Joining block

The joining block can be positioned by the positioning pins.







(8) Install the joining block cleaner shoe.

The joining block cleaner shoe can be positioned by the positioning pin.





(9) Install the faulty separated capsule pusher.

The faulty separated capsule pusher can be positioned by the positioning pin.





(10) Install the cap disk.

The cap disk can be positioned by the positioning pins.

* Put the cap disk on a position where the stamp mark of disk center base and the segment stamp mark on cap disk match.





(11) Install the cleaner upper shoe.

The cleaner upper shoe can be positioned by the positioning pin.





(12) Install the upper joining plate.





(13) Install the discharging chute.

The discharging chute can be positioned by the key.

(a) Tighten the chute fixing knob.
(b) Install the compressed air couplers.
(2 green/yellow compressed air tubes)
(2 red/blue compressed air tubes)





(14) Install the transfer plate on the transfer plate holder.

The transfer plate can be positioned by the spigot joint.





(15) Insert the transfer plate spacer between the transfer plate unit and the unit attaching arm, then install.

(a) Install the compressed air couplers.
(2 green/yellow compressed air tubes)

(b) Push the transfer plate to the attaching arm definitely. Tighten the retaining screws.

(c) Confirm the alignment of holes in the transfer plate and the cap disk using the centering jigs.



(16) Separating block unit

(a) Install the separating blocks (upper) and (lower) at the same time.
The separating blocks can be positioned by the positioning pin.



(b) Install the TP shoe base.

(c) Install the faulty loading sensor.



(d) Install the TP shoe.



(e) Install the separating block

The separating block can be positioned by the positioning pin.

* Take care not to contact the bottom side of separating block (lower) with the body disk.

(f) Install the compressed air couplers and the connector for sensor.

(2 green/yellow compressed air tubes and 1 connector for faulty loading sensor)



(17) Confirm whether the centering jig can move smoothly between the cap disk and the transfer plate.
Use only 1 jig for check.

(18) Install the feed drum, the rectified roller, and the transfer roller.
Set the match mark of the shaft and that of the drum/roller mounting section.





(19) Install the service hopper, hopper shoe and capsule hopper.
Be careful not to tilt.
After setting, confirm that a gap between feed drum and service hopper is uniform.









LFA Machines Tablet Press

TDP 5® Tablet Press User Manual



Copyright Notice

Important Safety Information

READ THIS BEFORE OPERATING MACHINE

Intended Use

The intended use of this machine is to press dry raw materials into tablet form.
Potential misuse of this machine includes:

- Applying too much force to the powder.
- Trying to fill the Die with powder by hand.
- Inserting Tooling that is too big for the machine.
- Not properly mounting the machine.
- Using powders that could explode under pressure.
- Using wet or damp material.

Personal Protection

For personal protection while transporting the TDP 5®, abide by these actions:

- Use an engine hoist to lift the machine.
- Wear steel toe boots to prevent foot injury.
- Wear heavy duty grip gloves to ensure firm grasp on machine.
- Wear back support belt to prevent injury if needed.

For personal protection while operating the TDP 5®, abide by these actions:

- Avoid wearing loose jewelry to prevent machine entanglement.
- Contain long hair to prevent machine entanglement.
- Wear safety goggles.
- Wear disposable latex/rubber gloves.
- Wear a hairnet (food grade products only).
- Wear a beard net if needed (food grade products only).

General Hazards

- Be aware of risk of entanglement and pinch point due to moving parts.
- Do not operate in a wet environment or with wet hands due to risk of electrical shock or burn.
- Do not operate if any wires are damaged, pinched, or frayed due to risk of electrical shock or burn.
- Keep out of reach of children.
- Keep fingers away from all moving parts.
- Ensure that it is secured to a workbench to prevent from falling.
- Inspect machine before use.
- Check that nuts and bolts are suitably tightened.
- Use this machine only for its intended use as described in this manual.
- Turn off and unplug the machine before conducting cleaning and maintenance.
- Do not modify the machine in any way.

Important Safety Information

READ THIS BEFORE OPERATING MACHINE

Symbols

WARNING

This signals potential risk for personal injury.

WARNING

This signals potential risk for electrical shock.

CAUTION

This signals potential risk for damage to the machine or other parts.

Modes for Stopping

In the case of an emergency during manual operation, immediately stop turning the Hand Wheel and remove yourself from the TDP 5®.

In the case of an emergency during motor operation, immediately press the red OFF button (see below) and unplug.



Prop. 65 Statement for CA Residents

Based on LFA's current level of knowledge of our machines, the TDP 5® does not require a Proposition 65 warning label.

Important Safety Information

READ THIS BEFORE OPERATING MACHINE

Installation and Safety Assessment

Due to the nature and design of this machine and its intended use in an industrial environment, it is important that before use it is installed in a cage with a mode of stopping on the outside of the cage. LFA Machines has decided that we can not possibly foresee all of the environments or situations in which this machine could be used or installed and therefore have determined that the end user must install the machine in a way that is appropriate and safe for its use.

Once the machine has been installed, it is critical that you conduct a safety assessment to ensure that it complies with all local and industry accepted safety regulations.

If you require guidance on the installation of the machine or conducting a safety assessment, please contact LFA Machines.

This machine is sold as an Unfinished Machine under the Machinery Directive (2006/42/EC) Article 13.

Warning for Explosive Material

This machine is not explosion proof. LFA recommends that you test your materials' explosivity before running them through this machine. If your materials are indeed explosive, do not use them with this machine.

Table of Contents

Table of Contents - Continued


20
23
22
18
19
29
17
21
16
14
15
13
12
11
10
24
9
25
7
26
6
27
28
3
4
1
8
2
5

TDP 5® Parts List

1. TDP 5® Base (#AEC0000)
2. Lower Drift Pin Assembly Cogs (#AEC0012)
3. Lower Drift Pin Assembly Locking Bar (#AEC0013)
4. Lower Drift Pin Assembly Lifting Bar (#AEC0034)
5. Lower Drift Pin Assembly (#AEC0011)
6. Boot Bolt and Spring (inside Boot) (#AEC0051; #AEC0055)
7. Base Plate (#AEC0008)
8. Ejection Guard (#AEC0009)
9. Boot (#AEC0036)
10. Boot Timing Bar (#AEC0018)
11. Upper Drift Pin Assembly Mounting Block (#AEC0010)
12. Upper Drift Pin Assembly (#AEC0002)
13. Upper Drift Pin Assembly Locking Nut (#AEC0006)
14. Upper Drift Pin Assembly Rod Eye and Clevis (#AEC0005)
15. Boot Timing Cam (#AEC0038)
16. Hand Wheel (#AEC0046)
17. Top Cam Drive Shaft (#AEC0037)
18. Eccentric Sheave (#AEC0033)
19. Eccentric Sheave Strap (#AEC0004)
20. Cam Drive Cog (inside Cam Drive Cog Safety Cover) (#AEC0050)
21. Electrical Drive Flywheel (#AEC0021)
22. Pinion Gear (#AEC0022)
23. Lower Drift Pin Assembly Timing Rod Runner Bolt (#AEC0015)
24. Lower Drift Pin Assembly Timing Rod (#AEC0014)
25. V Belt (Drive Belt) (#H108012028)
26. Motor (#AEC0042)
27. Electrical Box and Connecting Cables (#AEC0053)
28. Motor Mounting Plate (#AEC0041)
29. Hopper (#AEC0030)

Preface



The TDP 5® Tablet Press has the ability to press small quantities of tablets in a wide variety of sizes from a powder formulated with dry granular materials and an excipient. By generating up to 50 kN of pressure with either electrical or manual power, the TDP 5® can produce up to 4,800 tablets an hour with interchangeable dies. This machine can create most types of tablets, including irregularly shaped pills, up to 20 mm in diameter and 8 mm thick. Useful for work in the field and on location, the TDP 5® is popular with a range of industries such as hospitals, research facilities, and laboratories in the pharmaceutical, food, and chemical industries.

The purpose of this document is to support your understanding of the TDP 5®'s components, features, functions, and design. With this manual, you will be able to successfully operate and maintain your TDP 5® machine.

The user manual's content includes:

- Important safety information
- TDP 5® installation instructions
- Description of the TDP 5®'s operation
- TDP 5® maintenance information
- Appendix with supplemental information

Training

TDP 5® training is essential for the machine's successful operation and your personal safety. There are several methods to prepare you for working with the TDP 5®.

Off-Site Training

LFA offers free training at our UK, USA, and Taiwan facilities for all our customers and their teams. For more information, go to https://www.lfatabletpresses.com/services

Training via Video Chat/Phone

Using an online video chat system, an LFA technician can interact face-to-face with you and assist with your understanding of the machine. Or, if you prefer, LFA can provide training via phone for all customers who call the office. To set up a training, call or email your local LFA office:

UK
Phone
+44 01869250234
Email
support.uk@lfamachines.com

USA
Phone
+1 (682) 312-0034
Email
support.usa@lfamachines.com

Taiwan
Phone
+886 422031790
Email
support.asia@lfamachines.com

LFA Articles

LFA writes informative articles about desktop tablet presses, which includes instructions, procedures, and guides. To access the articles, go to https://www.lfatabletpresses.com/articles

LFA Videos

LFA has created several videos involving the TDP 5® and other desktop tablet presses. To access the videos, go to https://www.lfatabletpresses.com/videos or https://www.youtube.com/user/TabletPilPress

Installation

Tools and Materials Needed

Before you install and operate the TDP 5®, it is best to have the following tools and materials on hand for general operation and maintenance:

- Engine hoist or lift and lifting strap
- Mounting materials such as:
  - Non-slip pad (such as a yoga mat cut to fit the machine's base) OR anti-vibration pads
  - Power drill
- Hammer
- Gear puller
- Rubber mallet
- Copper pipe around 22 mm in diameter
- Metric wrench set
- Circlip pliers
- Pliers/grippers
- Flathead screwdriver
- Set of metric Allen keys with ball ends
- Long wire pipe cleaner
- Lubricant (NSF approved for food grade products)
- Grease gun
- Toothbrush
- Bagless vacuum
- Sanitizer (e.g. Member's Mark Commercial Sanitizer)
- Cleaning brush set
- Plastic sheet or something similar to cover machine
- Safety goggles
- Disposable latex/rubber gloves
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

The Appropriate Workstation for the Machine

Find a stable workspace surface that supports the TDP 5®'s 125 kg (about 275 lbs) weight, such as a wooden bench (use stainless steel if for food grade industry). Another important thing to consider is to find a bench that has a suitable working height for you. This machine also has a single phase 240 V or 110 V (± 10%) electrical requirement, so ensure that it is near an appropriate power plug.

Environmental Conditions

It is important that the environment in which you operate and store the TDP 5® has the appropriate temperature and relative humidity levels. These two environmental factors can potentially cause the machine to rust and/or cause the tablets to have a lower quality. The table below shows the acceptable temperature and relative humidity levels:

Machine	Temperature		Humidity
TDP 5	°C	°F	45-65% RH
	18-24	64-75	

...pping crate will contain the following:

1. The assembled TDP 5®



2. The Tooling (already installed)



3. The Hopper

4. The De-Jamming Bar



Note: The Hand Wheel Handle is packaged with the De-Jamming Bar.

Unpacking the TDP 5®

Watch a video of a TDP 5® unboxing at https://www.lfatabletpresses.com/videos/tdp-5-unboxing-setup

Tools Needed

- Flathead screwdriver
- Hammer
- 17 mm wrench

Instructions

1. Pry open each of the clips on the shipping container with a flathead screwdriver.



1.1 Note: Hammer the clips even further down to aid in removing the shipping container from the base.

2. Lift the top of the shipping container from its base, which is bolted to the TDP 5®.
3. Remove the plastic wrapping and set the Hopper aside.

3.1 Note: Save the wrapping for future transport and/or storage.

4. Remove the bolts from the shipping container's base with a wrench.



4.1 Note: Keep the bolts and the shipping container's base in case you need to move or relocate the TDP 5®.

Assembly

The TDP 5® comes almost fully assembled. Insert the Hopper into the Boot like so:



Mounting the TDP 5®

WARNING: To prevent personal injury, wear steel toe boots and heavy duty grip gloves while transporting the TDP 5®.

LFA does NOT recommend carrying the machine manually but rather with an engine hoist. At least two people should be involved (one operating the engine hoist and one stabilizing the machine) in removing the machine from the shipping container and placing it in the workspace.

Transporting the TDP 5®

Tools and Materials Needed

- Engine hoist and lifting strap

Instructions

1. Secure the engine hoist onto the eyelet bolt attached to the top of the TDP 5® Base.



2. Wrap the lifting strap to support both the bottom and top of the TDP 5®.
3. Carefully transport the machine to the desired workspace.

Bolting the TDP 5®

The TDP 5® Base comes with three bolts and three bolt holes. Because the machine's movement could cause it to fall off the workspace surface during operation, which creates potential for injury to self and to the machine, it is important to ensure that it will not move by bolting down the TDP 5®. There are other options as well that can prevent the TDP 5® from moving, which are described below:

Non-Slip Pad

Placing a pad or mat that grips the surface underneath the TDP 5® will stabilize any movement. What works well is anything similar to a yoga mat. Simply cut the pad to a size that is slightly bigger than the TDP 5®'s base, and then bolt the base through the mat and into the workspace surface.

Anti-Vibration Pads

Anti-vibration pads underneath the TDP 5®'s base not only absorb noises and vibrations, but also reduce the machine's movement. Similar to using a non-slip pad, the anti-vibration pads also need to be bolted through into the workplace surface.

WARNING: Anti-vibration pads with feet indentations, such as those used for washing machines, are not suitable for the TDP 5®. They may cause the machine to lose its balance and fall off the workspace surface, potentially resulting in personal injury.

Note: Before bolting the machine to the workspace surface, ensure that an appropriate electrical outlet (240 V or 110 V) is nearby.

Once you have determined where the bolts will be, drill three holes into the workspace surface. Then, insert the bolts through the TDP 5®'s base and the workspace surface and tighten them as necessary.

In accordance with Article 13 of the European Directive 2006/42/EC, LFA Machines sells the TDP 5® as a partly finished machine, and it is meant to be installed into and function as a part in a production line.

After the installation of this machine, the following measures need to be taken:

- **Shields must be installed in order to cover moving parts, those being in particular the Upper Punch, Upper Drift Pin Assembly, Lower Drift Pin Assembly, Boot, Top Cam Assembly, Hand Wheel, Electrical Drive Flywheel, and V-Belt.**
- **An emergency stop/emergency lockout/isolator switch must be installed on the outside of the machine.**
- **A risk assessment must be conducted on the entire production line.**

If you require guidance on the installation of the machine or conducting a safety assessment, please contact LFA Machines.

Manual and Electrical Controls

Basic Components



A description of the principal components follows:

- The **Hand Wheel** can be turned to start the cam track's direction.
- The **Top Cam Drive Shaft** guides the punches' movement.
- The **Hopper** holds the dry materials that will be compressed.
- The **Boot** moves the materials from the Hopper to the Tooling and ejects the tablets.
- The **Die** defines or molds the size and shape of the powder.
- The **Upper Punch** and **Lower Punch** compress the materials within the Die.

TDP 5® Process

The basic mechanism of the TDP 5® involves filling the Tooling (Die, Upper Punch, and Lower Punch) with powder, compressing the powder, and ejecting the tablet.

Filling the Tooling with Powder

The dry materials are poured into the Hopper, which funnels the powder into the Boot. As the Hand Wheel is manually operated, the Top Cam Drive Shaft withdraws the Upper Punch from the Die.

When the machine is operated by the motor, the Gearing initiates the movement of the Top Cam Drive Shaft, which withdraws the Upper Punch from the Die and sets the Lower Punch at the level at which the fill depth is adjusted.

Compressing the Powder

After the powder is filled in the Tooling, the Top Cam Drive Shaft drives the Upper Punch into the Die, which creates high pressure between both punches that allows the tablet to be compressed.

Ejecting the Tablet

After both punches compress the powder into a tablet, the Top Cam Drive Shaft withdraws the Upper Punch while the Lower Punch is pushed upward to expel the tablet. The tablet is then pushed out of the way by the Boot to prepare for the next tablet compression.

How to Create Tablets with the TDP 5®

Tools and Materials Needed

- Raw material formulation
- Fully assembled TDP 5® with Hopper
- Safety goggles
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: For personal protection while operating the TDP 5®, contain long hair and do not wear loose jewelry.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

1. Adjust the fill depth and punch pressure to the lowest level.
2. Pour the dry materials into the Hopper.
    2.1 Note: Ensure that the TDP 5® is unplugged from the electrical outlet.
3. Rotate the Hand Wheel in the direction indicated by the arrow located on the Cam Drive Cog Safety Cover.
    3.1 Note: Always manually operate the TDP 5® for one rotation of the Top Cam Drive Shaft to ensure that it is operating correctly.
4. Adjust the fill depth and punch pressure until the tablet is at the desired weight and thickness.
5. Plug in the TDP 5® to an electrical outlet.
6. Press the green button (O) to start the TDP 5 and the red button (—) to turn off the TDP 5®.



Settings and Adjustment

The TDP 5®'s settings can be adjusted. Tuning the Tooling can help with changing the tablets' characteristics and how they are ejected from the machine.

Ejection Height

When the Upper Punch is fully lifted, the Lower Punch in its highest position should be flush with the Die:



If the Lower Punch is above or below the Die's face, it will affect how smoothly the tablet is ejected. Adjusting the ejection height will help with this and can vary with different forms of Tooling.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, unplug the TDP 5® from the electrical outlet

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

1. Produce a test tablet to determine how the Tooling should be adjusted.
2. Remove the Ejection Tray with an Allen key.



3. Remove the Lower Drift Pin Assembly Locking Bar bolt with an Allen key.



4. Rotate the Upper Cog in the Lower Drift Pin Assembly by hand.



4.1 Note: To raise ejection height, turn clockwise. To lower ejection height, turn counterclockwise.

5. Run an ungloved finger over the Base Plate to ensure the Die is flush.

6. Secure the bolt in the Lower Drift Pin Assembly Locking Bar with an Allen key.



6.1 Note: Ensure that the Lower Drift Pin Assembly Locking Bar is situated vertically.

7. Reattach the Ejection Tray to the TDP 5®.



Fill Depth

At times, a tablet will be too light or too heavy, and its weight must change. Adjusting the fill depth determines the tablet's thickness and weight. This can be controlled by changing how high or low the Lower Punch sits.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

WARNING: To prevent any potential personal injury, unplug the TDP 5® from the electrical outlet.

1. Produce a test tablet to determine how the Tooling should be adjusted.
2. Rotate the machine until the Lower Drift Pin Assembly is at its highest position and the Boot is at the position to eject the tablet.
3. Remove the Ejection Tray with an Allen key.



4. Remove the Lower Drift Pin Assembly Locking Bar with an Allen key.



5. Rotate the Lower Cog in the Lower Drift Pin Assembly by hand.



5.1 Note: To increase the tablet weight, turn counterclockwise. To decrease the tablet weight, turn clockwise.

6. Replace the bar in the Lower Drift Pin Assembly Locking Bar with an Allen key.



6.1 Note: Ensure that the Lower Drift Pin Assembly Locking Bar is situated vertically.

7. Produce a test tablet to make sure the weight is correct.
8. Reattach the Ejection Tray to the TDP 5®.



Punch Pressure

Sometimes tablets come out too soft and will crumble easily, which happens often after increasing the fill depth. Or, the machine can jam and will not be able to turn over. To correct this, the punch pressure needs to be adjusted in order to increase the tablet's firmness/de-jam the machine.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 24 mm wrenches (2)
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, unplug the TDP 5® from the electrical outlet.

CAUTION: Overtightening can damage the Tooling and/or Boot.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

1. Produce a test tablet to determine how the Tooling should be adjusted.
2. Remove the Ejection Tray with an Allen key.



3. Remove any excess powder from the Base Plate.



4. Turn the Hand Wheel until the Upper Punch is raised.



5. Loosen the Upper Drift Pin Assembly Locking Nut with a wrench while keeping the Upper Drift Pin Assembly in place with another wrench.



6. Turn the Hand Wheel until the Upper Drift Pin Assembly is exposed.
7. Rotate the Upper Drift Pin Assembly with a wrench or by hand.



7.1 Note: To increase the pressure and harden the tablet, turn clockwise. To decrease the pressure and soften the tablet, turn counterclockwise.

8. Tighten the Upper Drift Pin Assembly Locking Nut with a wrench.
9. Reattach the Ejection Tray with an Allen key.



Maintenance

To ensure that the TDP 5® will have a long operational life, maintenance is essential. This section includes methods for replacing parts, troubleshooting solutions, and how often to grease and clean your machines to keep its performance optimal.

General Maintenance Prescriptions

- Use the maintenance checklist (found in the Appendix) before, during, and after machine operation.
- Make sure all grease points are maintained and regularly lubricated.
- Use an appropriate amount of lubricant. Excess grease can drip into the tablets as they are formed.
- Before reassembling the machine after cleaning, make sure that the parts are dried and oiled.
- Constantly check for any loose nuts and/or screws before, during, and after machine operation.
- If the machine is not used for more than a week, place the Tooling in an airtight container and cover in lubricant.

Lubrication

Regularly greasing your machine is vital to prolonging its operational life. Parts that are not greased properly can make the machine seize up and cause major problems later. LFA recommends maintaining a lubrication schedule for your TDP 5®, which can be found in this section.

Tools and Materials Needed

- Grease gun
- Lubricant/grease (food grade if machine has contact with the food or drug product)
- Set of metric Allen keys with ball ends
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, unplug the TDP 5® from the electrical outlet.

Instructions (continued on next page)

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

1. Rub a finger's worth of grease on the Boot Timing Cam's side.
    1.1 Note: Be sure to lubricate the Boot Timing Cam Runner.



2. Lubricate the Eccentric Sheave Strap's Grease Nipple with the grease gun.
    2.1 Note: Rotate the Hand Wheel during this to ensure grease gets in between the Eccentric Sheave and the Eccentric Sheave Strap.



3. Lubricate the Cam Drive Cog and Lower Drift Pin Assembly Timing Rod Runner Bolt.





4. Lubricate the Grease Nipple nearest to the Boot Timing Cam.



5. Lubricate the Pinion Gear.



Lubrication Schedule

LFA recommends the following TDP 5® parts to be lubricated according to the following frequency:

Part	Location	Image	Frequency	Type of Lubricant
Tooling heads	The heads of the Upper Punch and Lower Punch		Visually inspect and apply when dry	Assembly paste
Tooling (after cleaning)	Storage container		Apply after cleaning	Mineral oil
Eccentric Sheave Strap	The topmost Grease Nipple		Apply (a) after every 5000 tablets, (b) after a deep clean, or (c) when the press has not been used for an extended period of time	NLGI Grade 2
Cam Drive Cog	Cam track and Lower Drift Pin Assembly Timing Rod Runner Bolt		Apply (a) after every 5000 tablets, (b) after a deep clean, or (c) when the press has not been used for an extended period of time	NLGI Grade 2
Boot Timing Cam	Cam track and top of Boot Timing Bar		Apply (a) after every 5000 tablets, (b) after a deep clean, or (c) when the press has not been used for an extended period of time	NLGI Grade 2
Top Cam Drive Shaft	Grease Nipple nearest to Boot Timing Cam		Apply (a) after every 5000 tablets, (b) after a deep clean, or (c) when the press has not been used for an extended period of time	NLGI Grade 2
Pinion Gear	Between the Electrical Drive Flywheel and Cam Drive Cog		Apply (a) after every 5000 tablets, (b) after a deep clean, or (c) when the press has not been used for an extended period of time	NLGI Grade 2
Lower Drift Pin Assembly Timing Rod	The points at which the Lower Drift Pin Assembly, Upper Drift Pin Assembly Mounting Block, and TDP 5® Base meet.		Apply a small amount whenever the press will be left unattended for an extended period of time	Mineral oil

Dismantling for Repair and Replacement

Eventually due to wear and tear, some parts of the TDP 5® will need to be removed for repair and replacement. To prevent any delays in your tablet production, it is best practice to keep extra parts just in case.

To buy a TDP 5® part replacement, simply go to
https://www.lfatabletpresses.com/products/pill-press-machine-spare-parts/tdp-5-parts

Warranty
To access LFA's warranty policy, go to https://www.lfatabletpresses.com/warranty
If your part is eligible for warranty, have your part's serial number on hand and please contact LFA:

UK
Phone
+44 01869 250234
Email
support.uk@lfamachines.com

USA
Phone
+1 (682) 312-0309
Email
support.usa@lfamachines.com

Taiwan
Phone
+886 422031790
Email
support.asia@lfamachines.com

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Wear Parts and Causes of Damage

Wear Part	Cause of Damage
Tooling	The Tooling can become chipped or broken. Lead times for a new set of Tooling can take as long as 6-8 weeks, so LFA recommends having a spare set or two.
Boot	The TDP 5® Boot is formed from a toughened plastic. This part can become trapped between the Die Bore and the Upper Punch, which usually results from user error.

Tooling

If you want to change the shape and diameter of the tablet, or if the Upper Punch, Lower Punch, and/or Die you currently have is damaged, it is necessary to change the Tooling.
To buy new Tooling from LFA, simply go to https://www.lfatabletpresses.com/products/tablet-press-tooling
To watch a video of a TDP 5® Tooling change, go to https://www.lfatabletpresses.com/videos/how-to-change-tdp-punch-die-tooling

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 24 mm wrenches (2)
- Tooling/die set (Upper Punch, Die, and Lower Punch)
- Grippers or pliers
- Hammer (if Die is difficult to remove)
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Tooling

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Remove the Ejection Tray with an Allen key.



3. Loosen the Boot's set screw with an Allen key.



4. Remove the Boot Bolt and Spring underneath the Boot with an Allen key.



5. Take off the Boot carefully and remove any powder still inside it.
6. Loosen the bolts underneath the Base Plate with an Allen key.





7. Turn the Hand Wheel until the Upper Drift Pin Assembly is lowered.
8. Loosen the Upper Punch Die Locking Nut with a wrench while keeping the Upper Punch Drift Assembly in place with another wrench.
9. Remove the Upper Punch by hand.



9.1 Note: If you cannot remove by hand, carefully use grippers or pliers.

10. Remove the Base Plate with the Die still inside it.
11. Remove the set screw that locks the Die with an Allen key.
12. Take out the Die from the middle of the Base Plate.
    12.1 Lightly tap the Die with a hammer if it is difficult to remove.



13. Remove the bolt that locks the Lower Punch with an Allen key.
14. Remove the Lower Punch by hand.



14.1 Note: If you cannot remove by hand, carefully use grippers or pliers.

Note: To help ensure that the Die is inserted correctly, LFA recommends using an Insertion Ring. You can order the Die Seat Cleaner and Insertion Ring on our website at https://www.lfatabletpresses.com/die-seat-cleaner-insertion-ring



Replace the Tooling

15. Insert the new Lower Punch into the Lower Drift Pin Assembly.
16. Reinsert the bolt that locks the Lower Punch with an Allen key.



16.1 Note: Make sure that the Lower Punch's "keyed" section is facing forward.

17. Place the Base Plate onto the TDP 5® Base.
18. Insert the new Die into the middle of the Base Plate.
19. Reinsert the set screw that locks the Die with an Allen key.
    19.1 Note: Make sure the set screw is not fully tightened.



20. Insert the new Upper Punch into the Upper Drift Pin Assembly.
21. Tighten the Upper Punch Locking Nut onto the Upper Drift Pin Assembly with a wrench.



22. Rotate the Hand Wheel and carefully lower the Upper Punch into the Die.
    22.1 Note: Rotate the Hand Wheel to see that the Upper Punch smoothly enters the Die bore and that the Die is seated firmly in the Upper Drift Pin Assembly. To watch a video on proper Base Plate alignment, go to https://www.lfatabletpresses.com/videos/how-to-align-a-baseplate-on-a-tdp-5

23. Reinsert the Base Plate's bolts.
    23.1 Note: The Die's set screw can be fully tightened now.



24. Position the Boot back on the Base Plate.
25. Insert the Boot Timing Bar's end in the Boot
26. Resecure the Boot Bolt and Spring underneath the Boot with an Allen key.
27. Tighten the Boot's set screw with an Allen key.
28. Reattach the Ejection Tray with an Allen key.
29. Reinsert the Hopper.
30. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Boot Timing Bar

This part can become warped from collision, and it is critical to the TDP 5®'s operation. If you need to replace your TDP 5®'s Boot Timing Bar, the process is quite simple.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 13 mm wrench
- New Boot Timing Bar part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Boot Timing Bar

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Loosen the Boot Timing Bar bolt's nuts with a wrench.
3. Loosen the Boot Timing Bar bolt with an Allen key.
4. Remove the Boot Timing Bar's end from the Boot.







5. Remove the top part of Boot Timing Bar from the Boot Timing Cam.
    5.1 Note: To make removal easier, turn the Handle to rotate the Boot Timing Cam so you can easily access the Boot Timing Bar.
6. Remove the Boot Timing Cam Runner from the Boot Timing Bar by hand.
7. Remove the Boot Timing Bar from the Base Plate.



Replace the Boot Timing Bar

8. Place the Boot Timing Cam Runner on the new Boot Timing Bar.
9. Insert the new Boot Timing Bar with the runner into the side of the Boot Timing Cam.



10. Insert the new Boot Timing Bar's end in the Boot
11. Tighten the Boot Timing Bar bolt with an Allen key.
12. Tighten the Boot Timing Bar bolt's nuts with a wrench.





13. Reinsert the Hopper.
14. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Boot

Due to its constant movement, the Boot can wear down and prevent granular material from flowing smoothly. Replacing this part is a simple process. To watch a video of Boot removal, go to https://www.lfatabletpresses.com/videos/how-to-remove-the-boot-timing-bar-on-a-tdp-5

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- New Boot part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Boot

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Remove the Ejection Tray with an Allen key.



3. Loosen the Boot's set screw with an Allen key.



4. Remove the Boot Bolt and Spring underneath the Boot with an Allen key.



5. Take off the Boot carefully and remove any powder still inside it.



Replace the Boot

6. Position the new Boot on the Base Plate.
7. Insert the Boot Timing Bar's end in the new Boot.
8. Resecure the Boot Bolt and Spring underneath the new Boot with an Allen key.
9. Tighten the new Boot's set screw with an Allen key.
10. Reattach the Ejection Tray with an Allen key.
11. Reinsert the Hopper.
12. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Upper Drift Pin Assembly

The Upper Drift Pin Assembly holds the TDP 5®'s Upper Punch. Sometimes this part threads or bends, which interferes with smooth movement.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 24 mm wrenches (2)
- New Upper Drift Pin Assembly part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Upper Drift Pin Assembly

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Remove the Ejection Tray with an Allen key.



3. Loosen the Boot's set screw with an Allen key.
4. Remove the Boot Bolt and Spring underneath the Boot with an Allen key.




5. Take off the Boot carefully and remove any powder still inside it.
6. Loosen the bolts underneath the Base Plate with an Allen key.




7. Turn the Hand Wheel until the Upper Drift Pin Assembly is lowered.
8. Loosen the Upper Punch Die Locking Nut with a wrench while keeping the Upper Punch Drift Assembly in place with another wrench.




9. Remove the Upper Punch by hand.



9.1 Note: If you cannot remove by hand, carefully use grippers or pliers.

10. Remove the Base Plate with the Die still inside it.
11. Remove the bolt that locks the Die with an Allen key.
12. Take out the Die from the middle of the Base Plate.
    12.1 Tap the Die with a hammer if it is difficult to remove.



13. Remove the bolt that locks the Lower Punch with an Allen key.
14. Remove the Lower Punch by hand.



15. Loosen the Upper Drift Pin Assembly Locking Nut with a wrench.
16. Unscrew the Upper Drift Pin Assembly from the Upper Drift Pin Assembly Rod Eye and Clevis.





Replace the Upper Drift Pin Assembly

17. Screw in the new Upper Drift Pin Assembly onto the Upper Drift Pin Assembly Rod Eye and Clevis.



18. Tighten the Upper Drift Pin Assembly Locking Nut onto the Upper Drift Pin Assembly Rod Eye and Clevis by hand or with a wrench.



19. Reinsert the Lower Punch into the Lower Drift Pin Assembly.
20. Reinsert the bolt that locks the Lower Punch with an Allen key.



20.1 Note: Make sure that the Lower Punch's "keyed" section is facing forward.

21. Place the Base Plate onto the TDP 5® Base.
22. Insert the Die into the middle of the Base Plate.
23. Reinsert the bolt that locks the Die with an Allen key.

23.1 Note: Make sure the bolt is not fully tightened.



24. Insert the Upper Punch into the Upper Drift Pin Assembly.
25. Tighten the Upper Punch Die Locking Nut onto the Upper Drift Pin Assembly with a wrench.



- 25.1 Note: Rotate the Hand Wheel to see that the Upper Punch smoothly enters the Die bore and that the Die is seated firmly in the Upper Drift Pin Assembly. To watch a video on proper Base Plate alignment, go to https://www.lfatabletpresses.com/videos/how-to-align-a-baseplate-on-a-tdp-5

26. Reinsert the Base Plate's bolts.
    26.1 Note: The Die's bolt can be fully tightened now.



27. Position the Boot back on the Base Plate.
28. Insert the Boot Timing Bar's end in the Boot
29. Resecure the Boot Bolt and Spring underneath the Boot with an Allen key.
30. Tighten the Boot's set screw with an Allen key.
31. Reattach the Ejection Tray with an Allen key.
32. Reinsert the Hopper.
33. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Upper Drift Pin Assembly Rod Eye and Clevis

This part connects the Eccentric Sheave Strap and the Upper Drift Pin Assembly. It can become threaded or warped in the case of accidental collision and can be easily removed and replaced.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 24 mm wrenches (2)
- Circlip pliers
- New Upper Drift Pin Assembly Rod Eye and Clevis part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Upper Drift Pin Assembly Rod Eye and Clevis

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Remove the Ejection Tray with an Allen key.



3. Loosen the Boot's set screw with an Allen key.



4. Loosen the Boot's set screw with an Allen key.
5. Remove the Boot Bolt and Spring underneath the Boot with an Allen key.




6. Take off the Boot carefully and remove any powder still inside it.
7. Loosen the bolts underneath the Base Plate with an Allen key.




8. Turn the Hand Wheel until the Upper Drift Pin Assembly is lowered.
9. Loosen the Upper Punch Die Locking Nut with a wrench while keeping the Upper Punch Drift Assembly in place with another wrench.




10. Remove the Upper Punch by hand.



10.1 Note: If you cannot remove by hand, carefully use grippers or pliers.

11. Remove the Base Plate with the Die still inside it.
12. Remove the bolt that locks the Die with an Allen key.
13. Take out the Die from the middle of the Base Plate.

13.1 Tap the Die with a hammer if it is difficult to remove.



14. Remove the bolt that locks the Lower Punch with an Allen key.
15. Remove the Lower Punch by hand.



16. Loosen the Upper Drift Pin Assembly Locking Nut with a wrench.
17. Unscrew the Upper Drift Pin Assembly from the Upper Drift Pin Assembly Rod Eye and Clevis.



18. Remove the Upper Drift Pin Assembly Rod Eye and Clevis's circlip with circlip pliers.
19. Remove the Upper Drift Pin Assembly Rod Eye and Clevis's pin from the Eccentric Sheave Strap.

19.1 Note: Lightly tap the pin with a screwdriver or something similar to aid in its removal.



20. Remove the Upper Drift Pin Assembly Rod Eye and Clevis from the Eccentric Sheave Strap.



Replace the Upper Drift Pin Assembly Rod Eye and Clevis

21. Reinsert the Upper Drift Pin Assembly Rod Eye and Clevis's pin and secure it with a circlip.



22. Tighten the Upper Drift Pin Assembly Locking Nut onto the new Upper Drift Pin Assembly Rod Eye and Clevis by hand or with a wrench.



23. Screw the Upper Drift Pin Assembly into the new Upper Drift Pin Assembly Rod Eye and Clevis.



24. Reinsert the Lower Punch into the Lower Drift Pin Assembly.
25. Reinsert the bolt that locks the Lower Punch with an Allen key.



25.1 Note: Make sure that the Lower Punch's "head" section is facing forward.

26. Place the Base Plate onto the TDP 5® Base.
27. Insert the Die into the middle of the Base Plate.
28. Reinsert the bolt that locks the Die with an Allen key.



29. Insert the Upper Punch into the Upper Drift Pin Assembly.
30. Tighten the Upper Punch Die Locking Nut onto the Upper Drift Pin Assembly with a wrench.



30.1 Note: Rotate the Hand Wheel to see that the Upper Punch smoothly enters the Die bore and that the Die is seated firmly in the Upper Drift Pin Assembly. To watch a video on proper Base Plate alignment, go to https://www.lfatabletpresses.com/videos/how-to-align-a-baseplate-on-a-tdp-5

31. Reinsert the Base Plate's bolts.



32. Position the Boot back on the Base Plate.
33. Insert the Boot Timing Bar's end in the Boot
34. Resecure the Boot Bolt and Spring underneath the Boot with an Allen key.
35. Tighten the Boot's set screw with an Allen key.
36. Reattach the Ejection Tray with an Allen key.
37. Reinsert the Hopper.
38. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Lower Drift Pin Assembly

The Lower Drift Pin Assembly may need to be removed if any pins become stuck inside it and/or the Lower Drift Pin Assembly Cogs become jammed on it.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 24 mm wrenches (2)
- New Lower Drift Pin Assembly part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Lower Drift Pin Assembly

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Remove the Ejection Tray with an Allen key.



3. Loosen the Boot's set screw with an Allen key.
4. Remove the Boot Bolt and Spring underneath the Boot with an Allen key.





5. Take off the Boot carefully and remove any powder still inside it.
6. Loosen the bolts underneath the Base Plate with an Allen key.





7. Remove the Base Plate with the Die still inside it.
8. Remove the bolt that locks the Die with an Allen key.
9. Take out the Die from the middle of the Base Plate.
    9.1 Lightly tap the Die with a hammer if it is difficult to remove.



10. Remove the bolt that locks the Lower Punch with an Allen key.
11. Remove the Lower Punch by hand.



11.1 Note: If you cannot remove by hand, carefully use grippers or pliers.

12. Remove the Lower Drift Pin Assembly Locking Bar with an Allen key.



13. Rotate the Lower Drift Pin Assembly Cogs to remove them from the Lower Drift Pin Assembly.





14. Remove the bolts from the Upper Drift Pin Assembly Mounting Block with an Allen key.
15. Take off the Upper Drift Pin Assembly Mounting Block and remove the Lower Drift Pin Assembly.

Replace the Lower Drift Pin Assembly

16. Insert the new Lower Drift Pin Assembly into the Base and Upper Drift Pin Assembly Mounting Block.



17. Reattach the Upper Drift Pin Assembly Mounting Block to the Base with an Allen key.
    17.1 Note: Be sure that the Lower Drift Pin Assembly Timing Rod Runner Bolt is placed on the Cam Drive Cog.

18. Rotate one of the Lower Drift Pin Assembly Cogs onto the new Lower Drift Pin Assembly.



19. Raise the Lower Drift Pin Assembly Cog just below the bolt bore on the Lower Drift Pin Assembly.



20. Rotate the remaining Lower Drift Pin Assembly Cog onto the Lower Drift Pin Assembly below the Lower Drift Pin Assembly Timing Bar.



21. Rescrew the bolt into the Lower Drift Pin Assembly Locking Bar with an Allen key.



21.1 Note: Ensure that the Lower Drift Pin Assembly Locking Bar is situated vertically.

22. Reinsert the Lower Punch into the new Lower Drift Pin Assembly.
23. Reinsert the bolt that locks the Lower Punch with an Allen key.



23.1 Note: Make sure that the Lower Punch's "keyed" section is facing forward.

24. Place the Base Plate onto the TDP 5® Base.
25. Reinsert the Die into the middle of the Base Plate.
26. Reinsert the bolt that locks the Die with an Allen key.



27. Reinsert the Base Plate's bolts.



28. Position the Boot back on the Base Plate.
29. Insert the Boot Timing Bar's end in the Boot
30. Resecure the Boot Bolt and Spring underneath the Boot with an Allen key.
31. Tighten the Boot's set screw with an Allen key.
32. Reinsert the Hopper.
33. Reattach the Ejection Tray with an Allen key.
34. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Lower Drift Pin Assembly Timing Rod and Runner Bolt

The Lower Drift Pin Assembly Timing Rod and its Runner Bolt can be damaged due to overtightening and/or being under too much pressure.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 17 mm and 30 mm wrenches
- New Lower Drift Pin Assembly Rod and Runner Bolt parts
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Lower Drift Pin Assembly Timing Rod

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Remove the Ejection Tray with an Allen key.



3. Remove the Boot and Upper Punch from the machine.
   3.1 Note: For further information on removing these parts, please refer to the Tooling repair and replacement instructions on page 33.

4. Loosen the two nuts on the Lower Drift Pin Assembly Timing Rod with a wrench.



5. Move the Electrical Drive Flywheel and Cam Drive Cog to make more space.
   5.1 Note: For further information on how to access these parts, please refer to the Electrical Drive Flywheel repair and replacement instructions on page 72.
6. Remove the three screws from the Mounting Block with an Allen key.



7. Carefully pull off the Mounting Block from the machine.
8. Remove the Lower Drift Pin Assembly Timing Rod with its Runner Bolt from the Mounting Block.



9. Unscrew the nut on the Lower Drift Pin Assembly Timing Rod Runner Bolt with a wrench.

Replace the Lower Drift Pin Assembly Timing Rod

10. Insert the runner onto the new Lower Drift Pin Assembly Timing Rod Runner Bolt.
11. Tighten the nut onto the new Lower Drift Pin Assembly Timing Rod Runner Bolt with a wrench.
12. Insert the new Lower Drift Pin Assembly Timing Rod into the Mounting Block.
13. Place the Mounting Block (with the new Lower Drift Pin Assembly Timing Rod) onto the machine and place the Lower Drift Pin Timing Rod Runner Bolt with its runner into the Cam Drive Cog.

    13.1 Note: Ensure that the new Lower Drift Pin Assembly Timing Rod is inserted into the Lower Drift Pin Assembly Lifting Bar.

14. Re-tighten the two nuts on the Lower Drift Pin Assembly Timing Rod with a wrench.

    14.1 Note: Make sure that the Lower Drift Pin Assembly is fully down and adjust the two nuts until the Lower Drift Pin Assembly Lifting Bar is perfectly level and resting on the fill depth adjustment cog.



15. While holding the Mounting Block against the Base, tighten the three screws with an Allen key.
16. Re-install the Boot and the Upper Punch onto the machine.

    16.1 Note: For further information on installing these parts, please refer to the Tooling repair and replacement instructions on page 33.

17. Reinsert the Hopper.
18. Reattach the Ejection Tray with an Allen key.
19. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



V Belt

Although this part is rugged and long-lasting, after time it may become worn out and requires a replacement.

Tools and Materials Needed

- 19 mm wrench
- New V Belt part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5 from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the V Belt

1. Adjust the nuts on the Motor Support Arm with a 19 mm wrench to loosen the V Belt.
    1.1 Note: The closer the Motor Mounting Plate is to the TDP 5®, the looser the V Belt's slack will be.



2. Remove the V Belt from the Drive Belt Pulley and the Electrical Drive Flywheel.



Replace the V Belt

3. Place the new V Belt onto the Drive Belt Pulley and the Electrical Drive Flywheel.



4. Adjust the nut on the Motor Support Arm to tighten the V Belt.

    4.1 Note: The further away the Motor Mounting Plate is from the TDP 5®, the tighter the V Belt's slack will be. The correct tension for a new V Belt is [N] 141.64.



5. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Hand Wheel

Although this part is sturdy, it can be damaged from a fall or any other accident. Fortunately, it is a simple process to replace the Hand Wheel.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- Rubber mallet
- New Hand Wheel part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5 from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Hand Wheel

1. Loosen the Hand Wheel Cap's bolt with an Allen key.
2. Disengage the Hand Wheel from the engraved key on the Top Cam Drive Shaft.
    2.1 Note: Use a rubber mallet if the Hand Wheel is difficult to remove.

Replace the Hand Wheel

3. Insert the new Hand Wheel onto the Top Cam Drive Shaft's engraved key.
4. Secure the Hand Wheel Cap back on with an Allen key.
5. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.





Electrical Drive Flywheel

The V Belt drives this part to turn the Cam Drive Cog, which moves the Top Cam Drive Shaft. Whenever the machine seizes/jams, the De-Jamming Bar can be used on this part's holes to reduce the pressure of the Upper Drift Pin Assembly.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 19 mm wrench & 30 mm wrench
- Gear puller
- New Electrical Drive Flywheel part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Electrical Drive Flywheel

1. Adjust the nuts on the Motor Support Arm with a 19 mm wrench to loosen the V Belt.
    1.1 Note: The closer the Motor Mounting Plate is to the TDP 5®, the looser the V Belt's slack will be.



2. Remove the V Belt from the Drive Belt Pulley and the Electrical Drive Flywheel.



3. Remove the Rear Enclosure Plate off of the back of the TDP 5® with an Allen key.



4. Loosen the nut from the Pinion Gear Cam that connects the Pinion Gear and the Electrical Drive Flywheel to the TDP 5® Base with a 30 mm wrench.



5. Unscrew the Pinion Gear Cam and remove the Pinion Gear from the Electrical Drive Flywheel.

5.1 Note: Use a gear pulley if the Pinion Gear is difficult to pry out.



Replace the Electrical Drive Flywheel

6. Insert the Pinion Gear and the Pinion Gear Cam into the new Electrical Drive Flywheel.
7. Install the Pinion Gear, the Pinion Gear Cam, and the new Electrical Drive Flywheel into the TDP 5® Base by tightening the Pinion Gear Cam's nut.





8. Reattach the Rear Enclosure Plate to the back of the TDP 5® with an Allen key.
9. Place the V Belt back onto the Drive Belt Pulley and the new Electrical Drive Flywheel.





10. Adjust the nuts on the Motor Support Arm to tighten the V Belt.
    10.1 Note: The further away the mount is from the TDP 5®, the tighter the V Belt's slack will be. The correct tension for the V Belt is [N] 94.42.
11. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.





Boot Timing Cam

Although this part lasts long, it can become worn over time. To replace the Boot Timing Cam, the Hand Wheel must be removed first.

Tools and Materials Needed

- Heavy rubber mallet
- Set of metric Allen keys with ball ends
- 13 mm wrench
- New Boot Timing Cam part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Boot Timing Cam

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Loosen the Hand Wheel Cap's bolt with an Allen key.
3. Disengage the Hand Wheel from the engraved key on the Top Cam Drive Shaft.
    3.1 Note: Use a rubber mallet if the Hand Wheel is difficult to remove.



4. Loosen the Boot Timing Bar bolt's nuts with a wrench.
5. Loosen the Boot Timing Bar bolt with an Allen key.
6. Remove the Boot Timing Bar's end from the Boot.





7. Gently hit the Boot Timing Cam with a rubber mallet to disengage it from the engraved key on the Top Cam Drive Shaft.



Replace the Boot Timing Cam

8. Position the new Boot Timing Cam into the engraved key on the Top Cam Drive Shaft.
9. Place the Boot Timing Cam Runner on the Boot Timing Bar.
10. Insert the Boot Timing Bar with the runner into the side of the Boot Timing Cam.
11. Insert the Boot Timing Bar's end in the Boot
12. Tighten the Boot Timing Bar bolt with an Allen key.
13. Tighten the Boot Timing Bar bolt's nuts with a wrench.






14. Position the Hand Wheel onto the engraved key on the new Top Cam Drive Shaft.
15. Tighten the Hand Wheel Cap and its bolt with an Allen key.



16. Reinsert the Hopper.
17. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.





Pinion Gear

Although this part rarely needs to be replaced, it can become worn out or have broken teeth due to a large amount of use. Like the Electrical Drive Flywheel, removal and replacement of this part may take a little physical effort on your part.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 19 mm wrench & 30 mm wrench
- Gear puller
- New Pinion Gear part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Pinion Gear

1. Adjust the nuts on the Motor Support Arm with a 19 mm wrench to loosen the V Belt.
    1.1 Note: The closer the Motor Mounting Plate is to the TDP 5®, the looser the V Belt's slack will be.

2. Remove the V Belt from the Drive Belt Pulley and the Electrical Drive Flywheel.



3. Remove the Rear Enclosure Plate from the back of the TDP 5® with an Allen key.



4. Loosen the nut from the Pinion Gear Cam that connects the Pinion Gear and the Electrical Drive Flywheel to the TDP 5® Base with a 30 mm wrench.



5. Unscrew the Pinion Gear Cam and remove the Pinion Gear from the Electrical Drive Flywheel.

5.1 Note: Use a gear puller if the Pinion Gear is difficult to pry out.



Replace the Pinion Gear

6. Insert the new Pinion Gear and the Pinion Gear Cam into the Electrical Drive Flywheel.



7. Install the new Pinion Gear, the Pinion Gear Cam, and the Electrical Drive Flywheel into the TDP 5® Base.



8. Reattach the Rear Enclosure Plate to the back of the TDP 5® with an Allen key.



9. Place the V Belt back onto the Drive Belt Pulley and the Electrical Drive Flywheel.



10. Adjust the nuts on the Motor Support Arm to tighten the V Belt.
    10.1 Note: The further away the mount is from the TDP 5®, the tighter the V Belt's slack will be. The correct tension for the V Belt is [N] 94.42.



11. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Cam Drive Cog

Much similar to the Pinion Gear, the rare repair needed for this part is whenever the teeth are worn down due to a large amount of use.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- 19 mm & 30 mm wrench
- Gear puller
- New Cam Drive Cog part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Cam Drive Cog

1. Adjust the nuts on the Motor Support Arm with a 19 mm wrench to loosen the V Belt.
    1.1 Note: The closer the Motor Mounting Plate is to the TDP 5®, the looser the V Belt's slack will be.

2. Remove the V Belt from the Drive Belt Pulley and the Electrical Drive Flywheel.



3. Remove the Rear Enclosure Plate from the back of the TDP 5® with an Allen key.



4. Loosen the nut from the Pinion Gear Cam that connects the Pinion Gear and the Electrical Drive Flywheel to the TDP 5® Base with a 30 mm wrench.



5. Unscrew the Pinion Gear Cam and remove the Pinion Gear from the Electrical Drive Flywheel.

5.1 Note: Use a gear puller if the Pinion Gear is difficult to pry out.



Remove the Cam Drive Cog

6. Remove the Cam Drive Cog Safety Cover with an Allen key.
7. Remove the Cam Drive Cog Cap from the Cam Drive Cog with an Allen key.
8. Disengage the Cam Drive Cog from the engraved key on the Top Cam Drive Shaft.



9. Remove the Cam Drive Cog Cap from the Cam Drive Cog with an Allen key.
10. Disengage the Cam Drive Cog from the engraved key on the Top Cam Drive Shaft.



Replace the Cam Drive Cog

9. Insert the new Cam Drive Cog onto the engraved key on the Top Cam Drive Shaft.
10. Reinsert the Cam Drive Cog Cap on the new Cam Drive Cog with an Allen key.
11. Resecure the Cam Drive Cog Safety Cover over the new Cam Drive Cog with an Allen key.





12. Insert the Pinion Gear and the Pinion Gear Cam into the Electrical Drive Flywheel.
13. Install the Pinion Gear, the Pinion Gear Cam, and the Electrical Drive Flywheel into the TDP 5® Base.





14. Reattach the Rear Enclosure Plate to the back of the TDP 5® with an Allen key.
15. Place the V Belt back onto the Drive Belt Pulley and the Electrical Drive Flywheel.





16. Adjust the nuts on the Motor Support Arm to tighten the V Belt.
    16.1 Note: The further away the mount is from the TDP 5®, the tighter the V Belt's slack will be. The correct tension for the V Belt is [N] 94.42.
17. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.





Drive Belt Pulley

The Drive Belt Pulley is attached to the motor, which drives the V Belt to move the Cam Drive Cog.

Tools and Materials Needed

- 19 mm wrench
- Gear puller
- New Drive Belt Pulley part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Drive Belt Pulley

1. Adjust the nuts on the Motor Support Arm with a 19 mm wrench to loosen the V Belt.
    1.1 Note: The closer the Motor Mounting Plate is to the TDP 5®, the looser the V Belt's slack will be.
2. Remove the V Belt from the Drive Belt Pulley and the Electrical Drive Flywheel.
3. Disengage the Drive Belt Pulley from the engraved key on the Motor with a gear puller.







Replace the Drive Belt Pulley

4. Place the new Drive Belt Pulley into the engraved key on the Motor.



5. Place the V Belt onto the new Drive Belt Pulley and the Electrical Drive Flywheel.
6. Adjust the nuts on the Motor Support Arm to tighten the V Belt.

   6.1 Note: The further away the Motor Mounting Plate is from the TDP 5®, the tighter the V Belt's slack will be. The correct tension for the V Belt is [N] 94.42.



7. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Motor

Much similar to the Pinion Gear, the rare repair needed for this part is whenever the teeth are worn down due to a large amount of use.

Tools and Materials Needed

- 19 mm wrench
- Crosshead screwdriver
- Set of metric Allen keys with ball ends
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: If you do not have sufficient experience in wiring electrical items, do NOT attempt to replace this part at the risk of electrical shock.
Turn off and unplug the machine before replacing this part.

The TDP 5® motor is quite heavy. Be sure to have a firm hold on this part while you are removing the connecting bolts to prevent it from falling and possibly causing personal injury.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Motor

1. Remove the nut on the Motor Support Arm with a 19 mm wrench and take off the V Belt.
2. Remove the V Belt from the Drive Belt Pulley and the Electrical Drive Flywheel.





3. Remove the four connecting bolts from the Motor Mounting Plate with a wrench.





4. Remove the Drive Belt Pulley from the Motor with a gear puller.



5. Open the Motor's wiring box with a crosshead screwdriver.
6. Remove the Electrical Box's wires from the Motor with a crosshead screwdriver to free the Motor from the TDP 5®.



6.1 Note: if the wiring in your Motor is different, take a picture to use it as a reference later.

Replace the Motor

7. Position the new Motor behind the TDP 5® and the Motor Mounting Plate.



8. Insert the four bolts through the Motor Mounting Plate and into the Motor and tighten their nuts with a wrench.
9. Reinsert the Motor Support Arm into the Motor Mounting Plate and loosely tighten its nut with a 19 mm wrench.





10. Screw in the Electrical Box's wires in the appropriate position with a crosshead screwdriver.
    10.1 Note: Refer to step #6's photo or the picture you took of your motor's wiring.
11. Close the new Motor's wiring box with a crosshead screwdriver.

12. Insert the Drive Belt Pulley on the new Motor.



13. Place the V Belt onto the Drive Belt Pulley and the Electrical Drive Flywheel.



14. Adjust the nuts on the Motor Mounting Plate to tighten the V Belt.

    14.1 Note: The further away the Motor Mounting Plate is from the TDP 5®, the tighter the Belt's slack will be. The correct tension for the V Belt is [N] 94.42.

15. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.





Top Cam Drive Shaft

The Top Cam Drive Shaft drives many important parts in the TDP 5®'s upper assembly. These instructions explain how to remove and replace the Top Cam Drive Shaft, which involves the removal and replacement of all the other parts driven by it.

Please note that this contains abridged steps that direct you to other instructions found in this manual. If you need additional assistance, please refer to those detailed instructions.

Tools and Materials Needed

- Rubber mallet
- Set of metric Allen keys with ball ends
- 13 mm, 19 mm, 24 mm (2), & 30 mm wrenches
- Gear puller
- Circlip pliers
- Copper pipe around 22 mm in diameter
- New Top Cam Drive Shaft part
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

CAUTION: This part should only be replaced by experienced mechanics, engineers, or individuals who have a lot of experience with the TDP 5®. Gently tap the Top Cam Drive Shaft to avoid damaging parts.

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove the Top Cam Drive Shaft

1. Remove the Hopper carefully and catch any powder still inside of it.
2. Remove the Ejection Tray with an Allen key.



3. Remove the Boot Timing Bar and Boot.
    3.1 Note: Please refer to the repair Boot Timing Bar instructions on page 39 and repair Boot instructions on page 42 for further assistance.
4. Remove the V Belt.
    4.1 Note: Please refer to the repair V Belt instructions on page 69 for further assistance.
5. Remove the Electrical Drive Flywheel, Pinion Gear, and Cam Drive Cog.
    5.1 Note: Please refer to the repair Cam Drive Cog instructions on page 83 for further assistance.
6. Remove the Upper Punch, Upper Drift Pin Assembly, and Upper Drift Pin Assembly Rod Eye and Clevis.
    6.1 Note: Please refer to the repair Upper Drift Pin Assembly Rod Eye and Clevis instructions on page 51 for further assistance.
7. Loosen the Hand Wheel Cap's bolt with an Allen key.
8. Disengage the Hand Wheel from the engraved key on the Top Cam Drive Shaft.
    8.1 Note: Use a rubber mallet if the Hand Wheel is difficult to remove.



9. Hold the copper pipe at the Top Cam Drive Shaft shafts end that is furthest away from the Boot Timing Cam.
10. Gently tap the copper pipe against the Top Cam Drive Shaft with a rubber mallet to move it through the TDP 5's Base.
11. Continue to tap the Top Cam Drive Shaft with the copper pipe and rubber mallet until the Eccentric Sheave and Eccentric Sheave Strap disengage.
    11.1 Note: Be sure to catch these parts before they completely disengage.



12. Disengage the Boot Timing Cam from the Top Cam Drive Shaft's engraved key.
    12.1 Note: Use a rubber mallet if the Boot Timing Cam is difficult to remove.



13. Keep tapping the Top Cam Drive Shaft until it goes completely through the TDP 5®'s Base.



Replace the Top Cam Drive Shaft

14. Gently begin to tap the new Top Cam Drive Shaft through the TDP 5® Base and the Eccentric Sheave and Eccentric Sheave Strap.
15. Continue to tap the Top Cam Drive Shaft until it is completely through the TDP 5® Base.



16. Insert the Boot Timing Cam onto the new Top Cam Drive Shaft's engraved key.



17. Reinsert the Upper Punch, Upper Drift Pin Assembly, and Upper Drift Pin Assembly Rod Eye and Clevis.
    17.1 Note: Please refer to the repair Upper Drift Pin Assembly Rod Eye and Clevis instructions on page 51 for further assistance.
18. Reinsert the Cam Drive Cog, Pinion Gear, and Electrical Drive Flywheel.
    18.1 Note: Please refer to the repair Cam Drive Cog instructions on page 83 for further assistance.
19. Reinsert the V Belt over the Electrical Drive Flywheel.
    19.1 Note: Please refer to the repair V Belt instructions on page 69 for further assistance.
20. Reinsert the Boot and Boot Timing Bar.
    20.1 Note: Please refer to the repair Boot Timing Bar instructions on page 39 and repair Boot instructions on page 42 for further assistance.

21. Insert the Hand Wheel on the new Top Cam Drive Shaft's engraved key.
22. Tighten the Hand Wheel Cap's bolt with an Allen key.



23. Reattach the Ejection Tray with an Allen key.



24. Reinsert the Hopper carefully and catch any powder still inside of it.



Troubleshooting

Sometimes unavoidable issues will occur while operating the TDP 5®. Fortunately, there are several methods to remedy these issues.

Common Machine/Part Issues

Symptom	Possible Cause	Possible Solution
Machine freezes or locks up	Grease point areas are dry.	Regularly oil and grease all the Grease Nipple points.
	There is excess pressure on the Upper Drift Pin Assembly.	Rotate the Upper Drift Pin Assembly counterclockwise.
	The V Belt is loose.	Adjust the Motor Support Arm's nuts to tighten the V Belt (correct tension is [N] 94.42).
	The press is being started with the Upper Punch at a low point.	Adjust the starting position so that the Upper Punch is at the highest point.
Knocking sounds coming from machine	The Upper Punch and Lower Punch are colliding with the Die.	After loosening its bolts, readjust the Base Plate until it is correctly aligned. After that, tighten the bolts back.
	The Upper Drift Pin Assembly is slightly off.	Loosen the Base Plate bolts and rotate the machine until the Upper Punch is aligned with the Die's bore. After that, tighten the bolts back.
	The V Belt is loose.	Adjust the Motor Support Arm's nuts to tighten the V Belt (correct tension is [N] 94.42).
	The teeth of the Pinion Gear and/or Cam Drive Cog are broken.	Replace the broken part.
	The Upper Drift Pin Assembly is not dropping smoothly in the powder filling stage of the process.	Check that there is not a buildup of powder between the Lower Punch and the Die. Then check that the Lower Drift Pin Assembly has enough clearance to drop through the hole in the Base.
Heavy resistance during production	The high friction areas are either unclean, locked, worn out, or not greased properly.	Apply grease to the Grease Nipple points and all high friction areas on the machine.

Symptom	Possible Cause	Possible Solution
Inability to compact materials to tablet form	Boot is blocked and not enough materials are flowing out.	Check the Boot for a potential clog.
	The Boot Timing Bar is not secured.	Tighten the Boot Timing Bar's nuts and bolt.
	There is not enough pressure.	Rotate the Upper Drift Pin Assembly clockwise.
	The Lower Punch is broken.	Remove the Lower Drift Pin Assembly to access the broken Lower Punch. After removing it, replace the Tooling.
	The Lower Drift Pin Assembly is not dropping properly during filling.	Check that there is not a buildup of powder between the Lower Punch and the Die. Then check that the Lower Drift Pin Assembly has enough clearance to drop through the hole in the base.
	There are flowing issues with the mix.	If the machine is able to make tablets with LFA's Firmapress®, then the problem is your mix. Adjust your formulation. If still an issue, contact LFA for support.
Powder sticks to the Upper Punch	There is damage to the Tooling or the Tooling's design is causing sticking.	Remove and replace the Tooling (Upper Punch, Lower Punch, and Die).
	There are issues with the mix.	Adjust your formulation. If still an issue, contact LFA for support.
Powder sticks to the Lower Punch	There are issues with the mix.	Adjust your formulation. If still an issue, contact LFA for support.

Common Tablet Issues

Symptom	Possible Cause	Possible Solution
Double tablets	Previous tablet did not eject correctly.	Remove the double tablet manually from the Die bore.
	Excess granular materials were placed in the Die, which prevented the ejection of the existing tablet.	Clean the Tooling to remove any excess granular materials and make sure that it is clean and completely dry.
Cracked or broken tablets	There are problems with the formulation of the granules and ingredients.	If the machine is able to make tablets with LFA's Firmapress®, then the problem is your mix. Adjust your formulation. If still an issue, contact LFA for support.
	The Boot is not feeding enough material to be pressed in tablet form.	
	There is excess pressure.	Please read our article on Capping at https://www.lfatabletpresses.com/articles/tablet-capping
Shattered tablets	The Boot Timing Bar and the Boot are not adjusted properly.	Adjust the Boot Timing Bar by loosening/tightening its bolt and moving it.
	Air is becoming trapped in the tablet during compression.	Please read our article on Capping at https://www.lfatabletpresses.com/articles/tablet-capping
	The ejection height is incorrect.	Rotate the Upper Cog in the Lower Drift Pin Assembly by hand until the ejection height is at the correct level.
Inconsistent Tablet Weight	The Lower Drift Pin Assembly Locking Bar is loose.	Check that the Lower Drift Pin Assembly Locking Bar is secured to the Lower Drift Pin Assembly and the Lower Drift Pin Assembly Cogs.
	Not enough pressure is being exerted.	Rotate the Upper Drift Pin Assembly clockwise.
	There are flowing issues with the mix.	If the machine is able to make tablets with LFA's Firmapress®, then the problem is your mix. Adjust your formulation. If still an issue, contact LFA for support.
Soft tablets	There is too little punch pressure.	Rotate the Upper Drift Pin Assembly clockwise.
	There are flowing issues with the mix.	If the machine is able to make tablets with LFA's Firmapress®, then the problem is your mix. Adjust your formulation. If still an issue, contact LFA for support.
Uneven tablets	The Tooling is worn out.	Check the ingredients of your formula before you replace the Die, Upper Punch, and Lower Punch.

De-Jamming the TDP 5®

There are several reasons why a TDP 5® might jam such as:

- The fill depth is set too low and the pressure is set too high.
- There is a build up of powder sticking to the Tooling.
- Any powder buildup on the machine can cause tablets to eject backwards and not forwards, creating potential for a double tablet becoming stuck in the Die's bore.

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® before de-jamming it.

Tools and Materials Needed

- Set of metric Allen keys with ball ends
- De-Jamming Bar
- Hammer (if Die is difficult to remove)
- Cleaning brush
- 13 mm wrench
- Disposable latex/rubber gloves (for food grade products and to protect hands from grease)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Method 1: Use the De-Jamming Bar

Note: Please refer to the Dismantling for Repair and Replacement section for additional assistance.

1. Remove the Hopper carefully and catch any powder that is inside of it.



2. Loosen the Boot's set screw with an Allen key.
3. Remove the Boot Bolt and Spring underneath the Boot with an Allen key.





4. Take off the Boot carefully and remove any powder that is inside of it.



5. Insert the De-Jamming Bar into one of the holes on the Electrical Drive Flywheel.
6. Pull down the De-Jamming Bar until the Electrical Drive Flywheel gives way.

7. Reposition the Boot on the Base Plate correctly and insert the Boot Timing Bar's end in the boot.
8. Resecure the Boot Bolt and Spring underneath the Boot with an Allen key.





9. Tighten the Boot's set screw with an Allen key.



10. Turn the Hand Wheel for one rotation of the Top Cam Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Method 2: Run a Reverse Rotation

Note: Please refer to the Dismantling for Repair and Replacement section for additional assistance.

1. Remove the Hopper carefully and catch any powder that is inside of it.
2. Loosen the Boot's set screw with an Allen key.





3. Remove the Boot Bolt and Spring underneath the Boot with an Allen key.
4. Take off the Boot carefully and remove any powder that is inside of it.





5. Turn the Hand Wheel in the reverse direction for a few rotations.



6. Reposition the Boot on the Base Plate correctly and insert the Boot Timing Bar's end in the boot.
7. Resecure the Boot Bolt and Spring underneath the Boot with an Allen key.





8. Tighten the Boot's set screw with an Allen key.



9. Turn the Hand Wheel for one rotation of the Top Card Drive Shaft to ensure that the machine runs smoothly before plugging it in and turning it on.



Cleaning

During the TDP 5®'s operation, excess powder will find its way into parts of the machine, particularly in the Base, Hopper, Boot, Base Plate, and Tooling. It is important to clean the TDP 5 thoroughly to prevent rusting and cross contamination. To watch a video of a TDP 5® cleaning, go to https://www.lfatabletpresses.com/videos/cleaning-your-tdp-5-tablet-press

LFA recommends that the machine be cleaned after each operation.

Tools and Materials Needed

- Cleaning brush
- Long wire pipe cleaner
- Toothbrush
- Cleaner (such as heavy duty foam cleaner; NSF approved if food grade product)
- Set of metric Allen keys with ball ends
- 13 mm wrench
- 24 mm wrenches (2)
- Grippers or pliers (if parts are difficult to remove)
- Hammer (if Die is difficult to remove)
- Disposable latex/rubber gloves
- Bagless vacuum
- 3 clean cloths
- Potable water
- Bowl of warm soapy water (nothing abrasive)
- Sanitizer (e.g. Member's Mark Commercial Sanitizer)
- Hairnet and/or beard net (food grade products only)
- Safety goggles
- Sterile shoe covers (food grade products only)

WARNING: To prevent any potential personal injury, ALWAYS unplug the TDP 5® from the electrical outlet when replacing parts.

Instructions

Note: Wear safety goggles and latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Remove Parts

1. Remove the Hopper carefully and catch any powder still inside it.
2. Remove excess powder and any tablets from the Ejection Tray with a cleaning brush.
3. Remove the Ejection Tray with an Allen key.



4. Loosen the Boot's set screw with an Allen key.



5. Remove the Boot Bolt and Spring underneath the Boot with an Allen key.



6. Take off the Boot carefully and remove any powder still inside it.
7. Loosen the bolts underneath the Base Plate with an Allen key.





8. Turn the Hand Wheel until the Upper Drift Pin Assembly is lowered.
9. Loosen the Upper Punch Die Locking Nut with a wrench while keeping the Upper Punch Drift Assembly in place with another wrench.
10. Remove the Upper Punch by hand.





10.1 Note: If you cannot remove by hand, carefully use pliers or pliers.

11. Remove the Base Plate with the Die still inside it.
12. Remove the bolt that locks the Die with an Allen key.
13. Take out the Die from the middle of the Base Plate.
    13.1 Note: Lightly tap the Die with a hammer if it is difficult to remove.



14. Remove the bolt that locks the Lower Punch with an Allen key.
15. Remove the Lower Punch by hand.



15.1 Note: If you cannot remove by hand, carefully use grippers or pliers.

Clean the Base

16. Vacuum any powder/debris from the machine.
17. Spray the TDP 5® Base with the cleaner, particularly in the Tooling's location.
18. Rinse the cleaner off with potable water.
19. Sanitize the TDP 5® Base with a clean cloth.

Note: Before washing the Base Plate, LFA recommends using our Die Seat Cleaner. You can order the Die Seat Cleaner and Insertion Ring on our website at https://www.lfatabletpresses.com/die-seat-cleaner-insertion-ring



Clean the Parts

20. Take one of the parts removed from the machine and submerge it in the bowl of warm soapy water.
    20.1 Note: To ensure that all dirt and debris are removed, wash one part at a time.
21. Take a clean cloth and carefully wash the part thoroughly.
    21.1 Note: Use the toothbrush for difficult-to-remove debris. When cleaning tooling, use non-abrasive cleaning equipment such as a soft pipe cleaner and soft cloth.
22. Dry part immediately after it is cleaned and rinsed.
23. Sanitize part with a clean cloth.
24. Repeat steps 20-23 for each remaining part until they are all clean.



Cleaning Schedule Matrix

This cleaning matrix is intended as a guide only and is not an exhaustive list. All cleaning schedules will need to be adapted to the industry and product, following industry regulations and the material safety data sheets that come with specific products. Please check with your Food Safety Manager/Department, Quality Control Manager/Department, or other relevant internal departments at your company before using.

Storing the TDP 5®

After its thorough cleaning, the TDP 5® needs to be stored in the proper conditions. It is important to store it in an environment in which the machine is safe from rusting. The TDP 5®'s high traction areas and the Tooling need to be lubricated separately before you store them.

Tools and Materials Needed

- Plastic wrapping to cover machine
- Airtight container for Tooling (if in storage for more than a week)
- Grease gun
- Lubricant/grease (food grade lubricant if machine has a high chance of contact with the food or drug product)
- Disposable latex/rubber gloves (for food grade products and to protect hands from lubricant)
- Hairnet and/or beard net (food grade products only)
- Sterile shoe covers (food grade products only)

Instructions

Note: Wear latex/rubber gloves (and appropriate food grade attire if applicable) during this process.

Lubricating the Tooling

If you are not using the machine for more than a week, store the Tooling in an airtight container and cover it with lubricant to prevent rust formation. If not, simply lubricate each part of the Tooling and reinsert it back into the machine.

LFA's TDP® Tooling Case provides airtight storage and is perfect for transport and protection. Order at https://www.lfatabletpresses.com/tooling-case-tdp

1. Rub a finger's worth of grease on the Boot Timing Cam's side.
    1.1 Note: Be sure to grease around the Boot Timing Cam Runner.
2. Lubricate the Grease Nipple on top of the Eccentric Sheave Strap with the grease gun.
    2.1 Note: Rotate the Hand Wheel during this to ensure grease gets in between the Eccentric Sheave and the Eccentric Sheave Strap.
3. Lubricate the Grease Nipple nearest to the Boot Timing Cam.
    3.1 Note: Rotate the Hand Wheel during this to ensure grease gets in between the TDP 5® Base and Top Cam Drive Shaft.



4. Lubricate the Cam Drive Dog and Lower Drill Pin Assembly Timing Rod Runner Bolt.
5. Lubricate the Pinion Gear.



You can also lubricate any point of traction on the TDP 5® at your own discretion; just be sure not to over-lubricate.

Cover the TDP 5®

6. Carefully cover the TDP 5® with the plastic wrapping.
    6.1 Note: You can use the plastic wrapping that came with the machine in the shipping container.

Environmental Conditions

It is important that the environment in which you store the TDP 5® has the appropriate temperature and relative humidity levels. These two environmental factors can potentially cause the machine to rust and/or cause the tablets to have a lower quality. The table below shows the acceptable temperature and relative humidity levels:

Machine	Temperature		Humidity
TDP 5	°C	°F	45-65% RH
	18-24	64-75	

Appendix

Glossary

Term	Definition
API/Active Pharmaceutical Ingredient	Any substance or mixture of substances used that is an active ingredient in the drug product.
Binding agent	See excipient.
Die	The part of the Tooling that makes up the hole in which the powder is compressed and shaped into a tablet.
Die bore	The cavity inside the middle of the Die.
Die face	The very top flat surface of the Die.
Ejection height	The height at which the Lower Punch is lifted to for a tablet's ejection from the machine.
Excipient	An inactive substance that serves as the vehicle or medium for a drug or other API.
Fill depth	The amount of space that the powder can flow into in the Die.
Formulation	Powder mix of the excipient and the API that is compressed to make tablets.
Granular material	See Formulation.
Kilonewton (kN)	The force to accelerate a mass of 1 kg at a constant 1 m per second. The TDP® range's pressure is measured in this unit.
Punches	The Upper Punch and Lower Punch have concave endings in the shape of the desired tablet. When the punches meet, they compress the powder between.
Punch pressure	The adjustable amount of force that is used to press tablets.
TDP®	LFA trademarked term for desktop tablet press.
Tooling	Enables a tablet press to form tablets. It consists of a Die, Upper Punch, and Lower Punch.

Description of TDP 5® Parts

TDP Base (#AEC0000)
The TDP Base is the main base for the TDP 5®, and all working parts are connected to it. It is important that the TDP Base be fixed onto a stable and secure workbench.



Tooling
The Tooling consists of the Die, the Upper Punch, and the Lower Punch. This die set compresses the powder into the tablet. Order at https://www.lfatabletpresses.com/tdp-tooling



Lower Drift Pin Assembly Locking Bar (#AEC0013)
The Lower Drift Pin Assembly Locking Bar holds the Lower Drift Pin Assembly Cogs in place. Order at https://www.lfatabletpresses.com/tdp5-lower-pin-locking-bar



Lower Drift Pin Assembly Cogs (#AEC0012)
The Lower Drift Pin Assembly Cogs are used to adjust the tablet's fill depth and ejection height. They are located in the Lower Drift Pin Assembly. The Upper Cog adjusts the ejection height of the tablet. Turning it counterclockwise raises the ejection height, and turning it clockwise lowers it. The Lower Cog increases the tablet's fill depth (weight). Turning it clockwise increases the weight of the tablet, and turning it counterclockwise decreases the weight. Order at https://www.lfatabletpresses.com/tdp5-lower-pin-cogs



Boot (#AEC0036)
The Boot is where the dry granular materials are held for pressing. It fills the Die bore with the dry granular material and moves the finished tablet out of the Die before refilling it with the next batch of materials. Order at https://www.lfatabletpresses.com/tdp5-boot



Boot Bolt and Spring (#AEC0051; #AEC0055)
The Boot Bolt and Spring holds the Boot in place while the press is running and allows it to move back and forth. It is kept secure with the set screw on the side of the Boot. Order at https://www.lfatabletpresses.com/tdp5-boot-bolt-spring



Electrical Drive Flywheel (#AEC0021)
The Electrical Drive Flywheel is attached to the Motor via the V Belt. Order at https://www.lfatabletpresses.com/tdp5-drive-wheel



Upper Drift Pin Assembly (#AEC0002)
The Upper Drift Pin Assembly holds the Upper Punch in place while being able to adjust the punch pressure. It is attached to the Eccentric Sheave. Order at https://www.lfatabletpresses.com/tdp5-upper-drift-pin-assembly



Hopper (#AEC0030)
The Hopper is the funnel that holds the granular materials before it moves into the Boot to be pressed. Order at https://www.lfatabletpresses.com/tdp5-hopper

Eccentric Sheave Strap (#AEC0004)
The Eccentric Sheave Strap attaches the Upper Drift Pin Assembly to the Top Cam Drive Shaft. Order at https://www.lfatabletpresses.com/tdp5-eccentric-sheave-strap





Upper Drift Pin Assembly Rod Eye and Clevis (#AEC0005)
The Upper Drift Pin Assembly Rod Eye and Clevis is the part that connects the Eccentric Sheave to the Upper Drift Pin Assembly, which holds the Upper Punch. Order at https://www.lfatabletpresses.com/tdp5-upper-drift-assembly-cam



Top Cam Drive Shaft (#AEC0037)
All other TDP 5® parts are connected to the Top Cam Drive Shaft. As it is turned, all the parts of TDP 5® move. Order at https://www.lfatabletpresses.com/tdp5-top-cam



Grease Nipple
Grease Nipples are grease cap points that grease the TDP 5®'s gaps with high pressure. Order at https://www.lfatabletpresses.com/tdp5-grease-nipple



Boot Timing Cam (#AEC0038)
The Boot Timing Cam is responsible for the movement of the Boot Timing Bar, which allows the Boot to fill the Die bore with the dry granular materials needed to form the tablet. Order at https://www.lfatabletpresses.com/tdp5-boot-timing-cam



Eccentric Sheave (#AEC0033)
The Eccentric Sheave controls the timing of the Upper Drift Pin Assembly. Order at https://www.lfatabletpresses.com/tdp5-eccentric-sheave



Lower Drift Pin Assembly Timing Rod (#AEC0014)
The Lower Assembly Timing Rod raises the finished tablet out of the Die. Order at https://www.lfatabletpresses.com/tdp5-lower-assembly-timing-rod



Lower Drift Pin Assembly (#AEC0011)
The Lower Drift Pin Assembly is located below the base of the tablet. It holds the Lower Punch in place in the Die while the Upper Punch pushes down to form the tablet in the middle. Order at https://www.lfatabletpresses.com/tdp5-lower-pin-assembly



Upper Drift Pin Assembly Locking Nut (#AEC0006)
The Upper Drift Pin Assembly Locking Nut is a large nut used to secure the Upper Drift Pin Assembly in place. Order at https://www.lfatabletpresses.com/tdp5-upper-drift-pin-locking-nut

Boot Timing Drive Bar Runner (#AEC0022)
The Boot Timing Cam Runner is a round section that connects the Boot Timing Cam to the Boot Timing Bar, which keeps the timing. Order at https://www.lfatabletpresses.com/tdp5-boot-drive-runner



Cam Drive Cog (#AEC0050)
The Cam Drive Cog is attached to the Top Cam Drive Shaft and drives the Lower Drift Pin Assembly Timing Rod. Order at https://www.lfatabletpresses.com/tdp5-cam-drive-cog



Pinion Gear (#AEC0022)
The Pinion Gear amps up the Motor's torque to get the maximum amount of force available. Order at https://www.lfatabletpresses.com/tdp5-pinion-gear



Lower Drift Pin Assembly Timing Rod Runner Bolt (#AEC0015)
The Lower Drift Pin Assembly Timing Rod Runner Bolt connects the Lower Drift Pin Assembly Timing Rod to the Cam Drive Cog. Order at https://www.lfatabletpresses.com/tdp5-lower-assembly-timing-rod-runner-bolt



Motor (#AEC0042)
The Motor is mounted at the back of the TDP 5® Base and can be either 110 v or 220 v. Order at https://www.lfatabletpresses.com/tdp5-motor



Boot Timing Bar (#AEC0018)
The Boot Timing Bar moves the Boot and is timed by the Boot Timing Cam track. The rocking motion that the arm provides helps the Boot to fill the Die bore with the dry granular material for the next tablet. Order at https://www.lfatabletpresses.com/tdp5-boot-timing-bar



Electrical Box and Connecting Cables (#AEC0053)
The Electrical Box has the On/Off buttons, which are connected to the motor and an electrical plug via cables. Order at https://www.lfatabletpresses.com/tdp5-electrical-box-wires



Lower Drift Pin Assembly Lifting Bar (#AEC0034)
The Lower Drift Pin Assembly Lifting Bar lifts the Lower Drift Pin Assembly that holds the Lower Punch and helps push the tablets out of the Die. Order at https://www.lfatabletpresses.com/tdp5-lower-pin-lifting-bar



Base Plate (#AEC0008)
The Base Plate is not only the mount for the Boot, but also holds the Die in place. Order at https://www.lfatabletpresses.com/tdp5-base-plate

Drive Belt Pulley (#AEC0043)
This Drive Belt Pulley fixes on the Motor's keyed axle and has grooves that the V Belt fits into. The V Belt is also connected to the Electrical Drive Flywheel. Order at https://www.lfatabletpresses.com/tdp5-drive-belt-pulley



Lower Drift Pin Assembly Timing Rod Runner (#AEC0016)
The Lower Drift Pin Assembly Timing Rod Runner is inserted onto the Lower Drift Pin Assembly Timing Rod Runner Bolt and rests in the Cam Drive Cog. Order at https://www.lfatabletpresses.com/tdp5-lower-assembly-timing-rod-runner



Ejection Guard (#AEC0009)
The Ejection Guard rests in a groove on the Base Plate between the Lower Drift Pin Assembly Timing Rod and the Die. Order at https://www.lfatabletpresses.com/tdp5-ejection-guard



Ejection Tray (#AEC0049)
The Ejection Tray aids with the ejection of finished tablets. Order at https://www.lfatabletpresses.com/tdp5-ejection-tray



Upper Drift Pin Assembly Mounting Block (#AEC0010)
The Upper Drift Pin Assembly Mounting Block holds the Lower Drift Pin Assembly Timing Rod and the Upper Drift Pin Assembly. Order at https://www.lfatabletpresses.com/tdp5-upper-drift-pin-mounting-block



Cam Drive Cog Safety Cover (#AEC0044)
The Cam Drive Cog Safety Cover prevents users from coming into contact with the moving Cam Drive Cog. Order at https://www.lfatabletpresses.com/tdp5-cam-drive-cog-cover



Hand Wheel Cap
The Hand Wheel Cap is fixed onto the Hand Wheel's end. Order at https://www.lfatabletpresses.com/tdp5-fly-wheel-cap



Hand Wheel (#AEC0046)
The Hand Wheel can be used to turn over the TDP 5® manually. Order at https://www.lfatabletpresses.com/tdp5-fly-wheel



Rear Enclosure Plate (#AEC0045)
The Rear Enclosure Plate is located at the back of the TDP 5® Base and prevents dust powder collecting in the interior. Order at https://www.lfatabletpresses.com/tdp5-rear-enclosure-plate

Motor Mounting Plate (#AEC0041)
The Motor Mounting Plate is hinged and connects the Motor to the TDP 5® Base. It can be moved to adjust the tension of the V Belt. Order at https://www.lfatabletpresses.com/tdp5-motor-mounting-plate





V Belt (Drive Belt) (#H108012028)
The V Belt connects the Motor to the TDP 5®'s running parts. Order at https://www.lfatabletpresses.com/tdp5-v-belt-drive-belts

Hopper Holder (#AEC0035)
The Hopper Holder is a small bar that secures the Hopper in place. Order at https://www.lfatabletpresses.com/tdp5-hopper-holder



List of Electrical Components

Name of Part	Part Manufacturer	Part Serial Number	Quantity	Link to Manufacturer's Site
Red Switch	Rockwell Automation	800FD-F4X11	1	Rockwell Automation
Green Switch	Rockwell Automation	800FD-F4X11	1	Rockwell Automation
3 Phase AC Socket with Dust Cover	Guanghua Electronic Mall/ Dunhua Electronic Materials Co., Ltd.	6214CAP	1	Guanghua Electronic Mall/ Dunhua Electronic Materials Co., Ltd.
Contactor	Rockwell Automation	100-C09KF01	1	Rockwell Automation
Plastic Power Box	Yueqing Mingzhou Electric Co., Ltd.		1	Yueqing Mingzhou Electric Co., Ltd.

Material of Contact Parts

Contact Part	Material
Boot	MABS (Terlux HD 2822) plastic
Base Plate	S45C carbon steel
Tooling (Upper Punch, Lower Punch, and Die)	User specified
Ejection Tray	SUS304 stainless steel
Hopper	Polypropylene (PP) plastic

Technical Specifications

Number of dies	1
Max production capacity	4800/hour
Max diameter of tablet	20 mm
Max thickness of tablet	8 mm
Max fill depth	18 mm
Max pressure	50 kN
Number of filling stations	1
Double layered tablet	No
Motor power	0.75 kW
Number of phase	1
Amps	5.7 A @ 240 V; 11 A 110 V; 5.5 A @ 220 V
Volts	240 V (110 V and 220 V on request)
Overall size	800 mm x 400 mm x 700 mm
Dimensions with suggested working clearance	1700 mm x 1300 mm x 1600 mm
Weight	125 kg (275 lbs)

Maintenance Checklist

Before Operation	
☐	Visually inspect the tablet press and the parts.
☐	Ensure all locking nuts are tight.
☐	Visually inspect grease nipples and regrease where necessary.
☐	Tune the tablet press by hand to get the tablet size and weight correct.
☐	Manually operate the machine for at least two full rotations to ensure it is not jammed.
During Operation	
☐	Listen for irregular knocking or clicking sounds. If heard, stop operation and lubricate the desktop press.
☐	Watch for buildup of powder in front of the Boot. If occurring, either (a) make mix more granular, (b) check the Boot's base for damage, or (c) clear the buildup with a paintbrush.
☐	Occasionally check the Motor's temperature. If it starts to overheat, turn off the machine, let it cool down, and grease it to ensure smooth operation.
☐	Ensure that the Hopper does not run out of powder.
☐	Weigh a sample tablet and test for its hardness.
After Operation	
☐	Unplug machine and remove all excess powder with a bagless vacuum.
☐	Remove the Boot and the Tooling and clean the inside of the tablet press.
☐	Wipe down the other surfaces with a damp cloth.
☐	Apply a layer of food grade grease to the entire desktop tablet press.
☐	Lubricate all grease nipples.
☐	Store Tooling in an eirtight box with a small amount of grease.

Diagrams

TDP 5® Dimensions



TDP 5® Tooling Dimensions

TDP® International Tooling

Standard Dimensions



www.lfatabletpresses.com

TDP 5® Exploding Diagram



TDP 5® Wiring Diagram



ITEM	Part number	Product name	Specification	QTY.
13	1053500030	Nameplate	Ø22, mark: "0"	1
12	1051500041	Nameplate	Ø22, mark: "I"	1
11	1016100033	Wire-PVC	16AWG#1C,Blue,UL1015 HCW.101516.B	1165CM
10	1016100019	Wire-PVC	16AWG#1C,Brown,UL1015 HCW.101516.BR	14CM
9	1016100047	Wire-PVC	16AWG#1C,Y/G, UL1015 HCW.101516.YG	14CM

ITEM	Part number	Product name	Specification	QTY.
7	1012500022	Cable_PVC	1.25mm²6C,Black,HCW.N012500BR.N	0.7M
6	1058900005	PB1(R) Ø22	A-B, 1a1b,300V,5A, 800FD-F4X11(G)	1
5	1058900006	PB1(G) Ø22	A-B, 1a1b,300V,5A, 800FD-F4X11(R)	1
4	1051500013	Power socket	3P, Male+cover, 6214CAP	1
3	1055700002	CONTACTOR	A-B, AC3, 110V, 50/60Hz, 100-C09KD10	1
2	1051500020	Steel rail	W:35mm, length:1M	11CM
1	1058100013	BOX	GLC125, 125x125x100mm	1

TDP 5® Wiring Diagram



TDP 5® Mounting Diagram



Resources

Helpful Links

Warranty
For information regarding the warranty policy of the TDP 5® and other LFA products, please visit https://www.lfatabletpresses.com/warranty

LFA Website
In order to aid you in your tablet production, LFA Machines maintains a website that offers a breadth of useful information about the TDP 5® and other tablet presses. Use our online tools such as the Tablet Mix Calculator to help you in your formulation production or read our regularly published articles that cover a whole range of topics about tablet presses and tablet production.

Visit the LFA homepage at https://www.lfatabletpresses.com

LFA Machines YouTube Channel
Our YouTube videos provide you an opportunity to see how to use our tablet presses, common troubleshooting tips, and other LFA products such as capsule fillers and mixers. We regularly upload videos to give you a visual aid that will hopefully support you in your tablet production efforts. To watch our videos, visit https://www.youtube.com/channel/UCwtbcwia77ai7vX2o34FUkQ

LFA Machines Social Media
Social media is a great way to keep yourself updated on new developments and exciting things happening at LFA Machines. The list below contains our current social media pages:

Twitter: @lfatabletpress
Instagram: @lfatabletpresses
Facebook: https://www.facebook.com/lfatabletpresses
LinkedIn: https://www.linkedin.com/company/lfa-machines-oxford-ltd/

Contact Us

UK
LFA Machines Oxford Ltd
Unit 4B Rowood Estate
Murdock Road
Bicester, Oxfordshire OX26 4PP
+44 01869 250234
support.uk@lfamachines.com
Monday-Friday
9AM-5PM GMT

USA
LFA Machines DFW, LLC
6601 Will Rogers Blvd
Fort Worth, TX 76140
+1 (682) 312 0034
support.usa@lfamachines.com
Monday-Friday
8AM-6PM UTC (Central)

Germany
LFA Machines Düsseldorf GmbH
Business Parc Am Trippelsberg 92
Düsseldorf, North-Rhine
Westphalia 40589
+41 21188250223
verkauf@lfamachines.com

Taiwan
LFA Machines Taiwan Ltd
7F-5, No. 2, Sec. 2 Taiwan Blvd
West District, Taichung City 403
Taiwan
+886 422031790
support.asia@lfamachines.com
Monday-Friday
9AM-5PM GMT+8

LFA MACHINES

www.lfamachines.com

Green Mill CO2 Extraction System

SFE Pro™

operator's manual



GREEN MILL

pittsburgh made.

GREEN MILL

Table of Contents

GREEN MILL

GREEN MILL

1. system basics

This section provides the basic layout of major components of your SFE Pro.

abbreviation/acronym	full term
F#	filter number
SV#	solenoid valve number
PR#	pressure regulator number
EV#	extraction vessel number
CV#	collection vessel number
P1	pump
HE	heating heat exchanger
CHE	cooling heat exchanger
VHC	vessel heater control
RTD	temperature probe
RC#	recycle controller number

GREEN MILL

1.1 process flow diagram



*** AV1-3 apply only to dual systems*

GREEN MILL

1.2 system diagram, front



GREEN MILL

1.3 system diagram, rear



GREEN MILL

1.4 vessel switching cart diagram, front



GREEN MILL

1.5 vessel switching cart diagram, rear



GREEN MILL

2. parts and tools

You will require certain tools and parts to operate and maintain your SFE Pro. Additional parts may be ordered through the Green Mill website — access is password protected so please contact info@greemillsfe.com if you do not have the current password.

**indicates this part/tool is included with your SFE Pro*

tools/parts	part #
* ½" wrench	non-retail
* ¼" PTFE tape	non-retail
* 3/8" wrench	non-retail
* 7/16" wrench	non-retail
* 9/16" wrenches	non-retail
* 4-tank CO_2 manifold	330046
* allen key set	non-retail
* anti-seize	330041
check valve (recycle system)	330021
check valves 500 g/min	330009 (pack), 330008 (single) *contact Green Mill Supercritical to order if your system requires high-flow check valves*

GREEN MILL

collection valve	330018
cyclone tube	330019
(F2) large particulate filter	330007
* (F3) coalescing filter, 0.01 micron	330014 (pack), 330006 (single)
* (F3) filter seal	330037
* (F4) active carbon replacement	330012
* (F5) bonded microfiber filter element	330039
* (F5) filter seal	330038
outlet plug	330020
pump inlet and outlet tubing	330011
* pump seals and backup rings	330003
RTD probe	330015
* rupture disc — 5,500 psi	330047
* rupture disc — 7,500 psi	330048
* rupture disc — 8,000 psi	330049
* solenoid rebuild kit	330028
stainless steel funnel	330042
stainless steel tamping rod	330044
* vessel cap rest (per extraction vessel)	330050
* vessel spanner wrench	330051
vessel cap seal	330004

GREEN MILL

3. best practices

In order to run successful extractions with your SFE Pro, you will need to maintain certain conditions with your biomass, ambient temperatures and humidity, and other parameters.

This section outlines best practices to ensure you are set to operate your SFE Pro successfully.

GREEN MILL

3.1 biomass conditions

Overview:

A successful extraction begins with the quality and consistency of the biomass.

Conditions:

- Biomass should be dried to 5-7% moisture content or less. *Water can create a type of obstacle that is unfavorable to CO_2 extraction (e.g., inhibits the actual extraction of cannabinoids, may form carbonic acid, etc.) and can cause freezing within certain filters on the SFE Pro.*
- Grind size should be no larger than 400 micron (coffee grind) but not smaller than 30 micron (baby powder). *When material is powderized, it can pack too densely and encourage CO_2 to bypass the biomass.*
- Consistent size and free of debris (stems, seeds etc.).

Example:



GREEN MILL

3.2 spatial and ambient requirements

Overview:

The SFE Pro operates best under stable temperature conditions. Excess humidity or heat can create conditions that can cause strain on the chiller and SFE Pro, and can lead to inconsistency in run results.

Requirements:

- Ambient temperature should be between 16-24°C.
- Humidity levels should be low enough where there is not excessive condensation.
- Spatial requirements:
  - SFE Pro: 2-3' around the system
  - Chiller: 2' around the system. *You may also isolate the chiller in a separate room to reduce noise in the extraction space and meet the higher climate specifications of the chiller.*



GREEN MILL

3.3 vessel temp and pressure ranges

Overview:

The SFE Pro allows you to set the temperature and pressures of each vessel on the system. In order to create ideal extraction conditions you should adhere to certain ranges in pressure and temperature stated below.

Pressures must always cascade down from EV1 or EV2 to CV1 — CV3. Keep in mind, large drops in pressure create cooling conditions when inputting set pressures.



GREEN MILL

Parameters:

Extraction Vessel 1
- Temperature range: ambient +5° to 70°C
- Pressure range: 1,000 psi to 7,500 psi

Extraction Vessel 2 (optional)
- Temperature range: ambient +5° to 70°C
- Pressure range: 1,000 psi to 7,500 psi

Collection Vessel 1
- Temperature range: ambient +5° to 57°C
- Pressure range: 900 psi to 3,000 psi

Collection Vessel 2
- Temperature range: ambient +5° to 57°C
- Pressure range: 800 psi to 1,800 psi

Collection Vessel 3
- Temperature range: 18°C to 22°C
- Pressure range: 670 psi to 690 psi

Note: setting temperatures and pressures outside of these recommended ranges can push product or water into the pump and recycle system.

⚠ CAUTION:	To prevent the possibility of injury or property damage, avoid touching heater bands when energized. Heater bands may reach high temperatures during normal operation.

GREEN MILL

3.4 CO_2 management and supply

The SFE Pro pump requires liquid CO_2 supply for proper operation.

CO_2 for the SFE Pro will typically be supplied using high pressure cylinders that come in 50-pound and 75-pound sizes and require what is known as an *eductor tube, dip tube, or siphon tube* to draw liquid CO_2 from the bottom of the cylinder.

The CO_2 pressure in the cylinders should range from 700 psi to 950 psi, depending on temperature conditions in the room where the cylinders are stored. If the CO_2 pressure drops below this range, the system pump may improperly flow CO_2 throughout the system.

When storing the CO_2 cylinders, always secure them to a storage rack or alternative safe method (contact your gas supplier for recommendations).

In areas where the outdoor temperatures are extremely hot or cold, make sure to order the CO_2 cylinders a day in advance to allow them to acclimate to normal ambient temperature ranges — *do not allow ambient temperature to go below 16°C or above 24°C.*

GREEN MILL

3.4.1 cylinder manifold setup

Overview:

The cylinder manifold consists of four flex hoses to connect to your bay of CO_2 cylinders, a mounting bracket, a flex hose to connect to the SFE Pro, and a pressure gauge.

Supplies:

- CO_2 cylinders (4)
- 4-tank CO_2 manifold (Part 330046)
- bracket with straps
- drill
- bolts, screws, anchors, washers, etc.



Procedure:

1. Mount manifold to the wall approximately one foot above the CO_2 cylinders.
2. Mount the bracket for nesting the CO_2 cylinders against the wall directly below the manifold — about three quarters of the way up the cylinder bodies.
3. Using bracket straps, strap your cylinders to secure in place.

GREEN MILL

3.4.2 CO_2 cylinder swap – mid run

Overview:

If during an extraction run the CO_2 supply drops to 700 psi or below, it may be necessary to connect fresh CO_2 cylinders to the manifold to allow the run to continue. The following is the procedure for adding fresh CO_2 cylinders during a run.



Supplies:

- fresh CO_2 cylinders
- cylinder caps for spent cylinders
- adjustable wrench

Procedure:

GREEN MILL

1. Select one CO_2 cylinder to replace and close the associated ball valve at the manifold.

2. Close the nozzle valve at the CO_2 cylinder.

3. Using an adjustable wrench, slowly loosen the CGA 320 fitting and allow the CO_2 trapped in the line between the two valves at the manifold and cylinder nozzle to bleed out slowly.

4. Completely remove the high-pressure flex hose attached to the CO_2 manifold by unthreading the CGA 320 fitting.

5. Replace the cylinder cap and unstrap the spent CO_2 cylinder from the storage manifold; remove.

6. Strap the full CO_2 cylinder in its place and remove the cap.

7. From the CO_2 manifold, attach by hand the high-pressure flex hose using the CGA 320 fitting assembly. *Make sure to include the seal (small white plastic disc) when connecting the fittings to the CO_2 cylinder nozzles.*

8. Using the adjustable wrench, tighten the fitting to the cylinder nozzle.

9. Carefully open the nozzle valve on the cylinder.

10. *With the exception of freshly changed cylinders,* close all other ball valves at the manifold for the cylinders that were not replaced. This ensures that the new cylinder will not redistribute to the spent cylinders.

11. Open the ball valve at the manifold for the CO_2 cylinder that was just replaced.

12. Repeat steps as necessary for additional cylinders.

GREEN MILL

Truffly Made Gelatin System

Operating instructions

Universal Depositor



Follow these instructions for proper and safe use.
Keep for future reference.

Truffly Made Inc.

The easiest way to make candies

Imprint

Operating instructions for: Universal Depositor
Serial number: see nameplate on the machine

The document has been prepared by the technical editing department of Truffly Made, Inc.

The figures and visualizations in this document serve for general illustration purposes. Therefore images and functional possibilities may vary from the delivered machine. Truffly Made, Inc. reserves the right to amend this documentation and the contained descriptions and technical data without prior notice.

Truffly Made, Inc.
P.O. Box 180072,
CA 92118 Coronado
(+1) 619 500 3102
info@trufflymade.com
www.trufflymade.com

Table of contents

Table of contents

Purpose of the operating instructions

Before you operate the machine for the first time or if you are commissioned with any other work on the machine, you must read the operating instructions.

The use and handling of the machine described in the following as well as its operation are not self-evident and are explained in detail by the accompanying technical documentation.

Particularly observe chapter "2 Basic safety information".

Operating instructions

The operating instructions help you to use the machine as intended, in a proper, effective and safe way. Therefore read the following chapters thoroughly and carefully. If necessary, refer to the issues crucial to you time and again.

Residual risks

The operating instructions inform and warn you of any residual risks against which a risk reduction by constructive and protective measures is not or not fully effective.

Orientation in the operating instructions

Representation of general information symbols

These operating instructions contain the following general information symbols which guide you, the reader, through the operating instructions and provide you with important information.

Pictogram	Meaning
	**Caution, possible material damage** This pictogram indicates that an action could result in material damage to the machine if the instructions are not correctly complied with and implemented.
	**Important information** This pictogram indicates an important additional information which contains a warning against a hazard.
	**Staff qualification** This pictogram indicates which staff (target group) is admitted for the actions in the respective chapter.
➢	**Interim result** This symbol indicates interim results and important information in the instructions.

Table 1: General pictograms and their meaning

Representation of warnings

When operating a machine, it is always necessary to perform actions during which hazards may arise. These hazardous actions are preceded by warnings which must stringently be observed.

Important information on the warnings in the operating instructions

Observe all the warnings on the machine and in the documentation and proceed with utmost care in these cases. Additionally pass on any warnings to other users, too.

Warnings (as well as mandatory actions and prohibitions) ensure your personal safety!

Design of warnings in the operating instructions

Step	Information	Content	Example
1	Risk level	Severity and classification of the hazard by a signal word and a pictogram	
2	Type and source of hazard	Which type of hazard is there and where does it originate from?	Risk of burns due to contact with the hot plate of the machine
3	Possible consequences of the hazard	What will or can happen if the warning is not observed?	The hot plate of the machine heats up to approximately 150°C. Contact may cause burns of the skin.
4	Action to prevent or avoid the hazard	What has to be done? What has to be avoided? Which protective measures have to be adopted?	Never touch the hot plate with bare hands. Clean and maintain the hot plate only if the machine is switched off and the hot plate has cooled down.

Table 2: Structure of warnings

Orientation in the operating instructions

Classification of the risk level (signal words) of warnings

Risk level (signal word)	Meaning and consequences of non-observance	Warning
DANGER	**Imminent** danger resulting in **serious injuries or death**.	
WARNING	**Possibly** dangerous situation which could result in **serious injuries or death**.	
CAUTION	**Possibly** dangerous situation which could result in **minor injuries**.	
NOTE	Situation which can result in possible **material damage to the machine**	

Table 3: Design of warnings

Possible symbols in operating instructions

Warning symbols warn against danger zones, risks and obstacles.

Generic warning

Warning against dangerous electric voltage

Warning against hot surfaces

Warning against cuts

Warning against slipping

Warning against tripping

Warning against crushing of feet

Warning against crushing of fingers

Warning against crushing of fingers

Warning against heavy load

Mandatory action signs serve to prevent accidents

General mandatory action sign

Wear protective gloves

Read the operating instructions

1 Identification

1.1 Machine identification

Designation: Universal Depositor
Serial number: see nameplate on the machine

1.2 Manufacturer information

Company headquarters	
	Truffly Made, Inc.
	P.O. Box 180072,
	CA 92118 Coronado
	USA
Phone:	(+1) 619 500 3102
E-mail:	info@trufflymade.com
Internet:	www.trufflymade.com

Table 4: Manufacturer information

1.3 Nameplate

Nameplate of the machine

The nameplate clearly identifies the machine.

The nameplate is located on the back of the basic machine.



Figure 1: Position of the machine nameplate



Figure 2: Explanation of the machine nameplate

1 Machine designation

2 Serial number

Nameplates of heating components

Each heating component is equipped with its own nameplate. The nameplates are located at the front side of the machine. Their structure is identical.



Figure 3: Position of nameplate on heating components



Figure 4: Explanation of nameplate on heating component

1 Date of manufacture
2 Product label
3 Type, batch or serial number
4 Company address
5 Connection information
6 Input voltage
7 Component type

2 Basic safety information

2.1 Operator's duty of care

Important information

The machine has been planned, designed and built in due consideration of laws, directives and standards, a risk assessment and further technical specifications. It therefore corresponds to the state of the art and guarantees the maximum degree of safety.

In practical application, however, safety can only be achieved if all the required measures are adopted. It is subject to the operator's duty of care to plan these measures and to monitor their implementation.

Important information

The operator of the machine shall take care that the operating instructions are read and understood by the users.

Particularly the safety information and the information on maintenance and servicing must be observed.

Technical condition of the machine

The following requirements for the technical condition of the machine are imposed and must be ensured by the operator:

- The machine must only be used as intended.
- As a matter of principle, the machine must be checked for its perfect technical condition before switching it on.
- The correct functioning of the safety devices must be checked at regular intervals.
- The safety and warning information attached to the machine must not be removed and must regularly be checked for legibility and replaced, if necessary.
- No alterations, manipulations and changes to the machine must be made without authorization.
- The operating instructions must always be freely available at the place of operation in legible and complete state.

2.2 General work safety

2.2.1 Staff qualification

Important information on the staff qualification

Any work on the machine must only be performed by persons who have read and understood these instructions. Special installation and maintenance work must only be performed by qualified personnel.

⚠ WARNING

Hazard due to insufficient staff qualifications

There is the risk of serious injuries and considerable material damage if unqualified personnel performs any work on the machine.

➢ Unqualified personnel must not perform any work on the machine.

Machine operators / operating staff

Chocolatier or professions similar/related to confectioners. The person has completed a vocational training and has experience in the handling of confectionery masses. Can create recipes for confectionery masses and also recognize problems with the recipe during processing. Furthermore the person has knowledge of and advanced training in food hygiene.

Carrier

Transports the machine to the customer or to the installation site. Has experience in the handling of lift trucks, the correct handling of loads and securing of loads. Has a valid driving license for the lift trucks used (if required).

2.2.2 Authorized staff

Phase / chapter	Staff qualification
Transport, installation and storage	Carrier, machine operators / operating staff
Initial commissioning	Machine operators / operating staff
Preparing for operation	Machine operators / operating staff
Operation	Machine operators / operating staff
Maintenance and servicing	Machine operators / operating staff

Table 5: Authorized staff

Instruction

The staff working on the machine must regularly be trained and instructed on the machine by the operator.

2.2.3 Personal protective equipment

In compliance with applicable directives and regulations, the staff is obliged to wear the respective personal protective equipment (PPE). The required PPE must be provided by the operator. Proper use by the staff must be ensured by the operator.

Important information on the personal protective equipment

When performing any work on the machine, the staff must wear the respective PPE.

Observe the following list and the chapter-related list as well as the notes on personal protective equipment attached in the work area.

Personal protective equipment (PPE)

The degree of protective equipment must be assessed and determined for each individual case.

In the following a list of the recommended PPE:

Wear protective gloves

Protective gloves serve to protect the hands against abrasion, graze, puncture or deeper injuries as well as against contact with hot surfaces.

Only use the approved gloves provided by the operator of the machine.

2.3 Basic information

Read all the safety information and instructions. Failure to comply with the safety information and instructions can cause serious injuries. Keep any safety information and instructions for future reference.

- Children and adolescents must not operate this machine.
- Do not use this machine if you are tired, under the influence of drugs, alcohol or medicines.
- Avoid sharp kinks of the cable. Particularly during transport and storage of the machine do not wind the cable around the machine.
- Damaged cables or plugs must immediately be replaced.
- Do not dispose of the machine in the household waste.
- All parts of the machine coming into contact with foodstuffs must be cleaned before use.

2.4 Machine-specific hazards

2.4.1 Hazards due to electrical energy

⚠ DANGER

Hazard when working on live parts of the machine

When performing work on the machine you can come into contact with parts which carry dangerous voltage during operation. Touching live parts can lead to death.

- ➢ Any work on electric parts of the machine must only be performed by qualified electricians or electrically instructed persons under the guidance and supervision of a qualified electrician according to the electrotechnical rules.
- ➢ The protective enclosure of the machine must only be opened by the manufacturer.
- ➢ Have any repairs of the machine performed by the manufacturer.

2.4.2 Thermal hazards

⚠ WARNING

Risk of burns due to contact with the hot plate of the machine

The hot plate of the machine heats up to approximately 150°C. Contact may cause burns of the skin.

- ➢ Never touch the hot plate with bare hands.
- ➢ Clean and maintain the hot plate only if the machine is switched off and the hot plate has cooled down.

2.5 Safety and monitoring devices

2.5.1 General information

The safety devices of the machine serve to protect the staff against hazards produced by the machine which has been built according to applicable statutory provisions and which is safe to operate. Any danger zones which cannot be excluded by constructive measures are equipped with safety devices and, if necessary, are marked with warning signs on the machine and information on work safety in the operating instructions.

The machine must only be operated if all safety devices and safety-related devices are present and functional.

⚠ DANGER

Hazard due to removal of or tampering with safety devices

Removal of or tampering with safety devices can lead to serious, irreversible or even critical injuries resulting in death, to severe damage to health or significant material damage.

- Do not remove any safety devices.
- Do not tamper with any safety devices.
- Check all existing safety devices at regular intervals.

⚠ WARNING

Risk of accidents due to missing or defective safety devices

Any unauthorized modifications of the safety devices can lead to personal injury.

- Check the safety devices for perfect function prior to operation and replace any defective safety devices.
- Do not modify any safety devices.

2.5.2 Existing safety devices

2.5.2.1 Protective enclosure



Figure 5: Protective enclosure

All parts coming into contact with foodstuffs are made of stainless steel. This prevents potential contamination of the end product to the greatest possible extent. The machine has been designed for optimal cleaning and can therefore be disassembled to be able to clean all areas.

During operation, the enclosure protects the machine operator by preventing the access to hazardous areas (such as live parts).

Shimadzu Testing Equipment

SHIMADZU
Excellence in Science

C196-E099

High Performance Liquid Chromatograph

i-Series

Specifications



Maximum Reliability and Stability

— Fundamental functions assure analysis results —

ANALYTICAL INTELLIGENCE

Advanced

i-Series

High Performance Liquid Chromatograph

Use of Multiple Detectors Expands Application Range

In addition to the UV-visible (UV/VIS) absorbance detector or photodiode array (PDA) detector included as standard, a fluorescence detector or differential refractive index detector can be added.

Excellent Baseline Stability Unaffected by Circumstances

The UV/VIS detector and the PDA detector employ dual-temperature control (TC-Optics and flow cell) and provide measurements with a stable baseline hardly affected by room temperature fluctuation.

Supports High-Speed Multi-Analyte Processing

A 14-second injection cycle maximizes the number of samples that can be processed.

Moreover, a total of 1536 samples can be accommodated in right and left sample racks.

Autosampler Enhances Data Reliability

Excellent reproducibility for injection volumes less than 1 µL, wide linearity range and ultra-low carryover (<0.0025%) improve the reliability of data, especially for analyses of precious biological samples and direct analyses of concentrated samples.

Open Access Sample Placement

A direct access mechanism on sample racks allows the user to place the sample on racks that are not involved in sample injection even during analysis.

Furthermore, racks can be shared by multiple analysts, without interrupting the analysis of samples placed by others. Overall, this function enhances work efficiency.



System Monitoring via Smart Devices

System status and chromatograms can be viewed remotely from smart devices and home computers. Situations can be checked without needing to visit the laboratory.



Window on a Smartphone



Refined Usability

Control panel with a color LCD touch panel allows anyone to operate the instrument, regardless of experience level. Easily and reliably perform routine maintenance following on-screen instructions.

Displays Chromatogram in Real Time

The chromatogram real-time monitor allows the user to immediately confirm the success or failure of data, even in a computer-less laboratory environment.

Large-Capacity Column Oven Supports Up to 90°C

The Forced-air circulation method enhances column temperature stability. Maximum operating temperature of 90°C allows high-temperature analyses such as sugar analysis. Moreover, three 300 mm long columns or six 100 mm long columns can be accommodated.

Quaternary Solvent Delivery Unit

A 10 µL micro plunger ensures accurate quaternary gradient delivery. Optional reservoir switching valve further extends the solvent selection to seven so that the solvent for the flow path rinsing can be set.

Auto Shutdown Function Reduces Power Consumption

After analysis is complete, the auto shutdown function minimizes power consumption in standby mode and can reduce power consumption by at least 95% compared to normal standby mode.

Compact Footprint

The i-Series brings together all the functions required for LC analysis in an integrated form. With its space-saving design, which is only 410 mm wide, three units can be installed on a laboratory bench compared to only two comparable instruments from other companies. The instrument footprint does not change even if another detector is installed.

Specifications

	Model	LC-2050 (UV model without sample cooler)	LC-2050C (UV model)	LC-2050C 3D (PDA model)	LC-2050C LT (detector-less model)	LC-2060C (UV model)	LC-2060C 3D (PDA model)	LC-2060C 3D MT (PDA model)
	P/N	S228-65820-58	S228-65821-58	S228-65822-58	S228-65823-58	S228-65824-58	S228-65825-58	S228-65826-58
Pump	Degassing unit	Five Lines: Mobile phase 4 + Rinse solution 1 (Volume 400 µL)						
	Pumping method	Parallel-type double plunger						
	Pulsation	≤ 0.1 MPa (1.0 mL/min,10 MPa, Water)						
	Flow rate setting range	0.0001 to 10 mL/min						
	Flow rate accuracy	≤ ±1% or ≤ ±2 µL/min, below whichever is greater (0.01 to 2 mL/min, Specified condition) ≤ ±2% (2 to 5 mL/min, Specified condition)				≤ ±1% or ≤ ±2 µL/min, below whichever is greater (0.01 to 2 mL/min,1 to 40 MPa, Specified condition) ≤ ±2% or ≤ ±2 µL/min, below whichever is greater (0.01 to 3 mL/min, 40 to 60 MPa, Specified condition)		
	Flow rate precision	< 0.06 %RSD or < 0.02 minSD, below whichever is greater						
	Configuration	Four-solvent low-pressure gradient						
	Gradient / range of set concentrations	0 to 100%, in 0.1% steps						
	Gradient / concentration accuracy	±0.5% (0.1 to 2 mL/min, 1 to 20 MPa, Specified condition)						
	Gradient / concentration precision	±0.1% (1 mL/min,10 MPa, Specified condition)						
	Maximum pressure	50 MPa (0.0001 to 5 mL/min) 22 MPa (5.0001 to 10 mL/min)				70 MPa (0.0001 to 3 mL/min) 44 MPa (3.0001 to 5 mL/min) 22 MPa (5.0001 to 10 mL/min)		
	System Delay Volume	650 µL (Option: 460 µL, 1100 µL)				460 µL (Option: 650 µL, 1100 µL)		505 µL (Flow path 1) 765 µL (Flow path 2)
Autosampler	Injection method	Total-volume sample injection						
	Injection volume accuracy	±1% (50 µL, N = 10)						
	Injection volume setting range	0.1 to 100 µL (Option: 0.1 to 50 µL, 1 to 500 µL, 1 to 2,000 µL)				0.1 to 50 µL (Option: 0.1 to 100 µL, 1 to 500 µL, 1 to 2,000 µL)		
	Injection volume reproducibility	RSD < 0.20% (5.0–2000 µL) RSD < 0.25% (2.0–4.9 µL) RSD < 0.5% (1.0–1.9 µL) RSD < 1.0% (0.5–0.9 µL)						
	Cross-contamination	0.0025% (Caffeine, Specified condition)						
	Injection cycle time	Min. 14 sec (Specified condition)						
	Samples for processing	336 (1 mL), 216 (1.5 mL), 112 (4 mL), 4 (MTP/DWP)						
	Sample cooler	Not included	4 to 45°C (Room temperature needs to be 30°C or lower and the humidity 70% or less to go down to 4°C. Room temperature needs to be 15°C or higher to go up to 45°C.)					
	Injection linearity	> 0.9999 (1 to 100 µL, Specified condition)				> 0.9999 (1 to 50 µL, Standard Sample Loop, Specified condition), > 0.9999 (1 to 100 µL, 100 µL Sample Loop (Option), Specified condition)		
Column Oven	Heating and cooling method	Forced air circulation method						
	Containable column size	6 pieces at 10 cm max., 3 pieces at 10 to 30 cm						2 pieces at 10 to 30 cm
	Temperature control range	Room temperature – 12 to 90°C, Setting range 4 to 90°C						
	Temperature control precision	±0.1°C						
	Temperature stability	±0.8°C (Specified condition)						
	Flow rate switching valve	Max. 1 pc						Not allowed

	Model	LC-2050 (UV model without sample cooler)	LC-2050C (UV model)	LC-2060C (UV model)
	P/N	S228-65820-58	S228-65821-58	S228-65824-58
UV Detector	Wavelength range	190 to 700 nm		
	Spectral bandwidth	8 nm		
	Wavelength accuracy	≤ ±1 nm		
	Wavelength reproducibility	≤ ±0.1 nm		
	Noise level	≤ ±2.5 × 10^{-4} AU, (250 nm, Specified condition)		
	Drift	≤ 100 × 10^{-4} AU/h (250 nm, Specified condition)		
	Simultaneous monitoring of 2 wavelengths	Enable (Any 2 wavelengths of 190 to 370 nm or 371 to 700 nm)		
	Linearity	Up to 2.5 AU (5%)		
	Sampling rate	Up to 100 Hz		
	Light source	Deuterium (D_2) lamp		
	Flow cell	12 µL (10 mm, TC), 12 MPa		8 µL (10 mm, TC), 12 MPa
	Option cell	High-Speed: 8 µL (10 mm, TC), Semi-micro: 2.5 µL (5mm, TC)		Conventional: 12 µL (10 mm, TC), Semi-micro: 2.5 µL (5 mm, TC)

	Model	LC-2050C 3D (PDA model)	LC-2060C 3D (PDA model)	LC-2060C 3D MT (PDA model)
	P/N	S228-65822-58	S228-65825-58	S228-65826-58
PDA Detector	Wavelength range	190 to 800 nm		
	Spectral resolution	1.4 nm (Specified condition)		
	Slit width	1.2 nm, 8 nm		
	Device resolution	0.6 nm/pixel		
	Number of photodiode array elements	1024		
	Wavelength accuracy	≤ ±1 nm		
	Noise level	≤ ±3 × 10^{-4} AU (250 nm, reference: 350 nm, Specified condition)		
	Drift	≤ 500 × 10^{-5} AU/h (250 nm, reference: 350 nm, Specified condition)		
	Linearity	Up to 2 AU (5%)		
	Sampling rate	Up to 100 Hz		
	Light source	Deuterium (D_2) lamp (Standard), tungsten (W) lamp (option)		
	Flow cell	10 µL (10mm, TC), 12 MPa	8 µL (10 mm, TC), 12 MPa	
	Option cell	High-Speed: 8 µL (10 mm, TC), Semi-micro: 2.5 µL (5 mm, TC)	Conventional: 10 µL (10 mm, TC), Semi-micro: 2.5 µL (5 mm, TC)	

	Model	LC-2050 (UV model without sample cooler)	LC-2050C (UV model)	LC-2050C 3D (PDA model)	LC-2050C LT (detector-less model)	LC-2060C (UV model)	LC-2060C 3D (PDA model)	LC-2060C 3D MT (PDA model)
	P/N	S228-65820-58	S228-65821-58	S228-65822-58	S228-65823-58	S228-65824-58	S228-65825-58	S228-65826-58
Miscellaneous	Dimensions	W410×H605×D500 mm (Not including reservoir tray height)						
	Weight	58 kg	63 kg		53 kg	63 kg		64 kg
	Available pH range	1 to 13						
	Materials for parts in contact with liquids	Stainless steel (SUS316L, SUS316), FEP, PEEK, PTFE, perfluoroelastomer, ruby, sapphire, Hastelloy® C, GFP, ceramic, PFA, quartz, PPS				Stainless steel (SUS316L, SUS316), FEP, PEEK, PTFE, perfluoroelastomer, ruby, sapphire, Hastelloy C, UHMWPE, ceramic, PFA, quartz, PPS		
	Workstation	LabSolutions™ LC/GC Ver.5.103 or later, LabSolutions DB/CS Ver.6.103 or later (Incompatible with LCsolution™)						

Optional Detector Specifications

RID-20A



	RID-20A (S228-65306-58)
Reflective index measurement range	1 to 1.75 RIU
Noise level	≤ 2.5 nRIU
Drift	≤ 0.1 μRIU/h
Range	A mode: 0.01 to 500 μRIU P and L modes: 1 to 5000 μRIU
Response	No filtering, 0.05 to 10 sec, 11 steps
Polarity switching	With a switch
Zero adjustment	Auto zero, auto optical zero, baseline shift functions
Maximum operating flow rate	20 mL/min (150 mL/min with an option)
Temperature control of cell unit	30 to 60°C (0.01°C steps)
Cell capacity	9 μL
Material in contact with liquid	SUS316L, quartz, PTFE, Al_2O_3, ETFE
Maximum operating pressure	0.4 MPa (4 kgf/cm²)
Operating temperature range	4 to 35°C
Dimensions and weight	W260 × D420 × H140 mm, 12 kg

Note: Hexafluoroisopropanol (HFIP) cannot be used as the mobile phase.

RF-20A/RF-20Axs



	RF-20A (S228-65304-58)	RF-20Axs (S228-65305-58)
Light source	Xenon lamp	Xenon lamp, low-pressure mercury lamp (To check wavelength accuracy)
Wavelength range	0, 200 to 650 nm	0, 200 to 750 nm
Spectral bandwidth	20 nm	
Wavelength accuracy	±2 nm	
Wavelength precision	±0.2 nm	
S/N	Water Raman peak S/N 1200 min. Low background S/N > 9000	Water Raman peak S/N 2000 min. Low background S/N > 12000
Cell capacity	12 μL, 2 MPa (approx. 20 kgf/cm²), SUS316L, PTFE (fluororesin), quartz	
Cell temperature control range	—	4 to 40°C, 1°C steps
Cell temperature setting range	—	(Room temperature – 10°C) to 40°C
Functions	Four-wavelength detection, wavelength scanning	
Safety measures	Liquid-leakage sensor	
Operating temperature range	4 to 35°C	
Dimensions and weight	W260 × D420 × H210 mm, 16 kg	W260 × D420 × H210 mm, 18 kg

ELSD-LT III

	ELSD-LT III (S228-65900-58)
Nebulizing Method	Siphon splitting
Light Source	Semiconductor laser
Detector	Photodiode
Temperature Setting Range	Room temperature to 100 °C
Nebulizer Gas	Air or nitrogen*
Mobile Phase Flow Rate (Standard Nebulizer)	0.2 to 2 mL/min
Operating Temperature Range	4 to 35 °C
Operating Humidity Range	20 to 85 %
Dimensions and weight	W 250 × D 530 × H 330 mm, 15.5 kg

* Supply gas at a pressure of about 350 kPa. An air compressor may also be used.
A filter (P/N S228-45528-92) is also available for filtering out moisture and other matter from the compressor.

Main Optional Accessories

Solvent Delivery Units

Part Name	P/N	Description
FCV-11AL	S228-65611-58	This is the mobile phase selection valve (3 flow lines). An FCV-11AL connection kit is required to connect to an FCV-11AL unit.
FCV-11ALS	S228-65610-58	This is the mobile phase selection valve (1 flow line). An FCV-11AL connection kit is required to connect to an FCV-11AL unit.
FCV-11AL Connection Kit	S228-56249-41	This kit includes connector cables and other items necessary for connecting FCV-11AL and FCV-11ALS units.
780 µL Mixer Kit	S228-57313-41	This parts set includes a mixer and tubing for using TFA or other UV-absorbing substance as a mobile phase.
2 mL Mixer Kit	S228-57313-42	This parts set includes a mixer and tubing for using TFA or other UV-absorbing substance as a mobile phase.
Compatible Volume System Kit	S228-57796-42	This kit decreases the system volume to 650 µL.
Low Volume System Kit	S228-57796-43	This kit decreases the system volume to 460 µL.

Autosamplers

Part Name	P/N	Description
50 µL Sample Loop	S228-56074-44	This sample loop is used for injecting 50 µL volumes. (Standard configuration parts of LC-2060)
100 µL Sample Loop	S228-56074-42	This sample loop is used for injecting 100 µL volumes. (Standard configuration parts of LC-2050)
Optional 500 µL Sample Loop	S228-45405-41	This increases the injection volume to 500 µL.
Optional 2 mL Sample Loop	S228-45405-42	This increases the injection volume to 2 mL.
UHPLC Fitting (set of 1)	S228-56867-41	Fitting for inlet to high-pressure capacity column
UHPLC Fitting (set of 10)	S228-56867-43	Fitting for inlet to high-pressure capacity column
Sample Rack	S228-55735-41	Additional sample rack
Plate for 1 mL Sample Vials (set of 2)	S228-56197-41	Plate used to place 84 1 mL sample vials
Plate For 1.5 mL Sample Vials (set of 2)	S228-50830-92	Plate used to place 54 1.5 mL sample vials
Plate for 4 mL Sample Vials (set of 2)	S228-56197-42	Plate used to place 28 4 mL sample vials
Metal plate for 1.5ml Sample Vials (set of 1)	S228-61615-42	Plate used to place 54 1.5 mL sample vials

Column Ovens

Part Name	P/N	Description
Column Clamp ASSY B5	S228-15617-91	This set of clamps is for adding a column with an outside diameter between 6.4 and 9.5 mm.
Column Clamp ASSY B8	S228-15617-92	This set of clamps is for adding a column with an outside diameter between 9.5 and 12.7 mm.
FCV-14AH	S228-65614-58	Automatic column switching valve with 6 positions and 7 ports which is usable at a pressure of 34.3 MPa max.
FCV-34AH	S228-45185-41	Automatic column switching valve with 6 positions and 7 ports which is usable at a pressure of 100 MPa max.
FCV Mounting Kit	S228-55765-42	This parts kit is used to secure an FCV-14AH/ 34AH unit inside the column oven.
CMD	S228-37281-41	This column management device is used to record information about columns.
CMD Cable	S228-39991	This cable is used to connect between the CMD and main units.

UV Detectors

Part Name	P/N	Description
Recycle Valve	S228-56808-41	This low-pressure flow-line selection valve is used to recycle mobile phase.
Flow Cell for UV Detectors	S228-56167-41	This cell is compatible with conventional analysis. (Standard configuration parts of LC-2050)
UHPLC Cell for UV Detectors	S228-45621-41	This cell is compatible with UHPLC analysis. (Standard configuration parts of LC-2060)
Semi-Micro Cell for UV Detectors	S228-45605-46	This cell is compatible with semi-micro analysis.

PDA Detectors

Part Name	P/N	Description
W Lamp ASSY for PDA Detectors	S228-57110-41	This assembly includes a tungsten lamp and its socket used for high-sensitivity analysis in the long-wavelength region.
Flow Cell for PDA Detectors	S228-42593-43	This cell is compatible with conventional analysis. (Standard configuration parts of LC-2050)
High-Speed Cell for PDA Detectors	S228-45618-54	This cell is compatible with fast analysis. (Standard configuration parts of LC-2060)
Semi-Micro Cell for PDA Detectors	S228-45605-47	This cell is compatible with semi-micro analysis.

Other Options

Part Name	P/N	Description
Earthquake Reinforcement Kit	S228-56298-41	This kit is used to reinforce how the reservoir tray is attached.
1 L Mobile Phase Bottles (set of 5)	S228-38583-42	This is a set of five one-liter reservoir bottles for holding mobile phases.
Optional Detector Attachment Kit	S228-56245-41	This kit contains a top plate and reservoir tray for installing an additional detector.
Optional Optical Board	S228-55518-41	This board is used to install additional connectors for optical link cables. It is used to install fluorescence detector RF-20A series and other detectors.
Camera ASSY for Autosampler	S228-55517-41	This camera is installed inside autosamplers. It allows you to monitor the needle action via the computer screen.
Optional AD Board	S228-55519-41	This is an analog-digital converter board. It is used to input the detector signal as an analog signal, such as when a non-Shimadzu detector is connected.
Touch Panel Protecting Sheet	S228-59212-41	Protecting sheet for touch panel.
Upgrade Kit UV	S228-58993-41	Kit for upgrade from LC-2050 (UV model with sample cooler) to LC-2060.
Upgrade Kit PDA	S228-58993-42	Kit for upgrade from LC-2050 (PDA model) to LC-2060.
Smart Automation Kit (4-mobile phase)	S228-26004-44	This kit includes FCV-14AH for up to six columns switching and other parts.
Smart Automation Kit (7-mobile phase)	S228-26004-43	This kit includes FCV-14AH for up to six columns switching, FCV-11AL for solvent delivery of seven mobile phases and other parts.

ANALYTICAL INTELLIGENCE

- Automated support functions utilizing digital technologies, such as M2M, IoT, and Artificial Intelligence (AI), that enable higher productivity and maximum reliability.
- Allows a system to monitor and diagnose itself, handle any issues during data acquisition without user input, and automatically behave as if it were operated by an expert.
- Supports the acquisition of high quality, reproducible data regardless of an operator's skill level for both routine and demanding applications.

SHIMADZU

Shimadzu Corporation
www.shimadzu.com/an/

First Edition: November 2020 3655-10021-PDF/NS

Across International Vacuum Ovens,
rotary evaporator system and wiped film evaporation system

ACROSS INTERNATIONAL
AT SERIES VACUUM DRYING OVENS
USER'S MANUAL





www.AcrossInternational.com

AI NEW JERSEY	
Main Office:	111 DORSA AVE, LIVINGSTON, NJ 07039
Shipping:	119 DORSA AVE, LIVINGSTON, NJ 07039
Phone:	888-988-0899
Service Dept:	support@acrossinternational.com

AI NEVADA	
Main Office:	600 SPICE ISLANDS DR. SPARKS, NV 89431
Shipping:	600 SPICE ISLANDS DR. SPARKS, NV 89431
Phone:	888-988-0899
Service Dept:	support@acrossinternational.com

AI AT Series Vacuum Drying Ovens User's Manual. AT-UM030 Rev. G 03.01.2022

TABLE OF CONTENTS

1. SAFETY NOTES / ILLUSTRATED SYMBOLS

Thank you for choosing our AT Series. Please read this manual carefully before operating the unit. Keep this manual on-hand so it can be used by all operators of the unit. Across International is not responsible for any injury or damage caused by misuse.

Symbol	Explanation of Symbols / Explication des Symboles
	Watch out Important note *Attention Remarque Importante*
	Protective earth connection *Connexion de terre de protection*
	Caution Hot Surface *Attention Surface Chaude*
	Caution High Voltage *Attention Haute tension*
	Danger: Situation is dangerous and may result in death or serious injury *Danger: La situation est dangereuse et peut entraîner la mort ou des blessures graves*
	Attention: Beware of rotating objects *Attention: Attention aux objets en rotation*
	Attention: Wear protective gloves and goggles to prevent personal injury *Attention: Porter des gants et des lunettes de protection pour éviter les blessures*

2. PRECAUTIONS

English

- THIS IS NOT AN EXPLOSION PROOF OVEN. THIS OVEN IS NOT SUITABLE FOR USE IN CLASS I, II, OR III LOCATIONS, AS DEFINED BY THE NATIONAL ELECTRICAL CODE NFPA 70.
- NEVER LEAVE YOUR OVEN UNATTENDED WHILE OPERATING.
- Across International is not responsible for any loss of material inside the unit.
- DO NOT try to heat combustible or explosive materials, or materials that may release corrosive/erosive gases.
- Never clean the unit with flammable cleaners. Assure that all cleaning agents are completely evaporated and dried before reconnecting the unit to the power supply.
- Keep the unit away from any electromagnetic interferences, vibrations, flammable materials, fire, or corrosive/erosive gases.
- In the event of spelled of hazardous material in the oven chamber, please decontaminate the chamber properly before using the oven. Consult the MSDS of the material used for cleaning process or call Across International.
- Avoid vibration or any corrosive/erosive gases around the oven.
- Always wear thermal gloves and protective goggles during operation.
- Always make sure your unit is on the correct power source (110V or 220V) and grounded properly. Always use the power cord that comes with the unit. Never modify the cable or power plug.

  ⚠⚠
- The unit chamber should be cleaned and disinfected prior to use. There are many commercially available disinfectants available that are non-corrosive and non-abrasive and suitable for use on stainless steel surfaces.
- Do not use the unit as a positive pressure chamber.
- Do not position the equipment so that it is difficult to operate the disconnecting device.
- Consider conditions that may affect your oven's ability to accurately control its temperatures. Such as extreme heat from radiators, stoves, other ovens, autoclaves, etc. Avoid direct sun, fast-moving air currents, heating/cooling ducts, and high traffic areas.
- To ensure proper air circulation around the oven, allow a minimum of 12 inches between the oven and any walls or partitions.
- A separate circuit for the oven is strongly recommended to prevent possible loss of product due to overloading or failure of other equipment on a shared circuit.
- If the equipment is not used in a manner specified in this manual, the protection provided by the equipment may be impaired
- Returning shipment: Save the shipping crate until you are sure your unit is consistently working properly. If for any reason you must return the unit, first contact AI for a return material authorization (RMA) number.

3. INTRODUCTION

The AT DESKTOP series (0.9 and 1.9 cu ft) digital vacuum ovens feature an easy-to-clean stainless-steel chamber with a large tempered glass safety window and small footprints. Come standard with aluminum shelves which provides excellent temperature uniformity inside the chamber. Also come standard is the adjustable gas back fill capability with needle valve and vent port.

The AT SHELF-HEAT series (3.2, 7.5 and 16 cu ft) digital vacuum ovens feature production scale chamber built with easy-to-clean stainless steel, and large observation window with heavy duty 3/4" tempered safety glass. With our unique SHELF-HEAT technology, each shelf in these ovens comes with its own heater, in-shelf temperature sensor and temperature controller, together with great thermal-conducted aluminum, the result is perfect uniformity, accurate temperature, super-fast heating rates, minimum heat loss and very low power consumption.

Features

- Dual layer observation window with tempered safety glass. Radiant wall heating (0.9 and 1.9 cu ft models) provides optimal uniformity and conserves chamber space.
- New SHELF-HEAT technology with in-shelf temperature sensors give you perfect uniformity, super-fast heating rates and very low power consumption (3.2, 7.5 & 16 cu ft models).
- Easy-to-clean, heavy duty stainless steel interior for exceptional durability and ease of maintenance.
- Force-adjustable latch and one-piece door sealing gasket maintain consistent vacuum levels.
- This product is intended for indoor use only
- Built-in alarm alerts you when oven has been shut down by safety circuitry due to out of range temperature.
- Optional sliding and stackable shelves in different materials maximize your production scale.

⚠ Every one of our vacuum ovens goes through a 2-time 24-hour vacuum leak test, and is quality controlled in New Jersey or Nevada before leaving our warehouses.

⚠ The oven interior was cleaned at the factory, but not sterilized. Clean with a disinfectant that is appropriate for your application. Before initial use, run oven at 400°F without vacuum for 15 minutes to burn off any residue that may have been introduced during the manufacturing process.

4. SPECIFICATIONS

Model		AT09	AT19	AT32	AT75a	AT160
Electrical requirements		110V, 50/60Hz 1-PH/ 220V, 50/60Hz 1-PH				
Output Power		1500 W / 1200W	1500 W	1500 W	1500 W	1500 W
Environmental Operation Conditions		▪ Indoor use and altitude up to 2000m ▪ Temperature 5-40°C ▪ Max. relative humidity 80% for temperatures up to 30°C decreasing linearly to 50 % relative humidity at 40°C ▪ Mains supply volt fluctuations up to ±10 % of the nominal voltage ▪ Transient overvoltage up to the levels of overvoltage category II (See Note 1). ▪ Temporary overvoltage occurring on the mains supply. ▪ Applicable pollution degree of the intended environment (pollution degree 2 in most cases (See Note 2). Note 1: These levels of transient overvoltage are typical for equipment supplied from the building wiring. Note 2: Manufacturers may specify more restricted environmental conditions for operation, nevertheless the equipment must be safe within these normal environmental conditions.				
Chamber	Size (WxDxH)	12 x 12 x 11"	16.5 x 14.5 x 14"	18 x 18 x 18"	22 x 23.5 x 25"	25.6 x 30 x 35.5"
	Material	Stainless steel				
	Capacity	0.9 cubic foot	1.9 cubic foot	3.2 cubic feet	7.5 cubic feet	16 cubic feet
Temperature Controller	Controller	3rd gen low proportional gain, microcomputer PID controlled with LCD display				
	Range	Ambient to 480°F (248°C)				Ambient to 200°F (100°C)
	Display units	Fahrenheit or Celsius				
	Accuracy	± 1				
	Uniformity	±5% of setpoint				
	Dwelling Time	1 to 9999 minutes				
	Warm up time to 100°F	40 minutes	45 minutes	35 minutes	45 minutes	55 minutes
Vacuum		Ultimate vacuum level: better than 500 microns/millitorrs (may vary based on your altitude) Mechanical vacuum gauge range: 0 to 30" mercury Mechanical vacuum gauge type: oil-filled Vacuum port: KF25 flange x 1 Vent port: KF25 flange x 1				
Door gasket material		Silicone or Viton (Optional)				
Observation window		1/2" tempered safety glass		3/4" tempered safety glass		
Shelves	Included with oven purchase	4 aluminum slide-in shelves	5 aluminum slide-in shelves	3 non-removable aluminum shelves	5 non-removable aluminum shelves	6 non-removable aluminum shelves
	Size (W x D)	11.5 x 11.25"	16 x 14.25"	17.5 x 17.25"	22 x 23.25"	25 x 29.25"
	Maximum area	129.4 x 8 = 7 ft²	228 x 10 = 16 ft²	302 x 3 = 6 ft²	512 x 10 = 36 ft²	731 x 12 = 60 ft²
	Capacity	25 lbs. each	30 lbs. each	20 lbs. each	20 lbs. each	
	Distance between shelves	1.0 "	1.0 "	4.0 "	4.0 "	5.0 "
Unit Weight		90 lbs.	140 lbs.	260 lbs.	410 lbs.	710 lbs.
Shipping Weight		165 lbs.	240 lbs.	405 lbs.	640 lbs.	1118 lbs.
Unit Dimensions (WxDxH)		23.4 x 20 x 19"	28 x 23 x 21.75"	30.5 x 24 x 29"	35 x 31 x 38"	33 x 37 x 52"
Shipping Dimensions (WxDxH)		28 x 24 x 26"	32 x 27 x 29"	36 x 34 x 36"	40 x 39 x 43"	42 x 45 x 61"
Safety		Built-in circuit breaker, controller overheat protection, secondary over-temp protection dial				
In-door lights		White LED (pre-installed)				
Compliance		UL (E482564), CSA, CE				

Model		AT50x	AT75X
Electrical Requirement		110/220VAC, 50/60Hz, 1-PH	220VAC, 50/60Hz, 1-PH
Output Power		3000 W	4600 W
Environmental Operation Conditions		• Indoor use and altitude up to 2000m • Temperature 5-40°C • Max. relative humidity 80% for temperatures up to 30°C decreasing linearly to 50 % relative humidity at 40°C • Mains supply volt fluctuations up to ±10 % of the nominal voltage • Transient overvoltage up to the levels of overvoltage category II (See Note 1). • Temporary overvoltage occurring on the mains supply. • Applicable pollution degree of the intended environment (pollution degree 2 in most cases (See Note 2). Note 1: These levels of transient overvoltage are typical for equipment supplied from the building wiring. Note 2: Manufacturers may specify more restricted environmental conditions for operation, nevertheless the equipment must be safe within these normal environmental conditions.	
Chamber	Size (WXDXH)	19.75 x 21.5 x19.75"	22 x 23.5 x 25 "
	Material	Stainless Steel	
	Capacity	5 Cu Ft	7.5 Cu Ft
Temperature Controller	Controller	3rd gen low proportional gain, microcomputer PID controlled with LCD	
	Range	Ambient to 480°F (248°C)	
	Display Units	F or C	
	Accuracy	± 1	
	Uniformity	±7 % of set point	
	Dwelling Time	1 to 9999 minutes	
	Warm up to 100F	45 minutes	
Vacuum		Ultimate vacuum level: better than 500 microns/millitorrs (may vary based on your altitude) Mechanical vacuum gauge range: 0 to 30" mercury Mechanical vacuum gauge type: oil-filled Vacuum port: KF25 flange x 1 Vent port: KF25 flange x 1	
Door gasket material		Silicone or Viton (Optional)	
Observation Window		½" tempered safety glass	
Shelves	Included with oven purchase	7 aluminum pan-shaped shelves	9 aluminum pan-shaped shelves
	Size (WXDXH)	19.25 X 21 X 0.5"	21. 75 X 23 X 0.5"
	Distance between shelves	1.25"	
In door light		White LED (pre-installed)	
Unit Weight		390 lbs	450
Shipping Weight		640 lbs	765
Unit Dimensions		32.25 x 28 x 30	37 x 33.5 x 38
Shipping Dimensions		40 x 39 x 43	43 x 40 x 46
Safety		Built-in circuit breaker, controller overheat protection, secondary over-temp protection dial	
Warranty		2 Years	

Ai AT Series Vacuum Drying Ovens User's Manual

Model	AT160x-UL
Electrical Requirements	220V +/-10% 50/60Hz 1-PH 27A, 6,000 watts
Chamber	Size: 25.6 x 30 x 35.5" Material: Stainless steel Capacity: 16 cubic feet
Heater	5-sided heating (left 900W, right 900W, top 900W, bottom 900W, back 250W x 4)
Temperature Control	Controller: low proportional gain, microcomputer PID controlled with LCD display Range: ambient to 250°C (480°F) Display units: Fahrenheit or Celsius Uniformity: ± 7% of setpoint Dwelling timer range: 1 to 9999 minutes Heating speed • Ambient to 100°C: 40 mins • Ambient to 150°C: 1 hour • Ambient to 200°C: 2 hours • Ambient to 250°C: 2.5 hours
Vacuum	Ultimate vacuum level: better than 500 microns/millitorrs (may vary based on your altitude) Mechanical gauge range: 0 to 30 inch mercury Vacuum port: KF25 flange Vent port: KF25 flange Vacuum pump: Sold separately
Weight	Unit: 800 Lbs, shipping: 1320 Lbs
Dimensions	Unit: 44 x 38 x 51.5" Shipping: 50 x 47 x 59"
Shelves	Shelf size: 25 x 30" (WxDxH) Material: aluminum Style: pan-shape Capacity: 26 shelves max. Comes standard with oven purchase: 13 shelves Total area with 26 shelves: 89 sq ft or 12,857 sq inch Distance between the most adjacent shelves: 1.25 inches
Door Gasket Material	Silicone or Viton
Observation window	1/2" tempered safety glass
Safety	Built-in circuit breaker Overheat shutoff protection Secondary over-temp protection dial
In-Door Lights	White LED (pre-installed)
Compliance	ETL certified to UL and CSA standards
Warranty	2 years

Ai AT Series Vacuum Drying Ovens User's Manual

Model	AT19-500C
Electrical Requirements	220V +/-10% 50/60Hz 1-PH, 3,000 watts
Chamber	Size: 16.5 x 14.5 x 14" Material: Stainless steel Capacity: 1.9 cubic foot
Heater	4-sided heating (left 750W, right 750W, top 750W, bottom 750W)
Temperature Control	Controller: low proportional gain, microcomputer PID controlled with LCD display Range: ambient to 500°C Display units: Fahrenheit or Celsius • Dwelling timer range: 1 to 9999 minutes
Vacuum	Ultimate vacuum level: better than 500 microns/millitorrs (may vary based on your altitude) Mechanical gauge range: 0 to 30 inch mercury Vacuum port: KF25 flange Vent port: KF25 flange Vacuum pump: Sold separately
Weight	Unit: 190 Lbs, shipping: 270 Lbs
Dimensions	Unit: 28 x 20 x 21.75" With handle and vacuum port: 28 x 23 x 21.75" Shipping: 32 x 28 x 29"
Shelves	Included with oven purchase: 5 stainless steel slide-in shelves Capacity: 10 shelves max. Style: pan-shape Size: 16 x 14.25 inches Total area: 228 x 10 = 16 sq ft or 2,280 inch2 Distance between shelves: one inch
Door Gasket Material	Silicone or Viton
Observation window	1/2" tempered safety glass
Safety	Built-in circuit breaker Overheat shutoff protection
Warranty	2 years

5. COMPONENTS





AT09 and AT19 Models





AT32, AT75 and AT160 Models





AT50x, AT75x and AT160x Models



AT19-500C Model



Agilent Technologies

Vacuum Products Division

IDP-3 Dry Scroll Vacuum Pump

INSTRUCTION MANUAL

Manual No. 699904350
Revision D
September 2009

IDP-3
Dry Scroll Vacuum Pump



Warranty

Products manufactured by Seller are warranted against defects in materials and workmanship for twelve (12) months from date of shipment thereof to Customer, and Seller's liability under valid warranty claims is limited, at the option of Seller, to repair, to replace, or refund of an equitable portion of the purchase price of the Product. Items expendable in normal use are not covered by this warranty. All warranty replacement or repair of parts shall be limited to equipment malfunctions which, in the sole opinion of Seller, are due or traceable to defects in original materials or workmanship. All obligations of Seller under this warranty shall cease in the event of abuse, accident, alteration, misuse, or neglect of the equipment. In-warranty repaired or replaced parts are warranted only for the remaining unexpired portion of the original warranty period applicable to the repaired or replaced parts. After expiration of the applicable warranty period, Customer shall be charged at the then current prices for parts, labor, and transportation.

Reasonable care must be used to avoid hazards. Seller expressly disclaims responsibility for loss or damage caused by use of its Products other than in accordance with proper operating procedures.

Except as stated herein, Seller makes no warranty, expressed or implied (either in fact or by operation of law), statutory or otherwise; and, except as stated herein, Seller shall have no liability under any warranty, expressed or implied (either in fact or by operation of law), statutory or otherwise. Statements made by any person, including representatives of Seller, which are inconsistent or in conflict with the terms of this warranty shall not be binding upon Seller unless reduced to writing and approved by an officer of Seller.

Warranty Replacement and Adjustment

All claims under warranty must be made promptly after occurrence of circumstances giving rise thereto, and must be received within the applicable warranty period by Seller or its authorized representative. Such claims should include the Product serial number, the date of shipment, and a full description of the circumstances giving rise to the claim. Before any Products are returned for repair and/or adjustment, written authorization from Seller or its authorized representative for the return and instructions as to how and where these Products should be returned must be obtained. Any Product returned to Seller for examination shall be prepaid via the means of transportation indicated as acceptable by Seller. Seller reserves the right to reject any warranty claim not promptly reported and any warranty claim on any item that has been altered or has been returned by non-acceptable means of transportation. When any Product is returned for examination and inspection, or for any other reason, Customer shall be responsible for all damage resulting from improper packing or handling, and for loss in transit, notwithstanding any defect or non-conformity in the Product. In all cases, Seller has the sole responsibility for determining the cause and nature of failure, and Seller's determination with regard thereto shall be final.

If it is found that Seller's Product has been returned without cause and is still serviceable, Customer will be notified and the Product returned at the Customer's expense; in addition, a charge for testing and examination may be made on Products so returned.

3/1/00

IDP-3 Dry Scroll Vacuum Pump

This page intentionally left blank.

Contents

List of Figures

IDP-3 Dry Scroll Vacuum Pump

This page intentionally left blank.

Declaration of Conformity
Konformitätserklärung
Déclaration de Conformité
Declaración de Conformidad
Verklaring de Overeenstemming
Dichiarazione di Conformità
一致性声明
適合宣言
적합성 선언

Agilent Technologies

We
Wir
Nous
Nosotros
Wij
Noi
我们
私たち
우리는

Agilent, Inc.
121 Hartwell Avenue
Lexington, MA, 02421-3133 USA

declare under our sole responsibility that the product,
erklären, in alleiniger Verantwortung, daß dieses Produkt,
déclarons sous notre seule responsabilité que le produit,
declaramos, bajo nuestra sola responsabilidad, que el producto,
verklaren onder onze verantwoordelijkheid, dat het product,
dichiariamo sotto nostra unica responsabilità, che il prodotto,
基于独立承担责任的原则，特声明
は、当社単独の責任の下、この宣言が該当する製品
당사의 책임하에

IDP-3 Dry Scroll Vacuum Pump

to which this declaration relates is in conformity with the following standard(s) or other normative documents.
auf das sich diese Erklärung bezieht, mit der/den flogenden Norm(en) oder Richtlinie(n) übereinstimmt.
auquel se réfère cette déclaration est conforme à la (auz) norme(s) ou au(x) document(s) normatif(s).
al que se refiere esta declaración es conforme a la(s) norma(s) u otro(s) documento(s) normativo(s).
waamaar deze verklaring verwijst, aan de volende norm(en) of richtlijn(en) beantwoodt.
a cui se riferisce questa dichiarazione è conforme alla/e sequente/l norma/o documento/l normativo/i.
符合以下标准或其它标准文档要求。
が、以下の規格またはその他の基準書類に適合することを宣言します。
이 선언과 관련한 제품이 다음의 표준과 기타 표준 문서를 준수한다는 것을 선언합니다.

to which this declaration relates is in conformity with the following standards:

- 89/392/EEC Safety Requirements
- EN 60204-1 Safety of Machinery
- EN 61010-1 Safety Requirements
- EN 61000-6-2 EMC Immunity
- EN 61000-6-4 EMC Emissions
- EN 61326 EMC Immunity and Emissions

John Ehmann
Operations Manager
Agilent, Inc.
Vacuum Products Division
Lexington, Massachusetts, USA
October 2006

Instructions for Use

General Information

This equipment is designed for use by professionals. The user should read this instruction manual and any other additional information supplied by Agilent before operating the equipment. Agilent will not be held responsible for any events that occur due to non-compliance with these instructions, improper use by untrained persons, non-authorized interference with the equipment, or any action contrary to that provided for by specific national standards.

The IDP-3 is a hermetic, dry scroll vacuum pump. This pump is suitable for pumping air or inert gases. The pump is not intended to pump corrosive, explosive, or particulate-forming gases.

The following paragraphs contain all the information necessary to guarantee the safety of the operator when using the equipment. Detailed information is supplied in "Technical Information" on page 3.

This manual uses the following standard safety protocol:

WARNING 

The warning messages are for attracting the attention of the operator to a particular procedure or practice which, if not followed correctly, could lead to serious injury.

CAUTION 

The caution messages are displayed before procedures, which if not followed, could cause damage to the equipment.

NOTE 

The notes contain important information taken from the text.

Storage

When transporting and storing the pump, the following environmental requirements should not be exceeded:

Temperature:	−20 °C to +60 °C (−4 °F to 140 °F)
Relative humidity:	0 to 95% (non-condensing)

Preparation for Installation

The pump is supplied in a special protective packing. If this shows signs of damage, which may have occurred during transport, contact your local sales office.

Total weight of the packing, IDP-3 pump included, is approximately 10.5 kg (23 lbs).

WARNING 

When unpacking the pump, be sure not to drop it and avoid any kind of sudden impact or shock vibration to it.

NOTE 

Normal exposure to the environment cannot damage the pump. Nevertheless, it is advisable to keep the pump inlet closed until the pump is installed in the system.

Installation

Do not install or use the pump in an environment exposed to atmospheric agents (rain, snow, ice), dust, aggressive gases, or in explosive environments or those with a high fire risk.

If placing the IDP-3 pump inside an enclosure, provide ample room to supply ambient air to both the front and rear air intakes of the pump.

During operation, the following environmental conditions must be respected:

Temperature:	+5 °C to +40 °C (41 °F to 104 °F)
Relative humidity:	0 to 95% (non-condensing)

There are four versions of the IDP-3:

- 100 VAC, 50/60 Hz
- 115 VAC, 60 Hz
- 220-230 VAC, 50/60 Hz
- 24 VDC

CAUTION

Be certain that your electrical mains power voltage corresponds to that indicated on the rear of the pump.

For the:

- AC version, connect the pump to the power supply using an IEC-320 style power cord of at least 10 A capacity.
- DC version, connect to the power supply using the power cord supplied with the pump.

CAUTION

Never disturb the two hex head bolts on either side of the pump. Disturbing these bolts will cause loss of performance and/or pump damage.

Use

In order to reach maximum vacuum, the pump must be left running for about an hour with the inlet sealed.

There are no special instructions for starting the pump; it need only be switched on using the On/Off switch.

WARNING

The pump is designed for operation with neutral or noncorrosive fluids. It is absolutely forbidden to use it with potentially explosive or inflammable substances.

There are no special instructions for stopping the pump; it need only be disconnected from the electric power source by the On/Off switch.

Maintenance

Personnel responsible for pump operation and maintenance must be well-trained and aware of the accident prevention rules.

WARNING

- *Death may result from contact with high voltages. Always take extreme care and observe the accident prevention regulations in force.*
- *When machine is powered up, be careful of moving parts and high voltages.*
- *If you have to perform maintenance on the pump after a considerable time in operation, allow it to cool as the temperature of the outer surface may be in excess of 60 °C.*
- *Always disconnect your power supply to the pump before beginning maintenance work.*

NOTE

Before returning the pump to the factory for repair, the "Health and Safety" sheet attached to this instruction manual must be completed and sent to the local sales office. A copy of the sheet must be inserted in the pump package before shipping.

If a pump is to be discarded, it must be disposed of in accordance with specific national standards.

Technical Information

Table 1 Specifications

Model	IDP-3 Dry Scroll Single Hermetic Vacuum Pump
Interface dimensions	See Figure 1 on page 4
Peak pumping speed	❑ 50 Hz: 50 L/m, 3.0 m^3/hr (1.8 cfm) ❑ 60 Hz: 60 L/m, 3.6 m^3/hr (2.1 cfm) ❑ 24 VDC: 60 L/m, 3.6 m3/ hr (2.1 cfm) at full speed setting
Media	No corrosive, explosive or particulate forming gases
Ultimate pressure	2.5×10^{-1} Torr (3.3×10^{-1} mbar)
Maximum inlet pressure	1.0 atmosphere (0 psig)
Maximum outlet pressure	6.5 psig
Inlet connection	NW16
Exhaust connection	Female 1/4" National Pipe Thread (10 mm hose barb provided)
Gas ballast	Female 1/8" National Pipe Thread (adapter provided)
Ambient operating temperature	5 °C to 45 °C (41 °F to 113 °F)
Storage temperature	–20 °C to 60 °C (–4 °F to 140 °F)
Motor rating	❑ AC: 0.16 HP (0.12 kW) ❑ DC: 0.16 HP (0.12 KW) Peak rating: 0.27 HP (0.20 KW)
Operating voltages	❑ 1 phase/ 100 VAC, 50/60 Hz ❑ 1 phase/ 115 VAC, 60 Hz ❑ 1 phase/ 220-230 VAC, 50/60 Hz ❑ 24 VDC
Run current	See Table 3 on page 10
Motor thermal protection	Automatic thermal protection
Operating speed	❑ 60 Hz: 3200 RPM, 50 Hz: 2600 RPM ❑ 24V DC: variable speed, factory setting@ 3200 RPM
Cooling system	Air-cooled
Weight	Pump only: 9.5 kg (21 lbs) Shipping weight: 10.5 kg (23 lbs)
Leak rate (with exhaust and gas ballast sealed)	$<1 \times 10^{-6}$ sccs helium
Vibration level at inlet, per ISO 10816-1	≤ 1.5 mm/sec
Noise level, per ISO 11201	≤ 55 dBA
Conformance standards	See Declaration of Conformity

IDP-3 Dry Scroll Vacuum Pump



Figure 1 Interface Drawing with Dimensions (AC Version)

4

IDP-3 Dry Scroll Vacuum Pump



Figure 2 Interface Drawing with Dimensions (DC Version)



1. Front Cowling Screws; M5 (4)
2. Front Cowling
3. Inlet (NW16)
4. Inlet Screen
5. 10 mm Hose Barb
6. Gas Ballast Port (1/8" NPT adapter provided)
7. Frame
8. Base
9. Mounting Holes; (4) for 1/4" or M6 Hardware
10. Rear Cowling
11. Rear Cowling Screws: M5 (4)
12. On/Off Switch/Power Connection (IEC-320) or power cord with free leads for DC version
13. Hour Meter (optional)

Unpacking and Inspection

1. Orient the shipping container with *This End Up* on top.
2. Open the box and carefully lift the IDP-3 and foam blocks out of the box. Remove the foam blocks.
3. Save the carton and all packing materials.
4. Inspect the pump for damage. If there is shipping damage, contact the freight carrier and your local Agilent sales office immediately.

ACROSS INTERNATIONAL
THIN FILM SERIES
USER MANUAL



www.AcrossInternational.com

Ai NEW JERSEY	
Main Office:	111 DORSA AVE, LIVINGSTON, NJ 07039
Shipping:	119 DORSA AVE, LIVINGSTON, NJ 07039
Phone:	888-988-0899
Service Dept:	support@acrossinternational.com

Ai NEVADA	
Main Office:	600 SPICE ISLANDS DR. SPARKS, NV 89431
	1197 GRET ST., SPARKS, NV 89431
Shipping:	600 SPICE ISLANDS DR. SPARKS, NV 89431
Phone:	888-988-0899
Service Dept:	support@acrossinternational.com

Ai Thin Film User Manual Rev. B 07/05/2022

TABLE OF CONTENTS

1. SAFETY NOTES / ILLUSTRATED SYMBOLS

Thank you for choosing our Thin Film Series. Please read this manual carefully before operating the unit. Keep this manual on-hand so it can be used by all operators of the unit. Across International is not responsible for any injury or damage caused by misuse.

Symbol	Explanation of Symbols / Explication des Symboles
	Watch out Important note
	Protective earth connection
	Caution Hot Surface
	Caution High Voltage
	Danger: Situation is dangerous and may result in death or serious injury
	Attention: Beware of rotating objects
	Attention: Wear protective gloves and goggles to prevent personal injury

2. PRECAUTIONS

English

- THIS IS NOT AN EXPLOSION PROOF UNIT.
- NEVER LEAVE YOUR UNIT UNATTENDED WHILE OPERATING.
- Across International is not responsible for any loss of material inside the unit.
- DO NOT try to heat combustible or explosive materials, or materials that may release corrosive/erosive gases.
- Never clean the unit with flammable cleaners. Assure that all cleaning agents are completely evaporated and dried before reconnecting the unit to the power supply.
- Keep the unit away from any electromagnetic interferences, vibrations, flammable materials, fire, or corrosive/erosive gases.
- In the event of spelled of hazardous material in the unit, please decontaminate the unit properly before using it. Consult the MSDS of the material used for cleaning process or call Across International.
- Avoid vibration or any corrosive/erosive gases around the unit.
- Always wear thermal gloves and protective goggles during operation.
- Always make sure your unit is on the correct power source (110V or 220V) and grounded properly. Always use the power cord that comes with the unit. Never modify the cable or power plug.
- ⚠⚠ Do not unplug the unit during normal operation.
- The unit should be cleaned and disinfected prior to use. There are many commercially available disinfectants available that are non-corrosive and non-abrasive and suitable for use on stainless steel and glass surfaces.
- Do not use the unit as a positive pressure chamber.
- Do not position the equipment so that it is difficult to operate the disconnecting device.
- Consider conditions that may affect your unit's ability to accurately control its temperatures. Such as extreme heat from radiators, stoves, autoclaves, etc. Avoid direct sun, fast-moving air currents, heating/cooling ducts, and high traffic areas.
- To ensure proper air circulation around the setup allow a minimum of 12 inches between the unit and any walls or partitions.
- A separate circuit for the unit is strongly recommended to prevent possible loss of product due to overloading or failure of other equipment on a shared circuit.
- If the equipment is not used in a manner specified in this manual, the protection provided by the equipment may be impaired
- Returning shipment: Save the shipping crate until you are sure your unit is consistently working properly. If for any reason you must return the unit, first contact AI for a return material authorization (RMA) number.

3. INTRODUCTION

Continuous distillation, a form of distillation, is an ongoing separation in which a mixture is continuously (without interruption) fed into the process and separated fractions are removed continuously as output streams. Distillation is the separation or partial separation of a liquid feed mixture into components or fractions by selective boiling (or evaporation) and condensation. The process produces at least two output fractions. These fractions include at least one volatile distillate fraction, which has boiled and been separately captured as a vapor condensed to a liquid, and practically always a bottoms (or residuum) fraction, which is the least volatile residue that has not been separately captured as a condensed vapor.

Ai GLASS THIN FILM DISTILLATION SYSTEM FEATURES

- High precision PTFE rollers and inner glass surface allow a complete and uniform thin film on the heated surface, and prevent process residue
- Pre-installed cooling/heating tubing with fluid direction labels and M16 ports
- Low placed feeding flask for ease of operation
- Driving motor with magnetic coupling sealing ensures high vacuum level
- Constructed with high borosilicate glass 3.3, stainless steel and Viton gaskets for ultimate corrosion resistance
- Transparent glass system allows you to see entire process in real time
- Auto delay safety circuit for diffusion pump cooling
- Heavy-duty stainless-steel frame with station-able casters for mobility and stability
- Agilent diffusion pump with oil level indicator
- Huber immersion cooler down to -100°C (no dry ice needed) first trap only
- Ai on-site installation within contiguous US included
- UL/CSA certified

Ai STAINLESS STEEL THIN FILM DISTILLATION SYSTEM FEATURES

- High precision PTFE rollers and inner stainless-steel surface allow a complete and uniform thin film on the heated surface and leave minimum process residue
- Pre-installed cooling/heating tubing with fluid direction labels and M16 ports Driving motor with magnetic coupling sealing ensures high vacuum level Constructed with stainless steel and Viton gaskets for ultimate corrosion resistance
- Auto delay safety circuit for diffusion pump cooling
- Heavy-duty stainless-steel frame with station-able casters for mobility and stability
- Newly redesigned drain port with dual sight glass for easy cleaning and maintenance.
- Ai on-site installation within contiguous US included
- UL/CSA certified

4. SPECIFICATIONS

Model	TG-6
Throughput	2L to 5L per hour (base on processes and material fed)
Main Evaporator	Evaporating area: approximately 2,500 cm^2 Material: borosilicate glass Glass jacket volume: approx. 3L Heated circulator: 3kW heater, 300°C maximum operating temperature
Main Condenser	Condensing area: approximately 4,000 cm^2 Material: borosilicate glass Style: coil, Glass jacket volume: approx. 1.5L Cooling/heated circulator: 2kW heater, -25°C to 200°C operating temperature
Wiping System	Style: roller Roller material: PTFE Driving motor: speed-adjustable with magnetic coupling Motor controller: DELTA
Cold Trap	Material: borosilicate glass with polyethylene lid Depth: 17" Quantity: one Receiving flask volume: 1L Immersion cooler: Huber -100C TC-100e
Feeding System	**Gear pump x 1** Speed: 10L/hour max. (1.2mL/turn, 135 turn/minute), adjustable Material: stainless steel body with Viton gaskets Style: jacketed, heated Flask: glass, 10L, jacketed, refillable during operation, with lid Flask jacket volume: approx. 4L Heating controller: OMRON Heated circulator: 2kW heater, 200°C maximum operating temperature Construction: jacketed, heated, insulated stainless steel tubing
Distillate Discharge	Receiving flask volume: 10L, glass Drain passage: non-heated Sealing gasket: Viton
Residue Discharge	Receiving flask volume: 10L, glass Drain passage: heated and insulated Heating: heated tape with insulation Heating controller: Omron Sealing gasket: Viton
Vacuum System	Vacuum gauge: Agilent gauge with LCD display for high vacuum application (PCG-750) Vacuum pump: Welch CVRpro 30 with oil mist filter Diffusion pump: Agilent AX-65
Sealing gasket	All food grade Viton
Electrical Control Cabinet	Wiper motor controller x 1 Gear pump controller x 1 Feeding tubing heater controller x 1 Residue discharge heater controller x 1 Main power switch x 1 Vacuum pump switch x 1 Diffusion pump switch x 1
Main Mounting Frame	Heavy duty stainless steel, mounted on four station-able casters
Main Power	230±10% VAC, 600W, 1~phase 60Hz
Unit dimensions, weight	86x25x78", 1150lbs
Shipping dimensions, weight	1 Crate: 97x31x81", 1197 lbs. 1 pallet: 40x48x42", 450 lbs.
Compliance	UL, CSA

Model	TS-6
Throughput	2L to 5L per hour (base on processes and material fed)
Main Evaporator	Evaporating area: approximately 2,500 cm^2 Material: stainless steel Fluid jacket volume: approx. 3.5L Heated circulator: 3kW heater, 300°C maximum operating temperature
Main Condenser	Condensing area: approximately 2,500 cm^2 Material: stainless steel Style: coil Glass jacket volume: approx. 1.5L Cooling/heated circulator: 2kW heater, -25°C to 200°C operating temperature
Wiping System	Style: roller Roller material: PTFE Driving motor: speed-adjustable with magnetic coupling Motor controller: DELTA
Cold Trap	Material: stainless steel Depth: 16" Quantity: two Immersion cooler: PolyScience -80°C IP80 x 1 Receiving flask volume: 1L
Feeding System	**Gear pump x 1** Speed: 20L/hour max. (2.4 mL/turn, 135 turn/minute), adjustable Material: stainless steel body with Viton gaskets Style: jacketed, heated Flask: glass, 10L, jacketed, refillable during operation, with lid Flask jacket volume: approx. 4L Heating controller: OMRON Heated circulator: 2kW heater, 200°C maximum operating temperature Construction: jacketed, heated, insulated stainless steel tubing
Distillate Discharge	**Gear pump x 1** Speed: 10L/hour max. (1.2 mL/turn, 135 turn/minute), adjustable Material: stainless steel body with Viton gaskets Style: jacketed, heated Sight glass: front glass sight with easy-remove clamp Heated circulator: 2kW heater, 200°C maximum operating temperature Construction: heated, insulated stainless steel tubing
Residue Discharge	316L Stainless Steel Receiving Flask with Ball Valve and Sight Glass
Vacuum System	Vacuum gauge: Agilent gauge with LCD display for high vacuum application Vacuum pump: Welch CVRpro 30 with oil mist filter Diffusion pump: Agilent AX-65
Sealing gasket	All food grade Viton
Electrical Control Cabinet	Wiper motor controller x 1 Gear pump controller x 3 Distillate discharge tubing heater controller x 1 Residue discharge tubing heater controller x 1 Main power switch x 1 Vacuum pump switch x 1 Diffusion pump switch x 1
Main Mounting Frame	Heavy duty stainless steel, mounted on four station-able casters
Main Power	230±10% VAC, 600W, 1~phase 60Hz
Unit dimensions & weight	94 x 25 x 81" (WxDxH) , 1270 lbs
Shipping dimensions & weight	1 Crate : 92 x 30 x 91" (WxDxH) ,1341 Lbs 1 Pallet : 40 x 48 x 60" ,600 lbs
Compliance	UL, CSA

5. COMPONENTS



TG-6


6" stainless steel evaporator and condenser
Overhead motor
Immersion cooler
Jacketed feed tube
Jacketed feed flask
Distillate discharge heater
Residue discharge heater
Overhead motor
Material feed gear pump
Distillate gear pump
Residue gear pump
Vacuum pump
Main power
Diffusion pump
Vacuum valve
Vacuum gauge
Heater for material feeding system
Material feed gear pump
Evaporator heater
Manifold with two on/off valves
Dual-jacketed SST cold traps
Diffusion pump
Drain port sight glass
Vacuum pump
Heavy duty stainless steel frame
Lockable casters
Center cooling column circulator
Heater for discharge pumps
Distillate drain gear pump
Receiving Flask
Jacketed residue drain port
Jacketed distillate drain port

TS-6

9

6. INSTALLATION

⚠ Unit must be installed 2 feet away from the wall for easy access of main power switch.

CAUTION!

- Never fill circulated heaters or chillers with water; always use Ai recommended fluid.
- Always leave ample fluid space in heater reservoir to allow fluid heat expansion.
- Always keep system vacuum passage or drain valve open when heating up circulation jackets.
- Always make sure your vacuum pumps and diffusion pump fluid are clean and within limits.

6.1 Installation/Setup

Make sure the unit is secured and the wheels are locked before proceeding.
Check the alignment of every item and make sure nothing has shifted during transit.

- Check the alignment of the glass vessel.



- Check support rods.
- Check the tightness of every bolt and retighten if necessary.

6.1.1 Control Panel Installation

- Make sure the top screws are screwed in about half to three quarters of the way.
- Hang the control panel on the top two screws using the indents in the upper right and left corners

- With a long 5 mm Allen Key, screw in the bottom right and left screws.

- Tighten the top right and left panels to fully secure the control panel (shown in bullet point 2 of section 6.1.1)

6.1.1 Accessories Installation:

- Install the electrical panel of the left side using four bolts (assuming you are facing the unit)
- Connect the thermocouples, heaters, stirring motor and gear pumps aviation plugs into their appropriate connectors.
- Connect the ethernet cable
- Install the two receiving flasks to the bottom of the cold traps using the metal clamps.





- Install the insulated hoses to the distillate and residue discharge ports on the outfeed gear pumps using KF16 clamps and o-ring (TS-6 ONLY)



- Install the steering motor on top of the evaporator body and secure it using four bolts and connect the stirring motor wires as below.



6.1.2 Ancillary Equipment installation:

- Place the chiller/heaters & immersion cooler in their appropriate places.
  - Place KISS 205B on the top shelf – vessel jacket heater
  - TS-6 ONLY – Place the second KISS 205B on the bottom – discharge gear pumps
  - Place CC-308B on the middle shelf – evaporator heater
  - Place KISS K6 on the bottom shelf – condenser chiller
  - Place TC100e on the top left shelf and place the rigid coil prob in the first cold trap.
  - Place vacuum pump underneath the TC100e and plug in the vacuum pump power cord to the back of the electrical panel.



6.1.3 Hoses Connection:

The hoses on the system are labeled with inlet and outlet arrows.

Make sure the inlet and outlet lines are connected properly. TCU outlet connects to system's inlet and via versa.

Connect the hoses as below diagrams.

TS-6:

- Vessel jacket - inlet is vessel's bottom port; outlet is feed tube outlet – KISS 205B
- Evaporator heater- inlet is evaporator's bottom port; outlet is evaporator's top port– CC-308B
- Condenser – inlet is evaporator's right-side port; outlet is evaporator's bottom port – KISS K6

TG-6:

- Vessel jacket - inlet is vessel's bottom port; outlet is feed tube outlet – KISS 205B
- Evaporator heater- inlet is evaporator's bottom port; outlet is evaporator's top port– CC-308B
- Condenser – inlet is evaporator's right-side port; outlet is evaporator's left side port – KISS K6
- Distillate gear pump and thin film separator—inlet is separator's right port; outlet is outlet of



- Make sure the glass connections are secured and in 180-degree angle.



Baker Perkins Gelatin System

Baker Perkins
schenck process group

Feasibility Proposal for Coosa Medical Manufacturing

Depositor - ServoForm Mini

Document Ref: P22-123379r0 / December 12, 2022

www.bakerperkins.com/confectionery

lifetime support

Company Overview and Services Available

Baker Perkins was originally established in the eighteen hundreds and has operated as an established business in North America since the 1920's. The company traded under the names of Werner Lehara, APV Baker and in 2006 re-established itself under the Baker Perkins brand. In 2020, Baker Perkins was acquired by Schenck Process Group, where together we broaden our solution and distribution into food end-markets.

Baker Perkins Inc. is located in Grand Rapids, Michigan where our team specializes in a wide range of capabilities including:

- Mechanical Engineering Design
- Electrical and Controls Engineering
- Thermal Engineering
- Field Service
- Engineering Procurement
- Project Management
- Die Design, Manufacture, Coating and Supply
- 3D Printing
- New Product Development and Testing in our Innovation Center
- Shipping and Receiving

Lifetime Support

Baker Perkins can tailor the below service and support to meet your specific requirements. Baker Perkins Lifetime Support provides the following range of services:

- A 24 hour call center
- A dedicated parts and service team
- Site service support (scheduled and emergency)
- Bonded and Consignment stocks
- Online parts service



Plant and Process Enhancements

- Equipment upgrades and refurbishment
- Enhanced energy efficiency
- Process engineering
- Enhanced control systems
- Appraisal and customer training

Parts and Services Support with Full Spare Parts Inventory

Through its facilities in Grand Rapids and with support from our UK operations, Baker Perkins can provide:

- Maintenance and management of the entire process related to the design and supply of equipment, services, parts and dies
- Maintenance of records for over 10 million components
- Manufacturing, design and process capabilities allowing us to not only support Baker Perkins (Werner Lehara and APV Baker) equipment, but other OEM machines as well



Innovation and Process Development

- US and UK Innovation Centers offering a wide range of technologies and expertise for the development of recipes and process parameters
- Combined Baker Perkins internal expertise with tested and proven supply partners
- Adapting and implementing technologies from other markets to Baker Perkins equipment designs and applications to deliver advanced solutions to the markets we serve

Supply Chain

- Baker Perkins Inc. has a flexible supply chain model with the ability to source equipment and services internally either from our sister companies 120,000ft² manufacturing facility in the UK and/ or from a long established network of supply partners in North America.
- Quality standards are established by Baker Perkins in-house Manufacturing and Engineering staff and factory quality stage gates are systematically employed where products are outsourced.
- Baker Perkins Project Engineers and Managers monitor and confirm that Baker Perkins quality standards are being achieved during the production cycle whether manufactured in-house or with our partner companies. Standard and custom checklists are utilized for every Baker Perkins product produced. A final inspection is performed by the Engineer, Engineering Manager and, Project Manager to insure specifications have been achieved related to performance, quality and safety.

United States Facility

United Kingdom Facilities



Table of Contents

Contact Information

Your Baker Perkins contacts are:	Feasibility Proposal Prepared For:
Evan Falk *Account Manager* Phone: 616 780 2060 Email: evan.falk@bakerperkins.com	**Kevin Cox** *For Coosa Medical Manufacturing* Phone: 276 592 9033 Email: coxkw@prontomail.com
Marguerite (Maggie) DeShane *Sales Support Coordinator* Phone: 616 785 7537 Email: maggie.deshane@bakerperkins.com	

Equipment Introduction

This feasibility proposal covers the supply of a ServoForm Mini Depositor which is capable of producing high quality deposited sweets.

The scope of supply starts with the client's feed of cooked, colored and flavored candy syrup to the depositor hopper and ends at the discharge of the depositor with deposited candy syrup ready for forming.

The following are excluded:

- Mixing, dissolving, cooking of confectionary syrups, and incorporation of additives
- Moulds (supplied by customer OR ordered separately)
- Mould loading and unloading (this is a manual operation)
- Power cable and plug

The equipment has been specified to Baker Perkins mechanical and electrical standards.

The sweets products that can be produced with this specification are:

Single Component Sweets

Solid Hard Candy



Solid Jellies

Photographs and illustrations are typical examples only of the type of products that could be produced

Equipment Descriptions

Item 1.0 - One (1) Single Pump Bar ServoForm Mini Depositor

- Single row depositor
- Configured for solid only products
- 11 across depositing nozzles
- Local control panel with HMI Interface
- E-Won remote PLC access for troubleshooting

The Baker Perkins ServoForm Mini Depositor is designed to form confectionery pieces from cooked syrup containing colors, flavors and other ingredients on an automatic and continuous basis. The feeding of empty moulds and transfer of the filled moulds to the clients cooling area is a manual process.

The moulds and/or Baker Perkins Carrier Trays are manually placed on to fixed guides feeding a chain circuit, which automatically indexes them through the machine and synchronizes them to the depositing action.

A single depositing head is mounted over the moulds circuit with an encoder to maintain registration with the mould cavities during the deposit strokes. The depositing mechanism consists of a series of volumetric pumps operating submerged in a hopper of cooked syrup.

In operation, the depositor hopper should be topped up with freshly cooked syrup, ideally continuously or at short intervals to maintain as constant a hopper level as possible.

After the syrup has been deposited into the moulds they are carried through to the discharge end of the unit, where they need to be manually lifted off and placed on a table, or into Baker Perkins Mould Stacking Unit, or onto a cooling conveyor. Should a full mould not be removed from the depositor in a timely manner the unit will automatically stop.

The mould loading/unloading is a manual operation and should only be carried out by trained operators. It is important that the working instructions are read and operation process is strictly followed to ensure a safe working environment.

After the moulds have been allowed to cool so that the product has set firmly, and the product is demoulded, the moulds/carrier trays are returned to the infeed end of the depositor for re-use.

To obtain the most accurate piece weights the depositor should be kept supplied with moulds and running continuously during the planned production run. At the end of the run the depositor hopper can be filled with hot water and flushed through to a drain bucket below the mould conveyor.

Remote PLC Access
An 'eWon' unit fitted in the control panel to allow remote PLC access via a VPN connection for Baker Perkins to run diagnostics for troubleshooting if and when the client allows; the connection is not permanent. Network addressing information will be needed so the e-Won can be pre-configured before shipment.

ServoForm Mini Depositor Specification

Piston Stroke
- Electronic servo drive arrangement

Controls
- 10.4" HMI touchscreen with full graphical interface of the machine settings
- Recipe selection for quick configuration changes
- On the run dynamic speed, position and weight changes
- Variable mould configuration and selection
- Quick start, stop and pause buttons
- Independent closed loop control electric hopper and manifold heating
- Laser sensor for detecting mould position, allowing for random mould placement
- Maintenance/setup features from the HMI limiting the need for a laptop

Product and Mould Type

- Moulds supplied by customer or ordered through Baker Perkins (type, configuration and quantities to be determined)
    - Moulds that are supplied by customer will need to fit specific ServoForm Mini hopper design (11 across depositing nozzles requires an 11 across mould cavity configuration)

Mould Type Diagrams

Typically used with hard candy



Metal mould with pin eject

Typically used with pectin gummy



Metal mould with air eject

Typically used with gelatin gummy



Silicone mould with flexible cavity for ejection

Bridge and Hopper Arrangement
One hopper is required to produce solid products.

Hopper	Product
A	Solid

One manifold assemblies are specified:

Manifold	Product
1	Solid

Hopper Temperature Control

- Electric heating with insulated jackets



Single Bar Pump ServoForm Mini

Mould Conveyor

- Indexing conveyor system, manual mould feed and removal
- Limit switch to safeguard against moulds being pushed past the collection station

Main Frames

- Stainless steel side frames with integrated scrap tray

Item 2.0 - One (1) Set of Carrier Trays (10 trays)

A set of ten carrier trays to allow the use of silicone moulds. Silicone moulds are placed on the carrier trays which indexes them through the ServoForm Mini, synchronizing them with the deposit stroke.

Item 3.0 – One (1) Baker Perkins Two (2) Day Training Package

Baker Perkins will provide two (2) days of training in the proper installation, commissioning and operation of the equipment, in our Innovation Center in Grand Rapids, MI or in a virtual format or on-site at customer facility. This training will cover:

Installation:
- Unloading
- Main power connection

Commissioning:
- Checking proper functionality of all systems

Operation: demonstration of the ServoForm Mini Depositor including:
- Initial set-up
- Start-up
- Operator running adjustments
- Shut-down
- Cleaning
- Hopper removal and replacement

Maintenance:
- Safety precautions
- Operator controls
- General maintenance & lubrication
- Bills of material

Remote PLC Access
- Use of the 'e-Won' VPN unit for remote access for ServoForm Mini

Operating Parameters

Unless otherwise stated the equipment specification and prices in this document are based on the following standard operating parameters. Any deviation from these parameters may incur an additional charge.
Buyer to please confirm all details below.

Parameter	Value
Voltage	480 V ± 10%
Frequency	60 Hz ± 2%
Phases	3
Neutral	Yes
Earthing / Grounding	Yes
Control Voltage	24 VDC
Maximum ambient temperature *(35 °C)*	40 °C (104 °F)
Minimum ambient temperature *(5 °C)*	5 °C (41 °F)
Installation altitude *(1000 m / 3280 ft)*	1000 m (3280 ft)
Dust free area	Yes
Moisture free area	Yes
Explosive or flammable atmosphere	No
Maximum Relative Humidity *(50% at 40 °C / 90% at 20 °C)*	50% at 40 °C (104 °F) 90% at 20 °C (68 °F)
Maximum short circuit current interrupting capacity	10 kA
Panel cooling	Fan/Filter
Condensation	None
Supply Incomer Fusing	By Client

Explosive Atmospheres:
It is the customer's responsibility to define the probability of the existence of an explosive dust atmosphere in each area of the plant where unit machines are to be installed.

The equipment in this document is specified on the basis of it being sited in an unclassified area and therefore assumed not to be suitable for use in a potentially explosive atmosphere. Should the customer determine that the area of the plant where the unit machines are to be installed is anything other than unclassified then a revised feasibility proposal should be requested.

Seismic Design Category
It is the customer's responsibility to confirm if the equipment is to be installed in a Seismic designated location. Should this be the case then dependent upon the category the equipment specification, pricing and delivery may be subject to change.

Baker Perkins Standard Electrical Design Basis

Unless otherwise stated or an alternative is required for technical reasons, equipment supplied by Baker Perkins will have a control system designed to function using components as set out below.

Ref.	Item	Baker Perkins Standard	Agreed Variations To Standard
1	**Degree Of Protection**		
1.1	Control Panels	IP54 (NEMA12)	
1.2	Machine electrical components	IP54 (NEMA12)	
2	**Language**		
2.1	Fascias	Baker Perkins symbols	
2.2	Drawings	English	
2.3	Software documentation	English	
2.4	Instruction manuals	English on USB Stick or FTP Download	
2.5	HMI Language	English	
2.6	Bought out items: leaflets & manuals	English	
3	**Standards**		
3.1	Safety	BS EN ISO 12100-2010, PD 5304	
3.2	Wiring / Construction	BS EN 60204-1	
3.3	Electrical Drawings	IEC symbols, AutoCAD14 .dwg format	
4	**Materials**		
4.1	Enclosure	Mild Steel RAL7035/Stainless Steel 304 (See panel spec.)	
4.2	Panel Fascias	Aluminium Engraved / Perspex etched & rear sprayed	
4.3	Machine Trunking	Stainless Steel 304	
4.4	Machine flexible conduit	Kopex PVC	
4.5	Machine Solid Conduit	Stainless Steel 304	
5	**Variable Speed Drives**		
5.1	AC inverters	Rockwell	
5.2	Servo Drives	Rockwell	
6	**Motors**		
6.1	Manufacture - standard motors	IEC Metric	
6.2	Manufacture - geared motors	SEW / Lenze	
6.3	Dimensions	IEC metric	
6.4	Local isolators	Not Included	
7	**Control Gear**		
7.1	Relays	Rockwell 700	
7.2	Plug-in Relays	Omron	
7.3	Contactors	Rockwell 100	
7.4	Pushbuttons & Pilot Lights	Rockwell 800F	
7.5	Rotary switches	Rockwell 800F, Kraus & Naimer	
7.6	Temperature Controllers	Eurotherm	
7.7	Terminals	Rockwell 1492	
7.8	Isolators (disconnects)	Rockwell 194	
7.9	Overloads	Rockwell 193	
7.10	Solid state relays	Crydom	
7.11	Panel Meters	Eurotherm	
7.12	DC power supplies	Rockwell 1606	
7.13	Safety relays	Rockwell Guardmaster	

Ref.	Item	Baker Perkins Standard	Agreed Variations To Standard
8	**Components**		
8.1	Limit Switches	Rockwell	
8.2	Safety switches	Rockwell	
8.3	Proximity Switches	Pepperl & Fuchs	
8.4	Non rotation sensors	Telemecanique	
8.5	Photoelectrics	Sick	
8.6	Plugs and Sockets	Harting	
9	**Overcurrent Protection**		
9.1	MCB's	Rockwell 1492, 140M	
9.2	Fuses	Mersen	
10	**Cables**		
10.1	Entry	Top	
10.2	Single core cables	Min size 1 sq mm	
10.3	AC Power color	Black	
10.4	DC Power color	Black	
10.5	Power neutral color	Blue	
10.6	Earth (ground) color	Green / Yellow	
10.7	AC control color	Red_Red	
10.8	DC Control color	Blue_Blue	
10.9	Non-isolated interlocks color	Orange	
10.10	Type	Tri-rated, 105 deg C, BS623, UL1015, CSA TEW	
10.11	Multicore & screened	Black with numbered cores	
11	**PLC's**		
11.1	PLC	Rockwell	
11.2	HMI's	Rockwell	
11.3	SCADA		

Summary Information

Seller	Baker Perkins Inc.
Buyer **Account: 501455**	Coosa Medical Manufacturing 3841 Village Center Drive Hoover AL 35226 United States
Project Name	**Depositor - ServoForm Mini**
Date Ready for Dispatch	20-22 working weeks from order, receipt of deposit, and confirmation of all technical and commercial details, whichever is the latest, subject to confirmation at time of order. *No Party shall be liable for any delay in delivery of equipment or services that is caused by a Force Majeure Event, including COVID-19 related delays.*
Incoterm	Price stated is CPT – Carriage Paid To Customer's Facility
Terms of Payment	• 30% of purchase price with order – Due at order • 30% of purchase price due 60 days after order date • Balance of purchase price plus freight due prior to shipment, or within 30 days from notification that goods are ready for dispatch. If delayed through no fault of Baker Perkins whichever occurs first o Freight, packing & handling costs to be re-billed to customer at cost plus 10% with balance payment • If payments are not received according to the terms of payment, Baker Perkins reserves the right to apply the following options under Baker Perkins sole discretion: (1) The order may be considered cancelled, any monies received by Baker Perkins will not be refunded, plus any additional costs incurred beyond the value of the original payment(s), will be due within (30) days of notification. Or (2) The order may be placed on hold for a period; agreeable to Baker Perkins, but "hold" end "restart" costs as well as any other associated costs will be due within (30) days of notification.
Import Licence and Duties	Buyer's responsibility
Invoicing	To Buyer at above address
Shipping Instructions & Case Markings	To be agreed
Layout Drawing Number	To be confirmed
Control Side	To be confirmed
Language	Working Instructions: English, 1 set on USB only Instruction Plates: English & Symbols
Design Standards	Conforms to Baker Perkins Inc. Electrical / Mechanical Design Standards as set out in this document. Any amendments or variations thereto (if any) are set out in the Equipment Description Section and detailed as agreed variations.
Contact Materials	Food contact materials in Baker Perkins equipment are designed and selected in accordance with European regulation 1935/2004 covering materials intended to come into contact with food. If an alternative regulatory body certification is required Baker Perkins must be advised prior to order placement as additional charges may apply.
UL Requirements	UL rated electrical panel components will be used where possible. Unless otherwise stated within this document. UL compliance or certification is not included. If required a further feasibility proposal will be required.
Installation:	Not included

Commissioning:	Not included
Training:	See Item 3.0 – Provided through Baker Perkins Field Service Group
Paint Color (If Applicable)	Unless otherwise stated in this document, Baker Perkins Inc. standards are: – On-Machine Painting: RAL 7039 Quartz Grey Semi Matte Finish – Main Electrical Enclosures: RAL 7035 or Stainless Steel – On-Machine Electrical Enclosures: Stainless steel Non-standard paint colors will be subject to additional charge. Standard components such as motors and valves will be in the suppliers' own colors.
Special Notes	This feasibility proposal is subject to Baker Perkins Inc. General Terms and Conditions of Sale. **Please review operating parameters section and inform us of any amendments required.**

Emerald Scientific Grinder and Miscellaneous Items

FRITSCH

Cutting Mills



IDEAL FOR

CUTTING MILLS

Now available with variable rotational speed


FRITSCH Milling and Sizing


QUALITY
MADE IN GERMANY
FRITSCH. ONE STEP AHEAD.

FRITSCH Cutting Mills – fast, safe, simple

FRITSCH Advantage: Durability
Rotor knives and fixed knives are exchangeable in all FRITSCH Cutting Mills – your decision for long-lasting quality.



Optimal for material type
Rotor speed
Max. feed size (depending on the material and funnel)
Max. throughput (depending on the material and sieve size)
Sieve cassettes/sieve inserts (other sieve sizes available)
Rotor peripheral speed
Drive
Torque*

* depending on voltage and frequency

Overview of the FRITSCH Cutting Mill range





Universal Cutting Mill PULVERISETTE 19 with variable rotational speed for optimal cutting speed adjustment to your sample material		Cutting Mill PULVERISETTE 15	Power Cutting Mill PULVERISETTE 25
Fast effective comminution	**Powerful gentle comminution**	**For all common applications**	**Powerful pre-crushing even for larger samples**
Medium-hard, soft, brittle, tough, fibrous	Hard, tough-elastic, temperature-sensitive	Medium-hard, soft, fibrous	Medium-hard, soft, brittle, tough, fibrous
300–3000 rpm	50–700 rpm	2800/3400 rpm*	300/360 rpm*
70 x 80 mm	70 x 80 mm	70 x 70 mm	120 x 85 mm
60 l/h	60 l/h	50 l/h	85 l/h
0.2–6 mm	0.2–6 mm	0.25–20 mm	1–10 mm
1.57–15.7 m/s	0.26–3.66 m/s	14.92/17.9 m/s*	1.57/1.88 m/s*
Up to 5 kW three-phase motor with frequency converter and flywheel mass for stabilising the drive torque	Up to 2.8 kW three-phase motor with frequency converter and flywheel mass for stabilising the drive torque	Up to 2.1 kW three-phase motor or single-phase motor	Up to 2.6 kW three-phase motor
Up to 30 Nm	Up to 67 Nm	Up to 5.5 Nm	Up to 67 Nm

The sample material is comminuted according to the cutting principle of scissors between the cutting edges of the rotor and the fixed knives in the grinding chamber until the desired final fineness is achieved.

Patented ideas for better results

Our Cutting Mills come with a whole range of patented FRITSCH ideas – each one inspired by the work of our customers, developed according to our long-standing experience and optimised for practical applications. They make daily use easy and efficient and offer advantages which distinguish FRITSCH Cutting Mills from others.



PATENTED DESIGN

PATENTED DOUBLE FUNCTION BEARING OF THE ROTOR

PATENTED SIEVE CASSETTE

PATENTED COMBINATION

Especially convenient: A single plunger for filling in long solids and bulk solids – simply select the wide or the narrow end, depending on the material.



Clean Design for unmatched ease of cleaning

Available only from FRITSCH: For residue-free cleaning all grinding parts of our Cutting Mills can be removed within seconds without tools – unbeatable fast, simple and efficient. A clear advantage especially for the comminution of fibrous or tough materials, plastics or heterogeneous mixtures of materials, as well as for sample preparation for RoHS analyses.



FRITSCH Advantage

Wear-free labyrinth seals made of stainless steel on both sides of the rotor – on the shaft and in the lid

The labyrinth seals made of stainless steel are wear-free, offer effective contamination protection and no additional heat effect for your samples. They can be removed for fast, residue-free cleaning.



PULVERISETTE 19

Two models with variable rotational speed

YOUR ADVANTAGES

- Rotor speed 300–3000 rpm and 50–700 rpm, variable adjustable
- Max. feed size 70 x 80 mm, sieve cassettes 0.2–6 mm
- Collecting vessels 0.25 litres to 60 litres
- Optimised Clean Design for maximum ease of cleaning
- Practical operation directly on the front panel
- Maintenance-free 5 kW/2.8 kW three-phase motor with frequency converter
- Externally adjustable cutting gap
- Double cone bearing of the rotor for long service life
- 2-year guarantee



VARIABLE ROTATIONAL SPEED
for optimal adjustment of the cutting speed to your sample material.

FRITSCH-Advantage
Optimised Clean Design
We further optimised the Clean Design for both models of the FRITSCH Cutting Mill PULVERISETTE 19. The load-bearing head now consists completely of corrosion-resistant steel, and the seals of the grinding chamber were completely redesigned for improved protection against contamination.



PULVERISETTE 19

The perfect match for your application



Completely in stainless steel
Universal Cutting Mill PULVERISETTE 19 with funnel for long and bulk solids and 3 litre collecting vessel made of corrosion-resistant stainless steel 316L



TECHNICAL DATA

	Fast effective comminution	Powerful gentle comminution
Variable rotor speed	300–3000 rpm	50–700 rpm
Electrical details (three-phase motor with frequency converter and flywheel mass* for stabilising the drive torque)	for 380-460 V/3~, 50-60 Hz, 5000 watt*, 30 Nm for 200-240 V/1~, 50-60 Hz, 2350 watt*, 10 Nm for 100-120 V/1~, 50-60 Hz, 1725 watt*, 8 Nm	for 380-460 V/3~, 50-60 Hz, 2800 watt, 67 Nm for 200-240 V/1~, 50-60 Hz, 2350 watt*, 26 Nm for 100-120 V/1~, 50-60 Hz, 1725 watt*, 24 Nm
Weight		
Net	79 kg	83 kg
Gross	109 kg	113 kg
Dimensions w x d x h Table-mounting or on stand	44 x 79 x 56 cm	44 x 79 x 56 cm
Packaging w x d x h Wooden case	70 x 85 x 85 cm	70 x 85 x 85 cm
Emission sound pressure level at the workplace according to DIN EN ISO 3746 (depending on material to be ground, rotor and sieve cassette used!)	L_{pAd} = 78 dB	L_{pAd} = 75 dB
Order no. (order numbers for the stainless steel version 316L – see p. 22)	**380-460 V/3~** 19.3060.00 **200-240 V/1~** 19.3020.00 **100-120 V/1~** 19.3030.00	**380-460 V/3~** 19.3040.00 **200-240 V/1~** 19.3000.00 **100-120 V/1~** 19.3010.00



Universal Cutting Mill PULVERISETTE 19 with protected funnel and 10 litre collecting vessel on the space-saving FRITSCH universal support stand



Stable operation: rotor with double cone bearing on the shaft and in the lid



Different rotors for multi-functional use, e.g. disk milling cutter rotor

IDEAL FOR COMMINUTION OF

Plastics and textiles	Plastics, rubber, foils, leather, fabric, fibres
Agriculture and forestry	Wood, leaves, roots, animal feed, grain, corn, peat, tobacco, straw – can be fed in at full length
Environment	Paper, cardboard, derived fuels, metal-free waste, household waste, composites
Cannabis	Plant material, stalks, flowers, sample preparation for SFE processes and cannabinoids, oil extraction
RoHS	Mobile phone LCD glass, mobile phone keypads, electronic chips, circuit boards (assembled and disassembled)
Analytic	Coal, bones, horn, dragées, tablets, cork, drugs
Construction materials	Derived fuels
Chemistry	Heterogeneous mixtures of materials
Foodstuffs	Maize, malt, pasta, herbs, spices, dried meat

With a feed size (depending on the material) of up to 70 x 80 mm and a throughput of up to 60 l/h

EQUIPMENT

Instruments without funnel, cutting tool set (consisting of rotor and fixed knives), sieve cassette, collecting vessel and stand

- Required accessories

Funnel for long and bulk solids made of plastic or stainless steel 316L or protected funnel made of stainless steel with plastic sample pusher
Rotor with V-cutting edges and fixed knives made of hardened stainless steel, hardmetal tungsten carbide, or chromium-free tool steel, or
Rotor with straight cutting edges and fixed knives made of hardened stainless steel or chromium-free tool steel, or
Disk milling cutter rotor with indexable inserts and fixed knives made of hardmetal tungsten carbide
Sieve cassettes with trapezoidal or square perforation made of stainless steel 316L or chromium-free steel DC01
Collecting vessel 3 litres or collecting vessel for large quantities 10 litres

- Optional accessories

Universal support stand, stand with wheels or stand made of stainless steel 316L
Sample extraction with Cyclone separator
IQ/OQ documentation to support equipment qualification

Optimal sample exhaustion: FRITSCH Cyclone separators

FRITSCH Cyclone separators require an exhaust system which can be ordered along.

Clean, convenient, cool: Combine your FRITSCH Universal Cutting Mills PULVERISETTE 19 with a FRITSCH Cyclone separator for sample exhaustion. Its strong airflow ensures simple feeding, increases throughput, and reduces the thermal load of the samples.

At the same time, the powerful airflow of the FRITSCH Cyclone separators enables the use of finer sieve cassettes to achieve a higher final fineness – even for materials, which are otherwise difficult to comminute finely.
The result: especially fast and efficient comminution with minimised thermal load and significantly higher throughput – in addition to quick and easy cleaning.

FRITSCH high-performance Cyclone separator
made of stainless steel 304 with a 1 litre sample glass



Simple connection
to the PULVERISETTE 19

Connect
exhaust system



FRITSCH high-performance Cyclone separator

The FRITSCH high-performance Cyclone separator completely made of stainless steel 304 is particularly indispensable in the analytical sector and in the food and pharmaceutical industries, and for the processing of heterogeneous mixtures of material, e.g. in the cement industry. Due to its high surface quality, it offers enhanced resistance to corrosive media such as alkalis and acids and is especially easy to clean with a wide range of possible cleaning agents, without leaving any residues. In addition, it can be completely dismantled, fully emptied, flooded and sterilised, and thus offers reliable protection against cross-contamination. The FRITSCH high-performance Cyclone separator is available with both: flexible or solid piping made of stainless steel 304 and special seals. The high-performance Cyclone separator with solid piping should be used in combination with the stand with wheels. Choose according to your needs.

Especially convenient: The comminuted sample is drawn into a screwed-on collecting vessel or in a smaller sample glass, in which it can also be transported and stored.

FRITSCH small volume Cyclone separator

Especially for exhaustion of small sample quantities, we designed the compact FRITSCH small volume Cyclone separator. It is made of plastic, can be dismantled completely and cleaned in a dishwasher for reliably preventing contaminations. The comminuted sample is collected in a screwed-on sample glass of 250 or 500 ml volume.



PULVERISETTE 15

For a wide range of common applications

YOUR ADVANTAGES

- **Rotor speed up to 3400 rpm**
- **Max. feed size 70 x 70 mm, sieve inserts 0.25–20 mm**
- **Collecting vessel 3.5 litres or 60 litres**
- **Externally adjustable cutting gap**
- **Stable operation due to double rotor bearing**
- **2-year guarantee**



TECHNICAL DATA

Electrical details
400 V/3~, 50 Hz, 1790 watt, 5.5 Nm
220-240 V/1~, 50 Hz, 2150 watt, 4.8 Nm
200 V/3~, 60 Hz, 2140 watt, 5.5 Nm
100-120 V/1~, 60 Hz, 1900 watt, 3 Nm
Other voltages on request!

Weight
Net 32 kg
Gross 62 kg

Dimensions w x d x h
Table-mounting or on stand 42 x 48 x 69 cm

Packaging w x d x h
Wooden case 55 x 75 x 91 cm

Emission sound pressure level at the workplace according to DIN EN ISO 3746
L_{pA} = 78 dB
(depending on the material to be ground, rotor and sieve insert used)

Order no.	400 V/3~	220-240 V/1~	200 V/3~	100-120 V/1~
	15.4030.00	15.4020.00	15.4050.00	15.4010.00



Cutting Mill PULVERISETTE 15 with funnel for long and bulk solids and 3.5 litre collecting vessel



Very stable: rotor with double bearing on shaft and in the lid



Powerful PULVERISETTE 15 cutting rotor with 4 straight cutting edges

IDEAL FOR COMMINUTION OF

Plastics and textiles	Plastics, rubber, leather, fabric, fibres
Agriculture and forestry	Wood, leaves, roots, animal feed, grain, corn, peat, tobacco
Environment	Paper, cardboard, derived fuels, metal-free waste, household waste
RoHS	Mobile phone LCD glass, mobile phone keypads, disassembled circuit boards
Analytic	Coal, horn, dragées, tablets, cork, drugs
Construction materials	Derived fuels
Chemistry	Heterogeneous mixtures of materials
Foodstuffs	Maize, malt, pasta, herbs, spices, dried meat

» **With a feed size (depending on the material) of up to 70 x 70 mm and a throughput of up to 50 l/h**

EQUIPMENT

Instrument without funnel, cutting tool set (consisting of rotor and fixed knives), sieve inserts, collecting vessel and stand

- Required accessories

Funnel for long and bulk solids made of plastic or protected funnel made of stainless steel with plastic sample pusher
Rotor with straight cutting edges and fixed knives made of tool steel or chromium-free tool steel
Sieve inserts with trapezoidal or square perforation made of stainless steel 316L or chromium-free steel DC01
Collecting vessel 3.5 litres or collecting vessel for large quantities, 60 litres with filter hose

- Optional accessories

Universal support stand
IQ/OQ documentation to support equipment qualification

PULVERISETTE 25

Powerful pre-crushing

YOUR ADVANTAGES

- Rotor speed up to 360 rpm
- Max. feed size: 120 x 85 mm, sieve cassettes 1–10 mm
- Collecting vessel 3 litres or 10 litres
- High-torque geared motor
- Externally adjustable cutting gap
- Double cone bearing of the rotor for long service life
- 2-year guarantee



TECHNICAL DATA

	PULVERISETTE 25	PULVERISETTE 25/19
Electrical details	400 V/3~, 50/60 Hz, 2590 watt, 67 Nm Other voltages on request.	400 V/3~, 50/60 Hz, 8590 watt, 67 Nm Other voltages on request.
Weight		
Net	75 kg	238 kg
Gross	105 kg	298 kg
Dimensions w x d x h	45 x 65 x 63 cm Table-mounting or on stand	100 x 65 x 145 cm on included underframe
Packaging w x d x h	1 wooden case 68 x 85 x 90 cm	2 wooden cases 85 x 85 x 170 cm, 70 x 80 x 90 cm
Emission sound pressure level at the workplace according to DIN EN ISO 3746 *(depending on the material to be ground, rotor and sieve cassette used)*	L_{pA} = 71 dB	L_{pA} = 78 dB
Order no.	25.2030.00	19.5030.00



Power Cutting Mill PULVERISETTE 25
with 10 litre standard funnel for bulk solids and 10 litre collecting vessel for large quantities



Larger grinding chamber depth for larger material quantities



Closes particularly securely: the grinding chamber safety lock

IDEAL FOR COMMINUTION OF

Plastics and textiles	Plastics, rubber, films, leather, fabric, fibres
Agriculture and forestry	Wood, leaves, roots, animal feed, grain, corn, peat, tobacco, straw – can be fed at full length
Environment	Paper, cardboard, derived fuels, metal-free waste, household waste, composites
RoHS	Mobile phone LCD glass, mobile phone keypads, electronic chips, circuit boards (assembled and disassembled)
Analytic	Coal, bones, horn, dragées, tablets, cork, drugs
Construction materials	Derived fuels
Chemistry	Heterogeneous mixtures of materials
Foodstuffs	Maize, malt, pasta, herbs, spices, dried meat

With a feed size (depending on the material) of up to 120 x 85 mm and a throughput of up to 85 l/h

EQUIPMENT OF POWER CUTTING MILL PULVERISETTE 25

Instrument without funnel, cutting tool set (consisting of rotor and fixed knives), sieve cassette, collecting vessel and stand

- Required accessories

Standard funnel for bulk solids 10 litres made of stainless steel or protected funnel 3 litres made of stainless steel with plastic sample pusher

Standard rotor with V-cutting edges and fixed knives made of hardened stainless steel, hardmetal tungsten carbide or chromium-free tool steel, or Disk milling cutter rotor with indexable inserts and fixed knives made of hardmetal tungsten carbide

Sieve cassettes with trapezoidal or square perforation made of stainless steel 316L or chromium-free steel DC01

Collecting vessel 3 litres or collecting vessel for large quantities 10 litres

Further accessories

Universal support stand or stand with wheels

Configure your Cutting Mill

When ordering, you may configure your FRITSCH Cutting Mill by selecting the rotor and the sieve cassette or sieve insert according to your application. Alternatively, you may order several rotors and sieve cassettes to be prepared for multifunctional use. As it suits you best.







The **standard rotor made of hardened stainless steel with V-cutting edges** and fixed knives is particularly suited for size-reduction of tough-elastic materials and films due to its especially acute cutting angle and the high cutting action that results.

The rotor with V-cutting edges and fixed knives made of **hardmetal tungsten carbide** is especially suitable for comminution of hard-tough materials due to the combination of impact and cutting forces.

The **rotor with notched edges and fixed knives** made of **hardened stainless steel** is ideal for comminution of samples with residual moisture, such as food, feed or plants, and temperature-sensitive samples like plastics.
Due to its notched edges, the grinding chamber never closes completely, thus allowing optimum air flow in combination with the FRITSCH Cyclone separators. This significantly increases the throughput and makes the use of very fine sieves for larger quantities possible in the first place.
The rotor knives have two notched cutting edges and can be easily turned after one side is used up.
Your advantage: twice the service life.

The **rotor with straight cutting edges** which run parallel to the fixed knives is especially suitable for easily cuttable materials like hay, straw, fibrous and biological materials. The rotor knives have two cutting edges and can simply be turned when one side is used up.
Your advantage: double service life.

100% safety
The fixed knives of FRITSCH Cutting Mills are always made of the same material as the cutting edges of the rotor.

FRITSCH SUGGESTION

By selecting the material of the cutting tool sets and sieve cassettes, the abrasion properties can also be individually accommodated. The element analyses of the various materials can be found under www.fritsch.de directly by clicking on the accessories of each corresponding Cutting Mill.

FRITSCH-Advantage

Easy cleaning

The sieve cassettes with square perforation made of stainless steel 316L for all PULVERISETTE 19 models are laser-welded, which enables due to less dead spaces a significantly easier cleaning.





The finer the sieve openings, the finer the finished sample

The especially robust **disk milling cutter rotor** with indexable inserts and fixed knives made of **hardmetal tungsten carbide** can even comminute circuit board scrap with glass fibre residue and copper cable.

FRITSCH-Advantage

Quadruple service life

With the disk milling cutter rotor, the cutting plates can be turned four times and replaced individually. Damage or wear are no longer a reason to buy a completely new rotor.

Practical: FRITSCH sieve cassettes

The final fineness of each sample can be determined easily and variably through the selection of the sieve used: the finer the sieve, the finer the sample. The patented FRITSCH sieve cassettes available for the models PULVERISETTE 19 and PULVERISETTE 25 simplify the work enormously, guarantee a constant distance between the rotor and the sample material and ensure a reliable result. Sieve inserts are used with the Cutting Mill PULVERISETTE 15. Both can be selected in various trapezoidal and square perforation patterns in stainless steel 316L or chromium-free steel DC01.

Genuine hardmetal – Genuine chromium-free

We keep what others promise: If you select cutting tools made of hardmetal tungsten carbide, you have the guarantee that your sample is indeed completely processed by hardmetal – because only in FRITSCH Cutting Mills, the fixed knives are also made of tungsten carbide. Anything else offers only half the reliability.

And when chromium-free size reduction is required for sample preparation according to RoHS, e.g. for verification of hexavalent chromium – or for XRF analysis, FRITSCH cutting tool sets made of chromium-free tool steel offer absolute assurance.



Fixed knives of hardmetal tungsten carbide

ORDERING DATA

Order no.	Article
UNIVERSAL CUTTING MILL	
	PULVERISETTE 19
	
	Instruments without funnel, cutting tool set, sieve cassette, collecting vessel and stand
	300-3000 rpm - variable rotational speed adjustment
19.3060.00	for 380-460 V/3~, 50-60 Hz, 5000 watt
19.3020.00	for 200-240 V/1~, 50-60 Hz, 2350 watt
19.3030.00	for 100-120 V/1~, 50-60 Hz, 1725 watt
	> in a corrosion-resistant stainless steel version 316L
19.3160.00	for 380-460 V/3~, 50-60 Hz, 5000 watt
19.3120.00	for 200-240 V/1~, 50-60 Hz, 2350 watt
19.3130.00	for 100-120 V/1~, 50-60 Hz, 1725 watt
	50-700 rpm - variable rotational speed adjustment
19.3040.00	for 380-460 V/3~, 50-60 Hz, 2800 watt
19.3000.00	for 200-240 V/1~, 50-60 Hz, 2350 watt
19.3010.00	for 100-120 V/1~, 50-60 Hz, 1725 watt
	> in a corrosion-resistant stainless steel version 316L
19.3140.00	for 380-460 V/3~, 50-60 Hz, 2800 watt
19.3100.00	for 200-240 V/1~, 50-60 Hz, 2350 watt
19.3110.00	for 100-120 V/1~, 50-60 Hz, 1725 watt
	The PULVERISETTE 19 with voltage of "/3~"can **only** be operated on a three-phase supply network.
	Despite the frequency converter, the three-phase version "/3~" is definitely preferable instead of a single-phase version "/1~", because the three-phase version achieves a higher torque mass and pulling power.
	Funnels
19.1550.00	Standard funnel for long and bulk solids
19.1850.00	Protected funnel with sample pusher
19.1559.00	Funnel for long and bulk solids made of stainless steel 316L
	Collecting vessels made of stainless steel 316L
45.5730.00	Collecting vessel, 3 litres
45.5700.00	Collecting vessel for large quantities, 10 litres
	Cutting tool sets
45.5100.00	Standard rotor with V-cutting edges and fixed knives made of hardened stainless steel
45.5370.00	Rotor with V-cutting edges and fixed knives made of hardmetal tungsten carbide
45.5192.00	Rotor with notched edges and fixed knives made of hardened stainless steel
45.5185.00	Rotor with straight cutting edges and fixed knives made of hardened stainless steel
45.5200.00	Disk milling cutter rotor with indexable inserts and fixed knives made of hardmetal tungsten carbide
	Sieve cassettes made of stainless steel 316L
45.5405.10	0.2 mm trapezoidal perforation
45.5410.10	0.25 mm trapezoidal perforation
45.5420.10	0.5 mm trapezoidal perforation
45.5430.10	0.75 mm trapezoidal perforation
45.5440.10	1 mm trapezoidal perforation
45.5450.10	1.5 mm trapezoidal perforation
45.5460.10	2 mm trapezoidal perforation
45.5495.10	2 mm square perforation
45.5501.10	4 mm square perforation
45.5513.10	6 mm square perforation
45.5514.10	8 mm square perforation
45.5515.10	10 mm square perforation
	Accessories for chromium-free comminution
	Cutting tool sets made of chromium-free tool steel
45.5112.00	Rotor with V-cutting edges and fixed knives
45.5012.00	Rotor with straight cutting edges and fixed knives
	Sieve cassettes made of chromium-free steel DC01 (not rust-proof)
45.5420.09	0.5 mm trapezoidal perforation
45.5440.09	1 mm trapezoidal perforation
45.5460.09	2 mm trapezoidal perforation
45.5500.09	4 mm square perforation
45.5510.09	6 mm square perforation
	Sample exhaustion with Cyclone separators
	High-performance Cyclone separators
19.1900.00	High-performance Cyclone separator made of stainless steel 304 with flexible tube connection, incl. sample glass 1 litre
19.1940.00	High-performance Cyclone separator with solid piping made of stainless steel 304, incl. sample glass 1 litre
	Collecting vessels for high-performance Cyclone separators
83.3250.00	Sample glass 1 litre
83.3260.00	Sample glass 2 litres
83.3270.00	Sample glass 5 litres
45.8040.00	Collecting vessel, 20 litres made of stainless steel
45.8050.00	Collecting vessel, 60 litres made of stainless steel (not suitable for 19.1940.00)

Order no.	Article
	Small volume Cyclone separator
19.1930.00	Small volume Cyclone separator made of plastic, incl. 500 ml sample glass
	Collecting vessels for small volume Cyclone separator
27.1450.00	Sample glass 250 ml
27.1460.00	Sample glass 500 ml
	Exhaust system for high-performance Cyclone separators and small volume Cyclone separator
43.9070.00	Exhaust system, dust category "M" according to DIN EN 60335-2-69 for 230 V/1~, 50/60 Hz, 1000 watt
43.9055.00	Fleece filter bag for exhaust system (pack = 5 pieces)[1]
43.9052.00	Plastic bag for exhaust system (pack = 5 pieces)[1]
	[1] Remark: One pack/one piece is included in the scope of delivery of the exhaust system.
	Stands
45.5820.00	Universal support stand
45.5829.00	Stand cpl. welded, electrochemically polished made of stainless steel 316L
45.5800.00	Stand with wheels
	Certification
96.0250.00	IQ/OQ documentation (questionnaire format – implementation by customer)

- Collecting vessels are also available in further sizes.
- Cutting tool sets are also available in further materials.
- Sieve cassettes are also available in further perforations.

CUTTING MILL	
	PULVERISETTE 15
	
	Instrument without funnel, cutting tool set, sieve insert, collecting vessel and stand
15.4030.00	for 400 V/3~, 50 Hz, 1790 watt
15.4020.00	for 220-240 V/1~, 50 Hz, 2150 watt
15.4050.00	for 200 V/3~, 60 Hz, 2140 watt
15.4010.00	for 100-120 V/1~, 60 Hz, 1900 watt
	The PULVERISETTE 15 with voltage of "/3~" can **only** be operated on a three-phase supply network.
	The three-phase version "/3~" is definitely preferable instead of a single-phase version "/1~", because the three-phase version obtains more power, better effectiveness and greater energy efficiency.
	Other voltages on request!
	Funnels
15.1550.00	Funnel for long and bulk solids
15.4300.00	Protected funnel with sample pusher
	Collecting vessels
15.4400.00	Collecting vessel, 3.5 litres
15.4560.00	Collecting vessel for large quantities, 60 litres with filter hose
	Cutting tool set made of tool steel
15.4603.00	Rotor with straight cutting edges and fixed knives
	Sieve inserts made of stainless steel 316L
45.1200.10	0.25 mm trapezoidal perforation
45.1210.10	0.5 mm trapezoidal perforation
45.1220.10	0.75 mm trapezoidal perforation
45.1230.10	1 mm trapezoidal perforation
45.1240.10	1.5 mm trapezoidal perforation
45.1250.10	2 mm trapezoidal perforation
45.2190.10	2 mm square perforation
45.2200.10	4 mm square perforation
45.2210.10	6 mm square perforation
45.2220.10	8 mm square perforation
45.2230.10	10 mm square perforation
45.2300.10	20 mm square perforation
	Accessories for chromium-free comminution
	Cutting tool set made of chromium-free tool steel
15.4602.00	Rotor with straight cutting edges and fixed knives
	Sieve inserts made of chromium-free steel DC01 (non-rust-proof)
45.1211.09	0.5 mm trapezoidal perforation
45.1230.09	1 mm trapezoidal perforation
45.2200.09	4 mm square perforation
	Stand
45.5820.00	Universal support stand
	Certification
96.0400.00	IQ/OQ documentation (questionnaire format – implementation by customer)

- Sieve inserts are also available in further dimensions.

Order no.	Article

POWER CUTTING MILL

PULVERISETTE 25

Instrument without funnel, cutting tool set, sieve cassette, collecting vessel and stand

25.2030.00 for 400 V/3~, 50/60 Hz, 2590 watt

The PULVERISETTE 25 with voltage of "/3~" can **only** be operated on a three-phase supply network.

Other voltages on request!

Funnels

25.2700.00 Standard funnel for bulk solids, 10 litres
25.2850.00 Protected funnel with sample pusher, 3 litres

Collecting vessels

45.5730.00 Collecting vessel, 3 litres
45.5700.00 Collecting vessel for large quantities, 10 litres

Cutting tool sets

45.7000.00 Standard rotor with V-cutting edges and fixed knives made of hardened stainless steel
45.7370.00 Rotor with V-cutting edges and fixed knives made of hardmetal tungsten carbide
45.7200.00 Disk milling cutter rotor with indexable inserts and fixed knives made of hardmetal tungsten carbide

Sieve cassettes made of stainless steel 316L

45.7440.10 1 mm trapezoidal perforation
45.7460.10 2 mm trapezoidal perforation

45.7500.10 4 mm square perforation
45.7510.10 6 mm square perforation
45.7520.10 8 mm square perforation
45.7530.10 10 mm square perforation

Accessories for chromium-free comminution

Cutting tool set made of chromium-free tool steel

45.7112.00 Rotor with V-cutting edges and fixed knives

Sieve cassettes made chromium-free steel DC01 (not rust-proof)

45.7440.09 1 mm trapezoidal perforation
45.7460.09 2 mm trapezoidal perforation

45.7500.09 4 mm square perforation
45.7510.09 6 mm square perforation
45.7520.09 8 mm square perforation
45.7530.09 10 mm square perforation

Stands

45.5820.00 Universal support stand
45.5800.00 Stand with wheels

· Sieve cassettes are also available in further perforations.

Order no.	Article

CUTTING MILL COMBINATION

PULVERISETTE 25/PULVERISETTE 19

19.5030.00 for 400 V/3~, 50/60 Hz, 8590 watt
consisting of: Power Cutting Mill PULVERISETTE 25, Universal Cutting Mill PULVERISETTE 19 with variable rotational speed 300 to 3000 rpm, interposed sample divider, protected funnel with sample pusher, underframe, sample exhaustion with high-performance Cyclone separator and collecting vessel 60 litres as well as exhaust system; inclusive hardmetal tungsten carbide cutting tool sets and sieve cassettes made of stainless steel

The PULVERISETTE 25/PULVERISETTE 19 with voltage of "/3~" can **only** be operated on a three-phase supply network.

Other configurations and voltages on request!

FRITSCH



CuttingMillse-20-01-1/P

Operating instructions

UNIVERSAL CUTTING MILL

PULVERISETTE 19

Valid starting with: 19.3000/00005, 19.3010/00101, 19.3020/00571, 19.3030/00585, 19.3040/00509, 19.3060/00555 - 19.3100/00502, 19.3110/00001, 19.3120/00003, 19.3130/00502, 19.3140/00502, 19.3160/00516

Valid starting with : 19.4000/00001, 19.4020/00003, 19.4040/00005, 19.4060/00006



Read the instructions prior to performing any task!

Fritsch GmbH
Milling and Sizing
Industriestraße 8
55743 Idar-Oberstein, Germany
Telephone: +49 6784 70-0
Email: info@fritsch.de
Internet: www.fritsch.de

Certifications and CE conformity

Certification

Fritsch GmbH has been certified by the SGS-TÜV Saar GmbH.

An audit certified that Fritsch GmbH conforms to the requirements of the DIN EN ISO 9001:2015.

CE Conformity

The enclosed Conformity Declaration lists the guidelines the FRITSCH instrument conforms to, to be able to bear the CE mark.

Table of contents

Table of contents

Table of contents

1 Basic structure



1 Upper part of housing
2 Fixed knife 1
3 Closing lid
4 Fixed knife 2
5 Collecting vessel
5a Securing the collecting vessel
6 Safety switch / Safety switch bracket
7 U-profile
8 Lower part of housing
9 Sieve cassette
10 Rotor
11 Lock
12 Fixed knife 2
13 Latch clamp
14 Motor cover
15 Standard funnel

Basic structure



15 Standard funnel
14 Motor cover
16 Plunger, standard funnel
17 Ventilation grid
18 External 3-pole connection
19 USB interface
20 Mains plug



21 Sample pusher
22 Plunger (protected funnel)
23 Funnel lid
24 Protected funnel
25 Control panel
26 Fuse



a Display for speed and time
b Toggle function for the display
c Tooling Mode (P19 versions with speeds of 300 – 3000 rpm)
d Start motor
e Main switch with integrated overload protection
f Increase speed / Extend time
g Decrease speed / Shorten time
h Stop motor

2 Safety information and use

2.1 Requirements for the user

This operating manual is intended for persons assigned with operating and monitoring the Fritsch PULVERISETTE 19. The operating manual and especially its safety instructions are to be observed by all persons working on or with this device. In addition, the applicable rules and regulations for accident prevention at the installation site are to be observed. Always keep the operating manual at the installation site of the PULVERISETTE 19.

People with health problems or under the influence of medication, drugs, alcohol or exhaustion must not operate this device.

The PULVERISETTE 19 may only be operated by authorised persons and serviced or repaired by trained specialists. All commissioning, maintenance and repair work may only be carried out by technically qualified personnel. Qualified personnel are persons who, because of their education, experience and training as well as their knowledge of relevant standards, regulations, accident prevention guidelines and operating conditions, are authorised by those responsible for the safety of the machine to carry out the required work and are able to recognize and avoid possible hazards as defined for skilled workers in IEC 364.

In order to prevent hazards to users, follow the instructions in this manual.

Malfunctions that impair the safety of persons, the PULVERISETTE 19 or other material property must be rectified immediately. The following information serves both the personal safety of operating personnel as well as the safety of the products described and any devices connected to them: All maintenance and repair work may only be performed by technically qualified personnel.

This operating manual is not a complete technical description. Only the details required for operation and maintaining usability are described.

Fritsch has prepared and reviewed this operating manual with the greatest care. However, no guarantee is made for its completeness or accuracy.

Subject to technical modifications.

2.2 Scope of application



NOTICE

This laboratory instrument is designed for an 8-hour shift operation at 30 % duty cycle and not for continuous operation.

The duty cycle is defined as the ratio of load duration to run time. The run time is defined as load duration plus pause time. According to DIN EN 60034-1 (VDE 0530, IEC34-1) a continuous operation already takes place after a standardised run time of 10 minutes. At 30 % duty cycle (DC = ratio of load duration to run time) a load duration of 3 minutes and a pause time of 7 minutes would be within standard.

If the standardised run time of 10 minutes is exceeded, then, by definition, there would be a continuous operation and disproportionate temperature increases may occur, possibly involving increased wear.

The Universal Cutting Mill can be used for the fast comminution of soft, medium-hard, brittle, tough and fibrous materials like:

Sheet rubber, plastics, refuse-derived fuel, dry meat, leather, wood, coal, malt, paper/cardboard, peat, animal feed, pasta, tablets, leaves, pellets, spices, fabric, straw, maize, bones, roots, tobacco...

2.2.1 Operating principle



The material is fed through a funnel (example in image with standard funnel) into the cutting chamber. There, rotating knives (10) in combination with fixed knives (2,4,12) cut the material. The fine ground material falls through a sieve cassette (9) into the collecting vessel (5).

For fine comminution, the Fritsch high-performance cyclone separator (optional accessory 19.1907.00) can be used for the sample exhaustion. For a combination with the PULVERISETTE 19 L, ask Fritsch or your sales partner.

2.3 Obligations of the operator

Before using the PULVERISETTE 19, this manual is to be carefully read and understood. The use of the PULVERISETTE 19 requires technical knowledge; only commercial use is permitted.

The operating personnel must be familiar with the content of the operating manual. For this reason, it is very important that these persons actually receive the present operating manual. Ensure that the operating manual is always near the device.

The PULVERISETTE 19 may exclusively be used within the scope of applications set down in this manual and within the framework of guidelines put forth in this manual. In case of non-compliance or improper use, the customer assumes full liability for the functional capability of the PULVERISETTE 19 and for any damage or injury arising from failure to fulfil this obligation.

By using the PULVERISETTE 19 the customer agrees with this and recognizes that defects, malfunctions or errors cannot be completely excluded. To prevent risk of damage to persons or property or of other direct or indirect damage, resulting from this or other causes, the customer must implement sufficient and comprehensive safety measures for working with the PULVERISETTE 19.

Neither compliance with this manual nor the conditions and methods used during installation, operation, use and maintenance of the PULVERISETTE 19 can be monitored by Fritsch GmbH. Improper execution of the installation can result in property damage and thus endanger persons. Therefore, we assume

absolutely no responsibility or liability for loss, damage or costs that result from errors at installation, improper operation or improper use or improper maintenance or are in any way connected to these.

The applicable accident prevention guidelines must be complied with.

Generally applicable legal and other obligatory regulations regarding environmental protection must be observed.

2.4 Information on hazards and symbols used in this manual

Safety information

Safety information in this manual is designated by symbols. Safety information is introduced by keywords that express the extent of the hazard.

DANGER

This symbol and keyword combination points out a directly hazardous situation that can result in death or serious injury if not avoided.

WARNING

This symbol and keyword combination points out a possibly hazardous situation that can result in death or serious injury if not avoided.

CAUTION

This symbol and keyword combination points out a possibly hazardous situation that can result in slight or minor injury if not avoided.



NOTICE

This symbol and keyword combination points out a possibly hazardous situation that can result in property damage if not avoided.

Special safety information

To call attention to specific hazards, the following symbols are used in the safety information:



⚠ DANGER

This symbol and keyword combination points out a directly hazardous situation due to electrical current. Ignoring information with this designation will result in serious or fatal injury.

Safety information and use

⚠ DANGER

This symbol and keyword combination designates contents and instructions for proper use of the machine in explosive areas or with explosive substances. Ignoring information with this designation will result in serious or fatal injury.

⚠ DANGER

This symbol and keyword combination designates contents and instructions for proper use of the machine with combustible substances. Ignoring information with this designation will result in serious or fatal injury.

⚠ WARNING

This symbol and keyword combination points out a directly hazardous situation due to movable parts. Ignoring information with this designation can result in hand injuries.

⚠ WARNING

This symbol and keyword combination points out a directly hazardous situation due to hot surfaces. Ignoring information with this designation can result in serious burn injuries due to skin contact with hot surfaces.

Safety information in the procedure instructions

Safety information can refer to specific, individual procedure instructions. Such safety information is embedded in the procedure instructions so that the text can be read without interruption as the procedure is being carried out. The keywords described above are used.

Example:

1. Loosen screw.
2. 

   CAUTION

   Risk of entrapment at the lid.

   Close the lid carefully.
3. Tighten screw.

Tips and recommendations

This symbol emphasises useful tips and recommendations as wells as information for efficient operation without malfunction.

2.5 Device safety information

Please observe!

- Only use original accessories and original spare parts. Failure to observe this instruction can compromise the safety of the machine.
- Accident-proof conduct is to be strictly followed during all work.
- Comply with all currently applicable national and international accident prevention guidelines.

CAUTION

Wear hearing protection!

If a noise level of 85 dB(A) is reached or exceeded, ear protection should be worn to prevent hearing damage.

WARNING

The maximum accepted concentration (MAC) levels of the relevant safety guidelines must be observed; if necessary, ventilation must be provided or the machine must be operated under an extractor hood.

DANGER

Explosion hazard!

- When Comminution oxidizable substances, e.g. metals or coal, there is a risk of spontaneous combustion (dust explosion) if the share of fine particles exceeds a certain percentage. When Comminution these kinds of substances, special safety measures must be taken and the work must be supervised from a specialist.
- The PULVERISETTE 19 is not explosion protected and is not designed to missing definition for variable 'to_materialbearbeitung' explosive materials.

- Do not remove the information signs.

NOTICE

Immediately replace damaged or illegible information signs.

- Unauthorised alteration of the PULVERISETTE 19 will void Fritsch's declaration of conformity to European directives and void the guarantee.
- Only use the PULVERISETTE 19 when it is in proper working order, as intended and in a safety- and hazard-conscious manner adhering to the operating manual. In particular, immediately rectify any malfunctions that could pose a safety hazard.
- If, after reading the operating manual, there are still questions or problems, please do not hesitate to contact our specialised personnel.

FRITSCH

2.6 Protective equipment

- Protective equipment must be used as intended and may not be disabled or removed.
- All protective equipment must be checked regularly for integrity and proper functioning.
- The Universal Cutting Mill is equipped with a safety lock (11) which also protects the operator. This locks the front closing lid (3) during operation.
- The safety switches (11, 6) prevent operation of the Universal Cutting Mill, if the cutting chamber is not closed or a collecting vessel (8) has not been inserted.
- **Do not operate the device without a funnel (15 or 24)!**
  Funnels (15, 24) are mechanical safety devices that enable hazard-free filling.
- When changing the funnels (15, 24), disconnect the device from the mains and install the new funnel (15, 24) immediately! (↪ *Chapter 4.6 'Selecting and converting the funnels' on page 22*)

2.6.1 Securing the collecting vessel



The collecting vessel can only be removed once the closing lid has been opened.



Proceed as follows to open the cutting mill:

1. Connect the mill to the power supply.
2. Switch the mill on by the main switch.
3. Release the closing lid with the latch clamp and open the lid.
4. The bolt for securing the collecting vessel is released and the vessel can be removed.

To close the mill, proceed in the reverse order:

1. Position the collecting vessel.
2. Once the cutting accessories are installed, close the closing lid and tension the latch clamp. By closing the closing lid the securing bolt is pushed downward and the collecting vessel is thus secured.

2.6.2 Opening the cutting mill without mains connection

DANGER

The lock must only be released manually when the closing lid is closed.

The latch clamp of the door must be locked!

Only open the cutting mill in this way if there are problems with your mains supply or with the safety lock. Opening the mill during the grinding process could damage the device.





1. Insert the supplied triangular key into the bore hole under the safety lock (11) and turn it clockwise.
2. The closing lid (3) can be opened after opening the latch clamp (13).
3. At this time, it is not possible to switch on the Universal Cutting Mill. To switch it on, the safety lock (11) must be activated by turning the triangular key to the left, the closing lid (3) must be closed and the latch clamp (13) in locked position.

2.7 Hazardous points



- The closing lid (3) can be lifted out of the hinges. When opening the upper part of the housing (1), it is possible to leave the closing lid (3) in the hinge. If this is the case, make sure that the closing lid (3) does not lift out of the hinge when opening the upper part of the housing (1).



- When opening the upper part of the housing (1), there is an initial resistance.
- Make sure that the closing lid (3) is fully open!



- When opening the upper part of the housing (1), slowly swivel it open until the upper part of the housing (1) is resting on the rubber buffer – do not let it fall into end position.
- There is a crushing hazard when closing the upper part of the housing (1). Close it slowly!



- After checking if the rotor (10) is turning freely (➦ *Chapter 6.1.7 'Checking if the rotor is turning freely' on page 34*), the required hexagon socket screw key has to be removed immediately.

2.8 Electrical safety

2.8.1 Protection against restart

If there is a power failure and subsequent return of the voltage during operation, the mill stops and the lock of the grinding chamber opens automatically.

2.8.2 Overload protection

- The main switch turns itself off automatically in case of an overload. The PULVERISETTE 19 must be switched on again by the user.

3 Technical data

3.1 Dimensions

without funnel: 440 mm x 790 mm x 350 mm

(width x depth x height)

3.2 Weight

300 - 3000 rpm:

- 60 kg without funnel, cutting tool set, sieve cassette, collecting vessel, and stand
- 68 kg incl. standard accessories

50 - 700 rpm:

- 79 kg without funnel, cutting tool set, sieve cassette, collecting vessel, and stand
- 87 kg incl. standard accessories

PULVERISETTE 19 *large*

300 - 3000 rpm:

- 63 kg without funnel, cutting tool set, sieve cassette, collecting vessel, and stand

50 - 700 rpm:

- 82 kg without funnel, cutting tool set, sieve cassette, collecting vessel, and stand

3.3 Speed

Serial number	Rotational speed
19.3000.00	50 - 700 rpm
19.3010.00	50 - 700 rpm
19.3020.00	300 - 3000 rpm
19.3030.00	300 - 3000 rpm
19.3040.00	50 - 700 rpm
19.3060.00	300 - 3000 rpm
19.3100.00	50 - 700 rpm
19.3110.00	50 - 700 rpm
19.3120.00	300 - 3000 rpm
19.3130.00	300 - 3000 rpm

Serial number	Rotational speed
19.3140.00	50 - 700 rpm
19.3160.00	300 - 3000 rpm
19.4000.00	50 - 700 rpm
19.4020.00	300 - 3000 rpm
19.4040.00	50 - 700 rpm
19.4060.00	300 - 3000 rpm

3.4 Operating noise

The noise level is approx. 78 dB (A) when idle and 95 dB (A) when idle incl. cyclone separator. The value fluctuates strongly depending on the comminution material.

3.5 Voltage

19.3000.00	220-240 V / 1~	50 - 60 Hz
19.3010.00	100-120 V / 1~	50 - 60 Hz
19.3020.00	200-240 V / 1~	50 - 60 Hz
19.3030.00	100-120 V / 1~	50 - 60 Hz
19.3040.00	380-460 V / 3~	50 - 60 Hz
19.3060.00	380-460 V / 3~	50 - 60 Hz
19.3100.00	220-240 V / 1~	50 - 60 Hz
19.3110.00	100-120 V / 1~	50 - 60 Hz
19.3120.00	200-240 V / 1~	50 - 60 Hz
19.3130.00	100-120 V / 1~	50 - 60 Hz
19.3140.00	380-460 V / 3~	50 - 60 Hz
19.3160.00	380-460 V / 3~	50 - 60 Hz
19.4000.00	200-240 V / 1~	50 - 60 Hz
19.4020.00	200-240 V / 1~	50 - 60 Hz
19.4040.00	380-460 V / 3~	50 - 60 Hz
19.4060.00	380-460 V / 3~	50 - 60 Hz

3.6 Protection class

IP 21

3.7 Current consumption

- 19.3000.00 - 13 A
- 19.3010.00 - 16 A
- 19.3020.00 - 13 A
- 19.3030.00 - 16 A
- 19.3040.00 - 6 A
- 19.3060.00 - 13.5 A
- 19.3100.00 - 13 A
- 19.3110.00 - 16 A
- 19.3120.00 - 13 A
- 19.3130.00 - 16 A
- 19.3140.00 - 6 A
- 19.3160.00 - 13.5 A
- 19.4000.00 - 13 A
- 19.4020.00 - 13 A
- 19.4040.00 - 6 A
- 19.4060.00 - 13.5 A

Transient overvoltages in accordance with overvoltage category II are permitted.

3.8 Power consumption

- 19.3000.00 - 2350 W
- 19.3010.00 - 1725 W
- 19.3020.00 - 2350 W
- 19.3030.00 - 1725 W
- 19.3040.00 - 2800 W
- 19.3060.00 - 5000 W
- 19.3100.00 - 2350 W
- 19.3110.00 - 1725 W
- 19.3120.00 - 2350 W
- 19.3130.00 - 1725 W
- 19.3140.00 - 2800 W
- 19.3160.00 - 5000 W
- 19.4000.00 - 2350 W
- 19.4020.00 - 2350 W
- 19.4040.00 - 2800 W
- 19.4060.00 - 5000 W

3.9 Rotor torque

The torque depends on the device type.

300 - 3000 rpm:

- Up to 30 Nm

50 - 700 rpm:

- Up to 67 Nm

3.10 Electrical fuses

The fuses are integrated into the mains switch and in the back side.

3.11 Material

Feed size

Depending on material and funnel (15,24), up to 70 x 80 mm. Harder material max. 10 mm.

Batch-wise sample feeding!

Throughput

Depending on material property and sieve used, up to 60 l/h.

Feed size PULVERISETTE 19 L *large*

Depending on material and funnel, up to 120 x 85 mm. Harder material max. 20 mm.

Batch-wise sample feeding!

Throughput amount PULVERISETTE 19 L *large*

Depending on material property and sieve used, up to 85 l/h.

3.12 Final fineness

Achievable average final fineness depending on sieve insert, 0.2 - 6 mm.

4 Installation

4.1 Transport

CAUTION

When lifting off, at least 2 persons are required!

DANGER

Crushing hazard!

Due to falling during transport.

Wear safety shoes!

- Transport on transport palette with a forklift or pallet truck.
- When lifting the device hold it underneath at the back and front.

4.2 Unpacking

- Pull out the nails that fasten the crate to the transport pallet.
- Lift the crate off the transport pallet.
- Compare the contents of the delivery with your order.

4.3 Setting up

NOTICE

Allow the device to acclimatise for two hours before commissioning. High temperature differences can lead to condensation in the device and damage to the electronics after switching on.

Strong temperature fluctuations can occur during transport or interim storage. Depending on the temperature difference between the installation site and the transport or storage environment, condensation can form inside the device. This can damage the electronics if the devices are switched on too early. Wait for at least two hours after setup before switching on the device.

- 4 screws connect the cutting mill to the transport pallet.
  Remove the 4 screws.
- Lift the cutting mill off the transport pallet.

CAUTION

When lifting off, at least 2 persons are required!

4.4 Ambient conditions

- The device may only be operated indoors.
- The surrounding air may not carry any electrically conductive dust.
- The room temperature should be between 5 and 40 °C.
- Altitudes up to 2000 m NN.
- Maximum relative humidity 80% for temperatures up to 31 °C, linearly decreasing down to 50% relative humidity at 40 °C.
- Degree of pollution 2 according to IEC 664.

4.5 Fastening the Universal Cutting Mill

Screw the cutting mill tightly to the frame provided (acc. to instructions) or to a stable mount (table...). The following must be observed in order to fasten the device:

- Two U-profiles (7) are mounted on the bottom of the device. Insert the 4 screws provided through the bore holes in the U-profiles (7) and screw tightly to the frame or table. Other screws with the same diameter can also be used.



WARNING

Ensure that the device is safely fastened. Sizeable lateral forces can occur!

NOTICE

- Make sure that the cutting mill is easily accessible. On the right of the mill, there must be enough space to open the upper part of the housing together with the funnel.
- Make sure the ventilation grate on the back is not obstructed. **Risk of overheating!**

4.6 Selecting and converting the funnels

The PULVERISETTE 19 large is available with the protected funnel (25.2850.00) and the funnel for bulk solids (19.4225.00).

4.6.1 Selecting the funnel

The standard funnel (15) is used for long and bulk solids, for free-flowing material, but also for the comminution of long goods, like for example straw or wood. The protected funnel (24) is used for all other materials.

4.6.2 Converting from standard funnel to protected funnel

1. Close the cutting mill.
2. Switch main switch to 0.





3. Remove the mains plug (20).
4. Unscrew the four M6x12 cylinder head screws which fasten the standard funnel (15) to the upper part of the housing (1) using a hexagon socket screw key and lift off the standard funnel (15).





5. Insert the protected funnel (24) and fasten it with the four M6x12 cylinder head screws and the washers.
6. Connect the cutting mill again to the mains.
   ➡ The device is ready for operation.

4.6.3 Converting from protected funnel to standard funnel

1. Close the cutting mill.
2. Close the funnel lid (23).
3. Remove the mains plug
4. Unscrew the four M6x12 cylinder head screw which fasten the protected funnel (24) to the upper part of the housing (1) using a hexagon socket screw key and lift off the protected funnel (24).









5. Insert the standard funnel (15) and fasten it with the four M6x12 cylinder head screws and the washers.
6. Connect the cutting mill again to the mains.
7. Switch on main switch.
   ➡ The device is ready for operation.

4.6.4 Funnel for bulk solids PULVERISETTE 19 *large*



The funnel for bulk solids is used for free-flowing materials with a maximum particle feed size of 30 mm.

The funnel for bulk solids is fastened with four M6x12 cylinder head screws.

4.7 Electrical connection

Before establishing the connection, compare the voltage and current values stated on the type plate with the values of the mains system to be used.

(see ➥ *Chapter 3 'Technical data' on page 17*).

4.8 Set-up mode

NOTICE

Changing the setting *'Machine speed'* in setup mode can cause damage to the device. Never modify these settings without first consulting Fritsch Service.

To enter the setup mode, press and hold the *'Stop'* button while you switch on the device. Once you are in setup mode, the following display is shown in which you can specify 3 settings:



- a - Time display in minutes or seconds
- b - Connection of external devices - vibration feeder LABORETTE 24 (L) or cyclone separator (C)

  To use the cyclone separator, you need the adapter 19.3073.00.
- c - Machine speed

  Modify this setting only upon consulting Fritsch Service.

5 Initial start-up

5.1 Switching on



1. Connect the device to the mains with the mains plug (20).
2. Switch on the main switch on the front of the device.
3. Remove the cover cap of the central bore hole in the closing lid (3).



4. Insert the provided hexagon socket screw key through the central bore hole. Then turn the hexagon socket screw key to check if the rotor (10) is turning freely.



5. **Remove the hexagon socket screw key again!**
   - If the rotor (10) is not turning freely, proceed as described in *Chapter 6.1.3 'Setting the gap width of the knives' on page 31.*

NOTICE

This check must also be carried out every time the rotor, the fixed knives and the sieve cassette are changed!

6. Finally, insert the collecting vessel correctly.

5.2 Function check

Press the START button to switch on the device. This front closing lid (3) is now locked.

→ The cutting mill starts up.

NOTICE

Switch the device off immediately if there is an audible metal contact noise. This can happen if the fixed knives are set incorrectly. An indication of this could be shiny areas on the rotor, which show where the fixed knives must be readjusted. (See *Chapter 6.1.2 'Inserting / changing the fixed knives' on page 29*).

5.3 Switching off

Press the STOP button to switch off the device. After waiting a few seconds the closing lid (3) can be opened.

Switch off the main switch if the cutting mill is to be idle for a longer period of time (e.g. overnight).



CAUTION

Never unlock the latch clamp during operation!

Risk of permanent damage to the rotor.

6 Using the device

WARNING

If the grinding elements used are not original accessories, we provide no guarantee and exclude all liability for damage to the device.

6.1 Preparing a comminution

6.1.1 Opening the cutting mill



1. Switch on the main switch on the front.
2. Unlock the latch clamp (13).
3. Open the closing lid (3). It is possible to lift the closing lid (3) out of the hinge after opening. This is required for easier cleaning, for example.



4. Make sure that the closing lid (3) is fully open!

   Slowly swivel open the upper part of the housing (1) until it rests on the rubber buffer.

6.1.2 Inserting / changing the fixed knives



1. Open the cutting mill (see ➞ *Chapter 6.1.1 'Opening the cutting mill' on page 29*)
2. When inserting or changing the fixed knives (2, 4, 12) the rotor (10) and the sieve cassette (9) must be removed (see ➞ *Chapter 6.1.4 'Inserting / changing a rotor' on page 32* and ➞ *Chapter 6.1.5 'Inserting / changing a sieve cassette' on page 33*).
3. Loosen the retaining screws (A) to change or remove the fixed knives (2, 4, 12).

4. When inserting, fasten the fixed knives (2, 4, 12) with the retaining screw (A).

5. After mounting the rotor (10) (see ➦ *Chapter 6.1.4 'inserting / changing a rotor' on page 32*) set the gap width of the knives (see ➦ *Chapter 6.1.3 'Setting the gap width of the knives' on page 31*).

6.1.2.1 Installation position of the fixed knives



(12) Fixed knife 2
(2) Fixed knife 1
(4) Fixed knife 2

6.1.2.2 Installation position of the fixed knives with tungsten carbide cutting edge



(12) Fixed knife 2
(2) Fixed knife 1
(4) Fixed knife 2

NOTICE

Note the position of the Tungsten Carbide hard metal strips. These are marked BLUE in the image above.

6.1.3 Setting the gap width of the knives

The knife gap is set at the factory to approx. 0.2 mm.



1. Open the cutting mill (see ➞ *Chapter 6.1.1 'Opening the cutting mill' on page 29*).

A Retaining screw to fasten and loosen the fixed knife when setting the gap width of the knives.
B Threaded pins to set the cutting gap.

2. Loosen the middle retaining screws (A) on all 3 fixed knives (2, 4, 12) and unscrew them slightly.
3. Turn the rotor (10) so that the rotor knife and the fixed knife (2, 4, 12) are exactly opposite each other.

A, B (12) Retaining screw (A) and threaded pins (B) for fixed knife (12)
A,B (2, 4) Retaining screws (A) and threaded pins (B) for fixed knife (2, 4)

4. Screw in the right and left threaded pins (B) beside the retaining screw (A) equally until the fixed knives (2, 4, 12) come up against the rotor knives.
5. Then turn the threaded pins (B) evenly back by ¼ of a turn and retighten the retaining screw (A).
6. Set all 3 fixed knives (2, 4, 12) in this way.

   A knife gap of approx. 0.2 mm is then set using this method. This can be checked using a feeler gauge. (0.2 mm, approx. 2 sheets of printing paper, DIN A4 80 g)

NOTICE

The fixed knives must run parallel to the rotor knives so that the cutting load is distributed evenly across the whole length.

7. Insert the sieve cassette (9) (see ➞ *Chapter 6.1.5 'Inserting / changing a sieve cassette' on page 33*).
8. Close the cutting mill (see ➞ *Chapter 6.1.6 'Closing the cutting mill' on page 33*).

NOTICE

Check if the rotor is turning freely (see ➞ *Chapter 6.1.7 'Checking if the rotor is turning freely' on page 34*).

If this is not the case, proceed as described in ➞ *Chapter 6.1.3 'Setting the gap width of the knives' on page 31.*

This check must also be carried out every time the rotor and the knife are changed!

FRITSCH

6.1.4 Inserting / changing a rotor

CAUTION

Risk of injury!

Beware of the sharp edges of the rotor!

Wear safety gloves when changing the rotor!

Tooling Mode

Devices with a rotational speed of 300 - 3000 rpm, feature a 'Tooling Mode'. In this mode, the rotor can be blocked with opened door. This allows for a better replacement of the rotor.

The rotor must not be turned when Tooling Mode is activated!

Tooling Mode can be switched on only when the grinding chamber is open and switches itself off automatically again after 10 seconds or when the grinding chamber is closed.

An active Tooling Mode can be recognised by the lit LED direct at the button or the word 'tool' shown in the display.

1. Open the cutting mill (see ➡ *Chapter 6.1.1 'Opening the cutting mill' on page 29*).

2. Pull the rotor (10) forwards, wearing **safety gloves**. If the rotor (10) jams somewhat, lever it out carefully.



3. Clean the cone-shaped rotor holders (10).

4. Clean both cone-shaped holders (cones) in the closing lid (3) and on the holder.





5. Push the rotor (10) onto the rotor holder. Turn it clockwise until it engages in the 4 actuating pins (C) on the back. (Tooling Mode needs to be activated in devices with 300 - 3000 rpm)

6. Close the cutting mill (see ➦ *Chapter 6.1.6 'Closing the cutting mill' on page 33*).

NOTICE

Check if the rotor is turning freely (see ➦ *Chapter 6.1.7 'Checking if the rotor is turning freely' on page 34*).

If this is not the case, proceed as described in ➦ *Chapter 6.1.3 'Setting the gap width of the knives' on page 31.*

This check must also be carried out every time the rotor and the knife are changed!

6.1.5 Inserting / changing a sieve cassette

1. Open the cutting mill (see ➦ *Chapter 6.1.1 'Opening the cutting mill' on page 29*).



2. Pull out the sieve cassette (9) to the front. The rotor (10) must not be removed.

   Use the pulling tool (X) 45.5550.10 to pull out the sieve cassette (9): Insert the pulling tool into the two holes of the sieve cassette (9) past the bends of the pulling tool. While inserting the pulling tool, move it slightly up and down.



3. If the sieve cassette (9) is jammed, remove the comminution material under the fixed knife (12) on the left side of the housing with a screwdriver.

4. Before pushing in the sieve cassette (9) clean the cutting chamber thoroughly, so that everything can be closed tightly again.

5. Close the cutting mill (see ➦ *Chapter 6.1.6 'Closing the cutting mill' on page 33*).

6.1.5.1 Selecting the sieve cassette

Coarse material should be roughly crushed with the coarse 2-4 mm sieve and comminuted in the second work step to the desired final fineness. The sample exhaust system with cyclone separator can be used for fine comminution < 2 mm.

6.1.6 Closing the cutting mill

1. Before closing the cutting mill, clean the cutting chamber, the contact surfaces of the housing and, in particular, the locking surfaces of the lock.

2. Slowly swivel shut the upper part of the housing (1) until the funnel opening points upwards.
3. Insert the collecting vessel.
4. Close the closing lid (3).
5. Lock the latch clamp (13).

6.1.7 Checking if the rotor is turning freely



- To check if the rotor is turning freely, the closing lid has to be closed.
- Switch off the device at the main switch.
- Remove the cover cap of the central bore hole in the closing lid.



- Guide the hexagon socket screw key provided through the central bore hole in the closing lid.
- Now turn the hexagon socket screw key to check if the rotor is turning freely.



- Remove the hexagon socket screw key again **immediately!**
- If the rotor is not turning freely, proceed as described in ➞ *Chapter 6.1.3 'Setting the gap width of the knives' on page 31.*

NOTICE

Perform this test each time the rotor or fixed knife is changed, and after a gap adjustment!

6.2 Comminution procedure with standard funnel

CAUTION

Wear safety goggles for comminution using the standard funnel!

In the case of free-flowing material, particles could be ejected from the funnel.

1. Switch the device on at the main switch.
2. Close the cutting mill (see ➞ *Chapter 6.1.6 'Closing the cutting mill' on page 33*).
3. Push in the collecting vessel (5).
4. Pull the plunger out fully.

5. Switch on the device → press the Start button (see ➦ *Chapter 5.1 'Switching on' on page 27*).
6. Add some comminution material.

   ⇒An operating noise becomes audible.

   The quantity of comminution material varies depending on the particle feed size and the grindability of the comminution material. It is best to start with small quantities and increase them depending on the success of the comminution.
7. If necessary, press the comminution material into the cutting chamber with the plunger.
8. When the operating noise becomes quieter, the comminution procedure is complete.

   ➨ More comminution material can be added.

6.2.1 Using the plunger



The plunger has 2 different sides for feeding the sample material in the funnel to the grinding chamber. On the one hand, the smooth, round side is suitable for finer material. On the other hand, the cross-shaped, thinner side is suitable for long, fibrous material, like straw.

6.3 Comminution procedure with the protected funnel



1. Switch the device on at the main switch.
2. Close the cutting mill (see ➦ *Chapter 6.1.6 'Closing the cutting mill' on page 33*).
3. Push in the collecting vessel (5).
4. Pull the sample pusher (21) out fully.
5. Move the plunger (22) into the lower position.
6. Flip open the funnel lid (23), add some comminution material and close the lid again.

   The quantity of comminution material varies depending on the particle feed size and the grindability of the comminution material. It is best to start with small quantities and increase them depending on the success of the comminution.
7. Switch on the device → press the Start button (➦ *Chapter 5.1 'Switching on' on page 27*).





8. Move the sample pusher (21) down towards the plunger (22) until the comminution material is in front of the plunger (22).
9. Pull the plunger (22) upwards and move the sample pusher (21) fully downwards until the comminution material falls into the cutting chamber.
   ➧ A slight operating noise becomes audible.
10. Leave the sample pusher (21) down and move the plunger (22) downwards.
    ➧ The operating noise becomes louder.
11. Make pumping movements with the plunger (22). These pumping movements draw in and press out air through the blower filter above the collecting vessel. This air feeds the comminution material through the sieve or lifts it off the sieve and back into the process.
12. When the operating noise becomes quieter, the cutting procedure is complete.
    ➧ More comminution material can be added.

6.4 Overload of the cutting mill

When filling and making downward movements with the plunger (22) the operating noise must be observed. The sound level is nearly identical to the load on the machine. You can clearly hear from the pitch when the mill reduces speed due to overload.

Pulling the plunger (22) out on time reduces the load on the mill and protects the rotor (10), the fixed knives (2, 4, 12) and the sieve cassette (9).

NOTICE

If the cutting mill is overloaded, the fuse in the main switch switches the device off.

Then proceed as follows:

1. Allow the device to cool down.
2. Switch main switch back on after brief cooling phase.

6.5 Sample exhaust system with cyclone separator

For sample exhaustion with the high-performance cyclone separator in combination with the PULVERISETTE 19 large, please contact Fritsch or your sales partner.

The small volume cyclone separator is not recommended in combination with the PULVERISETTE 19 large.

6.5.1 High-performance cyclone separator

A dust exhaust system (43.9070.00) is needed to use the high-performance cyclone separator.



27 Adapter for exhaust system
28 Connection hose
29 Sleeve FDA
30 Cyclone separator
31 Dust exhaust connection
32 Sample bottle
33 Adapter for sample bottle
34 Swivelling stainless steel stand

CAUTION

Hearing damage!

Wear hearing protection during sample extraction with the cyclone separator!

(Optional accessory order number: 19.1907.00)

The sample exhaust system with high-performance cyclone separator can be used for fine comminution.

1. Open the closing lid.
2. Push the adapter for the exhaust system (27) into the lower part of the housing (8).



When using the cyclone separator, the filter above the collecting vessel is automatically covered by the adapter.



3. Attach one end of the connection hose (28) with the rubber sleeve (29) to the adapter for exhaust (27) and the other end to the cyclone separator (35).
4. Close the cutting mill with mounted standard funnel (15) (see ➦ *Chapter 6.1.6 'Closing the cutting mill' on page 33*).
5. Screw the sample bottle (31) onto the adapter (33) on the cyclone separator (30); make sure the connection hose is firmly connected and switch on the exhaust system.
6. Switch on the cutting mill (see ➦ *Chapter 5.1 'Switching on' on page 27*).
7. Add a little comminution material by hand and observe the operating noises. If the motor speed decreases audibly, reduce the supply of comminution material. A fast vortex of comminution material should form in the collection bottle.

The quantity of comminution material is based on the particle feed size and the grindability of the material. It is best to start with small quantities and increase them depending on the success of the comminution.

NOTICE

When the sample bottle (32) is 2/3 full, stop the comminution. To do this, switch off the cutting mill (see ➟ *Chapter 5.3 'Switching off' on page 28*) and the sample exhaust system. Then empty the sample bottle (32).

If comminution has not stopped when the bottle is 2/3 full, the effectiveness of the cyclone separator will decline.

If the vortex of comminution material in the collection bottle slows down, this means that the air throughput or air flow rate has decreased:

- grinding chamber is too full
- the sieve has to be cleaned and / or
- the filter of the exhaust system has to be cleaned.

NOTICE

The fine material (fine dust) of the sample collects in the filter of the sample exhaust system. Clean the filter from time to time by vacuuming or blowing out.

The sample exhaust system is recommended especially in combination with the standard funnel (15) for bulk and long solids.

6.5.1.1 19.1957.00 - Solid piping for P-19 / 19.4947.00 - Solid piping for P-19 L

All sample glasses, as well as the collecting vessel 20 litres made of stainless steel can be combined with the solid piping!



1 Solid piping with adapter
2 Cyclone mounting plate with Bosch profile
3 Stand plate with Bosch profile
4 Collecting vessel 20 l
5 High-performance cyclone separator
6 Hinge clamp
7 Sliding sleeve with 2 seals
8 Hinge clamp with one seal
9 Solid piping
10 Hinge clamp with one seal
11 Sliding sleeve with 2 seals
12 Hinge clamp
13 Adapter for sample extraction (P-19 - 19.1797.00 / P-19 L - 19.1794.00)

6.5.1.2 Use of the exhaust hose

When using the cyclone separator with exhaust you also have the possibility to use the standard funnel with exhaust. You need the hose 45.5987.00 for that. Attach it as follows:



1. If the standard funnel is mounted, remove the plastic attachment so that only the metal pipe can still be seen.
2. Mount the supplied adapter on this metal tube. Then connect the sleeve with the suction hose.
3. Once the Universal Cutting Mill and the exhaust system have been switched on, you can use the suction hose to suck in sample material that has a low density.

6.5.2 Small volume Cyclone separator



The small volume Cyclone separator can be used for the sample exhaustion of small sample quantities!

When using the small volume Cyclone separator in combination with the P-19, the cyclone can only be used actively with an extraction system.



1 Dust exhaust connection
2 Small volume cyclone separator
3 Stand
4 Collecting vessel
5 Particle inlet pipe for connecting to the adapter for sample exhaustion
6 Bushing for spiral hose (45.5984.16)
7 Adapter for sample exhaustion (19.1797.00)
8 Bushing for spiral hose (45.5984.16)
9 Hose for sample exhaustion (45.5979.16)

1. Connect all parts as shown in the previous image.
2. Switch on the exhaust system.
3. Switch on the PULVERISETTE 19.
4. Add the sample in small amounts into the funnel.
5. As soon as the collecting vessel underneath the small volume Cyclone separator is 3/4 full, stop adding the sample and empty or replace the collecting vessel!

6.5.3 Connect the switch box of the exhaust system

To automatically start the exhaust system with the grinding, use switch box 19.3073.00. To use the switch box, activate "Cyclone" mode as described in ➦ *Chapter 4.8 'Set-up mode' on page 25.*

Then connect the switch box to the P-19 using the data cable supplied and plug it into your power supply. Next plug the mains connection of the exhaust system into the power connection of the switch box.

The Cyclone separator exhaust system is automatically started and stopped when grinding is started!

7 Cleaning

NOTICE

Depending on the moisture content of the material to be comminuted, the mill must be freed from residues and cleaned after each grinding operation.

7.1 Housing

The cutting mill can be wiped down with a damp cloth when it is switched off. Disconnect the mains plug (20) from the electricity.

DANGER

Do not allow any liquids to flow into the device.

7.2 Cutting chamber

Clean the cutting chamber with a vacuum cleaner and brush, and with compressed air, if necessary.

CAUTION

Beware of dust exposure caused by cleaning with compressed air!

CAUTION

Klemmgefahr!

If the *'Tooling-Mode'* is activated (only for units with 300 - 3000 rpm), the motor shaft is blocked!



1. Unlock the latch clamp (13).
2. Open the closing lid (3) fully. This can be lifted out of the hinge at an opening angle of 90° for cleaning.
3. Activate *'Tool Mode'*. (Only with devices with 300 - 3000 rpm)

Cleaning



4. Slowly swivel open the upper part of the housing (1) with the closing lid (3) fully open until it is resting on the rubber buffer.
5. Clean the cutting chamber.

7.3 Funnel

Clean the funnels (15, 24) with a dust exhaust system and brush and also with compressed air, if necessary.

7.3.1 Standard funnel (15)

1. With the cutting chamber open, vacuum out the funnel from below
2. Clean the funnel from above.

7.3.2 Protected funnel (24)



1. Switch the device off at the main switch.
2. Pull the sample pusher (21) out of the protected funnel (24) until it stops. The sample pusher has 2 notches. The sample pusher can be set into these two positions.
3. Open the funnel lid (23).
4. Clean the protected funnel (24) from above.
5. Close the funnel lid (23).



6. Pull the plunger (22) out of the protected funnel (24) until it stops and fasten it with knurled screw (B).
7. Open the cutting chamber as described above.
8. Clean the protected funnel (24) from below.

If necessary!

It is also possible to remove the plunger (22) and the sample pusher (21) for cleaning. Switch off the main switch and disconnect the mains plug (20).

7.3.2.1 Removing sample pusher (21)



1. Open the funnel lid (23).
2. Unscrew the knurled screw (A).
3. The sample pusher (21) can be taken out.
4. Install in reverse order.

7.3.2.2 Removing the plunger (22)



1. Open the funnel lid (23).
2. Unscrew the Torx screws (D) with a screwdriver.
3. Close the funnel lid (23).



4. Unscrew the Torx screws (E) with a screwdriver.
5. Unscrew the knurled screw (C).
6. The plunger (22) can be taken out.
7. Install in reverse order.

7.3.3 Funnel for bulk solids PULVERISETTE 19 *large*



1. Open the funnel lid (A).
2. Unscrew the 4 socket-head screws (B) and knurled screw (D).
3. The plunger (C) can be taken out.
4. Install in reverse order.

7.4 Collecting vessel

Pull out the collecting vessel (5) and clean it. It can be vacuumed or wiped down with a damp cloth.

NOTICE

Close the cutting mill after cleaning and check for proper functioning. See ➦ *Chapter 5 'Initial start-up' on page 27.*

NOTICE

Make sure that the parts sit firmly when assembling.

7.5 Cleaning the filter foam mat

1. Vacuum the filter foam mat with the vacuum cleaner.
2. Subsequently wash it out with water. If necessary, you could use a tenside for cleaning.
3. Allow the foam mat to air-dry!

7.6 Cleaning the labyrinth seal

Depending on the material to be comminuted and the duration of the comminution, the labyrinth seal must be cleaned regularly. To do this, proceed as follows:

1. Open the grinding chamber.
2. Remove the rotor.



3. Position the anti-rotation device (a) on the tool holder. If necessary, turn the tool holder so that the bolts of the anti-rotation device do not rest on the bolts of the tool holder.
4. Loosen the hexagon socket screw in the tool holder.



5. Screw the hexagonal screw M10x130 into the tool holder. The narrow tip of the screw presses on the motor shaft inside the tool holder, pulling off the labyrinth seal.

6. Disassemble the hexagon head screw M10x130 and remove the anti-rotation device.



7. Clean the labyrinth seal and the seal of the cover plate.

Coat the seal ring with the enclosed Vaseline before the installation.



8. To mount the tool holder with labyrinth seal, position the cover plate on the labyrinth seal and place the tool holder with seal on the motor shaft.

Pay attention to the cut-out on the tool holder so that it can be pushed onto the motor shaft.



9. Take the anti-twist device and the M8x130 screw with the washer and mount it as shown in the picture.



10. When the labyrinth seal is completely pressed in, dismantle the M8x130 screw with the washer and remove the anti-rotation device.

11. Finally, screw the hexagon socket screw back into the tool holder.

7.7 Cleaning the labyrinth seal in the closing lid



Depending on the material to be comminuted and the duration of the comminution, the labyrinth seal in the closing lid must be cleaned regularly. To do this, proceed as follows:

1. Open the closing lid.
2. Hold your left hand against the inside of the closing lid to prevent the labyrinth seal from falling down!
3. To push out the labyrinth seal, use, for example, the hexagon socket screw key with which you check that the rotor is turning freely. Use it to press through the bore hole in the closing lid.

If you cannot remove the labyrinth seal just by pressing, close the closing lid with the sieve cassette inserted, but without the rotor. Take the hexagon socket screw key as described in the previous step and knock against it lightly with a hammer. The labyrinth seal should fall inwards onto the sieve cassette.

4. When the labyrinth seal has fallen out, clean it and press it back in again with your hand.

Grease the labyrinth seal at regular intervals to ensure that it can be easily mounted and removed.

8 Maintenance

⚠ DANGER

Mains voltage

- Before beginning with maintenance work, unplug the mains plug and protect the device against being unintentionally switched back on again!
- Indicate maintenance work with warning signs.
- Maintenance work may only be performed by specialised personnel.
- Put safety equipment back into operation after maintenance or repair work.

We recommend keeping a safety logbook ➞ Chapter 13 'Safety logbook' on page 60, where all work (maintenance, repairs.....) performed on the device is entered.

The most important element of maintenance is regular cleaning!





26 Exhaust filter
H Filter holder
F Filter foam mat

Maintenance

Function / Functional part	Task	Test	Maintenance interval
Exhaust filter (26)	Filtering exhaust air	Clean exhaust filter (26). To do this, lever out the filter holder (H) with a screwdriver or similar. Beat the filter foam mat (F). Clean using compressed air or vacuum cleaner. Replace the filter foam mat (F) if it is very heavily soiled. Item number: 90.0740.16 filter foam mat.	Before every comminution
Safety lock (11)	Locking the closing lid (3)	Is the closing lid (3) locked shut when the main switch is deactivated? If NOT → safety lock (11) defective. Disconnect the device from the mains immediately. Replace the safety lock (11).	Before each use
Safety switch (6)	Protecting the lower opening of the cutting chamber	Is the cutting mill running without the collecting vessel (5) or the adapter for exhaust system (27)? If YES → safety switch (6) defective. Disconnect the device from the mains immediately. Replace the safety switch (6).	Before each use
Rotor (10)	Comminuting material	Is the rotor (10) sharp? If NOT → resharpen	Before each use
Fixed knife (2,4,12)	Comminuting material	Are the fixed knives (2,4,12) sharp? Check visually! Maintenance: resharpen	Before each use
Cutting gap	Cutting procedure	Measure gap width. For setting see ➦ *Chapter 6.1.3 'Setting the gap width of the knives' on page 31.*	Whenever rotor and fixed knives are changed
Cones	Centring rotor (10)	Check cones for cleanliness and grooves. See ➦ *Chapter 6.1.4 'Inserting / changing a rotor' on page 32.*	After each rotor change
Filter, sieve and sample exhaust	Filtering exhaust air	Vortex of comminution material in the collection bottle slows down! For cleaning see ➦ *Chapter 7 'Cleaning' on page 43*	Before each use
Sealing rings / O-rings	Seal funnel and door	Check the seals for damages. Damage visible? If yes → replace	Before each use

9 Repairs



⚠ DANGER

Mains voltage!

- Before beginning with repair work, unplug the mains plug and protect the device against being unintentionally switched back on.
- Indicate repair work with warning signs.
- Repair work may only be performed by specialised personnel.
- Put safety equipment back into operation after maintenance work.

9.1 Checklist for troubleshooting

Fault description	Cause	Remedy
START button has been pressed but mill does not start up	Closing lid (3) not closed properly	Clean contact surface, close closing lid (3)
	Collecting vessel (5) or adapter for exhaust system (27) not inserted properly	Insert collecting vessel (5) or adapter for exhaust system (27) properly → until safety switch (11) engages.
	Coarse samples were added to the machine first and are blocking rotor start-up.	Open grinding chamber and remove sample material. → Switch on device before adding sample.
Mill stops running	Fuse in the main switch has triggered	Let the mill cool down and switch back on at the main switch (see ➦ *Chapter 6.4 'Overload of the cutting mill' on page 36*)
Comminution material is escaping	Material is extremely fine	Insert sample exhaust system (see ➦ *Chapter 6.5 'Sample exhaust system with cyclone separator' on page 36*)
Runs unevenly with strong vibrations	Rotor imbalance	Cones soiled (see ➦ *Chapter 6.1.4 'Inserting / changing a rotor' on page 32*)
	Bearing in closing lid (3) defective	Replace bearing
	Pieces broken off rotor (10)	Replace rotor (10) (➦ *Chapter 6.1.4 'Inserting / changing a rotor' on page 32*)
	Rotor and fixed knives are touching each other (audible metal contact noise)	Switch device off immediately, disconnect from mains, check gap widths and correct. Check rotor and fixed knives

Repairs

Fault description	Cause	Remedy
Runs unevenly with strong vibrations	Rotor and fixed knives are touching each other (audible metal contact noise)	for damage. (See ➦ *Chapter 6.1.2 'Inserting / changing the fixed knives' on page 29*)

9.2 Error messages

In case of several errors, these will be displayed in 3-second intervals!

No.	Fault description	Cause	Remedy
Er01	Collecting vessel not recognised!	Not inserted or inserted incorrectly.	Insert the collecting vessel correctly.
Er02	Collecting vessel safety circuit - channel discrepancy	A safety channel is not properly recognised.	Clean the safety switch and the actuator at the collecting vessel (if required with compressed air). If the error persists, contact Fritsch Service.
Er03	Short-circuit of an operating button		Contact Fritsch Service!
Er04	Motor temperature too high	The rotor is braked or the grinding chamber is too heavily soiled.	Clean the grinding chamber and the labyrinth seals (see ➦ *Chapter 7.6 'Cleaning the labyrinth seal' on page 46* and ➦ *Chapter 7.7 'Cleaning the labyrinth seal in the closing lid' on page 48*). Check that the rotor moves freely. If necessary, add grinding stock more slowly and evenly.
Er05	Grinding chamber door not closed	Door not closed properly, surfaces of the grinding chamber door contaminated, or locks defective.	Close the grinding chamber door before starting. If the error exists despite the grinding chamber door being closed, clean the door switch (if necessary with compressed air). If the error persists, contact Fritsch Service.
Er06	Door contact safety circuit - channel discrepancy		Clean the safety switch and the actuator at the door (if required with compressed air). If the error persists, please contact Fritsch Service.
Er07	Door lock cannot be fully closed	Safety switch or grinding chamber door soiled.	Check the safety switch at the door for soiling. Clean the safety switch (if required with compressed air). If the error persists, please contact Fritsch Service.

No.	Fault description	Cause	Remedy
Er08	Door lock cannot be fully opened.	Safety switch soiled	Check the safety switch at the door for soiling. Clean the safety switch (if required with compressed air). If the error persists, please contact Fritsch Service.
Er09	Door lock safety circuit - channel discrepancy		Check the safety switch at the door for soiling. Clean the safety switch (if required with compressed air). If the error persists, please contact Fritsch Service.
Er10	Motor initiator signals no speed during operation detected	The motor is blocked or not active.	Check the safety switch at the door for soiling. Clean the safety switch (if required with compressed air). If the error persists, please contact Fritsch Service.
Er11	Frequency converter signals no speed during operation detected	The motor is blocked or not active.	Clean the grinding chamber and the labyrinth seals (see ➦ *Chapter 7.6 'Cleaning the labyrinth seal' on page 46* and ➦ *Chapter 7.7 'Cleaning the labyrinth seal in the closing lid' on page 48*). Check that the rotor moves freely. If necessary, add grinding stock more slowly and evenly.
Er12	STO safety connection faulty		Contact Fritsch Service!
Er13	STO safety switch-off faulty		Contact Fritsch Service!
Er14	STO – discrepancy error		Contact Fritsch Service!
Er15	Frequency converter	Does not signal readiness	Switch off the device for 30 seconds. Then switch the device back on again. If the error persists, contact Fritsch Service.
Er16	Frequency converter	No frequency converter connected	Contact Fritsch Service!
Er17	Frequency converter	Frequency converter temperature too high	Wait until the device has cooled down and restart it after several minutes. Clean the grinding chamber and the labyrinth seals (see ➦ *Chapter 7.6 'Cleaning the labyrinth seal' on page 46* and ➦ *Chapter 7.7 'Cleaning the labyrinth seal in the closing lid' on page 48*). Check that the rotor moves freely. If necessary, add grinding stock more slowly and evenly.
Er18	Frequency converter	Speed is not reached	Switch off the device and clean the grinding chamber. Feed the grinding stock more slowly. Clean the grinding chamber and the labyrinth seals (see ➦ *Chapter 7.6 'Cleaning the labyrinth seal' on page 46* and ➦ *Chapter 7.7*

Repairs

No.	Fault description	Cause	Remedy
Er18	Frequency converter	Speed is not reached	*'Cleaning the labyrinth seal in the closing lid' on page 48*). Check that the rotor moves freely. If necessary, add grinding stock more slowly and evenly.
Er19	Frequency converter	Current limit reached	Switch off the device and clean the grinding chamber. Feed the grinding stock more slowly. Clean the grinding chamber and the labyrinth seals (see ➦ *Chapter 7.6 'Cleaning the labyrinth seal' on page 46* and ➦ *Chapter 7.7 'Cleaning the labyrinth seal in the closing lid' on page 48*). Check that the rotor moves freely. If necessary, add grinding stock more slowly and evenly.
Er20	Frequency converter	No communication possible	Contact Fritsch Service!
Er21	Frequency converter	Signals error	Press the "SPEED/TIME" button to display the error code of the frequency converter. Contact Fritsch Service with this information.
Er22	Grinding chamber door	Opens during operation	Check that the mechanical door lock is fit correctly. If the error persists, please contact Fritsch Service.

10 Disposal

It is hereby confirmed that FRITSCH has implemented the directive 2002/95/EC of the European Parliament and Council from 27th January 2003 for the limitation of the use of certain dangerous substances in electrical and electronic devices.

FRITSCH has registered the following categories according to the German electrical and electronic equipment act, section 6, paragraph 1, clause 1 and section 17, paragraphs 1 and 2:

Mills and devices for the preparation of samples have been registered under category 6 for electrical and electronic tools (except for large stationary industrial tools).

Analytical devices have been registered under category 9, monitoring and control instruments.

It has been accepted that FRITSCH is operating only in the business-to-business area. The German registration number for FRITSCH is WEEE reg. no. DE 60198769

FRITSCH WEEE coverage

Since the registration of FRITSCH is classified for bilateral transactions, no legal recycling or disposal process is described. FRITSCH is not obliged to take back used FRITSCH devices.

FRITSCH declares it is prepared to take back used FRITSCH devices for recycling or disposal free of charge whenever a new device is purchased. The used FRITSCH device must be delivered free of charge to a FRITSCH establishment.

In all other cases FRITSCH takes back used FRITSCH devices for recycling or disposal only against payment.

11 Guarantee terms

Guarantee period

As manufacturer, FRITSCH GmbH provides – above and beyond any guarantee claims against the seller – a guaranty valid for the duration of two years from the date of issue of the guarantee certificate supplied with the device.

Within this guarantee period, we shall remedy all deficiencies due to material or manufacturing defects free of charge. Rectification may take the form of either repair or replacement of the device, at our sole discretion. The guarantee may be redeemed in all countries in which this FRITSCH device is sold with our authorisation.

Conditions for claims against the guarantee

This guarantee is subject to the condition that the device is operated according to the instructions for use / operating manual and its intended use.

Claims against the guarantee must include presentation of the original receipt, stating the date of purchase and name of the dealer, together with the complete device type and serial number.

For this guarantee to take effect, the answer card entitled "Securing of Guarantee" (enclosed with the device) must be properly filled out and despatched without delay after receipt of the device and be received by us within three weeks or alternatively, ⇀ *online registration* must be carried out with the above-mentioned information.

Reasons for loss of the guarantee

The guarantee will not be granted in cases where:

- Damage has arisen due to normal wear and tear, especially for wear parts, such as: Crushing jaws, support walls, grinding bowls, grinding balls, sieve plates, brush strips, grinding sets, grinding disks, rotors, sieve rings, pin inserts, conversion kits, sieve inserts, bottom sieves, grinding inserts, cutting tools, sieve cassettes, sieve and measuring cell glasses.
- Repairs, adaptations or modifications were made to the device by unauthorized persons or companies.
- The device was not used in a laboratory environment and/or has been used in continuous operation.
- Damage is present due to external factors (lightning, water, fire or similar) or improper handling.
- Damage is present that only insubstantially affects the value or proper functioning of the device.
- The device type or serial number on the device has been changed, deleted, removed or in any other way rendered illegible
- The above-mentioned documents have been changed in any way or rendered illegible.

Costs not covered by the guarantee

This guarantee excludes any costs for transport, packaging or travel that accrue in the event the product must be sent to us or in the event that one of our specialist technicians is required to come to your site. Any servicing done by persons not authorised by us and any use of parts that are not original FRITSCH accessories and spare parts will void the guarantee.

Further information about the guarantee

The guarantee period will neither extend nor will a new period of guarantee begin in the event that a claim is placed against the guarantee.

Guarantee terms

Please provide a detailed description of the type of error or the complaint. If no error description is enclosed, we shall interpret the shipment as an assignment to remedy all recognisable errors or faults, including those not covered by the guarantee. Errors or faults not covered by the guarantee shall in this case be rectified at cost.

We recommend reading the operating manual before contacting us or your dealer, in order to avoid unnecessary inconvenience.

Ownership of defective parts is transferred to us with the delivery of the replacement part; the defective part shall be returned to us at buyer's expense.



NOTICE

Please note that in the event that the device must be returned, the device must be shipped in the original Fritsch packaging. Fritsch GmbH denies all liability for any damage due to improper packaging (packaging not from Fritsch).

Any enquiries must include a reference to the serial number imprinted on the type plate.

12 Exclusion of liability

Before using the product, be sure to have read and understood this operating manual.

The use of the product requires technical knowledge; only commercial use is permitted.

The product may be used exclusively within the scope of applications set down in this operating manual and within the framework of guidelines put forth in this operating manual and must be subject to regular maintenance. In case of non-compliance, improper use or improper maintenance, the customer assumes full liability for the functional capability of the product and for damage or injury arising from violating these obligations.

The contents of this operating manual are subject in entirety to copyright law. This operating manual and its contents may not be copied, further distributed or stored in any form, in part or in whole, without the prior written consent of Fritsch.

This operating manual has been prepared to the best of our knowledge and checked for accuracy at the time of printing. FRITSCH GMBH assumes no guarantee or liability whatsoever for the accuracy or completeness of the contents of this operating manual, including but not limited to the implied warranties of merchantability and fitness for a particular purpose, unless liability is expressly prescribed by applicable laws or jurisprudence.

FRITSCH GMBH expressly reserves the right to modify and/or update this operating manual without prior notice. The same applies to modifications and improvements to the products described in this operating manual. It is the responsibility of the user to ensure that they have the current version of this operating manual. For more information, please contact your local FRITSCH GMBH distributor or Fritsch GmbH, Industriestr. 8, D-55473 Idar-Oberstein.

Not all parts shown here are necessarily installed in the product. The buyer is not entitled to delivery of these parts. If interested, please contact your local FRITSCH GMBH distributor or Fritsch GmbH, Industriestr. 8, D-55743 Idar-Oberstein.

FRITSCH GMBH takes the greatest care to ensure that the quality, reliability and safety of your products are continuously improved and adapted to the state of the art. The supplied products as well as this operating manual conform to the current state of the art when they leave the sphere of influence of FRITSCH GMBH.

By using the product the customer agrees with this and recognizes that defects, malfunctions or errors cannot be completely excluded. To prevent risk of damage to persons or property or of other direct or indirect damage, resulting from this or other causes, the customer must implement sufficient and comprehensive safety measures for working with the product.

Fritsch GmbH excludes any liability, warranty, or other obligation to compensate for damages, regardless of whether this liability, warranty, or other obligation is explicit or implicit, contractual or arising from unlawful acts or prescribed contractually, by law, or otherwise. In no event shall the buyer be entitled to any compensation from Fritsch GmbH for any special, direct, indirect, coincidental or consequential damage, including but not limited to lost profits, lost savings, lost sales or financial loss of any kind or for compensation of third parties, for downtimes, for lost goodwill, for damage to or replacement of equipment and property, for costs or restoration of materials or goods related to the product or the use of our products, for other damage or injury to persons (including fatal

Exclusion of liability

injuries) or similar. The above exclusion of liability is limited by mandatory liability as prescribed by laws or jurisprudence. Liability for negligence is excluded in all cases.

No permission is given expressly, implicitly or otherwise for the use of patents, brands or other copyrights. We also assume no liability for copyright infringements or infringements of the rights of third parties arising from the use of this product.

Neither compliance with this operating manual nor the conditions and methods used during installation, operation, use and maintenance of the product can be monitored by Fritsch GmbH. Improper execution of the installation can result in property damage and thus endanger persons. Therefore, we assume absolutely no responsibility or liability for loss, damage or costs that result from errors at installation, improper operation or improper use or improper maintenance or are in any way connected to these.

13 Safety logbook

Date	Maintenance / Repair	Name	Signature

Date	Maintenance / Repair	Name	Signature

Safety logbook

Date	Maintenance / Repair	Name	Signature

14 Index





Fritsch GmbH
Milling and Sizing
Industriestraße 8
55743 Idar-Oberstein, Germany
Telephone: +49 6784 70-0
Email: info@fritsch.de
Internet: www.fritsch.de

License Type: Processor

Exhibit 15 – Receiving and Shipping Plan

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

Introduction

Our medical cannabis establishment is committed to receiving and shipping plans and procedures that maintain vendor and product safety, efficient operations, and compliance with all relevant requirements and guidance from the Alabama Medical Cannabis Commission ("AMCC"). Proper receiving and shipping of medical cannabis is paramount to the effectiveness of the medical cannabis program and the safety of all Alabama patients. We have crafted this plan to properly track all medical cannabis being received and shipped by our facility. Ala. Admin. Code r. 538-x-6-.06.03.f. Partnerships that we develop with secure transporters, other licensees, and state testing laboratories will conform to this secure and compliant plan.

Shipping and Receiving Team

As part of our vision to supply Alabama dispensaries with safe medical cannabis, we have assembled a security and shipping team of industry experts. They will guide our receiving, shipping, and security operations, and develop standard operating procedures ("SOPs") which keep our employees, products, and patients safe.

Our Head of Supply Chain Management ("HoSCM") will oversee our inventory procedures, including quality control for shipped and received products. They will also conduct internal inventory audits as part of our product safety and security plan. Our HoSCM has over a decade of experience managing supply chains and inspecting inventory. She has worked closely with corporate executives, developing successful strategic initiatives with her thorough understanding of product design and life cycle. Her many years of experience with supply chain and inventory management will enable them to implement a comprehensive program to account for all inventory.

Our Transportation Coordinator ("TC") will oversee our transportation operations. Our company will only employ drivers who are properly trained and licensed and we will verify that all vehicles and drivers maintain compliance with all applicable laws. Working with the HoSCM and the TC, our Chief Compliance Officer ("CCO") will train staff on regulatory compliance and will create checklists for adherence to proper shipping and receiving procedures and regulations. Our CCO, Justin Forrester, has over ten years of legal

experience. They will provide staff trainings and consistent compliance with all applicable statutes and regulations.

15.1 – Security of Received Products

All individual batches of cannabis received by our facility will undergo inspection to confirm they were appropriately prepared at their origin. This inspection will include verification of product identification, and confirmation that all products are secure in their containers at the time of receipt. Ala. Admin. Code r. 538-x-6-.06.03.f.01.

Receiving Area

Deliveries of cannabis will only be accepted at the rear entrance of our facility, accessible only with an authorized keycard. We will employ a security guard to patrol the interior of the building during business hours, and when we receive a delivery, they will supervise this process.

Our building will feature continuous video surveillance monitoring of the receiving area, the exterior of our facility near the area, and the entrance to the product vault. All areas will be appropriately lit to aid video surveillance. Received products may only be removed from the receiving area once the facility is closed and locked. The exterior receiving door may not be opened while products are being moved.

Process for Receiving

To request a shipment of cannabis, our facility will communicate with a licensed medical Cultivator or Integrated Facility in Alabama to place an order. Our facility and the originating facility will decide an expected time of delivery. All deliveries must be scheduled for secure receipt. When the secure transport team arrives at our premises, they will communicate with our security team for facility access. A security guard will then move to the rear of our facility where shipments are received. Our IM will open the receiving door of the facility and will inspect the delivery for accuracy and safety. This includes examination of secure transport containers and digital codes. If the delivery is not accurate, or is otherwise unsecured, we will communicate the inaccuracy to the delivering and originating licensee and reject the delivery. If we verify the shipment is secure and accurately labeled,

we will sign for the shipment. This action will transfer product responsibility to us in the chain of custody. Once the shipment is received and our facility is locked and fully secured, we will move the products to our receiving area for further quality assurance inspections.

15.2 – Received Product Labels

All batches and containers that arrive from a cultivator will be digitally coded to identify the Cultivator, plant tag number, date of harvest, and the date of the State Laboratory testing approval. Ala. Admin. Code r. 538-x-6-.06.03.f.02. All digitally coded data will be entered into our inventory system and the statewide seed-to-sale tracking system.

15.3 – Receiving Manifest

All cannabis received and accepted at our facility will be accompanied by the Secure Transporter manifest, and other appropriate documentation. When receiving products, a management team member will open the receiving door of the facility and inspect the manifest for accuracy. All manifest information will be accurate and duly executed by all appropriate parties. Ala. Admin. Code r. 538-x-6-.06.03.f.03.

A manifest is created once we request an order from a state licensed cultivator or integrated facility. The originating facility will securely transmit the shipping manifest to our facility prior to products leaving their facility. The originating licensee will provide all necessary secure transport details within the manifest. We will keep digital and physical copies of all manifests we receive for two years after the date of delivery. Manifests will be made immediately available to the AMCC upon request.

Rejecting Receipt

Despite all efforts, it could be the case that we must reject a delivery. Our CCO will create a mandatory compliance checklist for use by staff receiving shipments of cannabis inventory at our facility. If an incoming shipment in any way does not comply with shipping preparation, digital coding, tagging, packaging, labeling, recordkeeping, or other compliance items from our checklist, we will reject the shipment. If any product in the order is rejected, we will reject the entire order. Our inventory team will be fully trained on how to handle any shipment that is rejected during the shipping and receiving process.

We will immediately contact the secure transporter and originating facility regarding the details of the rejection. An estimated return time of rejected product will be determined and communicated between all involved entities. We will place rejected products in tamper proof containers that are shut and sealed by an authorized employee. After the package has been made tamper-evident, the manifest will be documented by both parties as a rejection. A documented and signed manifest will be left with each party. The time rejected products depart our facility and return to the originating facility will be recorded in the manifest. The originating facility must accept the rejected products and will conduct their own quality control investigation.

15.4 – Records of Received Products

The statewide seed-to-sale tracking system will serve as our master log for all cannabis inventory. All information from the digital code on the incoming cannabis, as well as the date and time of product arrival, will be logged into the statewide seed-to-sale tracking system. Ala. Admin. Code r. 538-x-6-.06.03.f.04.

When all the received products are in our secure facility, our IM will record the manifest in the seed-to-sale tracking system. Acquired products will be recorded by scanning each QR code. Once scanned, products will be placed on a cart to transfer the entire shipment at once into the vault. Ala. Admin. Code r. 538-x-6-.06.03.f.01. All details on rejected products will also be recorded in the statewide tracking system.

15.5 – Security of Shipped Products

Individual batches of medical cannabis products being shipped from our Processor facility will always be appropriately packaged, labeled, and inserted in secure containers, prior to transport. Ala. Admin. Code r. 538-x-6-.06.03.f.05. Medical cannabis, related products, and packaging thereof, will not be visible or recognizable outside the secure transport vehicle.

Shipping Area

Deliveries of cannabis will only be shipped from the rear entrance of our facility, accessible only with an authorized keycard. We will employ a security guard to patrol the

interior of the building during business hours, and when we are preparing a shipment, they will supervise this process. Our building will feature continuous video surveillance monitoring of the shipping area, the exterior of our facility near the area, and the entrance to the product vault. All areas will be appropriately lit to aid video surveillance.

Chain of Custody

Acceptable transfer of responsibility requires that both the secure transport staff and our inventory staff come to a full agreement that all products declared to be present, are in fact present. The accurate execution of this step is critical to secure a compliant shipment and delivery. Both parties will perform a detailed inventory check. First, our IM will present the shipping containers to the secure transport staff. Next, the secure transport staff will compare the QR codes affixed to the shipping container against the serialized numbers printed on the manifest. Once correlation is confirmed, secure transport staff will review the manifest to confirm that all the driver's information has been correctly recorded. When each staff member has full confidence that each manifested item is in fact present, and that all information is accurately displayed on the manifest, they will sign their name on the manifest. Once all related staff have verified with their signature, full responsibility of the product is transferred to the Secure Transporter.

Once custody is assumed by secure transport staff, they will load the shipping containers into the cargo area of the Secure Transportation vehicle. All loading and unloading activities will occur at our licensed premises under constant video surveillance, located in our fenced-in vehicle area with security lighting and cameras. Transportation staff will only load and unload shipments within view of surveillance cameras. Video surveillance will create an evidentiary record of all loading and unloading. Transporting agents will not open any shipping containers for any reason. Once shipping containers have been packed and sealed for transport, only our own managerial staff, the licensed business establishment accepting the delivery, or law enforcement officials will be allowed to open the container.

Secure Packaging

We will securely package all medical cannabis or cannabis products that leave our facility to prevent tampering. All shipments will be placed inside a designated and secure container within the secure transport vehicle. Each container will be tamper-evident with a digital code on the exterior associated with the product inside. Our employees will refuse to release shipments that have not been properly or securely packaged and labeled.

15.6 – Shipped Product Labels

All batches and containers being shipped from our Processor Facility will be digitally coded to identify our Processor Facility via name, license number, and address; type and quantity of product; date of processing; date of packaging; and the date of our laboratory testing approval. Ala. Admin. Code r. 538-x-6-.06.03.f.06.

Our IM will compile the information required for the QR code using our inventory tracking system. The IM will then generate the QR code, which will populate on the label with our label printing software. Inventory staff will print and firmly attach the label to the container.

15.7 – Shipping Manifest

All outgoing medical cannabis from our Processor Facility will be accompanied by a Secure Transporter's manifest and other appropriate documentation. Information thereon will be accurate and duly executed by all appropriate parties. Ala. Admin. Code r. 538-x-6-.06.03.f.07. At a minimum, manifests used for secure transport will include: name of the driver and any other individuals onboard; name of the requesting licensee; the address of the destination facility; weight and description of each individual package in the shipment, and the total number of individual packages; handling and storage instructions; date and time the medical cannabis shipment is placed into the transport vehicle; date and time the shipment is accepted at the delivery destination; the identity of the employee with custody of the medical cannabis; and, the circumstances, duration, and disposition of any other person who had custody or control of the shipment.

Our IM will coordinate with our TC and secure transport staff to generate a shipping manifest for each delivery. The IM will provide all necessary product details, including tag information, for the shipment. Our TC will configure a secure and efficient route with

delivery software. We will always log product and transport details in our inventory system. This will create a virtual record of each delivery prior to shipment. A digital copy of the manifest will be transmitted to the receiving licensee. No products will ever be shipped from our facility without a complete and compliant manifest.

A physical copy of the manifest will be provided to the driver of the secure transport vehicle. This paper manifest will be proof of authorization to transport medical cannabis products in Alabama. The driver will also be provided with physical and digital copies of the transportation route, which they will follow. If an alternate route is necessary in an emergency, the driver will contact the security office for advisement. All changes and reasons necessitating the change will be documented.

Transportation Procedures

We will always work with a Secure Transporter to transport medical cannabis in a safe, efficient, and professional manner between licensed facilities. Ala. Admin. Code r. 538-x-7-.02.03.a. When finished products are ordered for outbound delivery, our IM will assume responsibility for the movement of finished products from the storage vault to the shipping area via in/out cages. These cages are wheeled, lockable, metal repositories that can securely move large volumes of product between the storage vault and the loading area.

All cannabis and related products will be sealed and not accessible to transport personnel during transit. We will confirm that our Secure Transporter partner always maintains medical cannabis and related products in a moisture- and temperature-controlled environment while in transit to avoid deterioration or loss of efficacy. Ala. Admin. Code r. 538-x-7-.02.03.c. Each cannabis storage unit will be equipped with a tracking device that can always be monitored remotely by our management or the AMCC during transit. Ala. Admin. Code r. 538-x-7-.03.02.e.v. For additional security, we will confirm each secure transport vehicle will be equipped with GPS tracking, which is continuously transmitted to the TC and the AMCC during transit. Ala. Admin. Code r. 538-x-7-.03.02.e.xiv. If an emergency requires stopping the vehicle, employees will notify our security center and the Alabama law enforcement agency. They will immediately communicate the nature of the emergency and complete an incident report form provided by the AMCC upon their return to our facility. Ala. Admin. Code r. 538-x-7-.03.02.e.viii. We

will report any abnormal activity along the route and create a clear documentation trail of our products for law enforcement agencies.

We will confirm our Secure Transport partner always has at least two personnel in a vehicle if there is medical cannabis or related products within being transported to multiple destinations or more than ten miles. These two personnel will include the driver and one other authorized individual. If the only destination is a state testing laboratory, Secure Transporter may allow a solo designated driver, though the vehicle will never be unattended or out of their control. Ala. Admin. Code r. 538-x-7-.03.02.e.xii; Ala. Admin. Code r. 538-x-7-.03.02.e.ix. Vehicles will be inspected at the end of each delivery and at the end of each completed route to warrant no product has been mismanaged.

Each employee in a secure transport vehicle will always have communication access to our security center and 911. Drivers will have ready access to duress, panic, or hold-up alarms that may be activated in the event of an attempted diversion. Ala. Admin. Code r. 538-x-7-.03.02.e.vii. Secure Transport drivers will also be trained in secure procedures for law enforcement inspections. Ala. Code § 20-2A-65(c). All secure transport employees will carry ID, which upon request must be presented to law enforcement or AMCC officials. Ala. Admin. Code r. 538-x-7-.03.02.e.x.

Delivery Procedures

Upon arriving at the delivery location, Secure Transporter staff will communicate with the receiving facility employees. A security guard and authorized employee from the receiving facility will assist in safely and securely unloading cannabis containers from the cargo area of the transportation vehicle. The driver will always remain with the vehicle and any products within. Secure Transporter staff will record their arrival time on the transportation manifest. After the receiving agent confirms that the transported products are identical to the items stated on the manifest, the receiving agent will sign both manifests and assume custody of the product. Completed manifests will contain signatures of our secure transportation employee and the signature of the receiving agent who assumed custody of the product. One copy of the signed manifest will remain with the receiving location agent. The other copy will return to our facility.

Once the manifests are complete, our staff will again review the delivery details. In this final review, we will make sure all packages that were previously confirmed as delivered, have indeed been delivered. Once this confirmation has been made, our employee will then change the shipment status to "delivered" within the inventory tracking system. This will create a virtual record, which will be kept permanently by our TC, along with the manifest, as proof of delivery.

Shipment Rejection

In the case of a business licensee rejecting a delivery originating at our facility, a rejecting licensee employee must reseal all products in a tamper proof manner. After the package has been made tamper-evident, the manifest will be documented by both parties as a rejection. A documented and signed manifest will be left with the rejecting party, and one copy will return with the product to our facility. Upon notification of a rejected shipment, our IM will begin preparation for the rejected product. We will mandate that all product is securely transported or returned to the confines of the licensed facility from which it originated. When products are returned to us, we will launch a quality control investigation into the root cause.

15.8 – Records of Shipped Products

All information from the QR code related to outgoing medical cannabis products, as well as the date and time of shipment, will be recorded into the statewide seed-to-sale tracking system. Ala. Admin. Code r. 538-x-6-.06.03.f.08. The statewide seed-to-sale tracking system will serve as our master log for all cannabis inventory. We will also input all route plans, manifests, transport logs, freight bills, bills of lading, any free- on-board ("FOB") terms of sale documents, maintenance records, repair records, and insurance documentation into the seed-to-sale tracking system. All records will be kept for at least two years, and longer upon the request of the AMCC or law enforcement. Ala. Admin. Code r. 538-x-7-.03.02.e.xv. Transportation and related documents will be made available to the AMCC or its representatives during inspections and other official visits. Ala. Admin. Code r. 538-x-7-.03.02.e.xvi.

Conclusion

Our shipment and inventory procedures are based on best practices from other high security industries, including pharmaceutical distributors and HIPAA-regulated medical practitioners. We will thoroughly train all employees on our safety and security procedures, which we developed with guidelines from the AMCC, public safety officials, law enforcement agencies, and professional security organizations familiar with the cannabis industry. Security systems in our vehicles and at our facility will deter unauthorized access and keep all cannabis inventory secure. We will report any abnormal activity along our shipment route, maintain accurate record keeping, and create a clear documentation trail for local, state, and federal law enforcement agencies. Our Secure Transporter partners will always transport medical cannabis in a safe, efficient, and professional manner between licensed facilities. Ala. Admin. Code r. 538-x-7-.02.03.a. Our shipping and receiving plan will maintain the safety of patients, products, staff, and the State of Alabama.

REDACTED COPY

License Type: Processor

Exhibit 16 – Facilities

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

16.1 Facility Name and Type

Facility Name: Coosa Medical Manufacturing, LLC

Facility Type: Processing Facility

16.2 Physical Address & GPS Coordinates of Facility

2347 Montgomery Highway

Centreville, AL 35042

GPS Coordinates: 32.941532, -87.101753

16.3 Aerial Photograph of Facility



16.4 Proof of Authorization to Occupy Property

The Applicant OWNS the property identified in 16.2 above. See attached SALE agreement (identified as "SALE Agreement – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.4").

16.5 – Local Jurisdiction Approvals

Processing license applicants are not required to locate in a city/county that has specifically approved a medical cannabis ordinance. Please see the email from Alabama Medical Cannabis Commission dated 10.14.22 which is part of the Attachment noted below. Processing applicants are required to show zoning compliance. The applicant has included a letter from the City of Centreville confirming that Medical Cannabis Processing is allowed on the property located at 2347 Montgomery Highway, Centreville, AL 35042. (This address was just recently assigned to the property which is why the zoning letter indicates Parcel ID 1609293000015000.) This letter is identified as "Zoning Ordinance – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.5". The applicant has also included a letter of support from the Mayor of Centreville for Coosa locating there.

16.6 – Blueprint of Facility

The floorplan for the facility identified in 16.1 above is attached hereto and identified as "Floorplan – Coosa Medical Manufacturing Facility – Attachment to Exhibit 16, Section 16.6").

16.7 – Facility Timetable

The applicant has not begun construction of the processing facility yet. The applicant can complete the facility and be ready to operate in full compliance with AMCC rules 120 days after the license is awarded as members of the applicant have done in other states.

The applicant expects that it will be able to commence operations 120 after licensure by the Commission.

16.8 – Public Access to Facility

The Coosa Medical Manufacturing facility will NOT be open to the public.

16.9 – Facility Hours of Operation / After Hours Contact

The applicant anticipates the hours of operation for the facility to be as follows:

Monday – Friday	8:00 a.m. – 6:00 p.m. CT
Saturday	10:00 a.m. – 4:00 p.m. CT
Sunday	11:00 a.m. – 4:00 p.m. CT

After Hours Management Contact

Ala. Code § 36-12-40 (Personally Identifiable Information)

E-Mail: Ala. Code § 36-12-40 (Personally Identifiable Information)

Cell Ala. Code § 36-12-40 (Personally Identifiable Information)

Additional Notes on Exhibit 16:

The information contained in this exhibit is based on the best available knowledge to the applicant at the time of submission. The applicant will update or amend any information in this exhibit that may change. The applicant does not propose any additional facilities.

SALE Agreement – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.4

LOTS OR OTHER UNIMPROVED LAND SALES CONTRACT

Form Approved by Birmingham Association of REALTORS®, Inc.
March 20, 2006, Reformatted April 2013 *(Previous forms obsolete)*

Date: 11/21/22

The undersigned Buyer([redacted]) Ala. Code § 36-12-40 (Personally Identifiable Information) agrees to purchase and the undersigned Seller([redacted]) Ala. Code § 36-12-40 (Personally Identifiable Information) agrees to sell the following described lot(s) or other unimproved land and appurtenances thereto (the "Property") situated in the City of Centreville, County of Bibb, Alabama, on the terms stated below:

(Please print exact names in which title will be taken)

Address: Highway 382 Zip Code: 35042

Legal Description: 15+/- acre part of parcel # 07 16 09 29 3 000 015.000

and Parcel ID:

1. **THE TOTAL PURCHASE PRICE OF THE PROPERTY SHALL BE $** Ala. Code § 36-12-40 (Personal Financial Information)
Earnest Money under this Contract shall be $ [redacted]

(A) FINANCING: *(Check as applicable)*

☑ (1) Buyer will pay cash or obtain a loan for the Property with no financing contingency.

☐ (2) This Contract is contingent on Buyer obtaining approval of a loan in the amount of $_____ or _____% of the Purchase Price (excluding any financed loan costs) at the prevailing interest rate and loan costs. Buyer will apply for financing within ___ days (7 days if left blank), from the Finalized Date and will provide any and all credit, employment, financial and other information required by the mortgage lender. "Finalized Date" shall mean the date that appears under the signatures of the parties to this Contract. **No term of this financing contingency can be changed without written authorization of the Seller.**

☐ **(B) DEVELOPMENT:** *(Check if applicable)*

This Contract is contingent upon Buyer obtaining appropriate financing, applicable building permits, all utilities (electricity, gas, sewer and water) for use on the Property for the purpose intended. In the event there is not a public sewer system, this Contract is also subject to approval by proper Health Department authorities of a permit for installation of a septic tank. In the event of any one of these contingencies cannot be fulfilled on or before _____, 20__, Seller agrees to refund Earnest Money and this Contract shall become null and void. Buyer is responsible for determining whether all necessary utilities are on the Property and are available for the intended purpose of the Buyer.

2. **CLOSING DATE:** The sale shall be closed and the deed delivered on or before see addendum _____, 20___ at ___:___ a.m.___ p.m.___.

3. **EARNEST MONEY & BUYER'S DEFAULT:** Seller and Buyer hereby direct the Listing Company to hold the Earnest Money in trust until this Contract has been accepted and signed by all parties, at which time the Earnest Money will be promptly deposited into the escrow account of the

DigiSign Verified: 51EA537A-E308-4FE1-958C-A1C7FAEF30C4

Listing Company. In the event an offer or counteroffer is not accepted, the Earnest Money shall be returned to Buyer without a signed release. If the Contract is accepted and signed by all parties and the sale does not close, however, a separate mutual release signed by all parties to this Contract will be required before the Earnest Money will be disbursed. In the event either Buyer or Seller claims the escrowed funds without the agreement of the other party, any holder of the escrowed funds, as prescribed by Alabama Real Estate License Law Rule: 790-X-3-.03 (4), (5), must either retain the escrowed funds until there is a written mutual release among the parties or interplead the disputed portion of the funds into the appropriate court, and shall be entitled to deduct from the escrowed funds for court costs, attorney fees and other expenses relating to the interpleader; provided, however, that any Claim as defined in Paragraph 15 below shall remain subject to mediation and arbitration as set forth in said Paragraph. Seller, at Seller's option, may cancel this Contract if the Earnest Money check is rejected by the financial institution upon which it is drawn. In the event of default by Buyer, all deposits made hereunder may be forfeited as liquidated damages at the option of Seller, provided Seller agrees to the cancellation of this Contract, or alternatively, Seller may elect to pursue his or her available legal or equitable remedies against Buyer pursuant to Paragraph 15 below.

4. **AGENCY DISCLOSURE:**

The listing company is eXp Realty, LLC

The selling company is [redacted] Ala. Code § 36-12-40 (Personally Identifiable Information)

The listing company is: *(Two blocks may be checked)* ☑ An agent of the seller. ☐ An agent of the buyer.
☐ An agent of both the seller and buyer and is acting as a limited consensual dual agent.
☐ Assisting the ☐ buyer ☐ seller *(check one or both)* as a transaction broker.

The selling company is: *(Two blocks may be checked)* ☐ An agent of the seller. ☑ An agent of the buyer.
☐ An agent of both the seller and buyer and is acting as a limited consensual dual agent.
☐ Assisting the ☐ buyer ☐ seller *(check one or both)* as a transaction broker.

Buyer's In Ala. Code § 36-12-40 (Personally Identifiable Information)

5. **TITLE INSURANCE:** Seller agrees to furnish Buyer a standard form owner's title insurance policy at Seller's expense, issued by a company qualified to insure titles in Alabama, in the amount of the Purchase Price, insuring Buyer against loss on account of any defect or encumbrance in the title, subject to exceptions herein, including Paragraphs 6 & 8 below; otherwise, the Earnest Money shall be refunded in accordance with Paragraph 3 above. In the event owner's and mortgagee's title policies are required at closing, the total expense of procuring the two policies will be divided equally between Seller and Buyer, even if the mortgagee is the Seller. Seller shall have a reasonable length of time within which to perfect title or cure defects in the title to the Property.

6. **SURVEY:** Buyer ☐ does ☑ does not require a survey by a registered Alabama land surveyor of Buyer's choosing. The lender may require a survey and it is recommended that a new survey be obtained on all purchases. Available information indicates that the Property ☐ is ☑ is not located in a flood plain, but this should be confirmed by a flood plain certification and/or a current surveyor's statement in the survey which shall be the responsibility of Buyer. Further, unless otherwise agreed herein, the Property is purchased subject to utility easements, residential subdivision covenants and restrictions, if any, and building lines of record. It is the responsibility of Buyer to determine, prior to closing of this Contract, whether the foregoing materially impairs the use of the Property for intended purposes. Unless otherwise agreed herein, the survey shall be at Buyer's expense.

(see addendum--seller is providing survey)

The Birmingham Association of Realtors®, Inc. is not engaged in rendering legal, accounting or other professional service by approving this form. This form is published as a service to member real estate professionals and an explanation of its various provisions should be obtained from the appropriate professional. Because of varying state and local laws, competent legal or other advice should be secured before using any form. If a user of this form makes any substantive changes to any portions above, the form will no longer be an approved form.

Copyright© 2006 by the Birmingham Association of REALTORS®, Inc.

This contract is for use by Julie Holdsambeck. Use by any other party is illegal and voids the contract. InstanetForms

SALE Agreement – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.4

7. **PRORATIONS:** Ad valorem taxes, as determined on the date of closing, accrued interest on mortgage(s) assumed, and homeowners association, fire district or other dues, fees or assessments are to be prorated between Seller and Buyer as of the date of closing, and any existing escrow deposits shall be credited to Seller. Unless otherwise agreed herein, all ad valorem taxes except municipal are presumed to be paid in arrears for purpose of proration; municipal taxes, if any, are presumed to be paid in advance.

8. **CONVEYANCE:** Seller agrees to convey the Property to Buyer by General warranty deed (check ☐ if Buyer desires that title be held as joint tenants with rights of survivorship), free of all encumbrances except as permitted in this Contract. Seller and Buyer agree that any encumbrances not herein excepted or assumed may be cleared at the time of closing from sales proceeds. The Property is sold and is to be conveyed subject to any mineral and/or mining rights not owned by Seller. Seller understands that the present zoning classification is: Manufacturing. It is Buyer's responsibility to verify the current zoning classification.

9. **CONDITION OF THE PROPERTY: SELLER MAKES NO REPRESENTATIONS OR WARRANTIES REGARDING CONDITION OF THE PROPERTY EXCEPT TO THE EXTENT EXPRESSLY AND SPECIFICALLY SET FORTH HEREIN.** Purchaser has the obligation to determine any and all conditions of the Property material to Buyer decision to buy the Property, including without limitation, subsurface condition, including the presence or absence of sinkholes, mining activity, wells or buried tanks and other objects; soil conditions; and utility and sewer or septic availability and condition. Except as otherwise stated in this Contract, Buyer accepts the Property in its present "as is" conditions.

Buyer's I Ala. Code § 36-12-40 (Personally Identifiable Information)

10. **DISCLAIMER:** Seller and Buyer hereby acknowledge and agree that they have not relied upon any advice or representation of the Listing Broker or Company or the Selling Broker or Company or any of their sales associates ("brokers and sales associates"), and accordingly Seller and Buyer agree that no broker or sales associate shall be held responsible for any obligations or agreements that Seller or Buyer have to one another hereunder. Further, Seller and Buyer agree to discharge and release the brokers and sales associates from any claims, demands, damages, actions, causes of actions or suits at law arising in any way from this Contract related to the Property, and shall include but not be limited to the availability or location of utilities, sewer or septic system; the investment or resale value of the Property; subsurface or subsoil conditions such as sinkholes, mining or other soil conditions, including radon or other potentially hazardous gases or toxic materials; Property access, easements, covenants, restrictions, development structure, and appurtenances thereto, the availability of utilities or sewer service; and any matters affecting the character of the neighborhood; the past, present, or future financial stability of the developer, if any, or the future insurability of the Property; the investment or resale value of the Property; or any other matters affecting the willingness of the Seller and Buyer to sell or purchase the Property on the terms and at the Purchase Price herein set forth. Seller and Buyer acknowledge and agree that if such matters are of concern to them in the decision to sell or purchase the Property, they have sought and obtained i

Buyer's I Ala. Code § 36-12-40 (Personally Identifiable Information)

11. **SELLER WARRANTY:** Seller warrants that Seller has not received notification from any owners association or lawful authority regarding any unpaid assessments, pending assessments, pending public improvements, or repairs, replacements, or alterations to the Property that have not been satisfactorily made. Seller warrants that there is no unpaid indebtedness on the Property except as described in this Contract. These warranties shall survive the closing.

DigiSign Verified: 51EA537A-E308-4FE1-958C-A1C7FAEF30C4

12. **HAZARDOUS SUBSTANCES:** Seller and Buyer expressly acknowledge that the Broker(s) have not made an independent investigation or determination with respect to the existence or nonexistence of PCB transformers, or other toxic, hazardous or contaminated substances or gases in, on, or about the Property, or for the presence of underground storage tanks. Any such investigation or determination shall be the responsibility of Seller and/or Buyer and Broker(s) shall not be held responsible therefor.

13. **SELECTION OF ATTORNEY:** Buyer and Seller hereby ☐ do ☑ do not agree to share the fees of a closing attorney. Buyer and Seller acknowledge and agree that such sharing of fees may involve a conflict of interest on the part of the attorney and the attorney will require that an affidavit be signed at closing acknowledging the conflict of interest and Buyer's and Seller's acceptance of the same. The parties further acknowledge that they have a right to be represented at all times by separate and independent counsel in connection with this Contract and the closing thereof by an attorney of their own choosing at their own expense.

14. **OTHER OFFERS WHILE BUYER'S OFFER IS PENDING:** Buyer hereby acknowledges that offers other than Buyer's offer may have been made or may be made before Seller acts on or while Seller is considering Buyer's offer or counteroffer. While the Buyer's offer or counteroffer is pending, and before this Contract becomes effective, Seller hereby expressly reserves the right to reject Buyer's offer or counteroffer or to withdraw any offer previously made by Seller to Buyer relating to the Property, and to accept any other offer or counteroffer.

15. **MEDIATION AND ARBITRATION/WAIVER OF TRIAL BY JURY: All claims, disputes or other matters in question arising out of or relating in any way to this Contract or the breach thereof, including claims against any broker or sales associate, or relating to the relationship involved with, created by or concerning this Contract, including the involvement of any broker or sales associate ("Claim"), shall be submitted to mediation with a mutually agreed upon mediator within forty-five (45) days of notice of the Claim. In the event no mediated resolution is reached within sixty (60) days of the party's notice of the Claim, all Claims shall be resolved by binding arbitration by a single arbitrator in Birmingham, Alabama in accordance with the Commercial Arbitration Rules of the American Arbitration Association then in effect. EACH PARTY ACKNOWLEDGES THAT HE OR SHE IS KNOWINGLY WAIVING THE RIGHT TO A TRIAL BY JURY RELATING TO ALL CLAIMS. All disputes concerning the arbitrability of any Claim or the enforceability or scope of this provision shall be subject to the same binding arbitration. The parties shall bear equally the cost of the arbitrator and each party shall otherwise bear their own costs; provided the arbitrator shall have the authority to award costs as a part of this award to the extent authorized by applicable law. The arbitrator shall follow the law applicable to any Claim and shall be empowered to award any damages or other relief which would be available under the law applicable to any such Claim. The determination of the arbitrator shall be final, binding on the parties and non-appealable, and may be entered in any court of competent jurisdiction to enforce it. The parties acknowledge and agree that the transactions contemplated by and relating to this Contract, which may include the use of materials and components which are obtained from out-of-state and which otherwise include the use of interstate mails, roadways and commerce, involve interstate commerce, as that term is defined in the Federal Arbitration Act, 9 U.S.C. § 2.**

Buyer's I Ala. Code § 36-12-40 (Personally Identifiable Information)

The Birmingham Association of Realtors®, Inc. is not engaged in rendering legal, accounting or other professional service by approving this form. This form is published as a service to member real estate professionals and an explanation of its various provisions should be obtained from the appropriate professional. Because of varying state and local laws, competent legal or other advice should be secured before using any form. If a user of this form makes any substantive changes to any portions above, the form will no longer be an approved form.

Copyright© 2006 by the Birmingham Association of REALTORS®, Inc.

This contract is for use by Julie Holdsambeck. Use by any other party is illegal and voids the contract.

SALE Agreement – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.4

DigiSign Verified: 51EA537A-E308-4FE1-958C-A1C7FAEF30C4

16. FACSIMILE OR COUNTERPART SIGNATURES: This Contract may be executed and delivered by any party hereto by sending a facsimile of the signature or by a legally recognized e-signature. Such facsimile signature or legally recognized e-signature shall be binding upon the party so executing it upon the receipt of the signature by any other party.

17. ADDITIONAL PROVISIONS: Additional provisions to this Contract are set forth on the attached Addendum(s) # 1 which shall be signed by all parties and shall be part of this Contract.

18. OBLIGATION FOR FEES AND EXPENSES: Buyer and Seller acknowledge that in the event this Contract is cancelled or does not close for any reason, fees or costs paid in advance may be non-refundable.

19. ENTIRE AGREEMENT: This Contract constitutes the entire agreement between Buyer and Seller regarding the Property, and supersedes all prior discussions, negotiations and agreements between Buyer and Seller, whether oral or written. Neither Buyer, Seller, nor any broker or sales associate shall be bound by any understanding, agreement, promise, or representation concerning the Property, expressed or implied, not specified herein.

THIS IS A LEGALLY BINDING CONTRACT. IF YOU DO NOT UNDERSTAND THE LEGAL EFFECT OF ANY PART OF THIS CONTRACT, SEEK LEGAL ADVICE BEFORE SIGNING.

Ala. Code § 36-12-40 (Personally Identifiable Information)

Witness to Buyer's Signature — Buyer — (Date)

Witness to Buyer's Signature — Buyer — (Date)

Ala. Code § 36-12-40 (Personally Identifiable Information)

Witness to Seller's Signature — Seller — (Date)

Finalized Date: 22 November, 20 22
(Date on which last party signed or initialed acceptance of final offer)

EARNEST MONEY: Receipt of the earnest money in the amount identified in Paragraph 1 is hereby acknowledged. ☐ CASH ☐ CHECK

LISTING COMPANY: eXp Realty, LLC By _____ DATE _____, 20__

DigiSign Verified: 51EA537A-E308-4FE1-958C-A1C7FAEF30C4

exp REALTY

ADDENDUM TO SALES CONTRACT

Date: Addendum #1 11/21/22

This Addendum is a part of the Agreement on the Property located at 15 +/- acre part of Parcel # 07 16 09 29 3 000 015.000 Centreville AL 35042 and dated 11/21/22 between the undersigned Purchaser(s) and the undersigned Seller(s). The following contingencies apply to the purchase agreement, and will be removed by signed addenda as they are satisfied, if applicable:

1. Due diligence period of 45 days to begin on date of LOI execution, November 21, 2022.
2. Parties agree to escrow, title work, deed and closing to be performed by Kemmer Law in Centreville, AL. Title, deed, and closing fee to be split by buyer and seller.
3. $15,000 deposit is non-refundable and is to be deposited at the end of 45-day due diligence into escrow account at Kemmer Law.
4. Seller to provide new survey and legal description.
5. Seller to ensure proper Commercial zoning during due diligence period.
6. Seller has the right to bid on development/construction work on the property.
7. Execution date of purchase agreement will be on or before July 30, 2023, and will be determined by date of award of licensure by Alabama Medical Cannabis Commission (Commission). Close of sale to occur within 15 days of license being issued.

   In the event of the necessity of an additional Commission review, this date will automatically extend up to 45 days (no later than September 14, 2023).
8. 4% of gross selling price to be paid by the seller to Southpaw Properties upon closing.
9. If no license is awarded, this agreement automatically dissolves.

Ala. Code § 36-12-40 (Personally Identifiable Information)

Purchaser — Witness

Ala. Code § 36-12-40 (Personally Identifiable Information)

Seller — Witness

11-22-2022
Date

This contract is for use by Julie Holdsambeck. Use by any other party is illegal and voids the contract.

InstanetForms

Zoning Ordinance – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.5

City of Centreville

"Zoning Authorization"

The property located at **Parcel I.D. 1609293000015000** and containing 15+/- acres is zoned for **Commercial/M1.** The Centreville Zoning Ordinances permits Medical Cannabis Processing and Distribution in this District.

Mayor 11-28-22

Signature of Administrator Date

Please see attachment "A" for reference

Zoning Ordinance – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.5



Zoning Ordinance – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.5

City of Centreville

Mike Oakley, Mayor

1370 Walnut Street
Centreville, AL 35042
Phone (205) 926-3093
Fax (205) 926-3433

Coosa Medical Manufacturing

Letter of Support

Greetings,

I am writing this letter in support of Coosa Medical Manufacturing, LLC's application for a processing license. I have interacted with their team, been in touch via text, phone and Zoom with various members and have listened to and heard their plans. I firmly believe they are fully qualified to safely operate a business dealing with medical cannabis.

This business will provide an immediate economic impact, job creation and much-needed housing in our city limits. Their team, highly qualified and certified, will be an asset to our community and our county.

I would be more than happy to assist them should they be awarded a license.

Feel free to contact me if you require more information.

Sincerely,

Mike Oakley, Mayor

City of Centreville, AL

Zoning Ordinance – Coosa Medical Manufacturing- Attachment to Exhibit 16, Section 16.5

Monday, December 12, 2022 at 09:20:20 Central Standard Time

Subject: RE: Question re: local approval
Date: Friday, October 14, 2022 at 9:02:43 AM Central Daylight Time
From: Applications (AMCC)
To: Jeff Rabren
Attachments: image001.png

That is correct. The statute only requires local authorization for dispensing sites.

From: Jeff Rabren <Jeff@redlevelstrategies.com>
Sent: Friday, October 14, 2022 8:58 AM
To: Applications (AMCC) <applications@amcc.alabama.gov>
Subject: Question re: local approval

The requirement that a city or county affirmatively approve operation of a dispensing site via ordinance or resolution only applies to dispensaries, right? There is no requirement in the statute or proposed rules that requires this approval for a cultivation facility or a processing facility, correct?

Thank you.

Jeff Rabren

Ala. Code § 36-12-40 (Personally Identifiable Information)

[redacted]

Page 1 of 1

Floorplan – Coosa Medical Manufacturing Facility – Attachment to Exhibit 16, Section 16.6



Floorplan – Coosa Medical Manufacturing Facility – Attachment to Exhibit 16, Section 16.6

Floorplan - Coosa Medical Manufacturing Facility - Attachment to Exhibit 16, Section 16.6

COOSA MEDICAL CANNABIS MANUFACTURING
PROPERTY

Ala. Code § 36-12-40 (Security Plan)

[redacted]

DEC. 21, 2022
00000

ELECTRONIC SPECIALTY COMPANY
(since 1947)
PO Box 400
1320 Main Avenue
Dunbar, WV 25064
304-766-6277 voice
304-766-6270 fax

License Type: Processor

REDACTED COPY

Exhibit 17 – Security Plan

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

Introduction

We are foundationally committed to providing safe medical cannabis products in a secure manner to licensed medical cannabis dispensaries across the state of Alabama. To ensure that our facility will be secure, we have created a comprehensive security plan that addresses each aspect of our processing operation along with maintaining local, county, and state mandated security requirements, in addition to incorporating best practices from other highly regulated industries. We will provide effective controls and procedures to guard against theft and diversion of cannabis, unauthorized access to our premises, unauthorized access to our electronic systems, and protect against electronic records tampering. We will install, maintain in good working order, and operate a safety and security alarm system, along with an audio/visual surveillance system at our premises that will provide comprehensive protection against theft and diversion. Our safety measures will include barriers and rigid fencing to deter and prevent unauthorized entrance into areas containing cannabis and the theft of cannabis. We will utilize Metrc, the statewide seed-to-sale tracking system, as our internal comprehensive inventory system. Our facility's security overlay has been attached to the end of this document.

17.1 – Twenty-Four-Hour Alarm Systems



Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)

[redacted]

17.3 – Broadcast Communication Devices

Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)

Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)



Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)

[redacted]

17.10 – Records

Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)

Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)

[redacted]

Ala. Code § 36-12-40 (Security Plan)

Conclusion

We view the AMCC as a partner in our endeavor to operate a maximally compliant medical cannabis facility. A crucial component of our role in this partnership is creating, implementing, and training our staff on strong security procedures. We will make all information related to our security plan available to the AMCC and its inspectors. Ala. Admin Code. r. 538-x-6-.06.03.i.15. Our business will be ready and willing to provide rapid and efficacious assistance to the AMCC in its mission to maintain the safety and integrity of the regulated medical cannabis market in Alabama.

Ala. Code § 36-12-40 (Security Plan)



REDACTED COPY

License Type: Processor

Exhibit 18 – Personnel

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

FORM G: PERSONNEL ROSTER & VERIFICATION

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Complete the following information, current to within thirty (30) days prior to the date of application, for all personnel (each leader and employee) affiliated with the Applicant. Attach additional forms if

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name — Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN — Telephone — Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City — State — Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN — Telephone — Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City — State — Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name — Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN — Telephone — Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City — State — Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City State Zip

Form G: Personnel Roster & Verification
Page 2

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name | Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN | Telephone | Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City | State | Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name | Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN | Telephone | Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City | State | Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)

Leader/Employee Name | Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)

SSN | Telephone | Email

Ala. Code § 36-12-40 (Personally Identifiable Information)

Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)

City | State | Zip

Applicant Verification: The undersigned hereby verifies that the information provided hereinabove (and attached, as necessary) constitutes a complete and accurate roster of personnel of the Applicant. The undersigned further verifies that, if the Applicant is issued a business license, each individual listed hereinabove (and attached, as necessary) will be registered to the AMCC website and will undergo appropriate pre-employment background checks.

David Hardin	CEO/Owner
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/20/2022 | 2:58 PM PST
Signature of Verifying Individual	Verification Date

Form G: Personnel Roster & Verification
Page 3

FORM G: PERSONNEL ROSTER & VERIFICATION

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Complete the following information, current to within thirty (30) days prior to the date of application, for all personnel (each leader and employee) affiliated with the Applicant. Attach additional forms if necessary.

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name — Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN — Telephone — Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City — State — Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name — Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN — Telephone — Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City — State — Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name — Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN — Telephone — Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City — State — Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position
Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email
Ala. Code § 36-12-40 (Personally Identifiable Information)
Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position
Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email
Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address
Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position
Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email
Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address
Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position
Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email
Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address
Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Form G: Personnel Roster & Verification
Page 2

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Applicant Verification: The undersigned hereby verifies that the information provided hereinabove (and attached, as necessary) constitutes a complete and accurate roster of personnel of the Applicant. The undersigned further verifies that, if the Applicant is issued a business license, each individual listed hereinabove (and attached, as necessary) will be registered to the AMCC website and will undergo appropriate pre-employment background checks.

David Hardin
Printed Name of Verifying Individual

CEO/Owner
Title of Verifying Individual

David Hardin
Signature of Verifying Individual

12/20/2022 | 2:58 PM PST
Verification Date

Form G: Personnel Roster & Verification
Page 3

FORM G: PERSONNEL ROSTER & VERIFICATION

Coosa Medical Manufacturing, LLC
Business License Applicant Name

Processor
License Type

Complete the following information, current to within thirty (30) days prior to the date of application, for all personnel (each leader and employee) affiliated with the Applicant. Attach additional forms if

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position

Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email

Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address

Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position
Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email
Ala. Code § 36-12-40 (Personally Identifiable Information)
Street Address
Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position
Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email
Ala. Code § 36-12-40 (Personally Identifiable Information)
Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Ala. Code § 36-12-40 (Personally Identifiable Information)
Leader/Employee Name Title/Position
Ala. Code § 36-12-40 (Personally Identifiable Information)
SSN Telephone Email
Ala. Code § 36-12-40 (Personally Identifiable Information)
Ala. Code § 36-12-40 (Personally Identifiable Information)
City State Zip

Leader/Employee Name Title/Position

SSN Telephone Email

Street Address

City State Zip

Form G: Personnel Roster & Verification
Page 2

Leader/Employee Name | Title/Position

SSN | Telephone | Email

Street Address

City | State | Zip

Leader/Employee Name | Title/Position

SSN | Telephone | Email

Street Address

City | State | Zip

Leader/Employee Name | Title/Position

SSN | Telephone | Email

Street Address

City | State | Zip

Applicant Verification: The undersigned hereby verifies that the information provided hereinabove (and attached, as necessary) constitutes a complete and accurate roster of personnel of the Applicant. The undersigned further verifies that, if the Applicant is issued a business license, each individual listed hereinabove (and attached, as necessary) will be registered to the AMCC website and will undergo appropriate pre-employment background checks.

David Hardin
Printed Name of Verifying Individual

CEO/Owner
Title of Verifying Individual

David Hardin
Signature of Verifying Individual

12/20/2022 | 2:58 PM PST
Verification Date

Form G: Personnel Roster & Verification
Page 3

License Type: Processor

Exhibit 19 – Business Leadership Credentials

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

19.1 – Curriculum Vitae

Our most valuable and important asset is our people, and we will clearly demonstrate and substantiate this value within our business. Our team offers an exceptional level of relevant experience for serving medical cannabis patients in Alabama, and in this section, we will quantify the extraordinary skills, resources, and service level of our company by demonstrating the education, experience, and other credentials of our leadership, including but not limited to all scientists and engineers employed at each facility. Ala. Admin Code. r. 538-x-6-.06.03.d.01. Our team includes employees with science and engineering backgrounds, as well as employees with a business background in accounting, finance, managing, marketing, advertising, and public relations. We will become the leading cannabis company by leading the world in cannabis education, accessibility, and patient satisfaction, with high quality products backed by science. Our innovation will keep us at the forefront of cannabis science, unlocking the full potential of the plant while allowing our patients to customize their cannabis experience. This business credentials and hiring plan firmly identifies our company as an inclusive, intensively professional, and consistently compliant group of talented individuals.

Science and Engineering Employees

Our Chief Executive Officer ("CEO"), [redacted] is a strong leader and a practicing internal medicine physician with Preferred Pain Associates of Alabama. He received his Bachelor of Science from the University of Alabama Culverhouse College of Commerce, completed his internal medicine residency at Brookwood Baptist Health System in Birmingham, Alabama, and received his Medical Doctorate from the University of Alabama School of Medicine. [redacted] has extensive experience in science and healthcare, including primary care and sports medicine. He has researched musculoskeletal issues and pain management, consulting on projects with Major League Soccer on league-wide database initiatives, which led to an improvement of player safety and performance. In addition, our CEO was a private analytics consultant for Blue Cross Blue Shield of Alabama, and for other Birmingham-based healthcare companies. [redacted] has presented on pain management, statistical methods of injury prediction, and medical data analytics for international science conferences. Leveraging his deep knowledge of medicine and pain mitigation, [redacted] will lead our company focusing on patient care.

Our Chief Medical Officer ("CMO") held several clinical leadership positions, with patient care always a priority. He received his Bachelor of Science from Morehouse College in Atlanta, Georgia, and his Medical Doctorate from Meharry Medical College in Nashville, Tennessee. Ala Code § 36-12-40 (Personally Identifiable Information) was the Medical Director for the City of Birmingham Parks and Recreation activities at Legion Field and maintained responsibility for supervision and training of medical professional staff. He also served as the Medical Director for the National Football League in Europe, and as a medical consultant and physician at Alabama State University. Ala Code § 36-12-40 (Personally Identifiable Inform is also a successful business owner and opened his own practice–Brookwood Baptist Sports Medicine–five years ago in Birmingham.

Our Director of Processing ("DOP") has a Ph.D. in analytical chemistry focusing on mass spectrometry from the University of Alabama. Ala Code § 36-12-40 (Personally Identifiable Information) has scientific expertise with oils and fats, reverse engineering, plant extraction, biochemistry and industrial problem solving. An Alabama native, she began her career as a forensic scientist for the state of Alabama, and now serves as CEO of Southern Apothecary and CTO of StenCo LLC. Ala Code § 36-12-40 (Personally Id is active in industry standard developments and is in the ASTM International's D37 Committee on Cannabis. Ala Code § 36-12-40 (Personally Identif work has been published in leading journals, including Biochemistry, Journal of Nutrition, and Journal of Mass Spectrometry.

Employees with a Business Background

A native of Selma, Alabama, our Chief Operating Officer ("COO") Ala Code § 36-12-40 (Personally Iden has spent over 20 years in pharmaceutical research, specifically exploring timed-release medications, and protein and lipid isolation/purification. He received his Bachelor of Science in Chemistry and Physics from Troy State University, and his Master's in Business Administration from the University of North Alabama. He has actively led small to mid-size organizations, with roles encompassing quality assurance, manufacturing, engineering, and supply chain functions, and instituted focused initiatives for accountability and efficiency. While working as Director of Operations for a global biopharmaceutical company, our COO led a team of over 300 people, and maintained responsibility for the entire manufacturing and supply chain, with more than 30,000 unique products. Currently serving as the CEO of StenCo, LLC, he conceptualized and filed for multiple patents featuring biodegradable inventions. While at StenCo, Ala Code § 36-12-40 (Personally also led three concurrent entities through a global business technology accelerator program. He is a clear and engaged leader with a knack for

innovation and his experience in leading operations will be invaluable in directing our company operations.

Our Chief Compliance Officer ("CCO"), [redacted] is a juris doctorate certified to practice in Alabama. He studied law at the Michigan State University College of Law, after earning a Bachelor of Arts in Political Science from the University of Alabama, Tuscaloosa. He has provided legal counsel for nearly a decade, and is a partner at [redacted] Law in Birmingham, Alabama. He zealously protects clients' rights and began his career as a Public Defender for Tuscaloosa County. An Alabama native, he is familiar with and has positive working relationships with the local courts and legal community and will abide by and collaborate with the Alabama Medical Cannabis Commission ("AMCC").

Accounting and Finance

Our Chief Financial Officer ("CFO") is a Birmingham-based CPA with experience at a public accounting firm, a Fortune 500 company, and fast-growing startups. [redacted] received his Bachelor of Arts from Auburn University, and his Master of Accounting from the University of Alabama, Birmingham. [redacted] has performed audits of credit unions around the state of Alabama, budgeted and forecasted technology capital projects, and overseen independent contractor pay processes. [redacted] is the Accounting Lead at Flatfile, where he has developed the accounting department through expanding the team and making positive operational efficiency changes. He transitioned the company to Netsuite, making substantial financial savings, and implemented a consistent month end close process. He now also manages customer billing, vendor payments, sales commissions, and tax concerns. Previously, he was the Director of Accounting at Shipt during an acquisition by Target, and was responsible for all revenue, costs of goods sold, and financial statements.

Management Experience

Our Quality Assurance and Quality Control Director ("QAQCD") [redacted] is an analytical biogeochemist with over a decade of experience focused on research and method development and is currently investigating secondary metabolite identification in natural plant and fungal products. He received his BS in Biology and Chemistry from the University of Mount Union, and his MS in Marine Science from the University of North Carolina Chapel Hill. He has presented his research internationally and published dozens of peer-reviewed

publications on cannabinoids, terpenoids, flavonoids, and contaminants in cannabis, discussing novel and efficient analytical methods. [redacted] contributed to a chapter in Ed Rosenthal's Grow Guide, a near-sacred text in the cannabis industry. Our QAQCD has directed regulatory testing operations at a cannabis testing laboratory in California; in this role he developed analytical chemistry methodologies and established cohesive scientific teams. Previously, he was the VP of Scientific Operations, building relationships with dispensary owners and patients while leading a team of scientists to successful ISO 17205 accreditation in under four months. [redacted] has outstanding qualifications to have an extraordinarily effective QA and QC program, and this will directly benefit patient safety.

Our Director of Security ("DOS") [redacted] is an Alabaster Police Department Patrol Officer and previously served in the US Coast Guard. An Alabama native, [redacted] has personal connections with the Mobile Public Safety Director, Mobile Chief of Police, Mobile County Communications Director, the A.T.F. and US Marshals that will be leveraged to have a safe and compliant facility. His accolades throughout the military community show his dedication to safety and service. With the Coast Guard, [redacted] led successful team missions and managed all personnel on board search and rescue vessels. He is a disciplined leader with the proven ability to remain calm and deliver results under pressure and his deep experience will result in safety for those involved with our company.

Our Chief Formulation and Infusion Officer ("CFIO"), [redacted] is a strategic science advisor, with over 15 years of experience in scientific leadership roles. He received his B.S. in Chemistry and M.S. in Earth Science and Geochemistry from the University of Southern California in 2004 and 2007, respectively. He has worked extensively with extraction, refinement, and analytical techniques, with a goal of improving quality of life through function and innovation. He has exceptional communication skills and clearly translates scientific verbiage for commercial products and consumer wellness. For several years he has worked with True Terpenes to generate research and development plans that focus on cannabis application science. As their Director of Product Technology and Operation, he formed a product development team with analytical chemists and formulation technicians and onboarded PhD experts in vaping science. [redacted] thoroughly understands the extraction and infusion process and he will oversee the creation of safe and compliant medical cannabis products.

Marketing, Advertising, and Public Relations

Our Marketing Director, [redacted] has more than two decades of sales and marketing experience, including 14 years in highly regulated pharmaceutical industry sales. As the current VP of Sales and Marketing for a Pharmacy in Birmingham, [redacted] oversees daily sales, marketing performance, and a marketing team. He received his Bachelor of Science in Marketing from Florida State University and has experience with strategic marketing and action plans with multi-level advertising. While working as a Sales Manager, [redacted] established and managed multi-state marketing sales resulting in quarterly sales growth. With an educational background in business, knowledge of in-depth sales strategies, and many strong business relationships, [redacted] has exceptional presentation skills that support public relation communication and strict adherence to highly regulated medical sales and advertising.

19.2 – Leadership Roles

This section provides a detailed explanation of the role each leader, scientist or engineer will have in the processing of medical cannabis at our facility. Ala. Admin Code. r. 538-x-6-.06.03.d.02. We have constructed our organizational reporting to provide ample checks and balances, which will protect our products, patients, and community.

Chief Executive Officer ("CEO")

Our CEO is responsible for delegating and directing agendas, driving profitability, managing company organizational structure and strategy, and communicating with the board and management, all while providing inspiring leadership companywide. The CEO has authority over the senior planning and leadership teams to execute the strategic direction of the company and guides efforts toward achieving company objectives and defined goals. The CEO provides oversight for the company, continuously works to develop a company culture in line with the company mission and manages the fiscal and operational performance of the company. The CEO sets the tone and establishes precedent of decision making for the business, particularly as it relates to making our vision actionable and achievable.

Chief Medical Officer ("CMO")

Our Chief Medical Officer supports the company with scientific and medical expertise, aiding in the understanding of medical cannabis effects and research. The CMO will lead staff trainings, utilize operational and industry best practices, and develop patient educational materials in coordination with other staff. The CMO will stay up to date on new research within the cannabis industry, and medical innovation in general, and will inform the advisory board, executives, and company leadership of significant developments. The CMO will train staff on medical cannabis science and will educate them on the scientific properties of our products. The CMO will consistently research medical developments regarding cannabis and communicate updates to necessary personnel, including re-training staff when necessary. The CMO will work with other executive leadership to develop and revise company SOPs and collaborate to develop community outreach initiatives.

Director of Processing ("DOP")

The Director of Processing ("DOP") will create internal standards and operating procedures for our medical cannabis manufacturing. They will oversee the COO, CFO, Head of Infusion and Formulation, Humans Resources Director, Marketing Director, and IT Director. They will maximize the efficiencies of our processes and maintain the safety of our products. Our DOP will design our internal testing laboratory in coordination with our CEO and CMO. They will conduct or delegate training for inventory control, sales and customer satisfaction, and processing procedures.

Chief Operating Officer ("COO")

The COO manages operations, including development of standard operating procedures and staff training programs that are responsive and adaptable based on compliance with applicable law. The COO must analyze current and future market trends to help to achieve the company's profitability goals and other objectives. The COO works with branch executive teams to create and implement production plans; select equipment and materials; and, assist in selecting vendors for outsourced services. A top priority for our COO will be providing patients, caregivers, staff, and the surrounding community with easy business interactions daily, while adapting strategic plans for long-term aims.

Chief Compliance Officer ("CCO")

The CCO oversees daily operational compliance, and develops, maintains, and continuously improves upon internal comprehensive compliance programs designed for

acquiescence to the applicable federal, state, and municipal regulations. The CCO also acts as the communication link between our business and regulatory entities when implementing rule changes or producing official reports. The CCO manages licensing, bond, and renewal processes; monitors regulatory updates to verify or amend all standard operating procedures in compliance with local, state, and applicable federal regulations; audits inventories, systems, and reports; and creates, manages, and delivers compliance-based education and training.

Chief Financial Officer ("CFO")

The CFO is responsible for all financial activities and functions of our business. This includes building the core financial practices to meet the needs of expanding operations. Our CFO has the ability to integrate the finance function effectively into our operations, maintaining a strong financial infrastructure throughout the change. Our CFO will also obtain and manage all accounting personnel, third-party accounting, tax preparation, and financial services vendors. The CFO creates and implements a company budget and departmental budgets; develops and maintains relationships with financial institutions; audits the work of outside bookkeepers and accountants for accuracy and consistency with Generally Accepted Accounting Practices ("GAAP"); and delivers staff financial trainings.

Marketing Director

Our Marketing Director will guide our marketing, advertising, and public relations in compliance with all relevant laws. The Marketing Director works to manage and maintain our brand and company image, devise marketing strategies, create advertising materials, drive traffic and sales, and oversees content creation. They will manage any social media presence while maintaining integrity of our online brand; prepare quarterly marketing plans and reports for executive leadership; train and lead any internal marketing staff or related vendors; develop and approve marketing materials within the marketing budget and department; and, send materials for approval by the state, as required. The Marketing Director will work with executive leadership to develop educational materials and community outreach initiatives.

Director of Security ("DOS")

Our DOS will be tasked with creating and overseeing practices designed to keep our staff, vendors, and the neighboring community safe. The DOS formulates security SOPs and

protocols to maintain compliance with the state and local regulations with the goal to achieve zero product losses from diversion or criminal activity. The DOS will supervise the design, implementation, and maintenance of our comprehensive security plan. They will then train security and non-security personnel in diversion prevention efforts and employee safety. Our DOS will also build relationships with local law enforcement and emergency services to identify the company as a community partner and champion of safe facilities, and to foster a clear line of communication in emergencies.

Quality Assurance and Quality Control Director ("QAQCD")

Our company will insist on the highest quality systems, equipment, workmanship, and final produced products by deploying an impressively experienced QAQCD. They will create safe and compliant quality assurance ("QA") and quality control ("QC") procedures for our processing facility. The QAQCD will build strong relationships with testing laboratories and other businesses within our product chain of custody for the purpose of understanding and improving medical cannabis products. They will validate the incoming and outgoing medical cannabis products for quality, potency, and consistency, based on internal standards and industry best practices. They will assist with staff training programs, and operational best practices for the purpose of implementing an exceptional QA and QC program.

Supply Chain Manager

To maintain product safety, integrity, and availability, we will employ a Supply Chain Manager to oversee compliant tracking of every aspect of our product inventory. This will take place in our internal systems and include reports to the state through the seed-to-sale tracking system, Metrc. Our Supply Chain Manager will train staff that interact with Metrc and other inventory tracking software. The Supply Chain Manager creates, implements, and audits processes, protocols, and key performance indicators associated with inventory management so that inbound and outbound inventory workflow meets daily sales and operational demands.

Chief Formulation and Infusion Officer ("CFIO")

The CFIO oversees management of the extraction laboratory. The CFIO creates standard operating procedures to maximize the efficiency of extraction and manufacturing processes, focusing on safety and security of our facility and staff. The CFIO oversees all

extraction processes; trains and manages extraction staff; oversees research and development to formulate new products; designs extraction laboratory, production space layout, and equipment choices; and, works with the QAQCD to confirm internal quality control standards are met, to provide patients with safe and consistent medical cannabis products.

19.3 – Hiring Plan

We have developed a five-year hiring plan for our employees, which identifies the types of positions, required education, required experience, and expected roles of our personnel. Ala. Admin Code. r. 538-x-6-.06.03.d.03. We strive to hire personnel with diverse backgrounds and qualifications, and we plan to gradually increase our staff year over year as we naturally expand our business.

Our employee positions fall into several types: leadership, management, and staff; for hiring purposes, our required education and experience are based on these types. Leadership-level positions will require a college degree (and ideally beyond), at least ten years of relevant leadership experience, and a dedication to compliance, business strategy, and customer service. Management-level positions will require a college degree, at least five years of relevant management experience, and skills in multi-level communication, problem-solving in highly regulated industries, and leading compliant operations and teams. Staff-level positions require a high-school or commensurate degree, at least three years of relevant experience, and a deep respect for medical cannabis, patient wellbeing, our company's culture of compliance, and adherence to our standard processes. All employees must pass a security background check and be able to satisfactorily complete state-mandated and internal trainings, before beginning work.

Year One

In our first year, we will staff all critical positions and all leadership and management roles, as well as all our base-level of staff employees. At the end of year one, our staff will total approximately 16 people. Leadership team members will be hired first. Leadership roles, as described in 19.2 above, will include the CEO, CMO, COO, CCO, CFO, CFIO, and DOP. These seven roles comprise the executive team and will lead our strategic vision.

We will also hire four managerial staff to lead daily operations. These will include a DOS, QAQCD, the Supply Chain Manager, and Marketing Director as described above in 19.2.

Additional positions will include three extraction and formulation technician staff. These technicians will report to the CFIO, who will in turn report to the DOP. All formulation staff will safely implement processing standard operating procedures, producing consistent medical cannabis products with compliant packaging.

We will also hire two Security Officers. They will physically secure the facility, oversee the entrance and exit of all individuals, prevent diversion, and mitigate other crimes or misconduct. We will always have at least one security employee on the site during all operational hours.

Year Two

In our second year, we will not add new roles but will add two new extraction and formulation technicians to help support the anticipated increase in patient demand.

Year Three

In our third year, we will be producing the highest quality medical cannabis products in the State of Alabama. At the three-year mark of operations, there may be the possibility of expanding operations. To support this, we will budget an additional extraction technician as well as an additional Security Officer and will remain flexible based on our company needs.

Year Four

In our fourth year, we will assess the need to hire additional employees. We will budget one additional job that may be an additional extraction and infusion technician. The majority of our positions were filled at year one and as we get farther from the start of operations it becomes more difficult to predict the staffing needs of our company. For this reason, we will remain flexible but expect 21 total jobs to our company.

Year Five

We anticipate being fully staffed by year five. Of course, we must be flexible to the needs of our dispensary partners and therefore the operations of our business and may hire additional staff; however our current expectations are to have a total of 21 jobs by year five and possibly expand beyond this number if needed. Regardless of how many jobs are at our facility, we will always hire exceptional staff, and are prepared to increase our rate of hire during any startup year if the market develops quickly.

License Type: Processor

Exhibit 20 – Employee Handbook

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

EMPLOYEE HANDBOOK SUMMARY

The Employee Handbook contains more than 25 pages and because of this, the Applicant is required to provide a summary of the Handbook in no more than 5 pages. This Handbook contains all policies relevant to employment with **COOSA MEDICAL MANUFACTURING, LLC**. The Handbook details policies pertinent to work hours, attendance requirements, and timekeeping and payroll administration. You will also find information on our commitment to equal employment opportunity and our reporting procedures for any concerns you may have in that regard. Further, this Handbook contains policies on our standards of conduct, our commitment to a safe, healthy, and professional workplace, and our protocols related to employee discipline and termination. These policies are not intended to cover each individual circumstance that might arise during employment, but rather are intended to provide general information about what an employee can expect of the company and what we can expect of an employee.

Unless otherwise noted, these policies apply to all employees, regardless of title. Employees can refer to this Handbook as questions about policies arise. From time to time we will update policies. If you have specific questions not addressed by this Handbook or the Policies and Procedures Manual, please let us know. These policies are neither a contract nor an offer to enter into a contract. You should not construe or rely upon them as a contract of employment with the company or a promise of employment for any specific duration or a warranty of benefits of employment. We may change or withdraw policies at any time and without prior notice.

TABLE OF CONTENTS

COOSA MEDICAL MANUFACTURING, LLC

Employee Handbook

ABOUT COOSA

At Coosa Medical Manufacturing ("Coosa" or "the Company"), we embrace a culture of acceptance and inclusivity. We want people to feel safe to bring their whole self to work, without fear of judgment. Before you take-off as a Coosa team member, here are some simple values we want you to embrace:

- **Embrace Your Journey** - We are all on our own unique journey in life, full of ups and downs, twists and turns. Be proud of where you've come from, where you are, and where you're going. We are glad you chose to land at Coosa!

- **Embrace Your Community** - We can't do everything alone- it takes a village. Just as we as individuals need help at times on our journey, we should acknowledge and assist others on their journey. As a Coosa team member, not only will you brighten each customer's day, but you will have regular opportunities to give back to the communities we operate in.

- **Embrace Your Drive** - While we appreciate the help gained along our individual journey, we understand that the power to achieve our goals is within us as individuals and it is us that needs to take that first step every day. We know your contribution will make the Coosa team even stronger.

- **Embrace Your Space** - All of this together, creates your space now and in the future. Embrace it.

We are thrilled to have you part of the Coosa team, as we celebrate and support everyone on their personal journey. We ask that you always have an open mind, assume positive intent, and treat others as you would like to be treated.

Please take time to review the policies contained in this handbook. If you have questions, feel free to ask your supervisor or to contact Human Resources.

Welcome to the Coosa family!

SECTION 1: EQUAL EMPLOYMENT, NON-DISCRIMINATION, AND NON-HARASSMENT POLICY

A. EQUAL EMPLOYMENT OPPORTUNITY

The Company's policy is to select, place, train, and promote the best qualified individuals based upon relevant factors such as work quality, attitude and experience to provide equal employment opportunity for all employees in compliance with applicable local, state and federal laws. The Company does not discriminate against anyone based upon race, color, religion/creed, sex (including pregnancy), sexual orientation, gender identity, national origin, age, disabilities, height, weight, familial status, veteran status, genetic information, or any other protected classification.

This equal opportunity policy applies to all Company activities including but not limited to recruiting, hiring, training, transfers, promotions and benefits. Any employee who believes he/she/they has been discriminated against or harassed must immediately report this in writing to the Company and contact Human Resources.

Company conducts a pre-employment background check on all prospective employees and keeps a record of the results for the duration of the employee's employment with Company. The results of such background check may be shared with the Cannabis Regulatory Agency (CRA) upon request.

B. NON-DISCRIMINATION AND REQUESTS FOR ACCOMMODATIONS OF INDIVIDUALS WITH DISABILITIES

In accordance with the Americans with Disabilities Act and the Persons with Disabilities Civil Rights Act, the Company does not discriminate against qualified individuals with disabilities who can perform the essential functions of their positions with or without accommodation.

Qualified individuals with disabilities may make a written request for reasonable accommodation to a Direct Supervisor or Human Resources. Upon receipt of an accommodation request, a meeting may be scheduled with the requesting individual to

discuss and identify the precise limitations resulting from the disability and the potential accommodation that the Company might make to help overcome those limitations without undue hardship to the Company or undue risk to the health and safety of the requesting individual or other employees.

C. ANTI-DISCRIMINATION AND ANTI-HARASSMENT, INCLUDING SEXUAL HARASSMENT, POLICY

The Company is committed to providing a work environment in which all individuals are treated with respect and dignity. It is the Company's belief that each individual has the right to work in a professional atmosphere that promotes equal employment opportunities and prohibits discriminatory practices, including harassment; therefore, the Company expects that all relationships amongst persons in the workplace will be business-like and free of bias, prejudice, and harassment. Thus, the Company does not and will not tolerate discrimination against or harassment of or by its employees, contractors, consultants, agents, applicants, customers, or vendors. The term "harassment" includes, but is not limited to, slurs, jokes, and other verbal, graphic, or physical conduct relating to an individual's race, color, sex (includes discrimination against or harassment of individuals of the same sex), sexual orientation, gender identity or nonbinary status, pregnancy, religion, national origin, citizenship, age, disability, workers 'compensation claims, marital, veteran, or any other protected status. "Harassment" may include a range of subtle and not so subtle behaviors and also includes unwelcome or unwanted sexual advances, requests or demands for favors, offensive touching, and other types of conduct whether it be physical, verbal, graphic, or electronic communication (including e-mail and facsimiles) of a harassing or sexual nature involving individuals of the same or different gender. This includes, but is not limited to:

- **Unwelcome or unwanted physical contact or sexual advances including, but not limited to, patting, grabbing, pinching, brushing-up against, hugging, cornering, kissing, fondling, or any other similar physical contact.**

- **Unwelcome requests or demands for favors including, but not limited to, subtle or blatant expectations, pressures, requests or demands for sexual, unethical or illegal favors, or unwelcome requests for dates or contacts. Such unwelcome requests or demands may or may not relate to an implied or stated promise of preferential treatment, or a threat of negative consequences concerning employment, including, but not limited to, promotion, demotion, transfer, layoff, termination, pay or other form of compensation, and selection for training.**

- **Verbal and written abuse or unwelcome kidding including, but not limited to, that which is sexually-oriented, including same-sex harassment; commentary about an individual's body, sexual prowess or sexual deficiencies; inappropriate comments about race, color, religion, sex, sexual orientation, pregnancy, national origin, citizenship, age, disability, workers' compensation claims, marital, veteran, or other protected status; dirty jokes or other jokes which are unwanted and considered offensive or tasteless; or comments, innuendoes, epithets, slurs, negative stereotyping, leering, catcalls, or other actions that offend, whether sexually oriented or otherwise related to a prohibited form of discrimination or harassment.**

- **Any form of behavior that unreasonably interferes with work performance, including, but not limited to, unwanted sexual attentions, comments, interruptions, or other communications, whether sexually-oriented or otherwise related to a prohibited form of discrimination or harassment, that reduces productivity or time available to perform work-related tasks or otherwise interferes with work performance.**

- **Actions that create a work environment that is intimidating, hostile, abusive, or offensive because of unwelcome or unwanted conversations, suggestions, requests, demands, physical contacts or attentions, whether**

sexually oriented or otherwise related to a prohibited form of discrimination or harassment.

- **The distribution, display, or discussion of any written or graphic material, including calendars, posters, cartoons, or names, that belittles or shows hostility or aversion toward an individual, his/her/their relatives, friends or employees or a group because of race, color, religion, sex (including same sex discrimination or harassment), sexual orientation, gender identity, pregnancy, national origin, citizenship, age, disability, workers' compensation claims, marital, veteran or other protected status.**

All employees and applicants are covered by this policy and are strictly prohibited from engaging in any form of discriminatory or harassing conduct. Further, no employee has the authority to suggest to another employee or applicant that the individual's employment, continued employment, or future advancement will be affected in any way by entering into, or refusing to enter into, a personal relationship. Such conduct is a direct violation of this policy.

Conduct prohibited by this policy is unacceptable in the workplace and in any work-related setting outside the workplace, such as business trips, business meetings, and business-related social events. Normal, courteous, mutually respectful, pleasant, and non-coercive interactions between employees, contractors, consultants, agents, applicants, vendors, clients, or customers, that are acceptable to all parties are not considered to be prohibited harassment.

Violation of this policy will subject an employee to disciplinary action, up to and including immediate termination.

Retaliation is Prohibited

The Company prohibits retaliation against any individual who reports discrimination or harassment or participates in an investigation of such reports. Retaliation against an

individual for reporting harassment or discrimination or for participating in an investigation of a claim of harassment or discrimination is a serious violation of this policy and, like harassment or discrimination itself, will be subject to disciplinary action, up to and including termination.

Reporting Procedures and Investigation

The Company strongly urges the reporting of all incidents of discrimination, harassment or retaliation, regardless of the offender's identity or position. Individuals who believe that they have experienced conduct that they believe is contrary to the Company's policy or who have concerns about such matters should file their complaints with a Direct Supervisor, whereupon the matter will be discreetly and thoroughly investigated. The Company will then take immediate steps to stop any behavior which violates this policy and see that it does not repeat itself. Disciplinary action, up to and including termination, calculated to end the discrimination or harassment, will be taken, when appropriate, against the offender(s).

If an employee or applicant suffers discrimination or harassment from a supervisor, manager, or any employee, contractor, consultant, customer, vendor, or other third party and is not able to report, or is not comfortable reporting harassment to a Direct Supervisor or if a complaint concerning another employee, contractor, consultant, customer, vendor, supervisor, manager, or other third party is not handled to satisfaction, the employee must immediately contact Human Resources.

Employees who have experienced conduct that they believe is contrary to this policy have an obligation to take advantage of this complaint procedure. An employee's failure to fulfill this obligation could affect his or her rights in pursuing any claim.

Early reporting and intervention have proven to be the most effective method of resolving actual or perceived incidents of discrimination or harassment; therefore, while no fixed reporting period has been established, the Company strongly urges the prompt reporting of complaints or concerns so that rapid and constructive action can be taken.

The availability of this complaint procedure does not preclude individuals who believe that they are being subjected to harassing conduct from promptly advising the offender that his or her behavior is unwelcome and requesting that it be discontinued.

Responsive Action

Conduct constituting harassment, discrimination, or retaliation will be dealt with appropriately. Responsive action may include training, referral to counseling and/or disciplinary action such as warning, reprimand, withholding of a promotion or pay increase, reassignment, and temporary suspension without pay or termination, as the Company believes appropriate under all of the circumstances.

Patron Conduct

Employees working in a customer facing role with the Company must be aware that they may come into contact with intoxicated persons and must follow all laws, rules, and regulations, regarding any such intoxication. In the event an employee feels harassed by any patient, patron, customer, or visitor, the employee should immediately report to management as set forth above.

Employees should also be aware that the Company strictly forbids discrimination or harassment of any patron. If a patron feels they have suffered discrimination or harassment from an owner, agent, supervisor, manager, or any employee, the patron has the right to speak with an on-site manager.

Note that nothing in this policy shall prevent the management of the Company from refusing entry to or removing anyone who engages in violent, illegal, indecent, profane, or otherwise disorderly conduct, provided that management does not take any such actions in a discriminatory manner.

SECTION 2: EMPLOYMENT

A. AT-WILL

Employment at the Company is on an at-will basis unless otherwise stated in a written individual employment agreement. This means that either the employee or the Company may terminate the employment relationship at any time, for any reason, with or without notice.

Nothing in this employee handbook is intended to or creates an employment agreement, express or implied. Nothing contained in this or any other document provided to the employee is intended to be, nor should it be, construed as a contract that employment or any benefit will be continued for any period of time. In addition, no company representative is authorized to modify this policy for any employee or to enter into any agreement, oral or written, that changes the at-will relationship.

Any salary figures provided to an employee in annual or monthly terms are stated for the sake of convenience or to facilitate comparisons and are not intended and do not create an employment contract for any specific period of time.

Nothing in this statement is intended to interfere with, restrain, or prevent concerted activity as protected by the National Labor Relations Act. Such activity includes employee communications regarding wages, hours, or other terms or conditions of employment. Coosa employees have the right to engage in or refrain from such activities.

B. EMPLOYMENT CLASSIFICATION

In order to determine eligibility for benefits and overtime status and to ensure compliance with federal and state laws and regulations, the Company classifies its employees as shown below. The Company may review or change employee classifications at any time.

Exempt. Exempt employees are paid on a salaried basis and are not eligible to receive overtime pay.

Nonexempt. Nonexempt employees are paid on an hourly basis and are eligible to receive overtime pay for overtime hours worked.

Full-Time. Employees who are not in a temporary status and work a minimum of 32 hours weekly and maintain continuous employment status. Generally, these employees are eligible for the full-time benefits package and are subject to the terms, conditions, and limitations of each benefits program.

Part-Time. Employees who are not in a temporary status and who are regularly scheduled to work fewer than 30 hours weekly, but at least 20 hours weekly, and who maintain continuous employment status. Part-time employees are eligible for some of the benefits offered by the company and are subject to the terms, conditions, and limitations of each benefits program.

Casual Part-Time. Employees who are hired to supplement the workforce and work fewer than 25 hours weekly, but at least 20 hours per month. Casual Part-Time employees are not eligible for any benefits.

C. HOURS OF WORK & TIME RECORDS

An employee's time record is a legal record of the time an employee has worked. It is the basis upon which each employee is paid. A Direct Supervisor will assign hours of work to each individual. All nonexempt employees must accurately record the hours they work each day. Failure to do so will subject the employee to disciplinary action up to and including termination of employment.

Employees must notify their Direct Supervisor in the event of any discrepancy between hours reported and actual hours worked. Time records are the property of the Company.

It is a violation of Company policy for any employee to falsify a time record, or to alter another employee's time record. It is also a serious violation of Company policy for any employee, supervisor, or manager to instruct another employee to incorrectly or falsely report hours worked or alter another employee's time record to under, or over-report hours

worked. If any supervisor, manager or other employee instructs another employee to (1) incorrectly or falsely under or over-report hours worked, or (2) alter another employee's time records to inaccurately or falsely report that employee's hours worked, employee should report it immediately to a Direct Supervisor or other management.

An employee who needs to leave work for any reason, must obtain permission from a Direct Supervisor.

From time to time, Direct Supervisors may need to change employee schedules to meet scheduling or other needs. Notice will be given as far in advance as possible.

D. AVAILABILITY

It is important that we are able to accommodate a work/life balance for all team members. To accomplish this, team members must accurately communicate availability at time of hire. All team members must have some availability on our busiest days (Thursday – Sunday). Full-time nonexempt employees must have open availability Thursday through Sunday. Any changes to a team member's availability must be communicated to your Direct Supervisor at least one month in advance of needing the change. All changes are subject to manager approval. Should you need a temporary modification to this policy, a request would need to be submitted for approval to your direct supervisor.

E. ATTENDANCE

All employees are expected to arrive on time, ready to work, every day they are scheduled to work. If unable to arrive at work on time, or if an employee will be absent for an entire day, the employee must contact the supervisor as soon as possible. Any absenteeism or tardiness will result in discipline. Being more than 10 minutes late in excess of 3 times in a rolling 6-month period will result in termination absent extreme circumstance. Failure to show up or call in for a scheduled shift without prior approval may result in immediate termination. If an employee fails to report to work or call in to inform the supervisor of the absence for 3

consecutive days or more, the employee will be considered to have voluntarily resigned from employment.

F. BREAK POLICY

Employees are entitled to a 30-minute unpaid break if his/her/their shift exceeds 6-hours, and a 60-minute unpaid break if his/her/their shift exceeds 11-hours. Employees working shifts exceeding 11-hours may split their 60-minute break into two 30-minute breaks. Employees are not to perform any work while on their break. Employees must take their break off the floor and out of customer view or outside of the facility.

Employees are to take their break at a time to be determined by the employee's Direct Supervisor. If an employee works through the break interval and wishes to take a break (or needs to take a break outside of that interval), approval to take a break can be requested to a Direct Supervisor.

Food should not be consumed outside of a break period and must be consumed in the designated break area.

G. MANDATORY MEETINGS

If management schedules a mandatory employee meeting, employees will be paid for that time.

H. JOB PERFORMANCE

Communication between employees and supervisors or managers is very important. Discussions regarding job performance are ongoing and often informal. Employees should initiate conversations with their supervisors if they feel additional ongoing feedback is needed.

Formal performance reviews are offered at various points throughout the year. These reviews include a written performance appraisal and discussion between the employee and the supervisor about job performance and expectations for the future.

I. TERMINATION OF EMPLOYMENT

Voluntary Termination

While the Company hopes to mutually benefit from each individual's continued employment, it may become necessary for an employee to leave the job. In all cases of voluntary resignation (one initiated by the employee), employees are asked to provide a written notice to their supervisors at least 14 days in advance of the last day of work. Holidays and paid time off (PTO) will not be counted toward the 14-day notice. Employees who provide the requested amount of notice will be considered to have resigned in good standing and generally will be eligible for rehire.

An employee may be considered to have voluntarily resigned if the employee:

- **Fails to return from an approved leave of absence; or**
- **Fails to report to work without notice.**

Involuntary Termination

An employee may be involuntarily terminated for any reason.

J. EMPLOYEE REFERENCES (CURRENT AND FORMER EMPLOYEES)

All requests for references must be directed to Human Resources. No other manager, supervisor, or employee is authorized to release references of current or former employees. The Company's policy as to references for former employees is to disclose only the dates of employment and the title of the last position held.

K. PROPERTY RETURN

Employees are expected to return all Company property in their possession or control immediately upon termination of employment for any reason. The Company may take additional action deemed necessary to protect or recover its property.

SECTION 3: COMPENSATION

A. COMPENSATION POLICY

Initial compensation will be established at the commencement of employment with the Company.

It is Company policy and practice to accurately compensate employees and to do so in compliance with all applicable state and federal laws. To ensure that the employee is paid properly for all time worked and that no improper deductions are made, the employee must record correctly all work time and review their paychecks promptly to identify and report all potential errors.

Reviewing Pay Stubs

The Company makes every effort to ensure employees are paid correctly. Occasionally, however, inadvertent mistakes can happen. When mistakes do happen and are called to the Company's attention, immediate corrections will be made. Please review each pay stub upon retrieval to ensure it is accurate.

To Report Concerns or Obtain More Information

If there are any questions about deductions from pay, please contact a Direct Supervisor immediately. If there is suspicion of any improper deductions or pay does not accurately reflect hours worked, the employee should promptly report the matter to a Direct Supervisor. If not handled to satisfaction, the employee should immediately contact another officer of the Company.

B. OVERTIME AND HOLIDAY PAY

The Company recognizes that, due to operational needs, employees may be asked to work additional hours, beyond their normal work week.

Overtime is actual hours worked in excess of 40 in a single workweek. Nonexempt employees will be paid overtime compensation at the rate of one and one half their regular rate of pay for all hours over 40 actually worked in a single workweek. Nonexempt employees are compensated at the rate of one and one half their regular rate of pay for working Holidays named below. Holidays are:

- **New Year's Day (Holiday Hours of Operation: 12 PM to 9 PM)**
- **Easter (Holiday Hours of Operation: 12 PM to 7 PM)**
- **Memorial Day**
- **Juneteenth**
- **Independence Day**
- **Labor Day**

Christmas Eve is not recognized as a Holiday for holiday pay purposes, but retail locations will have shortened hours of operation (9 AM to 5 PM).

Unless otherwise indicated by management, all stores are closed:

- **Thanksgiving Day**
- **Christmas day**

Part-time nonexempt employees are eligible for 4 hours of holiday pay and full-time nonexempt employees are eligible for 8 hours of holiday pay for those holidays in which the store is closed for the entire day. Paid leave, such as holiday, PTO, bereavement time does not apply toward work time. All overtime work must be approved in advance by a Direct Supervisor or manager.

C. PAYROLL AND WAGE DEDUCTIONS

Various payroll deductions are made each payday to comply with and as allowed by federal and state laws, pertaining to taxes and insurance. Deductions will be made for the following:

Deductions Required By Law:

- **Federal and State Income Tax Withholding**
- **State Tax (where applicable)**
- **Local Tax (where applicable)**
- **Social Security (FICA)**
- **Medicare**
- **Garnishments (where applicable)**
- **State Disability Insurance (where applicable)**

Wage deductions may also be made to recover such items as payment for uniforms or other similar items. For all nonexempt employees, such deductions will only be made from the pay for the first forty (40) hours worked in a workweek. Such deductions will not result in an employee's regular rate of pay falling below the minimum wage.

Following the end of each calendar year, every employee will be supplied with their Wage and Tax Statement (W-2) form. The W-2 is mailed to the employee's last address on record. This statement summarizes the income and deductions for the year. If there are any questions regarding these deductions, please contact the Accounting Department.

Team members may accept tips from customers. Reporting of this income must be done in accordance with applicable federal and state law. The Accounting Department will provide further details.

D. ATTACHMENTS AND GARNISHMENTS

The Company does not accept attachments or garnishments except as required by law. Any attachments or garnishments will be executed in compliance with the applicable law. Any information related to attachments or garnishments should be forwarded to Human Resources.

E. WORKERS' COMPENSATION

The Company provides workers 'compensation insurance for all employees. Although employees should use caution in their work and follow all safety requirements and procedures as set forth by the Direct Supervisor, any type of injury sustained while on the job should be instantly brought to the attention of the Direct Supervisor. An accident report must be completed as soon as possible and by no later than the end of the shift. This report is to be signed by the injured employee.

F. AUTOMATIC (DIRECT) PAYROLL DEPOSIT

Automatic Payroll Deposit is a benefit that the Company provides its employees. Most employees find it convenient to have their regular paycheck automatically deposited in their bank account. The employee will be provided with an automatic deposit to complete, but it is permitted to choose a different form of payment.

G. EXPENSE REIMBURSEMENT

Reimbursement is authorized for reasonable and necessary expenses incurred in carrying out job responsibilities. All reimbursements are at the sole discretion of Coosa and each submission is reviewed on a case-by-case basis.

Unless otherwise agreed to between the Company and an employee, Employees serving in an official capacity for Coosa at conferences, meetings, or to conduct work at locations requiring travel away from their designated location that is further than the employee's normal work location, may be reimbursed for actual and necessary expenses incurred, such

as travel expenses, parking fees, meal costs (for out of state travel), lodging, fees incurred in entertaining clients or potential clients, and registration fees. Unless otherwise agreed to between Coosa and an employee, Employees authorized to use their personal cars for Company business are reimbursed at the U.S. Internal Revenue Service approved rate.

- **Authorization must be obtained in advance for expenses over $250.00.**
- **For out of state travel, employees must present a budget in-advance that must be approved.**
- **For out of state travel, the Company shall cover personal meals of employees of not more than $50 per day.**

All expenses to be reimbursed must be input into the Company reimbursement method (software program) and submitted within fourteen (14) days of the expenditure with receipts or, if the expenses are incurred due to a work trip, within fourteen (14) days of return from the trip. Original receipts must be provided for all expenditures made in order to claim reimbursement, or, in the case of a mileage reimbursement, be substantiated with documentary evidence, such as mileage logs. The Company may audit or otherwise verify the accuracy of submitted receipts and evidence.

Employees are responsible for all transportation costs between their designated work station and home during normal work hours or to conduct normal work business.

SECTION 4: BENEFITS

Human Resources will provide details on benefits for which you are eligible.

SECTION 5: CONFIDENTIALITY & DATA SAFEGUARDING

Safeguarding patient and customer data containing personal information from unauthorized disclosure, identity theft, or misuse is imperative.

A. HANDLING A POTENTIAL SECURITY BREACH

Employees who discover, or are notified of, a potential security breach of information held by Company must immediately report it to their Direct Supervisor. This includes lost, stolen, and misplaced information and equipment. The Direct Supervisor will immediately forward the information to his or her supervisor. Employees must immediately report: (a) the date and time of the potential security breach, (b) the type of personal information involved, (c) the type of device the information was stored on, e.g., laptop, USB drive, or tablet, and (d) advise if any law enforcement report was filed (such as in the case of criminal theft).

Coosa management will work with IT to determine if a breach has or is likely to have occurred.

If a security breach occurred or is likely to have occurred, Company and IT will determine whether the breach is likely to cause substantial loss or injury to, or result in identity theft with respect to one or more of Company's patients or customers, and in accordance with applicable law. Upon such determination, the Company will decide whether a review of internal controls is recommended to better ensure the integrity, security, and confidentiality of personal information.

If the Company determines that the security breach has or is likely to cause substantial loss or injury to, or result in identity theft with respect to one or more patients or customers, Coosa shall provide such notice as required by applicable laws.

B. USE AND PROTECTION OF COMPANY ASSETS

The Company's assets are to be used only for the legitimate business purposes of Coosa (and its related entities) and only by authorized employees or their designees. This includes both tangible and intangible assets.

Some examples of tangible assets include office equipment such as telephones, copy machines, computers, furniture, supplies, and production equipment. Some examples of intangible assets include intellectual property such as pending patent information, trade secrets, or other confidential or proprietary information (whether in printed or electronic form). All electronic media and communication systems, including email, intranet, internet access, and voicemail are Company assets and are to be used for appropriate business purposes only.

Employees, officers, and directors are responsible for ensuring that appropriate measures are taken to assure that the Company's assets are properly protected. Employees, officers, and directors should assist in the protection of confidential and proprietary information including technical, financial, marketing, and other business information that, if made available to the Company's competitors or to the public, would be advantageous to such competitors or detrimental to the Company. No employee, officer, or director should disclose or permit the release to any person (other than a fellow employee having a need to know such information) any confidential or proprietary information except as required by law.

In addition, employees, officers, and directors should take appropriate measures to ensure the efficient use of Company assets.

C. AGREEMENT TO VIDEO SURVEILLANCE

All team members consent to being recorded as a condition of employment. Our facilities have security cameras and surveillance that record 24/7/365. We want to provide the safest working environment as possible for our team members. Team members will be on camera while on company property, inside and outside. Obvious exceptions to this are restrooms or

other areas of personal privacy. Coosa's security team reviews security footage frequently. The Company reserves the right to search your belongings if you are on Company property. All suspected criminal activity must and will be reported to the CRA and local authorities within 24 hours of discovery.

SECTION 6: EMPLOYEE SAFETY & HEALTH

A. COMMITMENT TO SAFETY AND HEALTH

The safety, health, and security of employees is of the utmost importance to the Company. If, for some reason, any employee is concerned that s/he either lacks the training necessary to safely perform his/her job, or believes that conditions exist which present safety concerns, the employee should immediately notify their Direct Supervisor. Additionally, employees who observe unsafe work practices or conditions should immediately report such practices or conditions to their Direct Supervisor.

B. WORKPLACE THREATS/VIOLENCE

The Company is committed to providing a safe, violence-free workplace for our employees. Due to this commitment, we discourage employees from engaging in any physical confrontation with a violent or potentially violent individual or from behaving in a threatening or violent manner. Threats, threatening language, or any other acts of aggression or violence made toward or by any employee will not be tolerated. A threat may include any verbal or physical harassment or abuse, attempts to intimidate others, menacing gestures, stalking, or any other hostile, aggressive, and/or destructive actions taken for the purposes of intimidation. This policy covers any violent or potentially violent behavior that occurs in the workplace or at company-sponsored functions.

All Company employees bear the responsibility of keeping our work environment free from violence or potential violence. Any employee who witnesses or is the recipient of violent behavior should promptly inform their Direct Supervisor or Human Resources. All threats will be promptly investigated. No employee will be subject to retaliation, intimidation, or discipline as a result of reporting a threat in good faith under this guideline.

Any individual engaging in violence against the company, its employees, or its property will be prosecuted to the full extent of the law. All acts will be investigated, and the appropriate

action will be taken. Any such act or threatening behavior may result in disciplinary action up to and including termination.

The Company prohibits the possession of weapons on its property at all times, including our parking lots or company vehicles. Additionally, while on duty, employees may not carry a weapon of any type.

Weapons include, but are not limited to, handguns, rifles, automatic weapons, and knives that can be used as weapons (excluding pocketknives, utility knives, and other instruments that are used to open packages, cut string, and for other miscellaneous tasks), martial arts paraphernalia, stun guns, and tear gas. Any employee violating this policy is subject to discipline up to and including dismissal for the first offense.

The Company reserves the right to inspect all belongings of employees on its premises, including packages, briefcases, purses and handbags, gym bags, and personal vehicles on company property. In addition, the Company may inspect the contents of lockers, storage areas, file cabinets, desks, and workstations at any time and may remove all Company property and other items that are in violation of Company rules and policies.

C. INJURY/ACCIDENT REPORTING

Protecting the safety of our employees and visitors is the most important aspect of running our business. All employees have the opportunity and responsibility to contribute to a safe work environment by using commonsense rules and safe practices and by notifying management when any health or safety issues are present. All employees are encouraged to partner with management to ensure maximum safety for all.

In the event of an emergency, notify the appropriate emergency personnel by dialing 911. In case of a work-related injury or accident, please follow this procedure:

1. **Report all injuries immediately to the Direct Supervisor who will, if required, call for emergency medical assistance and arrange transportation to an appropriate facility. If emergency medical assistance is not required,**

the employee must contact their Direct Supervisor within 24 hours for instructions on how to access the nearest workers' compensation medical facility if such care is required. In all instances, the Direct Supervisor must be notified of the injury within 24 hours.

2. **After an injury or accident employees may not return to work unless they have submitted the appropriate documentation, establishing they are fit to return to work.**

3. **If an employee must obtain medical assistance during non-working hours (outside of the employee's usual work schedule), for a work-related injury that was reported by the employee at the time of the injury, but for which no medical assistance was required at the time, the employee should promptly notify their Direct Supervisor by the next scheduled workday. If the employee requires medical assistance after normal work hours, they can go to the nearest walk-in clinic or hospital emergency facility, advising them of the work-related injury. After treatment has been received, the employee must contact their Direct Supervisor so that an injury/accident report may be completed.**

D. RESPONSIBILITIES AND DUTIES

The Company depends on all of its employees to ensure workplace safety and health; therefore, all employees are expected to:

- **Follow all safety rules;**
- **Use and take care of any personal protective equipment required and provided;**
- **Ensure all safety features for tools and equipment are functioning properly;**
- **Avert any activity that places another in harm's way;**

- **Report and immediately replace damaged tools and equipment;**
- **Avoid horseplay, practical jokes, or other activities that create a hazard;**
- **Refrain from the consumption of alcohol, cannabis, or other recreational drugs during a shift or being under the influence of alcohol, cannabis, or recreational drugs during a shift; and**
- **Report any unsafe work practice and any injuries or accidents.**

E. ALCOHOL AND DRUG FREE WORKPLACE POLICY

Coosa is committed to maintaining a workplace free of substance abuse. No employee is allowed to consume, possess, sell, purchase, or be under the influence of alcohol or illegal drugs, as defined by federal law, on any property owned by or leased on behalf of Coosa, or in any vehicle owned or leased on behalf of Coosa.

The use of over-the-counter drugs and legally prescribed drugs is permitted as long as they are used in the manner for which they were prescribed and provided that such use does not hinder an employee's ability to safely perform his or her job. Employees should inform their supervisor if they believe their medication will impair their job performance, safety or the safety of others, or if they believe they need a reasonable accommodation when using such medication.

Coosa will not tolerate employees who report for duty while impaired by the use of alcohol or drugs. All employees should report evidence of alcohol or drug abuse to their supervisor or the General Manager immediately. In cases in which the use of alcohol or drugs creates an imminent threat to the safety of persons or property, employees are required to report the violation. Failure to do so may result in disciplinary action, up to and including termination of employment.

As a part of our effort to maintain a workplace free of substance abuse, Coosa employees may be asked to submit to a medical examination and/or clinical testing for the presence of

alcohol and/or drugs. Within the limits of federal, state, and local laws, Coosa reserves the right to examine and test for drugs and alcohol at our discretion.

As a condition of your employment with Coosa, employees must comply with this Drug & Alcohol Use Policy. Be advised that no part of the Drug & Alcohol Use Policy shall be construed to alter or amend the at-will employment relationship between Coosa and its employees.

Employees found in violation of this policy may be subject to disciplinary action, up to and including termination of employment.

F. HOUSEKEEPING AND ACCESS AT SITE

Employees must maintain good housekeeping and keep all paths of travel clear from debris. A few examples are:

- **Keep all walkways and stairways clear of trash/debris and other materials such as tools and supplies to prevent tripping.**
- **Keep boxes, scraps, and other materials picked up and in an organized manner.**
- **Place debris in appropriate dumpsters to prevent fire and tripping hazards.**
- **Ensure that there is adequate lighting and report any dimly lit areas, which may require additional or improved lighting.**

G. SAFETY AND SECURITY

Coosa is committed to providing a clean, safe, and healthful work environment for its employees. Maintaining a safe work environment, however, requires the continuous cooperation of all employees. Coosa and all employees must comply with all occupational safety and health standards and regulations established by the Occupational Safety and Health Act and state and local regulations.

Coosa's Employee Safety Plan will comply with all applicable OSHA Standards, which are the regulatory requirements established and published by OSHA pursuant to the Occupational Safety and Health Act of 1970 and subsequent laws. Coosa will also follow mandatory standards for general industry and any other applicable standards, as well as any guidance specific to the cannabis industry. 29 CFR 1910. Coosa will comply with standards for recording and reporting occupational injuries and illnesses. 29 CFR 1904. Since we will move and store cannabis plants and products in our facility, we will also account for common hazards and solutions for warehouse workers, such as: Ergonomic and Musculoskeletal Disorders; Forklifts; Materials Handling; Slips, Trips, and Falls; Hazardous Chemicals; Emergency Planning; Electrical Hazards; Lockout/Tagout; Heat Illness; Automation and Robotics; Refrigerated Warehousing; Temporary Workers; and, Stress and Fatigue.

Due to the potentially hazardous nature of our workplace, all team members are responsible for familiarity and compliance with OSHA, EPA, and state regulations regarding job safety and health protection. Coosa will cooperate with all reasonable OSHA and EPA inspections and compliance reviews. Coosa will provide training and materials explaining the applicable standards and guidelines for all employees during the initial getting acquainted period, and periodically when applicable regulations are revised or added. All employees are required to participate, and a record will be maintained of all those in attendance. OSHA's Hazard Communication Standard requires that warning labels with orange and orange- red biohazard symbols be affixed to containers of regulated waste or, alternatively, red bags may be used. Employees who may come into contact with hazardous materials are required to receive information and training after the start of employment. We will maintain additional information, including a copy of the safety data sheets ("SDS"), about any chemical used or stored in the facility, which is available to employees during working hours. Employees will undergo training on how to maintain OSHA safety protocols while on premises, such as: wearing PPE; allowing rest time for staff between tasks of 10-minute breaks every two hours of work and one hour lunch break between every four hours of work; and, reporting potential workplace hazards to our Chief Operating Officer ("COO"). Applicable material safety data sheets will be readily available in processing areas. We will use the Hazard

Analysis of Critical Control Points ("HACCP") system to identify specific safety hazards and measure and control them to ensure the safety of our products. HACCP is a science-based, systematic tool used in various industries to assess safety hazards and establish control systems that focus on prevention rather than relying exclusively on managing collateral damage. Coosa will use the HACCP system throughout all stages of production to avoid dangerous work environments throughout the processing workflow. Part of this process will be establishing Critical Control points throughout the production process and a system of measurements designed to monitor, evaluate, and control any variance or hazard to employee or visitor safety and security.

Next, Coosa will provide gloves, coveralls, and respirators for use in conjunction with hazardous and potentially health-afflicting materials. Coosa will also require PPE be used when participating with certain aspects of infusion. To ensure worker and consumer safety, Coosa will always identify, hold, and store toxic cleaning compounds, sanitizing agents, solvents used in the production of cannabis products, and other chemicals in a manner that protects against contamination. OSHA has identified falling and tripping as being major hazards associated with similar facilities and work environments. This is especially the case when floors are wet, damp, or otherwise coated in a way that makes them increasingly slippery. Coosa will require employees to wear slip-resistant shoes within production areas.

Coosa will utilize the following PPE for our employees' safety: Hand Protection (e.g., protective gloves, nitrile gloves) where cut hazards or potential exposure to corrosive liquids, blood, chemicals, or other infections materials exist; Head Protection (e.g., hard hats) where danger of falling objects exist; Eye Protection (e.g., goggles or glasses) where risk of eye injuries exists, such as punctures, abrasions, contusions, or burns; Face Protection (e.g., face shields) where danger of flying particles or materials exist; Foot Protection (e.g., steel-toed boots) where risks of foot injury from corrosive, poisonous, or hot substances, or from falling objects, crushing, or penetrating actions exist; Hearing Protection (e.g., ear plugs) where risks of hearing damage from occupational noise exist and exceed the acceptable sound levels of the OSHA Noise Standard; Respiratory Protection (e.g., respirator, gas masks) where respiratory health risks exist from inhaling smoke, fumes, particulate matter, etc.;

Clothing Protection (e.g., plastic aprons) where risk of splashing chemicals exists; and, Sanitation Equipment (e.g., shoe booties, hair nets, beard nets) where staff will be handling or manufacturing food or drugs.

Coosa will also keep Emergency Kits in marked locations throughout the facility for quick access in an employee safety emergency. Employees will check the emergency kit once per month to verify all contents are present, in working condition, and unexpired. The emergency kit will include: a fire extinguisher; bottled water; non-perishable food; flashlights with extra batteries; first aid kit (assorted bandages, gauze, antibiotic ointment, sterile gloves, tweezers, antiseptics, cleansing wipes, scissors, and common over-the-counter medications such as Tylenol and Benadryl); a basic toolbox (wrench, pliers, screwdriver, hammer); garbage bags; hand sanitizer; face masks or coverings; buckets; a battery-powered radio; a charged cellular phone with charging cord; and, a USB battery pack.

In addition, all employees are expected to obey safety rules and exercise caution and common sense in all work activities.

H. COMPLAINT AND REPORTING PROCEDURE

Employees should immediately report any unsafe conditions to their supervisor without fear of reprisal. In the case of an accident that results in injury, regardless of how seemingly insignificant the injury may appear, employees must notify their supervisor. If you believe it would be inappropriate to report the matter to your supervisor, you can report it directly to:

General Manager Employees who violate safety standards, cause hazardous or dangerous situations, or fail to report or, where appropriate, remedy such situations may be subject to disciplinary action, up to and including termination of employment.

I. RETALIATION PROHIBITED

Coosa expressly prohibits retaliation against anyone who reports unsafe working conditions or work-related accidents, injuries, or illnesses. Any form of retaliation will be subject to disciplinary action, up to and including termination of employment.

Questions or concerns regarding this policy should be directed to your supervisor or the Human Resources Director.

J. EMERGENCY CLOSINGS

The Company will always make every attempt to be open for business. In situations in which some employees are concerned about their safety, management may advise supervisors to notify their employees that the office is not closed, but that non-essential personnel may choose to leave work if he or she feels uncomfortable.

In extreme circumstances, management may call an official closing for all or part of the day. Employees who are working on-site as of the time of the closing, or were planning to complete a shift, will be paid for a full shift. If you leave earlier than the official closing time, you will be paid only for actual hours worked.

K. SECURITY

The purpose of Coosa's security policy is to protect Company assets and to maintain a safe working environment for all employees.

Facility Access:

All regular Coosa employees will be issued a key to gain access to Company facilities. Employees who are issued keys are responsible for their safekeeping. All lost or stolen keys must be reported to your supervisor as soon as possible.

Upon separation from the Company, and at any other time upon request, all keys must be returned to your supervisor.

Closing Procedures:

The last employee, or a designated employee, who leaves the office at the end of the business day assumes the responsibility to ensure that: all doors are securely locked; the alarm system is armed; thermostats are set on appropriate evening and/or weekend setting; and

all appliances and lights are turned off with the exception of the lights normally left on for security purposes.

Employees are not permitted on company property after hours without prior written authorization from management.

SECTION 7: STANDARDS OF CONDUCT & CORRECTIVE ACTION

A. DUTY TO REPORT CRIMINAL CHARGES

Employees are required to report any new or pending charges or convictions. If an employee is charged or convicted for a controlled substance-related felony or any other felony, it must immediately be reported to the regulating authority. Employees are required to provide a verbal report to their Direct Supervisor or the next available supervisor immediately and no more than 24 hours after any of the following:

- **Any arrest.**
- **The issuance of a criminal complaint or warrant.**
- **The issuance of a Personal Protection Order.**
- **The filing of a substantiated Protective Services complaint.**
- **The loss or suspension of a work-required license or certification.**

Each verbal report shall be followed within 24 hours by a written report to the employee's Direct Supervisor and management. Failure to provide an accurate written report will be considered a violation of this policy and may result in discipline up to and including dismissal.

Employees shall immediately report to their Direct Supervisor any credible work-related physical threat made against them or another employee or if they are involved in any work related incident that results in the filing of a police report.

B. DRESS CODE

An employee's personal appearance and hygiene is a reflection on the company. Building a culture of individual responsibility and mutual respect is critical to the Company's ongoing success as a company. A key element of this culture is the level of professionalism that

employees bring to the workplace every day in terms of both dress and behavior. All employees are required to present a clean, consistent, and professional appearance to represent the Company.

C. CONFLICTS OF INTEREST

A conflict of interest occurs when an individual's private interest interferes, or even appears to interfere, in any way, with the interests of the company as a whole; therefore, an employee, officer, or director must avoid any action which may involve, or may appear to involve, a conflict of interest with the company. If an employee, officer, or director considers undertaking any transaction or relationship that reasonably could be expected to give rise to an actual or apparent conflict or disparity of interest between his/her and the company or in his/her personal or professional relationship, the employee, officer, or director must disclose such activity in advance to the Direct Supervisor for review. Disclosure of any potential conflict is the key to remaining in full compliance with this policy.

D. SOLICITATION

Employees should be able to work in an environment that is free from unnecessary annoyances and interference with their work. In order to protect our employees and visitors, solicitation by employees is strictly prohibited while either the employee being solicited or the employee doing the soliciting is on "working time." "Working time" is defined as time during which an employee is not at a meal, on break, or on the premises immediately before or after his or her shift.

Employees are also prohibited from distributing written materials, handbills, or any other type of literature on working time and, at all times, in "working areas," which includes all office areas. "Working areas" do not include break rooms, parking lots, or common areas shared by employees during nonworking time.

Nonemployees may not trespass or solicit or distribute materials anywhere on company property at any time.

E. DISCIPLINARY MEASURES

Human Resources shall determine, or designate appropriate persons to determine, appropriate actions to be taken in the event of violations of this Handbook. Such actions shall be reasonably designed to deter wrongdoing and to promote accountability for adherence to this Handbook. In determining what action is appropriate in a particular case, management shall take into account all relevant information, including the nature and severity of the violation, whether the violation is intentional or inadvertent, the extent of the likely damage to the Company resulting from the violation and whether the individual has committed previous violations of this Handbook or other company policy.

Violations of the rules and policies of conduct set forth in this Handbook may result in one or more of the following disciplinary actions, as appropriate:

- **Warning;**
- **Reprimand (noted in the employee's personnel record);**
- **Probation;**
- **Demotion;**
- **Temporary suspension;**
- **Required reimbursement of losses or damages;**
- **Termination of employment; and/or**
- **Referral for criminal prosecution or civil action.**

Disciplinary measures may apply to any supervisor who directs or approves such actions or has knowledge of them and does not promptly correct them.

Reporting possible violations of this Handbook will not result in retaliation against such employee for making this report.

Conduct that violates this Handbook may also violate federal or state laws or laws outside the United States. Such violations may subject the employee, officer, or director to prosecution, imprisonment and fines.

F. CUSTOMER RELATIONS

The success of the Company depends upon Company's Core Values, including the quality of the relationships between Coosa, its employees, its customers, its suppliers, and the general public. The customer impression of the Company is greatly formed by the people who serve it. In a sense, regardless of position, each individual is Company's ambassador. The more goodwill that is promoted, the more the customers will respect and appreciate all that the Company has to offer.

Here are several actions employees can take to help give customers a good impression of the Company:

- **Act competently and deal with customers in a courteous and respectful manner.**
- **Communicate pleasantly and respectfully with other employees at all times.**
- **Follow up on orders and questions promptly, provide businesslike replies to inquiries and requests, and perform all duties in an orderly manner.**
- **Answer incoming calls with a positive attitude.**
- **Take great pride in the work and enjoy performing at a high level.**
- **Report any unusual or suspicious behavior to the Direct Supervisor.**

These are the building blocks for the success of the Company and all its employees.

G. SOCIAL MEDIA

At Coosa, we understand that social media can be a fun and rewarding way to share your life and opinions with family, friends and co-workers around the world. However, use of social media also presents certain risks and carries with it certain responsibilities. To assist you in making responsible decisions about your use of social media, we have established these guidelines for appropriate use of social media.

Guidelines. In the rapidly expanding world of electronic communication, social media can mean many things. Social media includes all means of communicating or posting information or content of any sort on the Internet, including to your own or someone else's web log or blog, journal or diary, personal web site, social networking or affinity web site, web bulletin board or a chat room, whether or not associated or affiliated with the Company, as well as any other form of electronic communication.

The same principles and guidelines found in Company's policies and three basic beliefs apply to your activities online. Ultimately, you are solely responsible for what you post online. Before creating online content, consider some of the risks and rewards that are involved. Keep in mind that any of your conduct that adversely affects your job performance, the performance of fellow associates or otherwise adversely affects members, customers, suppliers, people who work on behalf of the Company or Company's legitimate business interests may result in disciplinary action up to and including termination.

Know and follow the rules. Carefully read this Employee Handbook and ensure your postings are consistent with these policies. Inappropriate postings that may include discriminatory remarks, harassment, and threats of violence or similar inappropriate or unlawful conduct will not be tolerated and may subject you to disciplinary action up to and including termination.

Be respectful. Always be fair and courteous to fellow associates, customers, members, suppliers or people who work on behalf of the Company. Also, keep in mind that you are more likely to resolve work related complaints by speaking directly with your co-workers or

Direct Supervisor than by posting complaints to a social media outlet. Nevertheless, if you decide to post complaints or criticism, avoid using statements, photographs, video or audio that reasonably could be viewed as malicious, obscene, threatening or intimidating, that disparage customers, members, associates or suppliers, or that might constitute harassment or bullying.

Examples of such conduct might include offensive posts meant to intentionally harm someone's reputation or posts that could contribute to a hostile work environment on the basis of race, sex, disability, religion or any other status protected by law or Company policy.

Be honest and accurate. Make sure you are always honest and accurate when posting information or news, and if you make a mistake, correct it quickly. Be open about any previous posts you have altered. Remember that the Internet archives almost everything; therefore, even deleted postings can be searched. Never post any information or rumors that you know to be false about the Company's fellow associates, members, customers, suppliers, people working on behalf of Company or its competitors.

Post only appropriate and respectful content. Maintain the confidentiality of Company trade secrets and private or confidential information. Trade secrets may include information regarding the development of systems, processes, products, know-how and technology. Do not post internal reports, policies, procedures or other internal business-related confidential communications.

Do not create a link from your blog, website or other social networking site to a Company website without identifying yourself as a Company associate.

Express only your personal opinions. Never represent yourself as a spokesperson for the Company. If the Company is a subject of the content you are creating, be clear and open about the fact that you are an associate and make it clear that your views do not represent those of Coosa, fellow associates, members, customers, suppliers or people working on behalf of the Company. If you do publish a blog or post online related to the work you do or subjects associated with the Company, make it clear that you are not speaking on behalf of Coosa. It

is best to include a disclaimer such as “The postings on this site are my own and do not necessarily reflect the views of Coosa.”

Using social media at work. Refrain from using social media while on work time or on equipment we provide, unless it is work-related as authorized by your manager or consistent with the Company Equipment Policy. Do not use any Company email addresses to register on social networks, blogs or other online tools utilized for personal use.

Retaliation is prohibited. The Company prohibits taking negative action against any associate for reporting a possible deviation from this policy or for cooperating in an investigation. Any associate who retaliates against another associate for reporting a possible deviation from this policy or for cooperating in an investigation will be subject to disciplinary action, up to and including termination.

Media contacts. Associates should not speak to the media on Company’s behalf without contacting the Corporate Office. All media inquiries should be directed to them.

For more information. If you have questions or need further guidance, please contact Human Resources.

SECTION 8 – EMAIL/INTERNET POLICY

A. COMPANY BUSINESS

Voicemail, email, and Internet usage assigned to an employee's computer or telephone extensions are solely for the purpose of conducting Company business. Some job responsibilities at Coosa require access to the Internet and the use of software. Only people appropriately authorized, for Company purposes, may use the Internet or access additional software.

B. INTERNET USAGE

Internet use, on Company time, is authorized to conduct Company business only. Internet use brings the possibility of breaches to the security of confidential Company information. Internet use also creates the possibility of contamination to our system via viruses or spyware. Spyware allows unauthorized people, outside the Company, potential access to Company passwords and other confidential information.

Removing such programs from the Company network requires IT staff to invest time and attention that is better devoted to progress. For this reason, and to assure the use of work time appropriately for work, we ask employees to only use internet for company related purposes.

Additionally, under no circumstances may Company computers or other electronic equipment be used to obtain, view, or reach any pornographic, or otherwise immoral, unethical, or non-business-related Internet sites. Doing so can lead to disciplinary action up to and including termination of employment.

C. EMAIL USAGE

Email is only to be used for Company business only. Company confidential information must not be shared outside of the Company, without authorization, at any time. Employees are also not to conduct personal business using the Company computer or email.

Please keep this in mind, also, as employees consider forwarding non-business emails to associates, family or friends. Non-business-related emails waste company time and attention.

Viewing pornography, or sending pornographic jokes or stories via email, is considered sexual harassment and will be addressed according to our sexual harassment policy.

D. EMAILS THAT DISCRIMINATE

Any emails that discriminate against Team Members by virtue of any protected classification including race, gender, nationality, religion, and so forth, will be dealt with according to the harassment policy.

These emails are prohibited at Coosa. Sending or forwarding non-business emails will result in disciplinary action that may lead to employment termination.

E. COOSA OWNS EMPLOYEE EMAIL

Keep in mind that the Company owns any communication sent using company computers or that is stored on company equipment. Management and other authorized employees have the right to access any material in an employee's email or on an employee's computer at any time. Please do not consider a Team Member's electronic communication, storage or access to be private if it is created or stored at work.

F. CONFIDENTIAL INFORMATION

Employees shall not share information that is confidential and proprietary about the company. This includes information about trademarks, upcoming product releases, upcoming services, sales, finances, number of products sold; number of employees; company strategy; and any other information that has not been publicly released by the company.

These are given as examples only and do not cover the range of what the company considers confidential and proprietary. If an employee has any question about whether information has been released publicly or doubts of any kind, he or she should speak with his or her

Direct Supervisor before releasing information that could potentially harm our company, or our current and potential products, employees, partners, and guests. Employees may also want to be aware of the points made in any non-disclosure agreement that each Team Member may have signed when they joined our company.

Coosa's logo and trademarks may not be used without explicit permission in writing from the company. This is to prevent the appearance that an employee speaks for or represents the company officially.

G. RESPECT AND PRIVACY RIGHTS COMPONENTS

Speak respectfully about the company and our current and potential employees, guests, partners, and competitors. Do not engage in name calling or behavior that will reflect negatively on Coosa's reputation. Note that the use of copyrighted materials, unfounded or derogatory statements, or misrepresentation is not viewed favorably by Coosa and can result in disciplinary action up to and including employment termination.

Coosa encourages each employee to write knowledgeably, accurately, and using appropriate professionalism.

Honor the privacy rights of our current employees by seeking their permission before writing about or displaying internal company happenings that might be considered to be a breach of their privacy and confidentiality.

H. THE LEGAL LIABILITY

Recognize that each employee is legally liable for anything they write or present online. Employees can be disciplined by the company for commentary, content, or images that are defamatory, pornographic, proprietary, harassing, libelous, or that can create a hostile work environment. Employees can also be sued by company officials, competitors, and any individual or company that views the employee's commentary, content, or images as defamatory, pornographic, proprietary, harassing, libelous or creating a hostile work environment.

SECTION 9: EMPLOYEE RELATIONS

The Company strongly believes that a work environment where employees maintain clear boundaries between personal and business interactions is necessary for effective business operations. Employees, in any role, act as role models and affect the working environment of others.

This policy does not preclude or interfere with the rights of employees protected by the National Labor Relations Act or any other applicable statute concerning the employment relationship.

GUIDELINES

- **During working time and in working areas, employees are expected to conduct themselves in an appropriate workplace manner that does not interfere with others or with overall productivity.**

- **During nonworking time, such as lunches, breaks, and before and after work periods, employees engaging in personal exchanges in nonwork areas should observe an appropriate workplace manner to avoid offending other workers or putting others in an uncomfortable position.**

- **Employees who allow any personal relationship with a co-worker to adversely affect the work environment will be subject to some level of discipline, including counseling by HR for minor problems. Failure to change behavior and maintain expected work responsibilities is viewed as a serious disciplinary matter, with consequences up to termination.**

- **When a potential risk to Company is identified due to a romantic relationship between co-workers, Company will work with the parties involved to consider options for resolving the problem. The initial solution may be to make sure the parties no longer work together, either through a change of hours or location; however, employees should be aware that this**

solution may not be possible, and Company has no obligation to ensure a continuation of employment due to violation of this Employee Relations Policy. If one or both parties refuse to accept a reasonable solution offered by Company, such refusal will be deemed a voluntary resignation.

- **Any employee that fails to cooperate with Company's investigation into conflicts or problems caused by a romantic or sexual relationship between co-workers under this Employee Relations policy may be deemed insubordinate, which may result in disciplinary action.**
- **The provisions of this policy apply regardless of the sexual orientation or gender identity of the parties involved.**
- **Where doubts exist as to the specific meaning of the terms used above, employees should make judgments based on the overall spirit and intent of this policy.**
- **Any concerns about the administration of this policy should be addressed to Human Resources at [insert contact information].**

SECTION 10: CONCLUSION

The Company recognizes the value and importance of each of our employees and your contribution to our success.

We strive to offer you the best working conditions possible and trust that we can rely on your loyalty, hard work, and dedication for many years to come.

We have tried to give you some useful information about us and our policies. Naturally, not everything can be covered in this Handbook; however, please remember that supervisors and HR are always available to answer questions. If you have a question about this Handbook (or anything else), a suggestion, or a work-related problem, we encourage you to discuss it with your Direct Supervisor.

Your personal and professional growth with the Company is largely dependent upon you. We are glad to have you as a member of our team, and we wish you every success.

License Type: Processor

Exhibit 21 – Quality Control and Quality Assurance Plan

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

Introduction

We are dedicated to establishing procedures and products that are safe and consistent. Our quality control ("QC") and quality assurance ("QA") plan defines methods within the manufacturing process that will provide consistently safe, potent, and high-quality products, including testing at different stages of production, and a plan for any failed test samples. We designed this plan in alignment with industry best standards, good agricultural practices, good manufacturing practices, and regulatory compliance, with a focus on employee, patient, and community safety. Our executive team will review this plan at least annually to identify areas of improvement and implement changes. Ala. Admin. Code r. 538-x-3-.05.03.m.16.d. We will promptly notify the Alabama Medical Cannabis Commission ("the AMCC") of any changes to our QC/QA plan.

Our Head of Processing Operations, Dr. Heather Watson, will oversee our manufacturing and production processes and several key team members, including our Chief Operating Officer. Our Quality Assurance and Quality Control Director ("QAQCD") will report to the Chief Operating Officer. All three of these team leaders are remarkable scientific researchers with significant business expertise. Our QAQCD, Caleb King, is an analytical biochemist with a focus on method development and optimization, and he has spent more than a decade researching cannabis. He founded his own company, Tryptomics, which focuses on harm reduction through metabolite identification and quantification. Caleb has developed product quality standards, scaled testing capabilities, and directed regulatory testing operations. The QAQCD will provide open communication to authorities and law enforcement and oversee a team of quality assurance and quality control technicians. The quality assurance and control teams will validate all medical cannabis received by and shipped from our facility, mobilize in case of a recall, and maintain close professional relationships with testing laboratories to understand and improve medical cannabis products.

21.1 - Quality Manufacturing Processes

We will provide high quality products with consistent standards of safety, potency, stability, and lifespan. Ala. Admin. Code r. 538-x-6-.06.03.c.01. Each step of our manufacturing process will include quality control. Our QAQCD will construct our QA/QC

plan and perform reviews of the plan monthly during our first year of operation, and every six months thereafter. Furthermore, our QAQCD will provide open communication to authorities and law enforcement, while overseeing a team of quality assurance and quality control technicians. The quality assurance and control teams will validate all medical cannabis received by and shipped from our facility, mobilize in case of a recall, and maintain close professional relationships with testing laboratories to understand and improve medical cannabis products

We will utilize a foundational QA tool known as the PDCA cycle (short for "Plan, Do, Check, Act") in our QA/QC processes. The cycle begins by defining what objectives must be met to guarantee the quality of the product or process in question and developing a plan to accomplish those objectives. The next component is to carry out the plan in a small-scale, controlled environment, where outcomes can be easily measured, and real-world data gathered. After the plan is done, the execution will be checked by reviewing the results against desired outcomes, then identifying differences and similarities. Finally, action will be taken to address the root causes of undesirable outcomes identified in the previous step and adjustments will be made to the QA/QC plan to avoid these deviations in the future.

Our quality staff will continually employ the PDCA cycle to assess and improve our QA/QC plan and associated SOPs. When modifications to the QA/QC plan are necessary, the QAQCD will be responsible for all revisions, including SOP updates, and communication to the AMCC or other parties as needed. Furthermore, our Director of Compliance ("DOC") will update all documentation and associated SOPs with any regulatory changes, or process changes within the facility. We will always safely store and maintain meticulous records, including details of process revisions and QA/QC accomplishments.

For a QA/QC plan to function properly, provisions must be made for effective communication of the results from QA/QC activities to all affected parties. We will establish clear channels of communication and outline the responsibilities of each party. All changes and revisions made during reviews will be implemented into our written SOPs and forwarded to all appropriate parties, allowing staff throughout our operations to keep up to date on our continuously evolving business practices. All revisions to this plan will be clearly marked. In the event a major revision to the QA/QC plan is required, each copy will be reissued to all appropriate employees.

Functions of QA/QC

Although QA and QC are independent, both are interrelated functions overseen by the QAQCD. QA is process oriented, encompassing the entire production process through packaging of manufactured goods, and ends when the product leaves the facility and is sent to, and enters, the receiving medical cannabis facility. The ultimate goal of QA is to ensure patient safety. We will maximize the quality potential of the cannabis products we produce with high grade manufacturing equipment and the utilization of industrial and cannabis industry best practices.

Conversely, QC is product oriented, composed of in-process testing and testing of the final product. The role of QC is to develop testing methods, establish product specifications (e.g., the acceptable values for product quality standards), and perform the testing for every batch cultivated or manufactured. Another way to view the roles of QA and QC is when there is deviation in the QC process (e.g., a test was performed by QC outside of *its* validated processes). In such a case, the QC team would conduct the investigation into what went wrong, while the QA team would review that investigation for compliance.

Departmental directors and managers will develop a process for each stage of operations, validate the process (e.g., repeat the process multiple times to demonstrate that the process always yields a product with the same quality standards), and establish narrow "target" ranges and wider "acceptable" ranges for every process parameter. If deviations happen outside of the narrower range, but within the wider range, QA will accept that the product is safe though not optimal. If the deviations happen outside of the wider range, QA will reject the batch, or may require additional data to support the release of the product.

Records

Internal record keeping will document all cultivator details, packaging, ingredients, and medical cannabis concentrates utilized in each production batch or infused product, storage of cannabis, and any destruction or disposal. A harvest or batch number will be assigned to cannabis products to facilitate quick and easy identification in the event of a recall, and we have developed a detailed recall plan, submitted as part of this application. Ala. Admin. Code r. 538-x-6-.06.03.h. We will maintain these records for at least two years

and reference record keeping documents in the event of a recall. Our Chief Operating Officer will hold ultimate responsibility for the proper maintenance of our records. We will train all staff on accurate recordkeeping procedures.

Audits and Inspections

We will develop internal formalized inspections of our facility. The QAQCD will conduct weekly QA/QC inspections of manufacturing processes to identify problems, inadequacies, or gaps in any SOPs. They will confirm that our employees manufacture all cannabis products consistently and safely in accordance with our SOPs and applicable laws to provide safety, potency, stability, lifespan, and consistency among batches. Inspections will include a manual check of manufacturing materials and completed batches; direct oversight of manufacturing activities; and a report of all findings. The QAQCD will train and retrain staff as needed in response to the results of their inspections, significant errors identified by other managerial and leadership staff, changes in SOPs, or changes to regulatory requirements.

As an extra measure of protection for our staff, consumers, and the public, the QAQCD will conduct manufacturing line audits periodically and randomly throughout daily manufacturing activities, during manufacturing startup, and amidst shutdown operations. Audits will include inspections of equipment and inventory to confirm that manufacturing equipment and machines are in good operating order. The inspection will include identification of damage, defects, and overall structural integrity of manufacturing materials. Our manufacturing audit also evaluates overall manufacturing efficiency, downtime, and any product damage or loss caused by our manufacturing SOPs. This audit will identify manufacturing issues for which we will immediately work to find solutions and integrate them into our SOPs. We will also revise our manufacturing SOPs immediately to integrate any changes to packaging laws or regulations approved by the legislature or the AMCC.

We will promptly request all required inspections with the AMCC and other necessary state and local agencies prior to commencing operations. Management will make our entire facility accessible to necessary and authorized visitors for inspections. This will include each area used for receiving, preparation, production, manufacture for sale, storage,

distribution, or transportation of medical cannabis or medical cannabis products, as well as all associated utensils, fixtures, furniture, machinery, and devices. Management and other staff will perform sanitation inspections of manufacturing areas quarterly (on a staggered schedule) or after any pest response incident. Sanitary inspections will include a checklist of all production areas, with notes required for the conditions within the extraction and associated manufacturing areas. During this inspection, the managing staff member will record all observed deficiencies in physical controls and order their repair or lapses in cultural controls and order the completion of additional training. The observation of any physical deficiency or cultural lapse will result in a reevaluation of SOPs relating to that area or operation. Management and leadership level staff will update all existing SOPs involved with new best practices to avoid future deficiencies. Compliant procedures and regular inspections will guarantee that, if contaminants or pests are present on our premises, they are noted and addressed as quickly as possible.

Facility Sanitation

We will maintain a sanitary facility to prevent contamination of our medical cannabis and product inventory, which could lead to diminished quality and potentially impact patient safety. We will outfit our facility, including all floors, walls, and ceilings, in a manner to allow for easy cleaning and sanitation by minimizing areas where unsanitary conditions may develop, keeping our facility in good repair, and making all areas of the facility readily accessible by operations and sanitation staff. Assisted by our thoughtful facility design, sanitation staff will be able to easily perform daily cleanings to maintain the entirety of our building, fixtures, and other facilities in a sanitary condition, with all manufacturing areas maintained free of debris. In conjunction with constructing an easily cleanable facility, we will provide adequate lighting in all areas where medical cannabis is stored, and in all areas where equipment and utensils are kept or sanitized.

Sanitation staff will perform cleanings of all contact surfaces, including utensils and equipment used for preparation of cannabis or cannabis-infused products, as frequently as our procedures deem necessary to protect against contamination. To facilitate effective and adequate cleaning, our equipment and utensils will be designed and made of material and workmanship that is suitable for sanitary handling of cannabis and associated products.

Further, sanitation staff will only use sanitizing agents that are approved by the AMCC and will always use agents in full accordance with instructions on the product label. All cleaning and sanitation supplies intended for general facility upkeep will be held in a cleaning closet. Sanitation staff will identify all toxic cleaning compounds and sanitizing agents and store them in a manner in accordance with manufacturer's recommendations and product labels, as well as any applicable local, state, or federal law, rule, regulation, or ordinance.

Sanitation staff will also maintain all operating systems for waste in a manner as to not constitute a source of contamination in areas where cannabis is exposed. All litter, waste, and debris will be regularly disposed of in the proper waste system so as to not contribute to contamination in areas where cannabis is exposed. We will diligently monitor and screen our entire facility for pests while implementing and maintaining our pest prevention tactics. Part of these tactics will include the removal of rubbish to minimize the possible development of odor and/or harborage or breeding places for pests.

Employee Hygiene Practices

We will create and implement strict personal hygiene procedures for all individuals at our facility who may work in direct contact with cannabis and cannabis products. In order to maintain a sanitary facility, we will require that all employees bathe/shower before coming to work, wear a clean uniform each day, and maintain adequate personal hygiene. Employees who do not comply with policies regarding attire and grooming will be subject to disciplinary action, and all our employees will maintain a high level of personal hygiene. We will prohibit employees who feel sick or display symptoms of an illness from working their scheduled shift, including handling any cannabis or cannabis product. Employees with any illness, open lesion (e.g., boils, sores, infected wounds), or any other abnormal source of microbial contamination for which there is a reasonable possibility of contact with cannabis or cannabis products will be required to remain at home until their condition is remedied. Employees with a combined cough and fever will also be required to stay home from work.

Any employee with the following diseases or conditions will not be permitted to come to work or to handle cannabis products until cleared to return to work by a physician, in accordance with regulations applicable to food handlers:

- Amebiasis;
- Enterohemorrhagic E. coli;
- Shigellosis;
- Typhoid fever or paratyphoid fever;
- Hepatitis A, viral hepatitis, or jaundice of unspecified etiology; or,
- Persistent diarrhea.

The water supply at our facility will be safe, potable, and provide an adequate supply necessary for cannabis extraction and manufacturing operations. Plumbing will be carefully installed and maintained, and of adequate size and design to carry sufficient quantities of water to required locations throughout the facility. Facility plumbing will properly convey sewage and liquid disposable waste away from the facility with no cross-connections between the potable water lines and wastewater lines. Our facility will also feature sufficient and readily accessible toilet facilities, which sanitation staff will maintain in a sanitary condition and in good repair, with sinks suitable for handwashing located at each toilet facility.

We will provide our employees and visitors with fully stocked and convenient handwashing facilities furnished with running water at a temperature suitable for sanitizing hands. Such facilities will be located where good sanitary practices require employees to wash and sanitize their hands and will also include effective nontoxic sanitizing cleansers and sanitary towels or suitable hand drying devices. We will require all employees to wash hands thoroughly before starting each shift, before handling cannabis, and anytime hands become contaminated or soiled. When employees wash hands, all exposed skin up to the elbow must be scrubbed for 10 to 15 seconds with particular attention given to nail beds, under fingernails, in finger webs, and the thumb. We will require that hands must be washed, at a minimum:

- Before donning fresh gloves;
- After the use of the restroom;
- Before and after handling any cannabis product;

- After disposing of any waste, dirty surface, or taking out the garbage;
- After touching hair, face, body, clothes, or apron;
- After sneezing, coughing, or using a tissue;
- After handling any chemicals;
- After eating, drinking, smoking, chewing gum, or chewing tobacco;
- After handling money; and,
- After touching service animals.

We will train employees to use handwashing sinks only for handwashing. Other activities must occur in utility sinks. All designated handwashing facilities will feature large signs that clearly read in bold lettering, "FOR HANDWASHING ONLY." Signs with instructions for proper handwashing will be posted at handwashing stations and in restrooms to encourage proper practices, and we will include a demonstration of proper handwashing techniques in onboarding training.

Good Manufacturing Practices ("GMP")

Our approach to quality will be integrated into every stage in the manufacturing process and we will prioritize quality and safety at every level of our company. Leading this effort will be our Head of Processing Operations, Dr. Heather Watson. She is a leader and scientific researcher with 13 years of analytical chemistry experience with a focus on mass spectrometry and molecular characterization. Dr. Watson is the CEO of Southern Apothecary, which provides small batches of hemp extracts tested on their own laboratory instruments. This is her fifth year on the international ASTM D37 Committee on Cannabis, and she has published research in accredited scientific journals, including the Journal of Nutrition, Biochemistry, and the Journal of Mass Spectrometry. The Head of Processing Operations will work collaboratively with other staff, particularly the QAQCD and DOC, to guarantee our extensive operational standards comply with current GMP principles. All procedures, methods, and facilities will be fully prepared for an inspection from the AMCC prior to full operations and will continue to retain their integrity for subsequent inspections from the AMCC and other agencies ensuring the safety of our medical cannabis and medical cannabis products.

Through the implementation of a Quality Management System ("QMS"), we will model our approach to quality based on compliance with standards set forth by the U.S. Food and Drug Administration ("FDA"), which establish current good manufacturing practice in manufacturing for products fit for human consumption, such as dietary supplements and manufactured food. 21 C.F.R. §111; §117. For example, we will conduct comprehensive hazard analysis with adherence to the Hazard Analysis and Critical Control Point ("HACCP") system, which reduces food safety risks by identifying and controlling potential hazards at every part of the manufacturing process. 21 C.F.R. §117.130. Examples of Critical Control Points ("CCPs") and preventative controls in the production process are food allergen cross-contamination mitigation, established recall plans, and appropriate labeling practices. 21 C.F.R. §117.135. We will establish facility, equipment, and personnel sanitation in accordance with 21 C.F.R. §117.10, §117.35, §117.37, and §117.40. Our general food safety plan integrates all of the aforementioned concerns, in addition to many others, and will sufficiently meet standards for manufacturing quality and consistent medical cannabis and medical cannabis products fit for human consumption. 21 C.F.R. §117.126. We understand these standards are changing as the industry evolves and will remain informed of such changes.

In addition to the rigorous up to date GMP standards, our operations consider aspects of safety specific to the cannabis industry. For example, one significant consideration is how cannabinoid levels are affected by the heat of the manufacturing process. We have designed the production process based on product requirements and specifications established for each of our unique products. We will properly vet all source ingredients for consumable cannabis products from outside facilities (e.g., sugar and wheat) for their own facility GMP compliance, manufacturing practices, and general safety. Further, we will store cannabis that can support the rapid growth of undesirable microorganisms in humidity- and temperature-controlled rooms to prevent such growth.

Personal Protective Equipment

All employees and visitors are required to use PPE while within our facility. We will keep PPE readily available and adequately stocked in areas where it may be required. Staff

and visitors must inspect PPE prior to each use, and staff must dispose of any damaged equipment or mark it as damaged and send it for repair.

We will require all staff change into sterile clothing and dedicated footwear before entering the production areas (including extraction, associated manufacturing, and packaging areas) within the facility. Each staff member will don a sterile Tyvek® (or similar) suit, nitrile gloves, safety glasses, shoe covers, hair net, and a beard net (if applicable) before entering a production area, and then perform all operations in them. If staff observe a defect in their PPE or other staff members' they will immediately cease their current task, leave the area, remove all PPE, and reset all personal sanitation procedures before reentering the area. Staff will perform visual PPE inspections on themselves and others before undertaking significant activities where the absence of a team member during that process would have a significant negative impact upon the success of the activity or the safety of plants or team members. Should the implementation of single-use Tyvek® suits be deemed too costly long-term, we will pursue a contract for reusable sterile gowning with a local vendor. PPE serves the ultimate purpose of protecting cannabis and cannabis products from pests or other contaminants introduced by staff or other individuals within the facility. Additional PPE for manufacturing activities will include gas masks (available in extraction and post extraction areas for use if needed), chemical aprons, and lab coats.

We will provide gloves, coveralls, and respirators for use in conjunction with hazardous and potentially health-afflicting materials. We will require PPE be used when participating with certain aspects of extraction and manufacturing. We will identify, hold, and store chemicals, toxic cleaning compounds, sanitizing agents, and solvents used in the production of cannabis concentrates in a manner that protects against contamination.

Each task performed within the facility will have an associated SOP, which details the PPE required for the specific task. PPE available on site is identified in this chart:

PPE	Required Use
Hand Protection (e.g., protective gloves, nitrile gloves)	Where cut hazards or potential exposure to corrosive liquids, blood, chemicals, or other infectious materials exist.
Head Protection (e.g., hard hats)	Where danger of falling objects exists.

Eye Protection (e.g., goggles or glasses)	Where risk of eye injuries exists, such as punctures, abrasions, contusions, or burns.
Face Protection (e.g., face shields)	Where danger of flying particles or materials exist.
Foot Protection (e.g., steel-toed Boots)	Where risks of foot injury from corrosive, poisonous, or hot substances, or from falling objects, crushing, or penetrating actions exist.
Hearing Protection (e.g., ear plugs)	Where risks of hearing damage from occupational noise exist and exceed the acceptable sound levels of the OSHA Noise Standard.
Respiratory Protection (e.g., respirator, gas masks)	Where respiratory health risks exist from inhaling smoke, fumes, particulate matter, etc.
Clothing Protection (e.g., plastic aprons)	Where risk of splashing chemicals exists.
Sanitation Equipment (e.g., shoe booties, hair nets, beard nets)	Where staff will be handling or manufacturing food or drugs.

In addition to PPE, we will conspicuously place OSHA spill kits (compliant with *Title 29, Code of Federal Regulations*) and first aid kits throughout our facility. We will also install CO_2 detection alarms in areas where there could be a potential issue, such as extraction and post-extraction rooms.

Handling and Sanitation Standards

The procedures outlined in this subsection will maintain adequate sanitation principals in all areas of operations at our facility, including receiving, transporting, segregating, preparing, producing, packaging, and storing of cannabis and medical cannabis products. Throughout training for every process within the facility, instructors will emphasize the importance of sanitation for prevention of contamination. After extraction, some products will be subject to refinement procedures. To execute post extraction processes safely, management will train staff on how to handle compounds such as ethanol, and how to operate a laboratory using aseptic techniques. By teaching staff how to minimize the transmission of contaminants, we will operate a facility that manufactures safe, contaminate-free medical cannabis products. Other training specific to chemicals will include how to store different chemicals and cleaning compounds and how to sanitize equipment using any AMCC-approved sanitizing agents. We will train all relevant staff to inspect the quality of the locker and ensure that it always meets or exceeds the NFPA

Flammable Liquid Code #30 and OSHA Standard 1910.106 for storage of Class I, II, and III liquids. We have incorporated sanitation practices into SOPs for all activities within the facility such that every procedure concludes by returning the space in which it occurs to a clean baseline state. This will include all equipment used in the performance of such operations, such as scissors, buckets, carts, and other miscellaneous items. We will also properly dispose of all disposable items used in operations, with trash removed daily whenever they are full, and at the conclusion of activities. Collectively, these controls will help provide sanitary conditions, well maintained throughout all operations, to produce contaminate-free medical cannabis products.

21.2 - Testing

Production Testing

Product testing in the medical cannabis industry is crucial to patient safety, and we will follow all required AMCC testing protocols and utilize AMCC-approved state testing laboratories to assess the quality and safety of our medical cannabis and medical cannabis products we produce. Batches that have had samples submitted for testing will be retained and delegated to specific compartments or storage areas until the given batch has passed all mandatory testing. Finished products will not be released for sale until all testing has been completed, passed, and product specifications have been met. Quality control personnel will review these documents and release the appropriate products into the dispensing product stream.

We will conduct testing at distinct points between receiving materials, extraction, production stages, and the sale of our product. Ala. Admin. Code r. 538-x-6-.06.03.c.02. Before labeling a product for sale, we will officially test our products through a licensed state laboratory. We will log all testing results in the state seed-to-sale tracking system. Ala. Code § 20-2A-60(a). These practices will allow us to provide the highest quality medical cannabis products.

The QAQCD will work with management to develop a process for each manufactured product, validate the process, and establish narrow target ranges for every process parameter. In the event of nonconformance, the QA team will use a root cause analysis

method. The QA team will then review the investigation and make appropriate changes and validate the process to guarantee compliance with regulations.

Licensed Testing

We will conduct a variety of tests on our products, including in house testing and official testing through a State Testing Laboratory. Ala. Admin. Code r. 538-x-6-.06.03.c.03. We will make our cannabis products available to an independent, third-party cannabis testing laboratory approved by the AMCC for purposes of sampling for safety and ingredient testing. We will select an AMCC-approved, accredited, independent laboratory that has adopted an SOP with a validated method to test cannabis products. All testing laboratories we contract with must be able to provide accurate and validated test results for: cannabinoid content and potency, terpene profiles, heavy metals, chemical contamination, microbials, mycotoxins, residual pesticides, residual solvents, and any other testing protocols as established by the AMCC. Ala. Admin. Code r. 538-x-10-.04.06.a-i. We will only work with testing laboratories that comply with all Laboratory Standards outlined by the AMCC. Ala. Admin. Code r. 538-x-10-.05.

We will always conduct testing through a licensed State Testing Laboratory and adhere to all testing regulations and requirements before selling or transferring any medical cannabis products from our facility. Ala. Admin. Code r. 538-x-10-.01. Batches and lots that have had samples submitted to testing labs or the AMCC will be retained and delegated to a storage area in the intermediate vault until the given batch has passed all mandatory third-party testing. Finished products will not be released for sale until all testing has been completed, passed, and product specifications have been met. QC personnel will review these documents and release the appropriate products for sale.

All samples collected for testing will be derived from a single batch and will comprise at least ten grams and no more than thirty grams; a sample of medical cannabis product will be derived from a single batch and must be the lesser of one percent of the total product weight of the production run or ten units of product. Ala. Admin. Code r. 538-x-4-.07.12.o.03.b. All samples will be homogenized before testing. Ala. Admin. Code r. 538-x-4-.07.12.o.03.b. Under no circumstances will we sell or transfer the medical cannabis product to another licensee, patient, or caregiver, unless and until the State Testing

Laboratory clears us to do so based on the written results of successfully completed testing. Ala. Admin. Code r. 538-x-4-.07.12.o.03.c. All samples collected from our facility will be done in a manner that complies with applicable regulation from the AMCC. Ala. Admin. Code r. 538-x-10-.03.03. We will work closely with the State Testing Laboratory performing the testing to facilitate smooth and efficient testing procedures of all our medical cannabis and cannabis products. We will never use more than one State Testing Laboratory to perform official testing on the same batch or sample of product except as expressly provided in applicable law. Ala. Admin. Code r. 538-x-10-.03.04.b.

Internal Testing

We will go above and beyond the required testing by building an internal testing laboratory. This will serve to further patient safety, identify the exact point in the manufacturing process any quality failures occur, and enable us to perform research. Our research will focus on the relationship between environmental control parameters, process specification parameters, and the resulting changes in the product such as CBD content, THC content, terpene profile, availability, and density.

We will purchase i-series HPLC equipment from Shimadzu to analyze our products for potency. The i-series has excellent reproducibility for injections with wide linearity range and ultra-low carryover, improving the reliability of data. There is a real-time monitor that shows chromatogram details as they occur. The system uses forced air circulation to stabilize products at any temperature. Options for automated and remote functionality may increase our efficiency, though at the outset of our operations our testing will always be supervised by a human. Dedicated software with integration options will improve development efficiency, especially given the ability to migrate chromatograms from other lab equipment. This equipment is explicitly compatible with FDA regulations. 21 C.F.R. §11.

We will use additional equipment to analyze products for contaminants such as molds, insects, or debris. We may also purchase ICP-MS equipment to analyze products for heavy metals, and GC-MS equipment to analyze products for residual solvents. We will perform all internal testing in designated extraction or post-extraction rooms, which will be restricted areas under constant video surveillance, with access limited to authorized personnel who require such access for their job responsibilities.

For internal testing, random batch sampling, homogenous sampling, and other statistically sound sampling methodologies, we will follow testing lab protocols for collection of valid samples. When sampling takes place, we will take duplicate samples to ensure a retained sample is maintained on site and securely stored for a period of no less than one year past the set expiration date. Sampling will be conducted at multiple stages starting with extracted product testing, then prior to manufacturing, and finally, the finished product will be tested. Our retained samples will provide for adequate product remediation testing in the case a complaint is filed by a patient, caregiver, physician, or another medical cannabis establishment.

In-house sampling of extracted cannabis oils for use in medical cannabis products will be conducted by the use of sterile disposable pipets and placed in sealable sample containers, such as plastic laboratory 1.5ml snap cap sample vials. Samples will be taken while extract is being agitated by a magnet stir plate for homogeneity, and then labeled with the correct batch information. We will conduct random sampling of finished packaged products for quality protection.

Cannabis product specifications will include the potency levels intended for each product. We will utilize internal potency testing assays to correctly formulate finished products, label cannabis, and set product specifications. HPLC, in conjunction with a validated scientific method, will be utilized to measure the formulation THC:CBD ratios in finished products. We will not use this testing to supplant approved testing laboratory analysis, rather, internal testing will serve as an additional tool to guarantee the correct formulation of products. These tests will allow us to rework and reformulate products and confirm that product potency matches the product specifications set by QA/QC personnel.

21.3 - Returns and Remediation

Any test failure will be recorded in the seed-to-sale inventory system and will result in the entire cannabis batch associated with that result being quarantined. Ala. Admin. Code r. 538-x-6-.06.03.c.04; 538-x-10-.08.06. Within seven business days of test failure notification, we will communicate with the testing laboratory our acceptance of the result, or we will file to retest, challenge, or request remediation of the result. Ala. Admin. Code r.

538-x-10-.08.05.a-d. We understand that we may not challenge or request a retest by a State Testing Laboratory unless, at the time samples are initially taken for testing, we ensure that three samples are collected at the same time by a state testing laboratory using tamper-resistant containers. Ala. Admin. Code r. 538-x-10-.08.06. Furthermore, one of the samples will be taken by the state testing laboratory for testing and we will place the other two samples in a secure quarantine storage area at our facility for further retesting by a secondary state testing laboratory. Ala. Admin. Code r. 538-x-10-.08.06. We may choose to conduct business for retesting and remediation with a different licensed testing laboratory. Ala. Admin. Code r. 538-x-10-.08.02.a. If at any time, further testing cannot be performed due to the lack of available state testing laboratory to conduct further or additional tests, or the lack of viable samples from which to perform retesting, tiebreak testing, or challenge testing, we will either accept the result of the failed test and destroy or attempt remediation of the batch. Ala. Admin. Code r. 538-x-10-.08.06.a-b. If a sample failed testing based on AMCC pesticide standards, we will immediately recall cannabis products from that batch. Ala. Admin. Code r. 538-x-10-.04.06.g.03.

If a sample provided for retesting meets product standards, we will process, package, label, or sell that product, as notated in the statewide seed-to-sale tracking system and communicated by testing certificate. Ala. Admin. Code r. 538-x-10-.08.10. If, upon retesting, the sample fails the same official test, we will destroy and dispose of the entire batch. Ala. Admin. Code r. 538-x-10-.08.09. We will simultaneously initiate a recall on any cannabis products from that batch or associated products that are no longer within our possession.

We will utilize all available resources to retrieve unsafe products as soon as possible. We may be in contact with the AMCC for communication about community safety and resolution of the issue. Our recall tracking will include how much product from the recalled batch has been sold, product that is still available for sale, product that is in the process of transfer, product being processed, postharvest raw product we have received or stored, and all returned products. Ala. Code § 20-2A-60(a)(6)(a-e). We will coordinate transportation as needed between any other licensed cannabis businesses with impacted products and provide related documentation. Staff will receive all products returned to the facility, log them into the electronic inventory system, and immediately secure and quarantine them in a Restricted Area, physically separated from all other products within our facility.

We will work with Clean Management Environmental Group for the safe and compliant disposal of cannabis. All disposal of medical cannabis and related products will be recorded in our inventory system and synchronized to the statewide seed-to-sale tracking system. Clean Management Environmental Group has disposed of hazardous and other waste for three decades, including compliant cannabis waste disposal in California, with clear documentation trails and direct communication to the Department of Health and cannabis regulatory entities.

Upon completion of a recall, we will summarize details of the recall, record it in the digital inventory system, and submit a report to the AMCC. Our report will include: the total amount of recalled cannabis, including types, forms, batches, and lots; for whom the recalled cannabis was received; the means of transport of the recalled cannabis; the reason for the recall; the number of recalled samples, types, forms, and batched, there were sent to laboratories, and the dates of testing and results; the manner of disposal of recalled cannabis including who oversaw the disposal, method of disposal, date of disposal, and the amount disposed of by types, forms, and batched. We will submit inventory data to the AMCC prior to destruction of any recalled cannabis. Ala. Code § 20-2A-60(a)(4). We will also include any additional information deemed relevant by the AMCC.

Whenever a sample fails any testing, the QAQCD will initiate an investigation to determine when the contamination may have occurred, how it occurred, and whether company procedures to avoid such contamination were properly followed during production. If the investigation reveals that production staff did not fully comply with our existing SOPs, our executive team and departmental managers will retrain and discipline employees as necessary and, if possible, amend SOPs to avoid future misunderstandings of the correct procedures or to provide additional oversight to enforce the SOPs. If the investigation reveals any flaws or gaps in our SOPs that contributed to its occurrence, the QAQCD will work with management to revise relevant SOPs to avoid similar issues in the future.

Conclusion

Product testing and QA/QC in the cannabis industry are crucial to patient and public safety, and we are dedicated to following all required AMCC testing protocols, implementing

internal testing standards and methods, and utilizing approved state testing laboratories to assess the quality and safety of our medical cannabis and medical cannabis products we produce. Together, the testing standards set by our knowledgeable and experienced team will help us to provide safe and high-quality products with consistent potency, stability, and lifespan among batches of the same product. These standards and methods are based upon AMCC guidelines and industry best practices to exceed the requirements for testing product quality and safety.

License Type: Processor

Exhibit 22 – Contamination and Recall Plan

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

Introduction

We designed this plan in alignment with industry best standards, good manufacturing practices, and regulatory compliance, with a focus on safety. Our recall plan defines methods for adverse event notification, product returns, and investigative steps to be taken in the event a recall is required. Our executive team will review this plan at least annually to identify areas of improvement and implement changes. Ala. Admin Code. r. 538-x-3-.05.03.m.16.d. We will promptly notify the Alabama Medical Cannabis Commission ("the AMCC") of any changes to this plan. We will always regard complaints and adverse events related to our cannabis products with the utmost importance and urgency.

Internal record keeping will document all processing details, packaging, ingredients, and medical cannabis concentrates utilized in each production batch, storage of cannabis, and any destruction or disposal. We will maintain these records for at least two years and reference record keeping documents in the event of a recall. A harvest or batch number will be assigned to cannabis products for facilitation of quick and easy identification in the event of a recall. Ala. Admin Code. r. 538-x-6-.05.2.d.

Our plan also accounts for the safety of employees and others on the premises, notification of proper authorities, exploring the possibility of retesting or remediation, proper disposal of contaminated cannabis and medical cannabis, steps to be taken for the preservation of cannabis or medical cannabis, and the reasonable efforts to maintain access to medical cannabis by those who depend on it. Ala. Admin Code. r. 538-x-4-.07.12.o.04.

22.1 Adverse Event Notification

We will provide several avenues for individuals or businesses to report adverse effects experienced with our products. Ala. Code § 20-2A-60(a)(9). Physicians, caregivers, and patients will be able to report issues with products by directly contacting our facilities. Methods for this will include in person to any employee, electronically through our website, or by telephone. Our website will feature a report form for any adverse effects, complaints, or other comments. Our business phone number and email address will be displayed at our facility. Furthermore, our contact information will be on every product label. Certifying physicians can make updates directly to Metrc and the patient registry. We prefer and will encourage direct contact from patients who purchase our products.

Our Quality Assurance and Control Director ("QAQCD") will review each report submitted to our business and determine whether the comments qualify as an adverse event. Our Chief Compliance Officer ("CCO") and other essential staff will support this process as needed. For all product complaints, regardless of severity, we will respond to the individual within one business day - if the individual desires a response and provides contact information.

22.2 Factors for Recall

We understand the AMCC may, at its discretion, order our business to undertake a recall and we will always comply and cooperate with any such recalls. Upon receiving a complaint or notification considered to be an adverse event, our Chief Operations Officer ("COO") will alert the QAQCD and notify the AMCC. The safety of our products and Alabama medical cannabis patients is our priority. We will systematically test our products for pesticides, solvents, and heavy metals at different stages of the production process. We will utilize licensed state testing laboratories and conduct additional internal testing on all products. Our QAQCD will confirm that accurate labels with testing results are placed on each product.

Although Quality Assurance ("QA") and Quality Control ("QC") departments are interrelated functions they are distinct, and each has a role in recall and contamination procedures. Departmental directors and managers will develop a process for each stage of operations, validate the process (e.g., repeat the process multiple times to demonstrate that the process always yields a product with the same quality standards), and establish narrow "target" ranges and wider "acceptable" ranges for every process parameter. If deviations happen outside of the narrower range, but within the wider range, QA will accept that the product is safe though not optimal. If the deviations happen outside of the wider range, QA will reject the batch, or may require additional data to support the release of the product.

QA is process oriented, encompassing the entire production process from cultivation through packaging of manufactured goods, and ends when dispensing facilities have accepted the product and it undergoes their own QA and QC processes before sale to patients. The ultimate goal of QA is patient safety. Conversely, QC is product oriented, composed of in-process testing and testing of the final product. The role of QC is to develop

testing methods, establish product specifications (e.g., the acceptable values for product quality standards), and perform the testing for every batch cultivated or manufactured. Another way to view the roles of QA and QC is when there is deviation in the QC process, e.g., a test was performed by QC outside of its validated processes. In such a case, the QC team would conduct the investigation into what went wrong, while the QA team would review that investigation for compliance.

We will log all testing results in the state seed-to-sale tracking system. Ala. Code § 20-2A-60(a). Any test failure will result in the entire cannabis batch associated with that result being quarantined. Ala. Admin Code. r. 538-x-10-.08.06. Upon notification of a failed test, our managerial team will work with a state testing laboratory and either accept, retest, challenge, or request remediation of the result within seven days. Ala. Admin Code. r. 538-x-10-.08.05(a-d). If a sample failed testing based on Alabama Department of Agriculture pesticide standards, we will immediately recall cannabis and products from that batch. Ala. Admin Code. r. 538-x-10-.04.06.g.03.

If a sample provided for retesting meets product standards, we will process, package, label, or sell that product, as notated in the statewide seed-to-sale tracking system and communicated by testing certificate. Ala. Admin Code. r. 538-x-10-.08.10. If at any time, further testing cannot be performed due to the lack of available state testing laboratories or the lack of viable samples, we will accept the result of the failed test and order the destruction of the batch, or attempt remediation as allowed by regulation. Ala. Admin Code. r. 538-x-10-.08.06(a-b). If, upon retesting, the sample fails the same official test, we will order destruction and disposal of the entire batch, and we will document this action in the statewide seed-to-sale tracking system. Ala. Admin Code. r. 538-x-10-.08.09. We will simultaneously initiate a recall on any cannabis from that batch or associated products that are no longer within our possession.

22.3 Responsible Roles

We will designate a recall committee comprised of the QAQCD, Director of Security ("DOS"), and CCO. This committee is tasked with documenting the chain of custody for recalled products and notification to the appropriate parties. Our CCO will investigate any lapse in compliance related to the recall. The CCO and QAQCD will create appropriate recall

documentation and reports. The Director of Processing ("DOP") will certify investigative reports associated with the recall and submit them to the AMCC. All employees are important to the recall process; Our CCO and QAQCD will provide comprehensive trainings for staff on our recall procedures.

Our DOS is an Alabama native and has positive relationships with the local law enforcement community. The DOS will proactively introduce themselves to local police departments and first responders and communicate their contact information, along with contact details for our business generally. In the event of a recall, the DOS will notify these regulatory entities.

The QAQCD will oversee recall procedures and investigations. They will preside over the collection and record of our recalled products. Quality assurance and quality control staff will support these processes. We will contract with Clean Management Environmental Group for cannabis waste disposal. Clean Management Environmental Group has disposed of hazardous and other waste for three decades, including compliant cannabis waste disposal in California, with clear documentation trails and direct communication to the Department of Health and cannabis regulatory entities. Additional vendors that may support our recall resolution include food safety professionals, legal counsel, and state licensed testing laboratories. Certified Dispensers within their respective partnership locations will also be critical in a successful recall.

22.4 Safety of Premises and People

We will continuously protect the safety of our employees, all other individuals on the premises, and our products. Our DOS will hold ultimate responsibility for the safety of our premises and the functionality of our security systems. Our facility is designed with safety as a priority and will have an advanced air filtration system to mitigate odors and limit contamination factors. Electronic keycard access throughout our property will keep all products secured, whether in processing, stored for sale, or in quarantine. Our product storage vaults will be pharmaceutical grade, class five security based on US General Services Administration standards, and they will meet the highest DEA certification. 21 C.F.R. § 1301.72 (a)(3).

Our DOS and DOP will train all staff on appropriate safety and sanitation practices. Employees will be provided with personal protective equipment ("PPE") at all times when interacting with cannabis or cannabis products. PPE will include gloves, masks, coveralls, and face shields for regular operations. Any staff that work closely with machinery will wear additional PPE such as closed toe or steel toed shoes, and thicker gloves. We will have handwashing stations throughout our facility that are open for use by staff or visitors. Distinct sanitation stations will also be installed within cannabis processing rooms, which will further limit contamination factors.

All activities at our processing facility will be automatically recorded via video surveillance; all activities with cannabis will also be recorded in our inventory system. Our video surveillance footage will be continuously monitored, and any deviation from standard operating procedures will be inspected. These practices allow us to appropriately retrain individuals who are displaying unsafe habits or notify those who have come in contact with contaminants.

22.5 Seed-To-Sale Notification Protocols

We will utilize Dutchie for our internal inventory and tracking system, which will interface easily with Metrc and allow us and the AMCC to accurately track cannabis products. Ala. Admin Code. r. 538-x-4-.05.04. Dutchie is a cannabis industry leader for inventory and sales tracking. Our inventory records will show all licensees in the chain of custody related to an adverse event and allow us to contact any businesses or individuals that may have purchased or otherwise interacted with our products related to an adverse event.

Our internal record keeping will document all cultivator details, packaging, ingredients, and cannabis concentrates utilized in each production batch or medical product, storage of cannabis, and any destruction or disposal of medical cannabis or related products ordered by our company. We have a thorough record keeping system and we will maintain all business records for at least two years, and reference record keeping documents in the event of a recall. A harvest or batch number will be assigned to cannabis products to facilitate quick and easy identification in the event of a recall.

We will log all testing results in the state seed-to-sale tracking system. Ala. Code § 20-2A-60(a). Any test failure will result in the entire cannabis batch associated with that result being quarantined. Ala. Code § 20-2A-60(a)(6). We will diligently record where products are in our process, including which have been sold, are available for sale, are being transferred or processed into a new form, and any product that is in postharvest raw form. Ala. Code § 20-2A-60(a)(6)(a-e). If we find any adverse results related to our released products, we will contact individuals and businesses that purchased our products as soon as possible. We will take the additional step of noting the recall in the patient registry, so the patient's certifying physician is aware and may advise on patient health accordingly. We will operate with complete transparency during any contamination or recall event to protect public health.

The recall committee will coordinate transportation as needed between any other licensed cannabis businesses with impacted products and provide related documentation. Our notification will include our business name, license number, details of the contamination, and product return information. The recall committee will also encourage other licensees involved in the chain of custody delineation to stay in contact with the recall committee, and we have designated the QAQCD as their main point of contact. After confirmation of impacted products and their complete chain of custody, we will offer to provide reimbursement for recalled products and record subsequent refunds in our inventory system. Ala. Code § 20-2A-60(a)(10).

22.6 Returns and Remediation Process

We will utilize all available resources to retrieve recalled products back to our possession as soon as possible. Our well documented chain of custody allows us to track the movement of medical cannabis and medical cannabis products at every step of the process. Upon receipt of recalled medical cannabis and products, our QC team will review the product, track it in inventory control, and segregate it in our designated quarantine area until the AMCC authorizes disposal. We will clearly mark the recalled cannabis or products, making them easily distinguishable from sellable products. We will submit inventory data to the AMCC prior to destruction of any quarantined cannabis. Ala. Code § 20-2A-60(a)(4). We will also work with regulatory agencies as needed to protect public health during the

disposal process. If directed to do so by the AMCC, we may submit products for retesting or remediation.

Utilizing our meticulous inventory procedures, we will track which products remain to recall. All data associated with a recall will be recorded in our inventory system, including inventory of cannabis at our facility, the location of cannabis when it leaves our possession, and the documentation showing any cannabis material that was destroyed or disposed of by our facility. Staff will utilize production logs, invoices, transportation manifests, and shipping logs to confirm the accuracy of inventory system records.

We will establish a procedure to publicly communicate a recall of usable cannabis or cannabis products that present a probability of serious adverse health consequences with exposure. This will include a mechanism to contact all patients who have, or could have, obtained contaminated products from our facility, with clear instructions on product return. We will offer to provide reimbursement for the recalled product through our chain of custody process, and we will record subsequent refunds in the seed-to-sale system. Ala. Code § 20-2A-60(a)(10). We will provide several avenues for individuals to report adverse effects experienced with our products. Ala. Code § 20-2A-60(a)(9). If necessary and as approved by the AMCC, we may provide recall communication via traditional and social media platforms. Our recall tracking will include how much product from the recalled batch has been sold, product that is still available for sale, product that is in the process of transfer, product being processed, postharvest raw product, and all returned products. Ala. Code § 20-2A-60(a)(6)(a-e).

22.7 Crisis Reports to Regulatory Bodies

We will promptly and efficiently notify proper authorities in the event of discovery of product contamination. We will designate our QAQCD to initiate and implement a recall, maintain records of our recall activities, and provide communication with the AMCC, testing facilities, and other licensees as needed. Our DOS is an active member of the Alabama law enforcement community and has personal connections with the Mobile Public Safety Director, Mobile Chief of Police, Mobile County Communications Director, the Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”) and the US Marshals Service. He has proactively developed relationships with local authorities, including the Mayor of

Centreville, and will contact them directly in the event of a recall to protect our community. Our DOP will act as a point of escalation if necessary.

Within 12 hours of contamination or adverse event discovery, we will notify the AMCC by phone, email, or certified mail. Our notification will include our business name, license number, details of the contamination, and recall procedures performed thus far, if any. We may also be in contact with the Alabama Department of Agriculture and Department of Health for communication about community safety and resolution of the issue.

Upon completion of the recall, the recall committee will summarize details of the recall, record it in the digital inventory system, and submit a report to the AMCC. Our report will include: the total amount of recalled cannabis, including types, forms, batches, and lots; the names of the recall committee members; for whom the recalled cannabis was received; the means of transport of the recalled cannabis; the reason for the recall; the number of recalled samples, types, forms, and batched, that were sent to laboratories, the dates of testing and results; and the manner of disposal of recalled cannabis including who oversaw the disposal, method of disposal, date of disposal, and the amount disposed of by types, forms, and batched. We will submit inventory data to the AMCC prior to destruction of any recalled cannabis. Ala. Code § 20-2A-60(a)(4). We will also include any additional information deemed relevant by the AMCC.

22.8 Preserve and Protect Products

We will maintain our medical cannabis product integrity through proper storage and preservation techniques, based on industry standards. In the event of contamination or recall, we will implement additional procedures for the safe removal, secure transportation, and compliant temporary storage of our medical cannabis and related products. This process will allow continual access of safe products to the Alabama medical cannabis supply chain while we resolve the contamination or recall. We may apply for a temporary variance to support these recall procedures. Ala. Admin. Code. r. 538-x-4-.08.06. Our standard operating procedures will be followed as closely as possible, and modified by our COO as needed, while at a temporary facility. All products will be diligently tracked in the state seed-to-sale system.

We have defined QC and QA procedures to efficiently identify contamination and recall situations as they develop. Before they begin work at our facility, all staff will complete training on a spectrum of pests and potentially hazardous equipment and materials that may influence a recall. We will also train staff on proper processing, packaging, labeling, and storage conditions to prevent contamination by impurities or foreign substances. These trainings will help to protect our products. We will isolate affected cannabis products immediately upon notification of a recall and sequester unaffected products in a safe area. Once identified, managers will notify employees to activate recall procedures to protect our products. This will begin by the removal of safe cannabis stock in an orderly and secure manner; staff will collect storage containers of our products and load them into compliant transportation vehicles. Simultaneously, staff will log these products in the seed-to-sale tracking system. We will then transport our cannabis stock to a secure, AMCC approved, temporary storage facility. At this facility medical cannabis products will be made available for safe dispersal to patients.

We will provide continual access to medical cannabis for patients. If our facility is impacted by a recall, we will sequester safe cannabis for continual medical access. This may include the transportation of medical cannabis products to an AMCC-approved auxiliary site, for safe dispersal to patients in emergency situations. If all products under our control and in our possession are recalled or otherwise impacted by contamination, we will work with the AMCC and another licensed medical cannabis business to meet the continual needs of patients. In all recall related events, we will actively communicate updates to patients and their caregivers.

22.9 Investigation and Analysis

Any legitimized adverse event claim will undergo a rigorous investigation, led by our QAQCD, to determine the root cause – whether within our facility or beyond. Data from the initial complaint will be utilized and formalized in our records during this process. Reliable recordkeeping in all aspects of our business will provide a solid foundation for claim investigation. We will utilize inventory systems to link a potential product defect to associated batches, personnel, equipment, storage, and procedures.

The QAQCD will work with managers and other directors to develop a process for each product, validate that process, and establish narrow target ranges for every process parameter. In the instance of nonconformance, the QA team will use a root cause analysis method. The QA team will then review the investigation and make appropriate changes and validate the process to guarantee compliance with regulations. Our executive team will communicate with other impacted licensees to guarantee all factors are included in our investigation. We will revise our standard operating procedures immediately to integrate any changes and conduct additional staff training, as necessary. All analysis results will be confirmed by our DOP and included in our recall report to the AMCC.

Conclusion

We are dedicated to the safety of our patients, employees, and the community. Our recall plan provides specific procedures, defines timelines, and assigns roles and responsibilities if a safety issue arises with any of the cannabis or cannabis products within our facility control. While we will take every measure possible to prevent a contamination or recall incident, we recognize that there are a various number of reasons a recall may occur. Our exceptional team will run a responsible and ethical operation and we will always comply with a recall, whether voluntary or AMCC mandated.

Exhibit 23 – Marketing and Advertising Plan

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

23.1 – Any proposed logos, branding, messaging, or other marketing or advertising communications, providing exemplars of any specific advertisements.

We have created two proposed logos for our company. The first logo is a shortened version used on packaging and labeling. The second logo will be used on our website.

Proposed Logos

COOSA

COOSA MEDICAL MANUFACTURING, LLC

We are not planning to utilize any other types or forms of branding, messaging, or advertising. We will not be marketing to any patients directly. We will only be engaging in sales communications with dispensaries to purchase our product based on our core values of sustainability, biopharmaceutical quality, consistency, and affordability.

23.2 – Any specific media outlets or platforms where the marketing or advertising campaigns or programs will be utilized.

While our team includes a Sales and Marketing Director, we will not utilize any platforms or media outlets for advertising.

23.3 – The identity of any media outlet or third-party individual or entity who is projected to play any role in the Applicant's marketing or advertising efforts, and

copies of all contracts or contract forms proposed for use, if any, between itself and such media outlet or third-party individual or entity.

While our team includes a Sales and Marketing Director, we will not utilize any third parties or media outlets for advertising.

23.4 – Virtual renderings of all packaging to be provided by the Applicant, demonstrating the size, color, logo, artwork, or statements appearing on the packaging, as well as all child-resistant, tamper-evident, or other safety features, demonstrating conformity with the Act and the AMCC Rules.

Below are our proposed packaging designs. These are compliance with all rules and regulations including being non appealing to children, being child resistant, and being tamper-evident. Furthermore, all packaging materials are made from sustainable, recyclable materials to reduce our environmental impact.

Tincture Packaging

Suppository Packaging

Gelatin Packaging

Topical Packaging

23.5 – Exemplars of all proposed labeling, including labels on packaging, on containers and any inserts to be included in any packages, demonstrating conformity with the Act and the AMCC Rules.

We have created labels for each of our four proposed products. These are in compliance with all rules and regulations. Ala. Admin Code. r. 538-x-6-.05.

Proposed Labels for Tincture, Topical, Suppository, and Gelatin Products


Cultivator: Cultivator, LLC
Cultivator License Identification Number: 00000
Processor: Coosa Medical Manufacturing, LLC
Processor License Identification Number: 00000
Lot Number: 00000
Batch Number: 00000
COOSA
PRODUCT DETAILS:
Count: XX
Cannabinoid Content: XX.XX milligrams
THC Potency: XX.XX%
THCA Potency: XX.XX%
CBD Potency: XX.XX%
THC Per Container: 300 mg
INGREDIENTS:
Body Balm Base (MCT Oil, Beeswax, Essential Oils)MCT Oil, Cannabis Oil, Cannabis Terpenes
Do not use if safety seal is damaged or broken.
Store in a cool, dry place, away from sunlight.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
WARNING: This product may make you drowsy or dizzy. Do not drink alcohol with this product. Use care when operating a vehicle or other machinery. Taking this product with medication may lead to harmful side effects or complications. Consult your physician before taking this product with any medication. Women who are breastfeeding, pregnant, or plan to become pregnant should discuss medical cannabis use with their physicians.
TOPICAL
300 MG
Keep out of reach of children.
Product Tracking:
Universal State Symbol


Cultivator: Cultivator, LLC
Cultivator License Identification Number: 00000
Processor: Coosa Medical Manufacturing, LLC
Processor License Identification Number: 00000
Lot Number: 00000
Batch Number: 00000
COOSA
PRODUCT DETAILS:
Count: 10
Cannabinoid Content: XX.XX milligrams
THC Potency: XX.XX%
THCA Potency: XX.XX%
CBD Potency: XX.XX%
THC Per Container: 250 mg
INGREDIENTS:
Polypeg Suppository Base, MCT Oil, Cannabis Oil
Do not use if safety seal is damaged or broken.
Store in a cool, dry place, away from sunlight.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
WARNING: This product may make you drowsy or dizzy. Do not drink alcohol with this product. Use care when operating a vehicle or other machinery. Taking this product with medication may lead to harmful side effects or complications. Consult your physician before taking this product with any medication. Women who are breastfeeding, pregnant, or plan to become pregnant should discuss medical cannabis use with their physicians.
SUPPOSITORIES
250 MG
Keep out of reach of children.
Product Tracking:
Universal State Symbol


Cultivator: Cultivator, LLC
Cultivator License Identification Number: 00000
Processor: Coosa Medical Manufacturing, LLC
Processor License Identification Number: 00000
Lot Number: 00000
Batch Number: 00000
COOSA
PRODUCT DETAILS:
Count: 15
Cannabinoid Content: XX.XX milligrams
THC Potency: XX.XX%
THCA Potency: XX.XX%
CBD Potency: XX.XX%
THC Per Bottle: 300 mg
INGREDIENTS:
Gelatin Mixture (Pectin, Distilled Water, Sugar, Citric Acid, Corn Syrup), MCT Oil, Cannabis Oil, Food-Grade Botanical Terpenes
Do not use if safety seal is damaged or broken.
Store in a cool, dry place, away from sunlight.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Keep out of reach of children.
WARNING: This product may make you drowsy or dizzy. Do not drink alcohol with this product. Use care when operating a vehicle or other machinery. Taking this product with medication may lead to harmful side effects or complications. Consult your physician before taking this product with any medication. Women who are breastfeeding, pregnant, or plan to become pregnant should discuss medical cannabis use with their physicians.
GELATINS
300 MG
Product Tracking:
Universal State Symbol

License Type: Processor

Exhibit 24 – Website and Social Media

Verification

The undersigned verifies that the information contained in this Exhibit, including any attachments thereto, is accurate and complete, based on the best available information at the date of verification.

David Hardin	Managing Member
Printed Name of Verifying Individual	Title of Verifying Individual
David Hardin	12/14/2022 | 8:20 AM PST
Signature of Verifying Individual	Verification Date

24.1 – A complete site map of each website owned or operated by the Applicant.

This is a site map of our proposed website.



24.2 – The web address of each webpage, social media page, or other online site owned or operated by the Applicant.

Our website has not been created yet so it does not have an address. We will not have any social media pages.

The applicant has secured a Letter of Intent [redacted] for the insurance required by the Alabama Medical Cannabis Commission. Members of Coosa Medical Manufacturing have been involved in medical cannabis in other states and have never had issues procuring insurance at the levels required by the AMCC. Below is an email exchange with the commission on October 4th verifying that a Letter of Intent is sufficient to fulfill the requirements of this section.

Is this insurance required to be acquired before the submission on December 30?

The AMCC rules require applicants to show the ability to maintain such minimum levels of coverage. At the time of application, this may be evidenced by a letter of intent or other guarantee of coverage contingent upon licensure.

December 23, 2022

Coosa Medical Manufacturing, LLC
3841 Village Center Dr.,
Hoover, AL 35226

Re: Letter of Intent: Coosa Medical Manufacturing, LLC

To Whom It May Concern:

It is a pleasure for me to have the opportunity to recommend one of our valued clients: Coosa Medical Manufacturing, LLC a Medical Manufacturing, LLC has engaged our Cannabis Practice as their outsourced risk management and insurance team to help develop a risk analysis that will include several stages of their development:

1. Leasing/purchasing of the retail location
2. Construction activity to ready the site for operations
3. Operational stage (once cannabis is on the premise)

Part of this analysis will also consist of standard safety and loss control measures for entering and egress of the facility, burglar alarms, fire protection, specific requirements for storing the inventory, cash and vendor tracking systems.

Per our review, we intend to provide Coosa Medical Manufacturing, LLC the minimum requirements of insurance required by the state of Alabama for $2,000,000 in casualty, workers' compensation, liability and (as applicable) auto liability coverage. These coverages will be secured by insurance carriers with a minimum financial rating of AM Best A- VII.

The property and casualty insurance lines of coverage will include:

1. Property Coverages: TBD per buildout
    a. Building coverage
    b. Tenant Improvements and betterments
    c. Business Personal property
    d. Business Income and Extra Expense
    e. Indoor Crop Coverage
    f. Cannabis Inventory and finished products
2. Auto Liability: $2,000,000 combined single limit

Ala Code § 36-12-40 (Competitively Sensitive Information)

   a. Owned and Hired Non-Owned
3. General liability: $2,000,000 per occurrence; $2,000,000 aggregate
   a. Assault & Battery
4. Product Liability: $2,000,000 per occurrence; $2,000,000 aggregate
   a. Product withdrawal sub limits: $100,000
5. Workers Compensation: statutory limits
   a. Job descriptions
   b. Safety program
6. Professional Liability (E&O): $2,000,000 per occurrence and aggregate
7. Cyber Liability: $1,000,000 per occurrence; $2,000,000 aggregate
8. Employment Practice Liability: $1,000,000 per occurrence; $1,000,000 aggregate

Our history and review , management team, insurance and risk management plans clearly indicate a company thoroughly versed in the cannabis industry with a strong depth of experienced processes, procedures, and personnel.

Based upon our experience, our discussions and reviewing their preliminary applications for our Cannabis and Hemp insurance programs; we can foresee no difficulty in fulfilling the insurance policies required for managing their operations and compliance for all the city, county and state requirements.

If you have any questions, feel free to call our office.

Sincerely,

December 23, 2022

Alabama Medical Cannabis Commission
P.O. Box 309585
Montgomery, Alabama 36130

Re: Applicability of FORM I to Coosa Medical Manufacturing, LLC (the "Company")

To Whom It May Concern:

No entity possesses an ownership interest in the Company. All of the owners of the Company are individuals. As such, this exhibit is not applicable to the Company.

Coosa Medical Manufacturing, LLC

[redacted]
Ala. Code § 36-12-40 (Personally Identifiable Information)

Date Signed: 12/23/22

FORM K: Affidavit of Entity Applicant for
Alabama Medical Cannabis License

STATE OF ALABAMA)

)

Tuscaloosa **COUNTY**)

Before me, the undersigned notary, did appear the Affiant, who after being by me first duly sworn, did state under oath as follows (*please type or print legibly*):

1. NAME OF ENTITY APPLYING FOR LICENSE: Coosa Medical Manufacturing, LLC
2. NAME OF AFFIANT: [redacted]
3. AFFIANT'S POSITION WITH APPLICANT: Head of Operations
4. AFFIANT IS THE APPLICANT'S (*Check One*): ◉ Responsible Party ○ Contact Person
   (The affidavit of BOTH individuals is required)
5. TYPE OF LICENSE BEING SOUGHT BY APPLICANT (*Check One*):

○ Cultivator	◉ Processor	○ Secure Transporter
○ Dispensary	○ Integrated Facility	○ State Testing Laboratory

6. On behalf of the Applicant, I do hereby affirm under oath as follows:
   a. I, the undersigned Affiant named in paragraph 2 above, am an adult, over the age of 19 [redacted] competent to provide this Affidavit.
   INITIAL HERE

   [redacted] ition stated in paragraph 3 above, I have been duly authorized by the Applicant [redacted] in paragraph 1 above (hereinafter, "Applicant") to provide this Affidavit.
   copy of the entity applicant's written authorization to this Affidavit.)
   INITIAL HERE

   [redacted] nd and acknowledge that this Affidavit and the statements, information and [redacted] s or other exhibits accompanying it, are for the purpose of seeking one (1) [redacted] the type specified in paragraph 5 above, on behalf of the Applicant. Neither I [redacted] pplicant are seeking a different Alabama Medical Cannabis license on behalf of [redacted] dual or any other entity.
   INITIAL HERE

   [redacted] statements, information, documents and other exhibits provided in the [redacted] n are true and correct, based on my own personal knowledge and a diligent [redacted] ion by me. To the extent any information provided therein was heretofore outside my personal knowledge or ability to affirm, I have personally communicated with those within the Applicant's business who have such personal knowledge, whose duties

include knowledge of the facts stated and/or the integrity of the documents or other exhibits, and I am able, based on such communications, to attest to their currentness and [redacted] I and the Applicant affirm under penalty of perjury and other applicable der the AMCC Rules and Alabama law.
TIAL HERE

e. derstands and acknowledges that the license being applied for is a revocable nted by this state and is not a property right, and that this Application s not convey to, or otherwise entitle unto, the Applicant any rights to a

TIAL HERE

f. derstands, acknowledges, and will continue to respect and comply with regarding limited communication during the Application process.
TIAL HERE

g. nsents to all background checks, examinations, inspections, and search and MCC and law enforcement personnel during this Application process and the extent a license is awarded.
TIAL HERE

h. s no economic interest, as defined in the AMCC Rules, in any other license or or license under the Darren Wesley "Ato" Hall Compassion Act, § 20-2A-1, et Alabama 1975.
TIAL HERE

i. licant will at all times, to the best of our ability, comply with the AMCC Rules, e and maintain transparency with the AMCC, its staff and other agents.
TIAL HERE

j. ion provided in the Application is hereby affirmed under oath to be true s of the date of the Application's submission.
TIAL HERE

[redacted]

Ala. Code § 36-12-40 (Personally Identifiable Information)

Acting for and on behalf of:

Coosa Medical Manufacturing, LLC

Applicant

Sworn to and subscribed before me on this 20th day of December, 2022.

Lisa M Reed

Notary Public

My Commission Expires: 12.28.25

[SEAL]

LISA M REED
NOTARY PUBLIC
MY COMMISSION EXPIRES DEC. 28, 2025
ALABAMA STATE AT LARGE

FORM K: Affidavit of Entity Applicant for Alabama Medical Cannabis License

STATE OF ALABAMA)

)

Jefferson **COUNTY**)

Before me, the undersigned notary, did appear the Affiant, who after being by me first duly sworn, did state under oath as follows (*please type or print legibly*):

1. NAME OF ENTITY APPLYING FOR LICENSE: Coosa Medical Manufacturing, LLC
2. NAME OF AFFIANT: [redacted]
3. AFFIANT'S POSITION WITH APPLICANT: Owner
4. AFFIANT IS THE APPLICANT'S (*Check One*): ◯ Responsible Party ◉ Contact Person
   (***The affidavit of BOTH individuals is required***)
5. TYPE OF LICENSE BEING SOUGHT BY APPLICANT (*Check One*):

◯ Cultivator	◉ Processor	◯ Secure Transporter
◯ Dispensary	◯ Integrated Facility	◯ State Testing Laboratory

6. On behalf of the Applicant, I do hereby affirm under oath as follows:
   a. [redacted]signed Affiant named in paragraph 2 above, am an adult, over the age of 19 ompetent to provide this Affidavit.
   NITIAL HERE
   b. ion stated in paragraph 3 above, I have been duly authorized by the Applicant n paragraph 1 above (hereinafter, "Applicant") to provide this Affidavit.
   opy of the entity applicant's written authorization to this Affidavit.)
   NITIAL HERE
   c. nd and acknowledge that this Affidavit and the statements, information and or other exhibits accompanying it, are for the purpose of seeking one (1) he type specified in paragraph 5 above, on behalf of the Applicant. Neither I plicant are seeking a different Alabama Medical Cannabis license on behalf of ual or any other entity.
   NITIAL HERE
   d. tatements, information, documents and other exhibits provided in the Application are true and correct, based on my own personal knowledge and a diligent investigation by me. To the extent any information provided therein was heretofore outside my personal knowledge or ability to affirm, I have personally communicated with those within the Applicant's business who have such personal knowledge, whose duties

include knowledge of the facts stated and/or the integrity of the documents or other exhibits, and I am able, based on such communications, to attest to their currentness and accuracy. This I and the Applicant affirm under penalty of perjury and other applicable [redacted] nder the AMCC Rules and Alabama law.
NITIAL HERE

e. [redacted] nderstands and acknowledges that the license being applied for is a revocable ranted by this state and is not a property right, and that this Application oes not convey to, or otherwise entitle unto, the Applicant any rights to a
NITIAL HERE

f. [redacted] understands, acknowledges, and will continue to respect and comply with s regarding limited communication during the Application process.
NITIAL HERE

g. [redacted] onsents to all background checks, examinations, inspections, and search and AMCC and law enforcement personnel during this Application process and to the extent a license is awarded.
NITIAL HERE

h. [redacted] as no economic interest, as defined in the AMCC Rules, in any other license or for license under the Darren Wesley "Ato" Hall Compassion Act, § 20-2A-1, et f Alabama 1975.
NITIAL HERE

i. [redacted] pplicant will at all times, to the best of our ability, comply with the AMCC Rules, ate and maintain transparency with the AMCC, its staff and other agents.
NITIAL HERE

j. [redacted] ation provided in the Application is hereby affirmed under oath to be true as of the date of the [redacted] Ala. Code § 36-12-40 (Personally Identifiable Information)
NITIAL HERE

Acting for and on behalf of:

Coosa Medical Manufacturing, LLC
Applicant

Sworn to and subscribed before me on this 8th day of December, 2023.

Tammy Lee Clements
Notary Public

My Commission Expires: 9-14-2024

[SEAL]

TAMMY LEE CLEMENTS
MY COMMISSION EXPIRES
SEPTEMBER 14, 2024
NOTARY PUBLIC
STATE OF ALABAMA